Name	MOA	Target	Disease Area	Indication	Id	Phase
(R)-(-)-apomorphine	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, CALY, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A	neurology/psychiatry	Parkinson's Disease	BRD-K76022557-003-28-9, BRD-K76022557-003-02-7, BRD-K76022557-003-29-9, BRD-K76022557-001-03-9	Launched
(R)-(-)-rolipram	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D, PDE5A			BRD-K75516118-001-04-1, BRD-K75516118-001-04-1, BRD-K75516118-001-05-9, BRD-K75516118-001-03-3, BRD-K75516118-001-03-3	Phase 1
(R)-baclofen	benzodiazepine receptor agonist	GABBR1, GABBR2			BRD-K62353271-001-04-7, BRD-K62353271-001-04-7, BRD-K62353271-001-02-1	Phase 3
(S)-(+)-rolipram	phosphodiesterase inhibitor	PDE4B, PDE4D			BRD-K65856711-001-05-9, BRD-K65856711-001-05-9, BRD-K65856711-001-03-6, BRD-K65856711-001-03-6, BRD-K65856711-001-03-6, BRD-K65856711-001-04-4	Phase 1
[sar9,met(o2)11]-substance-p	tachykinin antagonist	TACR1			BRD-K89787693-001-02-9	Preclinical
A-1070722	glycogen synthase kinase inhibitor	GSK3A, GSK3B			BRD-K70329400-001-02-5, BRD-K70329400-001-02-5, BRD-K70329400-001-01-7, BRD-K70329400-001-01-7, BRD-K70329400-001-01-7, BRD-K70329400-001-01-7	Preclinical
A-1120	retinoid receptor ligand	RBP4			BRD-K59060513-001-02-5	Preclinical
A-317491	purinergic receptor antagonist	P2RX3			BRD-K38019854-323-01-4, BRD-K38019854-001-01-6, BRD-K38019854-001-01-6	Preclinical
A-33903					BRD-A40302156-001-01-9	Phase 2
A-366	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			BRD-K06182768-001-06-4, BRD-K06182768-001-06-4, BRD-K06182768-001-02-3, BRD-K06182768-001-03-1, BRD-K06182768-001-01-5, BRD-K06182768-001-04-9	Preclinical
A-381393	dopamine receptor antagonist				BRD-K00005339-001-01-9	Preclinical
A-412997	dopamine receptor agonist	DRD4			BRD-K62066682-300-02-9, BRD-K62066682-300-02-9, BRD-K62066682-300-01-0, BRD-K62066682-300-01-0	Preclinical
A-438079	purinergic receptor antagonist	P2RX7			BRD-K13223831-003-01-7, BRD-K13223831-003-02-9, BRD-K13223831-003-02-9	Preclinical
A-485	histone acetyltransferase inhibitor				BRD-K30233223-001-04-9, BRD-K30233223-001-04-9	Preclinical
A-582941	nicotinic receptor agonist	CHRNA7			BRD-K79743788-001-01-2, BRD-K79743788-001-02-9	Preclinical
A-61603	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D			BRD-K00004225-004-01-9, BRD-K00004225-004-01-9	Preclinical
A-674563	AKT inhibitor	AKT1, PKIA, PRKACA			BRD-K78177893-003-03-9, BRD-K78177893-001-02-4, BRD-K78177893-001-02-4	Preclinical
A-7	calmodulin antagonist				BRD-K03301001-003-03-3, BRD-K03301001-003-03-3, BRD-K03301001-003-03-3, BRD-K03301001-003-02-5, BRD-K03301001-003-02-5, BRD-K03301001-003-04-9	Preclinical
A-769662	AMPK activator				BRD-K41918892-001-06-7, BRD-K41918892-001-05-9, BRD-K41918892-001-09-9	Preclinical
A-784168	transient receptor potential channel antagonist	TRPV1			BRD-K87665527-001-01-3, BRD-K87665527-001-02-9	Preclinical
A-803467	sodium channel blocker	SCN10A			BRD-K28570407-001-04-6, BRD-K28570407-001-02-0	Preclinical
A-839977	purinergic receptor antagonist	P2RX7			BRD-K60427831-001-01-0, BRD-K60427831-001-02-9	Preclinical
A-867744	acetylcholine receptor allosteric modulator	CHRNA3, CHRNA4, CHRNA7			BRD-K33059059-001-02-9, BRD-K33059059-001-02-9, BRD-K33059059-001-01-0, BRD-K33059059-001-01-0, BRD-K33059059-001-01-0	Preclinical
A-887826	sodium channel blocker	SCN10A			BRD-K20239555-001-01-2, BRD-K20239555-001-02-9	Preclinical
A-922500	diacylglycerol O acyltransferase inhibitor	DGAT1			BRD-K81614372-001-02-1, BRD-K81614372-001-04-9, BRD-K81614372-001-03-9	Preclinical
A-939572	stearoyl-CoA desaturase inhibitor	SCD			BRD-K99308908-001-02-9, BRD-K99308908-001-02-9, BRD-K99308908-001-01-5	Preclinical
A-967079	transient receptor potential channel antagonist	TRPA1			BRD-K70744942-001-02-9, BRD-K70744942-001-01-2	Preclinical
A-987306	histamine receptor antagonist	ADORA1, AVPR1A, CCR1, CHRM1, CHRM2, CHRM3, CHRM4, DRD3, HTR1A, HTR1B, HTR2A, HTR2B, HTR3A, TACR2			BRD-K68982262-001-01-4, BRD-K68982262-001-02-9	Preclinical
AA-29504	GABA receptor positive allosteric modulator	GABRA1, GABRA4, GABRB3			BRD-K13944729-001-01-7, BRD-K13944729-001-02-9, BRD-K13944729-001-02-9	Preclinical
AAI101	lactamase inhibitor				BRD-K00003450-001-01-9	Phase 3
AB-423	HBV capsid assembly inhibitor				BRD-K00003109-001-01-9	Preclinical
abafungin	sterol methyltransferase inhibitor				BRD-K77432251-001-01-2	Phase 3
abamectin	benzodiazepine receptor agonist	GABBR1, GABBR2	infectious disease	gastrointestinal parasites	BRD-K00004970-001-01-9	Launched
abametapir	metalloproteinase inhibitor	MMP9			BRD-K65498798-001-01-7, BRD-K65498798-001-01-7	Phase 3
abarelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR			BRD-K00003158-001-01-9	Phase 3
ABBV-744	bromodomain inhibitor				BRD-K00003108-001-01-9	Phase 1
ABC-294640	sphingosine kinase inhibitor	SPHK2			BRD-K01825984-001-01-9	Phase 2
abemaciclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	BRD-K33622447-066-01-9, BRD-K33622447-066-01-9, BRD-K33622447-066-01-9, BRD-K33622447-066-01-9, BRD-K33622447-066-01-9, BRD-K33622447-066-01-9, BRD-K33622447-001-03-9, BRD-K33622447-001-03-9	Launched
ABT-072	RNA polymerase inhibitor				BRD-K00004730-001-01-9	Phase 2
ABT-202	acetylcholine receptor agonist				BRD-A29844814-300-01-5	Phase 1
ABT-239	histamine receptor antagonist	HRH1, HRH2, HRH3			BRD-K22749967-046-02-3	Phase 1
ABT-491	platelet activating factor receptor antagonist	PTAFR			BRD-K97233161-003-01-5, BRD-K97233161-003-01-5, BRD-K97233161-003-02-3	Phase 1
ABT-639	calcium channel blocker	CACNA1G, CACNA1H, CACNA1I			BRD-K11792081-001-01-4, BRD-K11792081-001-01-4	Phase 2
ABT-702	adenosine kinase inhibitor	ADK			BRD-K36021395-300-03-2, BRD-K36021395-300-02-4	Preclinical
ABT-724	dopamine receptor agonist	DRD4			BRD-K37714784-305-02-1, BRD-K37714784-305-02-1, BRD-K37714784-305-08-9, BRD-K37714784-305-08-9	Phase 2
ABT-737	BCL inhibitor	BCL2, BCL2L1, BCL2L2			BRD-K56301217-001-10-8, BRD-K56301217-001-10-8, BRD-K56301217-001-10-8, BRD-K56301217-001-10-8, BRD-K56301217-001-07-4, BRD-K56301217-001-07-4, BRD-K56301217-001-07-4, BRD-K56301217-001-01-7, BRD-K56301217-001-01-7, BRD-K56301217-001-01-7, BRD-K56301217-001-01-7, BRD-K56301217-001-01-7, BRD-K56301217-001-01-7, BRD-K56301217-001-01-7, BRD-K56301217-001-01-7, BRD-K56301217-001-12-4, BRD-K56301217-001-12-4	Phase 1/Phase 2
ABT-751	tubulin polymerization inhibitor	TUBB			BRD-K91623615-001-06-8, BRD-K91623615-001-05-0, BRD-K91623615-001-05-0, BRD-K91623615-001-05-0, BRD-K91623615-001-05-0, BRD-K91623615-001-05-0, BRD-K91623615-001-05-0, BRD-K91623615-001-09-9, BRD-K91623615-001-04-3	Phase 2
ABX-1431	monoacylglycerol lipase inhibitor				BRD-K00004603-001-01-9	Phase 2
ABX464	antiviral				BRD-K00003394-001-01-9	Phase 2
AC-186	estrogen receptor agonist	ESR2			BRD-K53788420-001-02-9, BRD-K53788420-001-01-1, BRD-K53788420-001-01-1	Preclinical
AC-261066	retinoid receptor agonist	RARB			BRD-K31144453-001-02-2, BRD-K31144453-001-03-9	Preclinical
AC-264613	PAR agonist	F2RL1			BRD-K81548480-001-02-0, BRD-K81548480-001-01-2, BRD-K81548480-001-01-2, BRD-K81548480-001-03-9	Preclinical
AC-55541	PARP inhibitor	PARP2			BRD-A27911617-001-01-7, BRD-A27911617-001-01-7	Preclinical
AC-55649	retinoid receptor agonist	RARA, RARB			BRD-K93176058-001-04-4, BRD-K93176058-001-03-6, BRD-K93176058-001-05-9, BRD-K93176058-001-05-9	Preclinical
AC-710	PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB			BRD-K15819326-001-02-9, BRD-K15819326-001-02-9, BRD-K15819326-001-01-6	Preclinical
AC-7954-(+/-)	urotensin receptor agonist	UTS2R			BRD-A49544621-003-03-6, BRD-A49544621-003-02-8, BRD-A49544621-003-02-8, BRD-A49544621-003-04-9	Preclinical
acalabrutinib	Bruton's tyrosine kinase (BTK) inhibitor	BTK	hematologic malignancy	mantle cell lymphoma (MCL)	BRD-K64034691-001-01-9, BRD-K64034691-001-01-9, BRD-K64034691-001-01-9, BRD-K64034691-001-01-9	Launched
acalisib	PI3K inhibitor	PIK3CB, PIK3CD			BRD-K92517771-001-01-2, BRD-K92517771-001-01-2	Phase 1
ACDPP	glutamate receptor antagonist	GRM5			BRD-K68633617-003-02-9, BRD-K68633617-003-02-9, BRD-K68633617-003-03-9	Preclinical
acebilustat	leukotriene inhibitor				BRD-K00003255-001-01-9	Phase 2
acebutolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension, ventricular arrhythmias	BRD-A29260609-003-26-0, BRD-A29260609-003-26-0, BRD-A29260609-003-26-0, BRD-A29260609-003-25-2	Launched
acecainide	polarization inhibitor	SCN5A			BRD-K07753030-003-17-6, BRD-K07753030-003-17-6, BRD-K07753030-003-17-6	Phase 3
aceclidine	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology	glaucoma	BRD-K01825000-001-02-9	Launched
aceclofenac	prostanoid receptor antagonist	PTGS2	rheumatology	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, periarthritis, lumbago, ischiadynia	BRD-K68538666-001-14-9, BRD-K68538666-001-12-3, BRD-K68538666-001-12-3, BRD-K68538666-001-12-3	Launched
acedapsone			infectious disease	leprosy	BRD-K97417064-001-02-4, BRD-K97417064-001-05-9	Launched
acedoben					BRD-K47195926-001-06-6, BRD-K47195926-001-07-9	Phase 2
acefylline	adenosine receptor agonist	ADORA1	pulmonary	asthma	BRD-K44004064-001-08-9, BRD-K44004064-001-07-3	Launched
aceglutamide			gastroenterology	peptic ulcer disease (PUD)	BRD-K13619941-001-02-9, BRD-K13619941-001-02-9, BRD-K13619941-213-01-8	Launched
acelarin	anticancer agent				BRD-K00003531-001-01-9	Phase 2/Phase 3
acemetacin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis	BRD-K67563174-001-19-9, BRD-K67563174-001-19-9, BRD-K67563174-001-19-9, BRD-K67563174-001-17-6, BRD-K67563174-001-16-8	Launched
aceneuramic-acid		CES1, SELE, SELP			BRD-K36262466-001-06-3	Phase 3
acenocoumarol	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	BRD-A65051990-001-12-9, BRD-A65051990-001-20-9	Launched
acepromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	sedative	BRD-K37814297-050-09-6, BRD-K37814297-050-09-6, BRD-K37814297-050-10-9	Launched
acesulfame-potassium					BRD-K50850824-237-03-0, BRD-K50850824-237-02-2, BRD-K50850824-237-04-8	Phase 3
acetanilide	hydrogen peroxide decomposition inhibitor				BRD-K11094367-001-11-9, BRD-K11094367-001-10-1, BRD-K11094367-001-09-3	Preclinical
acetarsol			gastroenterology	diarrhea	BRD-K99048103-001-19-2, BRD-K99048103-001-18-4, BRD-K99048103-001-20-0	Launched
acetazolamide	carbonic anhydrase inhibitor	AQP1, CA1, CA12, CA14, CA2, CA3, CA4, CA7	ophthalmology	glaucoma	BRD-K43457670-001-27-8, BRD-K43457670-001-27-8	Launched
acetohexamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	BRD-K52960356-001-13-0, BRD-K52960356-001-15-5	Launched
acetohydroxamic-acid	urease inhibitor	MMP12	infectious disease	urinary tract infections	BRD-K21615095-001-08-4	Launched
acetriazoic-acid					BRD-K46416130-001-06-9, BRD-K46416130-001-07-7, BRD-K46416130-001-07-7	Preclinical
acetyl-farnesyl-cysteine	methyltransferase inhibitor	PPARG	dermatology	acne vulgaris (AV)	BRD-K79437791-001-05-7, BRD-K79437791-001-05-7, BRD-K79437791-001-06-5, BRD-K79437791-001-06-5	Launched
acetyl-l-leucine			neurology/psychiatry	vertigo	BRD-K27406233-001-08-9, BRD-K27406233-001-07-7	Launched
acetyl-11-keto-beta-boswellic-acid	lipoxygenase inhibitor	HSD11B1, HSD11B2			BRD-A44696962-001-01-4	Phase 2
acetylcholine	acetylcholine receptor agonist	ACHE, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	neurology/psychiatry, gastroenterology, pulmonary	drowsiness, fatigue, headache, indigestion, chest congestion	BRD-K82381502-003-25-9, BRD-K82381502-003-24-9, BRD-K82381502-003-23-1	Launched
acetylsalicylsalicylic-acid	cyclooxygenase inhibitor				BRD-K46585355-001-15-9, BRD-K46585355-001-14-3, BRD-K46585355-001-14-3	Preclinical
acetylspiramycin	other antibiotic				BRD-K00004968-001-01-9	Preclinical
acexamic-acid	5 alpha reductase inhibitor	GAST	dermatology	wound healing	BRD-K72215350-001-07-9, BRD-K72215350-001-07-9, BRD-K72215350-001-06-5, BRD-K72215350-001-06-5, BRD-K72215350-001-06-5, BRD-K72215350-001-06-5, BRD-K72215350-001-06-5	Launched
acifran	cholesterol inhibitor	HCAR2, HCAR3			BRD-A29520968-001-03-5, BRD-A29520968-001-04-9, BRD-A29520968-001-02-7, BRD-A29520968-001-02-7	Phase 3
acipimox	cholesterol inhibitor	HCAR2	endocrinology	hyperlipidemia	BRD-K63736853-001-06-3, BRD-K63736853-001-04-8, BRD-K63736853-001-04-8, BRD-K63736853-001-07-9, BRD-K63736853-001-03-0, BRD-K63736853-001-03-0, BRD-K63736853-001-03-0	Launched
acitazanolast	mediator release inhibitor		allergy	allergic rhinitis	BRD-K74236708-001-02-7, BRD-K74236708-001-01-9, BRD-K74236708-001-01-9	Launched
acitretin	retinoid receptor agonist	RARA, RARB, RARG, RBP1, RXRA, RXRB, RXRG, STAT3	dermatology	psoriasis	BRD-K62012036-001-14-4, BRD-K62012036-001-14-4, BRD-K62012036-001-14-4, BRD-K62012036-001-14-4, BRD-K62012036-001-13-6	Launched
acivicin	gamma glutamyltransferase inhibitor	CTPS1			BRD-K13050541-001-01-9, BRD-K13050541-001-01-9	Phase 2
aclarubicin	topoisomerase inhibitor	TOP1, TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	BRD-K31965398-001-03-9	Launched
aclidinium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchitis, emphysema, chronic obstructive pulmonary disease (COPD)	BRD-K74363950-004-02-9, BRD-K74363950-004-01-0	Launched
acolbifene	estrogen receptor antagonist				BRD-K00004720-001-01-9	Phase 3
acoziborole	antitrypanosomal				BRD-K00003303-001-01-9	Preclinical
ACPC	glutamate receptor antagonist				BRD-K66465025-001-08-9, BRD-K66465025-001-05-1	Phase 1
acriflavine	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	BRD-M87138257-003-01-1, BRD-M87138257-003-01-1	Launched
acriflavinium	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	BRD-K97874492-300-10-7, BRD-K97874492-003-12-3	Launched
acrisorcin	other antifungal		infectious disease	fungal infection	BRD-M49658242-001-04-1	Launched
acrivastine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	BRD-K50163129-001-02-9, BRD-K50163129-001-02-9, BRD-K50163129-001-01-4, BRD-K50163129-001-01-4, BRD-K50163129-001-01-4	Launched
acrylate	mucus protecting agent				BRD-M00184283-001-01-1	Phase 3
ACT-132577	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	BRD-K34843150-001-03-0, BRD-K34843150-001-02-2, BRD-K34843150-001-01-4	Launched
ACT-462206	orexin receptor antagonist	HCRTR1, HCRTR2			BRD-K19781342-001-02-2, BRD-K19781342-001-01-4	Phase 1
actarit	interleukin receptor agonist		rheumatology	rheumatoid arthritis	BRD-K33483813-001-13-9, BRD-K33483813-001-10-0	Launched
ACTB-1003	FGFR inhibitor, VEGFR inhibitor	KDR, TEK			BRD-K35936936-001-01-6, BRD-K35936936-001-01-6, BRD-K35936936-001-01-6, BRD-K35936936-001-02-9	Phase 1
actinomycin-d	RNA polymerase inhibitor		oncology	Wilm's tumor, Ewing's sarcoma, rhabdomyosarcoma, testicular carcinoma	BRD-K16547679-001-01-5, BRD-K16547679-001-02-9, BRD-K16547679-001-03-9	Launched
actinoquinol					BRD-K08837089-236-01-6, BRD-K08837089-001-03-9	Preclinical
acumapimod	p38 MAPK inhibitor				BRD-K00003220-001-01-9	Phase 1
ACY-1215	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8			BRD-K82928847-001-04-7, BRD-K82928847-001-04-7, BRD-K82928847-001-07-9, BRD-K82928847-001-07-9, BRD-K82928847-001-07-9, BRD-K82928847-001-07-9	Phase 1/Phase 2
acyclovir	DNA polymerase inhibitor	PNP	infectious disease	genitial herpes, shingles, chicken pox	BRD-K32318651-001-26-0, BRD-K32318651-001-23-7, BRD-K32318651-001-22-9, BRD-K32318651-001-21-1, BRD-K32318651-001-24-5, BRD-K32318651-001-24-5, BRD-K32318651-001-24-5	Launched
AC1NDSS5					BRD-K10226125-245-01-5, BRD-K10226125-245-01-5	Phase 1
AC260584	cholinergic receptor agonist				BRD-K00004583-001-01-9	Preclinical
AD-5467	aldose reductase inhibitor	AKR1B1			BRD-A80280426-001-03-8, BRD-A80280426-001-02-0	Phase 2
adapalene	retinoid receptor agonist	RARA, RARB, RARG, RXRA, RXRB, RXRG	dermatology	acne vulgaris (AV)	BRD-K33127281-001-06-4, BRD-K33127281-001-06-4, BRD-K33127281-001-05-6, BRD-K33127281-001-05-6, BRD-K33127281-001-05-6, BRD-K33127281-001-04-9, BRD-K33127281-001-04-9, BRD-K33127281-001-04-9	Launched
adaprev	TGF beta receptor inhibitor	AKR1B1, GPI, HK1, M6PR, PYGM			BRD-A73427433-240-01-3, BRD-A73427433-240-01-3	Phase 3
adaptavir	CC chemokine receptor antagonist	CCR5			BRD-K37151368-001-01-7, BRD-K37151368-001-01-7, BRD-K37151368-001-01-7, BRD-K37151368-001-02-9	Phase 2
adarotene	retinoid receptor agonist	RARB, RARG			BRD-K00152668-001-01-5, BRD-K00152668-001-01-5, BRD-K00152668-001-01-5, BRD-K00152668-001-02-9	Phase 1
adatanserin	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR2A			BRD-K67789209-001-01-0, BRD-K67789209-001-01-0, BRD-K67789209-001-01-0	Phase 2
adavivint	WNT pathway inhibitor				BRD-K00003499-001-01-9	Phase 1
ADD-233089	benzodiazepine receptor agonist				BRD-K43055376-001-01-2, BRD-K43055376-001-02-9, BRD-K43055376-001-02-9	Phase 1
adefovir	DNA polymerase inhibitor		infectious disease	hepatitis B	BRD-K77484724-001-03-8, BRD-K77484724-001-02-0	Launched
adefovir-dipivoxil	DNA polymerase inhibitor		infectious disease	hepatitis B	BRD-K96159438-001-08-9, BRD-K96159438-001-07-1, BRD-K96159438-001-06-3	Launched
adelmidrol	anti-inflammatory agent		dermatology	dermatitis	BRD-K78097265-001-02-9, BRD-K78097265-001-01-6	Launched
ademetionine	methyltransferase stimulant, phosphodiesterase inhibitor		neurology/psychiatry	depression, attention-deficit/hyperactivity disorder (ADHD)	BRD-K78185697-001-02-5, BRD-K78185697-001-01-7	Launched
adenosine-phosphate	adenosine receptor agonist	ACSL1, ACSS1, ACSS2, ADCY1, ADK, CREB1, FBP1, HINT1, PDE4B, PDE4D, PIM1, PRKAA1, PRKAB1, PRKAB2, PYGL, TRPM4			BRD-K85767870-001-14-9	Launched
adenosine-triphosphate	adenosine receptor agonist	ABCA1, ABCB1, ABCB11, ABCC2, ABCC8, ABCC9, ABCG1, ABL1, ABL2, ACSL1, ACSS1, ACSS2, ACVR1, ACVR1B, ACVRL1, ADCY1, ADRBK1, ADRBK2, AFG3L2, AKT1, ALK, AMHR2, APAF1, ARAF, ASNA1, ASNS, ASS1, CDK15, GPR17, ITPR1, NAE1, NT5C2, P2RY1, P2RY11, P2RY13, P2RY2, P2RY4, PRKAA1, RYR1, RYR2, RYR3, SLC25A4, TNK2, TRPM4, TRPM7			BRD-K00003709-001-01-9	Phase 2
adiphenine	acetylcholine receptor antagonist	CHRNA1	neurology/psychiatry	spasms	BRD-K60907894-003-24-9, BRD-K60907894-003-24-9, BRD-K60907894-003-23-5, BRD-K60907894-003-22-7	Launched
adipic-acid	solute carrier family member inhibitor	SLC22A6			BRD-K10656395-001-02-1	Preclinical
adiporon	adiponectin receptor agonist	ADIPOR1, ADIPOR2			BRD-K68810443-003-03-9, BRD-K68810443-001-01-9, BRD-K68810443-001-01-9, BRD-K68810443-003-01-5, BRD-K68810443-001-02-7	Preclinical
ADL5859	opioid receptor agonist	OPRD1			BRD-K39624409-003-02-6, BRD-K39624409-003-03-4, BRD-K39624409-003-03-4, BRD-K39624409-003-03-4, BRD-K39624409-003-03-4, BRD-K39624409-003-04-2, BRD-K39624409-003-04-2	Phase 2
adomeglivant	glucagon receptor antagonist				BRD-K00003302-001-01-9	Preclinical
adoprazine	dopamine receptor antagonist, serotonin receptor agonist	DRD2, HTR1A			BRD-K34870043-001-01-8, BRD-K34870043-001-01-8, BRD-K34870043-001-02-9	Phase 2
adrafinil	adrenergic receptor agonist		neurology/psychiatry	fatigue	BRD-A90926615-001-02-7, BRD-A90926615-001-03-9, BRD-A90926615-001-01-9	Launched
adrenalone	adrenergic receptor agonist	ADRA1A	hematology	hemorrhage	BRD-K82343404-003-06-9, BRD-K82343404-003-06-9, BRD-K82343404-003-03-2, BRD-K82343404-003-02-4	Launched
adrenosterone	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1, HSD11B2			BRD-K17368287-001-18-3, BRD-K17368287-001-19-9	Preclinical
ADX-10059	glutamate receptor negative allosteric modulator	GRM5			BRD-K77911775-003-02-9, BRD-K77911775-003-01-8, BRD-K77911775-003-01-8, BRD-K77911775-003-01-8, BRD-K77911775-003-01-8	Phase 2
ADX-47273	glutamate receptor modulator	GRM5			BRD-K56543881-001-03-9, BRD-K56543881-001-02-7	Preclinical
AEE788	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR			BRD-K40718343-001-05-9, BRD-K40718343-001-05-9, BRD-K40718343-001-04-2, BRD-K40718343-001-03-4, BRD-K40718343-001-02-6	Phase 1/Phase 2
AEG3482	HSP inducer				BRD-K77634909-001-05-0, BRD-K77634909-001-03-5, BRD-K77634909-001-06-9	Preclinical
afalanine	dopamine receptor agonist	DRD2			BRD-K53205568-001-02-6, BRD-K53205568-001-04-9, BRD-K53205568-001-04-9	Phase 3
afamelanotide	melanocyte-stimulating hormone mimetic				BRD-K00003330-001-01-9	Launched
afatinib	EGFR inhibitor	EGFR, ERBB2, ERBB4	oncology	non-small cell lung cancer (NSCLC)	BRD-K66175015-332-01-6, BRD-K66175015-332-01-6, BRD-K66175015-332-01-6, BRD-K66175015-001-13-2, BRD-K66175015-001-13-2, BRD-K66175015-001-13-2, BRD-K66175015-001-09-0, BRD-K66175015-001-09-0, BRD-K66175015-001-09-0, BRD-K66175015-001-09-0	Launched
afimoxifene	estrogen receptor antagonist	ESR1, ESR2, ESRRG, PLD1, PRKCD, PRKCE, PRKCQ, PRKCZ			BRD-K04210847-001-21-9	Phase 2
afloqualone	acetylcholine receptor antagonist		neurology/psychiatry	sedative	BRD-K69247067-001-01-8, BRD-K69247067-001-01-8, BRD-K69247067-001-01-8	Launched
AFN-1252	FABI inhibitor				BRD-K23791635-001-01-3	Phase 2
afobazole	anxiolytic		neurology/psychiatry	anxiety	BRD-K37793595-003-01-7, BRD-K37793595-003-02-9	Launched
AF38469	sortilin inhibitor	SORT1			BRD-K47816470-001-01-8, BRD-K47816470-001-01-8, BRD-K47816470-001-01-8, BRD-K47816470-001-01-8	Preclinical
AG-1024	insulin growth factor receptor inhibitor	IGF1R			BRD-K08310154-001-03-8, BRD-K08310154-001-03-8	Preclinical
AG-14361	PARP inhibitor	PARP1			BRD-K00615600-001-12-9, BRD-K00615600-001-12-9, BRD-K00615600-001-12-9, BRD-K00615600-001-13-7, BRD-K00615600-001-13-7, BRD-K00615600-001-13-7, BRD-K00615600-001-13-7, BRD-K00615600-001-13-7, BRD-K00615600-001-13-7, BRD-K00615600-001-13-7, BRD-K00615600-001-13-7	Preclinical
AG-490	EGFR inhibitor, JAK inhibitor	EGFR, JAK2, JAK3			BRD-K47105409-001-15-2, BRD-K47105409-001-14-5, BRD-K47105409-001-13-7, BRD-K47105409-001-16-9	Preclinical
AG-555	tyrosine kinase inhibitor	CDK2			BRD-K34428485-001-18-4	Preclinical
AG-556	tyrosine kinase inhibitor				BRD-K81048131-001-03-9, BRD-K81048131-001-02-4	Preclinical
AGI-5198	isocitrate dehydrogenase inhibitor	IDH1			BRD-A56371469-001-03-3, BRD-A56371469-001-03-3, BRD-A56371469-001-03-3	Preclinical
AGI-6780	isocitrate dehydrogenase inhibitor	IDH2			BRD-K04691817-001-01-8, BRD-K04691817-001-01-8, BRD-K04691817-001-03-9	Preclinical
AGM-1470	cell cycle inhibitor	METAP2			BRD-A78111609-001-01-2	Phase 2
agmatine	nitric oxide synthase inhibitor	ADRA2C, ASIC3, CACNA1B, CHRNA1, GRIN1, KCNJ1, NISCH			BRD-K49738308-065-04-9, BRD-K49738308-065-04-9	Phase 3
AGN-194310	retinoid receptor antagonist	RXRA, RXRB, RXRG			BRD-K70262971-001-01-9, BRD-K70262971-001-01-9, BRD-K70262971-001-01-9	Phase 3
AGN-195183	retinoid receptor agonist	RARA			BRD-K32533226-001-01-3, BRD-K32533226-001-01-3	Phase 1/Phase 2
agomelatine	melatonin receptor agonist, serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B	neurology/psychiatry	depression	BRD-K84698278-001-03-4, BRD-K84698278-001-05-9, BRD-K84698278-001-05-9	Launched
AGP-103	membrane permeability inhibitor				BRD-K91495480-001-03-9, BRD-K91495480-001-02-2, BRD-K91495480-001-02-2	Launched
AH-7614	free fatty acid receptor antagonist	FFAR4			BRD-K10852420-001-03-9, BRD-K10852420-001-02-5, BRD-K10852420-001-02-5	Preclinical
AH11110	adrenergic receptor ligand	ADRA1B			BRD-A64808605-003-03-9, BRD-A64808605-003-03-9, BRD-A64808605-003-02-7	Preclinical
AH6809	prostanoid receptor antagonist	PTGDR, PTGER1, PTGER2, PTGER3			BRD-K59339270-001-03-4, BRD-K59339270-001-04-9, BRD-K59339270-001-02-6	Preclinical
AI-10-49	core binding factor inhibitor	CBFB			BRD-K89899948-001-01-7	Preclinical
AIM-100	tyrosine kinase inhibitor	TNK2			BRD-K85139301-001-02-9, BRD-K85139301-001-01-3	Preclinical
ajmaline	sodium channel blocker		cardiology	Wolff-Parkinson-White Syndrome (WPW)	BRD-K00005347-001-01-9, BRD-K00005347-001-01-9	Launched
AJ76-(+)	dopamine receptor antagonist	DRD2, DRD3, DRD4			BRD-K76677554-003-03-9, BRD-K76677554-003-02-1	Preclinical
AK-7	SIRT inhibitor	SIRT2			BRD-K09143580-001-02-9, BRD-K09143580-001-01-0	Preclinical
AKBA	lipoxygenase inhibitor	ALOX5			BRD-K54907283-001-01-2, BRD-K54907283-001-01-2, BRD-K54907283-001-01-2, BRD-K54907283-001-02-9	Phase 3
aklomide			infectious disease	coccidiosis	BRD-K26807903-001-04-3	Launched
AL-8697	p38 MAPK inhibitor	MAPK14			BRD-K44731351-001-02-9, BRD-K44731351-001-01-6	Preclinical
alacepril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	BRD-K51784806-001-01-6, BRD-K51784806-001-01-6, BRD-K51784806-001-02-9, BRD-K51784806-001-02-9	Launched
alafosfalin	bacterial cell wall synthesis inhibitor				BRD-K80403280-001-02-1, BRD-K80403280-001-02-1	Phase 1
alagebrium	glycosylation inhibitor				BRD-K96029467-003-01-9	Phase 2/Phase 3
alanine					BRD-A33317514-001-01-3	Launched
alanosine	antimetabolite				BRD-K00004718-001-01-9	Phase 2
alantolactone	apoptosis stimulant, STAT inhibitor	STAT3			BRD-K53731810-001-05-9, BRD-K53731810-001-04-3	Preclinical
alaproclate	serotonin receptor antagonist	SLC6A4			BRD-K01826783-003-07-9	Phase 2
alarelin	gonadotropin releasing factor hormone receptor antagonist	GNRH1			BRD-K42140276-402-01-4, BRD-K42140276-402-01-4	Launched
albendazole	tubulin polymerization inhibitor	TUBA1A, TUBB, TUBB4B	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	BRD-K79131256-001-20-9, BRD-K79131256-001-18-7, BRD-K79131256-001-17-9, BRD-K79131256-001-17-9, BRD-K79131256-001-17-9	Launched
albendazole-oxide	anthelmintic agent		infectious disease	cystic hydatid disease, parenchymal neurocysticercosis	BRD-A67060370-001-02-9, BRD-A67060370-001-04-5	Launched
albuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	BRD-K01825118-065-05-9, BRD-K01825118-065-04-9	Launched
alcaftadine	histamine receptor antagonist	HRH1	allergy	allergic conjunctivitis	BRD-K55991142-001-01-6	Launched
alclofenac	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis	BRD-K47492008-001-02-7, BRD-K47492008-001-02-7	Launched
alclometasone-dipropionate	glucocorticoid receptor agonist	CYP3A4, NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	BRD-A17407635-001-04-0	Launched
alcuronium	muscle relaxant	CHRM1, CHRM2, CHRM3, CHRM4, CHRNA7	neurology/psychiatry	muscle relaxant	BRD-A84907376-300-03-8	Launched
alda-1	aldehyde dehydrogenase activator	ALDH2			BRD-K06890060-001-09-1, BRD-K06890060-001-10-9	Preclinical
aldoxorubicin	topoisomerase inhibitor	TOP2A			BRD-K68928792-001-03-2, BRD-K68928792-001-02-4, BRD-K68928792-001-01-6	Phase 3
alectinib	ALK tyrosine kinase receptor inhibitor	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	BRD-K11267252-001-06-9, BRD-K11267252-001-04-4, BRD-K11267252-001-04-4	Launched
alendronate	bone resorption inhibitor	ATP6V1A, FDPS, PTPN4, PTPRE, PTPRS	orthopedics	osteoporosis	BRD-K75527158-360-05-6, BRD-K75527158-360-06-4, BRD-K75527158-360-04-9, BRD-K75527158-360-04-9, BRD-K75527158-360-07-2	Launched
alexidine	phosphatidylglycerophosphatase inhibitor	PTPMT1			BRD-A42335949-300-10-6, BRD-A42335949-300-10-6, BRD-A42335949-300-10-6, BRD-A42335949-300-10-6, BRD-A42335949-300-10-6, BRD-A42335949-300-10-6, BRD-A42335949-300-09-8	Preclinical
alfadolone-acetate	benzodiazepine receptor agonist				BRD-K51751936-001-09-1	Phase 2
alfuzosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	urology	benign prostatic hyperplasia (BPH)	BRD-K01826519-003-08-9, BRD-K01826519-003-07-9	Launched
algestone-acetophenide			endocrinology	contraceptive	BRD-K00005348-001-01-9	Launched
alibendol	antispasmodic		gastroenterology	bile stimulation	BRD-K60102752-001-02-2	Launched
alimemazine	histamine receptor agonist, histamine receptor antagonist	HRH1	neurology/psychiatry, allergy, pulmonary	sedative, urticaria, itching, cough suppressant	BRD-K01827280-046-12-9, BRD-K01827280-046-11-9, BRD-K01827280-045-07-9	Launched
alinidine	bradycardic effect 				BRD-K00004709-001-01-9	Phase 3
alisertib	Aurora kinase inhibitor	AURKA			BRD-K75295174-001-05-0, BRD-K75295174-001-05-0, BRD-K75295174-001-05-0, BRD-K75295174-001-05-0, BRD-K75295174-001-05-0, BRD-K75295174-001-01-9, BRD-K75295174-001-01-9, BRD-K75295174-001-01-9, BRD-K75295174-001-01-9, BRD-K75295174-001-01-9, BRD-K75295174-001-01-9, BRD-K75295174-001-01-9, BRD-K75295174-001-01-9	Phase 3
alisporivir	cyclophilin inhibitor				BRD-K00003135-001-01-9	Phase 3
alizapride	dopamine receptor antagonist		gastroenterology	nausea	BRD-K00003607-003-01-9	Launched
alizarin					BRD-K73191876-001-12-0, BRD-K73191876-001-11-2, BRD-K73191876-001-13-8	Preclinical
allantoin	cosmetic		dermatology	skin protectant	BRD-A96407378-001-15-1	Launched
allicin	cytokine production inhibitor	TRPA1, TRPV1			BRD-A60402836-001-01-0	Phase 2
allopurinol	xanthine oxidase inhibitor	XDH	rheumatology, urology	gout, kidney stones	BRD-K86307448-001-17-5, BRD-K86307448-001-19-1, BRD-K86307448-001-19-1, BRD-K86307448-001-16-7	Launched
allopurinol-riboside	anti-leishmanial agent, phosphorylase inhibitor				BRD-K00004728-001-01-9, BRD-A93407926-001-01-1	Phase 2
allylestrenol	steroidal progestin	ESR1, PGR, SLC6A9	obstetrics/gynecology	premature labor	BRD-K12872829-001-01-0	Launched
allylisothiocyanate	TRPV agonist	TRPA1			BRD-K33219225-001-01-9, BRD-K33219225-001-02-9	Preclinical
allylthiourea	nitrification inhibitor				BRD-K89634775-001-10-9, BRD-K89634775-001-08-1, BRD-K89634775-001-09-9	Preclinical
almitrine	neurotransmitter agonist	ATP1A1	pulmonary	chronic obstructive pulmonary disease (COPD)	BRD-K82677201-001-01-6, BRD-K82677201-001-01-6	Launched
almorexant	orexin receptor antagonist	HCRTR1, HCRTR2			BRD-K84810405-003-02-9, BRD-K84810405-003-01-1	Phase 3
almotriptan	serotonin receptor agonist	HTR1B, HTR1D	neurology/psychiatry	migraine headache	BRD-K67601717-001-03-8, BRD-K67601717-037-02-4, BRD-K67601717-037-04-9	Launched
aloe-emodin	anticancer agent	CASP8			BRD-K04851519-001-06-8	Preclinical
aloperine					BRD-K96391852-001-02-8, BRD-K96391852-001-03-6	Preclinical
alosetron	serotonin receptor antagonist	HTR3A			BRD-K46742498-003-12-9, BRD-K46742498-003-12-9, BRD-K46742498-003-11-0	Withdrawn
alovudine	DNA synthesis marker				BRD-K00004697-001-01-9	Phase 2
alpelisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	oncology	breast cancer	BRD-K54997624-001-06-0, BRD-K54997624-001-06-0, BRD-K54997624-001-06-0, BRD-K54997624-001-06-0, BRD-K54997624-001-06-0, BRD-K54997624-001-06-0	Launched
alpha-asarone	cytochrome P450 inhibitor, HMGCR inhibitor	HMGCR			BRD-K72536715-001-01-5	Preclinical
alpha-D-glucopyranose					BRD-K87424134-001-01-0	Preclinical
alpha-glucosyl-hesperidin	antioxidant				BRD-K00005238-001-01-9	Preclinical
alpha-linolenic-acid	omega 3 fatty acid stimulant	ELOVL4, FADS1, FADS2, FFAR1, FFAR4, PTGS2, SLC8A1, TRPV1			BRD-K33396764-001-11-1, BRD-K33396764-001-11-1, BRD-K33396764-001-11-1, BRD-K33396764-001-08-7, BRD-K33396764-001-08-7	Phase 3
alpha-methylhistamine-dihydrobromide-(R)-(-)	histamine receptor agonist	HRH3			BRD-K80028314-303-08-9, BRD-K80028314-303-02-6	Preclinical
alpha-methylhistamine-dihydrobromide-(S)-(+)	histamine receptor agonist	HRH3			BRD-K28308851-303-02-9, BRD-K28308851-303-01-8	Preclinical
alpha-methylserotonin	serotonin receptor agonist	HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4			BRD-K01826806-050-02-9	Preclinical
alpha-tochopherol	antioxidant		endocrinology	vitamin E deficiency	BRD-A82892199-001-04-1, BRD-A82892199-001-05-9	Launched
alpha-tochopheryl-acetate	antioxidant		endocrinology	vitamin E deficiency	BRD-A61850409-001-10-7	Launched
alpidem	benzodiazepine receptor agonist	GABRA1			BRD-K66896751-001-02-4, BRD-K66896751-001-02-4, BRD-K66896751-001-02-4	Withdrawn
alprenolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	angina pectoris	BRD-K01825817-003-02-9, BRD-K01825817-003-02-9	Launched
alrestatin	aldose reductase inhibitor	AKR1B1			BRD-K35498378-001-07-9, BRD-K35498378-001-08-9, BRD-K35498378-001-06-1	Preclinical
ALS-8112					BRD-K21415491-001-01-4, BRD-K21415491-001-01-4, BRD-K21415491-001-01-4	Phase 1
ALS-8176	RNA polymerase inhibitor				BRD-K00004605-001-01-9	Phase 1
altanserin	serotonin receptor antagonist	HTR2A			BRD-K00610438-003-03-3, BRD-K00610438-003-03-3, BRD-K00610438-003-06-9, BRD-K00610438-003-02-5, BRD-K00610438-003-02-5	Phase 2
althiazide	diuretic		cardiology	hypertension	BRD-A56675431-001-13-9, BRD-A56675431-001-13-9, BRD-A56675431-001-12-3	Launched
altinicline	nicotinic receptor agonist	CHRNA4, CHRNB2			BRD-K52681925-050-02-9, BRD-K52681925-050-01-6	Phase 2
altiratinib	MET inhibitor, VEGFR inhibitor	KDR, MET, TEK			BRD-K78627070-001-01-5, BRD-K78627070-001-01-5, BRD-K78627070-001-01-5, BRD-K78627070-001-01-5, BRD-K78627070-001-01-5, BRD-K78627070-001-01-5, BRD-K78627070-001-01-5	Phase 1
altrenogest	progestogen hormone	PGR	endocrinology	estrus	BRD-K50276048-001-02-9, BRD-K50276048-001-02-9	Launched
altretamine	DNA synthesis inhibitor		oncology	ovarian cancer	BRD-K67043667-001-26-4, BRD-K67043667-001-25-6	Launched
alverine	muscle relaxant	HTR1A	gastroenterology	irritable bowel syndrome, diverticular disease	BRD-K89055274-048-23-5, BRD-K89055274-048-24-9, BRD-K89055274-048-22-7	Launched
alvimopan	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	postoperative ileus	BRD-K07857022-002-02-9, BRD-K07857022-002-01-1, BRD-K07857022-002-01-1, BRD-K07857022-002-01-1	Launched
alvocidib	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM			BRD-K87909389-003-09-9, BRD-K87909389-003-09-9, BRD-K87909389-003-04-2, BRD-K87909389-003-04-2, BRD-K87909389-003-04-2, BRD-K87909389-003-03-4, BRD-K87909389-003-03-4, BRD-K87909389-003-03-4, BRD-K87909389-003-03-4	Phase 2
ALX-40-4C	CC chemokine receptor antagonist				BRD-K00003337-019-01-9	Preclinical
ALX-5407	glycine transporter inhibitor	SLC6A9			BRD-K53979406-003-03-6, BRD-K53979406-003-04-9, BRD-K53979406-003-02-8	Phase 1
AM-1241	cannabinoid receptor agonist	CNR1, CNR2			BRD-A66116161-001-02-3, BRD-A66116161-001-03-1, BRD-A66116161-001-03-1	Preclinical
AM-24	lipoxygenase inhibitor	ALOX5			BRD-K59013864-001-01-1, BRD-K59013864-001-01-1, BRD-K59013864-001-01-1	Phase 2
AM-251	cannabinoid receptor antagonist	CNR1, GPR18, GPR55			BRD-K92000912-001-14-9, BRD-K92000912-001-14-9, BRD-K92000912-001-11-8, BRD-K92000912-001-12-6	Preclinical
AM-281	cannabinoid receptor antagonist	CNR1, CNR2, GPR55			BRD-K59419204-001-03-9, BRD-K59419204-001-02-7	Preclinical
AM-404	cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist	CNR1, CNR2, FAAH, TRPV1			BRD-K55462201-001-08-9, BRD-K55462201-001-07-3, BRD-K55462201-001-07-3, BRD-K55462201-001-07-3, BRD-K55462201-001-07-3	Preclinical
AM-580	retinoid receptor agonist	RARA			BRD-K06854232-001-22-3, BRD-K06854232-001-19-9, BRD-K06854232-001-19-9, BRD-K06854232-001-19-9, BRD-K06854232-001-19-9	Preclinical
AM-630	cannabinoid receptor antagonist	CNR1, CNR2			BRD-K63533170-001-03-7, BRD-K63533170-001-03-7, BRD-K63533170-001-03-7, BRD-K63533170-001-03-7, BRD-K63533170-001-02-9, BRD-K63533170-001-02-9	Preclinical
AM-92016	potassium channel blocker	GRIN1			BRD-K01826811-003-03-9, BRD-K01826811-003-02-9, BRD-K01826811-003-02-9	Preclinical
amantadine	glutamate receptor antagonist	DRD2, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A	infectious disease, neurology/psychiatry	influenza A virus infection, Parkinson's Disease	BRD-K70330367-003-08-7, BRD-K70330367-003-08-7, BRD-K70330367-003-07-9	Launched
ambazone	DNA damage inducer				BRD-K11244467-002-01-8, BRD-K11244467-001-09-3, BRD-K11244467-001-08-5	Phase 1
ambenonium	cholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	BRD-K11292736-300-02-8, BRD-K11292736-300-02-8, BRD-K11292736-300-04-9, BRD-K11292736-300-04-9	Launched
ambrisentan	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	BRD-K41185545-001-03-9, BRD-K41185545-001-02-3	Launched
amcasertib	kinase inhibitor				BRD-K00003244-001-01-9	Phase 2
amcinonide	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-A36010170-001-04-0	Launched
AMD-3465	CC chemokine receptor antagonist	CXCR4			BRD-K03019184-439-01-0, BRD-K03019184-439-02-9, BRD-K03019184-439-02-9	Preclinical
amdinocillin	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	BRD-K41051431-001-02-4, BRD-K41051431-001-03-9	Launched
AMD11070	CC chemokine receptor antagonist	CCR5, CXCR4			BRD-K42948882-305-02-9, BRD-K42948882-305-01-1, BRD-K42948882-305-01-1	Phase 3
ameltolide	anticonvulsant				BRD-K48173020-001-02-9, BRD-K48173020-001-01-8	Preclinical
amenamevir	helicase primase inhibitor				BRD-K00004966-001-01-9, BRD-K00004966-001-01-9	Phase 1
ametantrone	anticancer agent				BRD-K00004726-001-01-9	Preclinical
amezinium	adrenergic receptor agonist	ADRB2	cardiology	hypotension	BRD-K51387999-067-01-6, BRD-K51387999-067-01-6	Launched
amfenac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-K82122102-323-01-1, BRD-K82122102-323-02-9	Launched
amflutizole	xanthine oxidase inhibitor	XDH			BRD-K50813454-001-01-9, BRD-K50813454-001-01-9, BRD-K50813454-001-01-9	Phase 2
AMG-PERK-44	PERK inhibitor	EIF2AK4			BRD-K04374714-003-02-9, BRD-K04374714-003-01-1, BRD-K04374714-003-01-1	Preclinical
AMG-176	MCL1 inhibitor				BRD-K43900408-001-02-9	Phase 1
AMG-208	tyrosine kinase inhibitor	MET			BRD-K32285926-001-02-1, BRD-K32285926-001-03-9	Phase 1
AMG-232	MDM inhibitor	MDM2			BRD-K64925568-001-01-8, BRD-K64925568-001-01-8, BRD-K64925568-001-01-8, BRD-K64925568-001-01-8, BRD-K64925568-001-01-8, BRD-K64925568-001-01-8, BRD-K64925568-001-02-6, BRD-K64925568-001-02-6, BRD-K64925568-001-02-6	Phase 2
AMG-319	PI3K inhibitor	PIK3CD			BRD-K21077415-001-01-5	Phase 2
AMG-337	MET inhibitor	MET			BRD-K27061362-001-01-6, BRD-K27061362-001-01-6, BRD-K27061362-001-01-6	Phase 2
AMG-487	CC chemokine receptor antagonist				BRD-K90239174-001-01-8, BRD-K90239174-001-01-8, BRD-K90239174-001-01-8, BRD-K90239174-001-02-9	Phase 2
AMG-487-(+/-)	CC chemokine receptor antagonist	CXCR3			BRD-A01307728-001-02-9, BRD-A01307728-001-01-4, BRD-A01307728-001-01-4	Phase 2
AMG-510	K-Ras inhibitor				BRD-K00010385-001-01-9, BRD-K00010385-001-01-9	Phase 1/Phase 2
AMG-517	TRPV antagonist	TRPV1			BRD-K34185671-001-03-9, BRD-K34185671-001-03-9, BRD-K34185671-001-02-8, BRD-K34185671-001-02-8	Phase 1
AMG-548	MAP kinase inhibitor	MAPK11, MAPK12, MAPK13, MAPK14			BRD-K86673452-001-01-7, BRD-K86673452-001-01-7, BRD-K86673452-001-02-5	Phase 1
AMG-925	CDK inhibitor, FLT3 inhibitor	CDK4, CDK6, FLT3			BRD-K97452254-001-01-3, BRD-K97452254-001-01-3, BRD-K97452254-001-01-3, BRD-K97452254-001-01-3	Phase 1
AMG-9810	TRPV antagonist	TRPV1			BRD-K01995783-001-02-4, BRD-K01995783-001-01-6, BRD-K01995783-001-01-6, BRD-K01995783-001-01-6, BRD-K01995783-001-03-9	Preclinical
AMG319	PI3K inhibitor	PIK3CD			BRD-A58947127-001-01-6	Phase 2
AMG458	MET inhibitor	MET			BRD-K21782625-001-02-4, BRD-K21782625-001-03-2, BRD-K21782625-001-04-0	Preclinical
AMG900	Aurora kinase inhibitor	AURKA, AURKB, AURKC			BRD-K21728777-001-03-9, BRD-K21728777-001-02-3, BRD-K21728777-001-02-3, BRD-K21728777-001-02-3, BRD-K21728777-001-02-3	Phase 1
AMI-1	protein arginine N-methyltransferase inhibitor	PRMT1			BRD-K75114721-304-02-6	Preclinical
amibegron	adrenergic receptor agonist	ADRB3			BRD-K24610819-003-02-6, BRD-K24610819-003-01-8, BRD-K24610819-003-01-8	Phase 3
amidopyrine	analgesic agent		dermatology	dermatitis herpetiformis (DH)	BRD-K12568846-001-17-9, BRD-K12568846-001-15-3, BRD-K12568846-001-14-6, BRD-K12568846-001-16-1, BRD-K12568846-001-16-1	Launched
amifampridine	potassium channel blocker		neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	BRD-K80262108-001-07-0, BRD-K80262108-001-08-9	Launched
amiflamine	monoamine oxidase inhibitor	MAOA, SLC6A2			BRD-A19401019-001-01-3, BRD-A19401019-001-01-3	Phase 1
amifostine	reducing agent	ALPPL2, ENPP1	nephrology	renal toxicity	BRD-K73947551-001-04-4	Launched
amiloride	sodium channel blocker	AOC1, ASIC1, ASIC2, ASIC3, PKD2, PKD2L1, PLAU, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC9A1, TRPC7, TRPV2	cardiology	hypertension, congestive heart failure	BRD-K97181089-003-24-7, BRD-K97181089-003-25-9, BRD-K97181089-003-25-9, BRD-K97181089-003-25-9, BRD-K97181089-310-06-3, BRD-K97181089-003-22-1, BRD-K97181089-003-23-9	Launched
amineptine	dopamine receptor agonist	SLC6A2, SLC6A4			BRD-K24219278-001-01-6, BRD-K24219278-001-02-9, BRD-K24219278-001-02-9	Withdrawn
aminocaproic-acid	plasminogen activator inhibitor	LPA, PLAT, PLG	hematology	fibrinolytic bleeding	BRD-K64931368-003-01-4, BRD-K64931368-001-14-1, BRD-K64931368-001-13-3	Launched
aminoglutethimide	glucocorticoid receptor antagonist	CYP11A1, CYP19A1	endocrinology, oncology	Cushing's syndrome, breast cancer	BRD-A25234499-001-18-3, BRD-A25234499-001-19-1, BRD-A25234499-001-19-1, BRD-A25234499-001-17-5, BRD-A25234499-001-21-9	Launched
aminoguanidine	nitric oxide synthase inhibitor	AKR1B1, NOS2, TIMP3			BRD-K25114078-003-08-1, BRD-K25114078-003-10-9, BRD-K25114078-003-07-3	Phase 3
aminohydroxybutyric-acid			neurology/psychiatry	epilepsy	BRD-A40777960-001-04-2, BRD-A40777960-001-05-9	Launched
aminolevulinic-acid-benzyl-ester					BRD-K59998349-003-01-4	Phase 1
aminomethyltransferase	nitric oxide synthase inhibitor	NOS2			BRD-A28318179-003-09-9, BRD-A28318179-003-08-5, BRD-A28318179-003-08-5	Preclinical
aminopentamide	acetylcholine receptor antagonist	CHRM1	gastroenterology	acute abdominal visceral spasm, hypertrophic gastritis (GHG), nausea	BRD-A69917777-065-02-2	Launched
aminopurvalanol-a	CDK inhibitor, tyrosine kinase inhibitor	CDK1, CDK2, CDK5			BRD-K07762753-001-06-9, BRD-K07762753-001-05-1, BRD-K07762753-001-04-4	Preclinical
aminothiadiazole	inosine monophosphate dehydrogenase inhibitor	ADORA3, IMPDH1			BRD-K94837153-001-02-8, BRD-K94837153-001-01-0	Phase 2
aminothiazole	cyclin D inhibitor	NOS2			BRD-K13421763-001-06-2, BRD-K13421763-001-05-4, BRD-K13421763-001-07-0	Preclinical
amiodarone	potassium channel blocker	ADRB1, CACNA1H, CACNA2D2, KCNA7, KCNH2	cardiology	ventricular arrhythmias	BRD-K17561142-003-33-3, BRD-K17561142-003-35-8, BRD-K17561142-003-35-8, BRD-K17561142-003-35-8, BRD-K17561142-003-35-8, BRD-K17561142-003-32-5, BRD-K17561142-003-32-5, BRD-K17561142-003-32-5	Launched
amiprilose	CD antagonist				BRD-K97643133-003-09-3	Phase 3
amiselimod	sphingosine 1-phosphate receptor modulator				BRD-K00003223-003-01-9	Phase 2
amisulpride	dopamine receptor antagonist	DRD2	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia	BRD-A60197193-001-13-8, BRD-A60197193-001-14-6	Launched
amitifadine	serotonin transporter (SERT) inhibitor	SLC6A2, SLC6A3, SLC6A4			BRD-A68942014-003-01-7, BRD-A68942014-003-01-7	Phase 3
amitraz	adrenergic receptor agonist	ADRA1A, ADRA2A	infectious disease	generalized demodicosis	BRD-K33335792-001-04-0, BRD-K33335792-001-05-9	Launched
amitriptyline	norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotoninâ€“norepinephrine reuptake inhibitor (SNRI)	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7, KCNA1, KCND2, KCND3, KCNQ2, KCNQ3, NTRK1, NTRK2, OPRD1, OPRK1, OPRM1, SIGMAR1, SLC6A2, SLC6A4	neurology/psychiatry	depression	BRD-K53737926-003-27-8, BRD-K53737926-003-25-2	Launched
amlexanox	histamine receptor modulator	FGF1, IL3, PDE4A, PDE4B, PDE4C, PDE4D, S100A12, S100A13	dental, pulmonary, ophthalmology, allergy	aphthous ulcers, asthma, conjunctivitis, allergic rhinitis	BRD-K29530284-001-08-9, BRD-K29530284-001-08-9, BRD-K29530284-001-06-2, BRD-K29530284-001-07-0	Launched
amlodipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNA2D1	cardiology	hypertension, chronic stable angina, vasospastic angina, coronary artery disease (CAD)	BRD-K01825117-074-11-9, BRD-K01825117-001-06-9, BRD-K01825117-001-06-9, BRD-K01825117-001-07-9	Launched
ammonium-glycyrrhizinate	thrombin inhibitor	HSD11B1, HSD11B2, SLCO1B1, SLCO1B3	dermatology	cosmetic	BRD-K83486494-001-02-9	Launched
ammonium-lactate		HCAR1	dermatology	xerosis cutis, ichthyosis vulgaris	BRD-M29182745-001-01-4, BRD-M29182745-001-02-2	Launched
ammonium-perfluorocaprylate	Pim kinase inhibitor	PIM1			BRD-K32531356-001-03-9, BRD-K32531356-001-01-9	Phase 1
AMN-082	glutamate receptor modulator	GRM7			BRD-K23335153-300-03-3, BRD-K23335153-300-02-5, BRD-K23335153-300-08-9, BRD-K23335153-300-08-9	Preclinical
amonafide	topoisomerase inhibitor	TOP2A, TOP2B			BRD-K56334280-001-05-1, BRD-K56334280-001-05-1	Phase 3
amorolfine	membrane integrity inhibitor		infectious disease	onychomycosis	BRD-A37390343-003-03-5, BRD-A37390343-003-03-5, BRD-A37390343-003-02-7, BRD-A37390343-003-04-3	Launched
amoxapine	norepinephrine reputake inhibitor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH4, HTR1A, HTR1B, HTR2A, HTR2B, HTR2C, HTR3A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	BRD-K02265150-001-26-5, BRD-K02265150-001-25-7, BRD-K02265150-001-27-3	Launched
AMPA-(RS)	glutamate receptor agonist	GRIN1			BRD-K01826817-001-04-9, BRD-K01826817-004-03-9	Preclinical
AMPA-(S)	glutamate receptor agonist	GRIA2, GRIN1			BRD-K92493880-001-03-0, BRD-K92493880-001-04-9, BRD-K92493880-001-04-9	Preclinical
ampalex	glutamate receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4			BRD-K24771047-001-02-9, BRD-K24771047-001-02-9, BRD-K24771047-001-01-6, BRD-K24771047-001-01-6	Phase 2
amperozide	dopamine receptor antagonist	FAAH, HTR2A	neurology/psychiatry	psychosis	BRD-K52397688-003-06-4, BRD-K52397688-003-06-4, BRD-K52397688-003-07-2	Launched
ampiroxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-A39172021-001-14-5, BRD-A39172021-001-13-7, BRD-A39172021-001-10-3, BRD-A39172021-001-09-5, BRD-A39172021-001-11-1	Launched
amprenavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K47827687-001-02-2, BRD-K47827687-001-02-2, BRD-K47827687-001-04-9	Launched
amprolium	thiamine uptake blocker		infectious disease	coccidiosis	BRD-K90027121-300-14-9, BRD-K90027121-300-13-2, BRD-K90027121-003-01-7	Launched
ampyrone	cyclooxygenase inhibitor				BRD-K20484910-001-16-9, BRD-K20484910-001-14-7	Preclinical
amrinone	phosphodiesterase inhibitor	PDE3A, PDE3B, PDE4B, TNF	cardiology	congestive heart failure	BRD-K45924332-001-16-8, BRD-K45924332-001-16-8, BRD-K45924332-001-24-9, BRD-K45924332-001-24-9, BRD-K45924332-001-24-9	Launched
amrubicin	topoisomerase inhibitor	TOP2A, TOP2B	oncology	small cell lung cancer	BRD-K13843533-001-02-5, BRD-K13843533-001-01-7, BRD-K13843533-001-01-7	Launched
amthamine	histamine receptor agonist	HRH2			BRD-K39670393-303-03-9, BRD-K39670393-303-02-1	Preclinical
amtolmetin-guacil	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	BRD-K70924353-001-01-2, BRD-K70924353-001-01-2, BRD-K70924353-001-01-2	Launched
amuvatinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor	KIT, MET			BRD-K66538826-001-07-2, BRD-K66538826-001-07-2, BRD-K66538826-001-07-2, BRD-K66538826-001-07-2, BRD-K66538826-001-07-2, BRD-K66538826-001-07-2, BRD-K66538826-001-01-5, BRD-K66538826-001-01-5	Phase 2
amyl-nitrite	atrial natriuretic peptide receptor agonist				BRD-K03326591-001-01-4	Preclinical
amyleine	local anesthetic				BRD-A09062839-003-10-0, BRD-A09062839-003-10-0, BRD-A09062839-003-10-0, BRD-A09062839-003-11-9	Preclinical
amylene-hydrate	local anesthetic				BRD-K93502141-001-02-4, BRD-K93502141-001-01-6	Preclinical
AMZ30	protein phosphatase inhibitor				BRD-K00256256-001-06-1	Preclinical
AM095	lysophosphatidic acid receptor antagonist				BRD-K23952234-236-03-4, BRD-K23952234-236-02-6, BRD-K23952234-236-02-6, BRD-K23952234-236-02-6, BRD-K23952234-236-02-6, BRD-K23952234-236-02-6, BRD-K23952234-236-02-6, BRD-K23952234-236-02-6, BRD-K23952234-236-02-6, BRD-K23952234-236-01-8	Preclinical
AM211	prostaglandin inhibitor				BRD-K00003152-001-01-9	Preclinical
AM679	cannabinoid receptor agonist, lipoxygenase inhibitor	ALOX5AP, CNR1, CNR2			BRD-K88443722-001-01-7	Preclinical
ANA-12	tropomyosin receptor kinase inhibitor	NTRK2			BRD-A19609491-001-02-9, BRD-A19609491-001-01-8	Preclinical
anabasine	acetylcholine receptor agonist				BRD-K01826509-001-09-9	Preclinical
anacetrapib	cholesteryl ester transfer protein inhibitor	CETP			BRD-K77118600-001-02-9	Phase 3
anagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	BRD-K05355328-001-02-9, BRD-K05355328-001-01-1	Launched
anagrelide	phosphodiesterase inhibitor	PDE3A	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms	BRD-K62200014-003-11-3, BRD-K62200014-003-11-3, BRD-K62200014-003-11-3, BRD-K62200014-001-02-6, BRD-K62200014-001-02-6, BRD-K62200014-001-02-6, BRD-K62200014-003-10-5, BRD-K62200014-003-10-5	Launched
anamorelin	growth hormone secretagogue receptor agonist	GHSR			BRD-K01174345-001-01-9, BRD-K01174345-001-02-9	Phase 3
anandamide	cannabinoid receptor agonist	CACNA1G, CACNA1H, CACNA1I, CNR1, CNR2, GLRA1, GPR18, GPR55, KCNA2, KCNK3, KCNK9, TRPM8, TRPV1			BRD-K42352790-001-05-3, BRD-K42352790-001-05-3, BRD-K42352790-001-05-3, BRD-K42352790-001-05-3, BRD-K42352790-001-11-9	Phase 2
anastrozole	aromatase inhibitor	CYP19A1	oncology	breast cancer	BRD-K52172416-001-14-8, BRD-K52172416-001-11-4, BRD-K52172416-001-10-6	Launched
andarine	androgen receptor modulator	AR			BRD-K82164249-001-03-5, BRD-K82164249-001-03-5, BRD-K82164249-001-03-5, BRD-K82164249-001-04-9	Phase 1
andrographolide	tumor necrosis factor production inhibitor	IL1B, IL6, NFKB1, NFKB2, TNF			BRD-K89282837-001-04-9	Phase 2
androstenone	steroid				BRD-A64011898-001-01-0, BRD-A64011898-001-01-0, BRD-A64011898-001-01-0	Preclinical
androsterone	androgen receptor agonist				BRD-K12329651-001-19-9, BRD-K12329651-001-18-8, BRD-K12329651-001-18-8	Preclinical
anecortave-acetate	angiogenesis inhibitor		ophthalmology	macular degeneration	BRD-K00005346-001-01-9	Launched
anethole	glutathione transferase stimulant				BRD-K49060658-001-08-0, BRD-K49060658-001-05-6, BRD-K49060658-001-07-2	Launched
anethole-trithione	glutathione transferase stimulant		dental	xerostomia	BRD-K92490248-001-04-1, BRD-K92490248-001-06-6, BRD-K92490248-001-06-6	Launched
anguidine	protein synthesis inhibitor	SLC5A1			BRD-K45724504-001-01-6, BRD-K45724504-001-01-6, BRD-K45724504-001-01-6, BRD-K45724504-001-01-6	Phase 2
anidulafungin	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, fungal infection, esophageal candidiasis	BRD-K00003560-001-01-9	Launched
aniracetam	glutamate receptor agonist	DRD2, GRIA1, GRIA2, GRIA3, GRIA4, HTR2A			BRD-K88611939-001-25-7, BRD-K88611939-001-26-9, BRD-K88611939-001-26-9, BRD-K88611939-001-23-2, BRD-K88611939-001-22-4	Launched
anisindione	vitamin K antagonist	GGCX	hematology	deep vein thrombosis (DVT)	BRD-K47458712-001-22-3, BRD-K47458712-001-17-3, BRD-K47458712-001-20-7, BRD-K47458712-001-20-7, BRD-K47458712-001-21-5, BRD-K47458712-001-18-1, BRD-K47458712-001-19-9	Launched
anisodamine	lipid peroxidase inhibitor	ADRA1A			BRD-A29623586-001-01-3, BRD-A29623586-001-01-3	Phase 3
anisomycin	DNA synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			BRD-K91370081-001-25-1, BRD-K91370081-001-25-1, BRD-K91370081-001-26-9, BRD-K91370081-001-26-9, BRD-K91370081-001-26-9	Preclinical
anisotropine	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	BRD-K71125570-004-15-6	Launched
anlotinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR, PDGFRB			BRD-K36949735-001-02-9, BRD-K36949735-001-01-1, BRD-K36949735-001-01-1, BRD-K36949735-001-01-1, BRD-K36949735-001-01-1	Launched
anpirtoline	serotonin receptor agonist	HTR1B			BRD-K55424922-003-03-6, BRD-K55424922-003-03-6, BRD-K55424922-003-04-9, BRD-K55424922-003-04-9, BRD-K55424922-003-02-8	Phase 1
ANR-94	adenosine receptor antagonist	ADORA2A			BRD-K31170746-001-01-6, BRD-K31170746-001-03-9	Preclinical
ansamitocin-p-3	apoptosis stimulant				BRD-K00003196-001-01-9	Preclinical
antagonist-g	neuropeptide receptor antagonist	MAPK8			BRD-K25863791-001-01-8, BRD-K25863791-001-01-8	Phase 1
antalarmin	corticotropin releasing factor receptor antagonist	CRHR1			BRD-K01363385-003-01-5, BRD-K01363385-003-01-5, BRD-K01363385-003-02-9	Preclinical
antazoline	antihistamine	HRH1	ophthalmology, otolaryngology	conjunctivitis, nasal congestion	BRD-K99300445-001-01-2, BRD-K99300445-003-22-9, BRD-K99300445-003-21-6, BRD-K99300445-003-20-8	Launched
anthralin	DNA synthesis inhibitor		dermatology	psoriasis	BRD-K04725460-001-12-1, BRD-K04725460-001-12-1, BRD-K04725460-001-10-5, BRD-K04725460-001-11-3	Launched
anthraquinone	CDC inhibitor	CDC25B			BRD-K15957397-001-05-9, BRD-K15957397-001-04-2	Preclinical
antimony-potassium					BRD-K00003675-409-01-9	Phase 2
antimycin-A	ATP synthase inhibitor	CYCS			BRD-K90152265-001-01-3	Preclinical
antioxine					BRD-K15541734-001-02-0, BRD-K15541734-001-01-2	Launched
AN2718	leucyl-tRNA synthetase inhibitor				BRD-K21920947-001-02-1, BRD-K21920947-001-01-3	Phase 1
AP-18	transient receptor potential channel antagonist	TRPA1			BRD-K32143970-001-01-9, BRD-K32143970-001-02-9	Preclinical
apabetalone	apolipoprotein expression enhancer	BRD3			BRD-K20001883-001-02-7, BRD-K20001883-001-02-7	Phase 3
apafant	platelet activating factor receptor antagonist	PTAFR			BRD-K28115081-001-03-5, BRD-K28115081-001-02-7, BRD-K28115081-001-04-9	Phase 3
apalutamide	androgen receptor antagonist		oncology	prostate cancer	BRD-K91308639-001-02-7, BRD-K91308639-001-02-7, BRD-K91308639-001-02-7, BRD-K91308639-001-04-9	Launched
apararenone	mineralocorticoid receptor antagonist				BRD-K00003492-001-01-9	Preclinical
apatinib	RET tyrosine kinase inhibitor	CSK, KDR, KIT, RET			BRD-K25244359-066-02-6, BRD-K25244359-066-03-4, BRD-K25244359-066-04-9	Phase 3
APC-100	androgen receptor antagonist, anti-inflammatory agent	AR			BRD-K07449869-001-01-5, BRD-K07449869-001-01-5	Phase 1/Phase 2
APcK-110	KIT inhibitor	KIT, STAT3			BRD-K72748448-001-01-0, BRD-K72748448-001-01-0, BRD-K72748448-001-02-9	Preclinical
APD597	glucose dependent insulinotropic receptor agonist	GPR119			BRD-K86226872-001-01-6	Phase 1
APD668	glucose dependent insulinotropic receptor agonist	GPR119			BRD-K10859802-001-01-0, BRD-K10859802-001-02-9	Phase 1
aphidicolin	RNA synthesis inhibitor				BRD-K85140930-001-12-7, BRD-K85140930-001-12-7, BRD-K85140930-001-13-9	Phase 1
API-001	sigma receptor antagonist	SIGMAR1			BRD-K26325692-003-02-9, BRD-K26325692-003-01-3, BRD-K26325692-003-01-3	Phase 2
API-1	AKT inhibitor	AKT1, AKT2, AKT3			BRD-K97840621-001-01-5, BRD-K97840621-001-01-5, BRD-K97840621-001-02-9	Preclinical
apigenin	casein kinase inhibitor, cell proliferation inhibitor	AKR1B1, AR, CDK6, CFTR, CYP19A1, CYP1B1, HSD17B1			BRD-K01493881-001-29-4, BRD-K01493881-001-29-4, BRD-K01493881-001-29-4, BRD-K01493881-001-28-6	Preclinical
apixaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, pulmonary embolism (PE), atrial fibrillation (AF), deep vein thrombosis (DVT)	BRD-K67121414-001-04-9, BRD-K67121414-001-04-9, BRD-K67121414-001-02-5, BRD-K67121414-001-03-3	Launched
apocynin	NADPH oxidase inhibitor	NOX4			BRD-K64990520-001-11-9, BRD-K64990520-001-12-9, BRD-K64990520-001-08-4, BRD-K64990520-001-08-4	Phase 1
apoptosis-activator-II	carboxylesterase inhibitor	BCHE, CES1			BRD-K15164005-001-06-4, BRD-K15164005-001-08-9, BRD-K15164005-001-04-9, BRD-K15164005-001-05-6	Preclinical
APR-246	p53 activator	TP53			BRD-A09004963-001-01-3	Phase 3
apraclonidine	adrenergic receptor agonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C	ophthalmology	glaucoma, intraocular pressure	BRD-K38911213-003-01-6	Launched
apramycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	BRD-K96737756-065-02-9	Launched
apratastat	matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor	ADAM17, MMP1, MMP13, MMP9			BRD-K06883221-001-02-9, BRD-K06883221-001-01-9, BRD-K06883221-001-01-9, BRD-K06883221-001-01-9	Phase 2
apremilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	dermatology, rheumatology	psoriasis, psoriatic arthritis	BRD-K93208532-001-02-5, BRD-K93208532-001-02-5, BRD-K93208532-001-02-5, BRD-K93208532-001-05-9	Launched
aprepitant	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	BRD-K52827117-001-04-9	Launched
apricitabine	nucleoside reverse transcriptase inhibitor				BRD-K55172746-001-01-3	Phase 3
aprindine	voltage-gated sodium channel blocker	CALM1, SCN5A	cardiology	cardiac arrythmia	BRD-K53236343-003-03-7, BRD-K53236343-003-03-7	Launched
apronal	cytochrome P450 modulator				BRD-K00003524-001-01-9	Preclinical
aptiganel	glutamate receptor antagonist	GRIN1			BRD-K63919159-003-08-8, BRD-K63919159-003-07-0, BRD-K63919159-003-07-0	Phase 3
APTO-253	krÃ¼ppel-like factor expression enhancer	KLF4			BRD-K68003372-001-01-6, BRD-K68003372-001-01-6, BRD-K68003372-001-01-6, BRD-K68003372-001-01-6	Phase 1
APY-29	serine/threonine kinase inhibitor	ERN1			BRD-K17511755-001-02-9, BRD-K17511755-001-02-9, BRD-K17511755-001-01-7	Preclinical
apyramide	cyclooxygenase inhibitor				BRD-K00004738-001-01-9	Preclinical
APY0201	phosphoinositide dependent kinase inhibitor	IL12A, IL12B, PIKFYVE			BRD-K38627885-001-01-9, BRD-K38627885-001-01-9, BRD-K38627885-001-01-9	Preclinical
AP1903		MTOR			BRD-K28383148-001-01-4, BRD-K28383148-001-02-9	Phase 1/Phase 2
AP26113	ALK tyrosine kinase receptor inhibitor	ALK, EGFR			BRD-K56032964-001-02-1, BRD-K56032964-001-02-1, BRD-K56032964-001-02-1, BRD-K56032964-001-02-1, BRD-K56032964-001-01-3	Phase 2
AQ-RA741	acetylcholine receptor antagonist	CHRM2			BRD-K81729199-001-03-6, BRD-K81729199-001-02-8, BRD-K81729199-001-04-9	Preclinical
AQ-13	antimalarial agent				BRD-K00003365-300-01-9	Phase 2
AQW-051	nicotinic receptor agonist				BRD-K00004705-001-01-9	Preclinical
AR-A014418	glycogen synthase kinase inhibitor	GSK3B			BRD-K67860401-001-07-2, BRD-K67860401-001-05-6, BRD-K67860401-001-05-6, BRD-K67860401-001-05-6, BRD-K67860401-001-05-6	Preclinical
AR-C155858	monocarboxylate transporter inhibitor	SLC16A1, SLC16A7			BRD-K42325600-001-02-9, BRD-K42325600-001-01-8	Preclinical
AR-12	phosphoinositide dependent kinase inhibitor	PDPK1			BRD-K90497590-001-08-3, BRD-K90497590-001-05-9, BRD-K90497590-001-07-5, BRD-K90497590-001-04-2	Phase 1
AR-42	HDAC inhibitor	HDAC1			BRD-K13167095-001-03-9, BRD-K13167095-001-03-9, BRD-K13167095-001-02-9	Phase 1
arachidonic-acid	cytochrome P450 inhibitor	CLCN2, KCNJ4, KCNK10, KCNK18, KCNK2, PRKCZ, PTGS1, TRPC6, TRPM2			BRD-K03070961-001-10-1, BRD-K03070961-001-08-5	Phase 1
aramchol	stearoyl-CoA desaturase inhibitor				BRD-K00004646-001-01-9	Phase 2/Phase 3
arbidol	cytochrome P450 inhibitor	CYP3A4	infectious disease	influenza A virus infection	BRD-K73881242-003-06-1, BRD-K73881242-003-02-0, BRD-K73881242-003-04-6, BRD-K73881242-003-03-8	Launched
arbutin	melanin inhibitor	TYR			BRD-K08037784-001-13-9, BRD-K08037784-001-12-6	Phase 2/Phase 3
ARC-239	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C			BRD-K93188295-300-03-9, BRD-K93188295-300-02-2	Preclinical
arctigenin	MEK inhibitor	CHUK, MAP2K1			BRD-K53523901-001-05-1, BRD-K53523901-001-04-4	Preclinical
arcyriaflavin-a	CDK inhibitor	CCND1, CDK4			BRD-K72726508-001-02-1, BRD-K72726508-001-02-1, BRD-K72726508-001-02-1, BRD-K72726508-001-02-1, BRD-K72726508-001-02-1, BRD-K72726508-001-06-9, BRD-K72726508-001-06-9, BRD-K72726508-001-03-9, BRD-K72726508-001-03-9	Preclinical
ardeparin	thrombin inhibitor	SERPIND1			BRD-K00003590-314-01-9	Withdrawn
arecaidine-but-2-ynyl-ester	acetylcholine receptor agonist	CHRM2			BRD-K63792901-075-02-1	Preclinical
arecaidine-propargyl-ester	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			BRD-K23922020-075-03-7, BRD-K23922020-075-03-7, BRD-K23922020-075-03-7, BRD-K23922020-075-03-7, BRD-K23922020-075-02-9, BRD-K23922020-075-02-9	Preclinical
arecoline	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			BRD-K88646909-004-17-9, BRD-K88646909-004-15-4, BRD-K88646909-004-16-2	Phase 1
argireline	neurotransmitter release inhibitor				BRD-K00003332-001-01-9	Phase 3
arglabin	farnesyltransferase inhibitor	FNTA, NFKB1			BRD-K62734952-001-01-0, BRD-K62734952-001-01-0, BRD-K62734952-001-01-0, BRD-K62734952-001-01-0, BRD-K62734952-001-01-0, BRD-K62734952-001-02-9	Launched
aripiprazole	serotonin receptor agonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7	neurology/psychiatry	depression, schizophrenia, bipolar disorder	BRD-K70358946-001-17-3, BRD-K70358946-001-15-7, BRD-K70358946-001-14-0	Launched
aripiprazole-lauroxil	serotonin receptor agonist		neurology/psychiatry	schizophrenia	BRD-K00004574-001-01-9	Launched
arofylline	phosphodiesterase inhibitor	PDE4A			BRD-K33852358-001-09-9, BRD-K33852358-001-09-9	Phase 3
arotinolol	adrenergic receptor antagonist	ADRB3	cardiology, neurology/psychiatry	hypertension, tremors	BRD-A28044053-001-01-7, BRD-A28044053-001-01-7	Launched
ARQ-092	AKT inhibitor	AKT2			BRD-K60171656-001-01-6, BRD-K60171656-001-01-6	Phase 1
ARQ-621	kinesin-like spindle protein inhibitor	KIF11			BRD-K43436647-001-01-7, BRD-K43436647-001-01-7, BRD-K43436647-001-02-5	Phase 1
ARRY-334543	EGFR inhibitor	ERBB2			BRD-K46386702-001-03-9, BRD-K46386702-001-02-1, BRD-K46386702-001-02-1	Phase 2/Phase 3
arsanilic-acid		LYZ			BRD-K24179883-001-17-9, BRD-K24179883-001-16-7	Phase 1
arsenic-trioxide	apoptosis stimulant	AKT1, CCND1, IKBKB, JUN, MAPK1, MAPK3, TXNRD1	gastroenterology	diarrhea	BRD-K32786395-001-01-2	Launched
artemotil			infectious disease	malaria	BRD-K96006160-001-03-7, BRD-K96006160-001-01-1, BRD-K96006160-001-02-9	Launched
articaine	local anesthetic		neurology/psychiatry	local anesthetic	BRD-A70514680-003-12-9, BRD-A70514680-003-11-2	Launched
arundic-acid	astrocyte modulating agent	PTGS2, S100B			BRD-K49223707-001-01-0	Phase 2/Phase 3
ARV-825	bromodomain inhibitor	BRD4			BRD-A00047421-001-01-7, BRD-A00047421-001-01-7	Preclinical
AS-1269574	glucose dependent insulinotropic receptor agonist	GPR119			BRD-K07656463-001-01-5, BRD-K07656463-001-01-5, BRD-K07656463-001-02-9, BRD-K07656463-001-02-9	Preclinical
AS-1892802	rho associated kinase inhibitor	ROCK1			BRD-K27051047-001-02-9, BRD-K27051047-001-02-9, BRD-K27051047-001-02-9, BRD-K27051047-001-01-0, BRD-K27051047-001-01-0	Preclinical
AS-1949490	SHIP2 phosphatase inhibitor	INPP5D			BRD-K61936403-001-02-5, BRD-K61936403-001-02-5, BRD-K61936403-001-01-7, BRD-K61936403-001-01-7	Preclinical
AS-2034178	free fatty acid receptor agonist	FFAR1			BRD-K75254015-001-02-9, BRD-K75254015-001-01-9, BRD-K75254015-001-01-9	Preclinical
AS-2444697	interleukin inhibitor	IRAK4			BRD-K73565918-003-01-4, BRD-K73565918-003-01-4, BRD-K73565918-003-02-9, BRD-K73565918-003-02-9, BRD-K73565918-003-02-9	Preclinical
AS-252424	PI3K inhibitor	PIK3CG			BRD-K14988953-001-04-4, BRD-K14988953-001-04-4, BRD-K14988953-001-03-6	Preclinical
AS-604850	PI3K inhibitor	PIK3CA, PIK3CG			BRD-K63915849-001-03-7	Preclinical
AS-703026	MEK inhibitor	MAP2K1, MAP2K2			BRD-K89014967-001-05-9, BRD-K89014967-001-05-9, BRD-K89014967-001-05-9, BRD-K89014967-001-04-3, BRD-K89014967-001-04-3, BRD-K89014967-001-04-3, BRD-K89014967-001-04-3	Phase 2
AS-77	potassium channel blocker	KCNA3, KCNA5, KCNN4			BRD-K62427771-001-02-9, BRD-K62427771-001-01-0, BRD-K62427771-001-01-0	Phase 1
ASA-404	angiogenesis inhibitor				BRD-K27938825-001-04-9, BRD-K27938825-001-02-4	Phase 3
asapiprant	prostaglandin inhibitor				BRD-K00003230-001-01-9	Preclinical
asaraldehyde	cyclooxygenase inhibitor	PTGS2			BRD-K88219015-001-11-9, BRD-K88219015-001-10-8	Preclinical
ASC-J9	androgen receptor enhancer	AR			BRD-K30331124-001-04-9, BRD-K30331124-001-01-7, BRD-K30331124-001-03-3, BRD-K30331124-001-02-5	Phase 2
asciminib	Bcr-Abl kinase inhibitor				BRD-K00003456-001-01-9	Phase 2
ascomycin	calcineurin inhibitor	FKBP1A			BRD-K88882192-001-03-3	Preclinical
asenapine	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A	neurology/psychiatry	schizophrenia, bipolar disorder	BRD-K00003551-050-01-9, BRD-K00003551-050-02-9	Launched
asimadoline	opioid receptor agonist	OPRK1			BRD-K00003477-001-01-9	Phase 3
asivatrep	transient receptor potential channel antagonist				BRD-K00003138-001-01-9	Phase 3
ASP-2535	glycine transporter inhibitor	SLC6A9			BRD-K07150325-001-02-5, BRD-K07150325-001-01-7	Phase 1
ASP-6537	cyclooxygenase inhibitor				BRD-K82239282-001-02-9	Preclinical
ASP-9521	aldo-keto reductase inhibitor				BRD-K00003301-001-01-9	Preclinical
aspartame		TAS1R2, TRPV1			BRD-K78841970-001-12-0, BRD-K78841970-001-14-6, BRD-K78841970-001-13-8, BRD-K78841970-001-13-8, BRD-K78841970-001-11-2	Launched
aspirin	cyclooxygenase inhibitor	AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain	BRD-K11433652-001-23-8, BRD-K11433652-001-17-0, BRD-K11433652-001-17-0, BRD-K11433652-001-16-2, BRD-K11433652-001-18-8	Launched
ASP3026	ALK tyrosine kinase receptor inhibitor	ALK			BRD-K06542892-001-03-9, BRD-K06542892-001-02-7, BRD-K06542892-001-01-9, BRD-K06542892-001-01-9, BRD-K06542892-001-01-9, BRD-K06542892-001-01-9	Phase 1
AST-1306	EGFR inhibitor	EGFR, ERBB2			BRD-K26838195-075-05-9, BRD-K26838195-075-04-9, BRD-K26838195-075-04-9, BRD-K26838195-075-04-9	Phase 1
astaxanthin	antioxidant				BRD-K51832961-001-01-4	Launched
astemizole	histamine receptor antagonist	HRH1, KCNH1, KCNH2			BRD-K37249724-001-25-7, BRD-K37249724-001-28-1, BRD-K37249724-001-28-1, BRD-K37249724-001-24-0	Withdrawn
astilbin	nuclear factor erythroid derived, like (NRF2) activator				BRD-K44845912-001-02-9	Preclinical
ASTX660	apoptosis inhibitor				BRD-K00003508-001-01-9	Phase 1/Phase 2
asunaprevir	HCV inhibitor				BRD-K87028197-001-01-3, BRD-K87028197-001-01-3, BRD-K87028197-001-01-3, BRD-K87028197-001-01-3, BRD-K87028197-001-02-9, BRD-K87028197-001-02-9	Phase 3
asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	NOS2, NOS3			BRD-K36269323-300-02-6, BRD-K36269323-300-02-6	Phase 1
AT-1015	serotonin receptor antagonist	HTR2A			BRD-K06496777-003-02-9, BRD-K06496777-003-01-4	Preclinical
AT-406	IAP antagonist 				BRD-K83030136-001-02-9	Phase 1
AT-7519	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK6, CDK9			BRD-K13390322-001-07-9, BRD-K13390322-001-06-3, BRD-K13390322-001-06-3, BRD-K13390322-001-06-3, BRD-K13390322-001-06-3, BRD-K13390322-001-06-3, BRD-K13390322-001-06-3	Phase 2
AT-9283	Aurora kinase inhibitor, JAK inhibitor	AURKA, AURKB, JAK2, JAK3, RPS6KA6, STK17A			BRD-K24576554-001-04-8, BRD-K24576554-001-04-8, BRD-K24576554-001-04-8, BRD-K24576554-001-04-8, BRD-K24576554-001-04-8, BRD-K24576554-001-05-5, BRD-K24576554-001-05-5, BRD-K24576554-001-05-5	Phase 2
ataluren	CFTR channel agonist, dystrophin stimulant	DMD	genetics, pulmonary	duchenne muscular dystrophy (DMD), cystic fibrosis	BRD-K94830329-001-04-9, BRD-K94830329-001-03-0	Launched
atazanavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K09757388-065-05-9, BRD-K09757388-065-04-0, BRD-K09757388-065-04-0	Launched
ATB-346	cyclooxygenase inhibitor	PTGER2			BRD-A52551912-001-02-9, BRD-A52551912-001-01-1	Phase 2
atenolol-(+)	adrenergic receptor antagonist				BRD-K68075732-001-11-8	Preclinical
atenolol-(+/-)	adrenergic receptor antagonist	ADRB1, ADRB2, LTF, PLA2G2E	cardiology	hypertension, angina pectoris	BRD-A20239487-001-25-6, BRD-A20239487-001-25-6, BRD-A20239487-001-24-9	Launched
atenolol-(-)	adrenergic receptor antagonist		cardiology	hypertension	BRD-K44993696-001-13-1, BRD-K44993696-001-13-1, BRD-K44993696-001-12-3	Launched
atglistatin	adipose triglyceride lipase inhibitor				BRD-K43363084-001-01-3, BRD-K43363084-001-01-3, BRD-K43363084-001-02-1, BRD-K43363084-001-03-9	Preclinical
aticaprant	opioid receptor antagonist				BRD-K00003342-001-01-9	Phase 2
atipamezole	adrenergic receptor antagonist		neurology/psychiatry	reverse sedative	BRD-K39252998-003-02-3, BRD-K39252998-003-01-5, BRD-K39252998-003-01-5, BRD-K39252998-003-03-9, BRD-K39252998-003-03-9	Launched
atiprimod	JAK inhibitor, STAT inhibitor	JAK2, STAT3			BRD-K38527262-300-01-0, BRD-K38527262-300-01-0, BRD-K38527262-300-01-0, BRD-K38527262-300-01-0, BRD-K38527262-300-01-0, BRD-K38527262-300-01-0, BRD-K38527262-300-01-0	Phase 2
atizoram	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D			BRD-K76614248-001-01-2, BRD-K76614248-001-01-2	Phase 2
ATN-161	integrin antagonist	ITGA5, ITGAV, ITGB1, ITGB3			BRD-K00521308-019-01-9, BRD-K00521308-019-01-9, BRD-K00521308-019-03-5, BRD-K00521308-019-03-5, BRD-K00521308-019-03-5	Phase 2
atomoxetine	norepinephrine transporter inhibitor	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)	BRD-K20141153-001-01-6, BRD-K20141153-003-14-9, BRD-K20141153-003-12-9, BRD-K20141153-003-13-7	Launched
atosiban	oxytocin receptor antagonist	AVPR1A, AVPR1B, AVPR2, OXTR	neurology/psychiatry, cardiology, endocrinology	stroke, angina pectoris, myocardial infarction, hyperlipidemia	BRD-A85261566-001-02-5, BRD-A85261566-001-03-3, BRD-A85261566-001-03-3, BRD-A85261566-001-01-7	Launched
atovaquone	mitochondrial electron transport inhibitor		infectious disease	pneumonia	BRD-A19795905-001-08-0, BRD-A19795905-001-07-2	Launched
ATPA	glutamate receptor agonist	GRIK1			BRD-A65145453-001-07-9, BRD-A65145453-001-07-9, BRD-A65145453-001-07-9, BRD-A65145453-001-07-9, BRD-A65145453-001-06-1	Preclinical
atractylenolide-i	JAK inhibitor				BRD-K00003732-001-01-9	Preclinical
atracurium	acetylcholine receptor antagonist		critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	BRD-K01826774-344-07-9	Launched
atrasentan	endothelin receptor antagonist	EDNRA			BRD-K16295392-003-01-3, BRD-K16295392-003-01-3, BRD-K16295392-003-01-3, BRD-K16295392-003-01-3	Phase 3
atropine-oxide	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			BRD-K00004526-001-01-9	Preclinical
atuveciclib	CDK9 inhibitor				BRD-K00003144-001-01-9	Phase 1
AT13387	HSP inhibitor	HSP90AA1			BRD-K58435339-001-06-3, BRD-K58435339-001-06-3, BRD-K58435339-001-03-0, BRD-K58435339-001-03-0, BRD-K58435339-001-03-0, BRD-K58435339-001-03-0	Phase 2
AT7867	AKT inhibitor	AKT2, GSK3B, PKIA, PRKACA			BRD-K12040459-001-07-8, BRD-K12040459-001-07-8, BRD-K12040459-001-07-8, BRD-K12040459-001-07-8, BRD-K12040459-001-06-0, BRD-K12040459-001-06-0, BRD-K12040459-001-06-0, BRD-K12040459-001-06-0	Preclinical
aurora-a-inhibitor-i	Aurora kinase inhibitor	AURKA			BRD-K53561341-001-09-1, BRD-K53561341-001-09-1, BRD-K53561341-001-09-1, BRD-K53561341-001-07-5, BRD-K53561341-001-07-5	Preclinical
aurothioglucose	PKC inhibitor	PRKCI	rheumatology	rheumatoid arthritis	BRD-K00003601-001-01-9, BRD-K00003601-001-01-9	Launched
AUT-1	potassium channel activator				BRD-K00005330-001-01-9	Preclinical
autotaxin-modulator-1	autotaxin inhibitor	ENPP2			BRD-A94640958-001-01-7, BRD-A94640958-001-01-7	Preclinical
AV-412	protein tyrosine kinase inhibitor	EGFR, ERBB2			BRD-K23190681-001-02-9, BRD-K23190681-001-01-1, BRD-K23190681-001-01-1	Phase 1
AV-608	tachykinin antagonist	TACR1			BRD-K96615647-001-02-9, BRD-K96615647-001-01-2	Phase 2
avacopan	complement inhibitor				BRD-K00003256-001-01-9	Phase 2
avadomide	antitumor agent				BRD-A88644406-001-02-9	Phase 2
avagacestat	gamma secretase inhibitor	PSEN1			BRD-K83720053-001-07-9, BRD-K83720053-001-07-9, BRD-K83720053-001-03-8, BRD-K83720053-001-03-8	Phase 2
avanafil	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	BRD-K65781196-001-04-8, BRD-K65781196-001-03-0, BRD-K65781196-001-03-0, BRD-K65781196-001-03-0	Launched
avapritinib	KIT inhibitor				BRD-K00003419-001-01-9	Launched
avasimibe	ACAT inhibitor	CES1			BRD-K67901620-001-04-9, BRD-K67901620-001-03-8, BRD-K67901620-001-03-8, BRD-K67901620-001-03-8, BRD-K67901620-001-03-8, BRD-K67901620-001-02-0	Phase 3
avatrombopag	thrombopoietin receptor agonist	MPL	hematology	thrombocytopenia	BRD-K68544925-001-01-1	Launched
AVE-0991	angiotensin receptor agonist	MRGPRX1			BRD-K36154108-001-01-7, BRD-K36154108-001-02-9	Preclinical
AVE-3085	nitric oxide synthase stimulant				BRD-K00004734-001-01-9	Preclinical
AVex-73	sigma receptor agonist				BRD-K00003435-003-01-9	Preclinical
avibactam	beta lactamase inhibitor		infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis	BRD-K85882401-323-01-5, BRD-K85882401-236-01-9, BRD-K85882401-236-02-7	Launched
avitinib	EGFR inhibitor				BRD-K00003294-050-01-9	Phase 2
AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	BTK, YES1			BRD-K87782578-001-03-9, BRD-K87782578-001-01-4, BRD-K87782578-001-01-4, BRD-K87782578-001-01-4, BRD-K87782578-001-01-4, BRD-K87782578-001-01-4, BRD-K87782578-001-01-4	Phase 2
AVN-492	serotonin receptor antagonist				BRD-K00003436-001-01-9, BRD-K00003436-001-01-9	Preclinical
AVN-944	inosine monophosphate dehydrogenase inhibitor	IMPDH1, IMPDH2			BRD-K62196610-001-01-6, BRD-K62196610-001-01-6, BRD-K62196610-001-01-6, BRD-K62196610-001-01-6, BRD-K62196610-001-01-6, BRD-K62196610-001-02-9	Phase 2
avobenzone	topical sunscreen agent		dermatology	cosmetic, sunscreen lotion	BRD-K14401183-001-12-9, BRD-K14401183-001-11-5, BRD-K14401183-001-10-7	Launched
avoralstat	kallikrein inhibitor				BRD-K00003224-001-01-9	Phase 3
avridine	immunostimulant				BRD-K26665484-001-01-8	Preclinical
AX-024	cytokine production inhibitor				BRD-K00003479-003-01-9	Preclinical
axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1, FLT1, FLT4, KDR, PLK4	oncology	renal cell carcinoma (RCC)	BRD-K29905972-001-10-5, BRD-K29905972-001-10-5, BRD-K29905972-001-10-5, BRD-K29905972-001-06-3, BRD-K29905972-001-06-3, BRD-K29905972-001-06-3, BRD-K29905972-001-06-3, BRD-K29905972-001-12-1, BRD-K29905972-001-08-9, BRD-K29905972-001-08-9, BRD-K29905972-001-11-3	Launched
AY-9944	hedgehog pathway modulator				BRD-K77012840-300-02-9, BRD-K77012840-300-01-6, BRD-K77012840-300-01-6, BRD-K77012840-300-01-6	Preclinical
AZ-10417808	caspase inhibitor	CASP3			BRD-K36258877-001-04-9, BRD-K36258877-001-03-1	Preclinical
AZ-10606120	purinergic receptor antagonist	P2RX7			BRD-K09907507-300-01-4, BRD-K09907507-300-02-9	Preclinical
AZ-12080282	hedgehog pathway inhibitor	DHH			BRD-K05973499-300-02-9, BRD-K05973499-300-01-0	Preclinical
AZ-628	RAF inhibitor	BRAF, RAF1			BRD-K05804044-001-12-8, BRD-K05804044-001-12-8, BRD-K05804044-001-12-8, BRD-K05804044-001-12-8, BRD-K05804044-001-06-0, BRD-K05804044-001-06-0, BRD-K05804044-001-14-4, BRD-K05804044-001-09-4, BRD-K05804044-001-09-4, BRD-K05804044-001-09-4, BRD-K05804044-001-09-4, BRD-K05804044-001-09-4	Preclinical
AZ-7371	antibacterial 				BRD-K14661019-001-02-9	Preclinical
azacyclonol	histamine receptor antagonist	HRH1			BRD-K97061094-001-22-9, BRD-K97061094-001-20-6, BRD-K97061094-001-21-4	Preclinical
azaguanine-8	purine antagonist	PNP			BRD-K53114651-001-11-9, BRD-K53114651-001-12-7	Preclinical
azalomycin-B	bacterial 50S ribosomal subunit inhibitor				BRD-K38292725-001-02-4	Preclinical
azaperone	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	sedative	BRD-K45861246-001-17-9, BRD-K45861246-001-14-2, BRD-K45861246-001-13-4, BRD-K45861246-001-15-9	Launched
azapropazone	cyclooxygenase inhibitor	PTGS2			BRD-A70182876-001-11-9, BRD-A70182876-001-10-8	Withdrawn
azaserine	purine antagonist				BRD-K47464228-001-14-9	Preclinical
azasetron	serotonin receptor antagonist	HTR3A, HTR3B	infectious disease	genitial herpes	BRD-K01826751-003-08-9, BRD-K01826751-003-07-9	Launched
azatadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	BRD-K77821588-050-01-7, BRD-K77821588-364-01-2, BRD-K77821588-332-02-9	Launched
azathioprine	dehydrogenase inhibitor	HPRT1, IMPDH1, PPAT	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis	BRD-K32821942-001-22-1, BRD-K32821942-001-21-3, BRD-K32821942-001-20-5, BRD-K32821942-001-20-5, BRD-K32821942-001-20-5, BRD-K32821942-001-20-5, BRD-K32821942-001-20-5	Launched
AZD0156	ATM kinase inhibitor				BRD-K69555850-001-02-9	Phase 1
AZD1080	glycogen synthase kinase inhibitor	GSK3A, GSK3B			BRD-K61041538-001-05-5, BRD-K61041538-001-04-8, BRD-K61041538-001-01-4, BRD-K61041538-001-03-0, BRD-K61041538-001-03-0	Phase 1
AZD1208	Pim kinase inhibitor	PIM1, PIM2, PIM3			BRD-K21908111-001-03-9, BRD-K21908111-001-01-8, BRD-K21908111-001-01-8, BRD-K21908111-001-01-8, BRD-K21908111-001-01-8	Phase 1
AZD1283	purinergic receptor antagonist	P2RY12			BRD-K77060810-001-04-9, BRD-K77060810-001-01-5, BRD-K77060810-001-01-5	Preclinical
AZD1390	ATM kinase inhibitor				BRD-K00003509-001-01-9, BRD-K00003509-001-01-9	Phase 1
AZD1446	acetylcholine receptor agonist	CHRNA4, CHRNB2			BRD-A44188509-001-01-2	Phase 2
AZD1480	JAK inhibitor	JAK1, JAK2, JAK3			BRD-K65928735-001-06-8, BRD-K65928735-001-04-3, BRD-K65928735-001-04-3	Phase 1
AZD1981	CRTH receptor antagonist	PTGDR2			BRD-K83186168-001-01-8, BRD-K83186168-001-01-8, BRD-K83186168-001-02-9	Phase 2
AZD2014	mTOR inhibitor	MTOR			BRD-K99113996-001-03-9, BRD-K99113996-001-02-0, BRD-K99113996-001-02-0, BRD-K99113996-001-02-0	Phase 2
AZD2461	PARP inhibitor				BRD-K85014146-001-03-9, BRD-K85014146-001-02-5, BRD-K85014146-001-02-5, BRD-K85014146-001-02-5	Phase 1
AZD2858	glycogen synthase kinase inhibitor	GSK3B			BRD-K85849709-001-02-9, BRD-K85849709-001-02-9, BRD-K85849709-001-01-5, BRD-K85849709-001-01-5, BRD-K85849709-001-01-5	Preclinical
AZD3264	IKK inhibitor	IKBKB			BRD-K14287049-001-01-3, BRD-K14287049-001-01-3	Preclinical
AZD3463	ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor	ALK, IGF1R			BRD-K24593301-001-01-5, BRD-K24593301-001-01-5, BRD-K24593301-001-04-9, BRD-K24593301-001-04-9, BRD-K24593301-001-02-3, BRD-K24593301-001-02-3, BRD-K24593301-001-02-3, BRD-K24593301-001-02-3, BRD-K24593301-001-02-3	Preclinical
AZD3514	androgen receptor modulator	AR			BRD-K84996356-001-01-1, BRD-K84996356-001-01-1, BRD-K84996356-001-01-1, BRD-K84996356-001-01-1, BRD-K84996356-001-01-1, BRD-K84996356-001-01-1, BRD-K84996356-001-03-9, BRD-K84996356-001-03-9	Phase 1
AZD3759	EGFR inhibitor	EGFR			BRD-K41626799-001-01-1	Phase 2/Phase 3
AZD3839	beta-secretase inhibitor	BACE1			BRD-K00004606-001-01-9, BRD-K00004606-001-02-9	Phase 1
AZD3965	monocarboxylate transporter inhibitor	SLC16A1			BRD-K25210703-001-01-9	Phase 1
AZD3988	diacylglycerol kinase inhibitor	DGAT1			BRD-K73984371-001-02-9, BRD-K73984371-001-01-1	Preclinical
AZD4282	glutamate receptor antagonist	AGXT, AGXT2, ALAS1, ALAS2, BAAT, GARS, GATM, GCAT, GCSH, GLDC, GLRA1, GLRA2, GLRA3, GLRB, GLYAT, GLYATL1, GLYATL2, GNMT, GPR18, GPRC6A, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3B, GSS, PIPOX, SHMT1, SHMT2, SLC32A1, SLC36A1, SLC6A5, SLC6A9			BRD-K72369578-001-04-1	Phase 1
AZD4547	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR			BRD-K28392481-001-05-1, BRD-K28392481-001-03-6	Phase 2/Phase 3
AZD4573	CDK9 inhibitor				BRD-K00003106-001-01-9	Phase 1
AZD4635	adenosine receptor antagonist				BRD-K00003443-001-01-9	Phase 1/Phase 2
AZD5069	CC chemokine receptor antagonist	CXCR2			BRD-K00003297-001-01-9	Phase 2
AZD5153	bromodomain inhibitor				BRD-K00003528-457-01-9	Phase 1
AZD5363	AKT inhibitor	AKT1, AKT2, AKT3			BRD-K99023089-001-03-7, BRD-K99023089-001-03-7, BRD-K99023089-001-06-9	Phase 3
AZD5438	CDK inhibitor	KCNH2			BRD-K72414522-001-08-3, BRD-K72414522-001-10-9, BRD-K72414522-001-10-9, BRD-K72414522-001-06-7, BRD-K72414522-001-06-7, BRD-K72414522-001-06-7, BRD-K72414522-001-06-7, BRD-K72414522-001-04-2, BRD-K72414522-001-04-2	Phase 1
AZD5582	XIAP inhibitor	BIRC2, BIRC3, XIAP			BRD-K88767641-001-01-7, BRD-K88767641-001-01-7, BRD-K88767641-001-01-7, BRD-K88767641-001-01-7	Preclinical
AZD5991	MCL1 inhibitor				BRD-K00005264-001-02-9	Phase 1
AZD6482	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			BRD-K58772419-001-08-8, BRD-K58772419-001-08-8, BRD-K58772419-001-08-8, BRD-K58772419-001-08-8, BRD-K58772419-001-07-0, BRD-K58772419-001-07-0, BRD-K58772419-001-07-0	Phase 1
AZD6738	ATR kinase inhibitor	ATR			BRD-A36013532-001-01-3	Phase 2
AZD6765	glutamate receptor antagonist	GRIN1			BRD-A94033181-001-01-4, BRD-A94033181-001-01-4	Phase 2
AZD7545	pyruvate dehydrogenase kinase inhibitor	PDK1			BRD-K52836380-001-05-9	Phase 1
AZD7594	glucocorticoid receptor modulator				BRD-K00003100-001-01-9	Phase 2
AZD7687	diacylglycerol O acyltransferase inhibitor	DGAT1			BRD-K31495718-001-01-1, BRD-K31495718-001-02-9	Phase 1
AZD7762	CHK inhibitor	CHEK1, CHEK2			BRD-K86525559-003-11-9, BRD-K86525559-001-04-5, BRD-K86525559-001-04-5, BRD-K86525559-001-04-5, BRD-K86525559-003-01-7, BRD-K86525559-003-01-7, BRD-K86525559-003-01-7, BRD-K86525559-001-07-8, BRD-K86525559-001-07-8	Phase 1
AZD7986	dipeptidyl peptidase inhibitor				BRD-K00003398-001-01-9	Phase 1
AZD8055	mTOR inhibitor	MTOR			BRD-K69932463-001-10-6, BRD-K69932463-001-10-6, BRD-K69932463-001-10-6, BRD-K69932463-001-10-6, BRD-K69932463-001-10-6, BRD-K69932463-001-10-6, BRD-K69932463-001-10-6, BRD-K69932463-001-17-1	Phase 1
AZD8330	MEK inhibitor	MAP3K1			BRD-K37687095-001-07-7, BRD-K37687095-001-07-7, BRD-K37687095-001-06-9, BRD-K37687095-001-06-9, BRD-K37687095-001-06-9	Phase 1
AZD8797	CC chemokine receptor antagonist				BRD-K03336321-001-02-9	Preclinical
AZD8835	PI3K inhibitor	PIK3CA, PIK3CD			BRD-K82894950-001-01-0, BRD-K82894950-001-01-0, BRD-K82894950-001-01-0	Phase 1
AZD8931	EGFR inhibitor	EGFR, ERBB2, ERBB3			BRD-K98572433-001-03-9, BRD-K98572433-001-03-9, BRD-K98572433-001-02-9, BRD-K98572433-001-02-9, BRD-K98572433-001-02-9	Phase 2
AZD9056	purinergic receptor antagonist				BRD-K13699028-003-02-9	Phase 2
AZD9272	glutamate receptor antagonist	GRM5			BRD-K61043483-001-01-5, BRD-K61043483-001-01-5, BRD-K61043483-001-02-9	Preclinical
AZD9496	estrogen receptor agonist	ESR1			BRD-K73235735-001-02-7, BRD-K73235735-001-02-7, BRD-K73235735-050-01-6	Phase 1
AZD9668	elastase inhibitor	ELANE			BRD-K31476763-001-01-5, BRD-K31476763-001-01-5, BRD-K31476763-001-02-9	Phase 2
azelaic-acid	tyrosinase inhibitor	AKR1D1, SRD5A2, TYR	dermatology	rosacea	BRD-K08976401-001-18-5, BRD-K08976401-001-18-5	Launched
azelastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	BRD-A68888262-003-16-9, BRD-A68888262-003-15-1, BRD-A68888262-003-17-9, BRD-A68888262-003-17-9	Launched
azeliragon	RAGE receptor antagonist	AGER			BRD-K51899933-001-02-6, BRD-K51899933-001-02-6, BRD-K51899933-001-02-6, BRD-K51899933-001-02-6, BRD-K51899933-001-02-6	Phase 3
azelnidipine	calcium channel blocker	CACNA1C	cardiology	hypertension	BRD-A01098288-001-06-0, BRD-A01098288-001-06-0, BRD-A01098288-001-06-0, BRD-A01098288-001-06-0, BRD-A01098288-001-06-0, BRD-A01098288-001-04-5, BRD-A01098288-001-02-9	Launched
azilsartan	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension	BRD-K81074237-001-04-9, BRD-K81074237-001-04-9, BRD-K81074237-001-03-1, BRD-K81074237-001-02-3, BRD-K81074237-001-02-3	Launched
azilsartan-medoxomil	angiotensin receptor antagonist	AGTR1, AGTR2	cardiology	hypertension	BRD-K25723200-237-01-9, BRD-K25723200-001-03-5, BRD-K25723200-001-03-5, BRD-K25723200-001-03-5, BRD-K25723200-001-02-7, BRD-K25723200-001-04-3, BRD-K25723200-001-04-3	Launched
azimilide	potassium channel blocker	KCNA5			BRD-K38913877-300-02-9, BRD-K38913877-300-01-9, BRD-K38913877-300-01-9	Phase 3
AZM-475271	SRC inhibitor	SRC			BRD-K51329597-001-01-3, BRD-K51329597-001-01-3, BRD-K51329597-001-02-9, BRD-K51329597-001-02-9	Preclinical
azodicarbonamide	DNA synthesis inhibitor				BRD-K87036601-001-02-4, BRD-K87036601-001-01-6	Phase 2
azomycin-(2-nitroimidazole)	protein synthesis inhibitor				BRD-K26824830-001-02-0, BRD-K26824830-001-03-8	Preclinical
azosemide	electrolyte reabsorption inhibitor	SLC12A1, SLC12A2	cardiology	edema	BRD-K68770713-001-01-8, BRD-K68770713-001-01-8, BRD-K68770713-001-01-8	Launched
AZ191	DYRK inhibitor	DYRK1B			BRD-K80935598-001-04-9, BRD-K80935598-001-02-9, BRD-K80935598-001-02-9, BRD-K80935598-001-01-1, BRD-K80935598-001-01-1, BRD-K80935598-001-01-1	Preclinical
AZ20	ATR kinase inhibitor	ATR, MTOR			BRD-K42436189-001-03-8, BRD-K42436189-001-01-2	Preclinical
AZ3146	monopolar spindle 1 kinase inhibitor				BRD-K59146805-001-04-5, BRD-K59146805-001-03-7, BRD-K59146805-001-05-2, BRD-K59146805-001-05-2	Preclinical
AZ505	histone lysine methyltransferase inhibitor	SMYD2			BRD-K76244476-362-02-5, BRD-K76244476-362-01-7	Preclinical
AZ5104	EGFR inhibitor	EGFR			BRD-K81958169-001-01-1	Preclinical
AZ7550	insulin growth factor receptor inhibitor				BRD-K00003515-003-01-9	Phase 1
AZ960	JAK inhibitor	JAK2			BRD-K64888243-001-05-9, BRD-K64888243-001-04-5, BRD-K64888243-001-04-5, BRD-K64888243-001-04-5, BRD-K64888243-001-04-5, BRD-K64888243-001-04-5, BRD-K64888243-001-04-5, BRD-K64888243-001-04-5, BRD-K64888243-001-03-7, BRD-K64888243-001-03-7	Preclinical
A0001					BRD-K57865272-001-02-0, BRD-K57865272-001-01-2	Phase 2
A12B4C3	polynucleotide kinase/phosphatase inhibitor	PNKP			BRD-A30000356-001-02-9, BRD-A30000356-001-01-9	Preclinical
A205804	ICAM1 expression inhibitor	ICAM1, SELE			BRD-K77627880-001-05-7, BRD-K77627880-001-05-7, BRD-K77627880-001-04-0, BRD-K77627880-001-04-0, BRD-K77627880-001-06-9, BRD-K77627880-001-06-9, BRD-K77627880-001-03-2	Preclinical
A61603	adrenergic receptor agonist	ADRA1A			BRD-A83650191-004-03-6, BRD-A83650191-004-02-8	Preclinical
A66	PI3K inhibitor	PIK3CA			BRD-K49055432-001-04-2, BRD-K49055432-001-04-2, BRD-K49055432-001-07-5	Preclinical
A740003	purinergic receptor antagonist	P2RX7			BRD-A78952587-001-02-3, BRD-A78952587-001-02-3, BRD-A78952587-001-01-5, BRD-A78952587-001-01-5, BRD-A78952587-001-01-5, BRD-A78952587-001-01-5, BRD-A78952587-001-03-9	Preclinical
A77636	dopamine receptor agonist	CALY			BRD-K72226571-003-02-9, BRD-K72226571-003-02-9, BRD-K72226571-003-01-2	Preclinical
A922500	diacylglycerol O acyltransferase inhibitor	DGAT1			BRD-K28861668-001-01-9	Preclinical
bacitracin	bacterial cell wall synthesis inhibitor	IDE	infectious disease	first-aid antibiotic	BRD-K14079729-001-01-1	Launched
bacitracin-zinc	bacterial cell wall synthesis inhibitor		infectious disease	first-aid antibiotic	BRD-K00003625-001-01-9	Launched
baclofen	benzodiazepine receptor agonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8	neurology/psychiatry	multiple sclerosis, spasms	BRD-K01826724-001-08-9, BRD-K01826724-003-07-9	Launched
BADGE	PPAR receptor antagonist	PPARG			BRD-A16694057-001-08-9, BRD-A16694057-001-06-8	Preclinical
bafetinib	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor	ABL1, BCR, LYN			BRD-K82196541-001-04-9, BRD-K82196541-001-04-9, BRD-K82196541-001-04-9, BRD-K82196541-001-04-9, BRD-K82196541-001-03-9, BRD-K82196541-001-03-9	Phase 2
bafilomycin-a1	ATPase inhibitor				BRD-K00010387-001-01-9, BRD-K00010387-001-01-9	Preclinical
BAG-956	phosphoinositide dependent kinase inhibitor	PIK3CG			BRD-K00652956-001-01-5, BRD-K00652956-001-01-5, BRD-K00652956-001-02-9	Preclinical
baicalein	lipoxygenase inhibitor	ALOX5, GLO1, PREP, SELL, SELP, TNF, XDH			BRD-K72327355-001-15-4, BRD-K72327355-001-15-4, BRD-K72327355-001-15-4, BRD-K72327355-001-13-9, BRD-K72327355-001-13-9, BRD-K72327355-001-14-7	Preclinical
bakuchiol	DNA polymerase inhibitor	HIF1A			BRD-K09785578-001-02-0, BRD-K09785578-001-02-0, BRD-K09785578-001-02-0, BRD-K09785578-001-01-2	Phase 2
balaglitazone	insulin sensitizer, PPAR receptor partial agonist	PPARG			BRD-A00147595-001-01-5, BRD-A00147595-001-02-9	Phase 3
balapiravir	RNA polymerase inhibitor				BRD-K47976015-001-02-9, BRD-K47976015-001-01-2, BRD-K47976015-001-01-2, BRD-K47976015-001-01-2	Phase 2
balicatib	cathepsin inhibitor	CTSK			BRD-K27204852-001-02-7, BRD-K27204852-001-03-9, BRD-K27204852-001-01-9, BRD-K27204852-001-01-9, BRD-K27204852-001-01-9	Phase 2
balofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	BRD-A47790386-001-02-8, BRD-A47790386-001-05-9, BRD-A47790386-001-03-6	Launched
baloxavir	endonuclease inhibitor				BRD-K00003496-001-01-9	Phase 3
baloxavir-marboxil	endonuclease inhibitor		infectious disease	influenza A virus infection	BRD-K00003495-001-01-9	Launched
balsalazide	cyclooxygenase inhibitor	ALOX5, PPARG, PTGS1, PTGS2	gastroenterology	ulcerative colitis	BRD-K00003656-001-01-9	Launched
bamaquimast	proton pump inhibitor				BRD-K00003411-001-01-9	Preclinical
bambuterol	adrenergic receptor agonist	ADRB2, BCHE	pulmonary	asthma	BRD-A17462676-003-11-6	Launched
BAM7	BAX activator	BAX			BRD-K07442505-001-03-6, BRD-K07442505-001-03-6, BRD-K07442505-001-03-6, BRD-K07442505-001-03-6, BRD-K07442505-001-03-6, BRD-K07442505-001-05-9	Preclinical
BAN-ORL-24	nociceptin/orphanin FQ receptor antagonist	OPRL1			BRD-K47049295-300-02-3, BRD-K47049295-300-03-1, BRD-K47049295-300-03-1, BRD-K47049295-300-01-5	Preclinical
banoxantrone	topoisomerase inhibitor	TOP2A			BRD-K00003159-300-01-9	Phase 1/Phase 2
barasertib	Aurora kinase inhibitor	AURKA, AURKB			BRD-K31928526-001-02-1, BRD-K31928526-001-02-1, BRD-K31928526-001-02-1	Phase 2/Phase 3
barasertib-HQPA	Aurora kinase inhibitor	AURKB			BRD-K63923597-001-10-0, BRD-K63923597-001-10-0, BRD-K63923597-001-10-0, BRD-K63923597-001-11-8, BRD-K63923597-001-11-8, BRD-K63923597-001-11-8, BRD-K63923597-001-11-8, BRD-K63923597-001-11-8, BRD-K63923597-001-08-4	Phase 2/Phase 3
bardoxolone	nuclear factor erythroid derived, like (NRF2) activator	NOS2, PPARG			BRD-K20545304-001-01-6, BRD-K20545304-001-01-6, BRD-K20545304-001-01-6, BRD-K20545304-001-01-6, BRD-K20545304-001-01-6	Phase 1
baricitinib	JAK inhibitor	JAK1, JAK2	rheumatology	rheumatoid arthritis	BRD-K53581288-001-02-9, BRD-K53581288-001-02-9, BRD-K53581288-001-02-9, BRD-K53581288-001-02-9	Launched
barium-6-O-phosphonato-D-glucose					BRD-K67760597-240-01-5	Preclinical
barnidipine	calcium channel blocker		cardiology	hypertension	BRD-K78781788-003-01-9, BRD-K78781788-003-01-9	Launched
basic-fuchsin					BRD-K26362911-003-01-1	Preclinical
basimglurant	glutamate receptor antagonist	GRM5			BRD-K62387885-001-01-9	Phase 2
basmisanil	GABA receptor inverse agonist				BRD-K00003221-001-01-9	Phase 2
batefenterol	acetylcholine receptor antagonist, adrenergic receptor agonist				BRD-K00003148-001-01-9	Phase 2
bavisant	histamine receptor antagonist	HRH3			BRD-K79595931-312-01-3, BRD-K79595931-312-02-9, BRD-K79595931-312-02-9	Phase 2
BAX-channel-blocker	cytochrome C release inhibitor	BAX			BRD-K01826533-300-02-9	Preclinical
BAY-K-8644-(+/-)	L-type calcium channel blocker				BRD-A05457250-001-08-4, BRD-A05457250-001-08-4, BRD-A05457250-001-08-4	Preclinical
BAY-K-8644-(s)-(-)	L-type calcium channel activator	CACNA1C			BRD-K14329163-001-03-9	Preclinical
BAY-W-9798	antioxidant				BRD-K44471774-001-01-8	Phase 2
BAY-11-7082	NFkB pathway inhibitor	RELA			BRD-K15025317-001-15-1, BRD-K15025317-001-15-1, BRD-K15025317-001-15-1, BRD-K15025317-001-15-1, BRD-K15025317-001-14-4, BRD-K15025317-001-17-7, BRD-K15025317-001-17-7, BRD-K15025317-001-17-7, BRD-K15025317-001-17-7, BRD-K15025317-001-17-7, BRD-K15025317-001-17-7, BRD-K15025317-001-17-7, BRD-K15025317-001-17-7	Preclinical
BAY-11-7085	NFkB pathway inhibitor	NFKBIA			BRD-K48684885-001-04-2, BRD-K48684885-001-04-2	Preclinical
BAY-1251152	CDK9 inhibitor				BRD-K00003533-001-01-9	Phase 1
BAY-1436032	isocitrate dehydrogenase inhibitor				BRD-K00003359-001-01-9	Phase 1
BAY-1895344	ATR kinase inhibitor				BRD-K00003422-003-01-9	Phase 1
BAY-2402234	dihydroorotate dehydrogenase inhibitor				BRD-K22379844-001-04-9, BRD-K22379844-001-04-9	Phase 1
BAY-41-2272	guanylyl cyclase activator	GUCY1A3, GUCY1B3			BRD-K32033120-001-02-9, BRD-K32033120-001-02-9, BRD-K32033120-001-01-1, BRD-K32033120-001-01-1	Preclinical
BAY-60-6583	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K32952627-001-02-9, BRD-K32952627-001-01-0	Preclinical
BAY-60-7550	phosphodiesterase inhibitor	PDE2A			BRD-K86932920-001-02-9	Preclinical
BAY-61-3606	SYK inhibitor	SYK			BRD-K53281329-300-01-5, BRD-K53281329-300-01-5, BRD-K53281329-300-01-5, BRD-K53281329-300-01-5, BRD-K53281329-300-01-5	Preclinical
BAY-8002	monocarboxylate transporter inhibitor				BRD-K00005331-001-01-9	Preclinical
BAY-85-8050					BRD-A11731518-001-01-7	Phase 1
BAY-87-2243	hypoxia inducible factor inhibitor	HIF1A			BRD-K70463136-001-01-5, BRD-K70463136-001-01-5, BRD-K70463136-001-01-5, BRD-K70463136-001-01-5, BRD-K70463136-001-01-5, BRD-K70463136-001-01-5, BRD-K70463136-001-02-9	Phase 1
BAY1125976	AKT inhibitor				BRD-K00003357-001-01-9	Phase 1
BAY1217389	kinase inhibitor				BRD-K00003143-001-01-9	Phase 1
bazedoxifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, endocrinology	osteoporosis, menopause	BRD-K90195324-015-04-9, BRD-K90195324-015-04-9, BRD-K90195324-015-04-9, BRD-K90195324-015-01-1, BRD-K90195324-003-02-5, BRD-K90195324-003-02-5, BRD-K90195324-003-02-5, BRD-K90195324-003-03-3, BRD-K90195324-003-03-3, BRD-K90195324-003-03-3, BRD-K90195324-003-03-3, BRD-K90195324-003-03-3, BRD-K90195324-003-03-3, BRD-K90195324-003-03-3	Launched
BAZ2-ICR	bromodomain inhibitor	ZNF215			BRD-K66830666-001-01-9, BRD-K66830666-001-02-7, BRD-K66830666-001-02-7	Preclinical
BC-11	urokinase inhibitor	PLAU			BRD-K14646328-004-02-9, BRD-K14646328-004-01-6	Preclinical
BCI-540	glutamate receptor agonist				BRD-K23672206-001-02-9, BRD-K23672206-001-01-4, BRD-K23672206-001-01-4	Phase 2
BCTC	TRPV antagonist	TRPV1			BRD-K66541497-001-01-7, BRD-K66541497-001-02-9	Preclinical
BCX-1470	complement inhibitor, serine protease inhibitor	CFD			BRD-K90472149-066-01-0, BRD-K90472149-066-01-0	Phase 1
BD-1008	sigma receptor antagonist				BRD-K17008822-303-02-1, BRD-K17008822-303-02-1	Preclinical
BD-1047	adrenergic receptor antagonist	SIGMAR1			BRD-K36864847-303-03-3, BRD-K36864847-303-02-5, BRD-K36864847-303-02-5	Preclinical
BD-1063	sigma receptor antagonist	SIGMAR1			BRD-K29668683-300-02-2	Preclinical
BE-2254	adrenergic receptor antagonist	ADRA1A			BRD-A24429032-003-03-2, BRD-A24429032-003-02-4	Phase 2
BEBT-908	PI3K inhibitor				BRD-K00003291-001-01-9	Preclinical
beclabuvir	antiviral				BRD-K00003128-001-01-9	Phase 2
beclamide	anticonvulsant		neurology/psychiatry	sedative, seizures	BRD-K44824027-001-03-9, BRD-K44824027-001-02-1	Launched
beclomethasone	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	BRD-A73385064-001-01-5, BRD-A73385064-001-01-5, BRD-A73385064-001-01-5	Launched
bedaquiline	ATPase inhibitor		infectious disease	tuberculosis	BRD-K90817094-001-05-9, BRD-K90817094-001-02-6, BRD-K90817094-001-02-6, BRD-K90817094-001-03-4	Launched
befuraline					BRD-K99077012-001-01-9	Phase 2
begacestat	gamma secretase inhibitor	PSEN1			BRD-K58319700-001-02-9, BRD-K58319700-001-01-1, BRD-K58319700-001-01-1	Phase 1
belinostat	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	BRD-K17743125-001-08-4, BRD-K17743125-001-08-4, BRD-K17743125-001-08-4, BRD-K17743125-001-08-4, BRD-K17743125-001-01-9, BRD-K17743125-001-01-9, BRD-K17743125-001-01-9	Launched
belizatinib	receptor tyrosine protein kinase inhibitor				BRD-K00003245-001-01-9	Preclinical
belotecan	topoisomerase inhibitor				BRD-K00003160-003-01-9	Phase 3
bemegride	chemoreceptor agonist	GABRA1	critical care	poison antidote	BRD-K14993104-001-06-9, BRD-K14993104-001-05-9, BRD-K14993104-001-05-9	Launched
bemesetron	serotonin receptor antagonist	HTR3A, HTR3B			BRD-K00004211-001-01-9	Phase 3
bemotrizinol			dermatology	sunscreen lotion	BRD-A92974210-396-01-0, BRD-A92974210-001-02-9	Launched
bempedoic-acid	AMPK inhibitor	ACLY			BRD-K63177377-001-01-8	Launched
benactyzine	butyrylcholinesterase inhibitor				BRD-K85030058-003-16-9	Preclinical
benaxibine					BRD-K00004531-001-01-9	Phase 1
benazepril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	BRD-K49807096-003-16-3, BRD-K49807096-003-17-1, BRD-K49807096-003-15-5, BRD-K49807096-003-14-8, BRD-K49807096-003-18-9, BRD-K49807096-003-18-9	Launched
bendamustine	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)	BRD-K17068645-003-05-9, BRD-K17068645-003-05-9, BRD-K17068645-003-04-2	Launched
bendazac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	BRD-K19515365-001-02-6	Launched
bendazol	nitric oxide synthase stimulant				BRD-K60379054-001-09-9	Launched
bendroflumethiazide	sodium/potassium/chloride transporter inhibitor	SLC12A1, SLC12A3	cardiology	hypertension	BRD-A80017228-001-25-7, BRD-A80017228-001-24-0, BRD-A80017228-001-27-3, BRD-A80017228-001-27-3	Launched
benfluorex	gluconeogenesis inhibitor	HMGCR			BRD-K00003672-003-01-9	Withdrawn
benfluralin		CYP1A1, CYP1A2, CYP2B6, CYP3A4, ESR1, MMP1, SULT2A1, UGT1A1			BRD-K33903083-001-03-5, BRD-K33903083-001-03-5	Phase 3
benfotiamine	antioxidant	AGER	rheumatology	lumbago	BRD-K05319475-396-01-2, BRD-K05319475-001-04-2, BRD-K05319475-001-06-9, BRD-K05319475-001-05-9	Launched
benidipine	calcium channel blocker	CACNA1C, CACNA1G	cardiology	hypertension	BRD-K97181463-003-02-9, BRD-K97181463-003-02-9, BRD-K97181463-003-02-9, BRD-K97181463-003-02-9, BRD-K97181463-003-02-9, BRD-K97181463-003-01-1, BRD-K97181463-003-03-7	Launched
benperidol	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	BRD-K79425933-001-11-9, BRD-K79425933-001-09-3	Launched
benproperine	antitussive	SCN5A	pulmonary	cough suppressant	BRD-K01826024-001-01-9	Launched
benserazide	DOPA decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	BRD-A61194565-003-28-8, BRD-A61194565-003-27-0	Launched
bentiromide		HPN	gastroenterology	pancreas diagnostic agent	BRD-K58794715-001-01-8, BRD-K58794715-001-03-4, BRD-K58794715-001-02-6	Launched
benurestat	urease inhibitor				BRD-K88553858-001-02-7, BRD-K88553858-001-03-9	Phase 1
benzalkonium	cationic surfactant		dermatology	abrasions, superficial cuts	BRD-K34234316-003-04-7, BRD-K34234316-003-05-4	Launched
benzbromarone	chloride channel blocker	ABCC1	rheumatology	gout	BRD-K11717138-001-31-9, BRD-K11717138-001-30-3, BRD-K11717138-001-29-5	Launched
benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]					BRD-A98083480-001-01-3	Preclinical
benzethonium	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	BRD-K72723676-003-17-8, BRD-K72723676-003-17-8, BRD-K72723676-003-17-8, BRD-K72723676-003-17-8, BRD-K72723676-003-17-8, BRD-K72723676-003-18-9, BRD-K72723676-003-18-9, BRD-K72723676-003-18-9, BRD-K72723676-003-18-9, BRD-K72723676-003-18-9, BRD-K72723676-003-18-9, BRD-K72723676-003-16-0, BRD-K72723676-003-16-0	Launched
benznidazole	DNA synthesis inhibitor		infectious disease	Chagas disease	BRD-K56156805-001-09-6	Launched
benzo[d]thiazole-2(3H)-thione					BRD-K55160477-001-04-7	Phase 1
benzocaine	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	BRD-K75466013-001-14-4, BRD-K75466013-001-16-9, BRD-K75466013-001-16-9, BRD-K75466013-001-13-6	Launched
benzoclidine					BRD-A45929034-001-09-5	Preclinical
benzofenac					BRD-K26556907-001-01-8, BRD-K26556907-001-01-8, BRD-K26556907-001-01-8	Phase 1
benzoic-acid	food preservative	DAO, HRSP12, PRDX5, RAB9A	infectious disease	tinea pedis	BRD-K53397409-001-12-3, BRD-K53397409-001-12-3, BRD-K53397409-001-11-5, BRD-K53397409-001-13-1	Launched
benzoin		CES1			BRD-A55748233-001-08-7, BRD-A55748233-001-12-9	Preclinical
benzonatate	local anesthetic	SCN5A	pulmonary	cough suppressant	BRD-K91699951-001-10-2	Launched
benzoquinonium-dibromide	cholinergic receptor antagonist	CHRNA1			BRD-K18772613-303-03-9, BRD-K18772613-303-02-4, BRD-K18772613-303-02-4	Preclinical
benzotript	CCK receptor antagonist	CCKAR, CCKBR			BRD-K33219230-001-07-9	Phase 1
benzoxiquine	antiinfective drug				BRD-K70327191-001-02-2	Preclinical
benzoyl-peroxide	oxidizing agent		dermatology	acne vulgaris (AV)	BRD-K59986511-001-04-9, BRD-K59986511-001-06-4	Launched
benzoylpas					BRD-K20431737-001-08-1, BRD-K20431737-001-09-9, BRD-K20431737-001-09-9	Preclinical
benzthiazide	carbonic anhydrase inhibitor	CA2	cardiology	hypertension, edema	BRD-K21450440-001-14-6, BRD-K21450440-001-14-6, BRD-K21450440-001-14-6, BRD-K21450440-001-14-6, BRD-K21450440-001-13-8, BRD-K21450440-001-15-3, BRD-K21450440-001-15-3	Launched
benztropine-mesylate	acetylcholine receptor antagonist	CHRM1, HRH1, SLC6A3	neurology/psychiatry	extrapyramidal symptoms (EPS), Parkinson's Disease	BRD-K68804560-066-03-9	Launched
benzydamine	prostanoid receptor antagonist		dental, otolaryngology	mouth inflammation, throat inflammation	BRD-K28542495-003-13-5, BRD-K28542495-003-12-7	Launched
benzyl-alcohol	local anesthetic		infectious disease	virus herpes simplex (HSV)	BRD-K98494274-001-03-6, BRD-K98494274-001-05-1	Launched
benzyl-benzoate	lipase inhibitor	LIPE	allergy	sweet itch	BRD-K52072429-001-10-3, BRD-K52072429-001-12-9, BRD-K52072429-001-11-1	Launched
benzyl-isothiocyanate	methylazoxymethanol acetate inhibitor				BRD-K80253852-001-04-4, BRD-K80253852-001-05-9	Preclinical
benzyldimethylhexadecylammonium	cationic surfactant				BRD-K23403298-003-01-9, BRD-K23403298-003-01-9, BRD-K23403298-003-01-9	Preclinical
benzyldimethyloctylammonium					BRD-K11576103-003-01-1	Preclinical
benzylpenicillin	penicillin binding protein inhibitor		infectious disease	celluitis, meningitis, endocarditis, syphilis, pneumonia, bacterial septicemia	BRD-K55191674-236-06-0, BRD-K55191674-237-18-3, BRD-K55191674-236-07-8	Launched
bephenium-hydroxynaphthoate	anthelmintic agent		infectious disease	ascariasis	BRD-K47878171-086-08-9, BRD-K47878171-086-06-0, BRD-K47878171-086-05-2, BRD-K47878171-086-07-8	Launched
bepotastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	BRD-K98624455-074-02-8, BRD-K98624455-074-02-8, BRD-K98624455-074-03-6	Launched
bepridil	calcium channel blocker	KCNQ4	cardiology	angina pectoris	BRD-A91008255-003-24-8, BRD-A91008255-003-24-8, BRD-A91008255-003-26-3, BRD-A91008255-003-25-5, BRD-A91008255-003-25-5	Launched
berberine	LDL receptor activator	LDLR			BRD-K14796088-311-27-9, BRD-K14796088-311-27-9, BRD-K14796088-003-26-8, BRD-K14796088-003-26-8, BRD-K14796088-003-25-0	Launched
bergapten					BRD-K12968785-001-13-3, BRD-K12968785-001-15-9, BRD-K12968785-001-12-5	Phase 3
besifloxacin	bacterial DNA gyrase inhibitor		ophthalmology	conjunctivitis	BRD-K10196357-003-02-0, BRD-K10196357-003-03-9	Launched
BET-BAY-002	bromodomain inhibitor				BRD-K72735080-001-01-0, BRD-K72735080-001-01-0, BRD-K72735080-001-01-0, BRD-K72735080-001-01-0, BRD-K72735080-001-02-9, BRD-K72735080-001-02-9	Preclinical
beta-amyloid-synthesis-inhibitor	beta amyloid synthesis inhibitor	APP			BRD-K38687824-001-02-5	Preclinical
beta-CCB	benzodiazepine receptor ligand	GABRA1, GABRG2			BRD-K87349602-001-03-8, BRD-K87349602-001-04-9	Launched
beta-elemene	apoptosis stimulant	MMP2, MMP9			BRD-K21045639-001-01-2	Launched
beta-funaltrexamine	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			BRD-K95110148-003-02-3, BRD-K95110148-003-02-3, BRD-K95110148-003-03-9, BRD-K95110148-003-01-5, BRD-K95110148-003-01-5	Preclinical
beta-glycerophosphoric-acid					BRD-K39061174-001-01-0	Preclinical
beta-hydroxy-beta-methylbutyrate	protein synthesis stimulant	MTOR			BRD-M02899238-238-01-6	Launched
beta-hydroxybutyrate		HCAR2			BRD-A41387824-001-06-0	Phase 1
beta-lapachone	topoisomerase inhibitor	TOP1			BRD-K28061410-001-07-4, BRD-K28061410-001-09-0, BRD-K28061410-001-05-8, BRD-K28061410-001-06-6, BRD-K28061410-001-06-6, BRD-K28061410-001-06-6, BRD-K28061410-001-06-6	Phase 2
beta-naphthol					BRD-K21164796-001-02-8	Preclinical
betahistine	histamine receptor agonist, histamine receptor antagonist	HRH1, HRH3	neurology/psychiatry	Meniere's disease	BRD-K91315211-300-15-9, BRD-K91315211-300-06-5, BRD-K91315211-300-05-7	Launched
betamethasone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-K39188321-001-14-9	Launched
betamethasone-butyrate-propionate			rheumatology	rheumatoid arthritis	BRD-K00004736-001-01-9	Launched
betamethasone-phosphate			rheumatology	rheumatoid arthritis	BRD-K00005349-304-01-9	Launched
betamipron	panipenem uptake inhibitor		nephrology	renal toxicity	BRD-K82142815-001-20-9, BRD-K82142815-001-19-1, BRD-K82142815-001-18-3	Launched
betaxolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	BRD-K01825592-001-02-9, BRD-K01825592-001-04-9	Launched
betazole	histamine receptor agonist	HRH2	gastroenterology	gastric hypersecretion diagnostic	BRD-K20075662-300-04-0	Launched
bethanechol	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4	urology	urinary retention	BRD-K00003637-003-01-9	Launched
BETP	GLP receptor positive allosteric modulator	GLP1R			BRD-K00004305-001-01-9	Preclinical
betrixaban	coagulation factor inhibitor	KCNH2	hematology	deep vein thrombosis (DVT)	BRD-K45275534-001-02-9, BRD-K45275534-001-01-3, BRD-K45275534-001-01-3, BRD-K45275534-001-01-3	Launched
bevantolol	adrenergic receptor antagonist		cardiology	angina pectoris, hypertension	BRD-K01825622-003-02-9, BRD-K01825622-003-02-9	Launched
bevenopran	opioid receptor antagonist				BRD-K00004680-001-01-9	Phase 1
bevirimat-dimeglumine	HIV capsid assembly inhibitor				BRD-K16898998-001-02-9, BRD-K16898998-001-01-6, BRD-K16898998-001-01-6	Phase 2
bexagliflozin	solute carrier family member inhibitor				BRD-K00003246-001-01-9	Phase 3
bexarotene	retinoid receptor agonist	RXRA, RXRB, RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	BRD-K92441787-001-08-9, BRD-K92441787-001-04-1, BRD-K92441787-001-04-1, BRD-K92441787-001-04-1	Launched
bezafibrate	PPAR receptor agonist	PPARA, PPARD, PPARG	cardiology	cholesterol	BRD-K46018455-001-29-9, BRD-K46018455-001-29-9, BRD-K46018455-001-27-6, BRD-K46018455-001-26-8	Launched
BFH772	VEGFR inhibitor				BRD-K00003368-001-01-9	Phase 2
BGP-15	PARP inhibitor				BRD-K00003393-300-01-9	Phase 2
BGT226	PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CG			BRD-K29415052-050-05-5, BRD-K29415052-050-05-5, BRD-K29415052-050-05-5, BRD-K29415052-050-05-5, BRD-K29415052-050-04-8, BRD-K29415052-050-06-3	Phase 1/Phase 2
BHQ	ATPase inhibitor	ATP2A1			BRD-K95603879-001-08-9, BRD-K95603879-001-07-5	Preclinical
BI-D1870	ribosomal protein inhibitor	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6			BRD-A81370665-001-06-9, BRD-A81370665-001-06-9, BRD-A81370665-001-06-9, BRD-A81370665-001-06-9, BRD-A81370665-001-06-9, BRD-A81370665-001-06-9, BRD-A81370665-001-04-4, BRD-A81370665-001-03-6	Preclinical
BI-224436	HIV integrase inhibitor				BRD-K53422148-001-01-8, BRD-K53422148-001-01-8	Phase 1
BI-2536	PLK inhibitor	BRD4, PLK1, PLK2, PLK3			BRD-K64890080-001-13-8, BRD-K64890080-001-13-8, BRD-K64890080-001-13-8, BRD-K64890080-001-13-8, BRD-K64890080-001-13-8, BRD-K64890080-001-02-1, BRD-K64890080-001-02-1, BRD-K64890080-001-02-1, BRD-K64890080-001-02-1	Phase 2
BI-409306	phosphodiesterase inhibitor				BRD-K00003120-001-01-9	Phase 1
BI-78D3	JNK inhibitor	MAPK8			BRD-K73982490-001-02-9, BRD-K73982490-001-02-9, BRD-K73982490-001-03-7, BRD-K73982490-001-03-7, BRD-K73982490-001-01-1, BRD-K73982490-001-01-1, BRD-K73982490-001-01-1, BRD-K73982490-001-01-1, BRD-K73982490-001-01-1	Preclinical
BI-847325	Aurora kinase inhibitor, MEK inhibitor	AURKA, AURKB, AURKC, MAP2K1, MAP2K2			BRD-K37492701-001-01-1, BRD-K37492701-001-02-9, BRD-K37492701-001-02-9, BRD-K37492701-001-02-9, BRD-K37492701-001-02-9	Phase 1
BIA-10-2474	Fatty acid hydrolase inhibitor				BRD-K00004735-001-01-9	Preclinical
BIBN4096	calcitonin antagonist	CALCA, CALCRL, RAMP1			BRD-K43927145-001-02-0, BRD-K43927145-001-03-8, BRD-K43927145-001-01-2, BRD-K43927145-001-01-2	Phase 2
BIBR-1532	telomerase inhibitor	TERT			BRD-K04623885-001-10-9, BRD-K04623885-001-07-5, BRD-K04623885-001-07-5, BRD-K04623885-001-07-5, BRD-K04623885-001-07-5	Preclinical
BIBU-1361	EGFR inhibitor	EGFR			BRD-K49294207-300-04-6, BRD-K49294207-300-03-8, BRD-K49294207-300-05-9	Preclinical
BIBX-1382	EGFR inhibitor	EGFR, ERBB2			BRD-K70914287-300-02-8, BRD-K70914287-300-04-9, BRD-K70914287-300-03-6	Phase 1
bicalutamide	androgen receptor antagonist	AR	oncology	prostate cancer	BRD-A29485665-001-14-4, BRD-A29485665-001-12-8, BRD-A29485665-001-11-0	Launched
bicifadine	dopamine reuptake inhibitor, serotonin receptor antagonist				BRD-K00004299-003-01-9	Phase 3
bictegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K00003247-001-01-9	Launched
bicuculline-(+)	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, KCNN1			BRD-K84363966-001-12-9	Preclinical
bicuculline-methochloride-(-)	GABA receptor antagonist				BRD-K19094907-003-16-9	Preclinical
bicyclol	NFkB pathway inhibitor	HSPA1A, HSPB1	infectious disease	hepatitis B, hepatitis C	BRD-K16546375-001-01-4	Launched
bifemelane	acetylcholine release enhancer	MAOA, MAOB	ophthalmology, neurology/psychiatry	glaucoma, senile dementia	BRD-K18779551-003-08-6, BRD-K18779551-003-09-9, BRD-K18779551-003-07-8	Launched
bifendate			infectious disease	hepatitis B, hepatitis C	BRD-K26581543-001-01-6, BRD-K26581543-001-01-6	Launched
bifonazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris	BRD-A94543220-001-24-7, BRD-A94543220-001-24-7, BRD-A94543220-001-24-7, BRD-A94543220-001-24-7, BRD-A94543220-001-23-9, BRD-A94543220-001-26-9	Launched
BIIB021	HSP inhibitor	HSP90AA1			BRD-K51967704-001-04-4, BRD-K51967704-001-04-4, BRD-K51967704-001-04-4, BRD-K51967704-001-03-6, BRD-K51967704-001-03-6	Phase 2
bilastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	BRD-K51937257-001-01-4, BRD-K51937257-001-02-9	Launched
bilobalide	GABA receptor modulator	GLRA1, GLRA2, GLRB, HTR3A, HTR3B			BRD-K32039267-001-07-9	Preclinical
bimatoprost	prostanoid receptor agonist	AKR1C3, PTGER1, PTGER3, PTGFR	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	BRD-K00003616-001-01-9	Launched
BIMU-8	serotonin receptor agonist	HTR4			BRD-K00004300-003-01-9	Preclinical
BINA	glutamate receptor positive allosteric modulator	GRM2			BRD-K00004296-001-01-9	Preclinical
bindarit	NFkB pathway inhibitor	CCL2, CCL7, CCL8			BRD-K36467523-001-03-9, BRD-K36467523-001-02-8	Phase 2
binimetinib	MEK inhibitor	MAP2K1, MAP2K2	oncology	melanoma	BRD-K82244583-001-02-9, BRD-K82244583-001-02-9, BRD-K82244583-001-01-3, BRD-K82244583-001-01-3, BRD-K82244583-001-01-3	Launched
BIO-1211	integrin antagonist	ITGA4, ITGB1			BRD-K03399463-001-01-6, BRD-K03399463-001-01-6	Phase 2
BIO-5192	integrin inhibitor	ITGA4, ITGB1			BRD-K21318844-001-02-9, BRD-K21318844-001-02-9, BRD-K21318844-001-01-4	Preclinical
bipenamol	dipeptidyl peptidase inhibitor	CTSC			BRD-K47690382-001-03-0, BRD-K47690382-001-03-0	Phase 2
biperiden	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	neurology/psychiatry	Parkinson's Disease	BRD-K01824983-001-02-9, BRD-K01824983-001-02-9, BRD-K01824983-001-03-9	Launched
birinapant	XIAP inhibitor	BIRC2, XIAP			BRD-K71221037-001-01-6, BRD-K71221037-001-01-6, BRD-K71221037-001-01-6, BRD-K71221037-001-01-6, BRD-K71221037-001-02-4, BRD-K71221037-001-02-4, BRD-K71221037-001-02-4, BRD-K71221037-001-06-5, BRD-K71221037-001-06-5	Phase 2
BIRT-377	lymphocyte function-associated antigen negative modulator	ICAM1			BRD-K64880136-001-02-6, BRD-K64880136-001-01-8	Preclinical
bis(maltolato)oxovanadium(IV)	tyrosine phosphatase inhibitor	PTPN1			BRD-K16180792-001-01-7, BRD-K16180792-001-01-7, BRD-K16180792-001-01-7, BRD-K16180792-001-01-7	Phase 2
bisacodyl	laxative		gastroenterology	constipation	BRD-K39987650-001-24-1, BRD-K39987650-001-26-9, BRD-K39987650-001-23-3	Launched
bisantrene	topoisomerase inhibitor				BRD-K00003395-001-01-9	Phase 2
bisindolylmaleimide-IX	PKC inhibitor	AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1			BRD-K06543683-066-02-1, BRD-K06543683-066-05-4, BRD-K06543683-066-03-9, BRD-K06543683-066-04-7	Preclinical
bismuth(III)-trifluoromethanesulfonate	direct substitution catalyst				BRD-M56276249-001-01-1	Preclinical
bismuth-oxalate					BRD-M02179497-001-01-1	Preclinical
bismuth-subcitrate-potassium			gastroenterology	duodenal ulcer disease	BRD-K01666936-453-01-9	Launched
bismuth-subgallate	nitric oxide synthase inhibitor	NOS1	gastroenterology	internal deoderant	BRD-K65978409-001-01-9	Launched
bisoctrizole					BRD-K00228584-001-02-9, BRD-K00228584-396-01-8	Phase 2
bisphenol-A	synthetic estrogen	AR, ESR1, ESR2, ESRRG, PPARG			BRD-K41494493-001-13-8, BRD-K41494493-001-13-8	Phase 1
bithionol	autotaxin inhibitor	ESR1, ESR2, MCL1			BRD-K39120595-304-04-7, BRD-K39120595-304-04-7, BRD-K39120595-304-04-7, BRD-K39120595-304-04-7, BRD-K39120595-304-04-7, BRD-K39120595-304-04-7, BRD-K39120595-304-04-7, BRD-K39120595-001-03-1	Withdrawn
bitopertin	glycine transporter inhibitor	SLC6A5, SLC6A9			BRD-K13756951-001-02-9, BRD-K13756951-001-01-4	Phase 3
bitoscanate	anthelmintic agent				BRD-K77548206-001-03-9, BRD-K77548206-001-02-9	Preclinical
BIX-01294	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			BRD-K26818574-001-06-3, BRD-K26818574-001-06-3, BRD-K26818574-001-06-3, BRD-K26818574-001-06-3, BRD-K26818574-305-08-4, BRD-K26818574-305-04-3, BRD-K26818574-305-04-3, BRD-K26818574-305-07-6, BRD-K26818574-305-07-6, BRD-K26818574-305-07-6, BRD-K26818574-305-07-6, BRD-K26818574-305-07-6	Preclinical
BIX-02189	MEK inhibitor	MAP2K5, MAPK7			BRD-K73368362-001-08-3, BRD-K73368362-001-07-5, BRD-K73368362-001-07-5	Preclinical
BL-5583	hypercalcaemic agent				BRD-K75282704-001-02-4, BRD-K75282704-001-02-4, BRD-K75282704-001-02-4, BRD-K75282704-001-02-4	Preclinical
blebbistatin-(+/-)	ATPase inhibitor	MYH14, MYH2			BRD-A75817871-001-06-7	Preclinical
blebbistatin-(-)	ATPase inhibitor				BRD-K61295575-001-03-6, BRD-K61295575-001-03-6	Preclinical
bleomycetin	EGFR expression inhibitor				BRD-K00004533-001-01-9	Launched
bleomycin	DNA synthesis inhibitor		hematologic malignancy, pulmonary, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, pleural effusion, testicular carcinoma, squamous cell carcinoma	BRD-K00003588-065-01-9	Launched
blonanserin	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	BRD-K25943794-001-03-9, BRD-K25943794-001-02-3, BRD-K25943794-001-02-3, BRD-K25943794-001-02-3	Launched
BLU9931	FGFR inhibitor	FGFR4			BRD-K72898849-001-01-8, BRD-K72898849-001-01-8, BRD-K72898849-001-01-8, BRD-K72898849-001-01-8	Preclinical
BLZ945	CSF1R inhibitor				BRD-K83157152-001-02-9	Phase 1/Phase 2
BML-190	cannabinoid receptor inverse agonist	CNR2			BRD-K94379058-001-05-0, BRD-K94379058-001-07-9, BRD-K94379058-001-07-9, BRD-K94379058-001-07-9, BRD-K94379058-001-06-8	Preclinical
BML-284	WNT agonist				BRD-K42624714-001-04-1, BRD-K42624714-001-04-1, BRD-K42624714-001-04-1	Preclinical
BMS-CCR2-22	CC chemokine receptor antagonist	CCR2			BRD-K15119094-001-01-1, BRD-K15119094-001-01-1, BRD-K15119094-001-02-9, BRD-K15119094-001-02-9	Preclinical
BMS-182874	endothelin receptor antagonist	EDNRA			BRD-K56509348-003-03-9, BRD-K56509348-003-04-9, BRD-K56509348-003-02-1	Phase 2
BMS-191011	potassium channel activator	KCNMA1			BRD-K95609758-001-04-5, BRD-K95609758-001-04-5, BRD-K95609758-001-03-7, BRD-K95609758-001-05-9, BRD-K95609758-001-05-9	Preclinical
BMS-191095	KATP activator, potassium channel agonist				BRD-K01231377-001-01-8, BRD-K01231377-001-01-8	Phase 1
BMS-207940	endothelin receptor antagonist				BRD-K00004634-001-01-9	Preclinical
BMS-214662	farnesyltransferase inhibitor				BRD-K00003203-001-01-9	Phase 1
BMS-265246	CDK inhibitor	CDK1, CDK2			BRD-K62814476-001-04-1, BRD-K62814476-001-04-1, BRD-K62814476-001-04-1, BRD-K62814476-001-04-1, BRD-K62814476-001-04-1, BRD-K62814476-001-04-1, BRD-K62814476-001-04-1, BRD-K62814476-001-03-3, BRD-K62814476-001-03-3, BRD-K62814476-001-03-3	Preclinical
BMS-299897	gamma secretase inhibitor				BRD-K02950022-001-02-9, BRD-K02950022-001-02-9, BRD-K02950022-001-02-9, BRD-K02950022-001-02-9	Phase 1
BMS-309403	fatty acid binding protein inhibitor	FABP4			BRD-K87956243-001-02-9, BRD-K87956243-001-01-9	Preclinical
BMS-345541	IKK inhibitor	CHUK, IKBKB			BRD-K13566078-003-07-9, BRD-K13566078-001-02-3, BRD-K13566078-001-02-3, BRD-K13566078-001-02-3, BRD-K13566078-001-02-3, BRD-K13566078-003-06-0, BRD-K13566078-003-06-0	Preclinical
BMS-387032	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor	CDK2, CDK7, CDK9			BRD-K43389698-001-07-3, BRD-K43389698-001-09-9, BRD-K43389698-001-09-9, BRD-K43389698-001-09-9	Phase 1
BMS-470539	melanocortin receptor agonist	MC1R			BRD-K22000702-300-01-4, BRD-K22000702-300-02-9	Preclinical
BMS-536924	IGF-1 inhibitor	AKT1, CCNE1, CDK2, CYP3A4, ERBB2, IGF1R, KDR, LCK, MAPK1, MET, PDGFRA, PDGFRB			BRD-K34581968-001-04-6, BRD-K34581968-001-04-6, BRD-K34581968-001-04-6, BRD-K34581968-001-05-3, BRD-K34581968-001-05-3	Preclinical
BMS-566419	inosine monophosphate dehydrogenase inhibitor	IMPDH1, IMPDH2			BRD-K56932272-001-01-1, BRD-K56932272-001-01-1, BRD-K56932272-001-01-1, BRD-K56932272-001-02-9, BRD-K56932272-001-02-9	Preclinical
BMS-582949	p38 MAPK inhibitor				BRD-K00003168-003-01-9	Phase 2
BMS-587101	integrin antagonist	ITGAL, ITGB2			BRD-K20093108-001-02-3	Phase 2
BMS-599626	EGFR inhibitor, protein tyrosine kinase inhibitor	EGFR, ERBB2, ERBB4			BRD-K07106112-300-01-2, BRD-K07106112-003-03-8, BRD-K07106112-003-03-8	Phase 1
BMS-626529	HIV attachment inhibitor				BRD-K97883416-001-01-4, BRD-K97883416-001-02-9	Phase 3
BMS-626531	p38 MAPK inhibitor				BRD-K00004550-001-01-9	Phase 1
BMS-649	retinoid receptor agonist	RXRA			BRD-K25991633-001-02-7, BRD-K25991633-001-02-7, BRD-K25991633-001-01-9, BRD-K25991633-001-01-9, BRD-K25991633-001-03-9	Preclinical
BMS-688521	ICAM1 antagonist, leukocyte function-associated antigen receptor antagonist	ICAM1			BRD-K85649978-001-02-1	Preclinical
BMS-690514	EGFR inhibitor, VEGFR inhibitor	EGFR, ERBB2, FLT3, KDR			BRD-K76239644-001-02-6, BRD-K76239644-001-02-6, BRD-K76239644-001-02-6, BRD-K76239644-001-04-9, BRD-K76239644-001-01-8, BRD-K76239644-001-01-8	Phase 2
BMS-707035	HIV integrase inhibitor				BRD-K49555808-001-03-9	Phase 2
BMS-770767	11-beta-HSD1 inhibitor				BRD-K00004655-001-01-9	Phase 2
BMS-777607	AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor	AXL, MERTK, MET, MST1R, TYRO3			BRD-K40738845-001-05-0, BRD-K40738845-001-06-9	Phase 1/Phase 2
BMS-779788	LXR agonist				BRD-K00003305-001-01-9	Phase 1
BMS-806	HIV attachment inhibitor				BRD-K55773932-001-03-8, BRD-K55773932-001-04-9, BRD-K55773932-001-02-0	Phase 1
BMS-813160	CC chemokine receptor antagonist				BRD-K00003512-001-01-9	Phase 2
BMS-817378	c-Met inhibitor, VEGFR inhibitor	KDR, MET			BRD-K81026553-234-01-8	Phase 1
BMS-833923	smoothened receptor antagonist	SMO			BRD-K33245965-001-03-4, BRD-K33245965-001-03-4, BRD-K33245965-001-03-4, BRD-K33245965-001-03-4, BRD-K33245965-001-03-4, BRD-K33245965-001-01-8, BRD-K33245965-001-02-6	Phase 2
BMS-863233	CDC inhibitor	CDC7, PIM1			BRD-K12511835-003-01-2, BRD-K12511835-003-01-2, BRD-K12511835-003-02-0, BRD-K12511835-003-02-0, BRD-K12511835-003-02-0	Phase 1/Phase 2
BMS-906024	gamma secretase inhibitor				BRD-K29343434-001-02-9	Phase 1
BMS-911543	JAK inhibitor				BRD-K00003189-001-01-9	Phase 1/Phase 2
BMS-935177	Bruton's tyrosine kinase (BTK) inhibitor				BRD-K00004721-001-01-9	Preclinical
BMS-983970	notch signaling inhibitor				BRD-K22316123-001-01-9, BRD-K22316123-001-01-9, BRD-K22316123-001-01-9, BRD-K22316123-001-01-9	Phase 1
BMS-986020	lysophosphatidic acid receptor antagonist	LPAR1			BRD-K00004586-001-01-9	Phase 2
BMS-986142	Bruton's tyrosine kinase (BTK) inhibitor				BRD-K00004591-001-01-9	Phase 2
BMS-986158	bromodomain inhibitor				BRD-K00003423-001-01-9, BRD-K00003423-001-01-9	Phase 1/Phase 2
BMS-986195	Bruton's tyrosine kinase (BTK) inhibitor				BRD-K00003110-001-01-9	Phase 1
BMS-986205	indoleamine 2,3-dioxygenase inhibitor				BRD-K00003418-001-01-9	Phase 3
BMY-14802	sigma receptor antagonist	HTR1A			BRD-A15435692-003-03-9, BRD-A15435692-003-02-3, BRD-A15435692-003-02-3, BRD-A15435692-003-02-3, BRD-A15435692-003-02-3, BRD-A15435692-003-02-3	Phase 2
BMY-45778	IP1 prostacyclin receptor agonist	PTGIR			BRD-K84895041-001-04-9, BRD-K84895041-001-02-4	Preclinical
BMY-7378	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HTR1A			BRD-K31054881-300-07-9, BRD-K31054881-300-03-9, BRD-K31054881-300-04-7, BRD-K31054881-300-04-7	Preclinical
BNC105	tubulin polymerization inhibitor				BRD-K20468903-001-01-6, BRD-K20468903-001-01-6, BRD-K20468903-001-01-6, BRD-K20468903-001-02-4	Phase 2
BNTX	opioid receptor antagonist	OPRD1, OPRK1, OPRM1				Preclinical
boceprevir	HCV inhibitor	CMA1, CTSA, CTSF, CTSK, CTSL, CTSS	infectious disease	hepatitis C	BRD-A09735281-001-03-3, BRD-A09735281-001-04-1, BRD-A09735281-001-04-1, BRD-A09735281-001-02-5	Launched
bonaphthone					BRD-K34149328-001-01-3, BRD-K34149328-001-02-1	Phase 3
bopindolol	adrenergic receptor antagonist		cardiology	hypertension, coronary artery disease (CAD)	BRD-K01825685-035-01-9, BRD-K01825685-035-01-9	Launched
bornyl-acetate					BRD-A41385909-001-02-1, BRD-A41385909-001-01-3	Preclinical
BOS-172722	monopolar spindle 1 kinase inhibitor				BRD-K00003111-001-01-9	Phase 1
bosentan	endothelin receptor antagonist	EDNRA, EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	BRD-K74763371-002-04-0	Launched
bosutinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, SRC inhibitor	ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK	hematologic malignancy	chronic myeloid leukemia (CML)	BRD-K99964838-001-15-9, BRD-K99964838-001-15-9, BRD-K99964838-001-12-7, BRD-K99964838-001-11-9, BRD-K99964838-001-11-9, BRD-K99964838-001-11-9, BRD-K99964838-001-11-9	Launched
BP-554	serotonin receptor agonist	HTR1A			BRD-K45479396-050-02-3, BRD-K45479396-050-02-3, BRD-K45479396-050-03-9, BRD-K45479396-050-03-9, BRD-K45479396-050-01-5	Preclinical
BP-897	dopamine receptor agonist	ADRA1A, ADRA1D, ADRA2A, DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2B			BRD-K17378184-001-06-9, BRD-K17378184-300-05-9	Phase 2
BQ-123	endothelin receptor antagonist	EDNRA			BRD-K00003554-001-01-9	Phase 2
BQ-788	endothelin receptor antagonist	EDNRB			BRD-K02490038-236-03-8, BRD-K02490038-236-01-2, BRD-K02490038-236-01-2	Phase 1
BQU57	Ras GTPase inhibitor	RALA, RALB			BRD-A40257118-001-02-0, BRD-A40257118-001-01-2	Preclinical
BRD4770	histone lysine methyltransferase inhibitor	EHMT2			BRD-K72264770-001-03-2, BRD-K72264770-001-04-0, BRD-K72264770-001-04-0	Preclinical
BRD7389	ribosomal protein inhibitor	RPS6KA1, RPS6KA2, RPS6KA3			BRD-K15107389-001-03-6, BRD-K15107389-001-02-8, BRD-K15107389-001-02-8, BRD-K15107389-001-02-8	Preclinical
BRD9876	kinesin inhibitor	KIF11			BRD-K89329876-001-07-8, BRD-K89329876-001-08-9	Preclinical
bremelanotide	melanocortin receptor agonist	MC1R, MC2R, MC3R, MC4R, MC5R	neurology/psychiatry	hypoactive sexual desire disorder	BRD-K06328344-015-01-7, BRD-K06328344-015-01-7	Launched
brequinar	dihydroorotate dehydrogenase inhibitor	DHODH			BRD-K96123349-236-02-8, BRD-K96123349-236-02-8, BRD-K96123349-236-02-8	Phase 2
bretazenil	GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			BRD-K96936751-001-02-2, BRD-K96936751-001-01-4, BRD-K96936751-001-03-9	Phase 2
bretylium	norepinephrine inhibitor	ATP1A1	cardiology	ventricular arrhythmias, ventricular fibrillation (VF), ventricular tachycardia (VT)	BRD-K49669424-075-19-2, BRD-K49669424-001-01-6, BRD-K49669424-075-20-9, BRD-K49669424-075-20-9	Launched
brexpiprazole	dopamine receptor partial agonist	DRD2	neurology/psychiatry	depression, schizophrenia	BRD-K00911143-001-01-9, BRD-K00911143-001-01-9, BRD-K00911143-001-01-9, BRD-K00911143-001-02-9, BRD-K00911143-001-02-9, BRD-K00911143-001-02-9	Launched
briciclib	cyclin D inhibitor	CCND1			BRD-K05531427-001-01-7, BRD-K05531427-001-01-7, BRD-K05531427-001-01-7	Phase 1
brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	ALK, EGFR	oncology	non-small cell lung cancer (NSCLC)	BRD-K56981171-001-01-0, BRD-K56981171-001-01-0, BRD-K56981171-001-01-0, BRD-K56981171-001-02-8, BRD-K56981171-001-02-8, BRD-K56981171-001-02-8, BRD-K56981171-001-02-8, BRD-K56981171-001-02-8	Launched
brilliant-green			infectious disease	antiseptic	BRD-K60348325-065-09-9, BRD-K60348325-065-09-9, BRD-K60348325-065-09-9, BRD-K60348325-065-09-9	Launched
brincidofovir	antiviral				BRD-K00004672-001-01-9	Phase 3
brivanib	FGFR inhibitor, VEGFR inhibitor	CYP3A4, FGFR1, FLT1, KCNH2, KDR			BRD-K28428262-001-04-1, BRD-K28428262-001-04-1, BRD-K28428262-001-04-1, BRD-K28428262-001-04-1	Phase 3
brivanib-alaninate	FGFR inhibitor, VEGFR inhibitor	FGFR3			BRD-K57187269-001-04-0, BRD-K57187269-001-04-0, BRD-K57187269-001-03-2, BRD-K57187269-001-03-2, BRD-K57187269-001-02-4, BRD-K57187269-001-02-4	Phase 3
brivudine	DNA directed DNA polymerase inhibitor		infectious disease	shingles	BRD-A63675168-001-01-6	Launched
BRL-15572	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			BRD-K01826777-003-08-9, BRD-K01826777-003-07-9, BRD-K01826777-003-07-9, BRD-K01826777-003-07-9	Preclinical
BRL-26314	cholesterol inhibitor	LPL			BRD-A57806482-001-01-4, BRD-A57806482-001-01-4, BRD-A57806482-001-01-4	Phase 1
BRL-37344	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			BRD-K07507905-236-03-4, BRD-K07507905-236-03-4, BRD-K07507905-236-02-6, BRD-K07507905-236-02-6	Phase 2
BRL-44408	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C			BRD-K01825677-050-02-9, BRD-K01825677-050-01-9	Preclinical
BRL-50481	phosphodiesterase inhibitor	PDE7A, PDE7B			BRD-K84266862-001-04-0, BRD-K84266862-001-03-2, BRD-K84266862-001-03-2, BRD-K84266862-001-06-9	Preclinical
BRL-52537	opioid receptor agonist	OPRK1			BRD-A37347161-003-03-9, BRD-A37347161-003-02-6, BRD-A37347161-003-02-6	Preclinical
BRL-54443	serotonin receptor agonist	HTR1E, HTR1F			BRD-K17868609-001-04-3, BRD-K17868609-001-06-9, BRD-K17868609-001-06-9, BRD-K17868609-001-05-0	Preclinical
brolitene	muscle relaxant	RYR1	rheumatology	lumbago	BRD-K76021681-001-02-2, BRD-K76021681-001-01-4	Launched
bromantan	dopamine reuptake inhibitor, serotonin reuptake inhibitor		neurology/psychiatry	neurasthenia	BRD-K86358349-001-02-0, BRD-K86358349-001-02-0, BRD-K86358349-001-01-2, BRD-K86358349-001-01-2	Launched
bromebric-acid	DNA synthesis inhibitor, purine antagonist				BRD-K17874929-236-02-0	Preclinical
bromfenac	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-K47679368-236-01-7	Withdrawn
bromhexine	mucolytic agent		pulmonary	chest congestion	BRD-K47631482-003-08-9, BRD-K47631482-003-07-0, BRD-K47631482-003-06-2, BRD-K47631482-003-06-2, BRD-K47631482-003-06-2, BRD-K47631482-003-06-2	Launched
bromindione	anticoagulant				BRD-K50490982-001-08-2, BRD-K50490982-001-09-9	Phase 2
bromisoval	anti-inflammatory agent				BRD-K00003522-001-01-9	Preclinical
bromopride	dopamine receptor antagonist	DRD2	gastroenterology	nausea, vomiting, gastroesophageal reflux disease (GERD)	BRD-K73642618-001-13-3, BRD-K73642618-001-13-3, BRD-K73642618-001-14-9	Launched
bromosporine	bromodomain inhibitor				BRD-K44665581-001-03-9, BRD-K44665581-001-02-6, BRD-K44665581-001-02-6, BRD-K44665581-001-01-8, BRD-K44665581-001-01-8, BRD-K44665581-001-01-8, BRD-K44665581-001-01-8	Preclinical
bromperidol	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	BRD-K78643075-001-11-6, BRD-K78643075-001-11-6, BRD-K78643075-001-12-9, BRD-K78643075-001-12-9	Launched
brompheniramine	histamine receptor antagonist	HRH1	allergy, otolaryngology	allergic rhinitis, common cold	BRD-K01825159-050-02-9	Launched
bronopol			obstetrics/gynecology	mastitis	BRD-K33457401-001-02-9, BRD-K33457401-001-01-1	Launched
bropirimine	interferon inducer				BRD-K17500877-001-04-9, BRD-K17500877-001-02-1, BRD-K17500877-001-03-9	Phase 3
broxaldine					BRD-K36222532-001-02-9, BRD-K36222532-001-01-8, BRD-K36222532-001-01-8	Preclinical
broxaterol	adrenergic receptor agonist	ADRB2			BRD-A08316590-001-01-3	Phase 3
broxuridine	antimetabolite				BRD-K79095980-001-11-9, BRD-K79095980-001-09-6	Phase 2
broxyquinoline	antiprotozoal agent				BRD-K23301018-001-12-9, BRD-K23301018-001-10-9, BRD-K23301018-001-09-1, BRD-K23301018-001-11-7	Phase 1
bruceantin	protein synthesis inhibitor				BRD-A36057565-001-01-0, BRD-A36057565-001-01-0, BRD-A36057565-001-01-0, BRD-A36057565-001-02-9, BRD-A36057565-001-02-9	Phase 2
brucine	glycine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			BRD-K68077509-330-01-9	Preclinical
BS-181	CDK inhibitor	CDK7			BRD-K31313613-300-06-9, BRD-K31313613-300-01-8, BRD-K31313613-003-05-9, BRD-K31313613-003-04-2, BRD-K31313613-003-04-2, BRD-K31313613-003-04-2, BRD-K31313613-003-04-2	Preclinical
BT-11	cAMP stimulant				BRD-K00003444-001-01-9	Phase 2
BTB06584	ATPase inhibitor	ATP5F1			BRD-K37933329-001-01-6, BRD-K37933329-001-02-4, BRD-K37933329-001-03-9	Preclinical
BTB1	mitotic kinesin inhibitor	KIF18A			BRD-K89000287-001-01-1, BRD-K89000287-001-01-1, BRD-K89000287-001-02-9	Preclinical
BTK-IN-1	Bruton's tyrosine kinase (BTK) inhibitor				BRD-K00003437-001-01-9	Preclinical
BTS					BRD-K64178227-001-10-8, BRD-K64178227-001-11-9, BRD-K64178227-001-09-0	Preclinical
BTS-54505	dopamine reuptake inhibitor	SLC6A2, SLC6A3, SLC6A4			BRD-A68304895-003-03-0, BRD-A68304895-003-02-2, BRD-A68304895-003-02-2, BRD-A68304895-003-02-2, BRD-A68304895-003-04-9	Withdrawn
BTS-71321					BRD-K00010938-001-01-9	Phase 2
BTS-72664	GABA receptor antagonist	GABBR1			BRD-A65793993-001-01-6	Phase 1
BTT-3033	integrin inhibitor	ITGA2, ITGB1			BRD-K01492390-001-02-9, BRD-K01492390-001-01-9, BRD-K01492390-001-01-9	Preclinical
BTZ043-racemate	DPRE1 inhibitor				BRD-A53037217-001-04-9, BRD-A53037217-001-02-0	Phase 1/Phase 2
BU-224	imidazoline receptor ligand	MAOA, MAOB			BRD-K55344148-003-02-6, BRD-K55344148-003-02-6, BRD-K55344148-003-02-6	Preclinical
BU-239	imidazoline receptor agonist, imidazoline receptor ligand				BRD-K11696279-003-02-3, BRD-K11696279-003-02-3, BRD-K11696279-003-02-3, BRD-K11696279-003-02-3, BRD-K11696279-003-02-3, BRD-K11696279-003-02-3, BRD-K11696279-003-03-1	Preclinical
bucetin	analgesic agent				BRD-A88684804-001-04-3, BRD-A88684804-001-05-9	Withdrawn
bucillamine	immunosuppressant		rheumatology	rheumatoid arthritis	BRD-K24697665-001-02-2, BRD-K24697665-001-01-4	Launched
buclizine	histamine receptor antagonist	HRH1	neurology/psychiatry	migraine headache	BRD-A91444184-300-01-9, BRD-A91444184-300-01-9	Launched
budipine	glutamate receptor antagonist	GRIN1	neurology/psychiatry	Parkinson's Disease	BRD-K18324993-001-01-6, BRD-K18324993-001-01-6	Launched
bufexamac	cyclooxygenase inhibitor	HDAC10, HDAC6			BRD-K36660044-001-25-9, BRD-K36660044-001-25-9, BRD-K36660044-001-24-2, BRD-K36660044-001-23-4	Withdrawn
buflomedil	adrenergic receptor antagonist, calcium channel blocker	ADRA1A	cardiology	peripheral artery disease (PAD)	BRD-K19462402-003-25-9, BRD-K19462402-003-25-9, BRD-K19462402-003-25-9, BRD-K19462402-003-25-9, BRD-K19462402-003-24-6, BRD-K19462402-003-23-8	Launched
bumetanide	solute carrier family member inhibitor	CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5	cardiology	edema, congestive heart failure	BRD-K38197229-001-31-5, BRD-K38197229-001-29-9, BRD-K38197229-001-32-9, BRD-K38197229-001-32-9, BRD-K38197229-001-28-1	Launched
bunazosin	adrenergic receptor antagonist	ADRA1A	ophthalmology	glaucoma, intraocular pressure	BRD-K35034482-001-01-8, BRD-K35034482-003-02-9	Launched
buparlisib	PI3K inhibitor	PIK3CA, PIK3CG			BRD-K42191735-001-08-7, BRD-K42191735-001-05-3, BRD-K42191735-001-05-3	Phase 3
buparvaquone	antiprotozoal agent		infectious disease	protozoan infection	BRD-A07947329-001-02-9, BRD-A07947329-001-01-4	Launched
buphenine	adrenergic receptor agonist	ADRB2	rheumatology	Raynaud's disease	BRD-A36267905-003-19-2, BRD-A36267905-003-18-4	Launched
bupicomide	adrenergic receptor antagonist	ADRB1			BRD-K51700582-001-01-2, BRD-K51700582-001-01-2	Phase 1
bupivacaine	sodium channel blocker	KCNA5, SCN10A	neurology/psychiatry	peripheral nerve block, caudal epidural block, lumbar epidural block	BRD-K00003636-001-01-9	Launched
bupranolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology, ophthalmology	hypertension, glaucoma	BRD-A48420483-001-02-3, BRD-A48420483-001-03-9, BRD-A48420483-001-01-5, BRD-A48420483-001-04-9, BRD-A48420483-001-04-9	Launched
bupropion	dopamine reuptake inhibitor	SLC6A2, SLC6A3	neurology/psychiatry	depression	BRD-K01826729-003-06-9	Launched
buramate	antiepileptic				BRD-K30360804-001-01-3, BRD-K30360804-001-02-9	Preclinical
buserelin	gonadotropin releasing factor hormone receptor agonist		oncology, obstetrics/gynecology	prostate cancer, endometriosis	BRD-K00003161-015-01-9	Launched
buspirone	serotonin receptor agonist	DRD2, HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)	BRD-K93461745-003-25-0, BRD-K93461745-003-23-5, BRD-K93461745-003-26-9, BRD-K93461745-003-24-3	Launched
busulfan	DNA inhibitor		hematologic malignancy	chronic myeloid leukemia (CML)	BRD-K23204545-001-16-4, BRD-K23204545-001-15-6, BRD-K23204545-001-18-0	Launched
butabindide	tripeptidyl peptidase inhibitor	TPP2			BRD-K40581315-034-01-5, BRD-K40581315-034-02-9	Preclinical
butacaine	local anesthetic		neurology/psychiatry	local anesthetic	BRD-K99622919-001-23-0, BRD-K99622919-001-22-2, BRD-K99622919-001-24-8	Launched
butaclamol	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A			BRD-K20620780-003-15-6	Phase 2
butalbital	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2	neurology/psychiatry	headache, muscle relaxant	BRD-K71350836-001-02-4, BRD-K71350836-001-02-4	Launched
butamben	sodium channel blocker				BRD-K27217864-001-23-9, BRD-K27217864-001-22-3, BRD-K27217864-001-22-3	Withdrawn
butaprost	prostaglandin receptor agonist				BRD-K00004715-001-01-9	Preclinical
butein	EGFR inhibitor, SRC inhibitor	ACE			BRD-K17497770-001-03-6, BRD-K17497770-001-04-4, BRD-K17497770-001-04-4, BRD-K17497770-001-04-4	Preclinical
butenafine	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	BRD-K90630139-003-05-9, BRD-K90630139-003-05-9, BRD-K90630139-003-05-9, BRD-K90630139-003-06-9	Launched
buthionine-sulfoximine	glutathione transferase inhibitor	GCLM			BRD-A47706533-001-02-6	Phase 1
butibufen	cyclooxygenase inhibitor				BRD-A46136514-001-01-2, BRD-A46136514-001-01-2, BRD-A46136514-236-02-9	Withdrawn
butoconazole	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	BRD-K01824994-008-03-9, BRD-K01824994-001-02-9	Launched
butofilolol	adrenergic receptor antagonist				BRD-A27274504-001-01-6	Phase 2
butyl-paraben	DNA synthesis inhibitor				BRD-K08287586-001-14-3, BRD-K08287586-001-14-3	Preclinical
butylated-hydroxyanisole	antioxidant				BRD-K93035859-001-07-6, BRD-K93035859-001-08-9	Preclinical
butylated-hydroxytoluene	carbonic anhydrase inhibitor	CA2			BRD-K53153417-001-10-4, BRD-K53153417-001-10-4, BRD-K53153417-001-13-9	Phase 1
butylidenephthalide	cyclooxygenase inhibitor				BRD-K02260986-001-03-9	Phase 1/Phase 2
butylphthalide	potassium channel antagonist	KCNK2	neurology/psychiatry	stroke	BRD-A59378440-001-01-3	Launched
butylscopolamine-bromide	cholinergic receptor antagonist		gastroenterology	abdominal pain	BRD-K01825841-004-02-9	Launched
BU226	imidazoline receptor ligand				BRD-K56115039-003-03-9, BRD-K56115039-003-02-1, BRD-K56115039-003-02-1, BRD-K56115039-003-02-1	Preclinical
BVD-523	MAP kinase inhibitor				BRD-K28965160-001-01-1, BRD-K28965160-001-01-1, BRD-K28965160-001-02-9	Phase 2
BVT-2733	11-beta hydroxysteroid dehydrogenase inhibitor	HSD17B1			BRD-K01742705-001-01-7	Preclinical
BW-A4C	lipoxygenase inhibitor	ALOX5			BRD-K80194255-001-01-9, BRD-K80194255-001-01-9	Phase 1
BW-B70C	lipoxygenase inhibitor	ALOX5			BRD-A55946879-001-04-9, BRD-A55946879-001-03-7	Preclinical
BW-180C	opioid receptor agonist	OPRD1, OPRM1			BRD-K00003548-001-01-9	Phase 2
BW-348U87	antiviral				BRD-K00004593-001-01-9	Preclinical
BW-373U86	opioid receptor agonist	OPRD1			BRD-K74990253-001-03-9, BRD-K74990253-001-02-8, BRD-K74990253-001-02-8	Preclinical
BW-616U	monoamine oxidase inhibitor	MAOA			BRD-K07061232-001-01-8, BRD-K07061232-001-01-8	Preclinical
BW-723C86	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			BRD-K01826747-003-10-9, BRD-K01826747-003-11-9, BRD-K01826747-003-09-9	Preclinical
BX-795	IKK inhibitor	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1			BRD-K47983010-001-15-3, BRD-K47983010-001-09-6, BRD-K47983010-001-12-0, BRD-K47983010-001-14-6	Preclinical
BX-912	pyruvate dehydrogenase kinase inhibitor	CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1			BRD-K49669041-001-08-4, BRD-K49669041-001-08-4	Preclinical
BYK-204165	PARP inhibitor	PARP1			BRD-K61665160-001-02-3, BRD-K61665160-001-01-5, BRD-K61665160-001-01-5, BRD-K61665160-001-01-5, BRD-K61665160-001-01-5, BRD-K61665160-001-01-5, BRD-K61665160-001-03-9	Preclinical
C-021	CC chemokine receptor antagonist	CCR4			BRD-K98179423-300-01-3, BRD-K98179423-300-01-3, BRD-K98179423-300-01-3, BRD-K98179423-300-01-3, BRD-K98179423-300-02-9, BRD-K98179423-300-02-9	Preclinical
C-1	protein kinase inhibitor	PRKCA			BRD-K72462751-001-03-5, BRD-K72462751-001-03-5, BRD-K72462751-001-02-7, BRD-K72462751-001-02-7	Preclinical
C-751					BRD-K15337272-001-01-3	Preclinical
CA-4948	kinase inhibitor				BRD-K00003511-001-01-9	Phase 1
cabagin			gastroenterology	dyspepsia	BRD-K41504985-005-01-5, BRD-K41504985-003-02-9	Launched
cabaletta	pharmacological chaperone				BRD-K54028654-001-02-6	Phase 2
cabazitaxel	microtubule inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	prostate cancer	BRD-K10384176-001-02-9	Launched
cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	KDR, MET, RET	oncology	medullary thyroid cancer (MTC)	BRD-K51544265-001-06-7, BRD-K51544265-001-04-2, BRD-K51544265-001-04-2, BRD-K51544265-001-04-2, BRD-K51544265-001-04-2, BRD-K51544265-001-04-2, BRD-K51544265-001-03-4, BRD-K51544265-001-03-4, BRD-K51544265-001-03-4, BRD-K51544265-001-03-4	Launched
CaCCinh-A01	calcium-activated chloride channel inhibitor	CLCA1			BRD-A90751343-001-02-9, BRD-A90751343-001-01-0	Preclinical
cadazolid	antibacterial 				BRD-K00003370-001-01-9	Phase 3
cadralazine	adrenergic receptor antagonist		cardiology	hypertension	BRD-A78134170-001-01-3, BRD-A78134170-001-01-3	Launched
cafestol	pregnane X receptor agonist				BRD-K46741531-001-02-4	Launched
caffeic-acid	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor	ALOX5, MIF			BRD-K09900591-001-29-9, BRD-K09900591-001-29-9, BRD-K09900591-001-26-7, BRD-K09900591-001-25-9	Preclinical
caffeic-acid-phenethyl-ester	HIV integrase inhibitor	RELA			BRD-K96188950-001-16-9, BRD-K96188950-001-17-9, BRD-K96188950-001-15-1	Preclinical
caffeine	adenosine receptor antagonist, phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADORA3, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, PIK3CA, PIK3CB, PIK3CD, PRKDC, RYR1, RYR2, RYR3	neurology/psychiatry	fatigue, drowsiness	BRD-K02404261-001-16-7, BRD-K02404261-001-16-7, BRD-K02404261-001-16-7	Launched
calcipotriol	vitamin D receptor agonist	VDR	dermatology	psoriasis	BRD-K56429665-001-09-6, BRD-K56429665-001-09-6, BRD-K56429665-001-09-6, BRD-K56429665-001-09-6, BRD-K56429665-002-01-1, BRD-K56429665-002-01-1, BRD-K56429665-002-01-1, BRD-K56429665-001-07-0	Launched
calcitonin	calcitonin agonist		orthopedics	osteoporosis	BRD-K00005332-019-01-9	Launched
calcium-levofolinate					BRD-K97009491-238-05-9, BRD-K97009491-238-03-8, BRD-K97009491-238-02-0, BRD-K97009491-238-04-6	Launched
Calhex-231	calcium sensing receptor negative allosteric modulator	CASR			BRD-K19811997-003-02-9, BRD-K19811997-003-02-9, BRD-K19811997-003-01-3	Preclinical
calpeptin	calpain inhibitor				BRD-K26134695-001-04-4, BRD-K26134695-001-04-4, BRD-K26134695-001-05-9, BRD-K26134695-001-05-9, BRD-K26134695-001-05-9, BRD-K26134695-001-05-9, BRD-K26134695-001-05-9, BRD-K26134695-001-03-6	Preclinical
camicinal	motilin receptor agonist	MLNR			BRD-K23248433-001-02-9, BRD-K23248433-001-01-8, BRD-K23248433-001-01-8	Phase 2
CaMKII-IN-1	calcium/calmodulin dependent protein kinase inhibitor	AKT1, CAMK2A, CAMK4, MYLK			BRD-K35772771-001-02-1, BRD-K35772771-001-01-3	Preclinical
camobucol	anti-inflammatory agent				BRD-K00004732-001-01-9	Preclinical
camostat-mesilate	protease inhibitor	PRSS1	gastroenterology	pancreatitis	BRD-K43806473-066-03-9, BRD-K43806473-066-04-9, BRD-K43806473-066-02-1	Launched
camphor-(+)					BRD-K10034334-001-08-9, BRD-K10034334-001-03-3	Phase 2
camphor-(1R)	TRPV activator	TRPV1			BRD-K15714472-001-04-5	Phase 1
camptothecin	topoisomerase inhibitor	TOP1			BRD-K37890730-001-17-7, BRD-K37890730-001-17-7, BRD-K37890730-001-15-1, BRD-K37890730-001-15-1, BRD-K37890730-001-15-1, BRD-K37890730-001-16-9	Phase 3
camylofine-chlorhydrate			gastroenterology	abdominal pain	BRD-A91733352-300-03-7, BRD-A91733352-300-04-5, BRD-A91733352-300-05-2	Launched
canagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	BRD-K90868879-001-04-9, BRD-K90868879-001-03-8, BRD-K90868879-001-02-0	Launched
candesartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure	BRD-K84091759-001-11-9, BRD-K84091759-001-11-9, BRD-K84091759-001-10-5, BRD-K84091759-001-08-9, BRD-K84091759-001-07-1, BRD-K84091759-001-07-1	Launched
candesartan-cilexetil	angiotensin receptor antagonist		cardiology	hypertension, congestive heart failure, hypertension	BRD-A65671304-001-08-3, BRD-A65671304-001-07-5, BRD-A65671304-001-07-5, BRD-A65671304-001-07-5, BRD-A65671304-001-07-5, BRD-A65671304-001-09-9, BRD-A65671304-001-09-9	Launched
candicidin	fungal ergosterol inhibitor		infectious disease	vulvovaginal candidiasis	BRD-A37348498-015-01-4	Launched
canertinib	EGFR inhibitor	AKT1, EGFR, ERBB2, ERBB4			BRD-K50168500-001-07-9, BRD-K50168500-001-07-9, BRD-K50168500-001-07-9, BRD-K50168500-001-07-9, BRD-K50168500-001-01-2, BRD-K50168500-001-01-2, BRD-K50168500-001-01-2	Phase 3
cangrelor	purinergic receptor antagonist		cardiology	myocardial infarction	BRD-K00004669-001-01-9	Launched
canrenone	mineralocorticoid receptor antagonist	NR3C2			BRD-K81644801-001-08-9	Withdrawn
cantharidin	protein phosphatase inhibitor		dermatology	blisters	BRD-K80684056-001-09-3, BRD-K80684056-001-06-9, BRD-K80684056-001-05-1, BRD-K80684056-001-04-4	Launched
capadenoson	adenosine receptor agonist	ADORA1			BRD-K97025174-001-01-4, BRD-K97025174-001-01-4, BRD-K97025174-001-02-9	Phase 2
capobenic-acid					BRD-K04282412-001-16-3	Preclinical
capreomycin	protein synthesis inhibitor		infectious disease	tuberculosis	BRD-K00005140-065-02-9	Launched
capromorelin	growth hormone secretagogue receptor agonist				BRD-K00003188-046-01-9	Preclinical
caprylic-acid					BRD-K35170555-001-12-9, BRD-K35170555-001-09-5	Launched
capsaicin	TRPV agonist	CFTR, TRPV1	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis	BRD-K50590187-001-20-7, BRD-K50590187-001-19-9	Launched
capsazepine	TRPV agonist	TRPV1, TRPV4			BRD-K44849676-001-11-3, BRD-K44849676-001-12-9, BRD-K44849676-001-12-9, BRD-K44849676-001-10-5	Preclinical
captamine					BRD-K81645907-001-01-1, BRD-K81645907-003-01-7	Preclinical
captan					BRD-A79857384-001-03-6	Phase 1
caracemide	ribonucleotide reductase inhibitor	RRM1			BRD-K62790656-001-01-1, BRD-K62790656-001-01-1	Phase 2
caramiphen	cholinergic receptor antagonist	CHRM1, CHRM2	neurology/psychiatry	Parkinson's Disease	BRD-K59895502-001-01-9, BRD-K59895502-001-01-9	Launched
carazolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	angina pectoris, cardiac arrythmia, hypertension, myocardial infarction	BRD-A50675490-001-01-0, BRD-A50675490-001-01-0	Launched
carbachol	cholinergic receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA2	ophthalmology	intraocular pressure	BRD-K75037734-003-14-7, BRD-K75037734-003-15-9, BRD-K75037734-003-13-9	Launched
carbamazepine	carboxamide antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	BRD-K71799949-001-38-0, BRD-K71799949-001-38-0, BRD-K71799949-001-36-4, BRD-K71799949-001-35-6	Launched
carbaril	acetylcholinesterase inhibitor				BRD-K54208592-001-09-4, BRD-K54208592-001-10-9	Launched
carbarsone	antiprotozoal agent		infectious disease	amebiasis	BRD-K94848716-001-11-6, BRD-K94848716-001-12-9	Launched
carbazochrome			hematology	hemorrhage	BRD-A11070335-236-02-1, BRD-A11070335-236-03-9, BRD-A11070335-236-03-9	Launched
carbendazim	microtubule inhibitor, tubulin polymerization inhibitor	TP53, TUBB	infectious disease	fungicide	BRD-K12906202-001-06-2, BRD-K12906202-001-06-2	Launched
carbenicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	BRD-A13078313-304-09-9, BRD-A13078313-304-06-5, BRD-A13078313-304-08-1, BRD-A13078313-304-05-7, BRD-A13078313-304-07-3	Launched
carbenoxolone	11-beta hydroxysteroid dehydrogenase inhibitor	GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, HSD11B1, PANX1, PANX2, PANX3	gastroenterology, dental	peptic ulcer disease (PUD), mouth inflammation	BRD-K12765235-304-04-9	Launched
carbetapentane	acetylcholine receptor antagonist	CHRM2	otolaryngology, pulmonary	common cold, nasal congestion, bronchitis	BRD-K06181161-048-16-9, BRD-K06181161-048-15-1	Launched
carbetocin	oxytocin receptor agonist	OXTR	hematology	hemorrhage	BRD-K56107812-001-01-7	Launched
carbimazole	antithyroid agent	TPO	endocrinology	hyperthyroidism	BRD-K87156652-001-14-9, BRD-K87156652-001-11-9, BRD-K87156652-001-12-7, BRD-K87156652-001-13-5	Launched
carbinoxamine	histamine receptor antagonist	HRH1	allergy, ophthalmology, otolaryngology, dermatology	allergic rhinitis, conjunctivitis, vasomotor rhinitis, dermatographism	BRD-K01826745-050-08-9	Launched
carboxyamidotriazole	calcium channel blocker	CXCL8			BRD-K68408772-001-05-4, BRD-K68408772-001-05-4, BRD-K68408772-001-05-4, BRD-K68408772-001-06-9	Phase 3
carboxylosartan	angiotensin antagonist	AGTR1			BRD-K23533833-001-01-9	Phase 1
carboxypyridine-disulfide					BRD-K26530649-001-01-6, BRD-K26530649-001-01-6, BRD-K26530649-001-01-6	Phase 2
cardiogenol-C	cardiomyogenesis inducer				BRD-K99174507-003-03-8, BRD-K99174507-003-02-0, BRD-K99174507-003-04-9	Preclinical
cardionogen-1	WNT signaling inhibitor	CTNNB1			BRD-K50905564-001-08-9, BRD-K50905564-001-07-7	Preclinical
carebastine	histamine receptor antagonist	HRH1			BRD-K49554218-001-01-0	Phase 1
carfilzomib	proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9	hematologic malignancy	multiple myeloma	BRD-K15179879-001-11-9, BRD-K15179879-001-11-9, BRD-K15179879-001-03-2, BRD-K15179879-001-03-2, BRD-K15179879-001-03-2, BRD-K15179879-001-03-2, BRD-K15179879-001-03-2, BRD-K15179879-001-03-2	Launched
carglumic-acid	carbamoyl phosphate synthase activator	CPS1	metabolism	hyperammonemia	BRD-K60240222-001-02-9, BRD-K60240222-001-01-4	Launched
caricotamide	NADPH quinone oxidoreductase inhibitor	NQO2			BRD-K90215590-001-01-4	Phase 2
cariporide	sodium/hydrogen exchanger inhibitor	SLC9A1			BRD-K21670884-001-01-9	Phase 3
cariprazine	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	schizophrenia	BRD-K57764956-001-02-8, BRD-K57764956-001-02-8	Launched
carmofur	thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	BRD-K11630072-001-12-4, BRD-K11630072-001-13-2, BRD-K11630072-001-13-2, BRD-K11630072-001-11-6	Launched
carmoxirole	dopamine receptor agonist	DRD2			BRD-K82484965-003-04-3, BRD-K82484965-003-04-3, BRD-K82484965-003-03-5	Phase 2
carmustine	DNA alkylating agent, DNA inhibitor	GSR	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma	BRD-K36234266-001-09-8, BRD-K36234266-001-09-8	Launched
carnitine-(D/L)					BRD-A89594340-003-12-3, BRD-A89594340-003-11-5, BRD-A89594340-003-11-5, BRD-A89594340-003-13-1	Phase 3
carnosine	antiglycating agent				BRD-A96051074-001-02-2	Phase 2
caroverin	cytochrome P450 inhibitor				BRD-K70161083-003-05-5, BRD-K70161083-001-06-9	Phase 3
caroxazone	monoamine oxidase inhibitor	MAOA, MAOB			BRD-K92129045-001-01-6, BRD-K92129045-001-01-6, BRD-K92129045-001-01-6	Withdrawn
carprofen	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	BRD-A17411484-001-11-9, BRD-A17411484-001-10-1, BRD-A17411484-001-13-9	Launched
carsalam	analgesic agent				BRD-K13238618-001-06-9, BRD-K13238618-001-05-9	Preclinical
carteolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	BRD-A42167015-003-10-2	Launched
carumonam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	BRD-K71026158-304-01-0	Launched
carvedilol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	myocardial infarction, hypertension	BRD-K01826535-001-02-9, BRD-K01826535-001-02-9	Launched
carzenide		CA1, CA12, CA14, CA2, CA6, CA9			BRD-K09295674-001-09-8	Preclinical
casanthranol-variant			gastroenterology	constipation	BRD-K12413266-001-01-3, BRD-K12413266-001-02-1	Launched
casin	GTPase inhibitor	CDC42			BRD-A25043798-001-02-9, BRD-A25043798-001-01-2	Preclinical
caspofungin	bacterial cell wall synthesis inhibitor, fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, esophageal candidiasis, aspergillosis, peritonitis, fungal infection	BRD-K00002625-402-02-9	Launched
castanospermine	glucosidase inhibitor	GAA, GBA			BRD-K20897876-001-11-8, BRD-K20897876-001-10-0	Phase 2
catharanthine	tubulin polymerization inhibitor				BRD-K92377961-001-04-9, BRD-K92377961-001-03-7, BRD-K92377961-001-02-9	Preclinical
cathepsin-inhibitor-1	cathepsin inhibitor	CTSB, CTSL, CTSV			BRD-K40269473-001-02-2, BRD-K40269473-001-03-0	Preclinical
CAY10505	PI3K inhibitor	PIK3CG			BRD-K40366680-001-05-9, BRD-K40366680-001-05-9, BRD-K40366680-001-04-1, BRD-K40366680-001-03-3	Preclinical
CB-03-01	androgen receptor antagonist	AR			BRD-K41779183-001-01-2, BRD-K41779183-001-01-2, BRD-K41779183-001-02-0, BRD-K41779183-001-02-0, BRD-K41779183-001-02-0	Phase 3
CB-10-277	DNA synthesis inhibitor				BRD-K59929863-001-02-9, BRD-K59929863-001-01-9, BRD-K59929863-001-01-9	Phase 1
CB-5083	valosin-containing protein inhibitor	VCP			BRD-K49048664-001-02-0, BRD-K49048664-001-01-2, BRD-K49048664-001-01-2	Phase 1
CB-839	glutaminase inhibitor	GLS			BRD-K58070273-001-03-3, BRD-K58070273-001-03-3, BRD-K58070273-001-03-3, BRD-K58070273-001-03-3, BRD-K58070273-001-04-1	Phase 2
CBiPES	glutamate receptor positive allosteric modulator	GRM2			BRD-K34675210-003-01-4, BRD-K34675210-003-01-4, BRD-K34675210-003-02-9	Preclinical
cbl0137	histone chaperone inhibitor				BRD-K00003273-003-01-9	Phase 1
CBS-1114	lipoxygenase inhibitor	ALOX5			BRD-K91874254-001-01-4	Phase 1
CC-115	DNA protein kinase inhibitor, mTOR inhibitor	MTOR			BRD-K16755045-003-01-7, BRD-K16755045-003-01-7, BRD-K16755045-001-01-1, BRD-K16755045-003-02-5	Phase 2
CC-223	mTOR inhibitor	MTOR			BRD-K88737571-001-02-2, BRD-K88737571-001-01-4	Phase 2
CC-401	JNK inhibitor	MAPK8			BRD-K00004320-300-01-9	Phase 1
CC-90003	MAP kinase inhibitor				BRD-K00003116-001-01-9	Phase 1
CC-930	JNK inhibitor				BRD-K48213016-001-01-8, BRD-K48213016-001-01-8, BRD-K48213016-001-01-8, BRD-K48213016-001-01-8, BRD-K48213016-001-02-9	Phase 2
CCG-1423	apoptosis stimulant	RHOC, SRF			BRD-A79726147-001-02-9, BRD-A79726147-001-01-5	Preclinical
CCG-50014	G protein signaling inhibitor	RGS4, RGS8			BRD-K08893438-001-08-9, BRD-K08893438-001-06-4, BRD-K08893438-001-04-9, BRD-K08893438-001-04-9, BRD-K08893438-001-04-9, BRD-K08893438-001-03-1	Preclinical
CCG-63802	G protein signaling inhibitor	RGS4			BRD-K26970495-001-02-7, BRD-K26970495-001-01-9	Preclinical
CCG-63808	G protein signaling inhibitor	RGS4			BRD-K68474505-001-02-7, BRD-K68474505-001-01-9	Preclinical
CCMQ	homoquinolinic acid binding inhibitor				BRD-K06159959-001-03-9, BRD-K06159959-001-02-0	Preclinical
CCT-031374	WNT signaling inhibitor	CTNNB1			BRD-K90999434-004-02-9, BRD-K90999434-004-01-7	Preclinical
CCT018159	HSP inhibitor	HSP90AA1, HSP90AB1			BRD-K65503129-001-07-1, BRD-K65503129-001-07-1, BRD-K65503129-001-06-3	Preclinical
CCT128930	AKT inhibitor				BRD-K76406695-001-02-9, BRD-K76406695-001-02-9, BRD-K76406695-001-02-9, BRD-K76406695-001-02-9, BRD-K76406695-001-05-9	Preclinical
CCT129202	Aurora kinase inhibitor	AURKA, AURKB, AURKC			BRD-K57136142-001-02-4, BRD-K57136142-001-03-2, BRD-K57136142-001-04-9	Preclinical
CCT137690	Aurora kinase inhibitor	AURKA, AURKB, AURKC			BRD-K03289018-001-02-7, BRD-K03289018-001-03-5, BRD-K03289018-001-04-3, BRD-K03289018-001-05-9	Preclinical
CCT196969	RAF inhibitor				BRD-K00005244-001-01-9, BRD-K00005244-001-01-9	Preclinical
CCT245737	kinase inhibitor				BRD-K00003276-001-01-9	Preclinical
CC4	nicotinic receptor agonist	CHRNB2			BRD-K17751100-001-02-9, BRD-K17751100-001-01-1	Preclinical
CD-437	retinoid receptor agonist	RARG			BRD-K28907958-001-05-0, BRD-K28907958-001-05-0, BRD-K28907958-001-04-3, BRD-K28907958-001-04-3, BRD-K28907958-001-04-3, BRD-K28907958-001-04-3, BRD-K28907958-001-04-3	Preclinical
CDBA					BRD-A08079565-001-01-8, BRD-A08079565-001-01-8, BRD-A08079565-001-01-8	Phase 3
CDK1-5-inhibitor	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK5, GSK3B			BRD-K87932577-001-04-9, BRD-K87932577-001-02-4, BRD-K87932577-001-02-4, BRD-K87932577-001-02-4	Preclinical
CDK9-IN-6	CDK inhibitor	CDK9			BRD-K43914553-001-01-5, BRD-K43914553-001-01-5, BRD-K43914553-001-01-5	Preclinical
CDPPB	glutamate receptor positive allosteric modulator	GRM5			BRD-K02213468-001-02-3, BRD-K02213468-001-03-9	Preclinical
cebranopadol	opioid receptor agonist	OPRL1, OPRM1			BRD-K48141473-001-01-7, BRD-K48141473-001-01-7, BRD-K48141473-001-02-9	Phase 3
cediranib	KIT inhibitor, VEGFR inhibitor	CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB			BRD-K86930074-001-06-9, BRD-K86930074-001-05-0, BRD-K86930074-001-05-0, BRD-K86930074-001-05-0, BRD-K86930074-001-05-0	Phase 3
cedrol					BRD-A61188230-001-01-6	Phase 2
cedrol-(+)	sedative				BRD-K96362839-001-01-9, BRD-K96362839-001-02-9	Phase 2
cefaclor	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	pneumonia, skin infections, urinary tract infections, respiratory tract infections, tonsillitis, pharyngitis	BRD-K20338176-001-19-9, BRD-K20338176-001-18-5, BRD-K20338176-001-17-7, BRD-K20338176-001-16-9	Launched
cefadroxil	bacterial cell wall synthesis inhibitor	SLC15A1, SLC15A2, SLC22A6, SLC22A8	infectious disease, otolaryngology	urinary tract infections, skin infections, tonsillitis, pharyngitis	BRD-K63242551-001-10-9	Launched
cefalonium	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	BRD-K15514357-001-05-6, BRD-K15514357-002-06-9	Launched
cefathiamidine	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	BRD-K63835048-001-01-0	Launched
cefazolin	bacterial cell wall synthesis inhibitor	PON1	infectious disease	urinary tract infections, skin infections, bacterial septicemia, endocarditis, surgical prophylaxis, bone and joint infections	BRD-K99750640-236-20-3, BRD-K99750640-236-18-7, BRD-K99750640-236-19-5	Launched
cefcapene-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, pneumonia, urinary tract infections	BRD-K27515606-311-02-8, BRD-K27515606-311-02-8, BRD-K27515606-003-01-3, BRD-K27515606-311-01-0	Launched
cefdinir	bacterial cell wall synthesis inhibitor	MPO	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis	BRD-K15766189-001-09-8, BRD-K15766189-001-09-8, BRD-K15766189-001-10-6, BRD-K15766189-001-08-0	Launched
cefepime	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, urinary tract infections, skin infections, intra-abdominal infections	BRD-A12077521-003-01-5	Launched
cefetamet	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	ear infections, pneumonia, otitis, sinusitis, bronchitis, urinary tract infections	BRD-K27798832-001-01-5, BRD-K27798832-001-02-9	Launched
cefetamet-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	BRD-K21372554-001-01-1, BRD-K21372554-003-01-7, BRD-K21372554-003-02-5	Launched
cefiderocol	antibacterial 				BRD-K00003257-001-01-9	Launched
cefixime	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	urinary tract infections, otitis, pharyngitis, tonsillitis, gonorrhea, bronchitis	BRD-K71059170-341-02-5, BRD-K71059170-001-11-6, BRD-K71059170-001-12-4	Launched
cefmenoxime	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	BRD-K00003661-003-01-9	Launched
cefminox	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	BRD-K77073709-435-01-2, BRD-K77073709-435-02-9	Launched
cefotetan	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, respiratory tract infections, skin infections, gynecologic infections, chlamydia, intra-abdominal infections, bone and joint infections, surgical prophylaxis	BRD-A78723049-001-01-2, BRD-A78723049-001-01-2	Launched
cefotiam	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia, bone and joint infections, respiratory tract infections, skin infections, urinary tract infections	BRD-K02275692-300-01-8, BRD-K02275692-300-02-6	Launched
cefotiam-cilexetil	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-A76661185-300-02-4, BRD-A76661185-300-01-6	Launched
cefoxitin	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections	BRD-K70976396-236-27-8, BRD-K70976396-236-25-2, BRD-K70976396-236-26-0, BRD-K70976396-236-26-0	Launched
cefozopran	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-K46970505-003-02-9, BRD-K46970505-003-01-9, BRD-K46970505-003-01-9	Launched
cefpirome	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	BRD-K56542719-065-01-4, BRD-K56542719-065-01-4, BRD-K56542719-065-01-4	Launched
cefradine	bacterial cell wall synthesis inhibitor	CYP3A4	infectious disease, otolaryngology	respiratory tract infections, otitis, skin infections, urinary tract infections, tonsillitis, pharyngitis, pneumonia	BRD-K13797099-001-02-9, BRD-K13797099-001-01-1, BRD-K13797099-001-03-9	Launched
ceftaroline-fosamil	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, pneumonia	BRD-K37252028-349-01-8	Launched
ceftibuten	bacterial cell wall synthesis inhibitor		pulmonary, otolaryngology	bronchitis, otitis, pharyngitis, tonsillitis	BRD-K11124378-001-04-6, BRD-K11124378-335-03-0, BRD-K11124378-335-01-4, BRD-K11124378-335-02-2, BRD-K11124378-002-01-0	Launched
ceftizoxim	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, urinary tract infections, gonorrhea, pelvic inflammatory disease, intra-abdominal infections, bacterial septicemia, skin infections, bone and joint infections, meningitis	BRD-K04301924-236-03-2, BRD-K04301924-236-01-6, BRD-K04301924-236-02-4	Launched
ceftobiprole	antiinfective drug				BRD-K00003117-001-01-9	Phase 3
celecoxib	cyclooxygenase inhibitor	CA12, PDPK1, PTGS2	rheumatology, endocrinology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, primary dysmenorrhea (PD)	BRD-K02637541-001-22-2, BRD-K02637541-001-18-0, BRD-K02637541-001-17-2	Launched
celgosivir	glucosidase inhibitor				BRD-K00003204-003-01-9	Phase 2
celiprolol	adrenergic receptor antagonist	ADRA2A, ADRB1, ADRB2	genetics	Ehlers-Danlos syndrome (EDS)	BRD-A95602221-003-02-1, BRD-A95602221-003-03-9	Launched
cenerimod	sphingosine 1-phosphate receptor modulator				BRD-K00003248-001-01-9	Phase 2
cenicriviroc	CC chemokine receptor antagonist				BRD-K00003181-001-01-9	Phase 3
cenobamate	GABA receptor modulator, voltage-gated sodium channel blocker				BRD-K00003249-001-01-9	Launched
centanafadine	dopamine reuptake inhibitor				BRD-K00004588-001-01-9	Phase 3
centazolone	monoamine oxidase inhibitor				BRD-K31329721-001-08-2, BRD-K31329721-001-08-2, BRD-K31329721-001-08-2	Phase 1
centhaquin	analgesic agent				BRD-K00004619-001-01-9	Phase 1
centpropazine	inositol monophosphatase inhibitor				BRD-A28958257-001-02-0, BRD-A28958257-001-02-0, BRD-A28958257-001-01-2, BRD-A28958257-001-01-2	Phase 3
CEP-32496	RAF inhibitor	BRAF, RAF1			BRD-K20722021-001-02-1, BRD-K20722021-001-02-1, BRD-K20722021-001-02-1, BRD-K20722021-001-02-1, BRD-K20722021-001-02-1, BRD-K20722021-001-02-1, BRD-K20722021-001-03-9	Phase 1/Phase 2
CEP-33779	JAK inhibitor	JAK2			BRD-K37237504-001-02-7, BRD-K37237504-001-03-5, BRD-K37237504-001-03-5, BRD-K37237504-001-03-5, BRD-K37237504-001-03-5, BRD-K37237504-001-04-9, BRD-K37237504-001-04-9	Preclinical
CEP-37440	ALK tyrosine kinase receptor inhibitor	ALK			BRD-K72827473-001-01-0, BRD-K72827473-001-01-0, BRD-K72827473-001-01-0, BRD-K72827473-001-01-0, BRD-K72827473-001-02-8, BRD-K72827473-001-02-8	Phase 1
CEP-40783	AXL kinase inhibitor				BRD-K00003396-001-01-9	Preclinical
cephalosporin-c-zn	bacterial cell wall synthesis inhibitor				BRD-K00025564-001-01-9	Preclinical
cephalothin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, surgical prophylaxis	BRD-K28210218-236-08-1, BRD-K28210218-236-09-9	Launched
cephradine	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, respiratory tract infections, urinary tract infections	BRD-A90807417-001-04-5	Launched
ceramide	phosphoenolpyruvate carboxylase activator, serine/threonine protein phosphatase activator		dermatology	cosmetic	BRD-K41707108-001-05-6	Launched
ceritinib	ALK tyrosine kinase receptor inhibitor	ALK, FLT3, IGF1R, INSR, TSSK1B	oncology	non-small cell lung cancer (NSCLC)	BRD-K22149900-001-06-2, BRD-K22149900-001-06-2, BRD-K22149900-001-06-2, BRD-K22149900-001-06-2, BRD-K22149900-001-06-2, BRD-K22149900-001-05-4, BRD-K22149900-001-05-4, BRD-K22149900-001-05-4, BRD-K22149900-001-05-4, BRD-K22149900-001-05-4, BRD-K22149900-001-03-9, BRD-K22149900-001-03-9, BRD-K22149900-001-03-9, BRD-K22149900-001-03-9, BRD-K22149900-001-03-9, BRD-K22149900-001-01-3	Launched
cerulenin	fatty acid synthase inhibitor	FASN	infectious disease	fungal infection	BRD-K52075040-001-09-7, BRD-K52075040-001-09-7, BRD-K52075040-001-09-7	Launched
ceruletide	CCK receptor agonist	CCKAR			BRD-K00003320-001-01-9	Preclinical
cetaben	ACAT inhibitor, cholesterol inhibitor	PPARA			BRD-K86954340-001-01-7, BRD-K86954340-001-01-7, BRD-K86954340-001-01-7	Phase 2
cetilistat	triacylglycerol lipase inhibitor	PNLIP			BRD-K94863486-001-02-2, BRD-K94863486-001-01-4	Phase 3
cetirizine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	BRD-K01826520-300-10-9, BRD-K01826520-300-11-9, BRD-K01826520-300-12-9	Launched
cetrimonium			dermatology	cosmetic	BRD-K47079459-004-14-9, BRD-K47079459-004-14-9, BRD-K47079459-004-04-6, BRD-K47079459-004-04-6, BRD-K47079459-004-04-6, BRD-K47079459-004-04-6, BRD-K47079459-004-05-3	Launched
cetrorelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR, LHCGR	endocrinology	premature luteinizing hormone surges	BRD-K76315403-015-02-5, BRD-K76315403-015-02-5, BRD-K76315403-015-03-9	Launched
cetylpyridinium			dental	gingivitis, mouth inflammation	BRD-K87700323-003-05-1, BRD-K87700323-003-05-1, BRD-K87700323-003-05-1, BRD-K87700323-003-05-1, BRD-K87700323-003-05-1, BRD-K87700323-311-08-9, BRD-K87700323-311-08-9, BRD-K87700323-311-08-9, BRD-K87700323-003-04-4, BRD-K87700323-003-06-9	Launched
cevimeline	acetylcholine receptor agonist	CHRM3	rheumatology	sjogren's syndrome	BRD-K00004291-003-01-9	Launched
cevipabulin	microtubule stimulant, tubulin polymerization inhibitor	TUBB			BRD-K00003570-001-01-9	Phase 1
CE3F4	rap guanine nucleotide exchange factor inhibitor	RAPGEF3			BRD-A47940219-001-02-9, BRD-A47940219-001-01-4	Preclinical
CFI-400945	serine/threonine kinase inhibitor				BRD-K27040396-051-02-9	Phase 2
CFI-402257	dual specificity protein kinase inhibitor				BRD-K00003409-001-01-9	Phase 1/Phase 2
CFM-1571	guanylate cyclase activator				BRD-K64341947-003-03-2, BRD-K64341947-003-02-4	Preclinical
CFM-2	glutamate receptor antagonist				BRD-K42859542-001-04-9, BRD-K42859542-001-03-3	Preclinical
CFTRinh-172	chloride channel blocker	CFTR			BRD-K72004355-001-03-5, BRD-K72004355-001-02-7, BRD-K72004355-001-04-9, BRD-K72004355-001-01-9, BRD-K72004355-001-01-9	Preclinical
CF102	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K52396582-001-07-9, BRD-K52396582-001-06-7, BRD-K52396582-001-06-7, BRD-K52396582-001-06-7	Phase 2
CG-400549	FABI inhibitor				BRD-K48888725-001-02-7, BRD-K48888725-001-01-9	Phase 2
CGH2466	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			BRD-K82028950-300-03-7, BRD-K82028950-300-02-9, BRD-K82028950-300-02-9, BRD-K82028950-300-02-9, BRD-K82028950-300-02-9	Preclinical
CGK-733	ATM kinase inhibitor, ATR kinase inhibitor	ATM, ATR			BRD-A50737080-001-03-0, BRD-A50737080-001-07-9, BRD-A50737080-001-06-3, BRD-A50737080-001-02-2, BRD-A50737080-001-02-2, BRD-A50737080-001-05-5	Preclinical
CGM097	MDM inhibitor	MDM2			BRD-K79584249-001-02-1, BRD-K79584249-001-02-1, BRD-K79584249-001-02-1, BRD-K79584249-001-01-3, BRD-K79584249-001-01-3, BRD-K79584249-001-01-3, BRD-K79584249-001-01-3	Phase 1
CGP-12177	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			BRD-A40084411-003-09-9, BRD-A40084411-003-07-7	Phase 1
CGP-13501	GABA receptor modulator	GABBR1			BRD-K95851186-001-08-9, BRD-K95851186-001-08-9, BRD-K95851186-001-07-8, BRD-K95851186-001-07-8	Preclinical
CGP-20712A	adrenergic receptor antagonist	ADRB1, ADRB3			BRD-K01827291-066-05-9	Preclinical
CGP-25454A	dopamine receptor antagonist				BRD-K00003372-003-01-9	Preclinical
CGP-37157	mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor	SLC8A1			BRD-A35623999-001-06-5, BRD-A35623999-001-06-5, BRD-A35623999-001-07-9, BRD-A35623999-001-07-9, BRD-A35623999-001-05-7	Preclinical
CGP-37849	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			BRD-A90272038-001-02-5, BRD-A90272038-001-01-7	Phase 1
CGP-39551	NMDA receptor antagonist				BRD-K00004626-001-01-9	Preclinical
CGP-52411	EGFR inhibitor	EGFR			BRD-K13087974-001-03-3, BRD-K13087974-001-03-3, BRD-K13087974-001-02-5, BRD-K13087974-001-02-5	Preclinical
CGP-53353	EGFR inhibitor, PKC inhibitor	EGFR, PRKCB			BRD-K32292990-001-03-6, BRD-K32292990-001-04-4	Preclinical
CGP-54626	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			BRD-A74208568-003-02-3, BRD-A74208568-003-04-9, BRD-A74208568-003-01-5	Preclinical
CGP-55845	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			BRD-K00004232-003-02-9, BRD-K00004232-003-01-9	Preclinical
CGP-57380	MAP kinase inhibitor	AURKB, LCK, MKNK1, MKNK2, SGK1			BRD-K42500029-001-04-3, BRD-K42500029-001-03-5, BRD-K42500029-001-06-8	Preclinical
CGP-60474	CDK inhibitor	CDK1, CDK2			BRD-K79090631-001-23-9, BRD-K79090631-001-22-3, BRD-K79090631-001-22-3, BRD-K79090631-001-22-3	Preclinical
CGP-71683	neuropeptide receptor antagonist	NPY5R			BRD-K34321528-003-02-0, BRD-K34321528-003-02-0, BRD-K34321528-003-01-2, BRD-K34321528-003-03-9	Preclinical
CGP-74514	CDK inhibitor	CDK1			BRD-K56239177-300-02-9, BRD-K56239177-300-01-3, BRD-K56239177-300-01-3, BRD-K56239177-300-01-3	Preclinical
CGP-78608	glutamate receptor antagonist				BRD-K60946979-003-02-9, BRD-K60946979-003-01-7	Preclinical
CGP-7930	GABA receptor modulator	GABBR1			BRD-K65786282-001-08-3, BRD-K65786282-001-08-3, BRD-K65786282-001-08-3, BRD-K65786282-001-09-9, BRD-K65786282-001-07-5, BRD-K65786282-001-07-5, BRD-K65786282-001-07-5	Preclinical
CGS-15943	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K49049886-001-08-7, BRD-K49049886-001-08-7, BRD-K49049886-001-08-7, BRD-K49049886-001-08-7, BRD-K49049886-001-08-7, BRD-K49049886-001-08-7, BRD-K49049886-001-08-7, BRD-K49049886-001-13-7, BRD-K49049886-001-13-7, BRD-K49049886-001-13-7, BRD-K49049886-001-13-7, BRD-K49049886-001-13-7, BRD-K49049886-001-13-7, BRD-K49049886-001-13-7, BRD-K49049886-001-13-7, BRD-K49049886-001-13-7, BRD-K49049886-001-13-7	Preclinical
CGS-20625	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			BRD-K68103045-001-03-7, BRD-K68103045-001-02-9, BRD-K68103045-001-02-9, BRD-K68103045-001-02-9, BRD-K68103045-001-04-9	Phase 1
CGS-21680	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K27176996-003-10-9	Preclinical
CGS-9896	GABA receptor antagonist	GABRA1, GABRB2, GABRG2			BRD-K54093161-001-01-8, BRD-K54093161-001-01-8	Preclinical
CH-170					BRD-K24820488-001-01-7	Phase 1
CH-5183284	fibroblast growth factor inhibitor	FGFR1, FGFR2, FGFR3			BRD-K11683436-001-01-7, BRD-K11683436-001-01-7, BRD-K11683436-001-02-5	Phase 2
CHC	monocarboxylate transporter inhibitor	SLC16A1			BRD-K60302405-001-08-6, BRD-K60302405-001-04-5	Preclinical
CHF5074	gamma secretase modulator	PSEN1			BRD-K34508702-001-02-4	Phase 2
chicago-sky-blue-6b	glutamate inhibitor, macrophage migration inhibiting factor inhibitor	MIF			BRD-K56483981-342-06-4, BRD-K56483981-342-07-2	Preclinical
chidamide	HDAC inhibitor	HDAC10, HDAC3	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	BRD-K28537285-001-01-8, BRD-K28537285-001-01-8, BRD-K28537285-001-01-8, BRD-K28537285-001-01-8	Launched
chiniofon	antiprotozoal agent		infectious disease	amebiasis	BRD-K52284881-236-02-4, BRD-K52284881-001-03-9	Launched
CHIR-124	CHK inhibitor	CHEK1			BRD-K02241333-001-02-7, BRD-K02241333-001-02-7, BRD-K02241333-001-02-7	Preclinical
CHIR-98014	glycogen synthase kinase inhibitor	GSK3A, GSK3B			BRD-K42973005-001-07-9, BRD-K42973005-001-04-0, BRD-K42973005-001-04-0, BRD-K42973005-001-04-0	Preclinical
CHIR-99021	glycogen synthase kinase inhibitor	CDK1, GSK3A, GSK3B, MAPK1			BRD-K16189898-003-03-3, BRD-K16189898-003-03-3, BRD-K16189898-003-03-3, BRD-K16189898-001-21-9, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8, BRD-K16189898-001-12-8	Preclinical
chloralose					BRD-K00004971-001-01-9	Preclinical
chlorambucil	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma	BRD-K29458283-001-29-9	Launched
chloramine-T			infectious disease	bacterial gill disease	BRD-K93546328-236-02-8, BRD-K93546328-236-03-9	Launched
chloramphenicol-palmitate	protein synthesis inhibitor		infectious disease, endocrinology	meningitis, fever, cholera	BRD-K33742430-001-01-1	Launched
chloramphenicol-sodium-succinate	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	BRD-K25209357-236-01-2	Launched
chlorcyclizine	histamine receptor antagonist		allergy	allergic rhinitis	BRD-A57133233-003-12-9, BRD-A57133233-003-11-0, BRD-A57133233-003-11-0	Launched
chlorfenson	other antifungal				BRD-K89409436-001-01-4	Phase 2
chlorhexidine	membrane integrity inhibitor		dermatology, infectious disease, dental	cosmetic, skin infections, gingivitis	BRD-K52256627-300-06-6, BRD-K52256627-300-06-6, BRD-K52256627-300-06-6, BRD-K52256627-300-06-6, BRD-K52256627-300-06-6, BRD-K52256627-300-05-8, BRD-K52256627-300-05-8	Launched
chlorindanol					BRD-K01653460-001-01-1, BRD-K01653460-001-02-9	Preclinical
chlorindione					BRD-K61802864-001-09-9, BRD-K61802864-001-08-8	Preclinical
chlorisondamine-diiodide	acetylcholine receptor antagonist	CHRNA1			BRD-K18030938-302-03-9, BRD-K18030938-302-02-7	Preclinical
chlormadinone-acetate	5 alpha reductase inhibitor	PGR	endocrinology	hypermenorrhea, amenorrhea, oligomenorrhea, polymenorrhea	BRD-K38704569-001-18-9	Launched
chlormezanone	GABA receptor modulator	GABRA1			BRD-A20348246-001-15-8, BRD-A20348246-001-15-8, BRD-A20348246-001-16-9, BRD-A20348246-001-14-1, BRD-A20348246-001-13-3	Withdrawn
chlormidazole	fungal lanosterol demethylase inhibitor		infectious disease	fungal infection	BRD-K60443845-001-08-6, BRD-K60443845-001-08-6, BRD-K60443845-001-08-6, BRD-K60443845-001-09-9	Launched
chlorobutanol			neurology/psychiatry	anesthetic, sedative	BRD-K39495750-001-01-2, BRD-K39495750-001-02-0, BRD-K39495750-001-02-0	Launched
chlorocresol	ryanodine receptor activator		infectious disease	first-aid antiseptic	BRD-K89056082-001-07-7, BRD-K89056082-001-06-9, BRD-K89056082-001-08-5	Launched
chlorophyllin			urology	urinary incontinence	BRD-K23728266-001-01-1	Preclinical
chloroprocaine	sodium channel blocker	ATP1A1, CHRNA10, GRIN3A, HTR3A, SCN10A, SLC6A3	neurology/psychiatry	local anesthetic	BRD-K86864073-001-01-1	Launched
chloropyramine	histamine receptor antagonist	HRH1	cardiology, ophthalmology, allergy, pulmonary	edema, conjunctivitis, allergic rhinitis, asthma	BRD-K83257731-003-25-9, BRD-K83257731-003-25-9, BRD-K83257731-003-25-9, BRD-K83257731-003-23-5, BRD-K83257731-003-23-5, BRD-K83257731-003-23-5	Launched
chloroquine	antimalarial agent	MRGPRX1	infectious disease	malaria, amebiasis	BRD-A91699651-316-10-9, BRD-A91699651-316-09-1, BRD-A91699651-316-09-1, BRD-A91699651-316-11-7, BRD-A91699651-316-11-7, BRD-A91699651-316-11-7	Launched
chlorothiazide	diuretic	CA1, CA2, CA4, SLC12A3	cardiology	hypertension	BRD-K88682005-001-16-6, BRD-K88682005-001-17-9, BRD-K88682005-001-17-9, BRD-K88682005-001-15-8	Launched
chlorothymol					BRD-K04358951-001-02-9, BRD-K04358951-001-01-0	Launched
chlorotrianisene	estrogenic hormone	ESR1, ESR2	endocrinology, oncology	menopause, prostate cancer	BRD-K27062708-001-24-9, BRD-K27062708-001-23-1, BRD-K27062708-001-23-1, BRD-K27062708-001-23-1	Launched
chloroxine	opioid receptor antagonist	OPRK1	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff	BRD-K17075857-001-17-6, BRD-K17075857-001-17-6, BRD-K17075857-001-17-6, BRD-K17075857-001-17-6, BRD-K17075857-001-17-6, BRD-K17075857-001-18-4, BRD-K17075857-001-18-4, BRD-K17075857-001-16-8	Launched
chloroxoquinoline					BRD-K83335125-001-07-0	Launched
chloroxylenol	ATP synthase inhibitor		infectious disease	skin infections	BRD-K17223896-001-11-9, BRD-K17223896-001-10-0	Launched
chlorphenamine	histamine receptor antagonist		allergy	allergic rhinitis, urticaria	BRD-K01826567-050-16-9	Launched
chlorphenesin	muscle relaxant		neurology/psychiatry	muscle relaxant, sedative	BRD-A92262698-001-02-5, BRD-A92262698-001-01-7	Launched
chlorphenoxamine	histamine receptor antagonist				BRD-K00003537-001-01-9	Preclinical
chlorphensin-carbamate	muscle relaxant		neurology/psychiatry	spasms	BRD-A39230911-001-10-2	Launched
chlorproguanil	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	BRD-K25494650-003-01-8, BRD-K25494650-003-01-8	Launched
chlorpromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALM1, CHRM1, CHRM3, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR2A, HTR2B, HTR2C, HTR6, HTR7, KCNH2, ORM1, ORM2, SMPD1, TRPC5	neurology/psychiatry, gastroenterology, hematology, infectious disease	schizophrenia, nausea, vomiting, acute intermittent porphyria (AIP), tetanus	BRD-K89997465-001-10-3, BRD-K89997465-001-10-3, BRD-K89997465-003-43-0, BRD-K89997465-003-43-0, BRD-K89997465-003-44-8	Launched
chlorpropamide	ATP channel blocker	ABCC8, KCNJ10	endocrinology	diabetes mellitus	BRD-K97746869-001-29-9, BRD-K97746869-001-27-0, BRD-K97746869-001-26-2, BRD-K97746869-001-26-2, BRD-K97746869-001-26-2	Launched
chlorpropham	antiviral				BRD-K59590127-001-04-5, BRD-K59590127-001-04-5	Phase 1
chlorpyrifos	acetylcholinesterase inhibitor	ACHE			BRD-K08303368-001-10-0, BRD-K08303368-001-10-0, BRD-K08303368-001-11-9	Launched
chlorquinaldol	other antibiotic		infectious disease	fungal infection	BRD-K90374350-001-11-9, BRD-K90374350-001-11-9, BRD-K90374350-001-10-0, BRD-K90374350-001-09-2, BRD-K90374350-001-09-2, BRD-K90374350-001-09-2, BRD-K90374350-001-09-2	Launched
chlortetracycline	protein synthesis inhibitor		ophthalmology	conjunctivitis	BRD-K00003353-003-01-9, BRD-K00003353-003-01-9	Launched
chlorthalidone	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7, SLC12A1	cardiology, gastroenterology, rheumatology, nephrology	hypertension, edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure	BRD-A26384407-001-25-1, BRD-A26384407-001-26-9, BRD-A26384407-001-26-9	Launched
chlorzoxazone	bacterial 30S ribosomal subunit inhibitor	KCNMA1, KCNN4	neurology/psychiatry	muscle relaxant	BRD-K98174813-001-26-9, BRD-K98174813-001-18-0, BRD-K98174813-001-17-2	Launched
cholesterol		RORA			BRD-K19338361-001-03-9	Preclinical
cholic-acid	bile acid	ADH1C, CES1, COX4I1, COX5A, COX5B, COX6A2, COX6B1, COX6C, COX7A1, COX7B, COX7C, COX8A, ESRRG, FABP6, FECH, GPBAR1, MT-CO1, MT-CO2, MT-CO3, PLA2G1B	gastroenterology, neurology/psychiatry, genetics	bile acid synthesis disorders, peroxisomal disorders, Zellweger syndrome	BRD-K43164539-001-12-9, BRD-K43164539-001-11-5	Launched
choline-alfoscerate	acetylcholine precursor				BRD-K00003587-001-01-9	Launched
CHPG	glutamate receptor agonist	GRM5			BRD-A19381518-001-04-9, BRD-A19381518-001-04-9, BRD-A19381518-001-02-1	Preclinical
CHR-6494	serine/threonine kinase inhibitor	GSG2			BRD-K76259716-019-01-1, BRD-K76259716-019-01-1, BRD-K76259716-019-01-1, BRD-K76259716-001-01-9, BRD-K76259716-001-01-9	Preclinical
chromanol-(+/-)	potassium channel blocker				BRD-M02075109-001-01-1	Preclinical
chromanol-293B-(-)-[3R,4S]	potassium channel blocker				BRD-K27911943-001-02-8, BRD-K27911943-001-03-9	Preclinical
chromocarb	antispasmodic				BRD-K94720315-001-11-9, BRD-K94720315-001-10-4, BRD-K94720315-001-10-4, BRD-K94720315-001-09-6	Launched
chrysin	breast cancer resistance protein inhibitor	AKR1B1, CDK6, CYP19A1, CYP1B1			BRD-K22861715-001-18-9, BRD-K22861715-001-17-4, BRD-K22861715-001-17-4, BRD-K22861715-001-17-4	Phase 1
chrysophanic-acid	EGFR inhibitor	EGFR, MTOR			BRD-K59284035-001-08-9, BRD-K59284035-001-07-9	Preclinical
chuanxiongzine					BRD-K25691735-001-12-9, BRD-K25691735-001-09-5	Phase 2
CH223191	aryl hydrocarbon receptor antagonist	AHR			BRD-K22314899-001-02-4	Preclinical
CH5132799	PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			BRD-K28352084-001-02-3, BRD-K28352084-001-02-3, BRD-K28352084-001-03-1, BRD-K28352084-001-04-9	Phase 1
CH55	retinoid receptor binder	RARA, RARB			BRD-K71487808-001-03-6, BRD-K71487808-001-02-8	Preclinical
CI-844					BRD-K83022601-001-01-0	Phase 2
CI-923	acetylcholine receptor antagonist				BRD-A50016482-001-01-7, BRD-A50016482-001-01-7	Phase 1
CI-953	voltage-gated sodium channel blocker				BRD-K00004748-001-01-9	Phase 1
CI-966	GAT inhibitor	SLC6A1			BRD-K67680372-003-03-4, BRD-K67680372-003-03-4, BRD-K67680372-003-04-9, BRD-K67680372-003-02-6	Phase 1
CI-976	ACAT inhibitor	ACAT1, CES1			BRD-K88544581-001-08-7, BRD-K88544581-001-06-1, BRD-K88544581-001-06-1, BRD-K88544581-001-06-1, BRD-K88544581-001-06-1, BRD-K88544581-001-09-9, BRD-K88544581-001-09-9	Phase 1
ciaftalan-zinc	reactive oxygen species stimulant				BRD-K01423020-001-01-2	Phase 1
cianidanol	fatty acid synthase inhibitor	PTGS1			BRD-K58736316-001-09-5, BRD-K58736316-001-10-9	Withdrawn
cibenzoline	sodium channel blocker		cardiology	cardiac arrythmia	BRD-A20742938-036-03-7, BRD-A20742938-036-03-7, BRD-A20742938-036-03-7	Launched
ciclesonide	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	BRD-K35245662-001-02-9, BRD-K35245662-001-01-2, BRD-K35245662-001-01-2, BRD-K35245662-001-01-2	Launched
ciclopirox	membrane integrity inhibitor	ATP1A1	infectious disease	onychomycosis	BRD-K13044802-213-21-5, BRD-K13044802-001-02-4, BRD-K13044802-213-25-6, BRD-K13044802-001-03-2, BRD-K13044802-001-03-2, BRD-K13044802-001-03-2, BRD-K13044802-001-03-2, BRD-K13044802-213-24-9, BRD-K13044802-213-20-7	Launched
cicloprofen	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-A94965935-001-01-6, BRD-A94965935-001-01-6	Preclinical
CID-16020046	G protein-coupled receptor antagonist	GPR55			BRD-K00004311-001-01-9	Preclinical
CID-2011756	protein kinase inhibitor	PKD1			BRD-K92781136-001-09-9, BRD-K92781136-001-08-9	Preclinical
CID-2745687	G protein-coupled receptor antagonist	GPR35			BRD-K06405316-001-03-3, BRD-K06405316-001-04-9	Preclinical
CID-5458317	MAP kinase phosphatase inhibitor	MAPK3			BRD-A08840375-001-01-3, BRD-A08840375-001-01-3	Preclinical
cidofovir	DNA polymerase inhibitor		infectious disease	acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis	BRD-K96153583-001-05-1, BRD-K96153583-001-04-4, BRD-K96153583-001-06-9	Launched
ciglitazone	PPAR receptor agonist	PPARG			BRD-A93000692-001-08-1, BRD-A93000692-001-08-1, BRD-A93000692-001-08-1	Phase 2
cilazapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	BRD-K96177243-002-04-9, BRD-K96177243-002-04-9	Launched
cilengitide	integrin antagonist	ITGAV, ITGB3			BRD-K57252450-001-02-5, BRD-K57252450-001-02-5, BRD-K57252450-001-02-5	Phase 3
cilnidipine	calcium channel blocker	CACNA1B	cardiology	hypertension	BRD-K00004281-001-01-9, BRD-K00004281-001-01-9	Launched
cilofexor	FXR agonist				BRD-K00004595-001-01-9	Phase 3
cilomilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4D			BRD-K00003550-001-01-9	Phase 3
cilostamide	phosphodiesterase inhibitor	PDE3A, PDE3B			BRD-K28578425-001-09-6, BRD-K28578425-001-07-0, BRD-K28578425-001-07-0	Preclinical
cilostazol	phosphodiesterase inhibitor	PDE3A, PDE3B	cardiology	claudication	BRD-K67017579-001-28-1, BRD-K67017579-001-28-1, BRD-K67017579-001-29-9, BRD-K67017579-001-26-5, BRD-K67017579-001-26-5, BRD-K67017579-001-27-3	Launched
ciluprevir	serine protease inhibitor				BRD-K00004667-001-01-9, BRD-K00004667-001-01-9	Preclinical
CIM-0216	transient receptor potential channel agonist	TRPM3			BRD-A75514485-001-01-9, BRD-A75514485-001-02-9, BRD-A75514485-001-02-9	Preclinical
cimaterol	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			BRD-A65440446-001-06-9, BRD-A65440446-001-04-1	Preclinical
cimetidine	histamine receptor antagonist	HRH2, SLC29A4, SLC47A1, SLC47A2	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma	BRD-K34157611-001-21-0, BRD-K34157611-001-15-2, BRD-K34157611-001-14-5, BRD-K34157611-001-14-5, BRD-K34157611-001-16-0	Launched
cimetropium	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	BRD-A99899486-004-01-9	Launched
cinacalcet	calcium channel activator	CASR	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia	BRD-K73838513-003-05-5, BRD-K73838513-003-05-5, BRD-K73838513-003-05-5, BRD-K73838513-003-05-5, BRD-K73838513-003-05-5, BRD-K73838513-003-05-5, BRD-K73838513-003-01-4	Launched
cinaciguat	guanylate cyclase activator	GUCY1A3, GUCY1B3			BRD-K73440166-003-02-9, BRD-K73440166-001-01-3, BRD-K73440166-001-01-3	Phase 2
cinalukast	leukotriene receptor antagonist	CYSLTR1			BRD-K53720352-001-05-7, BRD-K53720352-001-04-0, BRD-K53720352-001-03-2	Phase 2
cinanserin	serotonin receptor antagonist	HTR2A			BRD-K40901640-003-06-9, BRD-K40901640-003-01-6	Preclinical
cinchocaine	sodium channel blocker	CALM1, SCN10A, SCN5A	neurology/psychiatry	local anesthetic	BRD-K99121711-003-20-5, BRD-K99121711-001-21-9, BRD-K99121711-003-19-7	Launched
cinchonine	P glycoprotein inhibitor	CYP2D6			BRD-K36551084-001-04-9	Preclinical
cinchophen	analgesic agent		rheumatology	gout	BRD-K72915123-001-19-9, BRD-K72915123-001-18-1, BRD-K72915123-001-17-3	Launched
cinepazet	vasodilator				BRD-K00531707-001-01-3	Launched
cinepazide	calcium channel activator				BRD-K46839850-050-06-9, BRD-K46839850-050-04-2, BRD-K46839850-050-05-9	Withdrawn
cinflumide	muscle relaxant				BRD-K25154476-001-01-4	Phase 2
cinnamaldehyde	aldose reductase inhibitor, TRPV agonist	TRPA1			BRD-K26875402-001-13-9	Preclinical
cinobufotalin	anticancer agent				BRD-K00003354-001-01-9	Phase 1
cinoxacin	topoisomerase inhibitor		infectious disease	urinary tract infections	BRD-K14704277-001-23-4, BRD-K14704277-001-22-6	Launched
cinoxate			dermatology	sunscreen lotion	BRD-K17828029-001-02-9, BRD-K17828029-001-01-5, BRD-K17828029-001-01-5	Launched
CINPA-1	CAR antagonist	NR1H4, NR1I3, PPARG			BRD-K24570280-001-01-8, BRD-K24570280-001-07-9	Preclinical
cinromide					BRD-K66241279-001-01-8, BRD-K66241279-001-02-9	Phase 3
cintirorgon	ROR agonist				BRD-K00003458-001-01-9	Phase 1/Phase 2
cintriamide					BRD-K24507548-001-01-8	Preclinical
cipamfylline	phosphodiesterase inhibitor				BRD-K00004625-001-01-9	Phase 2
cipargamin	antimalarial agent				BRD-K27811785-001-02-9	Phase 2
cipemastat	metalloproteinase inhibitor	ADAM17, MMP1, MMP13, MMP2, MMP3, MMP8, MMP9			BRD-K95362002-001-01-1	Phase 3
ciprofibrate	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	BRD-A49358627-001-14-6, BRD-A49358627-001-14-6, BRD-A49358627-001-13-8	Launched
ciprofloxacin	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology	otitis	BRD-K04804440-001-09-5, BRD-K04804440-001-13-7, BRD-K04804440-001-08-7	Launched
ciproxifan	histamine receptor antagonist	ADRA2A, ADRA2C, HRH3, HRH4, HTR3A			BRD-K01767299-050-03-9, BRD-K01767299-050-02-1	Preclinical
CIQ	glutamate receptor potentiator	GRIN2C, GRIN2D			BRD-A35425966-001-02-3, BRD-A35425966-001-01-5, BRD-A35425966-001-01-5	Preclinical
cirazoline	adrenergic receptor agonist	ADRA1A			BRD-K54142781-003-13-4, BRD-K54142781-003-11-8	Preclinical
cis-aconitic-acid		ACO2			BRD-K71756122-001-02-5	Preclinical
cis-ACPD	glutamate receptor agonist	GRM2, GRM3, GRM6, GRM7, GRM8			BRD-K00004205-001-01-9	Preclinical
cis-exo-camphanediol-2,3	nitric oxide stimulant	NOS3			BRD-K41962502-001-01-8	Phase 1
cis-urocanic-acid	serotonin receptor agonist	HTR2A			BRD-K52670952-003-02-2, BRD-K52670952-003-02-2, BRD-K52670952-003-01-4, BRD-K25146005-001-01-0	Phase 2
cis-9,trans-11-conjugated-linoleic-acid					BRD-K80025777-001-01-4, BRD-K80025777-001-01-4, BRD-K80025777-001-05-9	Launched
cisapride	serotonin receptor agonist	HTR2A, HTR3A, HTR4, KCNH2			BRD-K06895174-001-03-6, BRD-K06895174-001-04-9, BRD-K06895174-001-02-8	Withdrawn
cisatracurium	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry, critical care	muscle relaxant, endotracheal intubation	BRD-K17498618-344-04-9, BRD-K17498618-344-03-4, BRD-K17498618-344-02-6	Launched
citalopram	selective serotonin reuptake inhibitor (SSRI)	ADRA1A, CHRM1, HRH1, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	BRD-A47598013-004-17-8, BRD-A47598013-004-18-6, BRD-A47598013-004-16-0	Launched
citarinostat	HDAC inhibitor				BRD-K00003202-001-01-9	Phase 1
CITCO	constitutive androstane receptor (CAR) agonist	NR1I3			BRD-K53263234-001-06-0, BRD-K53263234-001-05-2, BRD-K53263234-001-07-9, BRD-K53263234-001-07-9	Preclinical
citiolone	lipotropic, mucolytic agent				BRD-A57957888-001-08-0	Preclinical
CJ-033466	serotonin receptor agonist	HTR4			BRD-K21306330-001-01-0, BRD-K21306330-001-02-9	Preclinical
CJ-13610	lipoxygenase inhibitor				BRD-K00004624-001-01-9	Phase 2
CK-101	EGFR inhibitor				BRD-K00005246-001-01-9	Preclinical
CK-636	actin related protein inhibitor	ACTR2, ACTR3, ARPC1B, ARPC2, ARPC3, ARPC4, ARPC5			BRD-K81572616-001-01-9, BRD-K81572616-001-02-7, BRD-K81572616-001-03-9	Preclinical
CKD-712	NFkB pathway inhibitor	JAK2, STAT1			BRD-A26458246-004-02-1, BRD-A26458246-004-02-1, BRD-A26458246-004-01-3	Phase 1
CKI-7	casein kinase inhibitor	CSNK1G2			BRD-K34303607-300-02-2	Preclinical
CL-218872	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2			BRD-K00662280-001-10-2, BRD-K00662280-001-11-9, BRD-K00662280-001-09-4	Phase 1
CL-225385					BRD-K87573013-001-01-0	Phase 2
cladribine	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	ADA, PNP, POLA1, POLE, POLE2, POLE3, POLE4, RRM1, RRM2, RRM2B	hematologic malignancy	hairy cell leukemia	BRD-K93034159-001-31-9, BRD-K93034159-001-25-8, BRD-K93034159-001-25-8, BRD-K93034159-001-25-8, BRD-K93034159-001-25-8, BRD-K93034159-001-25-8	Launched
clamikalant	ATP-sensitive potassium channel antagonist				BRD-K00004576-001-01-9	Preclinical
clanfenur	anticancer agent				BRD-K62378877-001-05-9	Preclinical
clavulanate	beta lactamase inhibitor		otolaryngology	otitis	BRD-K94250879-235-03-9, BRD-K94250879-001-01-9	Launched
clebopride	dopamine receptor antagonist	ACHE, DRD2	gastroenterology	nausea	BRD-K17294426-050-12-3, BRD-K17294426-050-12-3, BRD-K17294426-037-13-9	Launched
clemastine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	BRD-K30240666-051-16-7, BRD-K30240666-051-15-9, BRD-K30240666-051-17-9, BRD-K30240666-051-13-4, BRD-K30240666-051-14-2	Launched
clemizole	HCV inhibitor		allergy	allergic rhinitis	BRD-K04704168-003-15-0, BRD-K04704168-003-16-9, BRD-K04704168-003-14-3, BRD-K04704168-003-14-3	Launched
clenbuterol	adrenergic receptor agonist	ABCC8, ADRB2, KCNJ11	pulmonary	chronic obstructive pulmonary disease (COPD), asthma	BRD-K00003701-003-01-9	Launched
cleviprex	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S	cardiology	hypertension	BRD-A01563671-001-02-7, BRD-A01563671-001-03-9, BRD-A01563671-001-03-9, BRD-A01563671-001-03-9	Launched
clevudine	DNA polymerase inhibitor		infectious disease	hepatitis B	BRD-K00003562-001-01-9	Launched
clidinium	acetylcholine receptor antagonist	CHRM1, CHRM3	gastroenterology	peptic ulcer disease (PUD), irritable bowel syndrome, enterocolitis	BRD-K01827265-004-09-9, BRD-K01827265-004-09-9, BRD-K01827265-004-09-9, BRD-K01827265-004-10-9	Launched
climbazole	enzyme inducer		dermatology	dandruff, eczema	BRD-A61676498-001-06-6, BRD-A61676498-001-05-8	Launched
clinafloxacin	bacterial DNA gyrase inhibitor				BRD-K01825499-003-02-9, BRD-K01825499-003-03-9	Phase 3
clindamycin-palmitate	bacterial 50S ribosomal subunit inhibitor		infectious disease	intra-abdominal infections, skin infections, pneumonia, peritonitis, gynecologic infections	BRD-K10759270-003-01-1	Launched
clinofibrate	lipase clearing factor inhibitor	LPL	endocrinology	hypertriglyceridemia	BRD-A90625545-001-03-9, BRD-A90625545-001-02-0	Launched
clioquinol	chelating agent	OPRK1			BRD-K09255212-001-16-6, BRD-K09255212-001-16-6, BRD-K09255212-001-16-6	Withdrawn
clobenpropit	histamine receptor antagonist	HRH1, HRH2, HRH3, HRH4			BRD-K71430621-303-04-9, BRD-K71430621-303-04-9, BRD-K71430621-303-02-3, BRD-K71430621-303-02-3, BRD-K71430621-303-02-3	Preclinical
clobetasone-butyrate	corticosteroid agonist	NR3C1	dermatology	eczema, psoriasis, dermatitis	BRD-K58810291-001-16-2, BRD-K58810291-001-16-2	Launched
clobutinol	antitussive				BRD-A43809092-003-02-1	Withdrawn
clocortolone-pivalate	steroid	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	BRD-K38003476-001-09-1, BRD-K38003476-001-09-1, BRD-K38003476-001-09-1, BRD-K38003476-001-10-9, BRD-K38003476-001-10-9	Launched
clodronic-acid	bone resorption inhibitor	SLC25A4, SLC25A5, SLC25A6	orthopedics, endocrinology, hematologic malignancy	osteoporosis, hyperparathyroidism, hypercalcemia, multiple myeloma	BRD-K72542090-304-02-4, BRD-K72542090-304-04-0, BRD-K72542090-304-03-2	Launched
clofarabine	ribonucleotide reductase inhibitor	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	BRD-K34022604-001-09-0, BRD-K34022604-001-09-0, BRD-K34022604-001-09-0, BRD-K34022604-001-06-6, BRD-K34022604-001-06-6, BRD-K34022604-001-06-6, BRD-K34022604-001-06-6, BRD-K34022604-001-05-8	Launched
clofazimine	GK0582 inhibitor		infectious disease	leprosy	BRD-K56614220-001-19-0, BRD-K56614220-001-18-2, BRD-K56614220-001-21-6, BRD-K56614220-001-21-6	Launched
clofedanol	histamine receptor antagonist	HRH1	pulmonary	cough suppressant	BRD-A15687940-001-05-6	Launched
clofibrate	PPAR receptor agonist	LPL, PPARA	endocrinology, cardiology	hyperlipidemia, cholesterol	BRD-K45252063-001-13-6, BRD-K45252063-001-14-4, BRD-K45252063-001-14-4, BRD-K45252063-001-12-8	Launched
clofibric-acid	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	BRD-K19111024-001-20-9, BRD-K19111024-001-22-9, BRD-K19111024-001-19-1, BRD-K19111024-001-18-3	Launched
clofilium	potassium channel blocker	KCNA5, KCNH1			BRD-K02680176-075-12-9, BRD-K02680176-075-11-1, BRD-K02680176-075-11-1	Phase 2
clofoctol	protein synthesis inhibitor		infectious disease	gram-positive bacterial infections	BRD-K02900412-001-11-3, BRD-K02900412-001-11-3, BRD-K02900412-001-11-3, BRD-K02900412-001-12-1	Launched
clomesone	DNA inhibitor				BRD-K39230570-001-01-1	Phase 1
clomethiazole	GABA receptor antagonist, GABA receptor modulator	GABRA1	neurology/psychiatry	Parkinson's Disease, sedative, muscle relaxant	BRD-K50422030-003-02-6, BRD-K50422030-001-05-3, BRD-K50422030-001-05-3	Launched
clomifene	estrogen receptor antagonist	ESR1	obstetrics/gynecology	infertility	BRD-K29950728-048-17-4, BRD-K29950728-048-17-4, BRD-K29950728-048-16-6, BRD-K29950728-048-18-2, BRD-K29950728-048-18-2, BRD-K29950728-048-18-2, BRD-K29950728-048-18-2, BRD-K29950728-048-18-2, BRD-K29950728-048-18-2, BRD-K29950728-048-18-2	Launched
clomipramine	serotonin transporter (SERT) inhibitor	GSTP1, HTR2A, HTR2B, HTR2C, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	BRD-K52989797-003-28-0, BRD-K52989797-003-29-9, BRD-K52989797-003-27-2, BRD-K52989797-003-26-4, BRD-K52989797-003-26-4	Launched
clonidine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	cardiology, neurology/psychiatry	hypertension, attention-deficit/hyperactivity disorder (ADHD)	BRD-K98530306-003-18-3, BRD-K98530306-003-22-9, BRD-K98530306-003-22-9, BRD-K98530306-003-17-5, BRD-K98530306-003-16-7	Launched
clonixin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, infectious disease	rheumatoid arthritis, soft tissue infection	BRD-K18399440-001-11-9	Preclinical
clonixin-lysinate	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	BRD-M63173034-001-03-6, BRD-M63173034-001-03-6, BRD-M63173034-001-02-8	Launched
clopamide	sodium/chloride cotransporter inhibitor		cardiology	hypertension	BRD-K15567837-001-19-5, BRD-K15567837-001-19-5	Launched
cloperastine	antitussive		pulmonary	cough suppressant	BRD-A80908310-003-13-8, BRD-A80908310-003-14-6	Launched
cloperastine-fendizoate	potassium channel antagonist					Preclinical
clopidogrel	purinergic receptor antagonist	P2RY12	cardiology, neurology/psychiatry	myocardial infarction, stroke, peripheral artery disease (PAD), acute coronary syndrome (ACS)	BRD-K27721098-065-09-4, BRD-K27721098-065-08-6, BRD-K27721098-065-08-6, BRD-K27721098-065-10-2, BRD-K27721098-065-10-2, BRD-K27721098-065-10-2	Launched
clopidol			infectious disease	coccidiosis	BRD-K80036624-001-04-0, BRD-K80036624-001-06-9	Launched
cloprostenol-(+/-)	prostaglandin receptor agonist	PTGDR, PTGER1, PTGER3, PTGFR, TBXA2R	obstetrics/gynecology	endometriosis	BRD-K17850764-236-11-9	Launched
cloranolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	hypertension	BRD-A04971881-003-01-3	Launched
clorgiline	monoamine oxidase inhibitor	MAOA			BRD-K73251053-003-21-4, BRD-K73251053-003-22-2, BRD-K73251053-003-22-2, BRD-K73251053-003-23-9	Phase 2
clorotepine	adrenergic receptor antagonist, dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD2, HRH1, HTR2C, HTR6	neurology/psychiatry	psychosis	BRD-A19053834-050-09-5, BRD-A19053834-050-09-5	Launched
clorprenaline	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	asthma	BRD-K01825579-003-03-9	Launched
clorsulon	glycolysis inhibitor		infectious disease	gastrointestinal roundworms, lungworms, liver flukes, lice, mites	BRD-K97521363-001-16-1, BRD-K97521363-001-17-9, BRD-K97521363-001-15-3	Launched
closantel	chitinase inhibitor, NFkB pathway inhibitor		infectious disease	liver flukes	BRD-K01825680-001-02-9, BRD-K01825680-236-01-9	Launched
clotiapine			neurology/psychiatry	psychosis	BRD-K10990317-001-04-5, BRD-K10990317-001-04-5	Launched
clotrimazole	cytochrome P450 inhibitor, imidazoline receptor ligand	CYP3A4, KCNN4, NR1I2, NR1I3, TRPM2, TRPM4, TRPM8	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis	BRD-K15916496-001-29-5, BRD-K15916496-001-27-9, BRD-K15916496-001-26-1, BRD-K15916496-001-30-9	Launched
cloxyquin	potassium channel activator	KCNK18			BRD-K46982791-001-10-9, BRD-K46982791-001-10-9, BRD-K46982791-001-09-4	Preclinical
clozapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CALY, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia	BRD-K37289225-001-36-4, BRD-K37289225-001-34-9, BRD-K37289225-001-35-6, BRD-K37289225-001-37-2	Launched
CL316243	adrenergic receptor agonist	ADRB3, UCP1, UCP2, UCP3			BRD-K06467130-304-02-7	Phase 2
CM-4620	calcium release activated channel modulator				BRD-K00003438-001-01-9	Phase 2
CMPD-1	p38 MAPK inhibitor	GNRHR, MAPK14			BRD-K54095730-001-04-9, BRD-K54095730-001-03-1, BRD-K54095730-001-03-1	Preclinical
CNQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			BRD-K19438463-304-01-2, BRD-K19438463-001-05-5, BRD-K19438463-001-06-9	Phase 1
CNX-2006	EGFR inhibitor	EGFR			BRD-K24869513-001-02-1, BRD-K24869513-001-03-9	Preclinical
CNX-774	Bruton's tyrosine kinase (BTK) inhibitor	BTK			BRD-K48443249-001-02-9, BRD-K48443249-001-01-0, BRD-K48443249-001-01-0, BRD-K48443249-001-01-0, BRD-K48443249-001-01-0	Preclinical
CO-101244	glutamate receptor antagonist	GRIN2B			BRD-K55677650-003-03-7, BRD-K55677650-003-02-9, BRD-K55677650-003-04-9, BRD-K55677650-003-04-9	Preclinical
CO-102862	sodium channel blocker	SCN4A, SCN9A			BRD-K70912147-001-01-8, BRD-K70912147-001-01-8, BRD-K70912147-001-01-8	Phase 1
cobicistat	cytochrome P450 inhibitor	CYP3A4, CYP3A43, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K51040301-001-03-9, BRD-K51040301-001-03-9, BRD-K51040301-001-02-1, BRD-K51040301-001-02-1	Launched
cobimetinib	MEK inhibitor	MAP2K1	oncology	melanoma	BRD-K03390685-001-01-7, BRD-K03390685-001-01-7, BRD-K03390685-001-01-7, BRD-K03390685-001-01-7, BRD-K03390685-001-01-7, BRD-K03390685-001-01-7, BRD-K03390685-001-03-9, BRD-K03390685-001-03-9	Launched
coenzyme-A		ACAT2, CRAT, CS, DBI, HMGCR, KAT2A, KAT2B, KAT5			BRD-A67956599-002-01-3	Launched
coenzyme-Q10					BRD-K75043328-001-05-9, BRD-K75043328-001-04-2, BRD-K75043328-001-03-4	Launched
COH29	ribonucleotide reductase inhibitor				BRD-K00003307-001-01-9	Phase 1
colforsin	adenylyl cyclase activator	ADCY2, ADCY5			BRD-A55416093-001-06-4, BRD-A55416093-001-06-4	Phase 2
colforsin-daproate	adenylyl cyclase activator				BRD-K19388745-003-01-7, BRD-K19388745-003-01-7, BRD-K19388745-003-01-7, BRD-K19388745-003-01-7, BRD-K19388745-003-01-7, BRD-K19388745-003-01-7	Launched
colfosceril-palmitate	pulmonary surfactant		pulmonary	respiratory distress syndrome (RDS)	BRD-K01825113-001-02-9, BRD-K01825113-001-03-9	Launched
colistin	bacterial permeability inducer		infectious disease	gram-negative bacterial infections, gram-negative bacterial infections	BRD-K01666935-065-02-9, BRD-K01666935-326-01-9	Launched
combretastatin-A-4	tubulin polymerization inhibitor				BRD-K61195623-001-02-9, BRD-K61195623-001-01-4	Phase 2
compound-w	beta-secretase inhibitor	BACE1			BRD-K98143539-001-02-2, BRD-K98143539-001-02-2, BRD-K98143539-001-03-9	Preclinical
compound-401	DNA dependent protein kinase inhibitor	MTOR, PRKDC			BRD-K19655798-001-01-9, BRD-K19655798-001-01-9, BRD-K19655798-001-02-9	Preclinical
compound-58112					BRD-K76139886-003-01-3, BRD-K76139886-003-01-3	Preclinical
conivaptan	vasopressin receptor antagonist	AVPR1A, AVPR2	endocrinology	hyponatremia	BRD-K37385792-003-03-9, BRD-K37385792-003-02-1	Launched
convallatoxin	cardiac glycoside				BRD-K00004559-001-01-9	Preclinical
copanlisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	follicular lymphoma	BRD-K24666289-001-02-3, BRD-K24666289-001-04-9, BRD-K24666289-001-04-9, BRD-K24666289-001-04-9, BRD-K24666289-001-04-9, BRD-K24666289-001-04-9, BRD-K24666289-001-05-9	Launched
copper-histidine		SLC15A3, SLC15A4, SLC38A5			BRD-K36449075-001-01-0, BRD-K36449075-001-02-9	Phase 3
COR-170	cannabinoid receptor inverse agonist	CNR2			BRD-K74965187-001-02-9, BRD-K74965187-001-01-3	Preclinical
cordycepin	DNA inhibitor				BRD-K65428967-001-09-2, BRD-K65428967-001-08-4, BRD-K65428967-001-10-9, BRD-K65428967-001-10-9	Phase 1/Phase 2
corosolic-acid	PKC inhibitor, protein tyrosine kinase inhibitor	HSD11B1, PTPN1			BRD-K27885593-001-06-8, BRD-K27885593-001-06-8, BRD-K27885593-001-06-8	Phase 2
CORT-108297	glucocorticoid receptor antagonist				BRD-K00004700-001-01-9	Preclinical
corticosterone	mineralocorticoid receptor agonist	HSD11B1, NCOA1, NR3C2			BRD-K73589401-001-25-1, BRD-K73589401-001-23-6, BRD-K73589401-001-26-9	Preclinical
cortodoxone	androgen receptor antagonist	AR			BRD-K32891457-001-16-3, BRD-K32891457-001-16-3, BRD-K32891457-001-15-5	Phase 3
cot-inhibitor-1	MAPK-interacting kinase inhibitor	MAP3K8			BRD-K98710228-001-01-6	Preclinical
cot-inhibitor-2	MAPK-interacting kinase inhibitor	MAP3K8			BRD-K49468759-001-05-9, BRD-K49468759-001-04-2	Preclinical
COTI-2	anticancer agent				BRD-K00003348-001-01-9	Phase 1
cotinine	nicotine metabolite				BRD-K94144010-001-14-9, BRD-K94144010-001-13-9	Phase 2
coumarin	vitamin K antagonist	CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP2A6	gastroenterology, pulmonary	ulcerative colitis, asthma, celiac disease	BRD-K23913458-001-20-7, BRD-K23913458-001-20-7, BRD-K23913458-001-19-9	Launched
coumophos	cholinesterase inhibitor				BRD-K41567533-001-08-3, BRD-K41567533-001-08-3, BRD-K41567533-001-11-9	Preclinical
CP-105,696	leukotriene receptor antagonist				BRD-K00004654-001-01-9	Preclinical
CP-316819	glycogen phosphorylase inhibitor	PYGL			BRD-K53913008-001-01-5, BRD-K53913008-001-01-5, BRD-K53913008-001-02-9	Preclinical
CP-339818	potassium channel blocker	KCNA3			BRD-K00004233-003-01-9	Preclinical
CP-376395	corticotropin releasing factor receptor antagonist	CRHR1			BRD-K31394475-001-01-9, BRD-K31394475-003-01-5	Phase 1
CP-471474	matrix metalloprotease inhibitor	MMP1, MMP13, MMP2, MMP3, MMP9			BRD-K33234937-001-01-7, BRD-K33234937-001-01-7, BRD-K33234937-001-02-9	Preclinical
CP-532623	cholesteryl ester transfer protein inhibitor	CETP			BRD-K36611520-001-01-6	Phase 1
CP-547632	kinase inhibitor				BRD-K00004719-001-01-9	Phase 2
CP-640186	acetyl-CoA carboxylase inhibitor	ACACA, ACACB			BRD-K26921335-003-01-2, BRD-K26921335-003-01-2	Preclinical
CP-673451	PDGFR tyrosine kinase receptor inhibitor	KIT, PDGFRA, PDGFRB			BRD-K43621685-001-05-9, BRD-K43621685-001-02-5, BRD-K43621685-001-02-5, BRD-K43621685-001-03-3, BRD-K43621685-001-03-3, BRD-K43621685-001-03-3, BRD-K43621685-001-03-3, BRD-K43621685-001-03-3, BRD-K43621685-001-03-3, BRD-K43621685-001-03-3, BRD-K43621685-001-03-3	Preclinical
CP-724714	EGFR inhibitor, protein tyrosine kinase inhibitor	ERBB2			BRD-K76908866-001-08-9, BRD-K76908866-001-07-6, BRD-K76908866-001-07-6, BRD-K76908866-001-07-6, BRD-K76908866-001-07-6	Phase 2
CP-775146	PPAR receptor agonist	PPARA			BRD-K96843359-001-02-6, BRD-K96843359-001-03-9	Preclinical
CP-91149	glycogen phosphorylase inhibitor	PYGL			BRD-K19171642-001-02-3, BRD-K19171642-001-02-3, BRD-K19171642-001-02-3, BRD-K19171642-001-03-1	Preclinical
CP-93129	serotonin receptor agonist	HTR1A			BRD-K81876028-300-03-9, BRD-K81876028-300-03-9, BRD-K81876028-300-02-0	Preclinical
CP-94253	serotonin receptor agonist	HTR1B			BRD-K33860217-003-04-0, BRD-K33860217-003-03-2	Preclinical
CP-945,598	cannabinoid receptor antagonist	CNR1			BRD-K09090949-001-02-9, BRD-K09090949-001-02-9, BRD-K09090949-001-01-9	Phase 3
CP-99994	tachykinin antagonist	TACR1			BRD-K09946180-300-01-6, BRD-K09946180-300-01-6, BRD-K09946180-300-02-9	Phase 2
CPA-inhibitor	carboxypeptidase inhibitor	CPA1, CPA2			BRD-A69126730-001-01-3, BRD-A69126730-001-01-3	Preclinical
CPCCOEt	glutamate receptor antagonist	GRM1			BRD-K00004223-001-01-9	Preclinical
CPI-0610	bromodomain inhibitor	BRD4			BRD-K19871656-001-01-3, BRD-K19871656-001-01-3, BRD-K19871656-001-02-9, BRD-K19871656-001-02-9, BRD-K19871656-001-02-9, BRD-K19871656-001-02-9	Phase 2
CPI-1189	tumor necrosis factor release inhibitor	TNF			BRD-K11073688-001-02-9, BRD-K11073688-001-01-6, BRD-K11073688-001-01-6, BRD-K11073688-001-01-6	Phase 2
CPI-1205	EZH2 inhibitor				BRD-K00003360-001-01-9	Phase 1/Phase 2
CPI-169	histone lysine methyltransferase inhibitor	EZH2			BRD-K97181972-001-01-9	Preclinical
CPI-203	bromodomain inhibitor	BRD4			BRD-K15811707-001-02-0, BRD-K15811707-001-02-0, BRD-K15811707-001-01-2, BRD-K15811707-001-01-2, BRD-K15811707-001-01-2	Preclinical
CPI-360	histone lysine methyltransferase inhibitor	EZH2			BRD-K18319422-001-01-7, BRD-K18319422-001-01-7	Preclinical
CPI-444	adenosine receptor antagonist				BRD-K00003442-001-01-9	Phase 1/Phase 2
CPI-613	pyruvate dehydrogenase inhibitor	PDHA1			BRD-A06916187-001-03-9, BRD-A06916187-001-02-9, BRD-A06916187-001-02-9	Phase 3
CPP	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			BRD-K66094457-001-02-3, BRD-K66094457-001-01-5, BRD-K66094457-001-01-5	Phase 2
CPSI-1306-(+/-)	macrophage migration inhibiting factor inhibitor	MIF			BRD-A81603255-001-02-9, BRD-A81603255-001-01-0, BRD-A81603255-001-01-0	Preclinical
CQS					BRD-K56839624-001-06-9	Preclinical
creatine		CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8			BRD-K19615002-001-02-3	Launched
creatinine					BRD-K13495773-001-15-9, BRD-K13495773-001-12-2, BRD-K13495773-001-11-4	Preclinical
creatinol-phosphate					BRD-K42991124-001-04-8, BRD-K42991124-001-03-0	Launched
crenigacestat	notch signaling inhibitor				BRD-K00003129-001-01-9	Preclinical
crenolanib	PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB			BRD-K22127577-001-03-7, BRD-K22127577-001-03-7, BRD-K22127577-001-03-7, BRD-K22127577-001-03-7, BRD-K22127577-001-06-9, BRD-K22127577-001-02-9, BRD-K22127577-001-02-9	Phase 3
cresol					BRD-K56940914-001-04-2	Launched
cresopirine					BRD-K58648841-001-04-7, BRD-K58648841-001-05-9	Preclinical
cridanimod	progesterone receptor agonist	PGR	infectious disease	influenza A virus infection	BRD-K97939847-001-12-0, BRD-K97939847-001-11-2	Launched
crisaborole	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	dermatology	dermatitis	BRD-K43230258-001-01-4, BRD-K43230258-001-01-4	Launched
crisdesalazine	free radical scavenger				BRD-K00004545-001-01-9	Preclinical
crizotinib	ALK tyrosine kinase receptor inhibitor	ALK, MET	oncology	non-small cell lung cancer (NSCLC)	BRD-K78431006-001-21-9, BRD-K78431006-001-21-9, BRD-K78431006-001-15-1, BRD-K78431006-001-15-1, BRD-K78431006-001-15-1, BRD-K78431006-001-10-2, BRD-K78431006-001-10-2, BRD-K78431006-001-10-2, BRD-K78431006-001-10-2, BRD-K78431006-001-11-0, BRD-K78431006-001-11-0, BRD-K78431006-001-11-0	Launched
croconazole	bacterial cell wall synthesis inhibitor		infectious disease	fungal infection	BRD-K73701464-003-01-3, BRD-K73701464-003-02-1	Launched
crolibulin	tubulin polymerization inhibitor				BRD-K00003162-001-01-9	Phase 1/Phase 2
cromakalim		KCNJ8			BRD-M89827113-001-01-5, BRD-M89827113-001-01-5	Phase 2
cromoglicic-acid	immunosuppressant	KCNMA1, S100P	pulmonary, ophthalmology, allergy, gastroenterology	asthma, conjunctivitis, urticaria, ulcerative colitis	BRD-K20920669-304-12-9, BRD-K20920669-304-10-9, BRD-K20920669-304-09-1	Launched
crotamiton	antipruritic		infectious disease	scabies	BRD-K57179821-001-15-4, BRD-K57179821-001-17-9	Launched
CRT0044876					BRD-K02816415-001-01-9, BRD-K02816415-001-01-9, BRD-K02816415-001-02-7	Preclinical
crystal-violet	other antibiotic				BRD-K00003324-003-01-9	Launched
CR8-(R)	CDK inhibitor	CCNA2			BRD-K40331046-305-02-3, BRD-K40331046-305-02-3, BRD-K40331046-305-01-5, BRD-K40331046-305-01-5, BRD-K40331046-305-01-5, BRD-K40331046-305-01-5, BRD-K40331046-305-03-9	Preclinical
CS-110266	dopamine receptor agonist	SLC6A3			BRD-K15519488-050-02-1, BRD-K15519488-050-02-1, BRD-K15519488-001-03-2, BRD-K15519488-050-01-3, BRD-K15519488-050-01-3, BRD-K15519488-050-01-3	Preclinical
CS-917	fructose biphosphate inhibitor	FBP1			BRD-K35601925-001-02-7, BRD-K35601925-001-02-7, BRD-K35601925-001-01-9, BRD-K35601925-001-01-9	Phase 2
CT-7758	integrin antagonist	ITGA4			BRD-K40870905-001-02-9, BRD-K40870905-001-01-7, BRD-K40870905-001-01-7, BRD-K40870905-001-01-7, BRD-K40870905-001-01-7, BRD-K40870905-001-01-7	Phase 2
CTEP	glutamate receptor antagonist	GRM5			BRD-K30572193-001-02-0, BRD-K30572193-001-02-0, BRD-K30572193-001-03-9, BRD-K30572193-001-03-9	Preclinical
CTS-1027	metalloproteinase inhibitor	MMP1, MMP13, MMP2, MMP3, MMP9			BRD-K53508936-001-02-8, BRD-K53508936-001-01-0, BRD-K53508936-001-01-0, BRD-K53508936-001-01-0	Phase 2
CTS21166	beta-secretase inhibitor	BACE1			BRD-K89071957-001-01-1, BRD-K89071957-001-01-1	Phase 1
CT7001	CDK inhibitor				BRD-K00003453-003-01-9	Phase 1/Phase 2
CU-CPT-4a	toll-like receptor inhibitor	TLR3			BRD-K58234744-001-02-9, BRD-K58234744-001-01-0	Preclinical
CU-T12-9	toll-like receptor agonist	TLR1, TLR2			BRD-K89462779-001-01-8, BRD-K89462779-001-02-9	Preclinical
CUDC-101	EGFR inhibitor	EGFR, ERBB2			BRD-K41278234-001-04-9, BRD-K41278234-001-03-0, BRD-K41278234-001-03-0	Phase 1
CUDC-427	apoptosis inhibitor	XIAP			BRD-K69351586-001-02-8, BRD-K69351586-001-01-0, BRD-K69351586-001-01-0, BRD-K69351586-001-01-0	Phase 1
CUDC-907	PI3K inhibitor	HDAC2, PIK3R1			BRD-K77638923-001-03-9, BRD-K77638923-001-03-9, BRD-K77638923-001-02-0, BRD-K77638923-001-02-0, BRD-K77638923-001-02-0	Phase 2
CUR-61414	smoothened receptor antagonist	DHH, IHH, SMO			BRD-K69624312-001-01-1	Phase 1
cutamesine	sigma receptor agonist	SIGMAR1			BRD-K90777969-300-03-9, BRD-K90777969-300-01-2, BRD-K90777969-300-01-2, BRD-K90777969-300-01-2, BRD-K90777969-300-02-0	Phase 2
CV-1808	adenosine receptor agonist	ADORA2A			BRD-K49197823-001-10-9, BRD-K49197823-001-10-9, BRD-K49197823-001-09-8, BRD-K49197823-001-09-8	Preclinical
CVT-10216	aldehyde dehydrogenase inhibitor	ALDH2			BRD-K60659193-001-01-0, BRD-K60659193-001-02-8	Phase 1
CW-008	PKA activator	PRKACA			BRD-K84068331-001-02-9, BRD-K84068331-001-01-9, BRD-K84068331-001-01-9	Preclinical
CX-4945	casein kinase inhibitor	CSNK2A1, CSNK2A2, DAPK3, HIPK3			BRD-K81458380-001-12-9, BRD-K81458380-001-04-9, BRD-K81458380-001-04-9, BRD-K81458380-001-04-9, BRD-K81458380-001-04-9	Phase 1/Phase 2
CX-516	glutamate receptor modulator				BRD-K25140590-001-04-9, BRD-K25140590-001-03-0	Phase 2/Phase 3
CX-5461	RNA polymerase inhibitor				BRD-K12787259-001-04-3, BRD-K12787259-001-05-9	Phase 1
CXD101	HDAC inhibitor				BRD-K00003388-001-01-9	Phase 1/Phase 2
cyacetacide					BRD-K39371216-001-02-9, BRD-K39371216-001-01-3	Preclinical
cyamemazine	serotonin receptor antagonist	HTR1A, HTR2A, HTR2C, HTR7	neurology/psychiatry	schizophrenia, anxiety	BRD-A42881122-001-01-1	Launched
cyclandelate	calcium channel blocker		cardiology, rheumatology	claudication, arteriosclerosis, Raynaud's disease	BRD-A27370296-001-03-0, BRD-A27370296-001-02-2, BRD-A27370296-001-04-8, BRD-A27370296-001-04-8, BRD-A27370296-001-04-8	Launched
cyclic-AMP		CNGA3, TRPM7			BRD-A41840684-001-01-8, BRD-A41840684-001-01-8	Preclinical
cyclizine	histamine receptor modulator	HRH1, SULT1E1	gastroenterology, neurology/psychiatry	nausea, vomiting, vertigo, motion sickness	BRD-K79501723-001-04-6, BRD-K79501723-300-01-8, BRD-K79501723-300-02-6	Launched
cyclobenzaprine	adrenergic receptor agonist, serotonin receptor agonist	HTR2A	neurology/psychiatry	spasms	BRD-K42348709-003-13-1, BRD-K42348709-003-14-9, BRD-K42348709-003-14-9	Launched
cyclocreatine	creatine kinase substrate				BRD-K14379200-001-04-7	Phase 1
cycloheximide	protein synthesis inhibitor	RPL3			BRD-K36055864-001-19-2, BRD-K36055864-001-20-0, BRD-K36055864-001-20-0, BRD-K36055864-001-20-0	Preclinical
cyclopamine	hedgehog pathway inhibitor				BRD-K58938839-001-06-9	Preclinical
cyclopenthiazide	thiazide diuretic		cardiology	hypertension, congestive heart failure	BRD-A41250306-001-11-7, BRD-A41250306-001-12-9, BRD-A41250306-001-12-9	Launched
cyclopentolate	acetylcholine receptor antagonist		ophthalmology	mydriasis, cycloplegia	BRD-A77291778-003-22-0, BRD-A77291778-001-23-9	Launched
cyclophosphamide	DNA alkylating agent	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP3A7	hematologic malignancy, oncology	Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer	BRD-A09722536-002-18-0, BRD-A09722536-002-19-8, BRD-A09722536-002-19-8, BRD-A09722536-002-17-2	Launched
CycLuc1					BRD-K00005335-001-01-9	Preclinical
CYC065	CDK inhibitor				BRD-K00003404-001-01-9	Phase 1
CYC116	Aurora kinase inhibitor	AURKA, AURKB, KDR			BRD-K64866502-001-04-7, BRD-K64866502-001-03-9, BRD-K64866502-001-03-9, BRD-K64866502-001-03-9, BRD-K64866502-001-03-9	Phase 1
CYM-50260	sphingosine 1-phosphate receptor agonist	S1PR4			BRD-K69877120-001-02-9, BRD-K69877120-001-01-7	Preclinical
CYM-50358	sphingosine 1-phosphate receptor antagonist	S1PR4			BRD-K80666802-003-02-9, BRD-K80666802-003-01-0	Preclinical
CYM-50769	neuropeptide receptor antagonist	NPBWR1			BRD-K27732927-001-04-9, BRD-K27732927-001-03-6	Preclinical
CYM-5442	sphingosine 1-phosphate receptor agonist	S1PR1			BRD-A43005764-003-01-5, BRD-A43005764-003-02-9	Preclinical
CYM-5520	sphingosine 1-phosphate receptor agonist	S1PR2			BRD-K29151923-001-01-5, BRD-K29151923-001-02-9	Preclinical
CYM-5541	sphingosine 1-phosphate receptor agonist	S1PR3			BRD-K75940276-001-04-9, BRD-K75940276-001-03-3, BRD-K75940276-001-03-3	Preclinical
cypermethrin			infectious disease	flea control	BRD-A62798249-001-04-4, BRD-A62798249-001-05-9	Launched
cyproheptadine	histamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, HRH1, HTR2A, HTR2C, HTR6, HTR7	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism	BRD-K28143534-003-26-7, BRD-K28143534-003-26-7, BRD-K28143534-003-26-7, BRD-K28143534-001-02-2, BRD-K28143534-001-02-2, BRD-K28143534-003-25-9, BRD-K28143534-003-25-9, BRD-K28143534-003-24-2	Launched
cyromazine					BRD-K36711084-001-02-0, BRD-K36711084-001-01-2	Launched
CYT-997	tubulin polymerization inhibitor	TUBB			BRD-K23363278-001-02-1	Phase 2
cytochalasin-B	microtubule inhibitor	ACTB			BRD-K26664453-001-13-9	Phase 2
cytochlor					BRD-K48988407-001-01-2	Phase 1
cyt387	JAK inhibitor	JAK1, JAK2, JAK3			BRD-K87737963-001-09-9, BRD-K87737963-001-07-8, BRD-K87737963-001-06-0, BRD-K87737963-001-06-0, BRD-K87737963-001-06-0, BRD-K87737963-001-06-0	Phase 3
CY208-243	dopamine receptor agonist	CALY			BRD-K79353516-001-05-0, BRD-K79353516-001-04-3	Phase 2
CZC-54252	leucine rich repeat kinase inhibitor	LRRK2			BRD-K87021635-003-03-9, BRD-K87021635-003-03-9, BRD-K87021635-003-02-2, BRD-K87021635-003-02-2	Preclinical
CZC24832	PI3K inhibitor	PIK3CG			BRD-K01377300-001-01-1, BRD-K01377300-001-02-9	Preclinical
C106					BRD-M12328004-001-01-8	Phase 3
C11-Acetate		ABAT, ACE, AKR1C3, CA2, CELA1, ESR2, FFAR2, FFAR3, HPRT1, LTA4H, MMP12, NOS1, NOS3, PLA2G1B, PTPN1, SOD1, TXN			BRD-K83914624-415-01-3	Phase 3
C188-9	STAT inhibitor				BRD-K00003114-001-01-9	Preclinical
C34	toll-like receptor inhibitor	TLR4			BRD-K43167535-001-01-3, BRD-K43167535-001-02-9	Preclinical
D,L-mevalonic-acid-lactone					BRD-A05674712-001-06-0	Preclinical
D-(+)-maltose		MGAM			BRD-K74377520-001-01-7, BRD-K74377520-001-02-9	Preclinical
D-alpha-tocopheryl-succinate					BRD-K64636206-001-02-7, BRD-K64636206-001-02-7	Launched
D-delta-tocopherol					BRD-K04657451-001-01-0	Launched
D-phenylalanine	enkephalinase inhibitor	CCBL1, CRH, HCAR3			BRD-K00911807-003-01-2, BRD-K00911807-001-03-2, BRD-K00911807-001-04-0	Preclinical
D-serine	glutamate receptor agonist	GLRA1, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SERPINB3			BRD-K71822263-001-03-2, BRD-K71822263-001-04-9	Launched
D-157495	decapping scavenger enzyme inhibitor				BRD-K29066607-001-02-9	Preclinical
D-3263	transient receptor potential channel agonist				BRD-K00003205-003-01-9	Phase 1
D-4476	TGF beta receptor inhibitor	CSNK1A1, CSNK1D, TGFB1			BRD-K09132007-001-07-5, BRD-K09132007-001-07-5, BRD-K09132007-001-11-7	Preclinical
D-64131	microtubule inhibitor	TUBB			BRD-K26997899-001-03-9, BRD-K26997899-001-03-9, BRD-K26997899-001-02-2, BRD-K26997899-001-02-2, BRD-K26997899-001-02-2, BRD-K26997899-001-02-2	Preclinical
D-7193					BRD-K32372024-001-01-0	Phase 2
DAA-1106	benzodiazepine receptor agonist	TSPO			BRD-K01080633-001-02-9, BRD-K01080633-001-01-9	Preclinical
dabigatran	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	BRD-K38168441-001-04-5, BRD-K38168441-001-02-9, BRD-K38168441-001-05-2, BRD-K38168441-001-03-7, BRD-K38168441-001-03-7, BRD-K38168441-001-03-7	Launched
dabigatran-etexilate	thrombin inhibitor	F2	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)	BRD-K57041787-001-03-9, BRD-K57041787-066-01-1, BRD-K57041787-001-02-6	Launched
dabrafenib	RAF inhibitor	BRAF, LIMK1, NEK11, RAF1, SIK1	oncology	melanoma	BRD-K09951645-001-11-8, BRD-K09951645-001-11-8, BRD-K09951645-001-11-8, BRD-K09951645-001-11-8, BRD-K09951645-001-11-8, BRD-K09951645-001-08-4, BRD-K09951645-001-06-8, BRD-K09951645-001-06-8	Launched
dacarbazine	DNA alkylating agent	PGD, POLA2	oncology, hematologic malignancy	melanoma, Hodgkin's lymphoma	BRD-K35520305-001-17-7, BRD-K35520305-001-16-9, BRD-K35520305-001-16-9	Launched
dacinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			BRD-K56957086-001-09-7, BRD-K56957086-001-09-7, BRD-K56957086-001-09-7, BRD-K56957086-001-09-7, BRD-K56957086-001-06-3, BRD-K56957086-001-06-3	Phase 1
daclatasvir	HCV inhibitor		infectious disease	hepatitis C	BRD-K82861010-001-02-5, BRD-K82861010-001-03-3, BRD-K82861010-001-03-3	Launched
dacomitinib	EGFR inhibitor	EGFR, ERBB2, ERBB4			BRD-K57169635-001-05-9, BRD-K57169635-001-04-5, BRD-K57169635-001-04-5, BRD-K57169635-001-04-5, BRD-K57169635-001-04-5, BRD-K57169635-001-04-5, BRD-K57169635-001-04-5	Launched
dactinomycin	RNA polymerase inhibitor	POLR2A	oncology	testicular carcinoma, Wilm's tumor, rhabdomyosarcoma, Ewing's sarcoma, gestational trophoblastic disease (GTD)	BRD-K70578146-001-06-7, BRD-K70578146-001-06-7	Launched
daidzein	estrogen receptor agonist	ESRRA, ESRRB, ESRRG, TRPC5			BRD-K42095107-001-22-1, BRD-K42095107-001-22-1, BRD-K42095107-001-18-9, BRD-K42095107-001-21-3, BRD-K42095107-001-16-3, BRD-K42095107-001-17-1	Phase 2
daidzin	antioxidant	ALDH2			BRD-K12979078-001-02-9	Phase 1
dalargin	opioid receptor agonist	OPRM1			BRD-A89196962-300-01-7, BRD-A89196962-300-01-7	Phase 2
dalbavancin	bacterial cell wall synthesis inhibitor	PNLIP	infectious disease	skin infections	BRD-K30177383-001-02-9, BRD-K30177383-001-01-0	Launched
dalcetrapib	cholesteryl ester transfer protein inhibitor	CETP			BRD-K18849474-001-05-9, BRD-K18849474-001-04-4, BRD-K18849474-001-03-6	Phase 3
dalfampridine	potassium channel blocker	KCNA1, KCNA10, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7, KCNB1, KCNB2, KCNC1, KCNC2, KCNC3, KCNC4, KCND1, KCND2, KCND3, KCNF1, KCNG1, KCNG2, KCNG3, KCNG4, KCNH1, KCNH2, KCNH3, KCNH4, KCNH5, KCNH6, KCNH7, KCNH8, KCNJ13, KCNJ5, KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5, KCNS1, KCNS2, KCNS3, KCNV1, KCNV2	neurology/psychiatry	multiple sclerosis	BRD-K22482860-001-21-4, BRD-K22482860-001-21-4, BRD-K22482860-001-20-6	Launched
dalfopristin	antibacterial 				BRD-K00003321-001-01-9	Preclinical
daltroban	thromboxane receptor antagonist	TBXA2R			BRD-K26813177-001-03-2	Phase 3
daminozide	KDM2A inhibitor	KDM2A, KDM7A, PHF8			BRD-K83452553-001-07-9, BRD-K83452553-001-05-8	Preclinical
danazol	estrogen receptor antagonist, progesterone receptor agonist	AR, CCL2, ESR1, GNRHR, GNRHR2, PGR	obstetrics/gynecology, cardiology	endometriosis, angioedema	BRD-K48970916-001-14-9, BRD-K48970916-001-14-9	Launched
danegaptide	gap junction modulator				BRD-K35589454-003-02-9, BRD-K35589454-003-01-1	Phase 2
danirixin	CC chemokine receptor antagonist	CXCR2			BRD-K13769342-001-01-5, BRD-K13769342-001-01-5	Phase 2
danofloxacin	bacterial DNA gyrase inhibitor		pulmonary	bovine respiratory disease (BRD)	BRD-K45916615-066-04-9, BRD-K45916615-066-02-5, BRD-K45916615-066-02-5	Launched
danoprevir	HCV inhibitor				BRD-K08111240-001-03-9, BRD-K08111240-001-03-9, BRD-K08111240-001-02-8	Phase 3
dantrolene	calcium channel blocker	RYR1, RYR3	neurology/psychiatry, endocrinology	spasms, malignant hyperthermia (MH)	BRD-K81272440-236-13-5, BRD-K81272440-236-14-9, BRD-K81272440-236-14-9, BRD-K81272440-236-12-7	Launched
dantron	laxative				BRD-K10065684-001-07-4, BRD-K10065684-001-07-4, BRD-K10065684-001-07-4, BRD-K10065684-001-08-9	Withdrawn
danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK			BRD-K07881437-001-03-8, BRD-K07881437-001-04-6, BRD-K07881437-001-04-6, BRD-K07881437-001-04-6	Phase 2
dapansutrile	anti-inflammatory agent				BRD-K00004659-001-01-9	Phase 2
daphnetin	protein kinase inhibitor				BRD-K61269089-001-05-5, BRD-K61269089-001-06-9	Preclinical
dapiprazole	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	ophthalmology	mydriasis	BRD-K33133047-001-01-8, BRD-K33133047-001-01-8	Launched
dapivirine	non-nucleoside reverse transcriptase inhibitor	CYP3A4, CYP3A5			BRD-K12885236-001-02-7, BRD-K12885236-001-02-7, BRD-K12885236-001-02-7, BRD-K12885236-001-02-7, BRD-K12885236-001-03-9	Phase 3
dapoxetine	selective serotonin reuptake inhibitor (SSRI)	HTR1A, HTR1B, HTR2C, SLC6A4	urology	premature ejaculation (PE)	BRD-K51579475-003-02-4, BRD-K51579475-003-02-4, BRD-K51579475-003-02-4, BRD-K51579475-003-03-2	Launched
daprodustat	hypoxia inducible factor inhibitor	EGLN1			BRD-K06455935-001-02-9, BRD-K06455935-001-01-3, BRD-K06455935-001-01-3	Phase 3
dapsone	bacterial antifolate	DHFR	dermatology, infectious disease	dermatitis herpetiformis (DH), leprosy	BRD-K62363391-001-26-9, BRD-K62363391-001-24-9	Launched
DAPT	gamma secretase inhibitor				BRD-K47177710-001-04-9, BRD-K47177710-001-03-1, BRD-K47177710-001-05-9, BRD-K47177710-001-05-9, BRD-K47177710-001-02-3	Preclinical
daptomycin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, endocarditis	BRD-K00003611-001-01-9	Launched
darapladib	phospholipase inhibitor	PLA2G7			BRD-K19085898-001-02-9, BRD-K19085898-001-01-8, BRD-K19085898-001-01-8, BRD-K19085898-001-01-8, BRD-K19085898-001-01-8, BRD-K19085898-001-01-8, BRD-K19085898-001-01-8, BRD-K19085898-001-01-8	Phase 3
darglitazone	PPAR receptor antagonist	PPARG			BRD-K82908348-001-01-9, BRD-K82908348-001-01-9	Phase 2
darusentan	endothelin receptor antagonist	EDNRA			BRD-K54863166-001-01-9, BRD-K54863166-001-01-9	Phase 3
dasabuvir	HCV inhibitor		infectious disease	hepatitis C	BRD-K02943813-001-01-9, BRD-K02943813-001-01-9, BRD-K02943813-001-01-9, BRD-K02943813-001-01-9, BRD-K02943813-001-02-9	Launched
dasatinib	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor, tyrosine kinase inhibitor	ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	BRD-K49328571-001-19-2, BRD-K49328571-001-19-2, BRD-K49328571-001-15-0, BRD-K49328571-001-15-0	Launched
dasotraline	dopamine-norepinephrine-serotonin reuptake inhibitor				BRD-K00003142-003-01-9	Phase 3
DAU-5884	acetylcholine receptor antagonist	CHRM3			BRD-K31633810-003-03-6, BRD-K31633810-003-04-9, BRD-K31633810-003-02-8	Preclinical
daucosterol	apoptosis stimulant				BRD-K14276241-001-01-2	Phase 2
dazmegrel	thromboxane synthase inhibitor	TBXAS1			BRD-K20738689-001-01-2	Phase 2
dazoxiben	thromboxane synthase inhibitor	TBXAS1			BRD-K82767007-001-01-1	Phase 2
DBeQ	ATPase inhibitor	CASP3			BRD-K59204667-001-05-6, BRD-K59204667-001-03-1, BRD-K59204667-001-03-1, BRD-K59204667-001-03-1	Preclinical
DBPR-211	cannabinoid receptor antagonist				BRD-K00004704-001-01-9	Preclinical
DBPR108	dipeptidyl peptidase inhibitor	DPP4			BRD-K83020231-001-01-2, BRD-K83020231-001-01-2, BRD-K83020231-001-01-2	Phase 1
DC-260126	free fatty acid receptor antagonist	FFAR1			BRD-K10596918-001-01-9, BRD-K10596918-001-02-9, BRD-K10596918-001-02-9	Preclinical
DCC-2618	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	KIT, PDGFRA			BRD-K49246350-001-01-1, BRD-K49246350-001-01-1	Phase 1
DCEBIO	potassium channel activator	KCNN2, KCNN3, KCNN4			BRD-K89299012-001-08-6, BRD-K89299012-001-08-6, BRD-K89299012-001-08-6, BRD-K89299012-001-07-8, BRD-K89299012-001-07-8, BRD-K89299012-001-06-0, BRD-K89299012-001-06-0	Preclinical
DCP-LA	protein kinase activator				BRD-K00005344-001-01-9	Preclinical
DCPIB	chloride channel blocker, gap junction modulator, glutamate inhibitor	SLC1A2			BRD-A39255369-001-03-1	Preclinical
DDR1-IN-1	discoidin domain receptor inhibitor	DDR1, DDR2			BRD-K61845293-300-03-9, BRD-K61845293-300-01-9	Preclinical
deazaguanine	DNA synthesis inhibitor				BRD-K00004562-001-01-9	Preclinical
Debio-0932	HSP inhibitor				BRD-K00003157-001-01-9	Phase 1
debrisoquin	adrenergic neuron blocker	SLC6A2	cardiology	hypertension	BRD-K80419150-001-02-4, BRD-K80419150-065-03-7, BRD-K80419150-065-03-7	Launched
decamethonium	acetylcholine receptor agonist	ACHE, CHRNA2	neurology/psychiatry	muscle relaxant	BRD-K49783248-303-15-9, BRD-K49783248-303-15-9, BRD-K49783248-303-08-4, BRD-K49783248-303-07-6	Launched
decamethoxine	antiseptic				BRD-A56320380-300-01-6	Phase 2
decernotinib	JAK inhibitor	JAK3			BRD-A95300432-001-01-3, BRD-A95300432-001-01-3	Phase 2/Phase 3
decitabine	DNA methyltransferase inhibitor	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)	BRD-K79254416-001-24-2, BRD-K79254416-001-22-6, BRD-K79254416-001-22-6, BRD-K79254416-001-31-9, BRD-K79254416-001-21-8, BRD-K79254416-001-21-8	Launched
declopramide	cell cycle inhibitor				BRD-K00004661-001-01-9	Preclinical
decloxizine	histamine receptor antagonist				BRD-K00003318-300-01-9	Preclinical
decoquinate	antiprotozoal agent		infectious disease	coccidiosis	BRD-K17641316-213-01-5, BRD-K17641316-001-05-9, BRD-K17641316-001-04-8, BRD-K17641316-001-02-2, BRD-K17641316-001-03-0	Launched
defactinib	focal adhesion kinase inhibitor	PTK2			BRD-K43578482-001-02-2, BRD-K43578482-001-02-2, BRD-K43578482-001-02-2, BRD-K43578482-001-02-2, BRD-K43578482-001-01-4, BRD-K43578482-001-01-4, BRD-K43578482-001-01-4, BRD-K43578482-001-01-4, BRD-K43578482-001-01-4, BRD-K43578482-001-04-9	Phase 2
deferasirox	chelating agent	CYP3A4	hematology	transfusional hemosiderosis, thalassemia, iron overload	BRD-K97010173-001-04-1, BRD-K97010173-001-04-1, BRD-K97010173-001-04-1, BRD-K97010173-001-06-9	Launched
deferasirox-iron-chelate					BRD-K00003219-001-01-9	Launched
deferiprone	chelating agent	UGT1A6	hematology	transfusional hemosiderosis, thalassemia, iron overload	BRD-K06878038-001-20-9, BRD-K06878038-001-18-6, BRD-K06878038-001-17-8	Launched
deferoxamine-mesylate	chelating agent		hematology	acute iron intoxication, iron overload	BRD-K09821361-066-24-1, BRD-K09821361-066-23-3, BRD-K09821361-066-25-8	Launched
deflazacort	glucocorticoid receptor agonist	NR3C1	rheumatology	joint inflammation	BRD-K30468934-001-02-9	Launched
degarelix	gonadotropin releasing factor hormone receptor antagonist	GNRHR	oncology	prostate cancer	BRD-K00003578-001-01-9	Launched
dehydroacetic-acid					BRD-K00025573-001-04-9, BRD-K00025573-001-05-9	Preclinical
dehydrocholate					BRD-A64125466-236-04-6	Preclinical
dehydrocholate-acid					BRD-K90976994-236-19-9, BRD-K90976994-001-20-9	Preclinical
dehydrocorydaline	acetylcholinesterase inhibitor	ACHE			BRD-K67186445-001-01-3, BRD-K67186445-001-02-1, BRD-K67186445-001-02-1	Phase 3
dehydroepiandrosterone-sulfate	androgen receptor agonist, estrogen receptor agonist	AR, ESR1, ESR2	endocrinology	menopause	BRD-K15360631-325-01-4	Launched
delafloxacin	antiinfective drug				BRD-K90991629-100-02-9	Phase 3
delamanid	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	BRD-K17480742-001-01-1, BRD-K17480742-001-01-1	Launched
delapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	BRD-K00573984-003-01-5, BRD-K00573984-003-01-5, BRD-K00573984-003-01-5	Launched
delavirdine	non-nucleoside reverse transcriptase inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K34068325-066-04-5, BRD-K34068325-066-02-9, BRD-K34068325-066-01-1, BRD-K34068325-066-03-7	Launched
delcasertib	PKC inhibitor				BRD-K00003468-001-01-9	Phase 1
delgocitinib	JAK inhibitor				BRD-K00003500-001-01-9	Phase 2
delivert	angiotensin receptor agonist	AGTR1, AGTR2	critical care	sepsis	BRD-K45503887-001-01-1, BRD-K45503887-001-02-9	Launched
delpazolid	antibacterial				BRD-K00003363-001-01-9	Phase 2
delphinidin	membrane permeability inhibitor	GLO1			BRD-K79107392-003-02-2, BRD-K79107392-003-01-4, BRD-K79107392-003-01-4	Phase 2
delta-tocotrienol	HMGCR inhibitor	HMGCR			BRD-K85776940-001-01-9, BRD-K85776940-001-01-9	Phase 1
deltarasin	phosphodiesterase inhibitor	KRAS			BRD-K90830492-305-01-4, BRD-K90830492-305-01-4, BRD-K90830492-305-02-9, BRD-K90830492-305-02-9, BRD-K90830492-305-02-9	Preclinical
demecarium	acetylcholinesterase inhibitor	ACHE, BCHE	ophthalmology	intraocular pressure, glaucoma	BRD-K51471001-303-07-9, BRD-K51471001-303-04-7, BRD-K51471001-303-04-7, BRD-K51471001-303-04-7, BRD-K51471001-303-04-7	Launched
demeclocycline	bacterial 30S ribosomal subunit inhibitor		endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, cholera, syphilis, listeria, anthrax, actinomycosis, tularemia, brucellosis	BRD-K00003347-003-01-9	Launched
denatonium-benzoate					BRD-K34122555-057-11-5, BRD-K34122555-057-12-9	Preclinical
denopamine	adrenergic receptor agonist		cardiology	angina pectoris	BRD-K00004656-001-01-9	Launched
denotivir	antiviral		infectious disease	virus herpes simplex (HSV), skin infections	BRD-K01773083-001-01-4, BRD-K01773083-001-01-4, BRD-K01773083-001-01-4	Launched
deoxyarbutin	tyrosinase inhibitor				BRD-A62562325-001-03-3, BRD-A62562325-001-02-5	Preclinical
deoxycholic-acid	biliverdin reductase A activator, G protein-coupled receptor agonist	FPR1, GPBAR1	endocrinology	submental fat	BRD-K41170226-001-13-8	Launched
deoxyepinephrine	adrenergic receptor agonist, dopamine receptor agonist	ADRA1A, DRD1, DRD2			BRD-K33151569-003-09-7, BRD-K33151569-003-10-5	Preclinical
deptropine	histamine receptor antagonist	HRH1			BRD-K00005351-050-01-9	Preclinical
dequalinium	PKC inhibitor	KCNN1, KCNN3	infectious disease	first-aid antiseptic	BRD-K77685957-300-10-9, BRD-K77685957-300-10-9, BRD-K77685957-300-09-1, BRD-K77685957-300-09-1, BRD-K77685957-300-09-1, BRD-K77685957-300-08-3	Launched
deracoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	BRD-K68558722-001-04-0, BRD-K68558722-001-05-9	Launched
derazantinib	tyrosine kinase inhibitor				BRD-K00003310-001-01-9	Phase 2
deserpidine	angiotensin converting enzyme inhibitor	ACE, SLC18A2	cardiology	hypertension	BRD-K29462201-001-02-7, BRD-K29462201-001-02-7, BRD-K29462201-001-02-7, BRD-K29462201-001-02-7, BRD-K29462201-001-01-9, BRD-K29462201-001-01-9, BRD-K29462201-001-01-9	Launched
desidustat	hypoxia inducible factor prolyl hydroxylase inhibitor				BRD-K00003452-001-01-9	Preclinical
desipramine	tricyclic antidepressant	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A4, SMPD1	neurology/psychiatry	depression	BRD-K60762818-003-25-2, BRD-K60762818-003-26-0	Launched
desisobutyryl-ciclesonide	cytochrome P450 inhibitor		allergy	allergic rhinitis	BRD-K00003103-001-01-9	Launched
deslanoside	Na/K-ATPase inhibitor	ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2	cardiology	congestive heart failure, cardiac arrythmia	BRD-K99919177-001-01-3, BRD-K99919177-001-01-3, BRD-K99919177-001-01-3, BRD-K99919177-001-01-3	Launched
desloratadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	BRD-K82357231-001-18-3, BRD-K82357231-001-21-9, BRD-K82357231-001-21-9, BRD-K82357231-001-19-1, BRD-K82357231-001-19-1, BRD-K82357231-001-19-1, BRD-K82357231-001-17-5	Launched
deslorelin	gonadotropin releasing factor hormone receptor agonist				BRD-K00003134-001-01-9	Phase 2
desmethylclozapine	acetylcholine receptor agonist	HTR2C			BRD-K10042277-001-05-0	Phase 2
desmopressin-acetate	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	endocrinology, urology	central diabetes insipidus, nocturnal enuresis	BRD-K00003582-015-01-9	Launched
desogestrel	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	BRD-K46061689-001-01-9, BRD-K46061689-001-01-9, BRD-K46061689-001-01-9, BRD-K46061689-001-01-9, BRD-K46061689-001-02-9	Launched
desoximetasone	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	BRD-K30697463-001-19-9	Launched
desoxycorticosterone-pivalate	corticosteroid agonist	NR3C2	endocrinology	Addison's disease	BRD-K26024145-001-01-9	Launched
desoxycortone	mineralocorticoid receptor agonist	NR3C1, NR3C2			BRD-K98521173-001-19-4, BRD-K98521173-001-19-4, BRD-K98521173-001-19-4, BRD-K98521173-001-19-4	Preclinical
desoxypeganine	acetylcholinesterase inhibitor, monoamine oxidase inhibitor	ACHE			BRD-K13819402-003-10-2, BRD-K13819402-003-10-2, BRD-K13819402-003-10-2, BRD-K13819402-003-11-9	Phase 1
desvenlafaxine	serotoninâ€“norepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	BRD-K01825598-036-02-9, BRD-K01825598-036-04-9, BRD-K01825598-036-03-9, BRD-K01825598-036-05-9, BRD-K01825598-036-06-9	Launched
detomidine	adrenergic receptor agonist	ADRA2A	neurology/psychiatry	sedative	BRD-K77597856-003-03-9, BRD-K77597856-003-03-9, BRD-K77597856-003-02-5	Launched
devazepide	CCK receptor antagonist				BRD-K31238592-001-02-9, BRD-K31238592-001-02-9	Preclinical
dexchlorpheniramine	histamine receptor antagonist		allergy, cardiology	allergic conjunctivitis, allergic rhinitis, urticaria, angioedema	BRD-K39462424-050-09-8, BRD-K39462424-050-10-9, BRD-K39462424-050-10-9	Launched
dexfosfoserine	membrane integrity inhibitor	CFTR, GRM4, GRM6, GRM7, GRM8, KCNC4, PDPK1, PIM1, PRKACA, PRKCQ, PYGL, PYGM, REG1A, RHO, SERPINB3, SMAD2, TAOK2			BRD-K30019776-001-01-9, BRD-K30019776-003-01-5	Preclinical
dexlansoprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE)	BRD-K05900209-001-02-6, BRD-K05900209-001-01-8, BRD-K05900209-001-04-2, BRD-K05900209-001-03-4	Launched
dexloxiglumide	CCK receptor antagonist	CCKAR			BRD-K07609981-001-01-7	Phase 3
dexmedetomidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	sedative	BRD-K18423410-003-03-3, BRD-K18423410-003-04-9, BRD-K18423410-003-02-5, BRD-K18423410-001-02-9	Launched
dexniguldipine	calmodulin antagonist	ADORA3			BRD-K44309363-003-02-1, BRD-K44309363-003-02-1, BRD-K44309363-003-02-1, BRD-K44309363-003-02-1, BRD-K44309363-003-02-1	Phase 2
dexpanthenol			gastroenterology	paralytic ileus	BRD-K71210479-001-05-5, BRD-K71210479-001-06-9	Launched
dexrazoxane	chelating agent, topoisomerase inhibitor	TOP2A, TOP2B	cardiology	cardiomyopathy	BRD-K07265709-003-05-6, BRD-K07265709-003-05-6, BRD-K07265709-003-05-6, BRD-K07265709-003-03-1, BRD-K07265709-003-04-9	Launched
dextran			hematology, critical care	thrombosis, hypovolemia	BRD-K67117832-001-01-9	Launched
dextromethorphan	glutamate receptor antagonist, sigma receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA7, CHRNB2, CHRNB4, CYBA, CYBB, GRIN3A, NCF1, NCF2, NCF4, OPRD1, OPRK1, OPRM1, PGRMC1, RAC1, RAC2, SIGMAR1, SLC6A2, SLC6A4	pulmonary	cough suppressant	BRD-K33211335-337-13-9, BRD-K33211335-004-01-7, BRD-K33211335-004-01-7	Launched
dextrorotation-nimorazole-phosphate-ester	antiinfective drug				BRD-K00003272-001-01-9	Preclinical
dextrose			endocrinology	hypoglycemia	BRD-K51431759-001-03-9, BRD-K51431759-001-03-9, BRD-K51431759-001-02-9	Launched
DFB	glutamate receptor agonist	GRM5			BRD-K82002057-001-03-9, BRD-K82002057-001-01-2, BRD-K82002057-001-01-2, BRD-K82002057-001-01-2	Preclinical
DG-172	PPAR receptor inverse agonist	PPARD			BRD-K75748943-300-01-3, BRD-K75748943-300-02-9	Preclinical
DG051	leukotriene synthesis inhibitor				BRD-K00003486-003-01-9	Preclinical
DH-97	melatonin receptor antagonist	MTNR1B			BRD-K06014311-001-03-8, BRD-K06014311-001-04-9, BRD-K06014311-001-02-0	Preclinical
DHBP	ryanodine receptor blocker				BRD-K41262162-303-11-9, BRD-K41262162-303-02-2	Preclinical
diacerein	interleukin inhibitor	IL1B	rheumatology	osteoarthritis	BRD-K69122748-001-10-1, BRD-K69122748-001-12-9, BRD-K69122748-001-12-9, BRD-K69122748-001-09-3, BRD-K69122748-001-11-9	Launched
diacetamate					BRD-K93611241-001-02-2, BRD-K93611241-001-03-9	Preclinical
diadenosine-tetraphosphate	adenosine kinase inhibitor	P2RY13, P2RY2			BRD-A52394261-419-01-7	Phase 1
dianhydrogalactitol	DNA alkylating agent				BRD-K68502831-001-01-2, BRD-K68502831-001-01-2, BRD-K68502831-001-02-9	Phase 3
diarylpropionitrile	estrogen receptor agonist	ESR2			BRD-A27143604-001-02-0, BRD-A27143604-001-03-9	Preclinical
diatrizoic-acid			radiology	contrast agent	BRD-K48247567-001-08-9, BRD-K48247567-001-01-9	Launched
diaveridine	dihydrofolate reductase inhibitor		infectious disease	coccidiosis	BRD-K97464279-001-04-9, BRD-K97464279-001-03-5, BRD-K97464279-001-03-5	Launched
diazoxide	potassium channel activator	ATP1A1, CA1, CA2, KCNJ11, KCNJ8, KCNMA1, SLC12A3	endocrinology	hypoglycemia	BRD-K73109821-001-22-7, BRD-K73109821-001-20-1, BRD-K73109821-001-23-9, BRD-K73109821-001-23-9, BRD-K73109821-001-19-3	Launched
dibekacin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	BRD-K48427910-001-01-1	Launched
dibenzepine	norepinephrine reputake inhibitor				BRD-K79145749-003-02-2, BRD-K79145749-003-03-0	Preclinical
dibenzothiophene					BRD-K46863940-001-05-4, BRD-K46863940-001-04-7, BRD-K46863940-001-06-2	Preclinical
dibutyl-phthalate		TRPA1			BRD-K73477617-001-09-9, BRD-K73477617-001-08-5	Preclinical
dichloroacetate	pyruvate dehydrogenase kinase inhibitor				BRD-M97302542-001-04-4, BRD-M97302542-001-04-4, BRD-M97302542-001-03-6	Phase 3
dichlorophen	anticestodal agent		infectious disease	hookworm, tapeworm	BRD-K62326629-001-20-8, BRD-K62326629-001-20-8, BRD-K62326629-001-20-8, BRD-K62326629-001-19-0, BRD-K62326629-001-19-0, BRD-K62326629-001-19-0, BRD-K62326629-001-19-0	Launched
dichlorvos	acetylcholinesterase inhibitor				BRD-K23779958-001-05-8, BRD-K23779958-001-08-9	Launched
diclazuril	antiprotozoal agent		infectious disease	equine protozoal myeloencephalitis (EPM)	BRD-A06426627-001-04-3, BRD-A06426627-001-06-9, BRD-A06426627-001-03-5, BRD-A06426627-001-03-5	Launched
diclofenac	cyclooxygenase inhibitor	AKR1C3, ALOX5, ASIC1, ASIC3, KCNQ2, KCNQ3, PLA2G2A, PPARG, PTGS1, PTGS2, SCN4A	rheumatology, neurology/psychiatry	rheumatoid arthritis, osteoarthritis, migraine headache	BRD-K08252256-236-33-8, BRD-K08252256-237-02-1, BRD-K08252256-224-02-9, BRD-K08252256-236-32-0	Launched
diclofenamide	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA4, CA7	ophthalmology, neurology/psychiatry	glaucoma, epilepsy	BRD-K71499074-001-13-9, BRD-K71499074-001-12-9	Launched
diclofensine	dopamine reuptake inhibitor	DRD1, MAOA, MAOB			BRD-A51078674-003-01-0, BRD-A51078674-003-02-9	Phase 3
dicloralurea					BRD-A41657926-001-03-0, BRD-A41657926-001-04-9	Preclinical
dicoumarol	NADPH inhibitor	CRYZ, NQO1, VKORC1	hematology	deep vein thrombosis (DVT)	BRD-K82236179-001-08-9, BRD-K82236179-213-01-0	Launched
dicyclohexylamine					BRD-K57091285-001-07-7, BRD-K57091285-001-08-9	Preclinical
dicycloverine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	irritable bowel syndrome	BRD-K68507560-003-25-3, BRD-K68507560-003-24-6, BRD-K68507560-003-26-1	Launched
didanosine	nucleoside reverse transcriptase inhibitor	PNP	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K99063460-001-16-9, BRD-K99063460-001-13-1, BRD-K99063460-001-12-3, BRD-K99063460-001-12-3, BRD-K99063460-001-12-3, BRD-K99063460-001-12-3	Launched
dideoxyadenosine	nucleoside reverse transcriptase inhibitor				BRD-K84794093-001-07-5, BRD-K84794093-001-07-5	Phase 1
didox	ribonucleotide reductase inhibitor	RRM1	oncology	breast cancer	BRD-K94146583-001-01-6	Launched
dienestrol	estrogen receptor agonist	ESR1	endocrinology	menopause	BRD-K95309561-001-27-9, BRD-K95309561-001-24-7, BRD-K95309561-001-24-7, BRD-K95309561-001-24-7	Launched
diethylcarbamazine	lipoxygenase inhibitor	ALOX5, PTGS1	infectious disease	filariasis	BRD-K45542189-048-23-9, BRD-K45542189-048-23-9, BRD-K45542189-048-22-1	Launched
diethylstilbestrol	estrogen receptor agonist	ESR1, ESR2, ESRRB, ESRRG			BRD-K45330754-001-22-5, BRD-K45330754-001-21-7, BRD-K45330754-001-21-7	Withdrawn
diethyltoluamide	ionotropic receptor IR40a activator		dermatology	sunscreen lotion	BRD-K94080537-001-11-9, BRD-K94080537-001-09-7, BRD-K94080537-001-09-7	Launched
difenpiramide	cyclooxygenase inhibitor, prostaglandin inhibitor		neurology/psychiatry	pain relief	BRD-K96206066-001-07-9	Launched
diflorasone-diacetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses		Launched
difloxacin	bacterial DNA gyrase inhibitor		infectious disease	skin infections, urinary tract infections	BRD-K73923631-003-02-9, BRD-K73923631-003-01-1, BRD-K73923631-003-03-7	Launched
diflunisal	prostanoid receptor antagonist	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	BRD-K22031190-001-23-6	Launched
difluprednate	glucocorticoid receptor agonist	NR3C1	ophthalmology	endogenous uveitis	BRD-K72992801-001-16-9	Launched
diftalone	cyclooxygenase inhibitor		endocrinology	thyroiditis	BRD-K80076813-001-08-8, BRD-K80076813-001-08-8	Launched
digitoxigenin	ATPase inhibitor	ATP1A1			BRD-K18518344-001-16-9, BRD-K18518344-001-15-9, BRD-K18518344-001-15-9, BRD-K18518344-001-15-9, BRD-K18518344-001-15-9	Preclinical
digitoxin	ATPase inhibitor	ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, FXYD2	cardiology	congestive heart failure, cardiac arrythmia	BRD-K63668566-001-03-9, BRD-K63668566-001-03-9	Launched
digoxigenin	steroid				BRD-K18619710-001-15-9, BRD-K18619710-001-15-9, BRD-K18619710-001-14-4	Preclinical
digoxin	ATPase inhibitor	ATP1A1	cardiology	congestive heart failure, atrial fibrillation (AF)	BRD-K00004302-001-01-9, BRD-K00004302-001-01-9	Launched
dihomo-gamma-linolenic-acid	prostanoid receptor agonist	PTGS1, PTGS2			BRD-K20152659-001-10-3, BRD-K20152659-001-07-9, BRD-K20152659-001-04-6	Phase 2
dihydrexidine	dopamine receptor agonist	DRD1, DRD2, DRD3, DRD4, DRD5			BRD-K31471398-003-06-9, BRD-K31471398-003-06-9, BRD-K31471398-003-06-9, BRD-K31471398-003-01-5	Phase 2
dihydroergocristine	adrenergic receptor antagonist, prolactin inhibitor	ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7	neurology/psychiatry	senile dementia, cerebrovascular insufficiency	BRD-K97440753-066-19-9, BRD-K97440753-066-19-9, BRD-K97440753-066-20-9, BRD-K97440753-066-18-1, BRD-K97440753-066-18-1, BRD-K97440753-066-18-1, BRD-K97440753-066-18-1	Launched
dihydroergotamine	serotonin receptor agonist	ADRA2A, DRD2, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7	neurology/psychiatry	migraine headache	BRD-K72166146-066-06-2, BRD-K72166146-066-05-4, BRD-K72166146-066-07-9, BRD-K72166146-066-04-7	Launched
dihydromyricetin					BRD-K01614093-001-05-9, BRD-K01614093-001-04-2, BRD-K01614093-001-02-6, BRD-K01614093-001-03-4	Preclinical
dihydrostreptomycin	bacterial 30S ribosomal subunit inhibitor				BRD-M15413738-326-05-0	Withdrawn
dihydrotachysterol	vitamin analog	VDR	orthopedics, endocrinology	rickets, hypocalcemia, osteomalacia	BRD-A34455052-001-01-8	Launched
dihydroxyacetone			dermatology	skin protectant	BRD-K18637542-001-01-7	Launched
dihydroxyphenylglycine	glutamate receptor agonist	GRM1, GRM5			BRD-A20589515-001-02-9, BRD-A20589515-001-03-9	Preclinical
diiodothyropropionic-acid	thyroid hormone stimulant				BRD-K36802417-001-01-7	Phase 2
dilazep	adenosine reuptake inhibitor	SLC29A1	cardiology	coronary heart disease	BRD-K48722258-300-11-0, BRD-K48722258-300-10-2	Launched
dilmapimod	p38 MAPK inhibitor				BRD-K00003459-001-01-9	Phase 1
diloxanide	protein synthesis inhibitor		infectious disease	amebiasis	BRD-K10974103-001-21-1	Launched
diltiazem	calcium channel blocker	CACNA1C, CACNA1S, CACNA2D1, CACNG1, HTR3A, KCNA5	cardiology	hypertension, angina pectoris	BRD-K24023109-003-28-6, BRD-K24023109-003-28-6, BRD-K24023109-003-30-9, BRD-K24023109-003-30-9, BRD-K24023109-003-25-2, BRD-K24023109-003-26-0	Launched
DIM-C-pPhCO2Me	nuclear receptor antagonist				BRD-K00005337-001-01-9	Preclinical
dimaprit	histamine receptor agonist	HRH2, HRH3, HRH4			BRD-K23541596-300-07-2, BRD-K23541596-300-09-9, BRD-K23541596-300-09-9, BRD-K23541596-300-08-0	Preclinical
dimemorfan	sigma receptor agonist	SIGMAR1	pulmonary	cough suppressant	BRD-K29812331-011-01-7, BRD-K29812331-011-01-7, BRD-K29812331-011-01-7	Launched
dimenhydrinate	histamine receptor antagonist	HRH1	neurology/psychiatry, gastroenterology	motion sickness, nausea, vomiting		Launched
dimercaprol	chelating agent		neurology/psychiatry	metal toxicity	BRD-A56152450-001-03-8, BRD-A56152450-001-02-0	Launched
dimercaptosuccinic-acid	chelating agent	DNMT1	neurology/psychiatry	metal toxicity	BRD-K88701661-001-03-7, BRD-K88701661-001-02-9, BRD-K88701661-001-02-9, BRD-K88701661-001-02-9	Launched
dimesna	tubulin polymerization inhibitor				BRD-K30126819-304-04-9, BRD-K30126819-304-03-5, BRD-K30126819-304-02-7	Phase 3
dimethadione	oxazolidine antiepileptic				BRD-K43687498-001-09-8	Preclinical
dimethicone			dermatology	cosmetic	BRD-K26674746-001-01-4	Launched
dimethindene-(S)-(+)	acetylcholine receptor antagonist	HRH1			BRD-K83192048-050-03-5, BRD-K83192048-050-03-5, BRD-K83192048-050-03-5, BRD-K83192048-050-03-5, BRD-K83192048-050-02-7	Preclinical
dimethisoquin	local anesthetic		neurology/psychiatry	local anesthetic	BRD-K73391359-003-10-2, BRD-K73391359-003-11-9	Launched
dimethyl-fumarate	nuclear factor erythroid derived, like (NRF2) activator	KEAP1	neurology/psychiatry	multiple sclerosis	BRD-K31111078-001-04-2, BRD-K31111078-001-04-2, BRD-K31111078-001-05-9, BRD-K31111078-001-05-9, BRD-K31111078-001-03-4	Launched
dimethyl-isosorbide	cosmetic moisturizer				BRD-A17224697-001-01-0	Preclinical
dimetindene	cholinergic receptor antagonist, histamine receptor antagonist	HRH1	allergy	allergic rhinitis	BRD-K01826026-001-01-9	Launched
dimpylate	acetylcholinesterase inhibitor	ACHE	infectious disease	flea control	BRD-K60567437-001-10-2, BRD-K60567437-001-10-2, BRD-K60567437-001-13-9	Launched
dinaciclib	CDK inhibitor	CDK1, CDK2, CDK5, CDK9			BRD-K13662825-001-07-5, BRD-K13662825-001-07-5, BRD-K13662825-001-07-5, BRD-K13662825-001-07-5, BRD-K13662825-001-04-2, BRD-K13662825-001-04-2	Phase 3
dinitolmide			infectious disease	coccidiosis	BRD-K93240442-001-09-9, BRD-K93240442-001-08-4	Launched
dinoprost	prostacyclin analog	PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R	obstetrics/gynecology	labor induction	BRD-K81672972-001-03-1, BRD-K81672972-001-03-1, BRD-K81672972-234-15-9	Launched
dinoprostone	prostanoid receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, TBXA2R			BRD-K26521938-001-07-2, BRD-K26521938-001-09-8	Withdrawn
dioscin	apoptosis stimulant	CXCR3			BRD-K67340225-001-02-9	Preclinical
diosmetin	aryl hydrocarbon receptor agonist	CYP1B1	dermatology	cosmetic	BRD-K26862302-001-06-9, BRD-K26862302-001-05-2, BRD-K26862302-001-05-2, BRD-K26862302-001-05-2, BRD-K26862302-001-05-2	Launched
dioxybenzone	topical sunscreen agent				BRD-K22193694-001-14-9, BRD-K22193694-001-13-6	Preclinical
dipeptamin					BRD-K11595419-001-02-2, BRD-K11595419-001-01-4	Launched
diperodon	local anesthetic				BRD-A30693873-003-11-0, BRD-A30693873-003-12-8, BRD-A30693873-003-12-8, BRD-A30693873-003-13-6	Preclinical
diphemanil	acetylcholine receptor antagonist	CHRM3	neurology/psychiatry	spasms	BRD-K93441486-067-13-9, BRD-K93441486-067-13-9, BRD-K93441486-067-12-8	Launched
diphencyprone	immunostimulant				BRD-K51730347-001-06-4, BRD-K51730347-001-05-6	Phase 2
diphenhydramine	histamine receptor antagonist	HRH1	neurology/psychiatry	headache	BRD-K47278471-003-26-3, BRD-K47278471-003-26-3, BRD-K47278471-003-25-5	Launched
diphenidol	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	vertigo	BRD-K01663662-003-20-2, BRD-K01663662-003-20-2, BRD-K01663662-003-20-2, BRD-K01663662-003-21-0, BRD-K01663662-003-21-0	Launched
diphenyleneiodonium	nitric oxide synthase inhibitor	NOS2, NOS3			BRD-K65814004-003-03-9, BRD-K65814004-003-02-9, BRD-K65814004-003-02-9	Preclinical
diphenylguanidine					BRD-K12362304-001-07-3, BRD-K12362304-001-08-9	Preclinical
diphenylpyraline	dopamine reuptake inhibitor	HRH1, SLC6A3	allergy	allergic rhinitis	BRD-K22936972-003-23-6, BRD-K22936972-003-23-6, BRD-K22936972-003-22-8, BRD-K22936972-003-24-4	Launched
dipivefrine	adrenergic receptor agonist		ophthalmology	glaucoma, intraocular pressure	BRD-A47494775-003-11-3	Launched
dipraglurant	glutamate receptor negative allosteric modulator	GRM5			BRD-K64838454-001-01-0, BRD-K64838454-001-02-9	Phase 2
DIPT	dopamine reuptake inhibitor, serotonin reuptake inhibitor	HTR1A, HTR2A, HTR2C			BRD-K75385383-001-01-5	Launched
dipyridamole	phosphodiesterase inhibitor	ADA, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, SLC29A1	cardiology	coronary artery disease (CAD), peripheral artery disease (PAD), hypertension	BRD-K86301799-001-39-7, BRD-K86301799-001-36-3, BRD-K86301799-001-37-1, BRD-K86301799-001-37-1, BRD-K86301799-001-40-9, BRD-K86301799-001-40-9, BRD-K86301799-001-34-8, BRD-K86301799-001-35-5	Launched
dipyrocetyl	chelating agent		endocrinology, neurology/psychiatry	fever, pain relief	BRD-K47608922-001-05-9, BRD-K47608922-001-04-7	Launched
diquafosol	purinergic receptor activator				BRD-K00003514-342-01-9	Phase 3
diroximel-fumarate	anti-inflammatory agent				BRD-K87386013-001-01-7	Phase 3
disodium-sebacate		HBB			BRD-K66672047-304-01-3	Phase 1
disopyramide	sodium channel blocker	CHRM1, CHRM2, CHRM3, KCND2, KCND3, KCNH2, SCN5A	cardiology	ventricular tachycardia (VT), ventricular arrhythmias	BRD-A29734509-011-13-6, BRD-A29734509-011-12-8, BRD-A29734509-011-14-4, BRD-A29734509-011-14-4, BRD-A29734509-011-14-4	Launched
disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	ALDH2, DBH	neurology/psychiatry	abstinence from alcohol	BRD-K32744045-001-31-2, BRD-K32744045-001-31-2, BRD-K32744045-001-31-2, BRD-K32744045-001-31-2, BRD-K32744045-001-31-2, BRD-K32744045-001-30-4, BRD-K32744045-001-34-6, BRD-K32744045-001-34-6, BRD-K32744045-001-34-6, BRD-K32744045-001-34-6, BRD-K32744045-001-34-6, BRD-K32744045-001-34-6, BRD-K32744045-001-34-6, BRD-K32744045-001-34-6	Launched
dithranol	DNA synthesis inhibitor		dermatology	psoriasis	BRD-K51807679-001-06-8	Launched
ditiocarb-sodium-trihydrate	immunostimulant	CA1, CA2, CA4			BRD-K40654626-236-02-3, BRD-K40654626-236-01-5	Phase 3
ditolylguanidine	sigma receptor agonist	GRIN1, GRIN2A, GRIN2B, SIGMAR1			BRD-K33459542-001-08-9, BRD-K33459542-001-07-4	Preclinical
dixanthogen					BRD-K05919151-001-01-6, BRD-K05919151-001-02-9	Preclinical
dixyrazine	antipsychotic				BRD-K00003339-001-01-9	Preclinical
dizocilpine-(+)	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			BRD-K58930050-050-16-6, BRD-K58930050-050-16-6, BRD-K58930050-050-17-9, BRD-K58930050-050-17-9, BRD-K58930050-050-15-8, BRD-K58930050-001-05-2	Preclinical
dizocilpine-(-)	glutamate receptor antagonist				BRD-K23163214-050-16-9, BRD-K23163214-050-16-9, BRD-K23163214-050-15-1, BRD-K23163214-051-01-9	Phase 1
DMAB-anabaseine	adrenergic receptor agonist	CHRNA7			BRD-K26573499-300-03-9, BRD-K26573499-300-02-1, BRD-K26573499-300-02-1, BRD-K26573499-300-04-9	Preclinical
DMH1	ALK tyrosine kinase receptor inhibitor	ACVR1			BRD-K39381259-001-01-0, BRD-K39381259-001-01-0, BRD-K39381259-001-01-0, BRD-K39381259-001-02-8, BRD-K39381259-001-02-8, BRD-K39381259-001-03-9	Preclinical
DMH4	VEGFR inhibitor	KDR			BRD-K40575944-001-02-9, BRD-K40575944-001-01-5, BRD-K40575944-001-01-5	Preclinical
DMNB	DNA dependent protein kinase inhibitor				BRD-K03564313-001-04-9, BRD-K03564313-001-03-3	Preclinical
DMP-543	acetylcholine release enhancer				BRD-K89274813-001-03-1, BRD-K89274813-001-02-3, BRD-K89274813-001-04-9	Phase 2
DMP-777	elastase inhibitor	MPO			BRD-K54936858-001-02-9, BRD-K54936858-001-01-6, BRD-K54936858-001-01-6	Phase 2
DMPS	chelating agent				BRD-A22971209-001-01-0	Phase 1
DNQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIK1, GRIN1, GRIN2A, GRIN2B			BRD-K64400208-001-09-1, BRD-K64400208-001-09-1, BRD-K64400208-304-01-6, BRD-K64400208-304-01-6, BRD-K64400208-001-08-3, BRD-K64400208-001-10-9	Preclinical
dobutamine	adrenergic receptor agonist	ADRB1, ADRB2	cardiology	congestive heart failure	BRD-A78322124-003-16-5, BRD-A78322124-003-18-1, BRD-A78322124-003-18-1, BRD-A78322124-003-17-3, BRD-A78322124-003-15-7, BRD-A78322124-003-15-7, BRD-A78322124-003-14-0, BRD-A78322124-003-14-0	Launched
docebenone	lipoxygenase inhibitor	ALOX5			BRD-K08290224-001-14-5	Phase 2
doconexent	PPAR receptor agonist	FFAR1, PTGS1, PTGS2			BRD-K39965020-001-09-1, BRD-K39965020-001-12-5	Launched
doconexent-ethyl-ester	omega 3 fatty acid stimulant		endocrinology	hypertriglyceridemia	BRD-K61937613-001-01-1	Launched
docosanol	lipase clearing factor inhibitor	TLR7	dental	cold sore	BRD-K50050533-001-05-9, BRD-K50050533-001-03-9, BRD-K50050533-001-04-7, BRD-K50050533-001-02-1	Launched
docusate	laxative		gastroenterology	constipation	BRD-A00092689-236-04-9, BRD-A00092689-236-03-8	Launched
dodecyl-sulfate		LYZ			BRD-K05680146-001-01-2	Preclinical
dofequidar	MRP inhibitor, P glycoprotein inhibitor	ABCB1			BRD-A14941520-051-01-0, BRD-A14941520-051-01-0	Phase 3
dofetilide	potassium channel blocker	KCNH1, KCNH2, KCNJ12, KCNK2			BRD-K86887724-001-12-2, BRD-K86887724-001-10-6, BRD-K86887724-001-10-6, BRD-K86887724-001-13-9, BRD-K86887724-001-09-8	Withdrawn
dolastatin-10	tubulin polymerization inhibitor	TUBB			BRD-K78567475-001-01-4, BRD-K78567475-001-01-4, BRD-K78567475-001-01-4, BRD-K78567475-001-01-4, BRD-K78567475-001-01-4, BRD-K78567475-001-01-4, BRD-K78567475-001-02-9	Phase 2
dolutegravir	HIV integrase inhibitor	CYP3A4, CYP3A5, CYP3A7, POU2F2, UGT1A1	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K67463151-001-02-9	Launched
domiphen					BRD-K30431096-004-02-9, BRD-K30431096-004-02-9, BRD-K30431096-004-01-3, BRD-K30431096-004-01-3, BRD-K30431096-004-01-3, BRD-K30431096-004-01-3	Preclinical
domperidone	dopamine receptor antagonist	DRD2, DRD3	infectious disease	fescue toxicosis	BRD-K38305202-001-18-2, BRD-K38305202-001-18-2, BRD-K38305202-001-17-4, BRD-K38305202-001-16-6	Launched
donepezil	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	Alzheimer's disease	BRD-A49160188-003-12-7, BRD-A49160188-003-11-9	Launched
donitriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR5A, HTR6			BRD-K31092604-003-03-5, BRD-K31092604-003-03-5, BRD-K31092604-003-03-5	Phase 2
dopamine	dopamine receptor agonist	DBH, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR7, SLC6A2, SLC6A3, SLC6A4	cardiology, neurology/psychiatry	ventricular arrhythmias, depression, headache, tremors	BRD-K43887077-003-26-3, BRD-K43887077-003-27-1, BRD-K43887077-003-27-1, BRD-K43887077-003-25-5	Launched
doramapimod	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK13, MAPK14			BRD-K74065929-001-10-9, BRD-K74065929-001-08-0, BRD-K74065929-001-08-0, BRD-K74065929-001-08-0, BRD-K74065929-001-07-2	Phase 2
doramectin			infectious disease	gastrointestinal roundworms	BRD-K00003581-001-01-9	Launched
doravirine	non-nucleoside reverse transcriptase inhibitor				BRD-K00003231-001-01-9	Launched
dorsomorphin	AMPK inhibitor	ACVR1, BMPR1A, BMPR1B, EPHA2, FKBP1A, FLT1, FLT3, KDR, LCK, MKNK1, PRKAA1, RPS6KA1, SRC			BRD-K54233340-300-05-1, BRD-K54233340-300-05-1, BRD-K54233340-001-07-9, BRD-K54233340-001-07-9, BRD-K54233340-001-07-9, BRD-K54233340-001-07-9	Preclinical
dorzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7	ophthalmology	intraocular pressure, glaucoma	BRD-K48617017-003-14-9	Launched
dosulepin	norepinephrine reuptake inhibitor, serotoninâ€“norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, SLC6A2, SLC6A4	neurology/psychiatry	depression	BRD-K54759182-003-08-0, BRD-K54759182-003-08-0, BRD-K54759182-003-09-8	Launched
DOTMP					BRD-K00004678-001-01-9	Preclinical
dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB			BRD-K85402309-406-01-8, BRD-K85402309-001-07-4, BRD-K85402309-001-07-4, BRD-K85402309-389-03-2, BRD-K85402309-001-06-6, BRD-K85402309-001-06-6, BRD-K85402309-389-04-0, BRD-K85402309-043-01-9, BRD-K85402309-043-01-9, BRD-K85402309-043-01-9, BRD-K85402309-043-01-9, BRD-K85402309-043-01-9, BRD-K85402309-043-01-9	Phase 3
doxazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	BRD-K01825125-066-05-9, BRD-K01825125-066-05-9	Launched
doxepin	histamine receptor antagonist	HRH1, SLC6A2, SLC6A4	neurology/psychiatry	depression, anxiety	BRD-K37694030-003-12-7, BRD-K37694030-003-11-9	Launched
doxofylline	adenosine receptor antagonist	ADORA1, PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	asthma	BRD-K70507123-001-11-9, BRD-K70507123-001-09-7, BRD-K70507123-001-09-7, BRD-K70507123-001-09-7, BRD-K70507123-001-08-9	Launched
doxorubicin	topoisomerase inhibitor	TOP2A	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma		Launched
doxylamine	histamine receptor antagonist	HRH1	neurology/psychiatry	sedative	BRD-A44008656-036-25-8, BRD-A44008656-036-24-1	Launched
DpC					BRD-K00004636-001-01-9	Phase 1
DPC-681	HIV protease inhibitor				BRD-K37087535-001-01-1	Phase 1
DPCPX	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K01824921-001-19-9, BRD-K01824921-001-18-5, BRD-K01824921-001-18-5	Phase 1
DPI-201106	sodium channel activator	ADRB2			BRD-A64553394-001-04-4	Phase 2
DPO-1	potassium channel blocker	KCNA5			BRD-K99922388-001-02-0, BRD-K99922388-001-03-9, BRD-K99922388-001-03-9	Preclinical
DPPE	histamine receptor antagonist	ABCB1, HRH1			BRD-K80315159-051-03-9, BRD-K80315159-051-02-0, BRD-K80315159-051-02-0	Phase 3
DQP-1105	glutamate receptor antagonist	GRIN2C, GRIN2D			BRD-A67976398-001-02-9, BRD-A67976398-001-02-9, BRD-A67976398-001-01-6	Preclinical
DR-2313	PARP inhibitor	PARP1, PARP3			BRD-K94920105-001-03-9, BRD-K94920105-001-05-9	Preclinical
DR-4485	serotonin receptor antagonist	HTR7			BRD-A39794701-003-02-9, BRD-A39794701-003-01-6, BRD-A39794701-003-01-6	Preclinical
DRF053-(R)	CDK inhibitor	CSNK1A1			BRD-K25486274-300-02-8, BRD-K25486274-300-01-0, BRD-K25486274-300-03-9	Preclinical
drofenine			neurology/psychiatry	spasms	BRD-A22267103-003-13-1, BRD-A22267103-003-14-9	Launched
droloxifene	selective estrogen receptor modulator (SERM)	ESR1			BRD-K38477637-001-01-0	Phase 3
dromostanolone-propionate	androgen receptor modulator	AR	oncology	breast cancer	BRD-A38706605-001-01-2, BRD-A38706605-001-01-2	Launched
dronedarone	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A	cardiology	atrial fibrillation (AF)	BRD-K05524748-001-05-9, BRD-K05524748-001-05-9, BRD-K05524748-003-04-4, BRD-K05524748-003-04-4, BRD-K05524748-003-04-4	Launched
droperidol	dopamine receptor antagonist	ADRA1A, DRD2, DRD3, DRD4, HTR2A	gastroenterology	nausea, vomiting	BRD-K97158071-001-19-9, BRD-K97158071-001-18-1, BRD-K97158071-001-17-3	Launched
dropropizine	antitussive		pulmonary	cough suppressant	BRD-A29349577-001-23-0, BRD-A29349577-001-22-2, BRD-A29349577-001-25-9, BRD-A29349577-001-24-8	Launched
drotaverine	phosphodiesterase inhibitor		obstetrics/gynecology	labor induction	BRD-K00633793-003-03-4, BRD-K00633793-001-01-2, BRD-K00633793-001-01-2, BRD-K00633793-001-01-2	Launched
droxicam	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis, osteoarthritis	BRD-K17219082-001-02-9, BRD-K17219082-001-01-1	Launched
droxidopa	norepinephrine precursor	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH	cardiology, neurology/psychiatry	hypertension, Parkinson's Disease	BRD-K20372197-001-04-9, BRD-K20372197-001-04-9, BRD-K20372197-001-02-3, BRD-K20372197-001-03-1, BRD-K20372197-001-03-1	Launched
droxinostat	HDAC inhibitor	HDAC6, HDAC8			BRD-K11558771-001-13-9, BRD-K11558771-001-13-9, BRD-K11558771-001-13-9, BRD-K11558771-001-13-9	Preclinical
DSM265	dihydroorotate dehydrogenase inhibitor				BRD-K35498911-001-02-9	Phase 2
DSPC					BRD-K00004570-001-01-9	Preclinical
DSR-6434	toll-like receptor agonist	TLR7			BRD-K46384285-001-02-9, BRD-K46384285-001-01-3	Preclinical
DS2-(806622)					BRD-K09619578-001-02-1, BRD-K09619578-001-01-3, BRD-K09619578-001-03-9	Preclinical
DU-728	structural glycoprotein antagonist	ITGA2B, ITGB3			BRD-K08859203-001-01-9, BRD-K08859203-001-02-9	Phase 1
duloxetine	norepinephrine reuptake inhibitor, serotoninâ€“norepinephrine reuptake inhibitor (SNRI)	HTR2A, HTR2C, HTR6, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD), muscle pain, peripheral neuropathy	BRD-K71103788-003-13-8, BRD-K71103788-003-12-0, BRD-K71103788-003-12-0, BRD-K71103788-003-12-0, BRD-K71103788-003-11-2, BRD-K71103788-003-11-2	Launched
DUP-697	cyclooxygenase inhibitor	PTGS2			BRD-K06221026-001-07-6, BRD-K06221026-001-08-9, BRD-K06221026-001-06-8	Phase 1
duvelisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			BRD-K93468883-001-02-0, BRD-K93468883-001-02-0, BRD-K93468883-001-02-0, BRD-K93468883-001-05-9	Launched
DVD-111					BRD-K22520627-001-01-7, BRD-K22520627-001-02-9	Phase 2
DWK-1339	beta amyloid aggregation inhibitor				BRD-K00003171-001-01-9	Preclinical
dyclonine	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	local anesthetic	BRD-K72259270-003-27-2, BRD-K72259270-003-27-2, BRD-K72259270-003-24-9, BRD-K72259270-003-25-6, BRD-K72259270-003-25-6, BRD-K72259270-003-23-1, BRD-K72259270-003-26-4	Launched
dynasore	dynamin inhibitor	DNM1, DNM1L, DNM2			BRD-K87718015-001-04-9, BRD-K87718015-001-01-9, BRD-K87718015-001-02-7, BRD-K87718015-001-02-7, BRD-K87718015-001-02-7, BRD-K87718015-001-02-7	Preclinical
dynole-34-2	dynamin inhibitor	DNM1			BRD-K23479488-001-01-3, BRD-K23479488-001-02-9	Preclinical
dyphylline	adenosine receptor antagonist, phosphodiesterase inhibitor	PDE4A	pulmonary	asthma, bronchitis, emphysema	BRD-A00827783-001-24-6, BRD-A00827783-001-23-8, BRD-A00827783-001-25-9	Launched
DY131	estrogen-related receptor agonist	ESRRB, ESRRG			BRD-K58343622-001-02-4, BRD-K58343622-001-01-6, BRD-K58343622-001-03-9	Preclinical
D609	phospholipase inhibitor				BRD-A77118605-237-09-5, BRD-A77118605-237-08-7, BRD-A77118605-237-07-9, BRD-A77118605-237-06-1	Preclinical
E-2001	antioxidant				BRD-K00004561-001-01-9	Preclinical
E-2012	gamma secretase modulator	APH1A, APH1B, PSENEN			BRD-K50564936-001-02-9, BRD-K50564936-001-01-6	Phase 1
E-4031	potassium channel blocker	KCNH1, KCNH2			BRD-K41713976-300-03-4, BRD-K41713976-300-06-9, BRD-K41713976-300-06-9, BRD-K41713976-300-02-6	Phase 1
E-64	calpain inhibitor, cysteine protease inhibitor	CTSS			BRD-K00004314-001-01-9, BRD-K00004314-001-01-9	Preclinical
eact	calcium-activated chloride channel inhibitor	ANO1			BRD-K53030960-001-02-9, BRD-K53030960-001-01-4	Preclinical
EB-47	PARP inhibitor	PARP1			BRD-K66998413-300-01-6, BRD-K66998413-300-01-6, BRD-K66998413-300-01-6, BRD-K66998413-300-02-9	Preclinical
ebastine	histamine receptor antagonist	CYP3A4, HRH1	allergy	allergic rhinitis, urticaria	BRD-K13314656-001-02-9, BRD-K13314656-001-01-0, BRD-K13314656-001-01-0, BRD-K13314656-001-01-0	Launched
EBPC	aldose reductase inhibitor	AKR1B1			BRD-K00004209-001-01-9	Preclinical
ebrotidine	histamine receptor antagonist	HRH2			BRD-K22421059-001-03-1, BRD-K22421059-001-02-3, BRD-K22421059-001-02-3, BRD-K22421059-001-01-5	Withdrawn
ebselen	cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor	ALB			BRD-K29359156-001-30-1, BRD-K29359156-001-30-1, BRD-K29359156-001-30-1	Phase 2/Phase 3
EC-144	HSP inhibitor	HSP90AA1, HSP90AB1			BRD-K41705163-001-02-9, BRD-K41705163-001-01-1, BRD-K41705163-001-01-1, BRD-K41705163-001-01-1	Preclinical
EC-23	retinoid receptor agonist	RARA, RARB, RARG			BRD-K81004638-001-01-7, BRD-K81004638-001-01-7, BRD-K81004638-001-02-5	Preclinical
ecabapide					BRD-K47371940-001-01-6, BRD-K47371940-001-01-6, BRD-K47371940-001-01-6	Phase 3
ecabet	gastrin inhibitor, urease inhibitor	NOXO1	ophthalmology	dry eye syndrome	BRD-K03353589-236-01-4, BRD-K03353589-236-01-4	Launched
ecamsule-triethanolamine			dermatology	skin protectant, sunscreen lotion	BRD-A60635434-001-01-1	Launched
echinomycin	DNA intercalating agent				BRD-K00010937-001-01-9	Phase 2
econazole	lanosterol demethylase inhibitor, sterol demethylase inhibitor	NPY1R, NPY2R, TRPM2, TRPV5	infectious disease	tinea pedis, tinea cruris, tinea corporis, tinea versicolor, cutaneous candidiasis	BRD-A51820102-008-28-9, BRD-A51820102-008-28-9, BRD-A51820102-008-28-9, BRD-A51820102-008-28-9, BRD-A51820102-008-28-9, BRD-A51820102-008-28-9, BRD-A51820102-008-29-9, BRD-A51820102-008-27-1	Launched
ectoine	anti-inflammatory agent				BRD-K34566599-001-03-9, BRD-K34566599-001-02-8	Launched
edaglitazone	PPAR receptor agonist	PPARG			BRD-K00004306-001-01-9	Phase 2
edaravone	nootropic agent	BCL2	neurology/psychiatry	stroke	BRD-K35458079-001-34-9, BRD-K35458079-001-33-1, BRD-K35458079-001-29-9, BRD-K35458079-001-35-6, BRD-K35458079-001-31-5, BRD-K35458079-001-28-1, BRD-K35458079-001-27-3	Launched
edasalonexent	NFkB pathway inhibitor				BRD-K00003258-001-01-9	Phase 3
edelfosine	phospholipase inhibitor				BRD-K01825687-001-02-9, BRD-K01825687-001-01-9	Phase 2
editol					BRD-A78588743-001-03-4, BRD-A78588743-001-04-9	Preclinical
EDO-S101	HDAC inhibitor				BRD-K00003432-001-01-9	Phase 1/Phase 2
edonerpic-maleate	beta amyloid inhibitor				BRD-K00003259-050-01-9	Preclinical
edoxaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)	BRD-K97058489-454-01-6, BRD-K97058489-454-01-6	Launched
edrophonium	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	myasthenia gravis	BRD-K81128206-003-25-9, BRD-K81128206-003-24-4, BRD-K81128206-003-24-4	Launched
EDTMP	chelating agent				BRD-K54542929-001-02-9, BRD-K54542929-001-01-7	Preclinical
EED226	polycomb protein inhibitor	EED			BRD-K19002914-001-01-3, BRD-K19002914-001-01-3	Preclinical
efaproxiral	hemoglobin oxygen release stimulant	HBA1, HBB			BRD-K37355418-001-02-9, BRD-K37355418-236-01-6, BRD-K37355418-236-01-6	Phase 3
efaroxan	adrenergic receptor antagonist	ADORA2A			BRD-A10739734-003-10-6, BRD-A10739734-003-10-6, BRD-A10739734-003-09-8	Phase 2
efatutazone	PPAR receptor agonist	PPARG			BRD-A24560335-300-02-9, BRD-A24560335-300-01-2, BRD-A24560335-300-01-2	Phase 2
efavirenz	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K40758068-001-10-9, BRD-K40758068-001-08-2, BRD-K40758068-001-08-2	Launched
efinaconazole	lanosterol demethylase inhibitor	CYP51A1	infectious disease	onychomycosis	BRD-A30774155-001-01-2	Launched
efletirizine	antihistamine				BRD-K00004551-001-01-9	Phase 3
eflornithine	ornithine decarboxylase inhibitor	ARG2, ODC1	dermatology	facial hair reduction	BRD-A96292436-003-16-1	Launched
efloxate	vasodilator				BRD-K55166090-001-09-0	Preclinical
efonidipine	calcium channel blocker		cardiology	hypertension	BRD-K00004292-003-02-9, BRD-K00004292-003-01-9	Launched
EF5	cytochrome P450 activator				BRD-K00004643-001-01-9	Phase 2
EGF816	EGFR inhibitor	EGFR			BRD-K22514639-001-05-7, BRD-K22514639-001-04-0, BRD-K22514639-001-04-0	Phase 2
eglumetad	glutamate receptor agonist	GRM2, GRM3, GRM6, GRM8			BRD-K65359424-001-02-1, BRD-K65359424-001-02-1, BRD-K65359424-001-01-3	Phase 2
EG00229	neuropilin receptor antagonist	NRP1			BRD-K50653584-019-01-4, BRD-K50653584-001-01-2	Preclinical
EHop-016	Ras GTPase inhibitor	RAC1, RAC3			BRD-K32289541-001-01-0, BRD-K32289541-001-01-0, BRD-K32289541-001-01-0, BRD-K32289541-001-01-0, BRD-K32289541-001-01-0, BRD-K32289541-001-01-0, BRD-K32289541-001-01-0	Preclinical
EIPA	sodium/hydrogen exchanger inhibitor, transient receptor potential polycystic inhibitor	ADRA2A, ASIC1, PKD2L1			BRD-K88120876-001-09-8, BRD-K88120876-001-10-9	Preclinical
EIT-hydrobromide	nitric oxide synthase inhibitor	NOS2, NOS3			BRD-K81623406-004-09-9, BRD-K81623406-004-08-3	Preclinical
EI1	histone lysine methyltransferase inhibitor	EZH2			BRD-K91535048-001-01-2	Preclinical
elacestrant	estrogen receptor degrader				BRD-K00003295-300-01-9, BRD-K00003295-300-01-9	Phase 3
elacridar	P glycoprotein inhibitor	ABCB1			BRD-K88807631-001-03-9, BRD-K88807631-001-03-9, BRD-K88807631-001-03-9, BRD-K88807631-001-02-1, BRD-K88807631-001-02-1, BRD-K88807631-001-01-3, BRD-K88807631-001-01-3, BRD-K88807631-001-01-3, BRD-K88807631-001-01-3, BRD-K88807631-001-01-3, BRD-K88807631-001-01-3	Phase 1
elactocin	exportin antagonist	XPO1				Phase 1
elacytarabine	antineoplastic agent	DCK			BRD-K00004609-001-01-9	Phase 3
elafibranor	PPAR receptor agonist	PPARA, PPARD, PPARG			BRD-K03165895-001-01-9, BRD-K03165895-001-01-9	Phase 3
elagolix	gonadotropin releasing factor hormone receptor antagonist	GNRHR			BRD-K55808645-001-02-2, BRD-K55808645-001-01-4	Launched
elbasvir	HCV inhibitor		infectious disease	hepatitis C	BRD-K09735259-001-01-3, BRD-K09735259-001-01-3	Launched
eldecalcitol	bone formation stimulant	VDR			BRD-K00003316-001-01-9	Phase 3
eleclazine	late sodium current inhibitor				BRD-K00003225-003-01-9	Phase 3
elemene	VEGFR inhibitor				BRD-K79565391-001-01-8	Phase 3
elesclomol	oxidative stress inducer	HSPA1A			BRD-K82135108-001-04-3, BRD-K82135108-001-04-3, BRD-K82135108-001-07-9, BRD-K82135108-001-07-9	Phase 3
eletriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2B, HTR7	neurology/psychiatry	migraine headache	BRD-K30652337-004-03-9, BRD-K30652337-004-03-9, BRD-K30652337-001-01-9, BRD-K30652337-004-01-3, BRD-K30652337-004-04-9, BRD-K30652337-004-02-1	Launched
elinogrel	purinergic receptor antagonist	P2RY12			BRD-K59271229-001-02-3, BRD-K59271229-001-01-5	Phase 2
eliprodil	glutamate receptor antagonist	GRIN1, GRIN2B			BRD-A61392169-001-02-7, BRD-A61392169-001-02-7, BRD-A61392169-001-02-7, BRD-A61392169-001-03-9	Phase 3
ellagic-acid	glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor	CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, GSK3B, PRKACA, PRKCA, PRKCB, SQLE, SYK			BRD-K30466858-001-11-9, BRD-K30466858-001-09-6, BRD-K30466858-001-09-6, BRD-K30466858-001-10-4, BRD-K30466858-001-08-8	Phase 2
ELN-441958	bradykinin receptor antagonist	BDKRB1			BRD-K50699835-001-01-2, BRD-K50699835-001-01-2	Preclinical
eltanexor	exportin inhibitor				BRD-K00003369-001-01-9	Preclinical
eltanolone	GABA receptor positive allosteric modulator	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2			BRD-K30827431-001-01-2, BRD-K30827431-001-01-2	Phase 3
eltoprazine	serotonin receptor agonist	HTR1A, HTR1B			BRD-K86171477-001-01-3, BRD-K86171477-001-03-9, BRD-K86171477-001-02-1	Phase 2
eltrombopag	thrombopoietin receptor agonist	MPL	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia	BRD-K00003572-001-01-9	Launched
eluxadoline	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	BRD-K39560679-001-01-1	Launched
elvitegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K54472332-001-03-4	Launched
emamectin	GABA receptor agonist				BRD-K00003516-057-01-9	Preclinical
embelin	HCV inhibitor, XIAP inhibitor	XIAP			BRD-K86727142-001-12-4, BRD-K86727142-001-12-4, BRD-K86727142-001-12-4, BRD-K86727142-001-12-4, BRD-K86727142-001-16-9, BRD-K86727142-001-16-9, BRD-K86727142-001-11-6, BRD-K86727142-001-13-2	Preclinical
EMD-1214063	hepatocyte growth factor receptor inhibitor	MET			BRD-K97963946-001-01-3, BRD-K97963946-001-01-3, BRD-K97963946-001-01-3, BRD-K97963946-001-02-9	Phase 2
EMD-386088	serotonin receptor agonist	HTR6			BRD-K47659338-003-03-6, BRD-K47659338-003-02-8, BRD-K47659338-003-04-9, BRD-K47659338-003-04-9	Preclinical
EMD-53998	phosphodiesterase inhibitor	TNNC1			BRD-A65248799-001-01-7, BRD-A65248799-001-01-7, BRD-A65248799-001-01-7, BRD-A65248799-001-01-7	Phase 1
EMD-66684	angiotensin receptor antagonist	AGTR1			BRD-K88759641-003-03-6, BRD-K88759641-003-04-9, BRD-K88759641-003-02-8, BRD-K88759641-003-02-8	Preclinical
EMD534085	kinesin inhibitor				BRD-K00003185-001-01-9	Preclinical
emedastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	BRD-K15010214-364-01-9, BRD-K15010214-364-02-7	Launched
emeramide	antioxidant				BRD-K00003226-001-01-9	Phase 2
emetine	protein synthesis inhibitor	RPS2			BRD-K03067624-312-22-9, BRD-K03067624-312-22-9, BRD-K03067624-001-02-3, BRD-K03067624-001-02-3, BRD-K03067624-001-02-3, BRD-K03067624-001-02-3, BRD-K03067624-001-02-3	Phase 2
emiglitate	alpha glucoside inhibitor				BRD-K00003206-001-01-9	Preclinical
emixustat	retinoid isomerohydrolase inhibitor				BRD-K00003290-003-01-9	Phase 3
emodepside	nematocide				BRD-K00003414-001-01-9	Phase 1
emodin	11-beta hydroxysteroid dehydrogenase inhibitor	CSNK2A1			BRD-K58685305-001-20-4, BRD-K58685305-001-20-4	Preclinical
emorfazone	anti-inflammatory agent, cyclooxygenase inhibitor		dental	mouth inflammation	BRD-K90629600-001-01-4	Launched
emoxipin					BRD-K28982731-001-01-6	Phase 3
empagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	BRD-K53765467-001-02-1, BRD-K53765467-001-03-9, BRD-K53765467-001-03-9	Launched
emricasan	caspase inhibitor	CASP1, CASP3, CASP7			BRD-K00023644-001-01-9, BRD-K00023644-001-01-9, BRD-K00023644-001-01-9	Phase 2
emtricitabine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K61452026-001-04-6, BRD-K61452026-001-06-9	Launched
enalapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure, left ventricular systolic dysfunction (LVSD)	BRD-K57545991-050-23-1, BRD-K57545991-050-23-1, BRD-K57545991-050-24-9, BRD-K57545991-050-25-9, BRD-K57545991-050-25-9	Launched
enalaprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	BRD-K99447003-335-03-3, BRD-K99447003-335-05-8, BRD-K99447003-335-02-5, BRD-K99447003-335-06-6, BRD-K99447003-335-06-6, BRD-K99447003-335-04-1, BRD-K99447003-335-04-1	Launched
enasidenib	isocitrate dehydrogenase inhibitor	IDH1	hematologic malignancy	acute myeloid leukemia (AML)	BRD-K70601687-001-01-3, BRD-K70601687-001-01-3, BRD-K70601687-001-01-3, BRD-K70601687-001-01-3	Launched
enbucrilate			dermatology	skin lacerations, tissue adhesive	BRD-K66918327-001-01-3	Launched
enciprazine	GABA receptor modulator	GABRA1			BRD-A62197763-001-01-1, BRD-A62197763-001-01-1, BRD-A62197763-001-01-1	Phase 3
encorafenib	RAF inhibitor	BRAF	oncology	melanoma	BRD-K00003576-001-01-9	Launched
enflurane	membrane permeability inhibitor	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	anesthetic	BRD-A51831848-001-02-9, BRD-A51831848-001-01-7, BRD-A51831848-001-01-7	Launched
enilconazole	sterol demethylase inhibitor	CYP19A1, CYP1A2, CYP2B6, CYP2C9, CYP2J2, CYP3A4, CYP3A5, NR1I2, PPARA, PTGER2	infectious disease	skin infections	BRD-K01825690-001-02-9, BRD-K01825690-065-01-9	Launched
eniluracil	dihydropyrimidine dehydrogenase inhibitor	AOX1, DPYD, XDH			BRD-K26425819-001-01-3	Phase 3
eniporide	sodium/hydrogen antiport inhibitor				BRD-K00004568-001-01-9	Preclinical
enisamium-iodide					BRD-K10029415-005-06-9, BRD-K10029415-005-07-9	Launched
ENMD-2076	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor	AURKA, FLT3, KDR, PDGFRA, PTK2, SRC			BRD-K68488863-001-04-9, BRD-K68488863-001-04-9, BRD-K68488863-001-04-9	Phase 2
enoxacin	topoisomerase inhibitor	TOP2A	infectious disease	urinary tract infections, gonorrhea	BRD-K78113049-002-20-9, BRD-K78113049-001-16-2, BRD-K78113049-001-15-4, BRD-K78113049-001-17-0	Launched
enoximone	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	BRD-K21152241-001-07-3, BRD-K21152241-001-07-3, BRD-K21152241-001-07-3, BRD-K21152241-001-07-3, BRD-K21152241-001-07-3, BRD-K21152241-001-07-3, BRD-K21152241-001-09-9	Launched
enprofylline	phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADORA3, PDE4A, PDE4B			BRD-K35007173-001-07-5, BRD-K35007173-001-07-5, BRD-K35007173-001-07-5, BRD-K35007173-001-07-5, BRD-K35007173-001-07-5, BRD-K35007173-001-08-9	Phase 3
enrofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	BRD-K76534306-001-22-7, BRD-K76534306-001-25-9, BRD-K76534306-001-21-9	Launched
entacapone	catechol O methyltransferase inhibitor	COMT	neurology/psychiatry	Parkinson's Disease	BRD-K83636919-001-07-9, BRD-K83636919-001-07-9, BRD-K83636919-001-04-8, BRD-K83636919-001-05-5, BRD-K83636919-001-03-0	Launched
entasobulin	tubulin polymerization inhibitor				BRD-K00004610-001-01-9	Preclinical
entecavir	DNA replication inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	BRD-K08206212-002-01-0	Launched
entinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC9			BRD-K77908580-001-10-4, BRD-K77908580-001-10-4, BRD-K77908580-001-10-4, BRD-K77908580-001-10-4, BRD-K77908580-001-15-9, BRD-K77908580-001-15-9, BRD-K77908580-001-15-9, BRD-K77908580-001-09-6, BRD-K77908580-001-09-6	Phase 3
entrectinib	ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor	ALK, NTRK1, NTRK2, NTRK3, ROS1	oncology	non-small cell lung cancer (NSCLC)	BRD-K39009484-001-01-4, BRD-K39009484-001-01-4	Launched
enzalutamide	androgen receptor antagonist	AR	oncology	prostate cancer	BRD-K56851771-001-06-8	Launched
enzastaurin	PKC inhibitor	AKT1, GSK3B, PRKCA, PRKCB, PRKCD, PRKCG			BRD-K79404599-001-15-9, BRD-K79404599-001-09-3, BRD-K79404599-001-09-3	Phase 3
EN460	endoplasmic reticulum oxidation inhibitor	ERO1A			BRD-K86063171-001-03-7, BRD-K86063171-001-02-9	Preclinical
EO-1428	p38 MAPK inhibitor	MAPK11, MAPK14			BRD-K42452249-001-02-5, BRD-K42452249-001-02-5, BRD-K42452249-001-03-3, BRD-K42452249-001-04-9	Preclinical
epalrestat	aldose reductase inhibitor	AKR1B1	nephrology	diabetic nephropathy	BRD-K98054437-001-11-5, BRD-K98054437-001-12-3, BRD-K98054437-001-09-9, BRD-K98054437-001-09-9, BRD-K98054437-001-08-1	Launched
eperezolid	bacterial 30S ribosomal subunit inhibitor				BRD-K47554101-001-02-9, BRD-K47554101-001-01-2, BRD-K47554101-001-01-2, BRD-K47554101-001-01-2	Phase 1
eperisone	acetylcholine receptor antagonist	CYP2J2	neurology/psychiatry	amyotrophic lateral sclerosis (ALS), spasms, head injury, spinal injury	BRD-K01825729-003-01-9	Launched
epetraborole	leucyl-tRNA synthetase inhibitor				BRD-K00003130-003-01-9	Preclinical
ephedrine	adrenergic receptor agonist	ACHE, ADRA1A, ADRB2, SLC18A2, SLC6A2	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	BRD-K45014108-003-01-8, BRD-K45014108-003-01-8	Launched
ephedrine-(racemic)	adrenergic receptor agonist	ADRA1A, ADRA2A, ADRB1, ADRB2, ATF1, ATF2, ATF3, ATF4, ATF5, ATF6, ATF7, FOS, IL2, JDP2, JUN, NFATC1, SLC6A2, SLC6A3, SLC6A4, TNF	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity	BRD-A54236247-003-04-3, BRD-A54236247-003-04-3	Launched
epiandrosterone	steroid	G6PD			BRD-K03972660-001-12-9	Preclinical
epicatechin-gallate-(-)	bacterial DNA gyrase inhibitor	BACE1, FASN			BRD-K50660797-001-04-4, BRD-K50660797-001-05-1	Phase 2
epiestriol					BRD-K00005352-001-01-9	Preclinical
epigallocatechin-(-)					BRD-K27529556-001-04-9	Phase 2
epigallocatechin-gallate-(-)	bacterial DNA gyrase inhibitor	ELANE, EP300, FASN, KAT2B, MMP14, MMP2			BRD-K55591206-001-20-7, BRD-K55591206-001-20-7, BRD-K55591206-001-22-3, BRD-K55591206-001-19-9, BRD-K55591206-001-18-1	Phase 2/Phase 3
epinastine	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	BRD-A98990573-003-01-3, BRD-A98990573-001-02-9	Launched
epinephrine	adrenergic receptor agonist, carbonic anhydrase activator, neurotransmitter	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, TNF	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma	BRD-K63126190-001-04-4, BRD-K63126190-046-03-1, BRD-K63126190-046-03-1, BRD-K63126190-001-05-1, BRD-K63126190-046-02-3, BRD-K63126190-001-03-6, BRD-K63126190-003-01-6, BRD-K63126190-003-01-6	Launched
epirizole	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-K39339537-001-22-9, BRD-K39339537-001-21-0	Launched
epitiostanol	androgen receptor agonist	AR	oncology	breast cancer	BRD-K02314383-001-01-3, BRD-K02314383-001-01-3, BRD-K02314383-001-01-3	Launched
epomediol	cholesterol inhibitor	CYP7A1	neurology/psychiatry	itching	BRD-A59329714-001-01-5	Launched
epoprostenol	prostacyclin analog	P2RY12, PTGER1, PTGER4, PTGIR, PTGIS	cardiology	hypertension	BRD-K64054020-001-03-5, BRD-K64054020-236-01-1, BRD-K64054020-236-01-1, BRD-K64054020-236-01-1	Launched
epothilone-B	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBB			BRD-K48935217-001-03-9	Phase 3
epothilone-D	microtubule stabilizing agent, tubulin polymerization inhibitor	TUBB			BRD-K52762805-001-01-2, BRD-K52762805-001-02-9	Phase 2
EPPTB	trace amine associated receptor antagonist	TAAR1			BRD-K42536037-001-02-9, BRD-K42536037-001-01-3, BRD-K42536037-001-01-3	Preclinical
eprazinone	mucolytic agent		pulmonary	bronchospasm	BRD-A72212290-300-01-4, BRD-A72212290-300-03-0, BRD-A72212290-300-02-2	Launched
eprinomectin	benzodiazepine receptor agonist		infectious disease	gastrointestinal roundworms, lungworms	BRD-K00003555-001-01-9	Launched
epristeride	5 alpha reductase inhibitor				BRD-K00003478-001-01-9	Preclinical
eprobemide	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	BRD-K17979676-001-02-9, BRD-K17979676-001-01-2, BRD-K17979676-001-01-2	Launched
eprodisate	amyloid protein inhibitor, antiamyloidogenic agent	SAA1			BRD-K11463116-304-01-9, BRD-K11463116-304-02-7, BRD-K11463116-304-03-5	Phase 3
eprosartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	BRD-K67977190-066-02-3, BRD-K67977190-066-02-3, BRD-K67977190-066-02-3, BRD-K67977190-066-03-1, BRD-K67977190-066-03-1	Launched
eptifibatide	platelet aggregation inhibitor	ITGA2B, ITGB3	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)	BRD-K68830460-015-01-5, BRD-K68830460-015-01-5	Launched
EPZ004777	histone lysine methyltransferase inhibitor	DOT1L			BRD-K69070623-003-01-7, BRD-K69070623-003-01-7, BRD-K69070623-001-01-1, BRD-K69070623-001-01-1, BRD-K69070623-001-02-9	Preclinical
EPZ005687	histone lysine methyltransferase inhibitor	EZH2			BRD-K57754230-001-02-7	Preclinical
EPZ011989	histone lysine methyltransferase inhibitor	EZH2			BRD-K87468701-001-01-0, BRD-K87468701-001-01-0, BRD-K87468701-001-01-0	Preclinical
EPZ015666	protein arginine N-methyltransferase inhibitor	PRMT5			BRD-K70446295-001-01-7, BRD-K70446295-001-01-7, BRD-K70446295-001-01-7, BRD-K70446295-001-01-7, BRD-K70446295-001-01-7, BRD-K70446295-001-01-7, BRD-K70446295-001-01-7, BRD-K70446295-001-01-7, BRD-K70446295-001-01-7	Preclinical
EPZ020411	protein arginine N-methyltransferase inhibitor	PRMT6			BRD-K33586289-003-02-8, BRD-K33586289-003-02-8, BRD-K33586289-003-01-0, BRD-K33586289-003-01-0	Preclinical
equilin	estrogen receptor agonist	HSD17B1			BRD-A88080608-001-04-2, BRD-A88080608-001-04-2, BRD-A88080608-001-04-2	Preclinical
equol	estrogen receptor agonist	ESR1, ESR2			BRD-K54847683-001-04-0, BRD-K54847683-001-04-0, BRD-K54847683-001-03-2	Launched
ER-27319	mediator release inhibitor, SYK inhibitor	SYK			BRD-K11927976-050-04-5, BRD-K11927976-050-04-5, BRD-K11927976-050-04-5, BRD-K11927976-050-02-9, BRD-K11927976-050-03-7, BRD-K11927976-050-03-7	Preclinical
ER-50891	retinoid receptor antagonist	RARA			BRD-K18347943-001-01-8, BRD-K18347943-001-02-9	Preclinical
erastin	ion channel antagonist	VDAC2			BRD-A25004090-001-08-4, BRD-A25004090-001-08-4, BRD-A25004090-001-08-4, BRD-A25004090-001-08-4, BRD-A25004090-001-09-2	Preclinical
eravacycline	antibacterial				BRD-K00003240-300-01-9	Launched
erbstatin-analog	EGFR inhibitor, tyrosine kinase inhibitor	EGFR			BRD-K35573744-001-06-8	Preclinical
ercalcitriol	vitamin D receptor agonist	VDR			BRD-K84163249-001-03-5, BRD-K84163249-001-03-5, BRD-K84163249-001-01-9, BRD-K84163249-001-01-9	Phase 1
erdafitinib	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4			BRD-K84868168-001-01-0, BRD-K84868168-001-01-0, BRD-K84868168-001-01-0, BRD-K84868168-001-01-0, BRD-K84868168-001-01-0	Launched
erdosteine	mucolytic agent		pulmonary, infectious disease	bronchitis, cough suppressant, chronic obstructive pulmonary disease (COPD), respiratory tract infections	BRD-A05515753-001-03-2, BRD-A05515753-001-02-4, BRD-A05515753-001-04-0, BRD-A05515753-001-05-9	Launched
ergonovine	adrenergic receptor agonist, serotonin receptor agonist	ADRA1A, HTR1E	hematology	postpartum hemorrhage (PPH)	BRD-K17311468-050-01-7	Launched
ergotamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, DRD1, DRD2, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, SLC6A2	neurology/psychiatry	migraine headache	BRD-K15380626-046-02-9, BRD-K15380626-046-02-9	Launched
eribulin	microtubule inhibitor		oncology	breast cancer	BRD-K00003156-066-01-9	Launched
ERK5-IN-1	MAP kinase inhibitor	MAPK7			BRD-K64857848-001-06-4, BRD-K64857848-001-06-4, BRD-K64857848-001-06-4	Preclinical
erlotinib	EGFR inhibitor	EGFR, NR1I2	oncology	non-small cell lung cancer (NSCLC), pancreatic cancer	BRD-K70401845-001-15-7, BRD-K70401845-001-15-7, BRD-K70401845-001-15-7, BRD-K70401845-001-15-7, BRD-K70401845-001-15-7, BRD-K70401845-001-15-7, BRD-K70401845-001-15-7, BRD-K70401845-003-09-6, BRD-K70401845-003-09-6, BRD-K70401845-003-09-6, BRD-K70401845-001-09-0, BRD-K70401845-001-09-0, BRD-K70401845-001-09-0, BRD-K70401845-001-09-0, BRD-K70401845-001-09-0, BRD-K70401845-001-09-0, BRD-K70401845-001-09-0	Launched
ertapenem	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections, skin infections, pneumonia, urinary tract infections, gynecologic infections, postpartum endomyometritis	BRD-A40472231-304-01-7	Launched
erteberel	estrogen receptor agonist	ESR1, ESR2			BRD-K80608265-001-01-6, BRD-K80608265-001-01-6	Phase 2
ertugliflozin	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	BRD-K00003574-001-01-9	Launched
erythritol					BRD-K79315489-001-09-9, BRD-K79315489-001-09-9, BRD-K79315489-001-07-8, BRD-K79315489-001-08-6	Launched
erythromycin-estolate	bacterial 50S ribosomal subunit inhibitor	ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	BRD-K39746403-084-05-6, BRD-K39746403-084-04-9	Launched
erythrosine	coloring agent				BRD-K07549832-304-03-9	Preclinical
esaprazole					BRD-K92426617-001-06-3, BRD-K92426617-001-05-5	Phase 2
esaxerenone	mineralocorticoid receptor antagonist				BRD-K00003374-001-01-9	Preclinical
escin	nitric oxide synthase stimulant		dermatology	varicose veins	BRD-K00010936-001-01-9	Launched
esculin	antioxidant				BRD-K51742987-001-05-6	Phase 1
ESI-09	EPAC inhibitor	RAPGEF3, RAPGEF4			BRD-K77139516-001-01-4, BRD-K77139516-001-02-2	Preclinical
eslicarbazepine-acetate	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	BRD-K61237927-001-02-9, BRD-K61237927-001-01-7	Launched
esmolol	adrenergic receptor antagonist	ADRB1	cardiology	ventricular tachycardia (VT), hypertension	BRD-K01825842-003-02-9, BRD-K01825842-003-02-9	Launched
esonarimod	antirheumatic drug				BRD-K00003282-001-01-9	Preclinical
estetrol	selective estrogen receptor modulator (SERM)	ESR1			BRD-K75445017-001-01-1	Phase 3
estradiol-acetate	estrogen receptor agonist	ESR1	endocrinology, obstetrics/gynecology	menopause, vaginal atrophy	BRD-K53319039-001-01-8	Launched
estradiol-benzoate	contraceptive agent	ESR1			BRD-K44412991-001-11-9	Preclinical
estradiol-cypionate	estrogen receptor agonist	ESR1	endocrinology	hypoestrogenism, menopause	BRD-K64984393-001-07-9	Launched
estradiol-3-O-sulfamate	steryl sulfatase inhibitor				BRD-K00004741-001-01-9	Phase 2
estramustine	DNA alkylating agent	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer		Launched
estramustine-phosphate	DNA synthesis inhibitor, microtubule inhibitor	ESR1, ESR2, MAP1A, MAP2	oncology	prostate cancer	BRD-K00077635-304-01-2, BRD-K00077635-304-02-9, BRD-K00077635-304-02-9	Launched
estropipate	estrogen receptor agonist	ESR1, ESR2	orthopedics, endocrinology, obstetrics/gynecology	osteoporosis, menopause, vaginal atrophy, hypoestrogenism	BRD-K51095933-231-16-9	Launched
etacrynic-acid	sodium/potassium/chloride transporter inhibitor	ATP1A1, SLC12A1	cardiology, gastroenterology, nephrology, rheumatology	hypertension, congestive heart failure, edema, hepatic cirrhosis, chronic renal failure, nephrotic syndrome	BRD-K63630713-001-27-9, BRD-K63630713-001-27-9, BRD-K63630713-001-25-8	Launched
etafenone	calcium channel blocker				BRD-K84971356-001-01-4, BRD-K84971356-001-01-4, BRD-K84971356-001-01-4, BRD-K84971356-001-01-4, BRD-K84971356-001-01-4, BRD-K84971356-001-01-4	Launched
etamsylate	hemostatic agent		hematology	hemorrhage	BRD-K71055333-224-07-9, BRD-K71055333-224-07-9, BRD-K71055333-224-05-8, BRD-K71055333-224-06-6	Launched
etanidazole	bacterial cell wall synthesis inhibitor				BRD-K96042922-001-09-8, BRD-K96042922-001-10-9	Phase 3
etazolate	phosphodiesterase inhibitor	GABRB3, PDE4A			BRD-K64755930-003-04-9, BRD-K64755930-003-03-2, BRD-K64755930-003-03-2	Phase 2
ETC-159	beta catenin inhibitor, porcupine inhibitor	PORCN			BRD-K54264768-001-01-2	Phase 1
ETC-206	MAPK-interacting kinase inhibitor				BRD-K00003115-001-01-9	Phase 1
etebenecid	uricosuric blocker				BRD-K24443618-001-10-2	Preclinical
eterobarb	anticonvulsant				BRD-K64834129-001-19-6, BRD-K64834129-001-19-6	Phase 2
ethacizin	anticonvulsant		cardiology	ventricular tachycardia (VT), Wolff-Parkinson-White Syndrome (WPW)	BRD-K10667240-001-01-7, BRD-K10667240-001-01-7	Launched
ethacridine-lactate-monohydrate	DNA intercalating agent				BRD-K24715592-043-02-2, BRD-K24715592-406-01-3, BRD-K24715592-406-03-9, BRD-K24715592-406-03-9, BRD-K24715592-406-02-1, BRD-K24715592-406-02-1, BRD-K24715592-406-02-1, BRD-K24715592-406-02-1	Preclinical
ethambutol	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	BRD-K93231391-300-06-4, BRD-K93231391-300-08-9, BRD-K93231391-300-05-6	Launched
ethamivan	respiratory stimulant				BRD-K38055836-001-22-9, BRD-K38055836-001-21-1	Preclinical
ethanolamine-oleate	immunostimulant	F12, FABP4, FFAR1, FFAR4, PLD2	gastroenterology	esophageal varices	BRD-M75061779-001-01-2	Launched
ethaverine	calcium channel blocker		neurology/psychiatry	muscle relaxant, spasms	BRD-K36756879-003-08-7, BRD-K36756879-001-09-9	Launched
ethenzamide	analgesic agent		neurology/psychiatry, endocrinology, otolaryngology	headache, fever, common cold	BRD-K88308881-001-08-9, BRD-K88308881-001-06-8, BRD-K88308881-001-06-8	Launched
ethimizol					BRD-K19672466-001-02-3, BRD-K19672466-001-04-9	Phase 1
ethionamide	mycolic synthesis inhibitor		infectious disease	tuberculosis	BRD-K33710385-001-05-9, BRD-K33710385-001-06-9, BRD-K33710385-001-28-9	Launched
ethopabate	antiprotozoal agent		infectious disease	coccidiosis	BRD-K02475039-001-01-0, BRD-K02475039-001-02-9, BRD-K02475039-001-02-9	Launched
ethosuximide	succinimide antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	epilepsy	BRD-A99633051-001-08-8, BRD-A99633051-001-07-0	Launched
ethotoin	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	BRD-A30205217-001-11-2, BRD-A30205217-001-12-0, BRD-A30205217-001-12-0	Launched
ethoxyquin	antioxidant				BRD-K56792340-001-14-9, BRD-K56792340-001-13-2	Preclinical
ethoxzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9	ophthalmology, gastroenterology	glaucoma, duodenal ulcer disease	BRD-K18131774-001-18-4, BRD-K18131774-001-17-6, BRD-K18131774-001-17-6	Launched
ethyl-paraben					BRD-K02464583-001-03-9, BRD-K02464583-001-02-2	Preclinical
ethyl-pyruvate	tumor necrosis factor production inhibitor				BRD-K47738867-001-01-5, BRD-K47738867-001-01-5	Phase 2
ethyl-vanillin					BRD-K82104468-001-08-9, BRD-K82104468-001-05-0	Preclinical
ethyl-2-(carbamoyloxy)benzoate					BRD-K21892374-001-01-6	Phase 1
ethylenediaminetetraacetic-acid	PKC inhibitor		neurology/psychiatry	metal toxicity	BRD-K82603084-408-01-1, BRD-K82603084-001-04-9	Launched
ethylnorepinephrine	bronchodilator				BRD-A68509429-003-03-9	Preclinical
ethynylcytidine	antimetabolite				BRD-K00003207-001-01-9	Preclinical
eticlopride	dopamine receptor antagonist	DRD2, DRD3, DRD4			BRD-K50417881-003-18-9, BRD-K50417881-003-17-4, BRD-K50417881-003-17-4	Preclinical
etidronic-acid	bone resorption inhibitor	ATP6V1A, PTPRS	endocrinology, orthopedics	Paget's disease, heterotopic ossification	BRD-K37949327-304-06-1, BRD-K37949327-001-09-9, BRD-K37949327-001-07-1, BRD-K37949327-001-07-1, BRD-K37949327-001-06-3	Launched
etifenin	renal function diagnostic agent				BRD-K63979671-001-11-9, BRD-K63979671-001-10-1	Preclinical
etifoxine	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA5	neurology/psychiatry	anxiety	BRD-K01826330-001-01-9	Launched
etilefrine	adrenergic receptor agonist	ADRA1A, ADRB1	neurology/psychiatry, otolaryngology, endocrinology, pulmonary	headache, nasal congestion, fever, cough suppressant, common cold	BRD-A09925278-003-05-6	Launched
etilevodopa	dopamine receptor agonist	DRD3			BRD-K90982969-003-01-8, BRD-K90982969-001-01-2, BRD-K90982969-001-01-2	Phase 3
etizolam	benzodiazepine receptor agonist	GABRA1	neurology/psychiatry	insomnia, anxiety	BRD-K68232413-001-02-9, BRD-K68232413-001-01-2, BRD-K68232413-001-01-2, BRD-K68232413-001-01-2	Launched
etofenamate	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	BRD-K73541271-001-03-6, BRD-K73541271-001-04-9	Launched
etofibrate	PPAR receptor agonist	PPARA	endocrinology	hypertriglyceridemia	BRD-K49338325-001-03-4	Launched
etofylline	adenosine receptor antagonist	ADORA1	pulmonary	asthma, bronchitis	BRD-K83064458-001-24-9, BRD-K83064458-001-24-9, BRD-K83064458-001-23-0, BRD-K83064458-001-23-0, BRD-K83064458-001-23-0	Launched
etofylline-clofibrate	platelet aggregation inhibitor	PPARA	endocrinology	hyperlipidemia	BRD-K49840922-001-05-1, BRD-K49840922-001-05-1, BRD-K49840922-001-06-9	Launched
etomoxir	carnitine palmitoyltransferase inhibitor	CPT1A			BRD-K32405725-001-02-8, BRD-K32405725-001-02-8	Phase 2
etonogestrel	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	BRD-K00003655-001-01-9	Launched
etoposide-phosphate	topoisomerase inhibitor	TOP2A	oncology	testicular carcinoma, small cell lung cancer	BRD-K72533376-001-01-2, BRD-K72533376-001-01-2, BRD-K72533376-001-01-2	Launched
etoricoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout, ankylosing spondylitis	BRD-K54770957-001-04-3, BRD-K54770957-001-04-3	Launched
etosalamide	anti-inflammatory agent				BRD-K60914966-001-01-4, BRD-K60914966-001-02-9	Preclinical
etoxybamide					BRD-K51364817-001-01-4	Phase 2
ETP-45658	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			BRD-K15858023-001-02-9, BRD-K15858023-001-01-0, BRD-K15858023-001-01-0	Preclinical
ETP-46464	ATR kinase inhibitor				BRD-K24556407-001-02-3, BRD-K24556407-001-02-3, BRD-K24556407-001-02-3, BRD-K24556407-001-02-3, BRD-K24556407-001-02-3, BRD-K24556407-001-02-3, BRD-K24556407-001-02-3, BRD-K24556407-001-02-3, BRD-K24556407-001-01-5, BRD-K24556407-001-01-5, BRD-K24556407-001-01-5	Preclinical
etrabamine	dopamine receptor agonist				BRD-K00004658-001-01-9	Phase 2
etrasimod	sphingosine 1-phosphate receptor antagonist				BRD-K00003139-001-01-9	Phase 3
etravirine	non-nucleoside reverse transcriptase inhibitor	CYP2C19, CYP2C9, CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K74717603-001-03-9, BRD-K74717603-001-02-2, BRD-K74717603-001-02-2, BRD-K74717603-001-02-2	Launched
etretinate	protein synthesis inhibitor	RARA, RXRG			BRD-K49076555-001-05-6, BRD-K49076555-001-03-1, BRD-K49076555-001-01-5, BRD-K49076555-001-04-9	Withdrawn
eucatropine	acetylcholine receptor antagonist				BRD-A37942872-001-21-9, BRD-A37942872-003-20-6	Preclinical
eugenol	androgen receptor antagonist	AR	dental	toothache	BRD-K32977963-001-05-0, BRD-K32977963-001-10-9	Launched
eupatilin	mucus protecting agent				BRD-K47031502-001-02-4, BRD-K47031502-001-02-4, BRD-K47031502-001-01-6	Launched
evacetrapib	cholesteryl ester transfer protein inhibitor	CETP			BRD-K16551357-001-04-9, BRD-K16551357-001-02-4, BRD-K16551357-001-03-2, BRD-K16551357-001-03-2	Phase 3
evans-blue	glutamate receptor negative allosteric modulator	GRIA1, PTPN1			BRD-K24548560-342-02-1, BRD-K24548560-342-02-1, BRD-K24548560-342-02-1, BRD-K24548560-342-03-9, BRD-K24548560-342-03-9	Launched
evatanepag	prostaglandin inhibitor	PTGER2, PTGER4			BRD-K11452913-001-01-9, BRD-K11452913-001-01-9	Phase 2
evenamide	voltage-gated sodium channel blocker				BRD-K00004688-001-01-9	Phase 2
evobrutinib	Bruton's tyrosine kinase (BTK) inhibitor				BRD-K00003405-001-01-9	Phase 2
evocalcet	calcium sensitizer				BRD-K00003250-001-01-9	Phase 3
evodiamine	ATPase inhibitor, TRPV agonist	TRPV1			BRD-A68631409-001-05-4, BRD-A68631409-001-06-2, BRD-A68631409-001-06-2, BRD-A68631409-001-06-2	Preclinical
EVP-6124	acetylcholine receptor agonist	CHRNA7			BRD-K71603915-003-01-8, BRD-K71603915-003-01-8, BRD-K71603915-003-01-8, BRD-K71603915-003-02-9	Phase 3
EVP4593	NFkB pathway inhibitor				BRD-K68395654-001-06-4, BRD-K68395654-001-06-4, BRD-K68395654-001-03-1, BRD-K68395654-001-05-6	Preclinical
EW-7197	TGF beta receptor inhibitor	ACVR1B, TGFBR1			BRD-K74396648-001-01-4, BRD-K74396648-001-01-4, BRD-K74396648-001-01-4, BRD-K74396648-001-01-4, BRD-K74396648-001-01-4	Phase 2
EX-527	SIRT inhibitor	SIRT1			BRD-A73908300-001-09-1, BRD-A73908300-001-09-1, BRD-A73908300-001-06-7	Phase 2
exalamide	membrane permeability inhibitor				BRD-K12609457-001-03-1, BRD-K12609457-001-04-9	Launched
examorelin	growth hormone releasing factor agonist	GHRHR, GHSR			BRD-K35304636-001-01-0	Phase 2
exatecan-mesylate	topoisomerase inhibitor	TOP1			BRD-K92150287-066-02-0, BRD-K92150287-066-02-0, BRD-K92150287-066-01-2, BRD-K92150287-066-03-9	Phase 3
exenatide	GLP receptor agonist	GLP1R	endocrinology	diabetes mellitus	BRD-K00003559-001-01-9	Launched
exherin	cadherin antagonist	CDH2			BRD-K81795818-019-02-9, BRD-K81795818-019-01-4, BRD-K81795818-019-01-4, BRD-K81795818-019-01-4, BRD-K81795818-019-01-4	Phase 2
exifone	nootropic agent	TYR			BRD-K65716359-001-04-7, BRD-K65716359-001-02-1	Withdrawn
exisulind	phosphodiesterase inhibitor	PDE5A			BRD-K37708699-001-01-4, BRD-K37708699-001-01-4, BRD-K37708699-001-01-4	Phase 3
exo-IWR-1	WNT signaling inhibitor negative control	TNKS			BRD-K96155658-001-01-5, BRD-K96155658-001-02-9	Preclinical
EXO-1	ARF inhibitor				BRD-K78633253-001-11-1, BRD-K78633253-001-12-9, BRD-K78633253-001-10-3	Preclinical
ezatiostat	glutathione transferase inhibitor	GSTP1			BRD-K98963219-001-03-8, BRD-K98963219-001-02-0, BRD-K98963219-001-01-2, BRD-K98963219-001-01-2	Phase 2
ezutromid	utrophin enhancer	UTRN			BRD-K25570267-001-01-4	Phase 2
E3330	NFkB pathway inhibitor				BRD-K00004649-001-01-9	Preclinical
E7046	prostanoid receptor antagonist				BRD-K00003449-001-01-9	Phase 1
E7449	PARP inhibitor	PARP1, PARP2, TNKS, TNKS2			BRD-K05444225-001-03-3, BRD-K05444225-001-02-5, BRD-K05444225-001-02-5, BRD-K05444225-001-01-7	Phase 2
E7820	angiogenesis inhibitor				BRD-K00003172-001-01-9	Phase 2
F-11440	serotonin receptor agonist	HTR1A			BRD-K87948281-001-02-9, BRD-K87948281-001-01-9	Phase 2
F-16915					BRD-K00003299-001-01-9	Preclinical
fadrozole	aromatase inhibitor	CYP11B1, CYP19A1	oncology	breast cancer	BRD-A25619068-003-03-4, BRD-A25619068-003-03-4	Launched
fagomine	glucosidase inhibitor	GLB1			BRD-K61536264-001-01-3	Phase 2
falecalcitriol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	BRD-K08251020-001-02-8, BRD-K08251020-001-02-8, BRD-K08251020-001-01-0, BRD-K08251020-001-01-0, BRD-K08251020-001-01-0, BRD-K08251020-001-01-0	Launched
famciclovir	DNA polymerase inhibitor		dental, infectious disease	cold sore, genitial herpes, shingles	BRD-K45033733-001-12-2, BRD-K45033733-001-11-4, BRD-K45033733-001-14-9	Launched
famotidine	histamine receptor antagonist	HRH2	gastroenterology	heartburn	BRD-K00673382-001-17-1, BRD-K00673382-001-18-9	Launched
famprofazone	cyclooxygenase inhibitor				BRD-A08255417-001-13-9, BRD-A08255417-001-14-7, BRD-A08255417-001-15-4	Preclinical
fananserin	dopamine receptor antagonist, serotonin receptor antagonist	HTR2A			BRD-K08998509-001-03-2, BRD-K08998509-001-02-4	Phase 2
fanetizole	neutrophil superoxide production				BRD-K60798049-001-03-8	Phase 3
fantofarone	calcium channel blocker				BRD-K00003465-001-01-9	Preclinical
farampator	ionotropic glutamate receptor agonist				BRD-K00003507-001-01-9	Preclinical
farnesyl-thiosalicylic-acid-amide	Ras GTPase inhibitor	HRAS			BRD-K14590126-001-01-6, BRD-K14590126-001-01-6, BRD-K14590126-001-01-6	Phase 1
faropenem	lactamase inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, urinary tract infections, sinusitis	BRD-A49622760-001-01-9	Launched
faropenem-medoxomil	lactamase inhibitor		otolaryngology, infectious disease, pulmonary	sinusitis, pneumonia, bronchitis, skin infections, urinary tract infections	BRD-K59045783-001-03-7, BRD-K59045783-001-02-9, BRD-K59045783-001-01-1	Launched
fasoracetam	GABA receptor antagonist				BRD-K00004571-001-01-9	Preclinical
fasudil	rho associated kinase inhibitor	PKIA, PRKACA, ROCK1, ROCK2	neurology/psychiatry	cerebral vasospasm	BRD-K76617868-001-05-5, BRD-K76617868-003-15-9, BRD-K76617868-003-10-1, BRD-K76617868-003-14-3, BRD-K76617868-003-14-3, BRD-K76617868-003-11-9, BRD-K76617868-003-11-9	Launched
favipiravir	RNA polymerase inhibitor				BRD-K04264130-001-01-4, BRD-K04264130-001-01-4	Phase 3
FCE-22250	DNA directed DNA polymerase inhibitor				BRD-K00004537-001-01-9	Phase 1
fdcyd	DNA methyltransferase inhibitor				BRD-K18157228-001-01-7, BRD-K18157228-001-01-7	Phase 2
febuprol	choleretic agent				BRD-K00004566-001-01-9	Launched
febuxostat	xanthine oxidase inhibitor	XDH	nephrology	hyperuricemia	BRD-K48367671-001-08-9, BRD-K48367671-001-07-5, BRD-K48367671-001-06-7, BRD-K48367671-001-05-9	Launched
fedratinib	FLT3 inhibitor, JAK inhibitor	BRD4, JAK1, JAK2, JAK3, TYK2	hematologic malignancy	myelofibrosis	BRD-K12502280-001-11-4, BRD-K12502280-001-11-4, BRD-K12502280-001-11-4, BRD-K12502280-001-11-4, BRD-K12502280-001-11-4, BRD-K12502280-001-11-4, BRD-K12502280-001-08-0, BRD-K12502280-001-08-0, BRD-K12502280-001-08-0, BRD-K12502280-001-08-0, BRD-K12502280-001-08-0	Launched
felbamate	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	neurology/psychiatry	epilepsy	BRD-K99107520-001-27-4, BRD-K99107520-001-29-9, BRD-K99107520-001-29-9, BRD-K99107520-001-29-9, BRD-K99107520-001-24-1, BRD-K99107520-001-24-1, BRD-K99107520-001-24-1, BRD-K99107520-001-25-8, BRD-K99107520-001-25-8, BRD-K99107520-001-23-3	Launched
felbinac	cyclooxygenase inhibitor	CTSL	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain	BRD-K91740057-001-21-9, BRD-K91740057-001-19-8	Launched
felbinac-ethyl	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-K26404903-001-01-5	Launched
felodipine	calcium channel blocker	CFTR	cardiology	hypertension	BRD-A30815329-001-12-1, BRD-A30815329-001-10-5, BRD-A30815329-001-08-9, BRD-A30815329-001-08-9	Launched
felypressin	vasopressin receptor agonist				BRD-K00003319-001-01-9	Preclinical
fenaclon					BRD-K08791496-001-01-0, BRD-K08791496-001-01-0, BRD-K08791496-001-02-9	Preclinical
fenbendazole	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites, gastrointestinal roundworms	BRD-K51318897-001-14-6, BRD-K51318897-001-15-3, BRD-K51318897-001-15-3	Launched
fenbufen	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-K12513978-001-26-9, BRD-K12513978-001-24-1	Launched
fenclonine-(+/-)	tryptophan hydroxylase inhibitor	PAH, TPH1, TPH2			BRD-K01825694-003-01-9, BRD-K01825694-001-02-9	Preclinical
fendiline	calcium channel blocker	HTR2B			BRD-A71033472-003-24-9, BRD-A71033472-003-24-9, BRD-A71033472-003-24-9, BRD-A71033472-003-23-9, BRD-A71033472-003-23-9, BRD-A71033472-003-23-9	Preclinical
fenebrutinib	Bruton's tyrosine kinase (BTK) inhibitor				BRD-K25290930-001-03-9	Phase 2
fenigam	benzodiazepine receptor agonist	GABBR1, GABBR2	neurology/psychiatry	posttraumatic stress disorder, anxiety, depression	BRD-A66920069-003-02-9, BRD-A66920069-001-01-3, BRD-A66920069-001-01-3	Launched
fenipentol	choleretic agent		gastroenterology	bile stimulation	BRD-A66284731-001-02-0, BRD-A66284731-001-03-9	Launched
fenobam	glutamate receptor antagonist	GRM5			BRD-K41160163-001-07-6, BRD-K41160163-001-06-8, BRD-K41160163-001-06-8, BRD-K41160163-001-08-9	Phase 2
fenofibrate	PPAR receptor agonist	MMP25, PPARA	endocrinology	hypercholesterolemia, hypertriglyceridemia	BRD-K50388907-001-32-0, BRD-K50388907-001-30-4, BRD-K50388907-001-29-6	Launched
fenofibric-acid	cytochrome P450 inhibitor	CLCN1, PPARA	cardiology	dyslipidemia	BRD-K30213273-001-01-6, BRD-K30213273-001-02-9, BRD-K30213273-001-02-9	Launched
fenoldopam	dopamine receptor agonist	DRD1, DRD4	cardiology	hypertension	BRD-K01826790-066-06-9, BRD-K01826790-066-06-9	Launched
fenoprofen	prostaglandin inhibitor	PTGS1, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	BRD-K01827286-340-05-9	Launched
fenoterol	adrenergic receptor agonist	ADRB2			BRD-K00003668-004-01-9	Withdrawn
fenoverine	acetylcholine receptor antagonist		neurology/psychiatry	spasms	BRD-K77564118-001-03-1	Launched
fenoxaprop-p-ethyl		NOS3			BRD-K44777569-001-01-7	Preclinical
fenretinide	apoptosis stimulant, retinoid receptor agonist	RARA			BRD-K89085489-001-24-0, BRD-K89085489-001-24-0, BRD-K89085489-001-23-2, BRD-K89085489-001-23-2, BRD-K89085489-001-22-4, BRD-K89085489-001-19-0	Phase 3
fenspiride	bronchodilator		pulmonary, otolaryngology	asthma, otitis, sinusitis, rhinopharyngitis, laryngitis	BRD-K26739552-003-16-9, BRD-K26739552-003-14-7, BRD-K26739552-003-15-4	Launched
fenthion	cholinesterase inhibitor				BRD-K67217586-001-08-0	Launched
fentiazac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology	muscle pain, joint pain	BRD-K16077845-001-08-9, BRD-K16077845-001-06-1	Launched
FERb-033	EGFR inhibitor	ERBB2			BRD-K61642990-001-02-8, BRD-K61642990-001-01-0, BRD-K61642990-001-03-9	Preclinical
ferroquine	antimalarial agent				BRD-K00003281-001-01-9	Phase 2
ferrostatin-1	ferroptosis inhibitor				BRD-K97375133-001-04-9, BRD-K97375133-001-01-3, BRD-K97375133-001-03-9, BRD-K97375133-001-02-1	Preclinical
ferulic-acid	antioxidant	CA1, CA12, CA14, CA2, CA4, CA6, CA9			BRD-K66295376-236-02-6, BRD-K66295376-236-01-8, BRD-K66295376-001-13-1, BRD-K66295376-001-13-1, BRD-K66295376-001-12-3	Phase 2
fesoterodine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	BRD-K46731503-001-05-9, BRD-K46731503-050-01-8, BRD-K46731503-051-04-0	Launched
fevipiprant	prostaglandin inhibitor				BRD-K00003232-001-01-9	Phase 2
fexaramine	FXR agonist	NR1H4			BRD-K08864679-001-03-0, BRD-K08864679-001-02-2, BRD-K08864679-001-02-2	Preclinical
fexinidazole					BRD-K37069697-001-01-3	Phase 3
fexofenadine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	BRD-A73368467-003-18-4, BRD-A73368467-003-19-2, BRD-A73368467-003-17-6, BRD-A73368467-003-16-8	Launched
fezolinetant	neurokinin receptor antagonist				BRD-K00003287-001-01-9	Phase 2
FG-2216	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1, EGLN2, HIF1A			BRD-K56807945-001-01-2	Phase 2
FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1, EGLN2, EGLN3			BRD-K14385366-001-04-4, BRD-K14385366-001-04-4, BRD-K14385366-001-04-4, BRD-K14385366-001-04-4, BRD-K14385366-001-02-8	Phase 3
FG-7142	GABA benzodiazepine site receptor inverse agonist				BRD-K61951118-001-08-7, BRD-K61951118-001-08-7, BRD-K61951118-001-09-9, BRD-K61951118-001-07-9	Preclinical
FGIN-1-27	inositol monophosphatase inhibitor	TSPO			BRD-K09778810-001-11-4, BRD-K09778810-001-11-4, BRD-K09778810-001-10-6, BRD-K09778810-001-10-6	Preclinical
FGIN-1-43	benzodiazepine receptor agonist	TSPO			BRD-K66093087-001-04-9, BRD-K66093087-001-04-9, BRD-K66093087-001-05-9, BRD-K66093087-001-03-1, BRD-K66093087-001-03-1	Preclinical
FH-535	PPAR receptor antagonist, WNT signaling inhibitor	PPARD, PPARG			BRD-K48112880-001-02-3, BRD-K48112880-001-04-9	Preclinical
FH1	hepatocyte function enhancer				BRD-K44777625-001-03-5, BRD-K44777625-001-05-0	Preclinical
fiacitabine	DNA synthesis inhibitor				BRD-K07160047-001-02-9, BRD-K07160047-001-01-3	Phase 2
fidarestat	aldose reductase inhibitor	AKR1B1			BRD-A63752151-001-01-2, BRD-A63752151-001-01-2	Phase 3
fidaxomicin	RNA polymerase inhibitor		gastroenterology	diarrhea	BRD-K00003591-001-01-9	Launched
filanesib	kinesin inhibitor, kinesin-like spindle protein inhibitor	KIF11			BRD-K37379014-001-01-2, BRD-K37379014-001-01-2, BRD-K37379014-001-01-2, BRD-K37379014-001-01-2, BRD-K37379014-001-02-0, BRD-K37379014-001-02-0	Phase 3
filgotinib	JAK inhibitor	JAK1, JAK2, JAK3, TYK2			BRD-K16803204-001-02-9, BRD-K16803204-001-01-6, BRD-K16803204-001-01-6, BRD-K16803204-001-01-6, BRD-K16803204-001-01-6	Phase 3
finafloxacin	bacterial DNA gyrase inhibitor		infectious disease, pulmonary	intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis	BRD-K98384930-001-02-9, BRD-K98384930-003-01-5, BRD-K98384930-003-01-5	Launched
fingolimod	immunosuppressant, sphingosine 1-phosphate receptor agonist	S1PR1, S1PR5	neurology/psychiatry	multiple sclerosis	BRD-K88025533-001-07-9, BRD-K88025533-001-07-9, BRD-K88025533-003-04-1, BRD-K88025533-003-04-1, BRD-K88025533-003-04-1, BRD-K88025533-003-04-1, BRD-K88025533-003-04-1, BRD-K88025533-003-03-3, BRD-K88025533-003-03-3, BRD-K88025533-003-03-3, BRD-K88025533-003-03-3	Launched
fipexide	psychoactive drug				BRD-K37688416-003-13-1	Withdrawn
FIPI	phospholipase inhibitor	PLD1, PLD2			BRD-K61560897-003-01-4, BRD-K61560897-003-02-9	Preclinical
fipronil	chloride channel blocker, GABA gated chloride channel blocker		infectious disease	flea control	BRD-A50675702-001-07-1, BRD-A50675702-001-08-9	Launched
firategrast	integrin antagonist	ITGA4			BRD-K17513304-001-01-9, BRD-K17513304-001-01-9, BRD-K17513304-001-01-9, BRD-K17513304-001-01-9, BRD-K17513304-001-01-9, BRD-K17513304-001-01-9, BRD-K17513304-001-01-9, BRD-K17513304-001-02-9	Phase 2
firocoxib	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	BRD-K09090523-001-02-1	Launched
firsocostat	acetyl-CoA carboxylase inhibitor				BRD-K00003236-001-01-9	Phase 2
fisetin	Aurora kinase inhibitor	CDK6, FASN			BRD-K31836715-001-07-9, BRD-K31836715-001-07-9, BRD-K31836715-001-05-0, BRD-K31836715-001-06-8	Preclinical
fisogatinib	fibroblast growth factor inhibitor				BRD-K00003377-001-01-9	Phase 1
FIT	opioid receptor agonist	OPRD1			BRD-K17896185-001-02-0	Preclinical
FK-33-824	opioid receptor agonist	OPRM1			BRD-A01907367-001-01-7, BRD-A01907367-001-01-7	Phase 2
FK-3311	cyclooxygenase inhibitor	PTGS2			BRD-K38350380-001-01-8, BRD-K38350380-001-01-8, BRD-K38350380-001-02-9	Phase 2
FK-409	guanylyl cyclase activator				BRD-K00005243-001-01-9	Phase 2
FK-866	niacinamide phosphoribosyltransferase inhibitor	NAMPT			BRD-K58550667-001-08-7, BRD-K58550667-001-08-7	Phase 2
FK-888	tachykinin antagonist	TACR1, TACR2			BRD-K83508485-001-03-5, BRD-K83508485-001-03-5, BRD-K83508485-001-02-7, BRD-K83508485-001-04-9	Phase 2
FK-962	somatostatin receptor agonist				BRD-K80607346-001-01-1, BRD-K80607346-001-01-1	Phase 2
flavin-adenine-dinucleotide		ACAD8, ACADM, ACADS, ACOX1, AIFM1, CYB5R1, CYB5R3, DAO, DLD, DPYD, ERO1LB, FDXR, GCDH, GFER, GSR, IL4I1, IVD, MAOA, MAOB, NOS1, NQO1, NQO2, POR, TXNRD1, XDH			BRD-K01666925-304-01-9	Preclinical
flavoxate	acetylcholine receptor antagonist	CHRM1, CHRM2	urology	urinary incontinence, interstitial cystitis (IC), urethritis, prostatitis	BRD-K47639036-003-06-6, BRD-K47639036-003-06-6	Launched
flecainide	sodium channel blocker	KCNA5, KCNA7, SCN5A	cardiology	ventricular tachycardia (VT), atrial fibrillation (AF), ventricular arrhythmias	BRD-A09472452-015-26-7, BRD-A09472452-015-26-7, BRD-A09472452-015-23-4, BRD-A09472452-015-23-4, BRD-A09472452-015-22-6, BRD-A09472452-015-22-6	Launched
fleroxacin	topoisomerase inhibitor	TOP2A	infectious disease, gastroenterology	gonorrhea, enteritis, diarrhea, respiratory tract infections	BRD-K61717546-001-07-9, BRD-K61717546-001-04-3, BRD-K61717546-001-05-0, BRD-K61717546-001-05-0	Launched
FLI-06	notch signaling inhibitor				BRD-A44500574-001-04-9, BRD-A44500574-001-04-9, BRD-A44500574-001-01-8, BRD-A44500574-001-01-8, BRD-A44500574-001-03-4, BRD-A44500574-001-03-4, BRD-A44500574-001-02-6, BRD-A44500574-001-02-6	Preclinical
flibanserin	serotonin receptor agonist	DRD4, HTR1A, HTR2A	neurology/psychiatry	hypoactive sexual desire disorder	BRD-K33637378-001-01-7	Launched
flindokalner	potassium channel agonist	KCNMA1, KCNN4, KCNQ2, KCNQ4, KCNQ5			BRD-K56740996-001-02-1, BRD-K56740996-001-02-1, BRD-K56740996-001-01-3	Phase 3
floctafenine	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-A23418262-001-01-5, BRD-A23418262-001-01-5, BRD-A23418262-001-01-5	Launched
flopropione	serotonin receptor antagonist	HTR1A	neurology/psychiatry	spasms	BRD-K43383936-001-05-2, BRD-K43383936-001-05-2, BRD-K43383936-001-05-2, BRD-K43383936-001-04-5	Launched
florfenicol	protein synthesis inhibitor		pulmonary	bovine respiratory disease (BRD)	BRD-K11298197-001-16-9, BRD-K11298197-001-12-0, BRD-K11298197-001-15-3	Launched
florifenine	anti-inflammatory agent				BRD-K00004567-001-01-9	Preclinical
flosequinan	phosphodiesterase inhibitor				BRD-A79643124-001-01-9	Withdrawn
FLT3-IN-1	FLT3 inhibitor				BRD-K00003510-001-01-9	Preclinical
fluconazole	sterol demethylase inhibitor	CYP51A1	infectious disease	esophageal candidiasis, meningitis	BRD-K05977355-001-19-0, BRD-K05977355-001-23-2, BRD-K05977355-001-18-2	Launched
flucytosine	other antifungal	DNMT1	infectious disease	bacterial septicemia, endocarditis, urinary tract infections, meningitis	BRD-K82143716-001-30-9, BRD-K82143716-001-20-7, BRD-K82143716-001-19-9, BRD-K82143716-001-19-9	Launched
fludarabine-phosphate	ribonucleotide reductase inhibitor	POLA1, POLD1, POLE, RRM1, RRM2, RRM2B	hematologic malignancy	chronic lymphocytic leukemia (CLL)	BRD-K71106091-001-06-1, BRD-K71106091-001-06-1, BRD-K71106091-001-09-5, BRD-K71106091-001-05-3	Launched
fludroxycortide	glucocorticoid receptor agonist	NR3C1, SERPINA6	infectious disease, dermatology	skin infections, psoriasis	BRD-K00824317-001-18-9	Launched
flufenamic-acid	chloride channel blocker	AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5			BRD-K44067360-001-30-3, BRD-K44067360-001-29-5	Preclinical
flumatinib	Bcr-Abl kinase inhibitor	ABL1, PDGFRB			BRD-K68870568-066-01-5, BRD-K68870568-066-01-5, BRD-K68870568-066-01-5, BRD-K68870568-066-01-5, BRD-K68870568-066-01-5, BRD-K68870568-066-02-9	Phase 3
flumazenil	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	sedative	BRD-K98769987-001-25-2, BRD-K98769987-001-23-7, BRD-K98769987-001-26-9, BRD-K98769987-001-21-1, BRD-K98769987-001-22-9	Launched
flumecinol					BRD-A44181516-001-01-8	Launched
flumequine	topoisomerase inhibitor		infectious disease	urinary tract infections	BRD-A69777949-001-25-9, BRD-A69777949-001-27-9, BRD-A69777949-001-24-2, BRD-A69777949-001-24-2, BRD-A69777949-001-24-2	Launched
flumethasone-pivalate	glucocorticoid receptor agonist	NR3C1, SERPINA6	allergy	allergic rhinitis	BRD-K00025599-001-01-9	Launched
flumexadol					BRD-A43518428-001-02-7, BRD-A43518428-001-01-9	Preclinical
flunarizine	calcium channel blocker	CACNA1G, CACNA1H, CACNA1I, CALM1, HRH1	neurology/psychiatry, cardiology	migraine headache, vertigo, peripheral artery disease (PAD)	BRD-K29582677-300-11-4, BRD-K29582677-300-08-0, BRD-K29582677-300-08-0, BRD-K29582677-300-08-0, BRD-K29582677-300-08-0, BRD-K29582677-300-10-6, BRD-K29582677-300-10-6, BRD-K29582677-300-09-8	Launched
flunisolide	cytochrome P450 inhibitor	NR3C1	allergy	allergic rhinitis	BRD-K49577446-001-12-9	Launched
flunixin-meglumin	prostanoid receptor antagonist		pulmonary	bovine respiratory disease (BRD)	BRD-K99984802-100-13-5, BRD-K99984802-100-14-9, BRD-K99984802-100-12-7	Launched
fluorescein		SLC22A6	ophthalmology	ophthalmology diagnostic	BRD-K21913543-001-02-4, BRD-K21913543-001-03-9	Launched
fluorometholone	glucocorticoid receptor agonist	NR3C1	ophthalmology	eye inflammation		Launched
fluorometholone-acetate		NR3C1	ophthalmology	eye inflammation	BRD-K02528732-001-01-6, BRD-K02528732-001-03-2, BRD-K02528732-001-02-4, BRD-K02528732-001-02-4	Launched
fluoromethylcholine					BRD-K51199656-003-01-4	Launched
fluoxetine	selective serotonin reuptake inhibitor (SSRI)	ANO1, HTR2B, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), bulimia nervosa, panic disorders, bipolar disorder	BRD-A31159102-003-30-4, BRD-A31159102-003-28-8, BRD-A31159102-003-31-2, BRD-A31159102-003-29-6	Launched
flupentixol	dopamine receptor antagonist	ADRA1A, CHRM1, DRD1, DRD2, DRD3, DRD5, HTR2A	neurology/psychiatry	schizophrenia, depression	BRD-K70487031-001-02-8, BRD-K70487031-001-02-8	Launched
fluphenazine	dopamine receptor antagonist	CALM1, DRD1, DRD2, DRD5, HRH1, HTR2A, HTR6, HTR7	neurology/psychiatry	schizophrenia	BRD-K55127134-300-11-2, BRD-K55127134-300-11-2, BRD-K55127134-300-11-2	Launched
fluphenazine-decanoate	dopamine receptor antagonist	DRD2, HTR1B, HTR4	neurology/psychiatry	schizophrenia	BRD-K27898013-001-01-4	Launched
flupirtine	glutamate receptor antagonist	ADRA2A, KCNQ1, KCNQ2	neurology/psychiatry	pain relief	BRD-K50720187-001-02-8, BRD-K50720187-050-09-0, BRD-K50720187-051-03-1, BRD-K50720187-051-03-1, BRD-K50720187-050-08-2, BRD-K50720187-051-02-3	Launched
fluprazine	serotonin receptor agonist	HTR1A, HTR1B			BRD-K44091134-001-01-9, BRD-K44091134-001-01-9	Phase 1
fluralaner	GABA receptor antagonist				BRD-K00003239-001-01-9	Preclinical
flurbiprofen-(+/-)	cyclooxygenase inhibitor		rheumatology	rheumatoid arthritis, osteoarthritis	BRD-A86044036-001-26-5, BRD-A86044036-001-30-9, BRD-A86044036-001-27-3	Launched
flurbiprofen-(S)-(+)	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	BRD-K69907333-001-07-2, BRD-K69907333-001-10-6	Launched
flurbiprofen-axetil	analgesic agent				BRD-K00004724-001-01-9	Launched
flurizan	gamma secretase inhibitor	APH1B, BACE1, IKBKG, PSEN1, PSEN2, PTGS1, PTGS2			BRD-K75410565-001-03-9, BRD-K75410565-001-03-9, BRD-K75410565-001-02-9, BRD-K75410565-001-02-9	Phase 3
flurofamide	urease inhibitor				BRD-K67445247-001-04-7, BRD-K67445247-001-03-9, BRD-K67445247-001-02-1	Preclinical
flurothyl					BRD-K14763542-001-02-3, BRD-K14763542-001-02-3, BRD-K14763542-001-03-1	Preclinical
fluroxene	local anesthetic				BRD-K56908511-001-01-2, BRD-K56908511-001-02-0	Preclinical
fluspirilene	dopamine receptor antagonist	CACNG1, DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A	neurology/psychiatry	schizophrenia	BRD-K77947974-001-16-3, BRD-K77947974-001-16-3, BRD-K77947974-001-16-3, BRD-K77947974-001-18-9	Launched
flutamide	androgen receptor antagonist	AHR, AR	oncology	prostate cancer	BRD-K28307902-001-23-3, BRD-K28307902-001-21-7, BRD-K28307902-001-20-9	Launched
flutrimazole	sterol demethylase inhibitor		infectious disease	mycosis	BRD-A00218260-001-03-4	Launched
fluvoxamine	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	BRD-K53517854-050-21-4, BRD-K53517854-050-22-9, BRD-K53517854-050-20-6, BRD-K53517854-051-01-4, BRD-K53517854-051-01-4	Launched
fmoc-L-leucine	PPAR receptor agonist				BRD-K15327298-001-05-5, BRD-K15327298-001-05-5	Phase 2
FN-1501	tyrosine kinase inhibitor				BRD-K00003096-001-01-9, BRD-K00003096-001-01-9	Phase 1
folic-acid	folate receptor ligand	FOLR2, FOLR3, SLC19A1, SLC46A1	hematology	megaloblastic anemia	BRD-K18673820-001-15-5	Launched
fomepizole	alcohol dehydrogenase inhibitor	ADH1A, ADH1B, ADH1C, AKR1A1, CAT	critical care	poison antidote	BRD-K56810756-003-07-7, BRD-K56810756-003-07-7, BRD-K56810756-001-08-9, BRD-K56810756-001-08-9, BRD-K56810756-001-03-0	Launched
fomocaine	voltage-gated sodium channel modulator		neurology/psychiatry	local anesthetic	BRD-K44942188-001-10-9, BRD-K44942188-001-09-1	Launched
fondaparinux	coagulation factor inhibitor	F10, SERPINC1	hematology	deep vein thrombosis (DVT)	BRD-K00003513-363-01-9	Launched
foretinib	VEGFR inhibitor	FLT1, FLT4, KDR, MET			BRD-K03449891-001-08-6, BRD-K03449891-001-08-6, BRD-K03449891-001-08-6, BRD-K03449891-001-08-6, BRD-K03449891-001-08-6, BRD-K03449891-001-06-0, BRD-K03449891-001-06-0	Phase 2
formononetin	alcohol dehydrogenase inhibitor	ADH1C, SLC5A2			BRD-K55567017-001-14-9, BRD-K55567017-001-12-3, BRD-K55567017-001-12-3	Preclinical
forodesine	purinergic receptor antagonist	PNP	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	BRD-K16505263-003-01-1, BRD-K16505263-003-02-9, BRD-K16505263-003-02-9, BRD-K16505263-003-02-9	Launched
foropafant	platelet activating factor receptor antagonist	PTAFR			BRD-K57774929-001-01-3, BRD-K57774929-001-01-3, BRD-K57774929-001-01-3	Phase 3
fosamprenavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K59110290-238-01-7, BRD-K59110290-238-01-7, BRD-K59110290-238-01-7, BRD-K59110290-238-02-9	Launched
fosaprepitant-dimeglumine	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	BRD-K23848629-401-05-2, BRD-K23848629-401-04-5, BRD-K23848629-401-02-9, BRD-K23848629-401-03-7, BRD-K23848629-401-03-7	Launched
fosbretabulin	tubulin polymerization inhibitor, VE-cadherin antagonist	CDH5			BRD-K06814349-304-02-7, BRD-K06814349-304-02-7, BRD-K06814349-304-01-9, BRD-K06814349-304-01-9	Phase 3
foscarnet	DNA polymerase inhibitor		infectious disease	cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)	BRD-K85146014-314-06-2, BRD-K85146014-314-05-4, BRD-K85146014-314-07-0, BRD-K85146014-314-08-8	Launched
fosfestrol	synthetic estrogen	ESR1, ESR2	oncology	prostate cancer	BRD-K20801936-001-01-9	Launched
fosfluconazole	other antifungal				BRD-K00003384-001-01-9	Preclinical
fosfosal	phosphodiesterase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-K28687144-001-07-9, BRD-K28687144-001-08-7, BRD-K28687144-001-08-7	Launched
fosfructose	fructose diphosphate stimulant				BRD-K27963513-236-01-3	Phase 3
fosinopril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	BRD-A51382177-236-03-0, BRD-A51382177-236-04-8, BRD-A51382177-236-04-8, BRD-A51382177-236-04-8, BRD-A51382177-236-04-8	Launched
fosinoprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	BRD-A33506612-001-01-2	Launched
fosphenytoin	sodium channel blocker	SCN5A	neurology/psychiatry	epilepsy, seizures	BRD-K53809807-304-02-4, BRD-K53809807-304-02-4, BRD-K53809807-304-01-6	Launched
fostamatinib	SYK inhibitor	SYK	hematology	chronic immune thrombocytopenia (ITP)	BRD-K85178109-001-03-1, BRD-K85178109-304-04-9, BRD-K85178109-001-02-3	Launched
fostemsavir	antiviral				BRD-K00003191-001-01-9	Phase 3
fotemustine	thioredoxin inhibitor		oncology	melanoma	BRD-A62893078-001-02-3, BRD-A62893078-001-01-5	Launched
foxy-5	WNT5a peptide mimetic	WNT5A			BRD-K13005598-001-02-3, BRD-K13005598-001-02-3	Phase 2
FPA-124	AKT inhibitor					Preclinical
FPH1-(BRD-6125)	hepatocyte function enhancer				BRD-K61250484-001-02-3, BRD-K61250484-001-03-1	Preclinical
FPL-12495	glutamate receptor antagonist				BRD-A09368919-001-01-7, BRD-A09368919-001-01-7, BRD-A09368919-001-01-7	Phase 1
FPL-55712	leukotriene receptor antagonist				BRD-A96456596-001-02-2, BRD-A96456596-001-02-2, BRD-A96456596-001-02-2, BRD-A96456596-001-03-9	Phase 1
FPL-62064	cyclooxygenase inhibitor, lipoxygenase inhibitor				BRD-K59875992-001-01-8, BRD-K59875992-001-01-8, BRD-K59875992-001-01-8	Phase 2
FPL-64176	calcium channel activator	CACNA1C, CACNA1S			BRD-K78959463-001-15-7, BRD-K78959463-001-15-7, BRD-K78959463-001-16-9, BRD-K78959463-001-16-9, BRD-K78959463-001-13-2	Preclinical
FPS-ZM1	RAGE receptor antagonist	AGER			BRD-K87691185-001-01-2, BRD-K87691185-001-01-2	Preclinical
FR-122047	cyclooxygenase inhibitor				BRD-K30990140-003-03-9, BRD-K30990140-003-02-4	Preclinical
FR-139317	endothelin receptor antagonist	EDNRA			BRD-K19318328-001-02-1, BRD-K19318328-001-02-1, BRD-K19318328-001-03-9, BRD-K19318328-001-01-3	Phase 1
FR-180204	MAP kinase inhibitor	MAPK1, MAPK3			BRD-K68756823-001-10-5, BRD-K68756823-001-07-1, BRD-K68756823-001-07-1, BRD-K68756823-001-11-3	Preclinical
FRAX486	serine/threonine kinase inhibitor	PAK1, PAK2, PAK3, PAK4			BRD-K57243773-001-02-4, BRD-K57243773-001-01-6, BRD-K57243773-001-01-6, BRD-K57243773-001-01-6, BRD-K57243773-001-01-6	Preclinical
frentizole	immunosuppressant				BRD-K07202345-001-19-4, BRD-K07202345-001-19-4, BRD-K07202345-001-19-4	Phase 1
freselestat	elastase inhibitor	CELA1, ELANE			BRD-K00004668-001-01-9	Preclinical
frovatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D	neurology/psychiatry	migraine headache	BRD-K08255599-365-01-1	Launched
fruquintinib	VEGFR inhibitor	KDR	oncology	colorectal cancer	BRD-K70504253-001-01-3, BRD-K70504253-001-01-3, BRD-K70504253-001-01-3	Launched
ftaxilide					BRD-K05724540-001-09-9, BRD-K05724540-001-08-5	Preclinical
ftorafur	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	BRD-K99383816-001-03-5, BRD-K99383816-001-03-5, BRD-K99383816-001-03-5, BRD-K99383816-001-02-7, BRD-K99383816-001-04-9	Launched
FT011	TGF beta receptor inhibitor				BRD-K00003378-001-01-9	Preclinical
fucoxanthin	anticancer agent				BRD-K00003355-001-01-9	Phase 2
fudosteine	mucolytic agent		pulmonary	chest congestion	BRD-K54838207-001-04-9, BRD-K54838207-001-03-8, BRD-K54838207-001-02-0	Launched
fumagillin	methionine aminopeptidase inhibitor	METAP2	infectious disease	microsporidiosis	BRD-A99367815-001-04-9, BRD-A99367815-001-01-5, BRD-A99367815-001-03-1, BRD-A99367815-001-03-1	Launched
fumonisin-B1		CERS1			BRD-K61915943-001-02-9	Preclinical
funapide	sodium channel blocker				BRD-K00004702-001-01-9	Preclinical
furagin	antibacterial				BRD-K00003314-001-01-9	Preclinical
furaltadone	bacterial DNA inhibitor		infectious disease	gram-negative bacterial infections	BRD-K01824979-003-03-9, BRD-K01824979-001-02-9	Launched
furamidine	protein arginine N-methyltransferase inhibitor	PRMT1			BRD-K77758223-300-02-9, BRD-K77758223-300-01-1	Preclinical
furazolidone	bacterial DNA inhibitor		gastroenterology, infectious disease	diarrhea, enteritis, cholera	BRD-K11756522-001-10-9, BRD-K11756522-001-09-9	Launched
furegrelate	thromboxane synthase inhibitor	TBXAS1			BRD-K55529781-236-03-8, BRD-K55529781-236-03-8	Phase 1
furosemide	diuretic	CA2, GPR35, SLC12A1, SLC12A2	cardiology, rheumatology	edema, hypertension, congestive heart failure, nephrotic syndrome	BRD-K78010432-001-24-9, BRD-K78010432-001-20-7, BRD-K78010432-001-27-9, BRD-K78010432-001-27-9, BRD-K78010432-001-27-9, BRD-K78010432-001-21-5	Launched
fursultiamine	vitamin B		metabolism	thiamine deficiency	BRD-A71157293-003-10-0, BRD-A71157293-001-11-9	Launched
furvina	quorum sensing signaling inhibitor				BRD-K00004693-001-01-9	Preclinical
fusidic-acid	bacterial 30S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	BRD-K78355918-236-09-9	Launched
futibatinib	FGFR inhibitor				BRD-K00003392-001-01-9	Phase 3
F351	TGF beta receptor inhibitor	TGFB1			BRD-K41267922-001-01-4, BRD-K41267922-001-02-9	Phase 2
g-caryophyllene	acetylcholinesterase inhibitor	ACHE			BRD-K26878113-001-01-6, BRD-K26878113-001-01-6	Preclinical
G-1	G protein-coupled receptor agonist	GPER1			BRD-K62696033-001-01-4, BRD-K62696033-001-02-9	Preclinical
G-15	estrogen receptor antagonist	GPER1			BRD-K00004290-001-01-9	Preclinical
G-749	tyrosine kinase inhibitor				BRD-K00003126-001-01-9	Preclinical
GABA-linoleamide	benzodiazepine receptor agonist				BRD-K46254452-001-01-5	Phase 2
gabapentin	calcium channel blocker	ADORA1, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CACNG2, CACNG3, CACNG4, CACNG5, CACNG6, CACNG7, CACNG8, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B	infectious disease, neurology/psychiatry	virus herpes simplex (HSV), shingles, seizures, restless leg syndrome	BRD-K62737565-001-09-5, BRD-K62737565-001-10-3, BRD-K62737565-001-10-3, BRD-K62737565-003-02-6	Launched
gabapentin-enacarbil	adrenergic receptor agonist	CACNA1G	neurology/psychiatry	restless leg syndrome, postherpetic neuralgia	BRD-A86665761-001-01-1	Launched
gabazine	GABA receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2			BRD-K79905821-004-04-4, BRD-K79905821-004-14-9, BRD-K79905821-004-14-9, BRD-K79905821-004-03-6, BRD-K79905821-004-03-6	Preclinical
gabexate	serine protease inhibitor	PRSS1, TPSAB1	gastroenterology	pancreatitis	BRD-K59256312-066-17-3, BRD-K59256312-066-13-2, BRD-K59256312-066-16-5, BRD-K59256312-066-15-7, BRD-K59256312-066-15-7, BRD-K59256312-066-14-0	Launched
gaboxadol	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRD, GABRR1, GABRR2, GABRR3			BRD-K89104321-003-16-3, BRD-K89104321-003-16-3, BRD-K89104321-003-15-5, BRD-K89104321-003-18-9, BRD-K89104321-003-14-8	Phase 3
gadobutrol	radiopaque medium		radiology	MRI contrast agent	BRD-K00003579-001-01-9	Launched
gadoterate-meglumine	radiopaque medium		radiology	MRI contrast agent	BRD-K11099631-001-08-4, BRD-K11099631-001-07-6	Launched
GAL-021	calcium channel blocker				BRD-K00003410-001-01-9	Preclinical
galantamine	acetylcholinesterase inhibitor	ACHE, BCHE, CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG	neurology/psychiatry	senile dementia	BRD-K49481516-001-01-5, BRD-K49481516-004-18-3, BRD-K49481516-004-18-3, BRD-K49481516-004-18-3	Launched
galeterone	androgen receptor modulator	AR, CYP17A1			BRD-K00004319-001-01-9	Phase 3
galidesivir	antiviral				BRD-K00003270-003-01-9	Phase 1
gallamine-triethiodide	acetylcholine receptor antagonist	CHRM2, CHRNA1	neurology/psychiatry	muscle relaxant	BRD-K43106192-320-12-9, BRD-K43106192-320-12-9, BRD-K43106192-320-12-9, BRD-K43106192-320-09-2, BRD-K43106192-320-10-0, BRD-K43106192-320-11-8	Launched
gallic-acid	beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist	CA1, CA12, CA14, CA2, CA4, CA6, CA9, SELP			BRD-K77345217-001-05-0, BRD-K77345217-001-06-9	Preclinical
gallium-triquinolin-8-olate					BRD-K46648676-001-01-8	Phase 1
gallopamil	L-type calcium channel blocker	ATP2A2	cardiology	hypertension, cardiac arrythmia	BRD-A52922642-001-03-7, BRD-A52922642-001-04-5, BRD-A52922642-001-04-5, BRD-A52922642-001-04-5, BRD-A52922642-001-04-5	Launched
gamithromycin	antibacterial 				BRD-K00003489-001-01-9	Preclinical
gamma-aminobutyric-acid	benzodiazepine receptor agonist	GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1			BRD-K77245796-003-01-6, BRD-K77245796-003-01-6, BRD-K77245796-001-23-9, BRD-K77245796-001-23-9	Preclinical
gamma-linolenic-acid	cyclooxygenase inhibitor, prostanoid receptor agonist	PTGS1, PTGS2			BRD-K18059238-001-13-8, BRD-K18059238-001-13-8, BRD-K18059238-001-10-4, BRD-K18059238-001-10-4, BRD-K18059238-001-11-2	Phase 2
ganaxolone	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6			BRD-K28217197-001-01-4, BRD-K28217197-001-01-4, BRD-K28217197-001-02-9	Phase 3
ganciclovir	DNA polymerase inhibitor		infectious disease	cytomegalovirus (CMV)	BRD-K22662435-001-18-3, BRD-K22662435-001-17-5, BRD-K22662435-001-19-1, BRD-K22662435-001-19-1	Launched
ganetespib	HSP inhibitor	HSP90AA1			BRD-K38852836-001-02-1, BRD-K38852836-001-02-1, BRD-K38852836-001-02-1, BRD-K38852836-001-02-1, BRD-K38852836-001-04-9, BRD-K38852836-001-04-9, BRD-K38852836-001-04-9	Phase 3
ganoderic-acid-a	JAK inhibitor				BRD-K00003733-001-01-9	Preclinical
GANT-58	GLI antagonist	GLI1			BRD-K64451768-001-05-4, BRD-K64451768-001-05-4	Preclinical
GANT-61	GLI antagonist	GLI1, GLI2			BRD-K09485525-001-03-9, BRD-K09485525-001-02-1, BRD-K09485525-001-02-1, BRD-K09485525-001-02-1, BRD-K09485525-001-02-1, BRD-K09485525-001-02-1, BRD-K09485525-001-02-1, BRD-K09485525-001-02-1	Preclinical
garenoxacin	topoisomerase inhibitor	TOP2A	infectious disease	respiratory tract infections	BRD-K77038618-356-01-3, BRD-K77038618-356-01-3	Launched
gastrodin					BRD-K15447284-001-02-9	Phase 2
gatifloxacin	bacterial DNA gyrase inhibitor				BRD-K01825698-213-01-9, BRD-K01825698-001-02-9	Withdrawn
gavestinel	glutamate receptor antagonist	GLRB, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B			BRD-K81981783-236-02-9, BRD-K81981783-236-02-9, BRD-K81981783-236-03-7, BRD-K81981783-236-01-1	Phase 3
GBR-12783	dopamine reuptake inhibitor				BRD-K92015269-300-02-9, BRD-K92015269-300-01-2, BRD-K92015269-300-01-2, BRD-K92015269-300-01-2, BRD-K92015269-300-01-2, BRD-K92015269-300-01-2	Preclinical
GBR-12935	dopamine reuptake inhibitor	AGTR1, SLC6A3			BRD-K50135270-300-09-9, BRD-K50135270-300-02-3	Preclinical
GBR-13069	dopamine reuptake inhibitor	SLC6A3			BRD-K92577649-300-01-2, BRD-K92577649-300-01-2, BRD-K92577649-300-01-2, BRD-K92577649-300-03-9	Preclinical
GDC-0068	AKT inhibitor	AKT1, AKT2, AKT3, PRKG1			BRD-K43002773-001-05-9	Phase 3
GDC-0077	PI3K inhibitor				BRD-K00003420-001-01-9	Phase 1
GDC-0084	mTOR inhibitor, PI3K inhibitor				BRD-K00003309-001-01-9	Phase 2
GDC-0152	XIAP inhibitor	BIRC2, BIRC3, BIRC7, XIAP			BRD-K68938568-001-01-7, BRD-K68938568-001-01-7, BRD-K68938568-001-01-7, BRD-K68938568-001-01-7, BRD-K68938568-001-02-9, BRD-K68938568-001-02-9	Phase 1
GDC-0349	Pim kinase inhibitor	PIK3CA			BRD-K43187018-001-02-5, BRD-K43187018-001-03-3, BRD-K43187018-001-03-3, BRD-K43187018-001-03-3, BRD-K43187018-001-03-3, BRD-K43187018-001-03-3, BRD-K43187018-001-04-9	Phase 1
GDC-0575	CHK inhibitor				BRD-K00003112-001-01-9	Phase 1
GDC-0623	MEK inhibitor				BRD-K46908090-001-03-0, BRD-K46908090-001-04-8, BRD-K46908090-001-02-2, BRD-K46908090-001-02-2, BRD-K46908090-001-01-4	Phase 1
GDC-0810	selective estrogen receptor destabilizer	ESR1			BRD-K61923022-001-02-4, BRD-K61923022-001-02-4	Phase 2
GDC-0834	Bruton's tyrosine kinase (BTK) inhibitor	BTK			BRD-A30984645-001-01-5, BRD-A30984645-001-01-5, BRD-A30984645-001-02-3, BRD-A30984645-001-02-3, BRD-A30984645-001-02-3, BRD-A30984645-001-02-3, BRD-A30984645-001-03-9, BRD-A30984645-001-03-9	Phase 1
GDC-0927	estrogen receptor antagonist				BRD-K00003101-001-02-9, BRD-K00003101-001-01-9	Phase 1
GDC-0941	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			BRD-K52911425-001-09-8, BRD-K52911425-001-09-8, BRD-K52911425-001-09-8, BRD-K52911425-001-09-8, BRD-K52911425-001-01-5, BRD-K52911425-001-01-5, BRD-K52911425-001-01-5	Phase 2
GDC-0980	mTOR inhibitor, PI3K inhibitor	FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK			BRD-K23228615-001-02-8, BRD-K23228615-001-02-8, BRD-K23228615-001-02-8, BRD-K23228615-001-02-8, BRD-K23228615-001-04-9, BRD-K23228615-001-04-9, BRD-K23228615-001-03-6, BRD-K23228615-001-03-6, BRD-K23228615-001-03-6	Phase 2
GDC-0994	MAP kinase inhibitor	MAPK1, MAPK3			BRD-A20830788-001-01-9, BRD-A20830788-001-01-9	Phase 1
gedunin	HSP inhibitor	HSP90AA1			BRD-K02703275-001-07-5	Preclinical
gefapixant	purinergic receptor antagonist				BRD-K00004589-001-01-9	Phase 3
gefitinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	BRD-K64052750-001-22-5, BRD-K64052750-001-22-5, BRD-K64052750-001-22-5, BRD-K64052750-001-22-5, BRD-K64052750-001-22-5, BRD-K64052750-001-22-5, BRD-K64052750-001-22-5, BRD-K64052750-001-17-5, BRD-K64052750-001-17-5, BRD-K64052750-001-17-5, BRD-K64052750-001-16-7, BRD-K64052750-001-23-3	Launched
gemcadiol	antilipemic				BRD-K43890836-001-01-6, BRD-K43890836-001-01-6, BRD-K43890836-001-01-6	Phase 2
gemcitabine-elaidate	apoptosis inhibitor, DNA synthesis inhibitor	CMPK1, RRM1, TYMS			BRD-K09456915-001-01-2, BRD-K09456915-001-01-2, BRD-K09456915-001-01-2, BRD-K09456915-001-01-2	Phase 1
gemfibrozil	lipoprotein lipase activator	LPL, PPARA, SLCO1B1, SLCO1B3, SLCO2B1	endocrinology, cardiology	hyperlipidemia, coronary heart disease	BRD-K11129031-001-26-7, BRD-K11129031-001-27-5, BRD-K11129031-001-27-5, BRD-K11129031-001-27-5	Launched
gemifloxacin	bacterial DNA gyrase inhibitor		pulmonary, infectious disease	bronchitis, pneumonia	BRD-A40787240-066-04-6	Launched
gemigliptin	dipeptidyl peptidase inhibitor				BRD-K00003182-001-01-9	Launched
genistein	tyrosine kinase inhibitor	CFTR, ESR1, ESR2, ESRRA, ESRRB, ESRRG, NCOA1, NCOA2, PPARG, PTK2B, TOP2A, TRPC5			BRD-K43797669-001-28-8, BRD-K43797669-001-28-8, BRD-K43797669-001-30-4, BRD-K43797669-001-29-6, BRD-K43797669-001-31-2	Phase 2/Phase 3
gentamycin	bacterial 50S ribosomal subunit inhibitor	HSPA8	infectious disease, critical care	bone and joint infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, sepsis	BRD-K97891829-065-02-9	Launched
gentiopicrin	glutamate receptor downregulator	GRIN2B			BRD-K33131085-001-07-2	Phase 3
genz-123346	glucosylceramidase inhibitor	UGCG			BRD-K70693421-001-01-1, BRD-K70693421-001-02-9	Preclinical
genz-644282	topoisomerase inhibitor	TOP1			BRD-K99475619-001-01-2, BRD-K99475619-001-01-2, BRD-K99475619-001-03-9	Phase 1
gepefrine	adrenergic receptor agonist		cardiology	hypotension	BRD-A04447196-001-01-8, BRD-A04447196-001-01-8	Launched
gepon					BRD-A56754222-001-01-2, BRD-A56754222-001-01-2	Phase 1
gepotidacin	topoisomerase inhibitor				BRD-K33499285-001-02-9	Phase 2
geranyl-farnesylacetate	mucin production enhancer				BRD-K02780233-001-02-5, BRD-K02780233-001-01-7	Phase 2
gestrinone	progesterone receptor antagonist	AR, ESR1, PGR	obstetrics/gynecology	endometriosis	BRD-K97472745-001-03-9, BRD-K97472745-001-01-8, BRD-K97472745-001-01-8, BRD-K97472745-001-01-8, BRD-K97472745-001-01-8	Launched
GF109203X	PKC inhibitor	PDPK1, PIM1, PRKCI, PRKCZ			BRD-K31342827-001-13-8, BRD-K31342827-001-15-3, BRD-K31342827-001-15-3, BRD-K31342827-001-06-2, BRD-K31342827-001-06-2, BRD-K31342827-001-06-2, BRD-K31342827-001-06-2	Preclinical
GGsTop	gamma glutamyltransferase Inhibitor	GGT1			BRD-A25625670-001-01-9, BRD-A25625670-001-02-7	Preclinical
GGTI-298	GGTase inhibitor	CDKN1A			BRD-K19669037-001-02-9, BRD-K19669037-001-01-1	Preclinical
gilteritinib	FLT3 inhibitor	FLT3			BRD-K72280606-001-01-2, BRD-K72280606-001-01-2, BRD-K72280606-001-01-2, BRD-K72280606-001-01-2	Launched
gimeracil	dihydropyrimidine dehydrogenase inhibitor	DPYD	oncology	gastric adenocarcinoma	BRD-K35687421-001-02-5, BRD-K35687421-001-03-3	Launched
ginkgolide-A	GABA receptor antagonist	GLRA1, GLRB			BRD-K42679315-001-08-9	Preclinical
ginsenoside-C-K	NFkB pathway inhibitor, nitric oxide synthase inhibitor	PTGS2			BRD-K01942833-001-01-8, BRD-K01942833-001-01-8	Phase 1
ginsenoside-RD	calcium channel blocker				BRD-A84810646-001-01-6, BRD-A84810646-001-01-6	Phase 3
ginsenoside-RE	anti-inflammatory agent				BRD-K00003326-001-01-9	Phase 1
ginsenoside-RE3	angiogenesis inhibitor, apoptosis stimulant	KCNH2			BRD-A44511856-001-01-4	Launched
givinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			BRD-K13810148-311-03-2, BRD-K13810148-311-03-2, BRD-K13810148-311-03-2, BRD-K13810148-311-03-2, BRD-K13810148-311-03-2, BRD-K13810148-311-03-2, BRD-K13810148-311-03-2, BRD-K13810148-001-02-1, BRD-K13810148-001-02-1, BRD-K13810148-001-02-1, BRD-K13810148-001-02-1, BRD-K13810148-001-02-1	Phase 3
GKA-50	glucokinase activator	GCK			BRD-K03827870-001-02-9, BRD-K03827870-001-02-9, BRD-K03827870-001-01-3	Preclinical
GKT137831	NADPH oxidase inhibitor	NOX1, NOX4			BRD-K79710622-001-03-7, BRD-K79710622-001-02-9, BRD-K79710622-001-01-1	Phase 2
GK921	transglutaminase inhibitor	TGM2			BRD-K38272302-001-02-7, BRD-K38272302-001-01-9	Preclinical
glafenine	DeltaF508-CFTR Correctors	CFTR			BRD-K01826515-003-11-9, BRD-K01826515-003-10-9	Withdrawn
glasdegib	hedgehog pathway inhibitor	SMO	hematologic malignancy	acute myeloid leukemia (AML)	BRD-K34341643-001-01-4, BRD-K34341643-001-01-4, BRD-K34341643-001-01-4, BRD-K34341643-001-01-4, BRD-K34341643-001-02-9	Launched
glecaprevir	serine protease inhibitor		infectious disease	hepatitis C	BRD-K00003260-001-01-9, BRD-K00003260-001-01-9	Launched
glesatinib	tyrosine kinase inhibitor				BRD-K00003288-003-01-9	Phase 2
gliclazide	ATP channel blocker, insulin secretagogue		endocrinology	diabetes mellitus	BRD-A61154809-001-15-9, BRD-A61154809-001-16-7, BRD-A61154809-001-18-9, BRD-A61154809-001-14-2	Launched
glimepiride	insulin secretagogue	ABCC8, KCNJ1, KCNJ11	endocrinology	diabetes mellitus	BRD-K34776109-001-16-6, BRD-K34776109-001-15-8, BRD-K34776109-001-19-9, BRD-K34776109-001-19-9, BRD-K34776109-001-14-1, BRD-K34776109-001-14-1	Launched
glipizide	sulfonylurea	ABCC8, KCNJ10, KCNJ11, PPARG	endocrinology	diabetes mellitus, hyperglycemia	BRD-K12219985-001-28-9, BRD-K12219985-001-26-1, BRD-K12219985-001-25-3	Launched
gliquidone	sulfonylurea	ABCC8, KCNJ10, KCNJ8	endocrinology	diabetes mellitus	BRD-K80396088-001-13-9, BRD-K80396088-001-12-0, BRD-K80396088-001-12-0, BRD-K80396088-001-12-0	Launched
Gln-1062	cholinesterase inhibitor				BRD-K00004731-001-01-9	Preclinical
GLPG0187	integrin antagonist				BRD-K00003380-001-01-9	Phase 1
GLPG0492	androgen receptor modulator	AR			BRD-K15893360-001-01-8, BRD-K15893360-001-01-8	Phase 1
GLPG0492-R-enantiomer	androgen receptor modulator	AR			BRD-K04643927-001-01-6, BRD-K04643927-001-01-6	Phase 1
GLPG1837	CFTR channel potentiator				BRD-K00003095-001-01-9	Phase 2
glucaric-acid					BRD-K60150658-432-01-5	Phase 1
gluconolactone		LCT			BRD-K04288422-001-04-4	Launched
glucosamine	glycosylated protein precursor	IL1B	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis, joint pain, backache	BRD-K29918010-003-04-1, BRD-K29918010-003-04-1, BRD-K29918010-003-05-9	Launched
glutathione	antioxidant	ESD, GGT1, GLO1, GLRX, GLRX2, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GPX8, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTZ1, HAGH, HPGDS, LTC4S, MGST1, MGST2, MGST3, TXNDC12			BRD-K69346723-001-04-8	Phase 3
glutathione-monoisopropyl-ester	lipid peroxidase inhibitor				BRD-K58937086-001-02-2, BRD-K58937086-001-01-4	Phase 2
gly-gln					BRD-K85066592-001-01-6	Phase 2
glyburide	ATP channel blocker, insulin secretagogue, sulfonylurea	ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1	endocrinology	diabetes mellitus, hyperglycemia	BRD-K36927236-001-36-7, BRD-K36927236-001-30-0, BRD-K36927236-001-30-0, BRD-K36927236-001-32-6, BRD-K36927236-001-31-8	Launched
glycerol-monolaurate	beta lactamase inhibitor				BRD-A10773072-001-03-4	Launched
glycerol-phenylbutyrate	sigma receptor ligand				BRD-K00003520-001-01-9	Phase 1
glycitein	tumor necrosis factor release inhibitor	TNF			BRD-K78303961-001-02-3, BRD-K78303961-001-02-3	Phase 3
glycopyrrolate	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	BRD-A81233518-004-16-1, BRD-A81233518-004-17-9	Launched
GM-1485	immunophilin ligand	FKBP1A			BRD-K00004613-001-01-9	Preclinical
GMX1778	NAMPT inhibitor	NAMPT			BRD-K69832040-001-01-9, BRD-K69832040-001-01-9, BRD-K69832040-001-01-9	Phase 1/Phase 2
GNE-7915	leucine rich repeat kinase inhibitor				BRD-K33963447-001-03-9	Preclinical
GNF-2	Bcr-Abl kinase inhibitor	ABL1, BCR			BRD-K97056771-001-15-9, BRD-K97056771-001-14-9, BRD-K97056771-001-13-1, BRD-K97056771-001-13-1	Preclinical
GNF-5	Bcr-Abl kinase inhibitor	ABL1, BCR			BRD-K87632963-001-05-9, BRD-K87632963-001-05-9, BRD-K87632963-001-03-0	Preclinical
GNF-5837	growth factor receptor inhibitor	NTRK1, NTRK2, NTRK3			BRD-K19975102-001-01-2, BRD-K19975102-001-02-0	Preclinical
GNF-7	glucokinase inhibitor, protein kinase inhibitor	GCK, TNK2			BRD-K69075588-001-01-3, BRD-K69075588-001-02-9, BRD-K69075588-001-02-9	Preclinical
go-6983	protein kinase inhibitor	PRKCA, PRKCB, PRKCD, PRKCG, PRKCZ			BRD-K36984403-001-02-7, BRD-K36984403-001-03-5, BRD-K36984403-001-03-5	Preclinical
golvatinib	VEGFR inhibitor	KDR, MET			BRD-K69001009-001-03-9, BRD-K69001009-001-02-8, BRD-K69001009-001-02-8, BRD-K69001009-001-02-8	Phase 2
gonadorelin	gonadotropin releasing factor hormone receptor agonist	GNRHR	obstetrics/gynecology	cystic ovaries, reproductive synchrony	BRD-K96874295-015-01-0	Launched
goserelin-acetate	gonadotropin releasing factor hormone receptor agonist	GNRHR, LHCGR	oncology, obstetrics/gynecology	prostate cancer, breast cancer, endometriosis	BRD-K99504665-001-01-2, BRD-K99504665-015-02-9	Launched
gossypol	BCL inhibitor, MCL1 inhibitor	BCL2			BRD-K19295594-001-17-6, BRD-K19295594-015-13-5, BRD-K19295594-001-16-8, BRD-K19295594-001-15-0, BRD-K19295594-015-14-3, BRD-K19295594-015-14-3, BRD-K19295594-015-14-3, BRD-K19295594-015-12-7	Phase 2
GPBAR-A	G protein-coupled receptor agonist	GPBAR1			BRD-K67397687-001-02-9, BRD-K67397687-001-02-9, BRD-K67397687-001-01-3	Preclinical
GPI-1046	FKBP inhibitor	FKBP1A			BRD-K44869961-001-01-6	Preclinical
GPi-688	glycogen phosphorylase inhibitor				BRD-A90201073-001-01-2, BRD-A90201073-001-02-9	Preclinical
GPP-78	NAMPT inhibitor	NAMPT			BRD-K83289131-003-04-9, BRD-K83289131-003-01-0, BRD-K83289131-003-01-0	Preclinical
GPR120-modulator-1	G protein-coupled receptor modulator	FFAR4			BRD-K19409553-001-01-6	Preclinical
GP1a	cannabinoid receptor agonist	CNR2			BRD-K65285700-001-02-3, BRD-K65285700-001-02-3, BRD-K65285700-001-02-3, BRD-K65285700-001-02-3, BRD-K65285700-001-02-3, BRD-K65285700-001-03-1	Preclinical
GP2a	cannabinoid receptor agonist	CNR2			BRD-K34608650-001-02-4, BRD-K34608650-001-03-9, BRD-K34608650-001-03-9	Preclinical
GR-103691	dopamine receptor antagonist	DRD3			BRD-K50891186-001-04-4, BRD-K50891186-001-04-4	Preclinical
GR-113808	serotonin receptor antagonist	HTR4			BRD-K49945136-001-11-9, BRD-K49945136-001-10-0	Preclinical
GR-127935	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6			BRD-K11911061-003-12-9, BRD-K11911061-003-12-9, BRD-K11911061-003-11-9, BRD-K11911061-003-11-9, BRD-K11911061-003-11-9	Preclinical
GR-135531	melatonin receptor agonist				BRD-K83023055-001-03-9, BRD-K83023055-001-02-7	Preclinical
GR-144053	integrin antagonist	ITGA2B, ITGB3			BRD-K12120659-305-03-9, BRD-K12120659-305-02-2, BRD-K12120659-305-02-2	Preclinical
GR-159897	tachykinin antagonist	TAC1, TACR2			BRD-K52394958-001-03-5, BRD-K52394958-001-03-5, BRD-K52394958-001-04-9, BRD-K52394958-001-02-7, BRD-K52394958-001-02-7	Preclinical
GR-235	estrogen receptor agonist, FXR antagonist, progesterone receptor agonist	NR1H4			BRD-K00004242-001-01-9	Launched
GR-79236	adenosine receptor agonist	ADORA1, ADORA2A			BRD-K40578143-001-03-9, BRD-K40578143-001-02-6, BRD-K40578143-001-02-6	Phase 1
gramicidin	bacterial permeability inducer		infectious disease	first-aid antibiotic	BRD-K45170529-001-01-3	Launched
gramine	norepinephrine reputake inhibitor				BRD-K26005076-001-12-8	Preclinical
granisetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	BRD-A10967948-003-06-3, BRD-A10967948-003-05-5	Launched
grapiprant	prostaglandin inhibitor	PTGER4	rheumatology	osteoarthritis	BRD-K62050508-001-01-0, BRD-K62050508-001-01-0	Launched
grazoprevir	HCV inhibitor		infectious disease	hepatitis C	BRD-K24943235-237-01-3, BRD-K24943235-001-01-3, BRD-K24943235-001-01-3, BRD-K24943235-001-02-9, BRD-K24943235-001-02-9	Launched
GR125487	serotonin receptor antagonist	HTR4			BRD-K62594868-082-09-9, BRD-K62594868-082-09-9, BRD-K62594868-082-08-6, BRD-K62594868-082-08-6	Preclinical
GR46611	serotonin receptor agonist	HTR1D			BRD-K98155362-001-08-5, BRD-K98155362-001-09-9, BRD-K98155362-001-09-9, BRD-K98155362-001-07-7	Preclinical
GS-143	ubiquitin ligase inhibitor	BTRC, NFKBIA			BRD-K99916169-001-01-9, BRD-K99916169-001-01-9, BRD-K99916169-001-02-9, BRD-K99916169-001-02-9	Preclinical
GS-39783	GABA receptor modulator	GABBR1			BRD-K75478907-001-03-9, BRD-K75478907-001-02-3, BRD-K75478907-001-02-3	Preclinical
GS-6201	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K68453341-001-01-1, BRD-K68453341-001-01-1, BRD-K68453341-001-01-1	Phase 1
GS-9620	toll-like receptor agonist	TLR7			BRD-K73585091-001-02-3, BRD-K73585091-001-01-5	Phase 2
GS-967	voltage-gated sodium channel blocker				BRD-K26526496-001-03-9	Preclinical
GS-9973	SYK inhibitor	SYK			BRD-K76719364-001-06-6, BRD-K76719364-001-06-6, BRD-K76719364-001-01-7, BRD-K76719364-001-04-1, BRD-K76719364-001-04-1, BRD-K76719364-001-02-5, BRD-K76719364-001-02-5, BRD-K76719364-001-02-5	Phase 2
GSK-J1	histone demethylase inhibitor	KDM6B			BRD-K32847255-001-01-1, BRD-K32847255-001-01-1, BRD-K32847255-001-02-9	Preclinical
GSK-J2	histone demethylase inhibitor				BRD-K82484347-001-02-0, BRD-K82484347-001-01-2, BRD-K82484347-001-01-2	Preclinical
GSK-J4	histone lysine demethylase inhibitor	KDM6A, KDM6B			BRD-K98203492-001-06-9, BRD-K98203492-001-02-9, BRD-K98203492-003-04-1, BRD-K98203492-003-04-1, BRD-K98203492-003-04-1, BRD-K98203492-003-04-1, BRD-K98203492-003-04-1, BRD-K98203492-003-04-1	Preclinical
GSK-J5	histone demethylase control				BRD-K55438324-001-01-8, BRD-K55438324-001-01-8	Preclinical
GSK-LSD-1	histone lysine demethylase inhibitor	KDM1A			BRD-K33521504-300-02-4, BRD-K33521504-300-01-6	Preclinical
GSK-3-inhibitor-IX	glycogen synthase kinase inhibitor, lipoxygenase inhibitor	GSK3A, GSK3B			BRD-K04923131-001-15-4, BRD-K04923131-001-15-4, BRD-K04923131-001-15-4, BRD-K04923131-001-15-4, BRD-K04923131-001-14-7, BRD-K04923131-001-14-7, BRD-K04923131-001-14-7, BRD-K04923131-001-14-7, BRD-K04923131-001-14-7	Preclinical
GSK0660	PPAR receptor antagonist	PPARD			BRD-K98684188-001-03-7, BRD-K98684188-001-02-9, BRD-K98684188-001-04-9	Preclinical
GSK1059615	PI3K inhibitor	PIK3CG			BRD-K06750613-001-04-0, BRD-K06750613-001-07-3, BRD-K06750613-001-07-3	Phase 1
GSK1070916	Aurora kinase inhibitor	AURKA, AURKB, AURKC, CYP2D6, CYP3A4			BRD-K36740062-001-07-9, BRD-K36740062-001-06-6, BRD-K36740062-001-06-6, BRD-K36740062-001-06-6	Phase 1
GSK1292263	glucose dependent insulinotropic receptor agonist	GRPR			BRD-K60341624-001-03-9, BRD-K60341624-001-02-2	Phase 2
GSK1562590	urotensin receptor antagonist	UTS2R			BRD-K36697397-003-02-9, BRD-K36697397-003-01-1	Preclinical
GSK163090	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D			BRD-K69669039-001-01-8, BRD-K69669039-001-01-8	Phase 2
GSK1838705A	insulin growth factor receptor inhibitor	ALK, IGF1R, INSR, RPS6KA1			BRD-K06749501-001-06-9, BRD-K06749501-001-05-4, BRD-K06749501-001-02-1, BRD-K06749501-001-02-1, BRD-K06749501-001-02-1, BRD-K06749501-001-03-9, BRD-K06749501-001-03-9	Preclinical
GSK189254	histamine receptor antagonist				BRD-K00003166-001-01-9	Phase 2
GSK1904529A	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand	IGF1R, INSR			BRD-K04833372-001-07-9, BRD-K04833372-001-06-2, BRD-K04833372-001-06-2	Preclinical
GSK2110183	AKT inhibitor	AKT1, AKT2, AKT3			BRD-K25412176-001-01-9, BRD-K25412176-001-01-9, BRD-K25412176-001-01-9, BRD-K25412176-001-01-9, BRD-K25412176-001-04-9	Phase 2
GSK2126458	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			BRD-K07972848-001-03-9, BRD-K07972848-001-03-9, BRD-K07972848-001-02-0, BRD-K07972848-001-02-0, BRD-K07972848-001-02-0, BRD-K07972848-001-02-0, BRD-K07972848-001-02-0	Phase 1
GSK2190915	lipoxygenase inhibitor	ALOX5AP			BRD-K15691453-236-01-6	Phase 2
GSK2193874	transient receptor potential channel antagonist	TRPV4			BRD-K90737788-001-02-9, BRD-K90737788-001-02-9, BRD-K90737788-001-01-9	Preclinical
GSK2194069	fatty acid synthase inhibitor	FASN			BRD-K95123482-001-01-6, BRD-K95123482-001-01-6, BRD-K95123482-001-02-9, BRD-K95123482-001-02-9	Preclinical
GSK2239633A	CC chemokine receptor antagonist				BRD-K00003364-001-01-9	Preclinical
GSK2256098	kinase inhibitor				BRD-K00003379-001-01-9	Phase 2
GSK2256294A	epoxide hydolase inhibitor	EPHX2			BRD-K62738477-001-01-7	Phase 1
GSK2330672	bile acid transporter inhibitor	SLC10A2			BRD-K05858796-001-01-7	Phase 2
GSK2334470	phosphoinositide dependent kinase inhibitor	AURKA, AURKB, PDPK1			BRD-K70642949-001-04-5, BRD-K70642949-001-04-5, BRD-K70642949-001-05-2	Preclinical
GSK239512	histamine receptor antagonist				BRD-K00004689-001-01-9	Preclinical
GSK256066	phosphodiesterase inhibitor	PDE4A			BRD-K37590257-001-03-9, BRD-K37590257-001-02-8, BRD-K37590257-001-02-8	Phase 2
GSK2578215A	leucine rich repeat kinase inhibitor	LRRK2			BRD-K30185465-001-04-9, BRD-K30185465-001-03-0	Preclinical
GSK2606414	protein kinase inhibitor	EIF2AK3, MYLK2			BRD-K81689258-001-04-8, BRD-K81689258-001-04-8, BRD-K81689258-001-04-8, BRD-K81689258-001-03-0, BRD-K81689258-001-02-2	Preclinical
GSK2636771	PI3K inhibitor	PIK3CB			BRD-K49215523-001-04-2, BRD-K49215523-001-04-2, BRD-K49215523-001-05-9, BRD-K49215523-001-05-9	Phase 2
GSK2656157	PERK inhibitor				BRD-K41104902-001-01-3	Preclinical
GSK269962	rho associated kinase inhibitor	ROCK1, ROCK2			BRD-K89464729-001-03-1, BRD-K89464729-001-03-1, BRD-K89464729-001-04-9, BRD-K89464729-001-04-9	Preclinical
GSK2801	bromodomain inhibitor	BAZ2A, BAZ2B			BRD-K48062199-001-01-8, BRD-K48062199-001-01-8	Preclinical
GSK2816126	histone lysine methyltransferase inhibitor	EZH2			BRD-K21867462-001-03-7, BRD-K21867462-001-02-9	Phase 1
GSK2830371	protein phosphatase inhibitor	PPM1D			BRD-K17472821-001-01-2, BRD-K17472821-001-01-2, BRD-K17472821-001-02-0	Preclinical
GSK2837808A	lactate dehydrogenase inhibitor	LDHA			BRD-K50679358-001-02-9, BRD-K50679358-001-01-1	Preclinical
GSK2838232	HIV gag inhibitor				BRD-K08398903-001-02-9, BRD-K08398903-001-01-1, BRD-K08398903-001-01-1	Phase 2
GSK2879552	histone lysine demethylase inhibitor	KDM1A			BRD-K09223495-001-01-4, BRD-K09223495-001-01-4, BRD-K09223495-001-01-4, BRD-K09223495-001-01-4	Phase 1/Phase 2
GSK2881078	androgen receptor modulator				BRD-K97656802-001-02-9	Phase 2
GSK2981278	ROR modulator				BRD-K00003292-001-01-9	Phase 1/Phase 2
GSK2982772	RIPK inhibitor				BRD-K00003429-001-01-9	Phase 2
GSK3117391	HDAC inhibitor				BRD-K00004614-001-01-9	Phase 1/Phase 2
GSK3179106	RET tyrosine kinase inhibitor				BRD-K00003373-001-01-9	Phase 1
GSK3326595	protein arginine N-methyltransferase inhibitor				BRD-K00003421-001-01-9	Phase 1/Phase 2
GSK356278	phosphodiesterase inhibitor				BRD-K00004711-001-01-9	Preclinical
GSK369796	potassium channel antagonist				BRD-K00003121-300-01-9	Phase 1
GSK37647	free fatty acid receptor agonist	FFAR4			BRD-K26514105-001-02-9, BRD-K26514105-001-01-7, BRD-K26514105-001-01-7	Preclinical
GSK3787	PPAR receptor antagonist	PPARD			BRD-K03155172-001-03-0, BRD-K03155172-001-02-2, BRD-K03155172-001-05-9	Preclinical
GSK429286A	rho associated kinase inhibitor	ROCK1			BRD-A10523515-001-11-1, BRD-A10523515-001-10-3, BRD-A10523515-001-07-9	Preclinical
GSK461364	PLK inhibitor	PLK1			BRD-K92428232-001-14-9, BRD-K92428232-001-10-6, BRD-K92428232-001-10-6, BRD-K92428232-001-10-6	Phase 1
GSK503	histone lysine methyltransferase inhibitor	EZH2			BRD-K72293620-001-01-7, BRD-K72293620-001-01-7	Preclinical
GSK650394	serum/glucocorticoid regulated kinase inhibitor	SGK1, SGK2			BRD-K14991967-001-04-2, BRD-K14991967-001-02-6, BRD-K14991967-001-02-6, BRD-K14991967-001-02-6, BRD-K14991967-001-02-6, BRD-K14991967-001-03-4, BRD-K14991967-001-03-4, BRD-K14991967-001-03-4	Preclinical
GSK656	leucyl-tRNA synthetase inhibitor				BRD-K00003483-003-01-9	Preclinical
GSK9027	glucocorticoid receptor agonist	NR3C1			BRD-K29328421-001-01-6, BRD-K29328421-001-01-6, BRD-K29328421-001-02-9	Preclinical
GSK923295	centromere associated protein inhibitor	CENPE			BRD-K89015388-001-02-9, BRD-K89015388-001-01-7	Phase 1
GTP-14564	FLT3 inhibitor, tyrosine kinase inhibitor	CSF1R, FLT3, KIT, PDGFRB			BRD-K16664969-001-04-1, BRD-K16664969-001-07-9, BRD-K16664969-001-03-3, BRD-K16664969-001-03-3, BRD-K16664969-001-03-3	Preclinical
GTS21	cholinergic receptor agonist	CHRNA7			BRD-K14235254-001-01-2, BRD-K14235254-300-02-9	Phase 1/Phase 2
guacetisal	immunosuppressant		pulmonary	cough suppressant	BRD-K00739965-001-01-9	Launched
guadecitabine	DNA methyltransferase inhibitor				BRD-K00003187-236-01-9	Phase 3
guaiacol	local anesthetic	CA2	pulmonary	cough suppressant	BRD-K96282009-001-08-8, BRD-K96282009-001-12-9	Launched
guaifenesin	expectorant		pulmonary	cough suppressant	BRD-A90515964-001-18-9, BRD-A90515964-001-16-5, BRD-A90515964-001-15-7	Launched
guanadrel	adrenergic inhibitor		cardiology	hypertension	BRD-A14262390-065-01-8, BRD-A14262390-065-01-8, BRD-A14262390-065-01-8, BRD-A14262390-065-01-8, BRD-A14262390-065-01-8	Launched
guancydine	antihypertensive agent				BRD-K00005334-001-01-9	Preclinical
guanfacine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	BRD-K32830106-003-21-2, BRD-K32830106-003-21-2, BRD-K32830106-001-02-6, BRD-K32830106-003-20-4, BRD-K32830106-003-20-4	Launched
guanidinoethyldisulfide-bicarbonate	nitric oxide synthase inhibitor	NOS2			BRD-K69191882-065-01-6	Phase 2
guanidinopropionic-acid	creatine kinase inhibitor	CKM			BRD-K50781608-001-02-1	Phase 2
guanosine		PNP			BRD-K67644125-001-03-9	Preclinical
Gue-1654	oxoeicosanoid receptor modulator	OXER1			BRD-K18745919-001-02-9, BRD-K18745919-001-01-3	Preclinical
guvacine	GABA uptake inhibitor	SLC6A1, SLC6A11, SLC6A12, SLC6A13			BRD-K01980392-003-11-6, BRD-K01980392-003-11-6, BRD-K01980392-003-11-6, BRD-K01980392-003-12-9	Preclinical
GW-0742	PPAR receptor agonist	PPARD			BRD-K82983861-001-06-8, BRD-K82983861-001-06-8, BRD-K82983861-001-05-0, BRD-K82983861-001-04-3, BRD-K82983861-001-07-9	Preclinical
GW-1100	G protein-coupled receptor agonist	FFAR1			BRD-K23614267-001-01-2	Preclinical
GW-1929	PPAR receptor agonist	PPARG			BRD-K00004238-003-01-9	Preclinical
GW-2580	cFMS kinase inhibitor	CSF1R			BRD-K24242599-001-02-8, BRD-K24242599-001-02-8	Preclinical
GW-311616	elastase inhibitor, leukocyte elastase inhibitor	ELANE			BRD-K37864785-001-01-0, BRD-K37864785-001-01-0, BRD-K37864785-001-02-9	Phase 1
GW-3965	LXR agonist	NR1H2, NR1H3			BRD-K33818169-003-05-3, BRD-K33818169-003-05-3, BRD-K33818169-003-04-6, BRD-K33818169-003-04-6, BRD-K33818169-003-06-9, BRD-K33818169-003-03-8	Preclinical
GW-405833	cannabinoid receptor agonist	CNR2			BRD-K10705233-001-02-2	Preclinical
GW-4064	FXR agonist	NR1H4			BRD-K88186167-001-05-5, BRD-K88186167-001-04-8, BRD-K88186167-001-04-8, BRD-K88186167-001-04-8, BRD-K88186167-001-04-8, BRD-K88186167-001-06-9	Preclinical
GW-438014A	neuropeptide receptor antagonist	NPY5R			BRD-K13039700-066-01-2, BRD-K13039700-066-01-2, BRD-K13039700-066-02-0	Preclinical
GW-441756	growth factor receptor inhibitor	NTRK1			BRD-K41312087-001-02-7, BRD-K41312087-001-01-9	Preclinical
GW-501516	PPAR receptor agonist	PPARA, PPARD			BRD-K14880289-001-03-0, BRD-K14880289-001-03-0, BRD-K14880289-001-03-0, BRD-K14880289-001-03-0, BRD-K14880289-001-03-0, BRD-K14880289-001-02-2	Phase 2
GW-542573X	calcium channel activator	KCNN1			BRD-K36485341-001-01-2, BRD-K36485341-001-02-9, BRD-K36485341-001-02-9	Preclinical
GW-583340	EGFR inhibitor	EGFR, ERBB2			BRD-K79930101-300-05-9, BRD-K79930101-300-04-5, BRD-K79930101-300-03-7	Preclinical
GW-627368	prostanoid receptor antagonist	PTGER4			BRD-K50005760-001-02-9, BRD-K50005760-001-01-1	Preclinical
GW-6471	PPAR receptor antagonist	PPARA			BRD-K20828910-001-03-9, BRD-K20828910-001-02-0, BRD-K20828910-001-02-0, BRD-K20828910-001-01-2	Preclinical
GW-7647	PPAR receptor agonist	PPARA			BRD-K96263742-001-15-5, BRD-K96263742-001-16-9, BRD-K96263742-001-14-8	Preclinical
GW-788388	ALK tyrosine kinase receptor inhibitor	LCK, MAPK14, TGFBR1			BRD-K78086729-001-03-5, BRD-K78086729-001-04-9, BRD-K78086729-001-02-7, BRD-K78086729-001-02-7	Preclinical
GW-803430	melanin inhibitor	KCNH2, MCHR1			BRD-K65576800-001-01-6, BRD-K65576800-001-01-6	Phase 1
GW-842166	cannabinoid receptor agonist	CNR2			BRD-K26823213-001-03-9, BRD-K26823213-001-03-9, BRD-K26823213-001-02-9	Phase 2
GW-843682X	PLK inhibitor	PLK1, PLK3			BRD-K90382497-001-10-7, BRD-K90382497-001-10-7, BRD-K90382497-001-14-9, BRD-K90382497-001-13-1, BRD-K90382497-001-13-1	Preclinical
GW-9508	free fatty acid receptor agonist, G protein-coupled receptor agonist	FFAR1, FFAR4			BRD-K71534238-001-12-6, BRD-K71534238-001-11-8, BRD-K71534238-001-13-9, BRD-K71534238-001-10-0	Preclinical
GW-9662	PPAR receptor antagonist	NCOA2, PPARG, RXRA			BRD-K93258693-001-19-9, BRD-K93258693-001-16-5, BRD-K93258693-001-17-3	Preclinical
GW274150	nitric oxide synthase inhibitor				BRD-K65840970-001-02-9	Phase 2
GYKI-52466	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			BRD-K24240364-003-09-6, BRD-K24240364-003-08-8, BRD-K24240364-003-02-1, BRD-K24240364-003-02-1	Preclinical
GZD824	Bcr-Abl kinase inhibitor	ABL1, BCR			BRD-K35329391-334-01-7, BRD-K35329391-334-01-7, BRD-K35329391-334-01-7, BRD-K35329391-334-01-7, BRD-K35329391-334-01-7, BRD-K35329391-334-02-5, BRD-K35329391-334-02-5	Preclinical
G007-LK	tankyrase inhibitor	TNKS, TNKS2			BRD-K12198961-001-01-8	Preclinical
H-151	STING antagonist				BRD-K00005333-001-01-9	Preclinical
H-89	PKA inhibitor	GSG2, PKIA, PRKACA			BRD-K27737647-300-03-0, BRD-K27737647-300-03-0, BRD-K27737647-300-03-0, BRD-K27737647-300-03-0, BRD-K27737647-300-03-0, BRD-K27737647-300-04-8, BRD-K27737647-300-08-9	Preclinical
HA-1004	calcium channel blocker				BRD-K05434375-001-06-5, BRD-K05434375-001-06-5, BRD-K05434375-001-06-5	Phase 2
HA-130	autotaxin inhibitor	ENPP2			BRD-K64452997-001-01-4, BRD-K64452997-001-02-9	Preclinical
HA-966-(R)-(+)	glutamate receptor agonist	GRIA1			BRD-K58046914-001-03-8, BRD-K58046914-001-04-9, BRD-K58046914-001-04-9	Preclinical
HA-966-(S)-(-)	glutamate receptor antagonist	GRIA1			BRD-K41304947-001-03-2, BRD-K41304947-001-04-9	Preclinical
halazone			infectious disease	disinfectant	BRD-K68091065-001-05-9, BRD-K68091065-001-04-7	Launched
halobetasol-propionate	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	BRD-K71487404-001-01-8	Launched
halofantrine	antimalarial agent	KCNN4	infectious disease	malaria	BRD-A51964809-003-12-6, BRD-A51964809-003-13-9	Launched
halofuginone	collagenase inhibitor	COL1A1, MMP2	rheumatology	scleroderma	BRD-K54247840-004-01-3, BRD-K54247840-004-01-3, BRD-K54247840-004-01-3, BRD-K54247840-004-01-3, BRD-K54247840-004-01-3	Launched
halopemide	phospholipase inhibitor	PLD1, PLD2			BRD-K50055394-001-03-6, BRD-K50055394-001-03-6, BRD-K50055394-001-03-6, BRD-K50055394-001-03-6	Phase 2
haloperidol	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, GRIN2B, HRH1, HTR1A, HTR1D, HTR2A, HTR2B, HTR7, KCNH1	neurology/psychiatry	schizophrenia, Tourette's disorder	BRD-K67783091-003-07-7, BRD-K67783091-001-25-3, BRD-K67783091-001-26-1, BRD-K67783091-001-26-1	Launched
haloperidol-decanoate	psychoactive drug	DRD2, DRD3, DRD4, HTR2A	neurology/psychiatry	schizophrenia	BRD-K80859331-001-01-5, BRD-K80859331-001-01-5	Launched
haloprogin	other antifungal		infectious disease	tinea pedis	BRD-K13238168-001-02-0, BRD-K13238168-001-02-0, BRD-K13238168-001-02-0	Launched
halothane	glutamate receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK12, KCNK13, KCNK15, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	general anaesthetic	BRD-A20550616-001-02-9, BRD-A20550616-001-03-7	Launched
harmane	monoamine oxidase inhibitor	MAOA, MAOB			BRD-K12630395-001-14-9	Preclinical
harringtonine	protein synthesis inhibitor				BRD-K00003715-001-01-9, BRD-K00003715-001-01-9	Phase 3
HA14-1	BCL inhibitor	BCL2			BRD-K18163608-001-02-3, BRD-K18163608-001-05-6, BRD-K18163608-001-05-6	Preclinical
HBED	chelating agent				BRD-K00004555-001-01-9	Phase 3
HC-030031	TRPA1 channel blocker	TRPA1			BRD-K73815512-001-03-9, BRD-K73815512-001-03-9, BRD-K73815512-001-02-5, BRD-K73815512-001-02-5, BRD-K73815512-001-02-5, BRD-K73815512-001-02-5	Phase 1
HC-067047	transient receptor potential channel antagonist	TRPV4			BRD-K03391209-001-02-0, BRD-K03391209-001-01-2, BRD-K03391209-001-01-2, BRD-K03391209-001-01-2, BRD-K03391209-001-01-2, BRD-K03391209-001-01-2, BRD-K03391209-001-01-2, BRD-K03391209-001-01-2, BRD-K03391209-001-01-2	Preclinical
HC-070	transient receptor potential channel antagonist				BRD-K00004601-001-01-9	Preclinical
heclin	ubiquitin ligase inhibitor	NEDD4, SMURF2, WWP1			BRD-K49788188-001-01-0, BRD-K49788188-001-01-0, BRD-K49788188-001-02-9, BRD-K49788188-001-02-9	Preclinical
HEMADO	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K34672903-001-02-5, BRD-K34672903-001-03-9, BRD-K34672903-001-01-7	Preclinical
hematoporphyrin			neurology/psychiatry	depression, psychosis	BRD-K01825010-001-02-9, BRD-K01825010-001-02-9	Launched
hematoxylin					BRD-K78342372-001-03-2, BRD-K78342372-001-03-2, BRD-K78342372-001-02-4	Preclinical
hemin	enzyme inducer		hematology, cardiology	acute intermittent porphyria (AIP), hypertension, ventricular tachycardia (VT)	BRD-K74057164-001-01-6, BRD-K74057164-001-01-6, BRD-K74057164-001-01-6	Launched
hemomex-s		PPARG			BRD-K15231341-001-02-9, BRD-K15231341-001-02-9, BRD-K15231341-001-01-5	Launched
hepsulfam	DNA cross-linking				BRD-K00004739-001-01-9	Preclinical
heptaminol	vasoconstrictor		cardiology	hypotension	BRD-A32988684-003-08-7, BRD-A32988684-003-09-9, BRD-A32988684-003-09-9	Launched
HER2-Inhibitor-1	EGFR inhibitor				BRD-K89709433-001-03-9, BRD-K89709433-001-02-8	Preclinical
hesperadin	Aurora kinase inhibitor	AURKB			BRD-K58122457-001-02-2, BRD-K58122457-001-02-2, BRD-K58122457-001-02-2, BRD-K58122457-003-01-0, BRD-K58122457-003-01-0, BRD-K58122457-003-01-0, BRD-K58122457-003-01-0, BRD-K58122457-003-03-9	Preclinical
hesperetin	ACAT inhibitor	DGAT1, MTTP, SOAT1, SOAT2			BRD-K30553453-001-14-9, BRD-K30553453-001-14-9, BRD-K30553453-001-13-2, BRD-K30553453-001-13-2	Launched
hetacillin	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	BRD-K00005353-001-01-9	Launched
hexachlorophene	potassium channel activator	GLUD1, SDHD	infectious disease	gram-positive bacterial infections	BRD-K99792991-001-34-9, BRD-K99792991-001-34-9, BRD-K99792991-001-34-9, BRD-K99792991-001-34-9, BRD-K99792991-001-34-9, BRD-K99792991-001-34-9, BRD-K99792991-001-34-9, BRD-K99792991-001-34-9, BRD-K99792991-001-36-9, BRD-K99792991-001-36-9, BRD-K99792991-001-36-9, BRD-K99792991-001-36-9, BRD-K99792991-001-36-9	Launched
hexamethonium	cholinergic receptor antagonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6			BRD-K10598093-303-08-9, BRD-K10598093-303-06-1, BRD-K10598093-303-05-3, BRD-K10598093-303-07-9, BRD-K10598093-303-07-9, BRD-K10598093-303-07-9	Preclinical
hexamethylenebisacetamide	AKT inhibitor, differentiation inducer, NFKB pathway inhibitor	AKT1			BRD-K04710043-001-17-8, BRD-K04710043-001-17-8, BRD-K04710043-001-17-8	Phase 2
hexaminolevulinate			radiology	diagnostic agent	BRD-K73753850-003-01-6, BRD-K73753850-003-01-6	Launched
hexasodium-phytate					BRD-K70007857-001-01-7	Phase 2
hexestrol	synthetic estrogen	AKR1C1, ESR1, ESR2	endocrinology	hypoestrogenism	BRD-K69253806-001-02-0, BRD-K69253806-001-03-8, BRD-K69253806-001-03-8, BRD-K69253806-001-05-3	Launched
hexetidine	local anesthetic		otolaryngology, infectious disease, dental, gastroenterology	pharyngitis, meningitis, laryngitis, gingivitis, ulcerative colitis	BRD-A18605525-001-12-4, BRD-A18605525-001-13-2, BRD-A18605525-001-14-0	Launched
hexoprenaline	adrenergic receptor agonist	ADRB2	pulmonary	asthma	BRD-A33894669-065-01-9	Launched
hexylcaine	sodium channel blocker	SCN5A	neurology/psychiatry	local anesthetic	BRD-A97730597-003-11-5, BRD-A97730597-003-12-9	Launched
hexylene-glycol		AKR1C3, CTPS1, DLG4, HSP90AA1, NOS3, PGF, PLA2G1B, PTPN1, SELP			BRD-A14234430-001-01-4, BRD-A14234430-001-02-9	Preclinical
hexylresorcinol	local anesthetic	TYR	infectious disease	skin infections, first-aid antiseptic	BRD-K99946902-001-09-9, BRD-K99946902-001-07-5, BRD-K99946902-001-07-5, BRD-K99946902-001-07-5	Launched
higenamine	adrenergic receptor agonist	ADRB2			BRD-A55204514-003-01-2, BRD-A55204514-003-01-2, BRD-A55204514-003-01-2, BRD-A55204514-003-01-2	Phase 1
hippuric-acid					BRD-K62914667-001-13-9	Preclinical
HJC-0350	GTPase inhibitor	RAPGEF4			BRD-K34411045-001-02-9, BRD-K34411045-001-01-9, BRD-K34411045-001-01-9	Preclinical
HKI-357	EGFR inhibitor	EGFR			BRD-K58811567-001-01-9, BRD-K58811567-001-02-7	Phase 1
HLCL-61	protein arginine N-methyltransferase inhibitor	PRMT5			BRD-K73746696-003-01-8, BRD-K73746696-003-01-8, BRD-K73746696-003-01-8	Preclinical
HM-30181	P glycoprotein inhibitor				BRD-K74319597-001-02-9	Phase 1
HMN-214	PLK inhibitor	PLK1			BRD-K70511574-001-06-9	Phase 1
HOKU-81	bronchodilator				BRD-K00003598-001-01-9	Preclinical
homatropine-methylbromide	acetylcholine receptor antagonist	CHRM5	ophthalmology	uveal tract inflammation	BRD-A54234250-004-02-9	Launched
homidium					BRD-K28354016-004-11-7, BRD-K28354016-001-12-9	Preclinical
homochlorcyclizine	antihistamine	HRH1	allergy	allergic rhinitis		Launched
homoharringtonine	protein synthesis inhibitor	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	BRD-K76674262-001-03-3, BRD-K76674262-001-03-3, BRD-K76674262-001-03-3, BRD-K76674262-001-03-3, BRD-K76674262-001-05-9, BRD-K76674262-001-05-9	Launched
homoquinolinic-acid	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			BRD-K30519779-001-03-1, BRD-K30519779-001-03-1, BRD-K30519779-001-04-9	Preclinical
homosalate	HSP inducer				BRD-A34751532-001-06-9, BRD-A34751532-001-07-9	Preclinical
homoveratrylamine	monoamine oxidase inhibitor				BRD-K59570838-001-09-9, BRD-K59570838-003-01-9	Preclinical
honokiol	AKT inhibitor	ALOX5, PTGS1, PTGS2			BRD-K98493452-001-15-9, BRD-K98493452-001-14-9, BRD-K98493452-001-14-9	Phase 3
hordenine					BRD-K93631643-001-03-2, BRD-K93631643-001-02-4	Preclinical
HP-228	nitric oxide synthase inhibitor				BRD-K00004723-001-01-9	Preclinical
hPGDS-IN-1	prostaglandin inhibitor				BRD-K00003140-001-01-9	Preclinical
HPPH	photosensitizing agent				BRD-K00003730-001-01-9	Phase 2
HQK-1001					BRD-K44963273-001-07-7, BRD-K44963273-001-06-9	Phase 2
HSR6071	antiallergic agent				BRD-K00004745-001-01-9	Preclinical
HT-2157	galanin receptor 3 antagonist				BRD-K00003386-001-01-9	Phase 1/Phase 2
HTH-01-015	protein kinase inhibitor	NUAK1			BRD-K58726989-001-01-9, BRD-K58726989-001-02-7	Preclinical
HTHQ	antioxidant				BRD-K00003389-001-01-9	Preclinical
HTMT	histamine receptor agonist	HRH4			BRD-K01825665-332-02-9, BRD-K01825665-332-01-9	Preclinical
hyaluronic-acid		C1QBP, CD44, HABP2, HAPLN1, HAPLN3, HAPLN4, HMMR, ICAM1, NCAN, VCAN	rheumatology, urology	osteoarthritis, interstitial cystitis (IC)	BRD-K59788572-236-01-3	Launched
hycanthone	RNA synthesis inhibitor		infectious disease	schistosomiasis	BRD-K50406511-001-26-0, BRD-K50406511-001-26-0	Launched
hydralazine	vasodilator		cardiology	hypertension	BRD-K82103381-003-07-8, BRD-K82103381-003-09-4, BRD-K82103381-003-09-4, BRD-K82103381-003-06-0, BRD-K82103381-003-08-6	Launched
hydrastine-(1R,9S)	tyrosine hydroxylase inhibitor				BRD-K02715688-001-09-9, BRD-K02715688-001-02-1, BRD-K02715688-001-02-1	Preclinical
hydrastinine	hemostatic agent				BRD-K92726801-311-01-6	Preclinical
hydrochlorothiazide	thiazide diuretic	CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A3	cardiology	hypertension, congestive heart failure	BRD-K13078532-001-27-6, BRD-K13078532-001-28-4, BRD-K13078532-001-28-4	Launched
hydrocortisone-acetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-K11612998-001-26-9	Launched
hydrocortisone-hemisuccinate					BRD-K00025601-002-01-9	Phase 2/Phase 3
hydrocortisone-phosphate			pulmonary, gastroenterology, hematologic malignancy, ophthalmology	asthma, nausea, vomiting, multiple myeloma, contact dermatitis, enteritis, colitis	BRD-K01824977-369-02-9	Launched
hydrocortisone-valerate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-K09968782-001-17-2	Launched
hydroflumethiazide	sodium/potassium/chloride transporter inhibitor	ATP1A1, CA1, CA12, CA2, CA4, CA9, KCNMA1, SLC12A1, SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, chronic renal failure, acute glomerulonephritis (AGN), hypertension	BRD-K36862742-001-27-9, BRD-K36862742-001-27-9, BRD-K36862742-001-25-6	Launched
hydroquinidine	antiarrhythmic		cardiology	cardiac arrythmia	BRD-K65866076-001-03-9, BRD-K65866076-001-03-9	Launched
hydroquinone	melanin inhibitor	TYR	dermatology	dyschromia	BRD-K11227669-001-07-8, BRD-K11227669-001-08-6	Launched
hydroxocobalamin	vitamin B				BRD-K00003525-003-01-9	Launched
hydroxyamphetamine	trace amine associated receptor agonist	TAAR1	ophthalmology	mydriasis	BRD-A80871782-004-06-9, BRD-A80871782-004-06-9, BRD-A80871782-001-07-9	Launched
hydroxychloroquine	antimalarial agent	TLR7, TLR9	infectious disease	malaria	BRD-A99117172-065-04-0, BRD-A99117172-065-05-7, BRD-A99117172-065-05-7	Launched
hydroxyfasudil	rho associated kinase inhibitor	PKIA, PRKACA, ROCK1			BRD-K77793136-003-03-0, BRD-K77793136-003-03-0, BRD-K77793136-003-03-0, BRD-K77793136-003-05-9	Preclinical
hydroxyprogesterone	progesterone receptor agonist	PGR	obstetrics/gynecology	spontaneous preterm birth	BRD-K44932450-001-16-8	Launched
hydroxyprogesterone-acetate	progesterone receptor agonist	PGR			BRD-K92902018-001-01-9	Launched
hydroxypropyl-beta-cyclodextrin					BRD-A01412266-001-01-0, BRD-A01412266-001-01-0, BRD-A01412266-001-01-0	Phase 2/Phase 3
hydroxysafflor-yellow-A	antitumor agent				BRD-K00003327-001-01-9	Preclinical
hydroxystilbamidine					BRD-K62186992-334-02-8	Launched
hydroxytacrine-maleate-(R,S)	cholinesterase inhibitor	ACHE			BRD-K01825165-001-02-9	Preclinical
hydroxytoluic-acid					BRD-K75608666-001-09-9, BRD-K75608666-001-09-9, BRD-K75608666-001-08-3	Preclinical
hydroxyurea	ribonucleotide reductase inhibitor	RRM1, RRM2, RRM2B	hematologic malignancy, oncology	chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)	BRD-K51747290-001-12-3, BRD-K51747290-001-15-6, BRD-K51747290-001-15-6, BRD-K51747290-001-15-6, BRD-K51747290-001-15-6, BRD-K51747290-001-13-1	Launched
hydroxyzine	antihistamine	HRH1	neurology/psychiatry, allergy, dermatology	anxiety, urticaria, itching, dermatosis	BRD-K01826510-300-06-9, BRD-K01826510-300-06-9	Launched
hygromycin-B	polypeptide synthesis inhibitor				BRD-A24252652-001-02-9	Preclinical
hymecromone	monoamine oxidase inhibitor	MAOA, MAOB			BRD-K46424862-001-15-8, BRD-K46424862-001-16-9, BRD-K46424862-001-14-1, BRD-K46424862-001-14-1	Phase 2
hypericin	tyrosine kinase inhibitor				BRD-K29673530-001-06-9, BRD-K29673530-001-06-9, BRD-K29673530-001-05-4, BRD-K29673530-001-05-4	Phase 3
hyperin	aldose reductase inhibitor	ACE, AKR1B1			BRD-A63780829-001-11-4, BRD-A63780829-001-11-4, BRD-A63780829-001-11-4, BRD-A63780829-001-11-4	Preclinical
hypoestoxide	IKK inhibitor	IKBKB, IL1B, TNF			BRD-K13881745-001-01-1	Phase 1
hypoxanthine	PARP inhibitor	PNP			BRD-K03739921-001-06-8, BRD-K03739921-001-06-8	Preclinical
H2L-5765834	lysophosphatidic acid receptor antagonist	LPAR1, LPAR3			BRD-K26439554-001-02-9, BRD-K26439554-001-01-3, BRD-K26439554-001-01-3	Preclinical
I-BET-762	bromodomain inhibitor	BRD2, BRD3, BRD4			BRD-K08109215-001-06-4, BRD-K08109215-001-06-4, BRD-K08109215-001-06-4, BRD-K08109215-001-05-6, BRD-K08109215-001-05-6, BRD-K08109215-001-05-6, BRD-K08109215-001-05-6	Phase 2
I-BET151	bromodomain inhibitor	BRD2, BRD3, BRD4			BRD-K36363294-300-01-4, BRD-K36363294-001-04-2, BRD-K36363294-001-04-2, BRD-K36363294-001-04-2, BRD-K36363294-001-04-2, BRD-K36363294-001-04-2	Preclinical
I-BRD9	bromodomain inhibitor	BRD9			BRD-K04972057-001-02-9, BRD-K04972057-001-01-1, BRD-K04972057-001-01-1, BRD-K04972057-001-01-1, BRD-K04972057-001-01-1, BRD-K04972057-001-01-1	Preclinical
I-BZA					BRD-K14762862-001-01-9, BRD-K14762862-001-01-9	Phase 2
I-BZA2					BRD-K71698503-003-02-9, BRD-K71698503-003-01-6	Phase 3
I-CBP-112	bromodomain inhibitor	CREBBP, EP300			BRD-K57090026-001-04-9, BRD-K57090026-001-02-4	Preclinical
IACS-10759	mitochondrial complex I inhibitor				BRD-K00003105-003-01-9	Preclinical
IB-MECA	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K31135544-001-08-9, BRD-K31135544-001-07-0, BRD-K31135544-001-07-0	Phase 3
ibandronate	bone resorption inhibitor	FDPS	orthopedics	osteoporosis	BRD-K08681769-323-04-5, BRD-K08681769-323-06-9, BRD-K08681769-323-05-2, BRD-K08681769-323-03-7	Launched
IBC-293	hydroxycarboxylic acid receptor agonist	HCAR3			BRD-K15196155-001-02-3, BRD-K15196155-001-03-9	Preclinical
iberdomide	cereblon modulator				BRD-K00003408-001-01-9	Preclinical
ibiglustat	glucosylceramidase inhibitor				BRD-K14063023-001-02-9	Preclinical
IBMX	phosphodiesterase inhibitor	ADORA1, PDE2A, PDE3B, PDE4D, PDE5A, PDE6G, PDE7A, PDE8A, PDE9A			BRD-K94979336-001-20-0, BRD-K94979336-001-20-0, BRD-K94979336-001-20-0, BRD-K94979336-001-23-9	Preclinical
ibotenic-acid	glutamate receptor agonist	GRIN1			BRD-A02971356-001-07-2, BRD-A02971356-001-09-9	Preclinical
ibrolipim	lipoprotein lipase activator	LPL			BRD-K62490786-001-01-1, BRD-K62490786-001-01-1	Phase 2
ibrutinib	Bruton's tyrosine kinase (BTK) inhibitor	BLK, BMX, BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)	BRD-K70301465-001-05-9, BRD-K70301465-001-05-9, BRD-K70301465-001-05-9, BRD-K70301465-001-05-9, BRD-K70301465-001-05-9, BRD-K70301465-001-02-6, BRD-K70301465-001-02-6, BRD-K70301465-001-02-6, BRD-K70301465-001-08-3	Launched
ibudilast	leukotriene receptor antagonist, phosphodiesterase inhibitor	IL1B, IL6, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A	pulmonary, neurology/psychiatry	asthma, stroke	BRD-K16444452-001-11-7, BRD-K16444452-001-12-9, BRD-K16444452-001-12-9, BRD-K16444452-001-09-1	Launched
ibuprofen	cyclooxygenase inhibitor		neurology/psychiatry, rheumatology, otolaryngology, obstetrics/gynecology, endocrinology, dental	headache, muscle pain, rheumatoid arthritis, backache, common cold, menstrual pain, fever, toothache	BRD-A17655518-001-24-4, BRD-A17655518-001-23-6	Launched
ibuprofen-(S)	cyclooxygenase inhibitor	ASIC1, PTGS1, PTGS2, SLC5A8	neurology/psychiatry	pain relief	BRD-K14965640-001-13-2, BRD-K14965640-001-12-4, BRD-K14965640-001-14-9	Launched
ibuprofen-lysine	cyclooxygenase inhibitor		cardiology	patent ductus arteriosus (PDA)	BRD-M64062803-001-03-9, BRD-M64062803-001-03-9, BRD-M64062803-001-02-1, BRD-M64062803-001-04-7	Launched
ibuprofen-piconol	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-A75224450-001-02-4, BRD-A75224450-001-02-4, BRD-A75224450-001-01-6	Launched
ibuproxam	cyclooxygenase inhibitor, prostaglandin inhibitor	ALOX5	endocrinology, rheumatology, neurology/psychiatry	fever, joint inflammation, pain relief	BRD-A40940854-001-01-1	Launched
ibutamoren	growth hormone secretagogue receptor agonist	GHR, GHSR			BRD-K44771174-066-03-9, BRD-K44771174-066-02-8, BRD-K44771174-066-01-0	Phase 2
ICA-069673	voltage-gated potassium channel activator	KCNQ2, KCNQ3			BRD-K59839632-001-01-0, BRD-K59839632-001-02-9, BRD-K59839632-001-02-9	Preclinical
ICA-110381	voltage-gated potassium channel activator	KCNQ2			BRD-K71686520-001-02-9, BRD-K71686520-001-02-9, BRD-K71686520-001-01-4	Preclinical
ICA-121431	sodium channel blocker	SCN1A, SCN3A			BRD-K03149601-001-02-6, BRD-K03149601-001-01-8, BRD-K03149601-001-01-8, BRD-K03149601-001-01-8	Preclinical
icaritin	PPAR receptor antagonist	PDE5A			BRD-K24476327-001-02-1, BRD-K24476327-001-01-3, BRD-K24476327-001-03-9	Phase 3
icatibant-acetate	bradykinin receptor antagonist	BDKRB2	cardiology	angioedema	BRD-K63772874-001-03-0, BRD-K63772874-001-03-0, BRD-K63772874-001-02-2, BRD-K63772874-001-01-4	Launched
ICG-001	beta-catenin inhibitor	CTNNB1			BRD-K73261812-001-05-9	Preclinical
ICI-118,551	adrenergic receptor antagonist	ADRB2, ADRB3			BRD-K74603273-003-02-9, BRD-K74603273-003-02-9, BRD-K74603273-003-01-1	Phase 2
ICI-162846	histamine receptor antagonist	HRH2			BRD-K66782112-001-03-9, BRD-K66782112-001-02-0	Phase 1
ICI-169369	serotonin receptor antagonist				BRD-K00004569-001-01-9	Phase 2
ICI-185,282	thromboxane receptor antagonist				BRD-K29133151-001-03-2, BRD-K29133151-001-03-2, BRD-K29133151-001-03-2	Phase 1
ICI-192605	thromboxane receptor antagonist	TBXA2R			BRD-K59433843-001-02-5, BRD-K59433843-001-03-9, BRD-K59433843-001-01-7	Phase 2
ICI-199441	opioid receptor agonist	CYP2D6, OPRD1, OPRK1, OPRM1, UTS2R			BRD-K73290745-003-03-4, BRD-K73290745-003-04-9, BRD-K73290745-003-02-6	Preclinical
ICI-215,001	adrenergic receptor agonist	ADRB3			BRD-K52487250-003-01-2	Preclinical
ICI-63197	phosphodiesterase inhibitor				BRD-K52219182-001-03-2, BRD-K52219182-001-04-9, BRD-K52219182-001-02-4, BRD-K52219182-001-02-4	Preclinical
ICI-89406	adrenergic receptor antagonist	ADRB1, ADRB2			BRD-A03359064-001-02-3, BRD-A03359064-001-03-9	Phase 1
icilin	TRPV agonist	TRPA1, TRPM8			BRD-K48869804-001-09-6	Phase 1
iclaprim	dihydrofolate reductase inhibitor				BRD-K00003415-001-01-9	Phase 3
icomucret	mucin production enhancer	LTB4R2			BRD-K41234004-001-03-1	Phase 3
icosapent	platelet aggregation inhibitor	ACSL3, ACSL4, FADS1, FFAR1, PPARD, PPARG, PTGS1, PTGS2, SLC8A1, TRPV1	endocrinology	hypertriglyceridemia	BRD-K47192521-001-05-4, BRD-K47192521-001-05-4, BRD-K47192521-001-06-2, BRD-K47192521-001-06-2	Launched
icotinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	BRD-K31698212-001-03-9, BRD-K31698212-001-02-9, BRD-K31698212-001-02-9, BRD-K31698212-001-02-9	Launched
iCRT-14	beta catenin inhibitor, WNT signaling inhibitor	CTNNB1, TCF4			BRD-K18634484-001-01-4, BRD-K18634484-001-02-9	Preclinical
IC261	casein kinase inhibitor	CSNK1A1, CSNK1D, CSNK1E, CSNK1G2			BRD-K09638361-001-02-2, BRD-K09638361-001-03-0	Preclinical
ID-1101	insulin sensitizer	INS			BRD-K90305467-001-01-3, BRD-K90305467-001-01-3	Phase 1
ID-8					BRD-K39166528-001-02-8, BRD-K39166528-001-02-8, BRD-K39166528-001-01-0, BRD-K39166528-001-01-0, BRD-K39166528-001-01-0, BRD-K39166528-001-01-0, BRD-K39166528-001-03-9	Preclinical
idalopirdine	serotonin receptor antagonist	HTR6			BRD-K79102359-003-01-6, BRD-K79102359-003-01-6, BRD-K79102359-003-01-6, BRD-K79102359-003-01-6, BRD-K79102359-003-02-9	Phase 3
idasanutlin	MDM inhibitor	MDM2, TP53			BRD-K62627508-001-01-5, BRD-K62627508-001-01-5, BRD-K62627508-001-01-5, BRD-K62627508-001-01-5, BRD-K62627508-001-01-5, BRD-K62627508-001-01-5, BRD-K62627508-001-06-9, BRD-K62627508-001-06-9	Phase 3
idazoxan	adrenergic receptor antagonist	ADRA2A, PTGS2			BRD-A18696154-001-02-2, BRD-A18696154-003-22-6, BRD-A18696154-003-21-8	Phase 3
idebenone	calcium channel modulator		neurology/psychiatry, ophthalmology	Alzheimer's disease, Friedreich's ataxia, Leber hereditary optic neuropathy (LHON)	BRD-K37516142-001-10-5, BRD-K37516142-001-10-5, BRD-K37516142-001-11-3, BRD-K37516142-001-13-9, BRD-K37516142-001-13-9, BRD-K37516142-001-13-9, BRD-K37516142-001-09-7	Launched
idelalisib	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	BRD-K60866521-001-07-1, BRD-K60866521-001-07-1, BRD-K60866521-001-04-8, BRD-K60866521-001-04-8	Launched
IDF-11774	hypoxia inducible factor inhibitor				BRD-K00003098-001-01-9	Preclinical
IDH-305	isocitrate dehydrogenase inhibitor				BRD-K00003457-001-01-9	Phase 2
IDO5L	indoleamine 2,3-dioxygenase inhibitor	IDO1			BRD-K22356203-001-01-8, BRD-K22356203-001-01-8, BRD-K22356203-001-02-9	Preclinical
IDRA-21	glutamate receptor positive allosteric modulator	GRIA1, GRIA2, GRIA3, GRIA4			BRD-A14344385-001-04-0, BRD-A14344385-001-04-0, BRD-A14344385-001-04-0, BRD-A14344385-001-05-9, BRD-A14344385-001-03-2	Preclinical
idramantone					BRD-K00003671-001-01-9	Preclinical
idronoxil	XIAP inhibitor	ENOX2, SPHK1			BRD-K74671368-001-01-8, BRD-K74671368-001-01-8, BRD-K74671368-001-01-8	Phase 3
IEM1460	glutamate receptor antagonist	GRIA2			BRD-K13829090-303-03-7, BRD-K13829090-303-04-9, BRD-K13829090-303-04-9, BRD-K13829090-303-04-9, BRD-K13829090-303-02-9	Preclinical
IEM1754	glutamate receptor antagonist	GRIA1			BRD-K80060353-303-03-9, BRD-K80060353-303-02-1, BRD-K80060353-303-04-9, BRD-K80060353-303-04-9	Preclinical
ifenprodil	adrenergic receptor antagonist, glutamate receptor antagonist	GRIN2B			BRD-K00004210-045-01-9	Launched
ifosfamide	DNA alkylating agent	CYP2A6, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP3A4, CYP3A5, CYP3A7, PTGS1	oncology, urology	testicular carcinoma, hemorrhagic cystitis	BRD-A67097164-001-18-7, BRD-A67097164-001-17-9	Launched
igmesine	sigma receptor agonist	SIGMAR1			BRD-A48376327-003-01-5, BRD-A48376327-003-01-5	Phase 2
iguratimod	cyclooxygenase inhibitor, NFkB pathway inhibitor	PTGS2	rheumatology	rheumatoid arthritis	BRD-K15426076-001-01-2, BRD-K15426076-001-02-9	Launched
IKK-16	IKK inhibitor	IKBKB			BRD-K14618467-003-02-6, BRD-K14618467-003-02-6, BRD-K14618467-003-02-6, BRD-K14618467-003-02-6, BRD-K14618467-003-02-6, BRD-K14618467-003-07-9, BRD-K14618467-003-03-4, BRD-K14618467-001-04-6	Preclinical
IKK-2-inhibitor	IKK inhibitor, SYK inhibitor	IKBKB			BRD-K26373640-001-06-9, BRD-K26373640-001-05-1, BRD-K26373640-001-07-7, BRD-K26373640-001-07-7	Preclinical
IKK-2-inhibitor-V	IKK inhibitor, NFkB pathway inhibitor	IKBKB			BRD-K74305673-001-07-0, BRD-K74305673-001-06-2, BRD-K74305673-001-06-2, BRD-K74305673-001-06-2, BRD-K74305673-001-06-2	Phase 1
ilaprazole	proton pump inhibitor		gastroenterology	gastroesophageal reflux disease (GERD)	BRD-K00003427-001-01-9	Launched
ilepcimide	anticonvulsant				BRD-K60480335-001-09-9	Phase 3
ilomastat	matrix metalloprotease inhibitor	ACAN, ADAM28, MMP1, MMP12, MMP13, MMP14, MMP2, MMP3, MMP8, MMP9			BRD-K51662849-001-05-4, BRD-K51662849-001-05-4, BRD-K51662849-001-05-4, BRD-K51662849-001-08-8, BRD-K51662849-001-08-8, BRD-K51662849-001-08-8, BRD-K51662849-001-08-8	Phase 3
iloperidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR6, HTR7	neurology/psychiatry	schizophrenia	BRD-K48722833-001-07-6	Launched
iloprost	platelet aggregation inhibitor, prostanoid receptor agonist	PTGDR, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, TBXA2R	pulmonary	pulmonary arterial hypertension (PAH)	BRD-A45664787-001-04-8	Launched
imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)	BRD-K92723993-001-12-5, BRD-K92723993-001-12-5, BRD-K92723993-001-12-5, BRD-K92723993-001-12-5, BRD-K92723993-001-12-5, BRD-K92723993-001-12-5, BRD-K92723993-001-06-7, BRD-K92723993-001-06-7, BRD-K92723993-066-22-7, BRD-K92723993-001-28-9	Launched
Imazodan	phosphodiesterase inhibitor				BRD-K96298462-001-08-9	Phase 1
imeglimin	gluconeogenesis inhibitor				BRD-K55822903-003-02-6, BRD-K55822903-003-01-8, BRD-K55822903-003-01-8	Phase 2
imetit	histamine receptor agonist	HRH3, HRH4			BRD-K33183200-303-06-9, BRD-K33183200-303-02-4	Preclinical
imexon	apoptosis stimulant, ribonucleotide reductase inhibitor				BRD-A78195072-001-06-2, BRD-A78195072-001-06-2, BRD-A78195072-001-06-2, BRD-A78195072-001-06-2	Phase 2
imidacloprid	acetylcholine receptor antagonist				BRD-K76609936-001-08-4	Launched
imidafenacin	acetylcholine receptor antagonist	CHRM1, CHRM3	neurology/psychiatry	spasms	BRD-K29626940-001-01-5, BRD-K29626940-001-02-3, BRD-K29626940-001-02-3	Launched
imidapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure	BRD-K11466259-003-04-1, BRD-K11466259-003-04-1	Launched
imidazoacridinone	anticancer agent				BRD-K00004617-001-01-9	Preclinical
imidurea	other antibiotic				BRD-K00003682-001-01-9	Preclinical
imiloxan	adrenergic receptor antagonist	ADRA2A, ADRA2B			BRD-A10903566-003-08-9, BRD-A10903566-003-07-7	Phase 1
imipenem	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections, endocarditis	BRD-K23200955-002-01-5, BRD-K23200955-002-02-3	Launched
imipramine	norepinephrine reputake inhibitor, serotonin reuptake inhibitor	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7, KCND2, KCND3, KCNH1, KCNH2, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry, urology	depression, nocturnal enuresis	BRD-K38436528-003-25-3, BRD-K38436528-003-26-1, BRD-K38436528-003-26-1, BRD-K38436528-003-26-1, BRD-K38436528-003-27-9	Launched
imiquimod	interferon inducer, toll-like receptor agonist	TLR7, TLR8	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)	BRD-K26657438-003-01-8, BRD-K26657438-001-17-8, BRD-K26657438-001-17-8, BRD-K26657438-001-15-2, BRD-K26657438-001-15-2	Launched
imirestat	aldose reductase inhibitor				BRD-K00003208-001-01-9	Preclinical
imisopasem-manganese	superoxide dismutase mimetic				BRD-K00003154-001-01-9	Preclinical
immepip	histamine receptor agonist	HRH3, HRH4			BRD-K25906698-303-03-9, BRD-K25906698-303-02-7	Preclinical
immethridine	histamine receptor agonist	HRH3			BRD-K49519092-303-03-0, BRD-K49519092-303-03-0, BRD-K49519092-303-02-2	Phase 1
impentamine	histamine receptor antagonist	HRH3			BRD-K20049318-303-03-9, BRD-K20049318-303-03-9, BRD-K20049318-303-02-1	Preclinical
IMREG-1					BRD-K00926464-001-02-9, BRD-K00926464-001-01-8	Phase 3
inarigivir	antiviral				BRD-K00003532-001-01-9	Phase 2
inarigivir-soproxil	antiviral				BRD-K00004751-001-01-9	Phase 2
INC-280	c-Met inhibitor	MET			BRD-K81016934-001-03-9, BRD-K81016934-001-02-0, BRD-K81016934-001-02-0, BRD-K81016934-001-02-0, BRD-K81016934-001-02-0	Phase 3
INCA-6	calcineurin inhibitor	NFATC1			BRD-K33308633-001-03-2, BRD-K33308633-001-02-4, BRD-K33308633-001-04-9	Preclinical
INCB-003284	CC chemokine receptor antagonist				BRD-K28059174-334-01-2	Phase 2
INCB-057643	bromodomain inhibitor				BRD-K00003102-001-01-9	Phase 1/Phase 2
INCB-3284	CC chemokine receptor antagonist	CCR2			BRD-K67628093-001-01-9, BRD-K67628093-001-01-9	Phase 2
incyclinide	matrix metalloprotease inhibitor				BRD-K00003344-001-01-9	Phase 2
indacaterol	adrenergic receptor agonist	ADRB1, ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	BRD-K89208535-050-02-9, BRD-K89208535-051-01-5	Launched
indalpine	selective serotonin reuptake inhibitor (SSRI)	SLC6A4			BRD-K64973364-001-01-4, BRD-K64973364-001-01-4	Withdrawn
indapamide	thiazide diuretic	CA2, HTR3A, KCNQ1	cardiology	hypertension, congestive heart failure	BRD-A95869247-001-29-9, BRD-A95869247-001-29-9, BRD-A95869247-001-26-9, BRD-A95869247-001-25-1	Launched
indatraline	norepinephrine transporter inhibitor	MAOA, MAOB			BRD-K01649396-003-08-9, BRD-K01649396-003-09-9, BRD-K01649396-003-07-1, BRD-K01649396-003-07-1, BRD-K01649396-003-07-1	Preclinical
indeglitazar	PPAR receptor agonist	NCOA1, PPARA, PPARD, PPARG			BRD-K00003177-001-01-9	Phase 2
indeloxazine	norepinephrine reuptake inhibitor, serotonin reuptake inhibitor				BRD-A59747053-003-01-3	Withdrawn
indibulin	tubulin polymerization inhibitor				BRD-K74057757-001-03-9, BRD-K74057757-001-01-9, BRD-K74057757-001-01-9, BRD-K74057757-001-02-7	Phase 1/Phase 2
indinavir	HIV protease inhibitor	CYP3A4, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K33226500-001-01-0, BRD-K33226500-001-01-0, BRD-K33226500-001-01-0, BRD-K33226500-001-01-0, BRD-K33226500-001-01-0, BRD-K33226500-001-01-0, BRD-K33226500-065-09-8	Launched
indiplon	benzodiazepine receptor agonist	GABRA1			BRD-K90948141-001-02-2, BRD-K90948141-001-01-4, BRD-K90948141-001-01-4, BRD-K90948141-001-01-4, BRD-K90948141-001-03-9	Phase 3
indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK5, GSK3A			BRD-K17894950-001-14-3, BRD-K17894950-001-14-3, BRD-K17894950-001-14-3	Phase 2/Phase 3
indirubin-3-monoxime	CDK inhibitor, glycogen synthase kinase inhibitor	CDK1, CDK2, CDK5, CDK5R1, GSK3B			BRD-K19136521-001-10-9, BRD-K19136521-001-08-9, BRD-K19136521-001-08-9	Preclinical
indisulam	CDK inhibitor	CA1, CA12, CA14, CA2, CA6, CA7, CA9			BRD-K17610631-001-03-3, BRD-K17610631-001-03-3, BRD-K17610631-001-03-3, BRD-K17610631-001-03-3	Phase 2
indium(III)-isopropoxide					BRD-M08274809-001-01-7	Preclinical
indium-tri(2-propanolate)					BRD-K42332878-001-01-9	Preclinical
indobufen	cyclooxygenase inhibitor, platelet aggregation inhibitor	PTGS1, PTGS2	hematology	thrombosis	BRD-A16296925-001-01-3	Launched
indocyanine-green	contrast agent	SLCO1B1	cardiology	vascular imaging agent	BRD-K80762071-236-02-5, BRD-K80762071-236-03-3, BRD-K80762071-236-03-3, BRD-K80762071-236-01-7	Launched
indole-3-carbinol	aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor	AHR			BRD-K01815685-001-15-5, BRD-K01815685-001-15-5	Phase 2/Phase 3
indole-3-pyrubate	melatonin receptor agonist				BRD-K09109825-001-07-3	Phase 2
indomethacin	cyclooxygenase inhibitor	GLO1, PLA2G2A, PPARA, PPARG, PTGDR2, PTGR2, PTGS1, PTGS2, SLC46A1	rheumatology, orthopedics	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, tendinitis	BRD-K57222227-001-29-3, BRD-K57222227-001-30-1, BRD-K57222227-001-30-1, BRD-K57222227-001-28-5	Launched
indoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	CXCR1, CXCR2, PTGS1, PTGS2			BRD-A44090213-001-25-6, BRD-A44090213-001-25-6, BRD-A44090213-001-25-6, BRD-A44090213-001-25-6, BRD-A44090213-001-27-9	Withdrawn
indoramin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2B, ADRA2C	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	BRD-K76953762-001-09-9, BRD-K76953762-001-09-9, BRD-K76953762-001-08-5	Launched
indoximod	indoleamine 2,3-dioxygenase inhibitor	IDO1			BRD-K93255255-001-02-1, BRD-K93255255-001-02-1, BRD-K93255255-001-02-1, BRD-K93255255-001-03-9	Phase 2
ingenol	PKC activator	PRKCD, PRKCE	dermatology	keratosis	BRD-K00003329-001-01-9	Launched
ingenol-mebutate	PKC activator	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG	dermatology	actinic keratosis (AK)	BRD-K93779381-001-02-9, BRD-K93779381-001-02-9, BRD-K93779381-001-01-9, BRD-K93779381-001-01-9, BRD-K93779381-001-01-9, BRD-K93779381-001-01-9	Launched
INH1	Hec1 inhibitor	NDC80			BRD-K70177501-003-01-4, BRD-K70177501-003-01-4, BRD-K70177501-003-01-4, BRD-K70177501-003-02-9	Preclinical
inimur	other antifungal				BRD-A71407503-001-02-6, BRD-A71407503-001-01-8	Launched
iniparib	PARP inhibitor	PARP1			BRD-K11153516-001-05-5, BRD-K11153516-001-05-5, BRD-K11153516-001-05-5	Phase 3
inositol	insulin sensitizer	CDIPT	obstetrics/gynecology	polycystic ovary syndrom (PCOS)	BRD-K52618540-001-10-9, BRD-K52618540-001-09-9	Launched
inositol-hexanicotinate			dermatology, cardiology, rheumatology, neurology/psychiatry	statis dermatitis, claudication, Raynaud's disease, hypertension, insomnia, atherosclerosis, restless leg syndrome, schizophrenia, psoriasis, acne vulgaris (AV)	BRD-K82800842-001-02-9, BRD-K82800842-001-02-9, BRD-K82800842-001-01-9	Launched
INS316	purinergic receptor antagonist				BRD-A29125379-314-01-7	Phase 2
INT-747	FXR agonist				BRD-K30968378-001-02-9, BRD-K30968378-001-01-9	Phase 3
INT-767	FXR agonist	GPBAR1			BRD-K33067152-236-01-1, BRD-K33067152-236-01-1	Phase 1
integrin-antagonist-1	integrin antagonist	ITGAV, ITGB6			BRD-K88165431-003-01-4, BRD-K88165431-003-01-4	Phase 1
INX-08189	antiviral				BRD-K00004752-001-01-9	Phase 2
iobenguane	antineoplastic agent		oncology, cardiology, endocrinology	neuroblastoma, congestive heart failure, pheochromocytoma	BRD-K43860855-065-10-1, BRD-K43860855-065-10-1, BRD-K43860855-065-11-9	Launched
iocetamic-acid	radiopaque medium		radiology	contrast agent	BRD-A37492983-001-10-3	Launched
iodipamide	radiopaque medium	ALB	radiology	contrast agent	BRD-K67261995-001-12-9, BRD-K67261995-001-11-7	Launched
iodixanol	radiopaque medium		radiology	contrast agent	BRD-A08660406-001-06-7, BRD-A08660406-001-05-9, BRD-A08660406-001-07-9	Launched
iodoantipyrine					BRD-K69216798-001-01-9	Preclinical
iododexetimide	acetylcholine receptor antagonist				BRD-A46813902-001-02-9, BRD-A46813902-001-01-6	Phase 2
iodophenpropit	histamine receptor antagonist	HRH3, HRH4			BRD-K51918615-303-02-9	Preclinical
iodoquinol	antiseptic		infectious disease	amebiasis	BRD-K75855670-001-15-9, BRD-K75855670-001-15-9, BRD-K75855670-001-14-2, BRD-K75855670-001-14-2	Launched
iohexol	radiopaque medium		radiology	contrast agent	BRD-A60217728-001-11-2, BRD-A60217728-001-12-9	Launched
iopamidol	radiopaque medium		radiology	contrast agent	BRD-K75868704-001-06-9, BRD-K75868704-001-05-3	Launched
iopanic-acid	thyroid hormone inhibitor				BRD-A42628519-001-12-4, BRD-A42628519-001-13-9	Withdrawn
iopodic-acid			radiology	contrast agent	BRD-K51956333-001-03-8, BRD-K51956333-001-03-8, BRD-K51956333-003-04-9	Launched
iopromide	radiopaque medium		radiology	contrast agent	BRD-A72075775-001-10-4, BRD-A72075775-001-11-2, BRD-A72075775-001-12-9	Launched
iothalamic-acid-d3	radiopaque medium				BRD-K98250023-001-01-0	Preclinical
ioversol	radiopaque medium		radiology	contrast agent	BRD-A65818372-001-05-3, BRD-A65818372-001-06-9	Launched
IOWH032	CFTR channel antagonist	CFTR			BRD-K84892605-001-02-9, BRD-K84892605-001-01-1, BRD-K84892605-001-01-1, BRD-K84892605-001-01-1	Phase 2
ioxaglic-acid	radiopaque medium		radiology	contrast agent	BRD-K79124250-001-08-9, BRD-K79124250-001-09-9	Launched
ioxilan	radiopaque medium		radiology	angiography	BRD-A09370961-001-02-9, BRD-A09370961-001-02-9, BRD-A09370961-001-01-0	Launched
IOX1	histone demethylase inhibitor	EGLN1, KDM3A, KDM4C, KDM6B			BRD-K70751730-001-11-2, BRD-K70751730-001-10-4	Preclinical
IOX2	hypoxia inducible factor inhibitor	EGLN1, KDM2A, KDM5C			BRD-K98251413-001-07-9, BRD-K98251413-001-06-5, BRD-K98251413-001-06-5, BRD-K98251413-001-04-0, BRD-K98251413-001-04-0	Preclinical
IPA-3	p21 activated kinase inhibitor	PAK1			BRD-K38727704-001-02-4, BRD-K38727704-001-01-6, BRD-K38727704-001-04-9, BRD-K38727704-001-03-2	Preclinical
IPAG					BRD-K82421491-001-04-9, BRD-K82421491-001-02-6, BRD-K82421491-001-02-6, BRD-K82421491-001-02-6	Preclinical
ipidacrine	acetylcholinesterase inhibitor	ACHE			BRD-K66896231-001-08-1, BRD-K66896231-001-08-1	Phase 3
IPI549	PI3K inhibitor				BRD-K00003385-001-01-9	Phase 2
ipragliflozin-L-proline	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	BRD-K51247865-001-01-2, BRD-K51247865-001-01-2, BRD-K51247865-001-02-9	Launched
ipratropium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	pulmonary	bronchospasm, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	BRD-K01826778-004-06-9	Launched
ipriflavone	bone resorption inhibitor		orthopedics	osteoporosis	BRD-K93618743-001-22-9, BRD-K93618743-001-21-0, BRD-K93618743-001-20-2	Launched
iproniazid	monoamine oxidase inhibitor	MAOA, MAOB			BRD-K88568253-011-19-9, BRD-K88568253-011-20-9, BRD-K88568253-011-20-9	Withdrawn
ipsapirone	serotonin receptor agonist	HTR1A			BRD-K90574421-001-03-5, BRD-K90574421-001-04-9	Phase 3
irbesartan	angiotensin receptor antagonist	AGTR1, JUN, SLC10A1	cardiology, nephrology	hypertension, diabetic nephropathy	BRD-K60038276-001-09-0, BRD-K60038276-001-09-0, BRD-K60038276-001-12-9, BRD-K60038276-001-12-9, BRD-K60038276-001-08-2	Launched
irganox-1010	antioxidant				BRD-K00004549-001-01-9	Preclinical
iRGD-peptide	integrin signaling activator				BRD-K00003335-001-01-9	Preclinical
IRL-2500	endothelin receptor antagonist	EDNRB			BRD-K98357249-001-03-9, BRD-K98357249-001-02-9	Preclinical
irosustat	steroid sulfatase inhibitor	CA2, STS			BRD-K87777313-001-02-2	Phase 2
irsogladine	phosphodiesterase inhibitor	PDE4A	gastroenterology	peptic ulcer disease (PUD)	BRD-K74195153-050-13-9, BRD-K74195153-050-12-1, BRD-K74195153-050-12-1, BRD-K74195153-050-14-9, BRD-K74195153-001-04-1	Launched
isavuconazole	cytochrome P450 inhibitor	CYP3A4			BRD-A17009129-001-01-3	Phase 3
isaxonine	nerve growth factor agonist				BRD-K95957366-001-02-6, BRD-K95957366-001-03-9	Withdrawn
isbufylline	phosphodiesterase inhibitor				BRD-K06762493-001-10-9, BRD-K06762493-001-08-1, BRD-K06762493-001-08-1	Phase 2
isepamicin	protein synthesis inhibitor		infectious disease	pneumonia, peritonitis	BRD-K74759733-001-01-9, BRD-K74759733-065-01-4	Launched
ISO-1	macrophage migration inhibiting factor inhibitor	MIF			BRD-A94055480-001-01-5, BRD-A94055480-001-02-9	Preclinical
isobutamben	local anesthetic				BRD-K96714749-001-01-0, BRD-K96714749-001-02-9	Preclinical
isobutyramide	gene expression stimulant	HBE1, HBG1			BRD-K54057105-001-01-2	Phase 2
isocarboxazid	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression	BRD-K93332168-001-11-5, BRD-K93332168-001-11-5, BRD-K93332168-001-11-5, BRD-K93332168-001-10-7, BRD-K93332168-001-10-7	Launched
isoconazole	fungal lanosterol demethylase inhibitor	CYP17A1	infectious disease	gram-positive bacterial infections	BRD-K01825590-008-03-9, BRD-K01825590-008-02-9	Launched
isodibut	aldehyde reductase inhibitor				BRD-K60241851-001-11-9, BRD-K60241851-001-11-9, BRD-K60241851-001-10-1	Phase 2
isoetharine	adrenergic receptor agonist		pulmonary	bronchospasm, asthma	BRD-A24587114-066-21-7, BRD-A24587114-066-22-5, BRD-A24587114-066-24-1, BRD-A24587114-066-23-3	Launched
isofloxythepin	dopamine receptor antagonist				BRD-A07704283-001-01-3, BRD-A07704283-001-01-3, BRD-A07704283-001-01-3	Phase 2
isoflupredone-acetate		NR3C1			BRD-K29173907-001-09-2, BRD-K29173907-001-09-2, BRD-K29173907-001-10-9	Preclinical
isoflurane	inhaled anaesthetic	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9	neurology/psychiatry	general anaesthetic	BRD-A31564021-001-02-6, BRD-A31564021-001-01-8	Launched
isoflurophate	cholinesterase inhibitor	ACHE, BCHE	ophthalmology	glaucoma	BRD-K56575995-001-03-0, BRD-K56575995-001-03-0, BRD-K56575995-001-02-2	Launched
isoguvacine	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			BRD-K66480997-003-10-0, BRD-K66480997-003-10-0, BRD-K66480997-003-11-9	Preclinical
isoleucine					BRD-A02232681-001-01-8	Launched
isoliquiritigenin	guanylate cyclase activator	GABBR1			BRD-K33583600-001-16-1, BRD-K33583600-001-16-1	Preclinical
isoniazid	FABI inhibitor	CYP1A2, CYP2C19, CYP2C8, CYP2E1, CYP3A4	infectious disease	tuberculosis	BRD-K87202646-001-39-9, BRD-K87202646-061-05-6, BRD-K87202646-001-32-6, BRD-K87202646-001-33-4, BRD-K87202646-061-04-9	Launched
isopentyl-4-methoxycinnamate			dermatology	sunscreen lotion	BRD-K37851352-001-01-0, BRD-K37851352-001-02-9	Launched
isoprenaline	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3	cardiology, pulmonary	bradycardia, heart block, asthma	BRD-A04322457-003-18-7, BRD-A04322457-003-18-7, BRD-A04322457-003-15-3, BRD-A04322457-003-17-9, BRD-A04322457-003-16-1	Launched
isopropamide-iodide	acetylcholine receptor antagonist	CHRM3, CHRM4	gastroenterology	peptic ulcer disease (PUD), gastrointestinal acidosis	BRD-K14127446-005-23-9, BRD-K14127446-005-23-9, BRD-K14127446-005-22-7, BRD-K14127446-005-22-7, BRD-K14127446-005-22-7	Launched
isopropyl-myristate			dermatology	cosmetic	BRD-K13409143-001-02-7, BRD-K13409143-001-01-9, BRD-K13409143-001-01-9	Launched
isopropyl-palmitate	cosmetic moisturizer		dermatology	cosmetic	BRD-K30758549-001-02-6, BRD-K30758549-001-01-8	Launched
isoquercitrin	antioxidant				BRD-K73991644-001-07-9	Phase 2/Phase 3
Isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,					BRD-K01826521-001-11-9, BRD-K01826521-003-10-9	Preclinical
isosorbide-dinitrate	nitric oxide stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, NPR1	cardiology	angina pectoris, coronary artery disease (CAD)	BRD-K55853390-001-13-2, BRD-K55853390-001-12-4, BRD-K55853390-001-12-4	Launched
isosorbide-mononitrate	nitric oxide stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	angina pectoris, coronary artery disease (CAD)	BRD-K82225283-001-03-1, BRD-K82225283-001-04-9, BRD-K82225283-001-04-9	Launched
isosteviol					BRD-A96529864-001-01-3	Phase 2
isotiquimide					BRD-A02933148-001-01-8, BRD-A02933148-001-01-8	Phase 1
isovaleramide	alcohol dehydrogenase inhibitor				BRD-K90069354-001-04-5, BRD-K90069354-001-01-1, BRD-K90069354-001-02-9, BRD-K90069354-001-03-7, BRD-K90069354-001-03-7	Phase 2
isoxepac	anti-inflammatory agent				BRD-K92116564-001-01-4	Phase 2
isoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-A75552914-001-16-8, BRD-A75552914-001-15-0, BRD-A75552914-001-17-6	Withdrawn
isoxsuprine	adrenergic receptor agonist	ADRB2	rheumatology, cardiology	Raynaud's disease, arteriosclerosis, Buerger's disease	BRD-K00003690-003-01-9, BRD-K00003690-003-01-9	Launched
ispinesib	kinesin inhibitor	KIF11			BRD-K64881305-001-06-0, BRD-K64881305-001-05-2, BRD-K64881305-001-05-2, BRD-K64881305-001-05-2, BRD-K64881305-001-05-2, BRD-K64881305-001-03-7, BRD-K64881305-001-03-7, BRD-K64881305-001-03-7	Phase 2
isradipine	calcium channel blocker	CACNA1D, CACNA1F, CACNA2D1	cardiology	hypertension	BRD-A90799790-001-20-7, BRD-A90799790-001-19-9, BRD-A90799790-001-16-5, BRD-A90799790-001-16-5, BRD-A90799790-001-16-5, BRD-A90799790-001-17-3	Launched
ISRIB	eukaryotic translation initiation factor inhibitor, PERK inhibitor	EIF2A, EIF2AK3			BRD-K12826175-001-02-4, BRD-K12826175-001-02-4, BRD-K12826175-001-02-4	Preclinical
istaroxime	ATPase inhibitor	ATP1A1			BRD-K95412502-003-01-5, BRD-K95412502-003-01-5, BRD-K95412502-003-01-5, BRD-K95412502-003-01-5, BRD-K95412502-003-02-9	Phase 2
istradefylline	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3	neurology/psychiatry	Parkinson's Disease, dyskinesia	BRD-K87774949-001-05-4, BRD-K87774949-001-07-0, BRD-K87774949-001-06-2, BRD-K87774949-001-03-9, BRD-K87774949-001-03-9, BRD-K87774949-001-04-7, BRD-K87774949-001-04-7	Launched
ISX-9	neural stem cell inducer	NEUROD1			BRD-K53903639-001-04-7, BRD-K53903639-001-01-3, BRD-K53903639-001-01-3, BRD-K53903639-001-01-3, BRD-K53903639-001-01-3, BRD-K53903639-001-01-3	Preclinical
itacitinib	JAK inhibitor	JAK1			BRD-K67482377-001-01-8, BRD-K67482377-001-01-8	Phase 3
ITD-1	TGF beta receptor inhibitor	TGFBR2			BRD-A56690687-001-02-9, BRD-A56690687-001-01-6	Preclinical
ITE	aryl hydrocarbon receptor agonist	AHR			BRD-K60298136-001-03-3, BRD-K60298136-001-04-1, BRD-K60298136-001-04-1	Preclinical
ITI214	phosphodiesterase inhibitor	PDE1A			BRD-K77987496-011-01-9, BRD-K77987496-011-01-9, BRD-K77987496-011-01-9	Phase 1/Phase 2
itopride	dopamine receptor antagonist	CHRM3, DRD2	gastroenterology, neurology/psychiatry	dyspepsia, gastroparesis, heartburn, nausea, vomiting, anorexia	BRD-K96740444-003-09-9, BRD-K96740444-003-09-9, BRD-K96740444-001-02-1, BRD-K96740444-001-02-1, BRD-K96740444-001-02-1	Launched
itraconazole	cytochrome P450 inhibitor		infectious disease	onychomycosis, histoplasmosis, blastomycosis, aspergillosis	BRD-K00004318-001-01-9	Launched
ITX3	GEF inhibitor	TRIO			BRD-K36515744-001-03-5, BRD-K36515744-001-02-7	Preclinical
ITX5061	SR-BI inhibitor				BRD-K76911699-003-03-9	Phase 1
IT1t	CC chemokine receptor antagonist	CXCR4			BRD-K73499906-300-02-9, BRD-K73499906-300-01-0	Preclinical
IU1	ubiquitin C-terminal hydrolase inhibitor	USP14			BRD-K45841694-001-12-5, BRD-K45841694-001-11-7, BRD-K45841694-001-10-9	Preclinical
ivabradine	HCN channel blocker, potassium channel blocker, sodium channel blocker	HCN1, HCN3, HCN4	cardiology	angina pectoris	BRD-K33972682-003-02-9, BRD-K33972682-003-02-9	Launched
ivacaftor	CFTR channel potentiator	CFTR	pulmonary	cystic fibrosis	BRD-K52818472-001-03-9, BRD-K52818472-001-02-2, BRD-K52818472-001-02-2, BRD-K52818472-001-02-2	Launched
ivosidenib	isocitrate dehydrogenase inhibitor	IDH1	hematologic malignancy	acute myeloid leukemia (AML)	BRD-K93073858-001-01-1, BRD-K93073858-001-01-1	Launched
IWP-L6	porcupine inhibitor	PORCN			BRD-K53234107-001-02-9, BRD-K53234107-001-01-6, BRD-K53234107-001-01-6	Preclinical
ixabepilone	microtubule stabilizing agent	TUBB	oncology	breast cancer	BRD-K03601870-001-02-9, BRD-K03601870-001-01-2, BRD-K03601870-001-01-2	Launched
ixazomib	proteasome inhibitor		hematologic malignancy	multiple myeloma	BRD-K78659596-001-11-9, BRD-K78659596-001-11-9, BRD-K78659596-001-11-9, BRD-K78659596-001-03-9, BRD-K78659596-001-03-9, BRD-K78659596-001-03-9, BRD-K78659596-001-03-9	Launched
ixazomib-citrate	proteasome inhibitor		hematologic malignancy	multiple myeloma	BRD-A66419424-001-02-4, BRD-A66419424-001-02-4, BRD-A66419424-001-02-4, BRD-A66419424-001-03-2	Launched
JAK3-inhibitor-V	JAK inhibitor	JAK3			BRD-K95676198-001-06-9, BRD-K95676198-001-05-9	Preclinical
JD-5037	cannabinoid receptor antagonist				BRD-K00003271-001-01-9	Preclinical
JDTic	opioid receptor antagonist	OPRK1			BRD-K95837862-300-03-9, BRD-K95837862-300-01-7	Phase 1
JHW-007	dopamine reuptake inhibitor	SLC6A3			BRD-K32892871-003-01-7, BRD-K32892871-003-02-9	Preclinical
JI-101	kinase inhibitor				BRD-K00003209-001-01-9	Phase 1/Phase 2
JIB04	histone lysine demethylase inhibitor	KDM4E			BRD-K76180386-001-04-9, BRD-K76180386-001-03-2, BRD-K76180386-001-01-6, BRD-K76180386-001-01-6, BRD-K76180386-001-01-6, BRD-K76180386-001-01-6, BRD-K76180386-001-02-4, BRD-K76180386-001-02-4, BRD-K76180386-001-02-4	Preclinical
JK-184	hedgehog pathway inhibitor				BRD-K38860038-001-03-8, BRD-K38860038-001-02-0, BRD-K38860038-001-01-2, BRD-K38860038-001-01-2, BRD-K38860038-001-01-2, BRD-K38860038-001-01-2	Preclinical
JLK-6	gamma secretase inhibitor	PSEN1			BRD-K22010301-001-04-6	Preclinical
JNJ-10191584	histamine receptor antagonist	HRH4			BRD-K15086322-050-02-1, BRD-K15086322-050-01-3, BRD-K15086322-050-03-9, BRD-K15086322-050-03-9	Preclinical
JNJ-10397049	orexin receptor antagonist	HCRTR1, HCRTR2			BRD-K61721596-001-02-8, BRD-K61721596-001-01-0	Preclinical
JNJ-16259685	glutamate receptor antagonist	GRM1			BRD-K25596805-001-02-6, BRD-K25596805-001-01-8, BRD-K25596805-001-03-9	Preclinical
JNJ-1661010	FAAH inhibitor	FAAH			BRD-K47376733-001-09-9, BRD-K47376733-001-08-1, BRD-K47376733-001-08-1, BRD-K47376733-001-10-9	Preclinical
JNJ-17203212	TRPV antagonist	TRPV1			BRD-K51770398-001-02-7, BRD-K51770398-001-01-9, BRD-K51770398-001-01-9, BRD-K51770398-001-03-9	Preclinical
JNJ-26481585	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, MDM2			BRD-K83837640-001-04-8, BRD-K83837640-001-04-8, BRD-K83837640-001-04-8, BRD-K83837640-001-05-9, BRD-K83837640-001-05-9	Phase 2
JNJ-26990990	anticonvulsant				BRD-K24864897-001-01-0	Phase 2
JNJ-27141491	CC chemokine receptor antagonist	CCR2			BRD-K41895652-001-02-9, BRD-K41895652-001-01-8	Preclinical
JNJ-37822681	dopamine receptor antagonist	DRD2			BRD-K31802667-001-01-9, BRD-K31802667-001-01-9	Phase 2
JNJ-38877605	tyrosine kinase inhibitor	MET			BRD-K02123250-001-06-7	Phase 1
JNJ-38877618	c-Met inhibitor				BRD-K00003094-001-01-9	Phase 1
JNJ-39758979	histamine receptor antagonist				BRD-K00003403-001-01-9	Phase 2
JNJ-40411813	glutamate receptor positive allosteric modulator	GRM2			BRD-K55029398-001-01-6	Phase 2
JNJ-42041935	hypoxia inducible factor prolyl hydroxylase inhibitor	PDK2			BRD-K01036220-001-01-0, BRD-K01036220-001-01-0	Preclinical
JNJ-42165279	FAAH inhibitor	FAAH			BRD-K70330032-001-01-1, BRD-K70330032-001-01-1	Phase 2
JNJ-47965567	purinergic receptor antagonist	P2RX7			BRD-K83547600-001-01-7, BRD-K83547600-001-02-9	Preclinical
JNJ-54175446	purinergic receptor antagonist				BRD-K00004575-001-01-9	Phase 1
JNJ-63533054	G protein-coupled receptor agonist	GPR139			BRD-K19482962-001-02-9, BRD-K19482962-001-01-8, BRD-K19482962-001-01-8	Preclinical
JNJ-64619178	protein arginine N-methyltransferase inhibitor				BRD-K30421675-001-04-9	Phase 1
JNJ-678	RSV fusion inhibitor				BRD-K00004600-001-01-9	Phase 1
JNJ-7706621	CDK inhibitor	AURKA, AURKB, CDK1, CDK2			BRD-K11636097-001-03-1, BRD-K11636097-001-03-1, BRD-K11636097-001-03-1, BRD-K11636097-001-03-1, BRD-K11636097-001-03-1, BRD-K11636097-001-04-9, BRD-K11636097-001-04-9, BRD-K11636097-001-04-9	Preclinical
JNJ-7777120	histamine receptor antagonist	HRH4			BRD-K17774839-001-03-7, BRD-K17774839-001-02-9, BRD-K17774839-001-07-9, BRD-K17774839-001-07-9	Preclinical
josamycin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	BRD-K00003705-001-01-9	Launched
JPH203	solute carrier family member inhibitor				BRD-K00003340-300-01-9	Preclinical
JTC-801	opioid receptor antagonist	OPRL1			BRD-K17705806-003-06-9, BRD-K17705806-003-04-4, BRD-K17705806-003-03-6, BRD-K17705806-003-03-6	Phase 2
JTE-013	lysophospholipid receptor antagonist	P2RY10, S1PR2			BRD-K43330982-001-03-1, BRD-K43330982-001-02-3, BRD-K43330982-001-04-9	Preclinical
JTE-607	cytokine production inhibitor	IL10, IL1B, IL6, TNF			BRD-K81405859-300-01-4, BRD-K81405859-300-01-4, BRD-K81405859-300-01-4, BRD-K81405859-300-02-2, BRD-K81405859-300-03-9	Phase 2
JTE-907	cannabinoid receptor inverse agonist	CNR2			BRD-K63150726-001-03-9, BRD-K63150726-001-02-1, BRD-K63150726-001-04-9	Phase 1
JW-55	tankyrase inhibitor	TNKS, TNKS2			BRD-K53328210-001-04-4, BRD-K53328210-001-04-4, BRD-K53328210-001-01-0, BRD-K53328210-001-01-0, BRD-K53328210-001-01-0, BRD-K53328210-001-01-0, BRD-K53328210-001-01-0	Preclinical
JW-642	monoacylglycerol lipase inhibitor	MGLL			BRD-K48424871-001-04-9, BRD-K48424871-001-03-1	Preclinical
JW-67	WNT pathway inhibitor	APC, AXIN1, GSK3B			BRD-K24554037-001-09-9, BRD-K24554037-001-08-3, BRD-K24554037-001-08-3	Preclinical
JW-74	tankyrase inhibitor, WNT signaling inhibitor	TNKS, TNKS2			BRD-K75664313-001-02-6, BRD-K75664313-001-04-9, BRD-K75664313-001-03-4	Preclinical
JX-401	p38 MAPK inhibitor	MAPK14			BRD-K05464208-001-08-1, BRD-K05464208-001-08-1, BRD-K05464208-001-05-7	Preclinical
JZL-184	monoacylglucerol lipase inhibitor	MGLL			BRD-K45446451-001-06-8, BRD-K45446451-001-05-0	Preclinical
JZL-195	FAAH inhibitor, monoacylglycerol lipase inhibitor	FAAH, MGLL			BRD-K38875233-001-04-9, BRD-K38875233-001-03-9	Preclinical
J147	BDNF inducer				BRD-K00004699-001-01-9	Phase 1
K-MAP					BRD-A45906415-001-01-9	Phase 2
K-Ras(G12C)-inhibitor-12	K-Ras inhibitor	KRAS			BRD-K90756851-001-01-1, BRD-K90756851-001-01-1, BRD-K90756851-001-02-9	Preclinical
K-Ras(G12C)-inhibitor-6	K-Ras inhibitor				BRD-K26305185-001-01-3, BRD-K26305185-001-02-1, BRD-K26305185-001-02-1, BRD-K26305185-001-03-9	Preclinical
K-strophanthidin	ATPase inhibitor	ATP1A1			BRD-K84595254-001-15-4, BRD-K84595254-001-15-4	Phase 2
K-247					BRD-A74648924-001-02-3	Phase 1
K-858	kinesin-like spindle protein inhibitor	KIF11			BRD-A67748489-001-10-0, BRD-A67748489-001-10-0	Preclinical
kaempferol	bone resorption inhibitor, estrogen-related receptor inverse agonist	AKR1B1, ALOX15B, ALOX5, AR, CYP1B1, GLO1, HSD17B1, UGT3A1			BRD-K12807006-001-18-5, BRD-K12807006-001-17-7, BRD-K12807006-001-22-9, BRD-K12807006-001-19-3	Preclinical
KAF-156	antimalarial agent				BRD-K00004578-001-01-9	Preclinical
kainic-acid	kainate receptor agonist	GRIA1, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5			BRD-K52459018-001-09-1, BRD-K52459018-001-10-9	Preclinical
kakonein	GABA receptor antagonist, serotonin receptor antagonist				BRD-A07815743-001-01-1, BRD-A07815743-001-01-1	Phase 2
karenitecin	topoisomerase inhibitor	TOP1			BRD-K00003176-001-01-9	Phase 3
kartogenin	chondrocyte differentiation stimulator	FLNA			BRD-K27584835-001-02-9, BRD-K27584835-001-01-6	Preclinical
kasugamycin	bacterial 30S ribosomal subunit inhibitor				BRD-K91644281-311-02-9	Preclinical
KB-R7943	sodium/calcium exchange inhibitor	SLC8A1, TRPC3, TRPC5, TRPC6			BRD-K17743697-066-04-4, BRD-K17743697-066-05-9, BRD-K17743697-066-03-6	Preclinical
KB-SRC-4	SRC inhibitor	SRC			BRD-K88154110-001-02-9, BRD-K88154110-001-02-9, BRD-K88154110-001-01-0	Preclinical
KBG	neprilysin inhibitor	MME			BRD-A00376169-001-01-6, BRD-A00376169-001-01-6	Phase 2
KD-023	ACAT inhibitor	ACACA, ACACB			BRD-K71164191-001-01-0, BRD-K71164191-001-01-0	Phase 2
KD025	rho associated kinase inhibitor	ROCK2			BRD-K88506063-001-01-8, BRD-K88506063-001-01-8, BRD-K88506063-001-01-8, BRD-K88506063-001-01-8, BRD-K88506063-001-02-9, BRD-K88506063-001-02-9	Phase 2
kenpaullone	CDK inhibitor, glycogen synthase kinase inhibitor	CCNB1, CDK1, CDK5, GSK3B			BRD-K37312348-001-17-6, BRD-K37312348-001-15-0, BRD-K37312348-001-15-0	Preclinical
ketanserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, SLC18A1, SLC18A2	cardiology	hypertension	BRD-K49671696-046-01-8, BRD-K49671696-045-09-9, BRD-K49671696-045-09-9, BRD-K49671696-045-08-5, BRD-K49671696-001-05-4	Launched
ketoconazole	sterol demethylase inhibitor	KCNA10	dermatology	seborrheic dermatitis	BRD-K29113274-001-26-7, BRD-K29113274-001-28-3, BRD-K29113274-001-27-5, BRD-K29113274-001-27-5, BRD-K29113274-001-27-5, BRD-K29113274-001-27-5, BRD-K29113274-001-30-9	Launched
ketohexokinase-inhibitor-1	kinase inhibitor				BRD-K00003341-001-01-9	Preclinical
ketoprofen	cyclooxygenase inhibitor	PTGS1, PTGS2, SLC5A8	rheumatology	rheumatoid arthritis, osteoarthritis	BRD-A97739905-001-26-5, BRD-A97739905-001-25-7, BRD-A97739905-001-29-9	Launched
ketorolac	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-K01825750-234-03-9, BRD-K01825750-001-01-9, BRD-K01825750-001-01-9	Launched
ketotifen	histamine receptor agonist, leukotriene receptor antagonist, phosphodiesterase inhibitor	HRH1	neurology/psychiatry	itching	BRD-K28936863-051-32-2, BRD-K28936863-051-32-2, BRD-K28936863-051-33-0, BRD-K28936863-051-31-4	Launched
kevetrin	p53 activator				BRD-K61339991-003-01-8, BRD-K61339991-003-01-8	Phase 1
KF-38789	P selectin inhibitor	SELP			BRD-A54927599-001-17-7, BRD-A54927599-001-16-9, BRD-A54927599-001-18-9	Preclinical
KG-5	RAF inhibitor	BRAF, FLT3, KIT, PDGFRB			BRD-K90747162-001-02-9, BRD-K90747162-001-02-9, BRD-K90747162-001-01-4	Preclinical
KH-CB19	CDC inhibitor	CLK1, CLK3, DYRK1A			BRD-K66430217-001-03-8, BRD-K66430217-001-03-8, BRD-K66430217-001-03-8	Preclinical
khellin	vasodilator				BRD-K80353807-001-24-6, BRD-K80353807-001-25-3	Phase 2
KHK-IN-1	hexokinase inhibitor	KHK			BRD-K84605263-003-01-6, BRD-K84605263-003-01-6, BRD-K84605263-003-01-6, BRD-K84605263-003-01-6, BRD-K84605263-003-01-6	Preclinical
KHS-101	neural stem cell inducer	TACC3			BRD-K78978711-003-03-9, BRD-K78978711-003-01-3, BRD-K78978711-003-01-3	Preclinical
KI-16425	lysophosphatidic acid receptor antagonist	LPAR1, LPAR3			BRD-A25569250-001-03-3	Preclinical
KI-20227	c-Fms inhibitor	CSF1R, KDR, KIT, PDGFRB			BRD-A88787317-001-02-9, BRD-A88787317-001-01-0	Preclinical
KI-8751	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			BRD-K47150025-001-06-1, BRD-K47150025-001-05-3, BRD-K47150025-001-05-3, BRD-K47150025-001-09-5	Preclinical
kifunensine	mannosidase inhibitor	MAN1B1, MAN2A1			BRD-K02898090-001-02-7, BRD-K02898090-001-02-7, BRD-K02898090-001-04-9, BRD-K02898090-001-04-9	Phase 1
kinetin	cell division inducer		dermatology	sunburn	BRD-K65667145-001-14-0, BRD-K65667145-001-14-0	Launched
ki16198	lipoprotein antagonist	LPA			BRD-A94323479-001-02-8, BRD-A94323479-001-02-8, BRD-A94323479-001-03-6	Preclinical
KL-001	proteasome inhibitor	CRY1, CRY2			BRD-A94580299-001-11-9, BRD-A94580299-001-10-4, BRD-A94580299-001-10-4	Preclinical
KM-0118	anticancer agent				BRD-K00005245-001-01-9	Phase 1
KME-4	prostaglandin inhibitor				BRD-K00004747-001-01-9	Preclinical
KML29	monoacylglucerol lipase inhibitor	MGLL			BRD-K46734292-001-03-6	Preclinical
KN-62	calcium/calmodulin dependent protein kinase inhibitor, purinergic receptor antagonist	AKT1, CAMK2A, CHEK1, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, P2RX7, PRKCA, ROCK1, RPS6KB1, SGK1			BRD-A81177136-001-12-7	Preclinical
KN-93	calcium/calmodulin dependent protein kinase inhibitor	CAMK2A			BRD-K93480852-003-01-0, BRD-K93480852-001-06-3, BRD-K93480852-001-05-5	Preclinical
Ko143	BCRP inhibitor	ABCB1, ABCC1			BRD-K64642496-001-04-0, BRD-K64642496-001-03-2, BRD-K64642496-001-03-2	Preclinical
KP-1212					BRD-K46690591-001-01-2	Phase 2
KPT-185	exportin antagonist	XPO1			BRD-K71467466-001-02-3, BRD-K71467466-001-02-3, BRD-K71467466-001-02-3	Preclinical
KPT-276	exportin antagonist	XPO1			BRD-K75352575-001-02-9, BRD-K75352575-001-01-3, BRD-K75352575-001-01-3, BRD-K75352575-001-01-3	Preclinical
KPT-9274	NAMPT inhibitor				BRD-K00004701-001-01-9	Phase 1
KR-33494	cell death inhibitor 				BRD-K00004587-001-01-9	Preclinical
KRCA-0008	ALK inihibitor	ALK			BRD-K40604024-001-02-9, BRD-K40604024-001-01-6	Preclinical
KRN-633	VEGFR inhibitor	FLT1, FLT4, KDR			BRD-K90993449-001-03-9, BRD-K90993449-001-02-7, BRD-K90993449-001-02-7	Preclinical
KS-176	BCRP inhibitor	ABCG2			BRD-K81053848-001-01-0, BRD-K81053848-001-02-9	Preclinical
KT-433	uricosuric agent				BRD-K66437909-001-01-0	Phase 2
KU-0063794	mTOR inhibitor	MTOR			BRD-K67566344-001-08-3, BRD-K67566344-001-07-5, BRD-K67566344-001-07-5	Preclinical
KU-55933	ATM kinase inhibitor	ATM, PRKDC			BRD-K25311561-001-10-7, BRD-K25311561-001-09-9	Preclinical
KU-60019	ATM kinase inhibitor	ATM			BRD-K36016295-001-06-0, BRD-K36016295-001-06-0, BRD-K36016295-001-06-0, BRD-K36016295-001-05-2, BRD-K36016295-001-04-5	Preclinical
kuromanin	ribosyl cyclase inhibitor	CD38			BRD-K51337109-003-01-3	Preclinical
KU14R	imidazoline receptor antagonist				BRD-A38747044-001-03-1, BRD-A38747044-001-03-1, BRD-A38747044-001-04-9, BRD-A38747044-001-02-3, BRD-A38747044-001-02-3	Preclinical
KW-2449	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor	ABL1, AURKA, AURKB, FLT3			BRD-K21718444-001-06-8, BRD-K21718444-001-06-8, BRD-K21718444-001-06-8	Phase 1
KW-2478	HSP inhibitor				BRD-K41213548-001-03-9, BRD-K41213548-001-03-9, BRD-K41213548-001-02-0, BRD-K41213548-001-02-0	Phase 1/Phase 2
KW-3902	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-A95683721-001-03-8, BRD-A95683721-001-03-8, BRD-A95683721-001-01-2	Phase 3
KX2-391	SRC inhibitor, tubulin polymerization inhibitor	SRC			BRD-K29968218-001-03-2, BRD-K29968218-001-02-4, BRD-K29968218-001-02-4, BRD-K29968218-001-02-4	Phase 3
kynurenic-acid	glutamate receptor antagonist	GPR35, GRIN1, GRIN2A, GRIN2B			BRD-K85872723-001-17-5, BRD-K85872723-001-15-9, BRD-K85872723-001-18-9	Phase 1
KY02111	WNT pathway inhibitor	DKK1			BRD-K13302470-001-04-9, BRD-K13302470-001-04-9, BRD-K13302470-001-04-9, BRD-K13302470-001-03-5, BRD-K13302470-001-02-7	Preclinical
K02288	bone morphogenic protein inhibitor	BMP1			BRD-K58568447-001-03-7, BRD-K58568447-001-03-7, BRD-K58568447-001-03-7, BRD-K58568447-001-02-9, BRD-K58568447-001-01-1, BRD-K58568447-001-01-1	Preclinical
K145	sphingosine kinase inhibitor	SPHK2			BRD-K12106308-003-01-9, BRD-K12106308-003-01-9, BRD-K12106308-003-01-9	Preclinical
L-(+)-rhamnose-monohydrate					BRD-K00003714-002-01-9	Preclinical
L-alanine		AARS, AARS2, ABAT, AGXT, AGXT2, GPRC6A, GPT, GPT2, KYNU, NFS1, PHYKPL, SLC1A4, SLC36A1, SLC7A8			BRD-K25125382-001-02-5	Launched
L-arginine	nitric oxide precursor	ARG2, ASL, ASS1, AZIN2, GPRC6A, NOS2, NOS3, SLC7A1, SLC7A3, SLC7A4	cardiology, neurology/psychiatry, urology, obstetrics/gynecology, otolaryngology	congestive heart failure, hypertension, coronary artery disease (CAD), claudication, senile dementia, erectile dysfunction, infertility, common cold	BRD-K06033833-003-03-3, BRD-K06033833-003-03-3	Launched
L-asparagine		ASNS, ASRGL1, NARS, NARS2, SLC1A5, SLC38A3			BRD-K06665116-001-02-6	Phase 3
L-asparagine-N-hydroxy					BRD-K82178523-001-01-6	Preclinical
L-aspartic-acid	metallic radical formation stimulant	ACY1, ACY3, ADSS, ADSSL1, ASNS, ASPA, ASPH, ASRGL1, ASS1, CAD, DARS, DARS2, GOT1, GOT2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, LYZ, PAICS, RNASE1, SLC1A1, SLC25A12, SLC25A13			BRD-K97163964-001-04-1, BRD-K97163964-001-04-1, BRD-K97163964-001-03-3	Launched
L-citrulline	nitric oxide stimulant	ASS1, DDAH1, DDAH2, GPRC6A, NOS1, NOS2, NOS3, OTC, PADI1, PADI2, PADI3, PADI4, PADI6	cardiology, urology	hypertension, erectile dysfunction	BRD-A12237696-001-05-9, BRD-A12237696-001-05-9, BRD-A12237696-001-04-2, BRD-A12237696-001-04-2	Launched
L-cysteine		CARS, CARS2, CBS, CDO-1, CDO1, CSAD, CTH, GCLC, GCLM, GOT1, GSS, MGMT, NFS1, SLC19A3	rheumatology	osteoarthritis, rheumatoid arthritis	BRD-K00795468-001-02-1	Launched
L-cysteinesulfinic-acid	glutamate receptor agonist	GRM1, GRM5, GSR, HMGCS2, PAPOLA, PRDX2			BRD-A25800195-001-02-2, BRD-A25800195-001-03-9	Preclinical
L-cystine		CTNS, SLC3A1, SLC7A11, SLC7A9			BRD-K99679910-001-02-3	Launched
L-ergothioneine	free radical scavenger				BRD-K26341917-001-01-3	Phase 3
L-glutamine		CTPS1, GLUL, GPRC6A, PPAT	gastroenterology, dental, neurology/psychiatry, rheumatology	diarrhea, mucositis, muscle pain, joint pain, peptic ulcer disease (PUD), ulcerative colitis, Crohn's disease, anxiety, insomnia	BRD-K83896451-001-06-7, BRD-K83896451-001-07-5	Launched
L-hydroxyproline					BRD-A12454076-001-01-9	Launched
L-kynurenine	aryl hydrocarbon receptor agonist				BRD-K20497775-001-06-9	Phase 1
L-leucine		BCAT1, BCAT2, LARS, LARS2, LCMT1, LCMT2			BRD-K12853841-001-02-2	Phase 3
L-lysine	serotonin receptor agonist	GPRC6A, KARS, SLC7A1, SLC7A2, SLC7A3, SLC7A4			BRD-K86016185-001-01-3	Phase 2
L-methionine	voltage-gated calcium channel ligand	BHMT, BHMT2, METAP2, MTR, MTRR	pulmonary, allergy, neurology/psychiatry	asthma, allergic rhinitis, depression, Parkinson's Disease, schizophrenia	BRD-K06502269-001-02-6	Launched
L-mimosine	dopamine beta hydroxylase inhibitor, eukaryotic translation initiation factor inhibitor	DBH, EIF5A			BRD-K00004529-001-01-9	Preclinical
L-monomethylarginine	nitric oxide synthase inhibitor	NOS1, NOS2			BRD-K20946707-001-01-9	Phase 3
L-NAME	nitric oxide synthase inhibitor	NOS3			BRD-K33141550-003-06-5, BRD-K33141550-003-11-9, BRD-K33141550-003-05-7	Phase 2/Phase 3
L-NIL	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			BRD-K60036103-003-02-9, BRD-K60036103-003-01-6	Preclinical
L-phenylisopropyladenosine					BRD-K25521961-001-06-9	Preclinical
L-proline	glutamate receptor agonist	EPRS, L3HYPDH, P3H1, P3H2, P3H3, P4HA1, P4HA2, PARS2, PPIA, PPIB, PPIC, PPIF, PPIG, PPIH, PRODH, PROSC, PYCR1, PYCR2, PYCRL, SLC6A14, SLC6A7			BRD-K01666412-001-02-0	Launched
L-quisqualic-acid	glutamate receptor agonist	FOLH1, GRIA2, GRIK1, GRIK2, GRM1, GRM2, GRM3, GRM5, GRM7, GRM8			BRD-K92404805-001-07-0, BRD-K92404805-001-07-0, BRD-K92404805-001-07-0, BRD-K92404805-001-08-9, BRD-K92404805-001-08-9	Preclinical
L-theanine	glutamate receptor antagonist				BRD-K04843140-001-04-9	Launched
L-threonine		TARS, TARS2, THNSL1			BRD-K75508643-001-02-6	Phase 2
L-valine					BRD-K59424860-001-02-9, BRD-K59424860-001-01-4	Phase 2
L-152804	neuropeptide receptor antagonist	NPY5R			BRD-K01827100-001-10-9, BRD-K01827100-001-16-9, BRD-K01827100-001-09-9	Preclinical
L-161982	prostanoid receptor antagonist	PTGER4			BRD-K39733634-001-03-4, BRD-K39733634-001-03-4, BRD-K39733634-001-02-6, BRD-K39733634-001-04-9	Preclinical
L-168049	glucagon receptor antagonist	GCGR			BRD-K18036262-001-03-6, BRD-K18036262-001-02-8, BRD-K18036262-001-02-8, BRD-K18036262-001-04-9	Preclinical
L-365260	CCK receptor antagonist	CCKAR, CCKBR, KCNQ1			BRD-K34277641-001-01-2	Phase 2
L-368899	oxytocin receptor antagonist	AVPR1A, AVPR2, OXTR			BRD-K00004282-003-01-9	Phase 1
L-655,708	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRG2			BRD-K13474508-001-02-0, BRD-K13474508-001-02-0, BRD-K13474508-001-03-9, BRD-K13474508-001-01-2, BRD-K13474508-001-01-2	Preclinical
L-655240	thromboxane receptor antagonist	PTGES			BRD-K89402695-001-03-1, BRD-K89402695-001-02-3	Phase 1
L-670596	prostanoid receptor antagonist				BRD-A85472596-001-03-9, BRD-A85472596-001-02-2, BRD-A85472596-001-02-2	Preclinical
L-689560	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			BRD-K74284736-001-03-1, BRD-K74284736-001-04-9, BRD-K74284736-001-02-3	Preclinical
L-690330	inositol monophosphatase inhibitor	IMPA1			BRD-K28470988-001-04-6	Preclinical
L-693403	sigma receptor agonist, sigma receptor antagonist	DRD2, SIGMAR1			BRD-K83322645-050-02-9, BRD-K83322645-050-01-9, BRD-K83322645-050-01-9, BRD-K83322645-050-01-9, BRD-K83322645-050-01-9	Preclinical
L-694247	serotonin receptor agonist	HTR1A, HTR1B, HTR1D			BRD-K18816859-001-06-9, BRD-K18816859-001-02-2	Preclinical
L-701252	glutamate receptor antagonist	GRIN1			BRD-K10176267-001-03-3	Preclinical
L-701324	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			BRD-K08109516-001-08-6, BRD-K08109516-001-08-6, BRD-K08109516-001-10-9, BRD-K08109516-001-07-8	Preclinical
L-732,138	tachykinin antagonist	TACR1, TACR2			BRD-K37952347-001-02-2, BRD-K37952347-001-02-2, BRD-K37952347-001-03-9, BRD-K37952347-001-01-4	Preclinical
L-733060	tachykinin antagonist	TACR1			BRD-K15791587-003-03-9, BRD-K15791587-003-02-5, BRD-K15791587-003-02-5, BRD-K15791587-003-02-5	Preclinical
L-741742	dopamine receptor antagonist	DRD3, DRD4, SCN1A, SCN3A			BRD-K13211965-003-03-9, BRD-K13211965-003-02-8	Preclinical
L-745870	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR6, HTR7			BRD-K05528470-305-03-0, BRD-K05528470-305-03-0, BRD-K05528470-305-02-2	Preclinical
L-755507	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3			BRD-K39359968-001-02-6, BRD-K39359968-001-01-8, BRD-K39359968-001-03-9	Preclinical
L-760735	tachykinin antagonist	TACR1			BRD-K30425481-003-01-0, BRD-K30425481-003-02-9	Preclinical
L-778123	farnesyltransferase inhibitor	FNTA, FNTB, PGGT1B			BRD-K10958118-003-01-5, BRD-K10958118-003-01-5, BRD-K10958118-003-01-5, BRD-K10958118-003-01-5, BRD-K10958118-003-02-9	Phase 1
L-798106	prostanoid receptor antagonist	PTGER3			BRD-K43905307-001-02-0, BRD-K43905307-001-01-2, BRD-K43905307-001-03-9	Preclinical
L-838417	GABA receptor partial agonist	GABRA1, GABRA2, GABRA3, GABRA5			BRD-K46647427-001-02-0, BRD-K46647427-001-02-0, BRD-K46647427-001-03-9	Preclinical
labetalol	adrenergic receptor antagonist	ADRA1D, ADRB1, ADRB2	cardiology	hypertension	BRD-K01825098-001-02-9, BRD-K01825098-001-02-9	Launched
lacidipine	calcium channel blocker	CACNA1C	cardiology	hypertension	BRD-K43586850-001-04-9, BRD-K43586850-001-04-9, BRD-K43586850-001-04-9, BRD-K43586850-001-02-9, BRD-K43586850-001-02-9, BRD-K43586850-001-02-9	Launched
lactulose	laxative		gastroenterology	portal-systemic encephalopathy (PSE)	BRD-K77258318-001-05-9, BRD-K77258318-001-04-6, BRD-K77258318-001-04-6	Launched
lafutidine	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)	BRD-K00003615-001-01-9	Launched
lamivudine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS), hepatitis B	BRD-K02992638-001-11-8, BRD-K02992638-001-13-9	Launched
lamotrigine	serotonin receptor antagonist, sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, bipolar disorder	BRD-K93460210-001-23-7, BRD-K93460210-001-22-9, BRD-K93460210-001-27-9, BRD-K93460210-001-27-9	Launched
lanabecestat	beta secretase inhibitor				BRD-K00003387-001-01-9	Phase 3
lanatoside-C	cardiac glycoside				BRD-A64242993-001-05-6, BRD-A64242993-001-05-6	Preclinical
landiolol	adrenergic receptor antagonist	ADRB1	cardiology	cardiac arrythmia	BRD-K86436199-003-01-3, BRD-K86436199-003-01-3	Launched
lanifibranor	PPAR receptor agonist				BRD-K00003462-001-01-9	Phase 2
lanoconazole	sterol demethylase inhibitor		infectious disease	fungal infection	BRD-A54275602-001-01-0	Launched
lansoprazole	ATPase inhibitor	ATP4A, ATP4B	gastroenterology	heartburn	BRD-K00004280-001-01-9	Launched
lapatinib	EGFR inhibitor	EGFR, ERBB2	oncology	breast cancer	BRD-K19687926-001-10-8, BRD-K19687926-001-10-8, BRD-K19687926-001-10-8, BRD-K19687926-379-07-4, BRD-K19687926-379-07-4, BRD-K19687926-001-04-1, BRD-K19687926-001-04-1, BRD-K19687926-001-04-1	Launched
lappaconite	sodium channel blocker				BRD-K00025602-004-02-9	Phase 2
laquinimod	immunosuppressant	CXCL2			BRD-K60918217-001-02-0, BRD-K60918217-001-04-9, BRD-K60918217-001-04-9, BRD-K60918217-001-03-8, BRD-K60918217-001-03-8	Phase 3
larazotide-acetate	tight junction regulator				BRD-K00003469-015-01-9	Phase 2
laropiprant	prostanoid receptor antagonist	PTGDR, PTGDR2, PTGER1, PTGER2, PTGER3, PTGFR, PTGIR, TBXA2R	cardiology	cholesterol	BRD-K48894757-001-02-9, BRD-K48894757-001-02-9, BRD-K48894757-001-02-9, BRD-K48894757-001-01-8, BRD-K48894757-001-01-8	Launched
larotrectinib	tropomyosin receptor kinase inhibitor	NTRK1, NTRK2, NTRK3			BRD-K36574127-001-01-3, BRD-K36574127-001-01-3	Launched
lasalocid	bacterial permeability inducer		infectious disease	coccidiosis	BRD-K10207760-236-13-9	Launched
lasmiditan	serotonin receptor agonist				BRD-K00003178-003-01-9	Launched
lasofoxifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, oncology	osteoporosis, breast cancer	BRD-M93148412-001-02-6, BRD-M93148412-001-01-8	Launched
latanoprost	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension, glaucoma	BRD-K10961822-001-05-1, BRD-K10961822-001-05-1	Launched
latrepirdine	glutamate receptor antagonist	HRH1, HTR6			BRD-K55703048-300-02-4, BRD-K55703048-001-07-7, BRD-K55703048-001-07-7, BRD-K55703048-300-01-6, BRD-K55703048-300-01-6	Phase 3
latrunculin-B	actin polymerization inhibitor	ACTA1, MKL1, SPIRE2			BRD-K61292460-001-02-3, BRD-K61292460-001-03-1	Phase 1
lauric-acid	bacterial permeability inducer	GPR84, HNF4A, LTF, LY96, PLA2G2A, TLR4			BRD-K67375056-001-07-9	Phase 3
lauric-diethanolamide					BRD-K11548689-001-02-9, BRD-K11548689-001-01-6	Preclinical
laurocapram					BRD-K35698076-001-02-9, BRD-K35698076-001-01-2	Phase 3
lazabemide	monoamine oxidase inhibitor	MAOB			BRD-K51486818-003-03-6, BRD-K51486818-003-02-8, BRD-K51486818-003-02-8	Phase 3
lazertinib	tyrosine kinase inhibitor				BRD-K00003501-001-01-9	Phase 1/Phase 2
LB-100	protein phosphatase inhibitor				BRD-K00025603-001-01-9	Phase 2
LB42708	farnesyltransferase inhibitor				BRD-K18834913-001-03-7, BRD-K18834913-001-01-1, BRD-K18834913-001-01-1, BRD-K18834913-001-01-1, BRD-K18834913-001-01-1, BRD-K18834913-001-01-1, BRD-K18834913-001-01-1, BRD-K18834913-001-01-1, BRD-K18834913-001-05-9, BRD-K18834913-001-02-9	Preclinical
LCL-161	XIAP inhibitor	BIRC2, XIAP			BRD-K08248804-001-01-8, BRD-K08248804-001-01-8, BRD-K08248804-001-01-8, BRD-K08248804-001-01-8, BRD-K08248804-001-01-8, BRD-K08248804-001-01-8, BRD-K08248804-001-01-8, BRD-K08248804-001-03-9	Phase 2
LCQ908	diacylglycerol O acyltransferase inhibitor	DGAT1			BRD-K20008181-001-01-3, BRD-K20008181-001-01-3, BRD-K20008181-001-01-3, BRD-K20008181-001-03-9, BRD-K20008181-001-03-9, BRD-K20008181-001-03-9	Phase 3
LCZ696	angiotensin receptor antagonist		cardiology	angioedema, hypotension		Launched
LDC1267	protein tyrosine kinase inhibitor	AXL, MERTK, TYRO3			BRD-K44715996-001-01-0, BRD-K44715996-001-01-0	Preclinical
LDN-209929	haspin kinase inhibitor	GSG2			BRD-K61795638-300-02-9, BRD-K61795638-300-01-0	Preclinical
LDN-212854	bone morphogenic protein inhibitor	ABL1, ACVR1, RIPK2			BRD-K59831625-001-03-9, BRD-K59831625-001-01-6, BRD-K59831625-001-01-6, BRD-K59831625-001-01-6, BRD-K59831625-001-01-6, BRD-K59831625-001-01-6, BRD-K59831625-001-01-6, BRD-K59831625-001-01-6, BRD-K59831625-001-02-4, BRD-K59831625-001-02-4	Preclinical
LDN-27219	tissue transglutaminase inhibitor	TGM2			BRD-K51485109-001-02-9, BRD-K51485109-001-01-4	Preclinical
LDN193189	bone morphogenic protein inhibitor	ACVR1, BMPR1A			BRD-K04853698-376-01-4, BRD-K04853698-376-01-4, BRD-K04853698-376-01-4, BRD-K04853698-376-01-4	Preclinical
LE-135	retinoid receptor agonist	RARB			BRD-K06593056-001-05-5, BRD-K06593056-001-05-5, BRD-K06593056-001-04-8	Preclinical
ledipasvir	HCV inhibitor		infectious disease	hepatitis C	BRD-K05446112-001-01-8, BRD-K05446112-001-01-8, BRD-K05446112-001-01-8, BRD-K05446112-001-02-9	Launched
leflunomide	dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor	AHR, DHODH, PTK2B	rheumatology	rheumatoid arthritis	BRD-K78692225-001-24-5, BRD-K78692225-001-23-7, BRD-K78692225-001-29-9, BRD-K78692225-001-22-9	Launched
lemborexant	orexin receptor antagonist	HCRTR1, HCRTR2			BRD-K78666663-001-01-6	Launched
lenalidomide	anticancer agent	TNF	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)	BRD-A17883755-001-06-1	Launched
leniolisib	PI3K inhibitor				BRD-K00003261-001-01-9	Phase 2/Phase 3
lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FLT4, KDR	oncology	thyroid cancer	BRD-K39974922-001-04-3, BRD-K39974922-001-04-3, BRD-K39974922-001-04-3, BRD-K39974922-001-04-3, BRD-K39974922-001-04-3	Launched
leonurine	anti-inflammatory agent				BRD-K00004696-001-01-9	Preclinical
LEQ506	G protein signaling inhibitor				BRD-K00003269-001-01-9	Phase 1
lercanidipine	calcium channel blocker	CACNA2D1	cardiology	hypertension	BRD-A18992208-003-02-7, BRD-A18992208-003-02-7, BRD-A18992208-003-02-7	Launched
lerisetron	serotonin receptor antagonist	HTR3A			BRD-K62398570-001-02-9, BRD-K62398570-300-01-2, BRD-K62398570-001-01-6	Phase 3
lersivirine	non-nucleoside reverse transcriptase inhibitor				BRD-K03289534-001-01-4, BRD-K03289534-001-02-9	Phase 2
lesinurad	uric acid diuretic	SLC22A12	rheumatology	gout	BRD-K75024268-001-01-0, BRD-K75024268-001-02-9	Launched
lestaurtinib	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor	FLT3, NTRK1			BRD-A27376179-001-01-3, BRD-A27376179-001-01-3, BRD-A27376179-001-01-3, BRD-A27376179-001-01-3, BRD-A27376179-001-01-3, BRD-A27376179-001-01-3, BRD-A27376179-001-01-3, BRD-A27376179-001-01-3, BRD-A27376179-001-01-3, BRD-A27376179-001-01-3, BRD-A27376179-001-01-3	Phase 3
leteprinim	nerve growth factor agonist				BRD-K21612934-001-01-1	Phase 2
letermovir	CMV terminase inhibitor		infectious disease	cytomegalovirus (CMV)	BRD-K94288301-001-01-7, BRD-K94288301-001-01-7, BRD-K94288301-001-02-9	Launched
letosteine	mucolytic agent		pulmonary, infectious disease	bronchitis, pneumonia	BRD-A32597168-001-03-6	Launched
letrazuril	antiinfective drug				BRD-K00003474-001-01-9	Phase 1
letrozole	aromatase inhibitor	CYP19A1	oncology	breast cancer	BRD-K88789588-001-17-9, BRD-K88789588-001-16-4, BRD-K88789588-001-14-9	Launched
leucomethylene-blue	nitric oxide production inhibitor, tau aggregation inhibitor	MAPT			BRD-K27460187-334-01-8	Phase 3
leucovorin	folate receptor ligand		oncology	osteosarcoma	BRD-K01825581-238-05-9, BRD-K01825581-399-03-9, BRD-K01825581-399-03-9, BRD-K01825581-399-02-9, BRD-K01825581-399-02-9	Launched
leucylleucine-methyl-ester					BRD-K81136890-003-01-6	Phase 2
leuprolide	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology	prostate cancer	BRD-K45300898-001-04-9, BRD-K45300898-015-05-9	Launched
levalbuterol	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm	BRD-K34469523-003-03-0, BRD-K34469523-003-03-0, BRD-K34469523-065-04-9	Launched
levallorphan	opioid receptor antagonist	CHRNA2, OPRM1	pulmonary	respiratory depression	BRD-K30634073-046-01-0, BRD-K30634073-046-01-0, BRD-K30634073-046-02-8	Launched
levamisole	acetylcholine receptor agonist	ALPL			BRD-K73107279-003-12-5, BRD-K73107279-003-13-9, BRD-K73107279-003-13-9, BRD-K73107279-003-11-7	Withdrawn
levamlodipine	calcium channel blocker		cardiology	hypertension	BRD-K00005329-074-01-9	Launched
levcromakalim	potassium channel activator	KCNJ5			BRD-K24526313-001-18-5, BRD-K24526313-001-17-7, BRD-K24526313-001-19-9, BRD-K24526313-001-20-9, BRD-K24526313-001-20-9	Phase 3
levetiracetam	calcium channel blocker	CACNA1B, SCN1A, SV2A	neurology/psychiatry	seizures	BRD-K49404994-001-13-3, BRD-K49404994-001-10-9, BRD-K49404994-001-10-9, BRD-K49404994-001-11-7, BRD-K49404994-001-11-7, BRD-K49404994-001-09-1	Launched
levo-phencynonate	acetylcholine receptor antagonist	CHRM1			BRD-A64698388-003-01-7	Launched
levobetaxolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	intraocular pressure, glaucoma	BRD-K43883465-003-02-9, BRD-K43883465-003-02-9, BRD-K43883465-003-01-5	Launched
levobunolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	ophthalmology	glaucoma, ocular hypertension	BRD-K31812033-003-12-9, BRD-K31812033-003-10-2, BRD-K31812033-003-11-0	Launched
levobunolol-(+)	adrenergic receptor antagonist				BRD-K73323637-003-10-9, BRD-K73323637-003-10-9, BRD-K73323637-003-10-9, BRD-K73323637-003-10-9	Preclinical
levobunolol-(+/-)	adrenergic receptor antagonist				BRD-A46876182-003-02-8, BRD-A46876182-003-02-8	Preclinical
levocabastine	histamine receptor antagonist	HRH1, NTSR2	ophthalmology	conjunctivitis	BRD-K33453211-003-11-5	Launched
levocarnitine		CRAT, CROT	endocrinology	carnitine deficiency	BRD-K59647213-001-10-5, BRD-K59647213-001-09-7	Launched
levocarnitine-propionate	carnitine palmitoyltransferase inhibitor	CRAT	neurology/psychiatry, endocrinology	peripheral neuropathy, carnitine deficiency	BRD-K84366268-003-01-0	Launched
levodopa	dopamine precursor	DRD1, DRD2, DRD3, DRD4, DRD5, GPR143	neurology/psychiatry	Parkinson's Disease	BRD-K34730807-001-16-8, BRD-K34730807-001-17-6, BRD-K34730807-001-15-0	Launched
levomenol			neurology/psychiatry, infectious disease	spasms, skin infections	BRD-K62751771-001-01-3	Launched
levomenthol		OPRK1, TRPA1, TRPM8, TRPV3	neurology/psychiatry	pain relief	BRD-K50329370-001-08-2, BRD-K50329370-001-09-0	Launched
levomepromazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR2A, HTR2C	neurology/psychiatry, gastroenterology	psychosis, schizophrenia, bipolar disorder, nausea, insomnia	BRD-K35559145-001-01-3, BRD-K35559145-050-08-5, BRD-K35559145-050-08-5	Launched
levomequitazine	histamine receptor antagonist	HRH1			BRD-A67616246-001-07-9, BRD-A67616246-001-07-9, BRD-A67616246-001-07-9, BRD-A67616246-001-07-9, BRD-A67616246-001-08-9	Phase 2
levonordefrin	vasodilator	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, SLC6A2	hematology	hemorrhage	BRD-K02976377-001-08-2, BRD-K02976377-001-07-4	Launched
levopropoxyphene	antitussive		pulmonary	cough suppressant	BRD-A54635441-078-09-1	Launched
levosimendan	calcium sensitizer	KCNJ11, KCNJ8, PDE3A, TNNC1	cardiology	congestive heart failure	BRD-K03095347-001-06-1, BRD-K03095347-001-06-1, BRD-K03095347-001-07-9, BRD-K03095347-001-07-9, BRD-K03095347-001-07-9, BRD-K03095347-001-05-3	Launched
levosulpiride	dopamine receptor antagonist	CA1, CA12, CA7, DRD2, DRD3	neurology/psychiatry, gastroenterology, urology	schizophrenia, psychosis, anxiety, vertigo, dyspepsia, irritable bowel syndrome, premature ejaculation (PE)	BRD-K51671335-001-12-2, BRD-K51671335-001-13-9, BRD-K51671335-001-13-9, BRD-K51671335-001-09-8, BRD-K51671335-001-10-6, BRD-K51671335-001-10-6	Launched
levothyroxine	thyroid hormone stimulant	THRA, THRB	endocrinology	myxedema coma	BRD-K30685142-001-17-0, BRD-K30685142-001-16-2, BRD-K30685142-001-15-4, BRD-K30685142-001-14-7	Launched
LFM-A13	Bruton's tyrosine kinase (BTK) inhibitor	BTK			BRD-A30655177-001-14-0, BRD-A30655177-001-14-0	Preclinical
LGD-6972	glucagon receptor antagonist				BRD-K00003132-001-01-9, BRD-K00003132-001-01-9	Phase 2
LGK-974	porcupine inhibitor	PORCN			BRD-K16810791-001-02-9, BRD-K16810791-001-01-0, BRD-K16810791-001-01-0, BRD-K16810791-001-01-0, BRD-K16810791-001-01-0, BRD-K16810791-001-01-0	Phase 2
LH846	casein kinase inhibitor	CSNK1D			BRD-K47409078-001-01-8, BRD-K47409078-001-02-6	Preclinical
liarozole	cytochrome P450 inhibitor	CYP19A1, CYP26A1			BRD-K00004284-300-01-9	Phase 2/Phase 3
licarbazepine	voltage-gated sodium channel blocker	SCN5A			BRD-A22642447-001-02-7, BRD-A22642447-001-02-7, BRD-A22642447-001-03-9, BRD-A22642447-001-01-9, BRD-A22642447-001-01-9	Phase 3
licochalcone-A	topoisomerase inhibitor	PTPN1			BRD-K99667445-001-03-9	Phase 3
licofelone	cyclooxygenase inhibitor, lipoxygenase inhibitor	ALOX5, PLA2G2E, PTGS2			BRD-K08439945-001-03-9, BRD-K08439945-001-01-3, BRD-K08439945-001-02-1	Phase 3
licogliflozin	sodium/glucose cotransporter inhibitor				BRD-K00003504-001-01-9	Preclinical
licostinel	NMDA receptor antagonist 				BRD-K81881550-001-03-9	Phase 1
lidamidine	adrenergic receptor agonist		gastroenterology	diarrhea	BRD-K68693535-001-03-4, BRD-K68693535-001-03-4	Launched
lidocaine	histamine receptor agonist	EGFR, SCN10A, SCN5A, SCN9A	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage	BRD-K52662033-001-19-0, BRD-K52662033-003-21-2, BRD-K52662033-003-21-2	Launched
lidoflazine	calcium channel blocker	SCN1A, SCN3A, SLC29A1	cardiology	coronary artery disease (CAD)	BRD-K62996583-001-11-9, BRD-K62996583-001-11-9, BRD-K62996583-001-10-3	Launched
lifirafenib	RAF inhibitor				BRD-K00003275-001-01-9	Phase 1/Phase 2
lifitegrast	lymphocyte function-associated antigen negative modulator		ophthalmology	dry eye syndrome	BRD-K60265345-001-02-9	Launched
ligustilide	tumor necrosis factor production inhibitor	TNF			BRD-K48875051-001-01-0, BRD-K48875051-001-01-0	Preclinical
limaprost-alfadex	prostanoid receptor agonist	PTGER1	cardiology	claudication	BRD-K25015158-001-01-2, BRD-K25015158-001-02-0, BRD-K25015158-001-02-0	Launched
LIMKi-3	LIM kinase inhibitor	LIMK1			BRD-K75373031-001-02-9, BRD-K75373031-001-01-7	Preclinical
linaclotide	guanylate cyclase activator	GUCY2C	gastroenterology	irritable bowel syndrome, constipation	BRD-K00003592-001-01-9	Launched
linalool	anticonvulsant				BRD-K01827427-001-05-9, BRD-K01827427-001-11-9	Phase 1
linaprazan	ATP-sensitive potassium channel inhibitor				BRD-K00003366-001-01-9	Preclinical
lincomycin	bacterial 30S ribosomal subunit inhibitor		gastroenterology	enteritis	BRD-K49384696-311-03-9, BRD-K49384696-003-04-9	Launched
lindane		GABRB1, GLRA1, GLRA2, GLRA3, GLRB	infectious disease	scabies	BRD-K93814253-001-06-8, BRD-K93814253-001-05-0, BRD-K93814253-001-04-3	Launched
linezolid	bacterial 50S ribosomal subunit inhibitor	MAOA, MAOB	infectious disease	pneumonia, skin infections	BRD-K66876909-001-15-9, BRD-K66876909-001-15-9, BRD-K66876909-001-12-6, BRD-K66876909-001-11-8, BRD-K66876909-001-11-8	Launched
linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK			BRD-K99749624-001-11-9, BRD-K99749624-001-07-0, BRD-K99749624-001-07-0, BRD-K99749624-001-07-0, BRD-K99749624-001-07-0, BRD-K99749624-001-07-0	Phase 3
linoleic-acid	oxidative stress inducer	FABP4, FFAR1, FFAR4, HNF4A, KCNB1, PPARG, TRPM8			BRD-K08973992-001-06-2	Phase 3
linopirdine	potassium channel blocker	KCNQ2, KCNQ3, KCNQ4, KCNQ5			BRD-K59332007-300-03-5, BRD-K59332007-300-08-9, BRD-K59332007-300-08-9, BRD-K59332007-300-02-7	Phase 3
linsitinib	IGF-1 inhibitor	IGF1R, INSR, INSRR			BRD-K86118762-001-08-9, BRD-K86118762-001-08-9, BRD-K86118762-001-01-8, BRD-K86118762-001-01-8, BRD-K86118762-001-01-8, BRD-K86118762-001-01-8, BRD-K86118762-001-01-8, BRD-K86118762-001-05-9	Phase 3
lintopride	serotonin receptor antagonist				BRD-K00004744-001-01-9	Preclinical
liothyronine	thyroid hormone stimulant	THRA, THRB	endocrinology	hypothyroidism, myxedema coma	BRD-K89152108-236-12-9, BRD-K89152108-236-06-8, BRD-K89152108-236-06-8, BRD-K89152108-236-08-4, BRD-K89152108-236-05-0, BRD-K89152108-236-07-6, BRD-K89152108-236-07-6	Launched
liothyronine-(isomer)					BRD-K46428823-001-02-5	Preclinical
lipoamide					BRD-A14440173-001-03-4, BRD-A14440173-001-04-9	Preclinical
liquiritin	antioxidant				BRD-K39084158-001-08-9	Preclinical
liraglutide	GLP receptor agonist	GLP1R	endocrinology	weight-loss aid, diabetes mellitus	BRD-K00003717-001-01-9	Launched
liranaftate	fungal squalene epoxidase inhibitor		infectious disease	fungal infection	BRD-K35775715-001-04-9, BRD-K35775715-001-03-1	Launched
lirimilast	phosphodiesterase inhibitor				BRD-K31339321-001-03-6, BRD-K31339321-001-03-6	Phase 2
lisadimate	topical sunscreen agent		dermatology	sunscreen lotion	BRD-A76533773-001-01-9	Launched
lisinopril	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology, endocrinology	hypertension, congestive heart failure, diabetes mellitus	BRD-K67966701-335-15-9, BRD-K67966701-335-15-9, BRD-K67966701-335-15-9, BRD-K67966701-001-11-6, BRD-K67966701-001-11-6, BRD-K67966701-001-10-8, BRD-K67966701-001-12-4, BRD-K67966701-001-12-4, BRD-K67966701-001-12-4	Launched
lisofylline	interleukin receptor antagonist, STAT inhibitor				BRD-A05334458-001-02-8, BRD-A05334458-001-03-9	Phase 2
lisuride	dopamine receptor agonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6	neurology/psychiatry	Parkinson's Disease	BRD-K67943528-050-01-4, BRD-K67943528-050-01-4, BRD-K67943528-050-03-9	Launched
lithium-acetoacetate		FAH			BRD-K73234506-235-02-1	Preclinical
lithocholic-acid	FXR antagonist, vitamin D receptor agonist	GPBAR1, NR1H4, NR1I2, VDR			BRD-K20986251-001-14-9	Preclinical
litronesib	kinesin-like spindle protein inhibitor	KIF11			BRD-K83029223-001-01-3, BRD-K83029223-001-01-3, BRD-K83029223-001-01-3	Phase 2
lixivaptan	vasopressin receptor antagonist	AVPR2			BRD-K59391348-001-01-7, BRD-K59391348-001-01-7, BRD-K59391348-001-01-7	Phase 3
LM-22A4	tropomyosin receptor kinase inhibitor	NTRK2			BRD-K70404782-001-02-9, BRD-K70404782-001-01-6, BRD-K70404782-001-01-6	Preclinical
LMI070	survival motor neuron protein modulator	SMN1			BRD-K08532119-001-02-9, BRD-K08532119-001-01-5	Phase 1/Phase 2
LMK-235	HDAC inhibitor	HDAC4, HDAC5			BRD-K49921286-001-02-6, BRD-K49921286-001-02-6, BRD-K49921286-001-01-8	Preclinical
LM11A-31	neurotrophic agent	NGFR			BRD-A04649065-001-01-7, BRD-A04649065-001-01-7	Phase 1
lobendazole	anthelmintic agent				BRD-K15834839-001-02-3, BRD-K15834839-001-02-3, BRD-K15834839-001-04-9	Preclinical
lobenzarit	immunosuppressant		rheumatology	rheumatoid arthritis	BRD-K55847762-304-01-7	Launched
lodenosine	antiretroviral 				BRD-K00004554-001-01-9	Phase 2
lodoxamide	histamine receptor antagonist		ophthalmology	vernal keratoconjunctivitis (VKC)	BRD-K66937583-001-01-2, BRD-K66937583-001-02-9, BRD-K66937583-001-02-9	Launched
lofemizole	cyclooxygenase inhibitor				BRD-K06388517-001-01-2, BRD-K06388517-001-01-2	Phase 3
lofepramine	norepinephrine reuptake inhibitor, serotoninâ€“norepinephrine reuptake inhibitor (SNRI)	HTR1A, SLC6A2, SLC6A4	neurology/psychiatry	depression	BRD-K82147103-003-05-6, BRD-K82147103-001-02-7	Launched
lofexidine	adrenergic receptor agonist		neurology/psychiatry	opioid withdrawal	BRD-A02990301-003-05-8, BRD-A02990301-003-06-6, BRD-A02990301-003-06-6, BRD-A02990301-003-07-4	Launched
lomefloxacin	bacterial DNA gyrase inhibitor		infectious disease	respiratory tract infections, urinary tract infections	BRD-K01825701-003-03-9, BRD-K01825701-213-01-9, BRD-K01825701-213-01-9	Launched
lomeguatrib	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			BRD-K27955832-001-05-2, BRD-K27955832-001-02-9, BRD-K27955832-001-02-9, BRD-K27955832-001-02-9	Phase 2
lomerizine	calcium channel blocker	CACNA1B, SCN5A	neurology/psychiatry	migraine headache	BRD-K62858456-001-01-8, BRD-K62858456-300-01-4, BRD-K62858456-300-01-4, BRD-K62858456-300-01-4, BRD-K62858456-300-01-4, BRD-K62858456-300-01-4, BRD-K62858456-300-01-4, BRD-K62858456-300-01-4	Launched
lometrexol	glycinamide ribonucleotide formyltransferase inhibitor	GART			BRD-K66036108-001-01-9	Phase 2
lomitapide	microsomal trigylceride transfer protein inhibitor	MTTP	endocrinology	hypercholesterolemia	BRD-K92213669-001-01-3, BRD-K92213669-001-01-3, BRD-K92213669-001-01-3, BRD-K92213669-001-02-9	Launched
lomustine	DNA synthesis inhibitor		hematologic malignancy, oncology	Hodgkin's lymphoma, brain tumors	BRD-K51768138-001-10-9, BRD-K51768138-001-09-1, BRD-K51768138-001-04-2, BRD-K51768138-001-04-2, BRD-K51768138-001-05-9, BRD-K51768138-001-07-5	Launched
lonafarnib	farnesyltransferase inhibitor	FNTA, HRAS, KRAS, NRAS			BRD-K41599323-001-02-3, BRD-K41599323-001-02-3, BRD-K41599323-001-02-3, BRD-K41599323-001-02-3, BRD-K41599323-001-02-3, BRD-K41599323-001-03-1	Phase 3
lonidamine	glucokinase inhibitor	GCK			BRD-K78513633-001-16-5, BRD-K78513633-001-15-7, BRD-K78513633-001-17-9, BRD-K78513633-001-13-2, BRD-K78513633-001-14-0	Launched
loperamide	opioid receptor agonist	CACNA1A, CALM1, OPRD1, OPRK1, OPRM1, POMC	gastroenterology	diarrhea	BRD-K61250553-003-32-2, BRD-K61250553-003-32-2, BRD-K61250553-003-32-2, BRD-K61250553-003-32-2, BRD-K61250553-003-30-6, BRD-K61250553-003-30-6, BRD-K61250553-003-29-8, BRD-K61250553-003-29-8	Launched
lopinavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K99451608-001-07-3, BRD-K99451608-001-07-3, BRD-K99451608-001-07-3, BRD-K99451608-001-08-9, BRD-K99451608-001-08-9	Launched
loracarbef	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, pulmonary	ear infections, laryngitis, bronchitis, pneumonia, urinary tract infections, skin infections	BRD-K28935038-001-02-2, BRD-K28935038-002-03-9	Launched
loratadine	histamine receptor antagonist	HRH1	allergy, neurology/psychiatry	allergic rhinitis, itching	BRD-K82795137-001-28-8, BRD-K82795137-001-26-2, BRD-K82795137-001-24-7, BRD-K82795137-001-29-9, BRD-K82795137-001-25-4	Launched
loreclezole	benzodiazepine receptor agonist	GABRB2, GABRB3			BRD-K09659835-003-02-9, BRD-K09659835-003-01-4	Phase 2
lorediplon	GABA receptor modulator	GABRA1			BRD-K42066335-001-01-0	Phase 2
lorglumide	CCK receptor antagonist	CCKAR, CCKBR			BRD-K01825818-236-02-9	Phase 1
lorlatinib	ALK tyrosine kinase receptor inhibitor	ALK	oncology	non-small cell lung cancer (NSCLC)	BRD-K99879819-001-03-9, BRD-K99879819-001-02-1, BRD-K99879819-001-02-1, BRD-K99879819-001-02-1, BRD-K99879819-001-02-1	Launched
lornoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, neurology/psychiatry	osteoarthritis, sciata	BRD-A90551241-001-09-0, BRD-A90551241-001-10-8, BRD-A90551241-001-10-8	Launched
losartan	angiotensin receptor antagonist	AGTR1	cardiology, nephrology	hypertension, diabetic nephropathy, hypertension	BRD-K76205745-237-22-9, BRD-K76205745-237-22-9, BRD-K76205745-237-22-9, BRD-K76205745-001-06-6, BRD-K76205745-001-06-6, BRD-K76205745-237-19-9, BRD-K76205745-237-16-5, BRD-K76205745-237-18-1	Launched
losmapimod	p38 MAPK inhibitor	MAPK14			BRD-K56195681-001-04-9, BRD-K56195681-001-01-0, BRD-K56195681-001-01-0, BRD-K56195681-001-01-0, BRD-K56195681-001-01-0, BRD-K56195681-001-01-0	Phase 3
lotamilast	phosphodiesterase inhibitor				BRD-K00003137-001-01-9	Preclinical
loxapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	schizophrenia	BRD-K39915878-036-25-1, BRD-K39915878-036-24-4, BRD-K39915878-001-26-9	Launched
LP-533401	tryptophan hydroxylase inhibitor				BRD-K00004673-001-01-9	Preclinical
LPA2-antagonist-1	lysophosphatidic acid receptor antagonist	LPAR2			BRD-K32322923-001-01-7, BRD-K32322923-001-01-7	Preclinical
LRRK2-IN-1	leucine rich repeat kinase inhibitor	LRRK2			BRD-K01436366-001-22-2, BRD-K01436366-001-20-6	Preclinical
LSN-2463359	glutamate receptor positive allosteric modulator	GRM5			BRD-K79337272-001-02-9, BRD-K79337272-001-01-6, BRD-K79337272-001-01-6	Preclinical
LSZ-102	selective estrogen receptor modulator (SERM)				BRD-K00004675-001-01-9, BRD-K00004675-001-01-9	Phase 1
LTA					BRD-K52914072-001-01-5	Phase 2
LTB4	leukocyte activator	LTB4R, LTB4R2			BRD-K53124401-001-03-8	Phase 2
LTX-315	anticancer agent				BRD-K00003300-001-01-9	Phase 2
Lu-AA-47070	adenosine receptor antagonist	ADORA2A			BRD-K83970940-001-02-9, BRD-K83970940-001-01-0, BRD-K83970940-001-01-0	Phase 2
lucanthone	endonuclease inhibitor	APEX1, TOP1, TOP2A			BRD-K00003521-001-01-9	Phase 2
lucitanib	FGFR inhibitor, VEGFR inhibitor	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET			BRD-K31309378-001-01-5, BRD-K31309378-001-01-5, BRD-K31309378-001-01-5, BRD-K31309378-001-01-5, BRD-K31309378-001-01-5, BRD-K31309378-001-01-5, BRD-K31309378-001-02-3, BRD-K31309378-001-02-3, BRD-K31309378-001-02-3, BRD-K31309378-001-02-3, BRD-K31309378-001-02-3, BRD-K31309378-001-02-3, BRD-K31309378-001-02-3	Phase 2
LUF-5834	adenosine receptor agonist	ADORA2A, ADORA2B			BRD-K67079690-001-02-9, BRD-K67079690-001-01-2	Preclinical
lufenuron	chitin inhibitor		infectious disease	flea control	BRD-A71774530-001-05-9, BRD-A71774530-001-05-9, BRD-A71774530-001-06-9	Launched
luliconazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	BRD-K71058253-001-02-9, BRD-K71058253-001-01-9, BRD-K71058253-001-01-9	Launched
lumacaftor	CFTR channel agonist	CFTR	pulmonary	cystic fibrosis	BRD-K69236721-001-03-9, BRD-K69236721-001-02-7	Launched
lumateperone	dopamine receptor modulator, serotonin receptor antagonist	DRD2, HTR2A			BRD-K10031916-075-02-1, BRD-K10031916-075-01-3, BRD-K10031916-075-01-3	Launched
lumiracoxib	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-K26901728-001-06-2, BRD-K26901728-001-06-2, BRD-K26901728-001-05-4	Withdrawn
lupanine	sodium channel blocker	INS			BRD-K00004532-009-01-9	Phase 1
lurasidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA2A, ADRA2C, DRD2, HTR1A, HTR2A, HTR7	neurology/psychiatry	schizophrenia	BRD-K51143828-003-03-1, BRD-K51143828-003-03-1, BRD-K51143828-003-03-1, BRD-K51143828-003-03-1	Launched
lurbinectedin	DNA binding agent				BRD-K00003211-001-01-9	Phase 3
lusaperidone	adrenergic receptor antagonist				BRD-K00004742-001-01-9	Preclinical
lusutrombopag	thrombopoietin receptor agonist				BRD-K93228461-001-02-9	Launched
lutein	antioxidant		ophthalmology	macular degeneration, cataracts, retinitis pigmentosa (RP)	BRD-K16742848-001-02-6, BRD-K16742848-001-01-8	Launched
luteolin	glucosidase inhibitor	TOP1			BRD-K05236810-001-19-0, BRD-K05236810-001-19-0	Phase 2
luzindole	melatonin receptor antagonist	MTNR1A, MTNR1B			BRD-K67013324-001-04-9, BRD-K67013324-001-05-9, BRD-K67013324-001-03-1	Preclinical
LXH254	RAF inhibitor				BRD-K00003107-001-01-9	Phase 1
LXR-623	LXR agonist	AR, NR1H2, NR1H3, NR1I2, NR3C1			BRD-K54520417-001-02-9, BRD-K54520417-001-01-2	Phase 1
LXS196	PKC inhibitor				BRD-K00003425-001-01-9	Phase 1
LX1031	tryptophan hydroxylase inhibitor	TPH1			BRD-K32101625-001-01-6, BRD-K32101625-001-02-9	Phase 2
LX7101	LIM kinase inhibitor, rho associated kinase inhibitor	LIMK2, ROCK1, ROCK2			BRD-K21038058-001-02-7, BRD-K21038058-001-01-9, BRD-K21038058-001-01-9	Phase 1/Phase 2
lycopene	free radical scavenger				BRD-K37083340-001-02-3	Launched
lylamine	cannabinoid receptor agonist	CNR1			BRD-K62289640-003-05-9, BRD-K62289640-003-05-9, BRD-K62289640-003-05-9, BRD-K62289640-003-02-7	Preclinical
lymecycline	bacterial 50S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	BRD-K00004536-001-01-9	Launched
lynestrenol	progestogen hormone		endocrinology	contraceptive	BRD-K39707084-001-05-8, BRD-K39707084-001-04-1	Launched
lypressin	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2	endocrinology	central diabetes insipidus	BRD-K93331255-001-03-9, BRD-K93331255-001-02-0, BRD-K93331255-001-02-0	Launched
LY2090314	glycogen synthase kinase inhibitor	GSK3B			BRD-K78055238-001-01-8, BRD-K78055238-001-01-8, BRD-K78055238-001-01-8, BRD-K78055238-001-01-8, BRD-K78055238-001-03-9	Phase 2
LY2109761	TGF beta receptor inhibitor	TGFBR1, TGFBR2			BRD-K47557313-001-02-7, BRD-K47557313-001-02-7, BRD-K47557313-001-02-7, BRD-K47557313-001-02-7, BRD-K47557313-001-02-7, BRD-K47557313-001-03-9	Preclinical
LY2140023	glutamate receptor agonist	GRM3			BRD-K49519144-001-04-6, BRD-K49519144-001-04-6, BRD-K49519144-001-04-6, BRD-K49519144-001-04-6, BRD-K49519144-001-03-8	Phase 3
LY215490	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4, GRIK1			BRD-K34313798-001-01-6	Phase 1
LY2157299	TGF beta receptor inhibitor	TGFBR1			BRD-K78118466-001-03-3, BRD-K78118466-001-03-3, BRD-K78118466-001-03-3, BRD-K78118466-001-04-9	Phase 2/Phase 3
LY2183240	FAAH inhibitor, FAAH reuptake inhibitor	FAAH			BRD-K37865504-001-05-8, BRD-K37865504-001-05-8, BRD-K37865504-001-04-1, BRD-K37865504-001-04-1	Preclinical
LY2228820	p38 MAPK inhibitor	MAPK14			BRD-K59227464-334-02-4, BRD-K59227464-334-02-4, BRD-K59227464-334-02-4, BRD-K59227464-334-03-2, BRD-K59227464-334-04-9	Phase 2
LY223982	leukotriene receptor antagonist	LTB4R			BRD-K35367061-001-01-1, BRD-K35367061-001-01-1	Phase 2
LY225910	CCK receptor antagonist	CCKBR			BRD-K33864865-001-03-3, BRD-K33864865-001-03-3, BRD-K33864865-001-04-9, BRD-K33864865-001-02-5, BRD-K33864865-001-02-5, BRD-K33864865-001-02-5	Preclinical
LY231617	lipid peroxidase inhibitor				BRD-K85804405-003-01-3, BRD-K85804405-003-01-3	Preclinical
LY2334737	antitumor agent, ribonucleotide reductase inhibitor				BRD-K04993719-001-01-7, BRD-K04993719-001-01-7, BRD-K04993719-001-02-9	Phase 1
LY2365109	glycine transporter inhibitor	SLC6A9			BRD-K13888115-003-03-0, BRD-K13888115-003-02-2	Preclinical
LY2452473	androgen receptor modulator	AR			BRD-K90171280-001-01-4	Phase 2
LY2510924	CC chemokine receptor antagonist				BRD-K00003131-001-01-9	Phase 2
LY255283	leukotriene receptor antagonist	LTB4R, LTB4R2			BRD-K92492521-001-03-7, BRD-K92492521-001-02-9, BRD-K92492521-001-05-9, BRD-K92492521-001-05-9	Preclinical
LY2584702	ribosomal protein inhibitor	RPS6KB1			BRD-K21833260-075-01-1, BRD-K21833260-075-02-9	Phase 1
LY2603618	CHK inhibitor	CHEK1			BRD-K14109347-001-05-9, BRD-K14109347-001-05-9, BRD-K14109347-001-06-9, BRD-K14109347-001-03-4, BRD-K14109347-001-03-4	Phase 2
LY2606368	CHK inhibitor	CHEK1			BRD-K20463415-300-01-4, BRD-K20463415-300-01-4, BRD-K20463415-300-01-4, BRD-K20463415-001-01-8, BRD-K20463415-001-01-8	Phase 2
LY266097	serotonin receptor antagonist	HTR2B			BRD-A64004759-003-01-9, BRD-A64004759-003-01-9, BRD-A64004759-003-02-9	Preclinical
LY2784544	JAK inhibitor	JAK2, JAK3			BRD-K25630527-001-03-8, BRD-K25630527-001-03-8, BRD-K25630527-001-03-8, BRD-K25630527-001-03-8, BRD-K25630527-001-03-8, BRD-K25630527-001-03-8, BRD-K25630527-001-02-0, BRD-K25630527-001-02-0, BRD-K25630527-001-02-0	Phase 2
LY2795050	opioid receptor antagonist				BRD-K00003195-001-01-9	Preclinical
LY2801653	MET inhibitor	MET			BRD-K18961567-001-01-1, BRD-K18961567-001-01-1, BRD-K18961567-001-01-1, BRD-K18961567-001-02-9	Phase 2
LY2811376	beta-secretase inhibitor	BACE1			BRD-K94534639-001-03-9, BRD-K94534639-001-02-5, BRD-K94534639-001-02-5, BRD-K94534639-001-02-5, BRD-K94534639-001-02-5, BRD-K94534639-001-02-5	Phase 1
LY2828360	cannabinoid receptor agonist				BRD-K00005249-001-01-9	Phase 2
LY2857785	CDK inhibitor	CDK9			BRD-K15382985-001-01-7, BRD-K15382985-001-01-7, BRD-K15382985-001-01-7	Preclinical
LY2874455	FGFR antagonist	FGFR1, FGFR2, FGFR3, FGFR4, KDR			BRD-K17203476-001-01-9, BRD-K17203476-001-01-9, BRD-K17203476-001-01-9, BRD-K17203476-001-01-9, BRD-K17203476-001-01-9, BRD-K17203476-001-01-9, BRD-K17203476-001-01-9, BRD-K17203476-001-02-9	Phase 1
LY288513	CCK receptor antagonist	CCKBR			BRD-K24675965-001-06-9, BRD-K24675965-001-04-1	Preclinical
LY2886721	beta-secretase inhibitor	BACE1			BRD-K51258098-001-02-9	Phase 1/Phase 2
LY294002	DNA dependent protein kinase inhibitor, mTOR inhibitor, phosphodiesterase inhibitor, PI3K inhibitor, PLK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIM1, PLK1, PRKCA, PRKDC, ROCK1, RPS6KB1, SGK1			BRD-K27305650-001-16-6, BRD-K27305650-001-16-6, BRD-K27305650-003-03-0, BRD-K27305650-003-02-2	Preclinical
LY2979165	glutamate receptor agonist	GRM2			BRD-K68220839-413-02-8, BRD-K68220839-413-02-8, BRD-K68220839-413-02-8, BRD-K68220839-413-02-8, BRD-K68220839-413-01-0	Phase 1
LY3000328	cathepsin inhibitor	CTSS			BRD-K21070437-001-01-4, BRD-K21070437-001-01-4, BRD-K21070437-001-01-4	Phase 1
LY3009120	RAF inhibitor	BRAF, RAF1			BRD-K38385169-001-04-5, BRD-K38385169-001-04-5, BRD-K38385169-001-03-7	Phase 1
LY3023414	mTOR inhibitor, PI3K inhibitor	MTOR			BRD-K82967180-001-01-6, BRD-K82967180-001-01-6, BRD-K82967180-001-01-6	Phase 2
LY303511	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	BRD2, BRD3, BRD4			BRD-K22385716-001-03-3, BRD-K22385716-001-03-3, BRD-K22385716-001-02-5, BRD-K22385716-001-02-5, BRD-K22385716-001-02-5, BRD-K22385716-001-02-5, BRD-K22385716-001-02-5, BRD-K22385716-001-04-9	Preclinical
LY310762	serotonin receptor antagonist	HTR1D			BRD-K41194171-003-09-7, BRD-K41194171-003-09-7, BRD-K41194171-003-09-7, BRD-K41194171-003-09-7	Preclinical
LY311727	phospholipase inhibitor				BRD-K00004565-001-01-9	Preclinical
LY3200882	TGF beta receptor inhibitor				BRD-K00003446-001-01-9	Phase 1
LY320135	cannabinoid receptor antagonist	CNR1			BRD-K78637815-001-02-2, BRD-K78637815-001-03-9, BRD-K78637815-001-03-9	Preclinical
LY3214996	ERK inhibitor				BRD-K00003416-001-01-9	Phase 1
LY3295668	Aurora kinase inhibitor				BRD-K00004722-001-01-9	Phase 1/Phase 2
LY334370	serotonin receptor agonist				BRD-K00003451-001-01-9	Preclinical
LY344864	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR7			BRD-K95899059-003-03-6, BRD-K95899059-003-02-8, BRD-K95899059-003-04-9	Preclinical
LY364947	p38 MAPK inhibitor, TGF beta receptor inhibitor	TGFBR1			BRD-K06234293-001-04-2, BRD-K06234293-001-04-2, BRD-K06234293-001-04-2, BRD-K06234293-001-04-2, BRD-K06234293-001-03-4, BRD-K06234293-001-05-9	Preclinical
LY393558	serotonin receptor antagonist	HTR1B, HTR1D, HTR2A, HTR2B			BRD-K08534264-001-01-4, BRD-K08534264-001-02-9	Preclinical
LY404187	glutamate receptor positive allosteric modulator	GRIA1, GRIA2, GRIA3, GRIA4			BRD-A50062753-001-01-3, BRD-A50062753-001-02-9	Preclinical
LY411575	gamma secretase inhibitor				BRD-K20013301-001-03-9, BRD-K20013301-001-02-6	Preclinical
LY450108	glutamate receptor modulator				BRD-K54538117-001-01-7, BRD-K54538117-001-01-7	Phase 1
LY456236	glutamate receptor antagonist	GRM1			BRD-K87696786-003-05-1, BRD-K87696786-003-05-1, BRD-K87696786-003-04-4, BRD-K87696786-003-06-9	Preclinical
m-chlorophenylbiguanide	serotonin receptor agonist	HTR3A, HTR3B			BRD-K36965586-003-10-9, BRD-K36965586-003-08-8	Preclinical
m-THP					BRD-K91147684-001-01-5	Phase 1
M-14157	ATP-sensitive potassium channel antagonist	KCNQ1			BRD-A96977263-001-03-7	Phase 2
M-25	smoothened receptor antagonist	DHH, IHH, SMO			BRD-K51265828-001-02-9, BRD-K51265828-001-01-0	Preclinical
m-3M3FBS	phospholipase activator	PLCB2, PLCB3, PLCD1, PLCG1, PLCG2			BRD-K09635314-001-04-2, BRD-K09635314-001-03-4	Preclinical
M-344	HDAC inhibitor	HDAC8			BRD-K45528773-001-08-0, BRD-K45528773-001-08-0, BRD-K45528773-001-07-2, BRD-K45528773-001-06-4	Preclinical
mabuprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	BRD-A93683007-001-01-9, BRD-A93683007-001-01-9, BRD-A93683007-001-02-7	Launched
mabuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	BRD-A13116749-003-01-6	Launched
macelignan	anti-inflammatory agent, antioxidant				BRD-K94948151-001-07-4	Preclinical
macitentan	endothelin receptor antagonist	EDNRA, EDNRB	endocrinology	contraceptive	BRD-K48812570-001-02-3, BRD-K48812570-001-04-9, BRD-K48812570-001-03-1, BRD-K48812570-001-03-1, BRD-K48812570-001-03-1, BRD-K48812570-001-03-1, BRD-K48812570-001-03-1, BRD-K48812570-001-03-1	Launched
macitentan-n-butyl-analogue	endothelin receptor antagonist				BRD-K00003167-001-01-9	Preclinical
macozinone	DPRE1 inhibitor				BRD-K16343284-001-02-9	Preclinical
madecassoside	anti-inflammatory agent				BRD-K00003328-001-01-9	Preclinical
madrasin	cell splicing inhibitor				BRD-K48905682-001-11-1, BRD-K48905682-001-11-1, BRD-K48905682-001-11-1, BRD-K48905682-001-11-1, BRD-K48905682-001-11-1	Preclinical
mafenide	carbonic anhydrase inhibitor	CA12, CA14, CA2, CA4, CA6, CA9	infectious disease	first-aid antibiotic, skin infections	BRD-K30649484-015-15-9, BRD-K30649484-003-13-7	Launched
magnolol	PPAR receptor agonist	GABRA1, PPARG			BRD-K26168087-001-09-7, BRD-K26168087-001-09-7	Preclinical
malathion	cholinesterase inhibitor	ACHE	infectious disease	lice	BRD-A01976766-001-06-8, BRD-A01976766-001-06-8, BRD-A01976766-001-04-3, BRD-A01976766-001-07-6	Launched
malic-acid		PKD2L1			BRD-A18396475-001-16-1, BRD-A18396475-001-15-3	Launched
malotilate	protein synthesis stimulant		gastroenterology	hepatic cirrhosis	BRD-K97884852-001-06-9, BRD-K97884852-001-05-4	Launched
maltobionic-acid	matrix metalloprotease inhibitor		dermatology	cosmetic	BRD-K01624185-001-05-7, BRD-K01624185-001-05-7, BRD-K01624185-001-05-7, BRD-K01624185-001-05-7	Launched
mandelic-acid					BRD-A91448670-001-06-4, BRD-A91448670-001-08-9	Launched
manidipine	calcium channel blocker	CACNA1C, CACNA1D	cardiology	hypertension	BRD-K01825587-300-02-9, BRD-K01825587-300-02-9	Launched
manitimus	dehydrogenase inhibitor				BRD-K00004729-001-01-9	Preclinical
mannitol-D	diuretic		neurology/psychiatry, ophthalmology, gastroenterology	intracranial pressure, intraocular pressure, constipation	BRD-K30374899-001-09-3, BRD-K30374899-001-09-3	Launched
maprotiline	norepinephrine reputake inhibitor, tricyclic antidepressant	SLC6A2	neurology/psychiatry	depression, dysthymic disorder	BRD-K03319035-003-18-9, BRD-K03319035-003-18-9	Launched
maraviroc	CC chemokine receptor antagonist	CCR5	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K00004293-001-01-9	Launched
marbofloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	BRD-K71926323-001-13-8, BRD-K71926323-001-14-6, BRD-K71926323-001-14-6, BRD-K71926323-001-12-0, BRD-K71926323-001-12-0, BRD-K71926323-001-12-0, BRD-K71926323-001-12-0	Launched
maribavir	cytomegalovirus inhibitor, protein kinase inhibitor	PYGM			BRD-K59524082-001-01-3, BRD-K59524082-001-01-3, BRD-K59524082-001-02-9	Phase 3
marimastat	matrix metalloprotease inhibitor	MMP1, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP2, MMP20, MMP21, MMP23A, MMP24, MMP25, MMP26, MMP27, MMP28, MMP3, MMP7, MMP8, MMP9			BRD-K21396683-001-04-8, BRD-K21396683-001-04-8, BRD-K21396683-001-04-8, BRD-K21396683-001-04-8, BRD-K21396683-001-03-0	Phase 3
maropitant	neurokinin receptor antagonist	TACR1	gastroenterology	vomiting	BRD-K76594255-001-01-6, BRD-K76594255-001-01-6	Launched
masitinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor	FGFR3, KIT, PDGFRA, PDGFRB	dermatology	mastocytoma	BRD-K71035033-001-08-9, BRD-K71035033-001-08-9, BRD-K71035033-001-08-9, BRD-K71035033-001-08-9, BRD-K71035033-001-07-1, BRD-K71035033-001-07-1	Launched
masoprocol	lipoxygenase inhibitor	ALOX5	dermatology	actinic keratosis (AK)	BRD-A87130939-001-07-9, BRD-A87130939-001-07-9, BRD-A87130939-001-07-9, BRD-A87130939-001-08-9	Launched
matrine	opioid receptor agonist	OPRK1			BRD-K08623988-001-02-8	Phase 2
mavacamten	myosin inhibitor 				BRD-K00003497-001-01-9	Phase 3
mavatrep	transient receptor potential channel antagonist				BRD-K00003237-001-01-9	Preclinical
mavoglurant	glutamate receptor antagonist	GRM5			BRD-K07790550-001-01-6, BRD-K07790550-001-01-6	Phase 2
maxacalcitol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	BRD-K47318833-001-03-9	Launched
maytansinol-isobutyrate					BRD-K15898725-001-01-7, BRD-K15898725-001-01-7	Preclinical
MBX-2982	glucose dependent insulinotropic receptor agonist	GPR119			BRD-K32218650-001-01-6, BRD-K32218650-001-01-6, BRD-K32218650-001-01-6, BRD-K32218650-001-01-6, BRD-K32218650-001-01-6, BRD-K32218650-001-01-6, BRD-K32218650-001-02-9	Phase 2
MC-1		AADAT, ABAT, AGXT, AGXT2, ALAS1, AZIN2, BCAT1, BCAT2, CBS, CCBL1, CCBL2, CSAD, CTH, DDC, FTCD, GAD1, GAD2, GADL1, GCAT, GLDC, GOT1, GOT2, GPT, GPT2, HDC, IGSF10, KYNU, MOCOS, NFS1, OAT, ODC1, PDXDC1, PDXP, PHYKPL, PNPO, PROSC, PSAT1, PYGB, PYGL, PYGM, SCLY, SDS, SDSL, SEPSECS, SGPL1, SHMT1, SHMT2, SPTLC1, SPTLC2, SPTLC3, SRR, TAT, THNSL1			BRD-K50712474-002-02-5, BRD-K50712474-001-02-7	Phase 3
MCC950	NOD like receptor inhibitor	NLRP3			BRD-K55418700-001-03-0, BRD-K55418700-001-02-2	Preclinical
McN-5652-(+/-)	selective serotonin reuptake inhibitor (SSRI)				BRD-K31168993-001-02-8, BRD-K31168993-001-03-9	Preclinical
MCOPPB	nociceptin/orphanin FQ receptor agonist	OPRL1			BRD-K73276278-305-01-1, BRD-K73276278-305-02-9	Preclinical
mCPP	serotonin receptor agonist	HTR1A, HTR1D, HTR1E, HTR2A, HTR2B, HTR2C, HTR6			BRD-K75844781-001-09-9, BRD-K75844781-003-08-0	Phase 2
MD-920	NFkB pathway inhibitor	AADACL2			BRD-K92758126-001-18-8, BRD-K92758126-001-20-9	Phase 1
mdivi-1	dynamin inhibitor	DNM1			BRD-K61128465-001-09-9, BRD-K61128465-001-10-7, BRD-K61128465-001-10-7	Preclinical
MDL-11939	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			BRD-A62057054-001-04-9, BRD-A62057054-001-03-1	Phase 2
MDL-27531	glycine receptor agonist				BRD-K50888640-001-01-6	Preclinical
MDL-29951	glutamate receptor antagonist	FBP1			BRD-K59753853-001-02-3, BRD-K59753853-001-02-3, BRD-K59753853-001-02-3, BRD-K59753853-001-02-3	Preclinical
MDL-72832	serotonin receptor agonist	HTR1A			BRD-K01825683-003-03-9, BRD-K01825683-003-01-9	Preclinical
MDL-73005EF	serotonin receptor antagonist	HTR1A			BRD-K01826803-003-03-9, BRD-K01826803-003-02-9	Phase 1
MDMS	DNA inhibitor				BRD-K70840370-001-01-9	Phase 2
ME-0328	PPAR receptor antagonist	PARP3			BRD-K24283677-001-02-9, BRD-K24283677-001-03-9, BRD-K24283677-001-01-9	Preclinical
mebendazole	tubulin polymerization inhibitor	TUBA1A, TUBB, TUBB4B	infectious disease	pinworm, whipworm, hookworm, ascariasis	BRD-K77987382-001-16-9, BRD-K77987382-001-13-2	Launched
mebeverine	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	BRD-A09467419-003-23-9, BRD-A09467419-003-22-4	Launched
mebicar	anxiolytic		neurology/psychiatry	anxiety	BRD-K76606751-001-02-9, BRD-K76606751-001-01-7, BRD-K76606751-001-01-7	Launched
mebrofenin			radiology	diagnostic agent	BRD-K96691275-001-01-2	Launched
mecamylamine	acetylcholine receptor antagonist	CHRNA1, CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB4	cardiology	hypertension	BRD-A20119038-003-07-8, BRD-A20119038-003-07-8, BRD-A20119038-003-07-8	Launched
mecarbinate					BRD-K28405228-001-06-7	Preclinical
meclinertant	neurotensin receptor antagonist	NTSR1, NTSR2			BRD-K25075681-001-02-0, BRD-K25075681-001-02-0	Phase 2/Phase 3
meclizine	constitutive androstane receptor (CAR) agonist	NR1I3	gastroenterology, neurology/psychiatry	nausea, vomiting, motion sickness	BRD-K01826560-300-20-9	Launched
meclocycline-sulfosalicylate	bacterial 50S ribosomal subunit inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	BRD-A07600638-060-05-2, BRD-A07600638-060-06-0, BRD-A07600638-060-04-5	Launched
meclofenamic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist	ALOX5, CNR1, KCNQ2, KCNQ3, PTGS1, PTGS2	rheumatology, neurology/psychiatry, endocrinology	joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)	BRD-K50398167-236-23-5, BRD-K50398167-236-22-7	Launched
meclofenoxate	nootropic agent		neurology/psychiatry	senile dementia, Alzheimer's disease	BRD-K10314788-003-13-9, BRD-K10314788-003-12-7	Launched
mecysteine	analgesic agent		pulmonary	chest congestion	BRD-K81993098-003-15-0	Launched
medetomidine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	sedative	BRD-A66563878-003-10-9, BRD-A66563878-003-06-9, BRD-A66563878-003-04-9, BRD-A66563878-003-05-9	Launched
medica-16	ATP citrase lyase inhibitor	FFAR1			BRD-K92908289-001-01-8	Phase 2
medorinone					BRD-K40715924-001-02-9, BRD-K40715924-001-01-1	Phase 1
medronic-acid	bone resorption inhibitor		radiology	skeletal imaging agent	BRD-K94072573-001-09-9, BRD-K94072573-001-09-9	Launched
medroxyprogesterone	progesterone receptor agonist	PGR	endocrinology	contraceptive	BRD-K99615199-001-19-9, BRD-K99615199-001-19-9, BRD-K99615199-001-18-5, BRD-K99615199-001-18-5, BRD-K99615199-001-18-5	Launched
medroxyprogesterone-acetate	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	BRD-K82216340-001-26-9	Launched
mefenamic-acid	cyclooxygenase inhibitor	KCNQ1, PTGS1, PTGS2, TRPM3	endocrinology	primary dysmenorrhea (PD)	BRD-K92778217-001-35-9, BRD-K92778217-001-32-7, BRD-K92778217-001-31-9	Launched
mefexamide	psychoactive drug				BRD-K20655524-003-13-9, BRD-K20655524-003-12-0, BRD-K20655524-003-12-0	Preclinical
mefloquine	adenosine receptor antagonist, hemoglobin antagonist		infectious disease	malaria	BRD-K40645748-003-17-9	Launched
megestrol	progesterone receptor agonist		oncology	breast cancer	BRD-K00004691-001-01-9	Launched
meglitinide	potassium channel blocker	CCR2			BRD-K51324732-001-01-0	Phase 2
meglumine	excipient				BRD-K28595280-001-04-5, BRD-K28595280-001-03-7, BRD-K28595280-001-05-2, BRD-K28595280-001-05-2	Launched
meglutol	HMGCR inhibitor	HMGCR			BRD-K00495673-001-05-2	Launched
meisoindigo	STAT inhibitor	STAT3			BRD-K14529030-001-01-9, BRD-K14529030-001-01-9, BRD-K14529030-001-01-9, BRD-K14529030-001-03-9, BRD-K14529030-001-03-9	Phase 3
MEK1-2-inhibitor	MEK inhibitor	MAP2K2			BRD-K12244279-001-05-8, BRD-K12244279-001-04-1	Preclinical
melanotan-ii	melanocortin receptor agonist				BRD-K75989555-001-02-9	Launched
melatonin	melatonin receptor agonist, nitric oxide synthase inhibitor	ASMT, CALM1, CALR, EPX, ESR1, HTR2B, MPO, MTNR1A, MTNR1B, NQO2, RORB	neurology/psychiatry	sleep cycle support	BRD-K97530723-001-24-1, BRD-K97530723-001-20-9, BRD-K97530723-001-19-1, BRD-K97530723-001-25-9	Launched
meldonium	gamma butyrobetaine hydroxylase inhibitor	BBOX1	cardiology	coronary artery disease (CAD)	BRD-K79392608-335-01-8, BRD-K79392608-335-01-8	Launched
melengestrol-acetate	progesterone receptor agonist				BRD-A42746051-001-02-9	Preclinical
melevodopa	dopamine precursor, dopamine receptor agonist	DDC	neurology/psychiatry	Parkinson's Disease	BRD-K18749874-003-09-9, BRD-K18749874-003-08-9	Launched
meloxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	BRD-K01826742-323-07-9, BRD-K01826742-323-07-9, BRD-K01826742-323-07-9	Launched
melperone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	psychosis	BRD-K92984783-003-06-5, BRD-K92984783-003-05-7, BRD-K92984783-003-07-9	Launched
melphalan	DNA alkylating agent, DNA inhibitor		hematologic malignancy	multiple myeloma	BRD-K87827419-001-16-8, BRD-K87827419-001-16-8, BRD-K87827419-001-14-3, BRD-K87827419-001-14-3	Launched
melphalan-n-oxide	hypoxia inducible factor inhibitor	HIF1A			BRD-K36394566-300-01-0	Phase 1
meluadrine					BRD-A07164067-001-01-2	Preclinical
memantine	glutamate receptor antagonist		neurology/psychiatry	Alzheimer's disease, senile dementia	BRD-K91938660-003-10-9	Launched
menadione	mitochondrial DNA polymerase inhibitor, phosphatase inhibitor	AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1	gastroenterology, neurology/psychiatry, dermatology, rheumatology	ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis	BRD-K78126613-001-30-9, BRD-K78126613-001-28-5, BRD-K78126613-001-28-5, BRD-K78126613-001-28-5, BRD-K78126613-001-27-7, BRD-K78126613-001-29-3, BRD-K78126613-001-29-3	Launched
menadione-bisulfite	vitamin K	GGCX, VKORC1, VKORC1L1			BRD-K01826025-236-01-9, BRD-K01826025-236-01-9	Phase 2
menatetrenone	bone resorption inhibitor		orthopedics	osteoporosis	BRD-K75864342-001-14-2, BRD-K75864342-001-14-2	Launched
menbutone			gastroenterology	bile stimulation	BRD-K53852914-001-02-9, BRD-K53852914-001-01-8	Launched
mepacrine	cytokine production inhibitor, NFkB pathway inhibitor, TP53 activator	PLA2G1B	infectious disease	giardiasis	BRD-A45889380-300-06-3, BRD-A45889380-300-07-1, BRD-A45889380-300-07-1, BRD-A45889380-300-07-1, BRD-A45889380-300-08-9, BRD-A45889380-300-08-9	Launched
meparfylon					BRD-A11662333-001-03-3	Preclinical
mepazine	MALT1 inhibitor (JH)	MALT1			BRD-K01825575-001-03-9, BRD-K01825575-001-03-9, BRD-K01825575-001-03-9	Phase 2
mepenzolate	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	BRD-A62421304-004-19-9, BRD-A62421304-004-18-9, BRD-A62421304-004-17-1	Launched
mephenesin	muscle relaxant		neurology/psychiatry	muscle relaxant	BRD-A55469827-001-07-4, BRD-A55469827-001-08-9	Launched
mephentermine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3	cardiology	hypotension	BRD-K18194590-065-08-0, BRD-K18194590-003-09-9, BRD-K18194590-003-09-9	Launched
mephenytoin	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	BRD-A83937277-001-10-5, BRD-A83937277-001-10-5, BRD-A83937277-001-10-5, BRD-A83937277-001-12-9	Launched
mepiroxol					BRD-K78299798-001-03-0, BRD-K78299798-001-02-2, BRD-K78299798-001-04-8	Preclinical
mepivacaine	potassium channel blocker, sodium channel blocker		neurology/psychiatry	local anesthetic	BRD-A03216249-003-24-3, BRD-A03216249-003-23-5, BRD-A03216249-003-25-9, BRD-A03216249-003-25-9	Launched
meprednisone		NR3C1			BRD-K18207669-001-03-9, BRD-K18207669-001-02-4	Launched
meprylcaine	local anesthetic				BRD-K65417056-003-10-1, BRD-K65417056-003-11-9	Preclinical
meptazinol	opioid receptor agonist	BCHE	neurology/psychiatry	pain relief	BRD-A02710418-003-13-4, BRD-A02710418-003-12-6, BRD-A02710418-003-12-6, BRD-A02710418-003-11-8	Launched
mepyramine	histamine receptor antagonist	HRH1	otolaryngology, obstetrics/gynecology	common cold, menstrual pain	BRD-K97564742-051-02-8, BRD-K97564742-050-34-9, BRD-K97564742-050-32-7, BRD-K97564742-050-32-7, BRD-K97564742-050-32-7, BRD-K97564742-050-31-9	Launched
mequinol		TYR	dermatology	skin depigmentation	BRD-K45216060-001-10-0, BRD-K45216060-001-09-2, BRD-K45216060-001-11-8	Launched
merbarone	topoisomerase inhibitor	TOP2A			BRD-K45152786-001-09-9, BRD-K45152786-001-08-4	Phase 2
merbromin	antiseptic		infectious disease	first-aid antiseptic	BRD-K21771665-304-04-2	Launched
mercaptopurine	immunosuppressant, protein synthesis inhibitor, purine antagonist	HPRT1, IMPDH1, IMPDH2, PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	BRD-K91601245-001-12-0, BRD-K91601245-001-12-0, BRD-K91601245-001-16-1, BRD-K91601245-001-13-8	Launched
mercaptosuccinic-acid					BRD-A43435802-001-02-0, BRD-A43435802-001-01-2	Launched
Merck60	HDAC inhibitor	HDAC1, HDAC2				Preclinical
mericitabine	HCV inhibitor				BRD-K69726595-001-02-9, BRD-K69726595-001-01-2, BRD-K69726595-001-01-2, BRD-K69726595-001-01-2, BRD-K69726595-001-01-2, BRD-K69726595-001-01-2	Phase 2
merimepodib	inosine monophosphate dehydrogenase inhibitor	IMPDH1			BRD-K09372874-001-01-0, BRD-K09372874-001-01-0, BRD-K09372874-001-01-0, BRD-K09372874-001-01-0, BRD-K09372874-001-01-0, BRD-K09372874-001-02-9, BRD-K09372874-001-02-9	Phase 2
mertansine	microtubule inhibitor				BRD-K00003293-001-01-9	Phase 2
mesalazine	cyclooxygenase inhibitor, lipoxygenase inhibitor, prostanoid receptor antagonist	ALOX5, CHUK, IKBKB, MPO, PPARG, PTGS1, PTGS2	gastroenterology	ulcerative colitis, inflammatory bowel disease	BRD-K28849549-001-12-6, BRD-K28849549-001-13-4, BRD-K28849549-001-13-4, BRD-K28849549-001-13-4, BRD-K28849549-001-11-8	Launched
mesoridazine	dopamine receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	BRD-K01827307-074-10-9, BRD-K01827307-074-12-9, BRD-K01827307-074-13-9, BRD-K01827307-074-11-9, BRD-K01827307-074-11-9, BRD-K01827307-074-11-9	Launched
mestinon	cholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	myasthenia gravis	BRD-K69688083-004-24-9, BRD-K69688083-004-23-1, BRD-K69688083-004-23-1, BRD-K69688083-004-23-1, BRD-K69688083-004-22-3	Launched
mesulergine	dopamine receptor agonist	HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, HTR7			BRD-K91336023-003-01-0, BRD-K91336023-003-03-9	Phase 2
meta-cresyl-acetate					BRD-K33442414-001-02-6	Preclinical
metacetamol	analgesic agent				BRD-K16474819-001-09-6	Preclinical
metacresol		INS			BRD-K22518984-001-01-8, BRD-K22518984-001-01-8, BRD-K22518984-001-04-9	Launched
metafolin					BRD-K28580965-238-03-9, BRD-K28580965-238-01-3, BRD-K28580965-238-02-1	Launched
metamizole	cyclooxygenase inhibitor, opioid receptor agonist	PTGS1			BRD-K76812510-236-14-8	Withdrawn
metaphit	phencyclidine receptor acylator				BRD-K95701999-066-06-9, BRD-K95701999-001-02-3	Preclinical
metaraminol	adrenergic receptor agonist	ADRA1A	cardiology	hypotension	BRD-K96253961-046-04-9, BRD-K96253961-046-05-6, BRD-K96253961-046-05-6, BRD-K96253961-046-03-1, BRD-K96253961-046-03-1	Launched
metatinib	Bcr-Abl kinase inhibitor	ABL1, BCR			BRD-K27182532-001-03-9, BRD-K27182532-001-02-3, BRD-K27182532-001-02-3, BRD-K27182532-001-02-3	Phase 1
metaxalone	muscle relaxant		neurology/psychiatry	muscle pain	BRD-A94709349-001-08-3	Launched
metazosin	adrenergic receptor antagonist	ADRA1A			BRD-A78277353-001-01-9	Phase 2
metenkephalin	immunostimulant	OPRD1			BRD-A38218502-001-01-2, BRD-A38218502-001-01-2	Phase 2
metergoline	dopamine receptor agonist, serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7	neurology/psychiatry, endocrinology	seasonal affective disorder, anxiety, hyperprolactinemia	BRD-K56699285-001-24-3, BRD-K56699285-001-24-3, BRD-K56699285-001-25-9, BRD-K56699285-001-23-5	Launched
metformin	insulin sensitizer	ACACB, PRKAB1	endocrinology	diabetes mellitus	BRD-K79602928-003-19-9, BRD-K79602928-003-21-5, BRD-K79602928-003-18-1, BRD-K79602928-003-18-1, BRD-K79602928-003-23-9, BRD-K79602928-003-23-9	Launched
methacholine	acetylcholine receptor agonist	CHRM2, CHRM4	pulmonary	bronchial hyperresponsiveness diagnostic	BRD-A18056626-003-23-9, BRD-A18056626-003-23-9, BRD-A18056626-003-22-3	Launched
methacycline	protein synthesis inhibitor		pulmonary	bronchitis	BRD-K00003351-003-01-9	Preclinical
methanesulfonyl-fluoride	acetylcholinesterase inhibitor	ACHE			BRD-K53896891-001-01-2, BRD-K53896891-001-01-2	Phase 2
methantheline	acetylcholine receptor antagonist	CHRM1, HRH2	gastroenterology, neurology/psychiatry, urology	peptic ulcer disease (PUD), irritable bowel syndrome, pancreatitis, dyskinesia, neurogenic bladder	BRD-K09859624-004-10-4, BRD-K09859624-004-11-9	Launched
methapyrilene	histamine receptor antagonist	HRH1			BRD-K47323024-003-25-1, BRD-K47323024-003-24-4	Withdrawn
metharbital	GABA receptor modulator	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2	neurology/psychiatry	epilepsy	BRD-K88143662-001-01-5, BRD-K88143662-001-01-5, BRD-K88143662-001-01-5, BRD-K88143662-001-01-5	Launched
methazolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA7	ophthalmology	glaucoma, intraocular pressure	BRD-K00002562-001-02-9	Launched
methenamine	bacterial DNA inhibitor		infectious disease	urinary tract infections	BRD-K30114692-001-15-9, BRD-K30114692-001-16-7	Launched
methiazole	anthelmintic agent				BRD-K02764365-001-13-6, BRD-K02764365-001-13-6	Preclinical
methicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-K34388247-236-09-0, BRD-K34388247-236-08-2	Launched
methimazole	antithyroid agent	TPO	endocrinology	hyperthyroidism	BRD-K54416256-001-18-1, BRD-K54416256-001-19-9, BRD-K54416256-001-19-9	Launched
methionine		METAP2			BRD-A39515206-001-01-9	Launched
methiopril	angiotensin converting enzyme inhibitor	ACE			BRD-K00004541-001-01-9	Phase 2
methocarbamol	muscle relaxant	CA1	neurology/psychiatry	muscle relaxant	BRD-A31521121-001-25-6, BRD-A31521121-001-28-9, BRD-A31521121-001-26-4, BRD-A31521121-001-26-4	Launched
methoprene-(s)					BRD-K34591242-001-04-3, BRD-K34591242-001-05-9	Preclinical
methotrexate	dihydrofolate reductase inhibitor	DHFR	oncology, hematologic malignancy, dermatology, rheumatology	gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis	BRD-K59456551-001-22-6, BRD-K59456551-001-22-6, BRD-K59456551-001-22-6, BRD-K59456551-001-22-6, BRD-K59456551-001-19-2, BRD-K59456551-001-20-0, BRD-K59456551-001-27-9, BRD-K59456551-001-27-9, BRD-K59456551-001-27-9	Launched
methoxamine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	cardiology	hypotension	BRD-A39189014-003-21-9, BRD-A39189014-003-22-7, BRD-A39189014-003-23-5, BRD-A39189014-003-23-5, BRD-A39189014-003-23-5	Launched
methoxsalen	DNA synthesis inhibitor	CYP1A1, CYP1A2, CYP2A13, CYP2A6, CYP3A4	dermatology	psoriasis	BRD-K63430059-001-16-4, BRD-K63430059-001-17-2	Launched
methoxyamine	DNA repair enzyme inhibitor	APEX1			BRD-K79277568-003-04-7	Phase 2
methoxyflurane	membrane permeability inhibitor	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, MT-ND1	neurology/psychiatry	general anaesthetic	BRD-K06152156-001-02-6, BRD-K06152156-001-02-6, BRD-K06152156-001-01-8, BRD-K06152156-001-01-8, BRD-K06152156-001-01-8	Launched
methoxyphenamine	adrenergic receptor agonist		pulmonary	asthma	BRD-A21474126-001-01-6	Launched
methsuximide	T-type calcium channel blocker	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	BRD-A57592049-001-01-6, BRD-A57592049-001-02-9, BRD-A57592049-001-02-9	Launched
methyclothiazide	chloride reabsorption inhibitor	SLC12A1, SLC12A3	cardiology	hypertension, edema	BRD-A95340155-001-09-7, BRD-A95340155-001-09-7	Launched
methyl-aminolevulinate	oxidizing agent	FCGR1A, FECH	dermatology	actinic keratosis (AK)	BRD-K01292611-003-17-8	Launched
methyl-nicotinate					BRD-K10132944-001-02-9, BRD-K10132944-001-01-1	Phase 2
methyl-salicylate			endocrinology, neurology/psychiatry	fever, pain relief	BRD-K10103010-001-05-9, BRD-K10103010-001-01-1	Launched
methyl-5-hydroxytryptamine					BRD-K01827294-050-06-9, BRD-K01827294-050-05-9	Preclinical
methylatropine-nitrate	acetylcholine receptor antagonist	CHRM1			BRD-K00004543-005-01-9	Preclinical
methylbenactyzium-bromide	cholinergic receptor antagonist				BRD-K00003518-004-01-9	Preclinical
methylbenzethonium-chloride	other antibiotic				BRD-K46531780-003-18-9, BRD-K46531780-003-19-7	Preclinical
methylcobalamin	vitamin B				BRD-K00003534-001-01-9	Phase 3
methyldopa	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C, DDC	cardiology	hypertension	BRD-K48578705-001-17-6, BRD-K48578705-001-19-9, BRD-K48578705-001-19-9, BRD-K48578705-001-14-3, BRD-K48578705-001-15-0, BRD-K48578705-001-16-8	Launched
methyldopate			cardiology	hypertension	BRD-K82259334-003-02-7, BRD-K82259334-003-02-7	Launched
methylene-blue	guanylyl cyclase inhibitor, nitric oxide production inhibitor	ACHE	hematology	methemoglobinemia	BRD-K54770538-311-01-0, BRD-K54770538-003-14-6	Launched
methylergometrine	dopamine receptor antagonist, serotonin receptor antagonist	DRD1, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C	hematology, neurology/psychiatry	postpartum hemorrhage (PPH), migraine headache	BRD-K34685430-050-13-9, BRD-K34685430-050-11-7, BRD-K34685430-050-12-5	Launched
methylnaltrexone	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	gastroenterology	constipation	BRD-K00003599-004-01-9	Launched
methylparaben	other antifungal		dermatology	cosmetic	BRD-K78321730-001-13-9, BRD-K78321730-001-10-8	Launched
methylprednisolone-aceponate	anti-inflammatory agent, glucocorticoid receptor agonist	NR3C1	endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology	congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia	BRD-K24452555-001-01-7, BRD-K24452555-001-01-7, BRD-K24452555-001-02-9	Launched
methylprednisolone-sodium-succinate	glucocorticoid receptor agonist		endocrinology, rheumatology, dermatology, pulmonary, allergy, infectious disease, ophthalmology, gastroenterology, hematology, neurology/psychiatry	hypercalcemia, thyroiditis, osteoarthritis, rheumatoid arthritis, seborrheic dermatitis, asthma, allergic rhinitis, shingles, conjunctivitis, ulcerative colitis, enteritis, anemia, multiple sclerosis, mycosis	BRD-K00003673-236-01-9	Launched
methylthiouracil			endocrinology	hyperthyroidism	BRD-K11900042-001-14-4, BRD-K11900042-001-13-6	Launched
methysergide	serotonin receptor antagonist	HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7	neurology/psychiatry	headache	BRD-K35941380-050-27-9, BRD-K35941380-050-28-9, BRD-K35941380-050-28-9	Launched
meticrane	diuretic		cardiology	edema	BRD-K58265391-001-13-9, BRD-K58265391-001-13-9, BRD-K58265391-001-11-9, BRD-K58265391-001-12-7	Launched
metipranolol	adrenergic receptor antagonist				BRD-A99388803-001-01-5	Withdrawn
metirosine	tyrosine hydroxylase inhibitor	TH	cardiology	hypertension	BRD-K83766205-001-04-9, BRD-K83766205-001-04-9, BRD-K83766205-001-03-8	Launched
metitepine	anti-HCVE2	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			BRD-K01826545-050-03-9, BRD-K01826545-050-03-9	Preclinical
metixene	acetylcholine receptor antagonist	CHRM5	neurology/psychiatry	Parkinson's Disease	BRD-K01826531-311-08-9	Launched
metoclopramide	dopamine receptor antagonist, serotonin receptor antagonist	CHRM1, DRD2, HTR3A, HTR3B, HTR4	gastroenterology	gastroparesis, nausea, vomiting	BRD-K75641298-003-25-0, BRD-K75641298-001-26-9	Launched
metocurine	acetylcholine receptor antagonist	CHRM2, CHRNA2	neurology/psychiatry	muscle relaxant	BRD-K16484091-001-01-1	Launched
metolazone	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	BRD-A61793559-001-15-6, BRD-A61793559-001-16-4, BRD-A61793559-001-14-9, BRD-A61793559-001-17-9, BRD-A61793559-001-17-9	Launched
metoxibutropate	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-A71725768-001-01-3, BRD-A71725768-001-01-3	Launched
metrifonate	acetylcholinesterase inhibitor	ACHE			BRD-A22101059-001-15-5, BRD-A22101059-001-13-0, BRD-A22101059-001-14-8, BRD-A22101059-001-14-8	Phase 3
metrizamide	radiopaque medium		radiology	contrast agent	BRD-A45543382-001-11-9, BRD-A45543382-001-10-0	Launched
metrizoic-acid	radiopaque medium		radiology	contrast agent	BRD-K99241550-001-04-3, BRD-K99241550-001-04-3, BRD-K99241550-001-03-5	Launched
metronidazole	DNA inhibitor	CYP2C9, CYP3A4	dermatology	rosacea	BRD-K52020312-001-25-0, BRD-K52020312-001-26-8	Launched
metyrapone	cytochrome P450 inhibitor	CYP11B1	nephrology	adrenal diagnostic agent	BRD-K46862739-001-15-0, BRD-K46862739-001-13-5, BRD-K46862739-001-14-3, BRD-K46862739-001-14-3	Launched
mexeneone					BRD-K18613660-001-05-5, BRD-K18613660-001-05-5, BRD-K18613660-001-05-5	Preclinical
mexiletine	sodium channel blocker	PLAU, SCN4A, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	BRD-A64092382-003-18-3, BRD-A64092382-003-19-1, BRD-A64092382-003-19-1, BRD-A64092382-003-17-5, BRD-A64092382-003-20-9, BRD-A64092382-003-20-9, BRD-A64092382-003-16-7	Launched
ME0328	PARP inhibitor	PARP3			BRD-A63444178-001-01-5, BRD-A63444178-001-01-5, BRD-A63444178-001-01-5	Preclinical
MF-101	estrogen receptor agonist	CYP19A1, XDH			BRD-K34328244-001-02-9, BRD-K34328244-001-01-4	Phase 3
MG-132	proteasome inhibitor	PSMB1			BRD-K60230970-001-17-5, BRD-K60230970-001-17-5, BRD-K60230970-001-17-5, BRD-K60230970-001-13-4, BRD-K60230970-001-13-4, BRD-K60230970-001-16-7, BRD-K60230970-001-16-7, BRD-K60230970-001-16-7, BRD-K60230970-001-16-7	Preclinical
MG-624	acetylcholine receptor antagonist	CHRNA7			BRD-K03128577-005-07-0, BRD-K03128577-005-08-9, BRD-K03128577-005-06-2	Preclinical
MGCD-265	VEGFR inhibitor	AXL, MET			BRD-K56277358-001-07-5, BRD-K56277358-001-07-5	Preclinical
MI-14	PI4K inhibitor	PI4KB			BRD-K26726854-001-01-0, BRD-K26726854-001-02-9	Preclinical
mianserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HRH1, HRH2, HTR2A, HTR2B, HTR2C, HTR6, HTR7	neurology/psychiatry	depression	BRD-A19661776-003-27-6, BRD-A19661776-003-28-4, BRD-A19661776-003-26-8, BRD-A19661776-003-25-0	Launched
mibampator	glutamate receptor modulator	GRIA1			BRD-K42981054-001-02-9, BRD-K42981054-001-02-9, BRD-K42981054-001-01-9, BRD-K42981054-001-01-9	Phase 2
mibefradil	T-type calcium channel blocker	ANO1, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CATSPER1, CATSPER2, CATSPER3, CATSPER4			BRD-K09549677-300-04-2, BRD-K09549677-300-03-4, BRD-K09549677-300-03-4, BRD-K09549677-300-03-4, BRD-K09549677-300-03-4, BRD-K09549677-300-03-4, BRD-K09549677-300-09-9	Withdrawn
miconazole	bacterial cell wall synthesis inhibitor	TRPM2, TRPV5	infectious disease, neurology/psychiatry	yeast infection, itching	BRD-K01826511-001-16-9, BRD-K01826511-008-18-9	Launched
micronomicin	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	BRD-K18552138-001-01-8, BRD-K18552138-065-01-3	Launched
midafotel	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			BRD-K45163704-001-02-3, BRD-K45163704-001-01-5	Phase 3
midecamycin	protein synthesis inhibitor		infectious disease	respiratory tract infections, ear infections, skin infections	BRD-K68822425-001-01-6	Launched
midodrine	adrenergic receptor agonist		cardiology	hypotension	BRD-A79981887-003-16-4, BRD-A79981887-003-16-4, BRD-A79981887-001-17-9, BRD-A79981887-001-17-9	Launched
midostaurin	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	FLT3, PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	BRD-K13646352-001-03-8, BRD-K13646352-001-03-8, BRD-K13646352-001-03-8, BRD-K13646352-001-03-8, BRD-K13646352-001-03-8, BRD-K13646352-001-03-8, BRD-K13646352-001-03-8, BRD-K13646352-001-03-8, BRD-K13646352-001-03-8, BRD-K13646352-001-02-0, BRD-K13646352-001-02-0, BRD-K13646352-001-02-0	Launched
mifobate	PPAR receptor antagonist	PPARG			BRD-K00004244-001-01-9	Phase 2
miglustat	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	BRD-K33251802-001-01-3, BRD-K33251802-003-15-9	Launched
milacemide	monoamine oxidase inhibitor	MAOB			BRD-K64338723-001-02-9, BRD-K64338723-001-02-9, BRD-K64338723-001-01-6, BRD-K64338723-001-01-6	Phase 3
milademetan	MDM inhibitor				BRD-K00003406-001-01-9	Phase 1
milnacipran	serotoninâ€“norepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A4	rheumatology	fibromyalgia	BRD-K00004287-003-01-9	Launched
milrinone	phosphodiesterase inhibitor	PDE2A, PDE3A, PDE3B, PDE5A	cardiology	congestive heart failure	BRD-K67080878-001-16-2, BRD-K67080878-001-16-2, BRD-K67080878-001-15-4, BRD-K67080878-001-15-4, BRD-K67080878-001-22-9, BRD-K67080878-001-22-9	Launched
miltefosine	membrane integrity inhibitor	PLA2G1B	infectious disease	leishmaniasis	BRD-K01824991-001-04-9	Launched
mimosine	DNA replication inhibitor	CCL2, SHMT1, SHMT2, TYR			BRD-K67642028-001-04-4, BRD-K67642028-001-03-6	Preclinical
minaprine	serotonin reuptake inhibitor	ACHE, CHRM1, DRD1, DRD2, HTR2A, HTR2B, HTR2C, MAOA, SLC6A4			BRD-K02867583-300-15-9, BRD-K02867583-300-08-9	Withdrawn
minerval	FAAH inhibitor				BRD-A74347210-001-01-7, BRD-A74347210-001-01-7, BRD-A74347210-001-01-7	Phase 1/Phase 2
minocycline	bacterial 30S ribosomal subunit inhibitor		endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis	BRD-K00003346-003-01-9	Launched
minodronic-acid	bone resorption inhibitor	FDPS, GGPS1	orthopedics	osteoporosis	BRD-K89337853-001-01-1, BRD-K89337853-001-02-9, BRD-K89337853-001-02-9	Launched
miocamycin	other antibiotic		infectious disease	urinary tract infections, chlamydia	BRD-K30764557-001-01-5	Launched
MIRA-1	apoptosis stimulant				BRD-K39706510-001-03-9	Preclinical
mirabegron	adrenergic receptor agonist	ADRB1, ADRB2, ADRB3	urology	urinary incontinence	BRD-K47949423-001-02-3, BRD-K47949423-001-02-3, BRD-K47949423-001-04-9, BRD-K47949423-001-03-1, BRD-K47949423-001-03-1	Launched
miridesap	amyloid protein inhibitor				BRD-K00003434-001-01-9	Preclinical
mirin	MRE11A exonuclease inhibitor	MRE11A			BRD-K55420858-001-02-8, BRD-K55420858-001-01-0	Preclinical
miriplatin	DNA synthesis inhibitor		oncology	hepatocellular carcinoma (HCC)	BRD-M78068755-001-02-0, BRD-M78068755-001-01-2	Launched
mirodenafil	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	BRD-K82967685-300-01-2, BRD-K82967685-300-01-2, BRD-K82967685-300-02-9	Launched
mirogabalin-besylate	calcium channel antagonist				BRD-K00003484-074-01-9	Preclinical
mirtazapine	adrenergic receptor antagonist, serotonin receptor antagonist	ADRA2A, ADRA2B, ADRA2C, HTR2A, HTR2C	neurology/psychiatry	depression	BRD-A64977602-001-16-7, BRD-A64977602-001-15-9, BRD-A64977602-001-17-9, BRD-A64977602-001-13-4, BRD-A64977602-001-14-2	Launched
misonidazole					BRD-A16263897-001-06-6	Phase 3
misoprostol	prostanoid receptor agonist	PTGER2, PTGER3, PTGER4, PTGIR	gastroenterology	duodenal ulcer disease	BRD-A72351335-001-04-5	Launched
mitapivat	pyruvate kinase isozyme activator				BRD-K00003136-001-01-9	Preclinical
mitoflaxone	antitumor agent	VWF			BRD-K35882976-001-04-7	Phase 2
mitomycin-C	DNA alkylating agent, DNA synthesis inhibitor		oncology	pancreatic cancer, gastric adenocarcinoma	BRD-K59670716-001-20-9	Launched
mitoquinone	antioxidant				BRD-K00003362-066-01-9, BRD-K00003362-066-01-9	Launched
mitotane	antineoplastic agent	CYP11A1, CYP11B1, ESR1	oncology	adrenal cortical carcinoma	BRD-A31204924-001-18-3, BRD-A31204924-001-14-2, BRD-A31204924-001-14-2, BRD-A31204924-001-17-5, BRD-A31204924-001-16-7, BRD-A31204924-001-13-4	Launched
mitoxantrone	topoisomerase inhibitor	TOP2A	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)	BRD-K21680192-300-15-1, BRD-K21680192-300-15-1, BRD-K21680192-300-15-1, BRD-K21680192-300-16-9, BRD-K21680192-300-16-9, BRD-K21680192-300-16-9, BRD-K21680192-300-16-9, BRD-K21680192-300-14-4	Launched
mivacurium	acetylcholine receptor antagonist	CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	BRD-A48465967-300-01-1	Launched
mivebresib	bromodomain inhibitor				BRD-K00003356-001-01-9, BRD-K00003356-001-01-9	Phase 1
mivobulin	microtubule inhibitor				BRD-K39576764-071-01-6	Phase 2
MIW-815	interferon inducer				BRD-K00003146-318-01-9	Preclinical
mizolastine	histamine receptor antagonist	HRH1	allergy	urticaria, allergic rhinitis	BRD-K21884483-001-04-9, BRD-K21884483-001-03-7	Launched
MJ-15	cannabinoid receptor antagonist	CNR1			BRD-K71315565-001-01-6, BRD-K71315565-001-02-9	Preclinical
MK-0354	niacin receptor agonist	HCAR2, HCAR3			BRD-K91405252-001-01-9	Phase 2
MK-0557	neuropeptide receptor antagonist				BRD-K00003190-001-01-9	Phase 3
MK-0608	antiviral				BRD-K00004557-001-01-9	Phase 1
MK-0752	gamma secretase inhibitor				BRD-K18850819-001-04-6, BRD-K18850819-001-04-6	Phase 1/Phase 2
MK-0773	androgen receptor modulator	AR			BRD-K38868394-001-02-9, BRD-K38868394-001-01-3, BRD-K38868394-001-01-3	Phase 2
MK-0812	CC chemokine receptor antagonist	CCR2			BRD-K14175878-036-02-9, BRD-K14175878-001-01-6, BRD-K14175878-001-01-6	Phase 2
MK-0893	glucagon receptor antagonist	GCGR			BRD-K16732600-001-02-9, BRD-K16732600-001-01-7, BRD-K16732600-001-01-7, BRD-K16732600-001-01-7, BRD-K16732600-001-01-7	Phase 2
MK-1064	orexin receptor antagonist				BRD-K00003304-001-01-9	Phase 1
MK-1775	WEE1 kinase inhibitor	WEE1			BRD-K54256913-001-08-7, BRD-K54256913-001-08-7, BRD-K54256913-001-08-7, BRD-K54256913-001-05-3	Phase 2
MK-1903	niacin receptor agonist				BRD-K00004660-001-01-9	Phase 2
MK-2206	AKT inhibitor	AKT1, AKT2, AKT3			BRD-K68065987-300-09-1, BRD-K68065987-300-09-1, BRD-K68065987-300-09-1, BRD-K68065987-300-09-1, BRD-K68065987-300-09-1, BRD-K68065987-300-09-1, BRD-K68065987-300-03-4, BRD-K68065987-300-03-4, BRD-K68065987-300-03-4, BRD-K68065987-300-03-4, BRD-K68065987-300-03-4, BRD-K68065987-300-03-4	Phase 2
MK-2295	TRPV antagonist	TRPV1			BRD-K43316319-001-01-8	Phase 2
MK-2461	FGFR inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB			BRD-K56405753-001-03-9, BRD-K56405753-001-02-4	Phase 1/Phase 2
MK-2894	prostaglandin inhibitor	PTGER4			BRD-K27983781-001-01-4	Preclinical
MK-3207	calcitonin antagonist	CALCA			BRD-K66911501-003-02-9, BRD-K66911501-003-01-2, BRD-K66911501-003-01-2	Phase 2
MK-3697	orexin receptor antagonist	HCRTR2			BRD-K95828359-001-01-0, BRD-K95828359-001-02-9	Phase 2
MK-4074	acetyl-CoA carboxylase inhibitor				BRD-K00003482-001-01-9	Phase 1
MK-5046	bombesin receptor agonist	BRS3, GRPR, NMBR			BRD-K03886848-001-01-8	Preclinical
MK-5108	Aurora kinase inhibitor	AURKA, AURKB, AURKC			BRD-K53665955-001-03-0, BRD-K53665955-001-03-0, BRD-K53665955-001-03-0, BRD-K53665955-001-03-0, BRD-K53665955-001-04-8, BRD-K53665955-001-04-8	Phase 1
MK-571	leukotriene receptor antagonist	ABCC2, CYSLTR1			BRD-A73679382-236-01-8, BRD-A73679382-236-01-8	Phase 2
MK-6096	orexin receptor antagonist	HCRTR1, HCRTR2			BRD-K03894385-001-01-1	Phase 2
MK-7246	CRTH receptor antagonist				BRD-K00003199-001-01-9	Preclinical
MK-7622	cholinergic receptor agonist				BRD-K00003194-001-01-9	Phase 2
MK-8033	c-Met inhibitor	MET			BRD-K55512740-001-01-6, BRD-K55512740-001-01-6, BRD-K55512740-001-02-9	Phase 1
MK-8245	stearoyl-CoA desaturase inhibitor	SCD			BRD-K29656036-001-02-5, BRD-K29656036-001-02-5, BRD-K29656036-001-02-5, BRD-K29656036-001-02-5, BRD-K29656036-001-03-9	Phase 2
MK-8617	hypoxia inducible factor prolyl hydroxylase inhibitor				BRD-K00003397-001-01-9	Preclinical
MK-8745	Aurora kinase inhibitor	AURKA			BRD-K25279140-001-01-5, BRD-K25279140-001-02-9	Preclinical
MK-886	lipoxygenase inhibitor				BRD-K20168484-001-07-9	Preclinical
MK-8998	T-type calcium channel blocker				BRD-K86677390-001-02-9	Phase 2
MKT-077	HSP inhibitor				BRD-K61695967-003-02-1, BRD-K61695967-003-01-3	Phase 1
MK2-IN-1	MAP kinase inhibitor	MAPKAPK2			BRD-K90316462-003-01-1	Preclinical
MLN0128	mTOR inhibitor	MTOR, PIK3CA, PIK3CD, PIK3CG			BRD-K59317601-001-05-5, BRD-K59317601-001-05-5, BRD-K59317601-001-05-5, BRD-K59317601-001-05-5, BRD-K59317601-001-06-9	Phase 2
MLN1117	PI3K inhibitor	PIK3CA			BRD-K73877023-001-01-9, BRD-K73877023-001-01-9	Phase 2
MLN2480	RAF inhibitor				BRD-K43410529-001-02-3, BRD-K43410529-001-02-3	Phase 1/Phase 2
MLN8054	Aurora kinase inhibitor	AURKA			BRD-K83963101-001-08-9, BRD-K83963101-001-06-9, BRD-K83963101-001-06-9, BRD-K83963101-001-06-9	Phase 1
MLN9708	proteasome inhibitor				BRD-K15203492-001-01-1, BRD-K15203492-001-02-9	Phase 3
ML10302	serotonin receptor partial agonist	HTR3A, HTR3B, HTR4			BRD-K69343602-003-01-3, BRD-K69343602-003-02-9, BRD-K69343602-003-02-9	Preclinical
ML130	NOD1 inhibitor				BRD-K89306950-001-13-3, BRD-K89306950-001-12-5, BRD-K89306950-001-14-9	Preclinical
ML133	potassium channel blocker				BRD-K33743361-003-08-9, BRD-K33743361-003-02-6	Preclinical
ML141	GTPase inhibitor	CDC42			BRD-A28422330-001-10-1, BRD-A28422330-001-11-9	Preclinical
ML161	protease-activated receptor inhibitor				BRD-K59036917-001-17-5, BRD-K59036917-001-16-7	Preclinical
ML167	CLK inhibitor, DYRK inhibitor	CLK4, DYRK1B			BRD-K64835161-001-02-8, BRD-K64835161-001-02-8	Preclinical
ML179	liver receptor homolog inverse agonist	NR5A2			BRD-K77547509-001-04-9, BRD-K77547509-001-03-3	Preclinical
ML193	G protein-coupled receptor antagonist	GPR55			BRD-K27539181-001-09-9, BRD-K27539181-001-09-9, BRD-K27539181-001-08-5	Preclinical
ML204	transient receptor potential channel antagonist	TRPC4, TRPC5			BRD-K80021413-001-08-8, BRD-K80021413-001-08-8	Preclinical
ML213	potassium channel activator	KCNQ4			BRD-K00004301-001-01-9	Preclinical
ML218	T-type calcium channel blocker	CACNA1G, CACNA1H, CACNA1I			BRD-K92995792-003-03-9, BRD-K92995792-003-02-9	Preclinical
ML228	hypoxia inducible factor activator	HIF1A			BRD-K44432556-001-05-5, BRD-K44432556-001-05-5, BRD-K44432556-001-01-4, BRD-K44432556-001-01-4, BRD-K44432556-001-01-4, BRD-K44432556-001-01-4, BRD-K44432556-001-01-4	Preclinical
ML277	potassium channel activator	KCNQ1			BRD-K60020910-001-03-9, BRD-K60020910-001-03-9, BRD-K60020910-001-02-5	Preclinical
ML281	serine/threonine kinase inhibitor	STK33			BRD-K48188942-001-03-7, BRD-K48188942-001-03-7, BRD-K48188942-001-01-1, BRD-K48188942-001-01-1, BRD-K48188942-001-01-1, BRD-K48188942-001-01-1, BRD-K48188942-001-01-1, BRD-K48188942-001-01-1, BRD-K48188942-001-01-1	Preclinical
ML297	inward rectifier potassium channel activator	KCNJ3			BRD-K51137250-001-02-6, BRD-K51137250-001-01-8, BRD-K51137250-001-01-8, BRD-K51137250-001-01-8, BRD-K51137250-001-01-8, BRD-K51137250-001-01-8	Preclinical
ML298	phospholipase inhibitor	PLD2			BRD-K24600306-003-02-9, BRD-K24600306-003-02-9, BRD-K24600306-003-01-9	Preclinical
ML314	neurotensin agonist	NTSR1			BRD-K92606079-001-02-0	Preclinical
ML323	ubiquitin specific protease inhibitor	USP1			BRD-K93942811-001-01-3, BRD-K93942811-001-01-3	Preclinical
ML324	histone lysine demethylase inhibitor	KDM4A			BRD-K25611237-001-02-1, BRD-K25611237-001-02-1	Preclinical
ML3403	MAP kinase inhibitor	CYP3A4, MAPK11, MAPK12, MAPK14			BRD-A29014990-001-03-9, BRD-A29014990-001-03-9, BRD-A29014990-001-02-3	Preclinical
ML347	ALK tyrosine kinase receptor inhibitor	ACVR1, ACVRL1, BMPR1A			BRD-K33892651-001-04-9, BRD-K33892651-001-02-4, BRD-K33892651-001-02-4, BRD-K33892651-001-02-4, BRD-K33892651-001-02-4, BRD-K33892651-001-03-2	Preclinical
ML348	lysophospholipase inhibitor	LYPLA1			BRD-K81044214-001-06-4, BRD-K81044214-001-07-9	Preclinical
ML365	potassium channel blocker	KCNK3, KCNK9			BRD-K02160913-001-02-7, BRD-K02160913-001-03-9	Preclinical
ML786	RAF inhibitor	BRAF, RAF1			BRD-K52644305-300-02-9, BRD-K52644305-300-01-3	Preclinical
ML9	myosin light chain kinase inhibitor	TRPC6			BRD-K68402494-003-03-5, BRD-K68402494-003-03-5, BRD-K68402494-003-04-3, BRD-K68402494-003-04-3	Preclinical
MM-102	WDR5/MLL interaction inhibitor				BRD-K68474068-019-02-9, BRD-K68474068-001-01-8	Preclinical
MM-11253	retinoid receptor antagonist	RARG			BRD-K98353094-001-01-6, BRD-K98353094-001-01-6, BRD-K98353094-001-02-9	Preclinical
MM-206	STAT inhibitor				BRD-K00004622-001-01-9	Preclinical
MMPX	phosphodiesterase inhibitor				BRD-K56077740-001-10-9, BRD-K56077740-001-09-2, BRD-K56077740-001-09-2	Preclinical
MMV-390048	PI4K inhibitor				BRD-K78973789-001-02-9	Preclinical
MM77	serotonin receptor antagonist	HTR1A			BRD-K50293352-300-03-9, BRD-K50293352-300-02-1	Preclinical
MN-64	tankyrase inhibitor	TNKS			BRD-K16183658-001-02-9, BRD-K16183658-001-01-4	Preclinical
MNITMT	lymphocyte inhibitor				BRD-K63151507-001-02-4, BRD-K63151507-001-03-9	Preclinical
mocetinostat	HDAC inhibitor	HDAC1, HDAC11, HDAC2, HDAC3			BRD-K16485616-001-13-9, BRD-K16485616-001-13-9, BRD-K16485616-001-12-1, BRD-K16485616-001-12-1, BRD-K16485616-001-08-9, BRD-K16485616-001-08-9	Phase 2
moclobemide	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression, anxiety	BRD-K07237224-001-22-9, BRD-K07237224-001-22-9, BRD-K07237224-001-20-4, BRD-K07237224-001-19-6	Launched
modaline					BRD-K25317177-065-01-4	Preclinical
moexipril	angiotensin converting enzyme inhibitor	ACE, ACE2	cardiology	hypertension	BRD-K34441861-003-06-2, BRD-K34441861-003-08-9, BRD-K34441861-003-08-9, BRD-K34441861-003-05-4, BRD-K34441861-003-07-0	Launched
mofegiline	monoamine oxidase inhibitor	MAOA, MAOB			BRD-K52598503-003-01-1, BRD-K52598503-003-01-1, BRD-K52598503-003-02-9	Phase 1
mofezolac	cyclooxygenase inhibitor	PTGS1	rheumatology, orthopedics	rheumatoid arthritis, osteoporosis	BRD-K49372556-001-04-1	Launched
moguisteine	ATP-sensitive potassium channel inhibitor				BRD-A87673115-001-04-1	Phase 2
molidustat	hypoxia inducible factor inhibitor	EGLN2			BRD-K01291782-001-02-9, BRD-K01291782-001-01-1, BRD-K01291782-001-01-1	Phase 3
molindone	dopamine receptor antagonist	DRD2, HRH1, HTR2A	neurology/psychiatry	schizophrenia	BRD-A65280694-003-13-7, BRD-A65280694-003-14-9	Launched
molsidomine	guanylate cyclase stimulant	GUCY1A3	cardiology	coronary artery disease (CAD)	BRD-K63861289-001-29-9, BRD-K63861289-001-29-9, BRD-K63861289-001-19-6	Launched
mometasone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-K50265942-001-01-2	Launched
monastrol	kinesin inhibitor	KIF11			BRD-A78377521-001-06-3, BRD-A78377521-001-06-3, BRD-A78377521-001-05-5, BRD-A78377521-001-05-5, BRD-A78377521-001-05-5	Preclinical
monensin	bacterial permeability inducer		infectious disease	gastrointestinal parasites	BRD-K55375480-236-04-9	Launched
monepantel	mTOR inhibitor				BRD-K00004607-001-01-9	Preclinical
monobenzone	melanin inhibitor	TYR	dermatology	skin depigmentation	BRD-K54262262-001-10-8, BRD-K54262262-001-12-4, BRD-K54262262-001-11-6, BRD-K54262262-001-11-6, BRD-K54262262-001-09-0	Launched
monocrotaline	antitumor agent				BRD-K65508953-001-13-9	Preclinical
monoctanoin			gastroenterology	gallstones	BRD-A48938994-001-15-8, BRD-A48938994-001-14-1	Launched
monomethyl-fumarate			neurology/psychiatry	multiple sclerosis	BRD-K00004695-001-01-9	Launched
monosodium-alpha-luminol					BRD-K79926543-001-07-6, BRD-K79926543-001-08-4, BRD-K79926543-001-08-4, BRD-K79926543-001-09-9	Launched
monostearin					BRD-A31454688-001-01-6	Preclinical
montelukast	leukotriene receptor antagonist	ALOX5, CYSLTR1	pulmonary, allergy	asthma, allergic rhinitis, exercise-induced bronchoconstriction (EIB)	BRD-K69470111-236-10-9, BRD-K69470111-001-01-2, BRD-K69470111-001-01-2, BRD-K69470111-236-08-9, BRD-K69470111-236-08-9, BRD-K69470111-236-09-7, BRD-K69470111-236-09-7, BRD-K69470111-236-09-7	Launched
moprolol	adrenergic receptor antagonist		cardiology, ophthalmology, neurology/psychiatry	hypertension, glaucoma, anxiety	BRD-A51747092-003-03-0, BRD-A51747092-003-03-0	Launched
moracizine	sodium channel blocker	SCN5A	cardiology	ventricular arrhythmias	BRD-K21548250-003-20-9, BRD-K21548250-003-20-9, BRD-K21548250-003-19-1	Withdrawn
morantel	acetylcholine receptor agonist		infectious disease	tapeworm	BRD-K71454870-048-06-3, BRD-K71454870-046-01-8	Launched
morin	cytochrome P450 inhibitor	ADORA2A, ESR2, FASN, MCL1, SLC22A12			BRD-K11590034-002-02-6, BRD-K11590034-002-03-4, BRD-K11590034-002-03-4, BRD-K11590034-002-03-4, BRD-K11590034-002-03-4, BRD-K11590034-002-04-2	Preclinical
morinidazole	other antibiotic	CYP51A1			BRD-A40546373-001-01-8	Launched
morniflumate	anti-inflammatory agent		neurology/psychiatry	pain relief	BRD-K38938675-001-01-4	Launched
moroxydine	antiviral		infectious disease	influenza A virus infection	BRD-K88786763-003-03-9	Launched
morphothiadin	antiinfective drug				BRD-K00003491-001-01-9	Preclinical
mosapride	serotonin receptor agonist	HTR4	gastroenterology	hypertrophic gastritis (GHG), gastroesophageal reflux disease (GERD), dyspepsia, irritable bowel syndrome	BRD-A39052811-048-12-8, BRD-A39052811-048-11-0	Launched
motapizone	phosphodiesterase inhibitor				BRD-K00004657-001-01-9	Preclinical
motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FLT1, FLT4, KDR, KIT			BRD-K99616396-001-06-9, BRD-K99616396-001-05-1, BRD-K99616396-001-05-1, BRD-K99616396-001-05-1, BRD-K99616396-316-04-6, BRD-K99616396-316-06-1, BRD-K99616396-316-06-1, BRD-K99616396-316-05-3	Phase 3
motolimod	toll-like receptor agonist	TLR8			BRD-K11785681-001-01-2, BRD-K11785681-001-01-2	Phase 2
moxalactam	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections, skin infections, bone and joint infections, pneumonia, urinary tract infections, meningitis	BRD-A08899266-001-06-9, BRD-A08899266-304-05-0	Launched
moxaverine	phosphodiesterase inhibitor		neurology/psychiatry	spasms	BRD-K12742203-003-01-7, BRD-K12742203-003-01-7	Launched
moxidectin	chloride channel antagonist		infectious disease	gastrointestinal parasites	BRD-K00003660-001-01-9	Launched
moxifloxacin	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology, pulmonary, infectious disease	sinusitis, bronchitis, pneumonia, skin infections, intra-abdominal infections	BRD-K66615216-003-14-8, BRD-K66615216-003-14-8, BRD-K66615216-003-13-0	Launched
moxisylyte	adrenergic receptor antagonist				BRD-K81144366-003-20-9, BRD-K81144366-003-19-7	Withdrawn
moxonidine	imidazoline receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	BRD-K77771411-003-12-3, BRD-K77771411-003-10-7, BRD-K77771411-001-12-7, BRD-K77771411-001-12-7, BRD-K77771411-001-12-7, BRD-K77771411-003-13-9, BRD-K77771411-003-13-9	Launched
mozavaptan	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2	endocrinology	hyponatremia	BRD-A31095847-001-03-9, BRD-A31095847-001-02-3, BRD-A31095847-001-02-3	Launched
MPEP	glutamate receptor antagonist	GRM1, GRM4, GRM5			BRD-K60690191-003-11-2, BRD-K60690191-001-03-3, BRD-K60690191-001-03-3, BRD-K60690191-003-09-6	Preclinical
MPI-0479605	mitotic kinase inhibitor	TTK			BRD-K45551181-001-03-9, BRD-K45551181-001-03-9, BRD-K45551181-001-03-9, BRD-K45551181-001-01-3, BRD-K45551181-001-04-7, BRD-K45551181-001-02-1	Preclinical
Mps-BAY-2a	monopolar spindle 1 kinase inhibitor	TTK			BRD-K18530250-001-01-6, BRD-K18530250-001-02-9	Preclinical
Mps1-IN-1	monopolar spindle 1 kinase inhibitor	TTK			BRD-K94853001-300-04-9, BRD-K94853001-300-04-9, BRD-K94853001-300-01-7	Preclinical
Mps1-IN-5	protein kinase inhibitor				BRD-K43812936-001-01-9, BRD-K43812936-001-02-9	Phase 1
MR-16728	acetylcholine release enhancer				BRD-A30590053-003-03-9, BRD-A30590053-003-02-9	Preclinical
MR-948	thromboxane synthase inhibitor	TBXAS1			BRD-K84883208-001-01-1	Phase 1
MRK-016	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			BRD-K44022883-001-01-7, BRD-K44022883-001-01-7, BRD-K44022883-001-02-5	Phase 1
MRK-409	benzodiazepine receptor agonist				BRD-K57416838-001-02-9, BRD-K57416838-001-01-1	Phase 1
MRK-560	gamma secretase inhibitor	APP			BRD-K68795758-001-01-1, BRD-K68795758-001-02-9, BRD-K68795758-001-02-9, BRD-K68795758-001-02-9	Preclinical
MRS-1220	adenosine receptor antagonist	ADORA2B, ADORA3			BRD-K37618799-001-04-8, BRD-K37618799-001-03-0, BRD-K37618799-001-03-0, BRD-K37618799-001-03-0, BRD-K37618799-001-03-0, BRD-K37618799-001-03-0, BRD-K37618799-001-03-0	Preclinical
MRS-1334	adenosine receptor antagonist	ADORA3			BRD-A06784547-001-03-9, BRD-A06784547-001-02-6, BRD-A06784547-001-02-6	Preclinical
MRS-1845	calcium channel blocker				BRD-A78093359-001-07-9, BRD-A78093359-001-06-3, BRD-A78093359-001-06-3	Preclinical
MRS-2578	purinergic receptor antagonist	P2RY6			BRD-K91135178-001-04-9, BRD-K91135178-001-04-9, BRD-K91135178-001-03-9, BRD-K91135178-001-02-1	Preclinical
MRX-2843	MER tyrosine kinase inhibitor				BRD-K00003417-001-01-9	Phase 1
MS-424	glutamate transporter modulator				BRD-K00004683-001-01-9	Phase 2
MSDC-0160	insulin sensitizer				BRD-K00003381-001-01-9	Phase 2
MSDC-0602K	mitochondrial pyruvate carrier modulator				BRD-K00004703-001-01-9	Phase 2
MSX-122	CC chemokine receptor antagonist	CXCR4			BRD-K25143390-001-01-0, BRD-K25143390-001-01-0, BRD-K25143390-001-01-0	Phase 2
MTPG	glutamate receptor antagonist	GRM2, GRM3			BRD-A28329383-001-03-9, BRD-A28329383-001-02-1	Preclinical
mubritinib	protein tyrosine kinase inhibitor	EGFR, ERBB2			BRD-K19061412-001-03-2, BRD-K19061412-001-04-0, BRD-K19061412-001-06-9, BRD-K19061412-001-02-4	Phase 1
muscimol	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRR1, GABRR2, GABRR3			BRD-K60441002-001-04-8, BRD-K60441002-001-06-9	Phase 1
MUT056399	FABI inhibitor				BRD-K72078047-001-01-7, BRD-K72078047-001-01-7	Phase 1
MY-5445	phosphodiesterase inhibitor, platelet aggregation inhibitor	PDE5A			BRD-K90524085-001-08-6, BRD-K90524085-001-08-6, BRD-K90524085-001-09-9, BRD-K90524085-001-07-8	Preclinical
mycophenolate-mofetil	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	BRD-K92428153-001-07-7, BRD-K92428153-001-07-7, BRD-K92428153-001-05-1, BRD-K92428153-001-04-4, BRD-K92428153-001-04-4, BRD-K92428153-001-08-9	Launched
mycophenolic-acid	dehydrogenase inhibitor, inositol monophosphatase inhibitor	IMPDH1, IMPDH2	transplant	organ rejection	BRD-K63750851-001-22-3, BRD-K63750851-001-22-3, BRD-K63750851-001-20-7, BRD-K63750851-001-18-1, BRD-K63750851-001-18-1, BRD-K63750851-001-18-1, BRD-K63750851-001-18-1, BRD-K63750851-001-19-9	Launched
myricetin	androgen receptor agonist, cytochrome P450 inhibitor	PIK3CG			BRD-K43149758-001-22-7, BRD-K43149758-001-22-7, BRD-K43149758-001-23-5	Preclinical
myricitrin	PKC inhibitor	NOS1, PRKCA			BRD-K48388905-001-12-9	Preclinical
myristyl-nicotinate	topical sunscreen agent				BRD-K88153212-001-01-9	Phase 1
M8-B	transient receptor potential channel antagonist	TRPM8			BRD-K90410034-003-01-1, BRD-K90410034-003-02-9, BRD-K90410034-003-02-9	Preclinical
N-(p-amylcinnamoyl)-anthranilic-acid	phospholipase inhibitor				BRD-K77817104-001-02-9	Preclinical
N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide					BRD-K57027742-001-01-1	Preclinical
N-[2-(piperidinylamino)ethyl]-4-iodobenzamide	sigma receptor ligand				BRD-K78844995-001-03-9, BRD-K78844995-001-02-6, BRD-K78844995-001-02-6	Preclinical
N-acetyl-D-glucosamine		B4GALT1, B4GALT2, B4GALT3, B4GALT4, NAGK, NAGLU, NAGPA, RENBP			BRD-K80653534-001-02-9, BRD-K80653534-001-01-7	Phase 2/Phase 3
N-acetyl-tyrosine					BRD-A24857382-001-03-4, BRD-A24857382-001-03-4	Launched
N-acetylcarnosine					BRD-K52523550-001-01-5	Launched
N-acetylglycyl-D-glutamic-acid	glutamate receptor agonist				BRD-K28121004-001-02-9, BRD-K28121004-001-01-1	Preclinical
N-acetylmannosamine					BRD-A92872453-001-01-8	Phase 2
N-acetyltryptamine	melatonin receptor agonist				BRD-K73700643-001-13-8, BRD-K73700643-001-13-8, BRD-K73700643-001-11-2, BRD-K73700643-001-14-9	Preclinical
N-alpha-methylhistamine-dihydrochloride	histamine receptor agonist	HRH4			BRD-K75390981-300-04-9, BRD-K75390981-300-04-9	Phase 3
N-benzylnaltrindole	opioid receptor antagonist				BRD-K00004214-003-01-9	Preclinical
N-cyclohexyl-2-benzothiazolesulfenamide					BRD-K64191834-001-03-1	Preclinical
N-hydroxynicotinamide					BRD-K28030264-001-02-7	Preclinical
N-methyl-(-)ephedrine-[1R,2S]					BRD-K82236108-001-05-9, BRD-K82236108-001-04-9	Preclinical
N-methylformamide					BRD-K33445938-001-01-8	Phase 2
N-methyllidocaine-iodide	antiarrhythmic medication				BRD-K60060639-005-02-2	Preclinical
N-methylpyrrolidone					BRD-K52732207-001-01-9	Phase 1
N-methylquipazine	serotonin receptor agonist				BRD-K62056274-332-02-9, BRD-K62056274-332-01-8	Preclinical
N-MPPP	opioid receptor agonist				BRD-K93806173-003-01-8, BRD-K93806173-003-01-8, BRD-K93806173-003-01-8, BRD-K93806173-003-01-8	Preclinical
N-oxydiethylenebenzothiazole-2-sulfenamide					BRD-K97360717-001-10-9, BRD-K97360717-001-09-2	Preclinical
N-salicoylaminophenol	ribonucleotide reductase inhibitor				BRD-K39693230-001-01-2	Phase 1/Phase 2
NAB-2	ubiquitin ligase transport promoter	NEDD4			BRD-K36804890-001-02-9, BRD-K36804890-001-02-9, BRD-K36804890-001-01-9	Preclinical
nabumetone	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	BRD-K65146499-001-27-9, BRD-K65146499-001-29-9, BRD-K65146499-001-29-9, BRD-K65146499-001-26-1	Launched
nadide	free radical scavenger	AHCY, AKR1A1, ALDH2, BLVRA, DHPS, DLD, GALE, HMGCR, HSD17B1, HSD17B4, IMPDH2, MGAM, P2RY11, SORD, TRPM2			BRD-K01824972-001-05-9, BRD-K01824972-001-04-9, BRD-K01824972-001-04-9	Launched
nadifloxacin	bacterial DNA gyrase inhibitor		dermatology, infectious disease	acne vulgaris (AV), skin infections	BRD-A24397426-001-10-4, BRD-A24397426-001-13-9, BRD-A24397426-001-09-6	Launched
nadolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3	cardiology	angina pectoris, hypertension	BRD-A87606379-001-22-4, BRD-A87606379-001-23-2	Launched
NADPH		DRD2, DRD3, DRD4, GHSR, HTR2A, HTR2C				Preclinical
nafadotride	dopamine receptor antagonist	DRD2, DRD3, HTR1A			BRD-A71262238-001-08-4	Preclinical
nafamostat	serine protease inhibitor	ASIC1, ASIC2, ASIC3, C1R, PRSS1, TPSAB1, TRPM7	cardiology	anticoagulent	BRD-K06674495-334-05-7, BRD-K06674495-334-04-0, BRD-K06674495-334-03-2, BRD-K06674495-334-03-2	Launched
naftidrofuryl	adrenergic receptor antagonist		cardiology	claudication	BRD-A67862938-034-14-9, BRD-A67862938-034-15-9, BRD-A67862938-034-15-9	Launched
naftifine	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	BRD-K74141488-003-11-2, BRD-K74141488-003-11-2, BRD-K74141488-003-11-2, BRD-K74141488-003-11-2, BRD-K74141488-003-12-9, BRD-K74141488-003-10-4	Launched
naftopidil	adrenergic receptor antagonist	ADRA1A	urology	benign prostatic hyperplasia (BPH)	BRD-K01826561-003-17-9, BRD-K01826561-003-16-9, BRD-K01826561-003-16-9	Launched
nalfurafine	opioid receptor agonist	OPRK1, OPRM1	nephrology	uremic pruritus	BRD-K89272869-003-01-8, BRD-K89272869-003-01-8	Launched
nalidixic-acid	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	BRD-K47886988-001-24-9, BRD-K47886988-001-22-2, BRD-K47886988-001-21-4	Launched
nalmefene	opioid receptor antagonist	OPRD1, OPRK1, OPRM1	pulmonary	respiratory depression	BRD-K68407436-003-02-7, BRD-K68407436-003-10-9, BRD-K68407436-003-10-9, BRD-K68407436-003-03-5	Launched
naloxegol	opioid receptor antagonist	OPRM1	gastroenterology	constipation	BRD-K41458421-034-01-6, BRD-K41458421-034-01-6	Launched
naltriben	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			BRD-K81275354-066-07-9	Preclinical
naltrindole	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			BRD-K34088084-003-06-9	Preclinical
Nampt-IN-1					BRD-K18280217-001-01-0	Preclinical
NAN-190	serotonin receptor agonist	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1F			BRD-K69195780-004-09-9, BRD-K69195780-004-08-4	Preclinical
napabucasin	STAT inhibitor	STAT3			BRD-K22064724-001-01-8, BRD-K22064724-001-01-8, BRD-K22064724-001-01-8, BRD-K22064724-001-02-6	Phase 3
napamezole	adrenergic receptor antagonist, monoamine reuptake inhibitor				BRD-K00004563-001-01-9	Preclinical
naphazoline	adrenergic receptor agonist	ADRA1A, ADRA2A	ophthalmology	eye irritation	BRD-K77641333-003-30-9, BRD-K77641333-003-30-9, BRD-K77641333-003-26-3, BRD-K77641333-003-27-1	Launched
naphthoquine-phosphate	antimalarial agent		infectious disease	malaria	BRD-K13664493-316-02-5, BRD-K13664493-316-03-3, BRD-K13664493-316-01-7	Launched
napirimus	immunosuppressant				BRD-K91234829-001-01-7	Phase 1
naproxen	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology	pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever	BRD-K59197931-236-22-9, BRD-K59197931-236-22-9, BRD-K59197931-236-21-1, BRD-K59197931-236-20-3, BRD-K59197931-001-04-5	Launched
naquotinib	EGFR inhibitor				BRD-K64114733-066-03-9	Phase 3
narasin	antiprotozoal agent		infectious disease	coccidiosis	BRD-A25608658-001-01-1, BRD-A25608658-001-01-1, BRD-A25608658-001-01-1, BRD-A25608658-001-01-1	Launched
naratriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	BRD-K61337602-003-04-9, BRD-K61337602-003-02-1, BRD-K61337602-003-03-9	Launched
naringenin	aromatase inhibitor, TRPV antagonist	CYP19A1, CYP1B1, ESR2, GLO1, HSD17B1			BRD-K08832567-001-12-9, BRD-K08832567-001-11-5	Phase 1
naringeninic-acid		HCAR2, PTGR1			BRD-K87122641-001-10-7, BRD-K87122641-001-08-1	Phase 1
naringin-dihydrochalcone	cytochrome P450 inhibitor				BRD-K72522627-001-02-9	Preclinical
narlaprevir	HCV inhibitor				BRD-K38287497-001-02-9, BRD-K38287497-001-02-9, BRD-K38287497-001-01-2, BRD-K38287497-001-01-2	Phase 3
NAS-181	serotonin receptor antagonist	HTR1B			BRD-K00004235-334-01-9	Preclinical
nastorazepide	CCK receptor antagonist	CCKBR			BRD-K17295893-001-02-9, BRD-K17295893-238-03-9, BRD-K17295893-001-01-0	Phase 2
nateglinide	insulin secretagogue	ABCC8, KCNJ10, KCNJ11, PPARG	endocrinology	diabetes mellitus	BRD-K44353683-001-10-9, BRD-K44353683-001-08-3, BRD-K44353683-001-13-9, BRD-K44353683-001-07-5, BRD-K44353683-001-12-5	Launched
NAV-26	voltage-gated sodium channel blocker	SCN9A			BRD-A84202322-001-02-9, BRD-A84202322-001-02-9, BRD-A84202322-001-01-7	Preclinical
navarixin	CC chemokine receptor antagonist	CXCR1, CXCR2			BRD-K82850175-001-02-9, BRD-K82850175-001-01-1, BRD-K82850175-001-01-1	Phase 2
navitoclax	BCL inhibitor	BCL2, BCL2L1, BCL2L2			BRD-K82746043-001-21-9, BRD-K82746043-001-21-9, BRD-K82746043-001-21-9, BRD-K82746043-001-19-3, BRD-K82746043-001-19-3, BRD-K82746043-001-19-3, BRD-K82746043-001-19-3, BRD-K82746043-001-15-1	Phase 2
naxagolide	dopamine receptor agonist				BRD-K00004670-001-01-9	Phase 3
NB-001	antiviral				BRD-K00004647-001-01-9	Preclinical
NBI-27914	corticotropin releasing factor receptor antagonist	CRHR1			BRD-K61177364-003-03-7, BRD-K61177364-003-09-9, BRD-K61177364-003-09-9, BRD-K61177364-003-02-9	Preclinical
NBI-74330-(+/-)	CC chemokine receptor antagonist	CXCR3			BRD-A86523169-001-02-9, BRD-A86523169-001-01-0	Preclinical
NBI-98782	vesicular monoamine transporter inhibitor				BRD-K15241725-001-02-9	Preclinical
NBQX	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIN1, GRIN2A, GRIN2B			BRD-K11796549-001-05-2, BRD-K11796549-001-05-2, BRD-K11796549-304-01-9, BRD-K11796549-001-04-5, BRD-K11796549-001-06-9, BRD-K11796549-001-06-9	Preclinical
NCS-382	GABA receptor antagonist	GABBR1, GABBR2, SLC52A2			BRD-K01826782-001-02-9	Preclinical
NCX-1015	interleukin sythesis stimulator				BRD-K00004749-001-01-9	Preclinical
NDD-094					BRD-K00004664-001-01-9	Preclinical
NDT-9513727	complement antagonist	C5AR1			BRD-K17539220-001-01-5, BRD-K17539220-001-02-9	Preclinical
NE-100	sigma receptor antagonist	SIGMAR1			BRD-K11443721-003-01-6, BRD-K11443721-003-01-6, BRD-K11443721-003-02-4	Phase 2
nebivolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	BRD-K00003617-003-01-9, BRD-K00003617-003-01-9	Launched
nebracetam	acetylcholine receptor agonist	CHRM1			BRD-A51355958-003-01-9, BRD-A51355958-003-01-9	Phase 3
NECA	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K14395568-001-17-1, BRD-K14395568-001-18-9, BRD-K14395568-001-18-9, BRD-K14395568-001-16-3	Launched
necrostatin-1	RIPK inhibitor	RIPK1			BRD-K01825019-001-06-9, BRD-K01825019-001-10-9, BRD-K01825019-001-08-9, BRD-K01825019-001-09-9	Preclinical
necrostatin-2	necroptosis inhibitor, RIPK inhibitor	RIPK2			BRD-K68851986-001-01-6, BRD-K68851986-001-01-6	Preclinical
nedocromil	histamine receptor antagonist	CYSLTR1, CYSLTR2, FPR1, HSP90AA1, PTGDR	neurology/psychiatry, ophthalmology	itching, conjunctivitis	BRD-K64716392-001-02-1, BRD-K64716392-001-03-9, BRD-K64716392-001-01-3	Launched
nefazodone	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA1B, ADRA2A, CYP3A4, HTR1A, HTR2A, HTR2C, SLC6A2, SLC6A3, SLC6A4			BRD-K90789829-001-07-8, BRD-K90789829-001-07-8, BRD-K90789829-003-12-4, BRD-K90789829-003-13-9	Withdrawn
nefiracetam	acetylcholine receptor agonist, benzodiazepine receptor agonist	CHRM1			BRD-K65678996-001-09-7, BRD-K65678996-001-05-5, BRD-K65678996-001-04-8, BRD-K65678996-001-04-8	Phase 3
nefopam	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	BRD-K01826512-003-11-9, BRD-K01826512-003-12-9	Launched
nelarabine	DNA synthesis inhibitor, T cell inhibitor	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL)	BRD-K84466663-001-08-9, BRD-K84466663-001-08-9, BRD-K84466663-001-05-4	Launched
nelfinavir	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K74117820-066-10-8, BRD-K74117820-066-10-8, BRD-K74117820-066-10-8, BRD-K74117820-066-10-8, BRD-K74117820-066-10-8, BRD-K74117820-001-08-9, BRD-K74117820-001-08-9	Launched
nelociguat	guanylate cyclase stimulant				BRD-K00003315-001-01-9	Preclinical
nelotanserin	serotonin receptor inverse agonist				BRD-K00003466-001-01-9	Phase 2
nemazoline	adrenergic receptor agonist, adrenergic receptor antagonist				BRD-K00004662-001-01-9	Phase 2
nemiralisib					BRD-K00003285-001-01-9	Phase 2
nemonapride	dopamine receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia	BRD-K47289124-001-03-9	Launched
nemorexant	orexin receptor antagonist				BRD-K00003505-001-01-9	Preclinical
nemorubicin	topoisomerase inhibitor	TOP1, TOP2A			BRD-K51911221-001-01-2, BRD-K51911221-001-01-2, BRD-K51911221-001-01-2, BRD-K51911221-001-02-9	Phase 2
neo-gilurytmal			cardiology	cardiac arrythmia	BRD-A53539450-004-01-7, BRD-A53539450-004-01-7	Launched
neohesperidin					BRD-K00003712-001-01-9	Preclinical
neostigmine	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	BRD-K18922609-004-25-9, BRD-K18922609-004-24-9, BRD-K18922609-004-22-3, BRD-K18922609-004-23-1, BRD-K18922609-004-23-1	Launched
nepafenac	cyclooxygenase inhibitor	PTGS1, PTGS2	ophthalmology	eye inflammation	BRD-K04112579-001-07-0	Launched
nepicastat	dopamine beta hydroxylase inhibitor	DBH			BRD-K09126848-003-03-5, BRD-K09126848-003-01-9, BRD-K09126848-003-02-7	Phase 2
neratinib	EGFR inhibitor	EGFR, ERBB2, KDR	oncology	breast cancer	BRD-K85606544-001-13-9, BRD-K85606544-001-09-1, BRD-K85606544-001-09-1, BRD-K85606544-001-09-1, BRD-K85606544-001-09-1, BRD-K85606544-001-09-1	Launched
nerbacadol	cyclooxygenase inhibitor				BRD-K43647122-001-01-3	Phase 3
neridronic-acid	bone resorption inhibitor	FDPS	endocrinology	brittle bone disease, Paget's disease	BRD-K60212747-001-02-9, BRD-K60212747-236-01-1, BRD-K60212747-236-01-1	Launched
nesbuvir	RNA polymerase inhibitor				BRD-K79989959-001-01-4, BRD-K79989959-001-01-4, BRD-K79989959-001-02-9	Phase 2
netilmicin	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	BRD-K00003604-315-01-9	Launched
netupitant	tachykinin antagonist	TACR1	gastroenterology	nausea, vomiting	BRD-K97428065-001-01-2, BRD-K97428065-001-01-2, BRD-K97428065-001-01-2, BRD-K97428065-001-02-9	Launched
neurodazine	neurogenesis of non-pluripotent C2C12 myoblast inducer				BRD-K22631935-001-03-5, BRD-K22631935-001-02-7, BRD-K22631935-001-02-7	Preclinical
neuropathiazol	neural stem cell inducer	BMP2, LIF			BRD-K28567778-001-02-7, BRD-K28567778-001-01-9, BRD-K28567778-001-01-9, BRD-K28567778-001-01-9, BRD-K28567778-001-01-9	Preclinical
Neu2000	ionotropic glutamate receptor antagonist				BRD-K00003470-001-01-9	Phase 2
nevirapine	non-nucleoside reverse transcriptase inhibitor	CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP3A4, CYP3A5	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K15502390-001-20-9, BRD-K15502390-001-19-1	Launched
nexturastat-A	HDAC inhibitor	HDAC1, HDAC6			BRD-K70402238-001-02-8, BRD-K70402238-001-02-8, BRD-K70402238-001-02-8, BRD-K70402238-001-04-9, BRD-K70402238-001-04-9	Preclinical
NFKB-activation-inhibitor-II	NFkB pathway inhibitor	RELA			BRD-K83354763-001-07-9, BRD-K83354763-001-03-7, BRD-K83354763-001-06-0	Preclinical
NG-nitro-arginine	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			BRD-K89223384-001-05-2, BRD-K89223384-001-04-5	Phase 1
NGB-2904	dopamine receptor antagonist	DRD3			BRD-K05181084-003-04-5, BRD-K05181084-003-04-5, BRD-K05181084-003-03-7, BRD-K05181084-003-03-7	Preclinical
NGD-94-1	dopamine receptor antagonist	DRD4			BRD-K28639661-001-01-6, BRD-K28639661-001-02-9	Phase 1
NGD-98-2	corticotropin releasing factor receptor antagonist	CRHR1			BRD-K81779590-003-01-6, BRD-K81779590-003-02-9	Preclinical
NGP555	gamma secretase modulator				BRD-K00003490-001-01-9	Phase 1
NHI-2	lactate dehydrogenase inhibitor	LDHA			BRD-K05653025-001-01-5, BRD-K05653025-001-02-9	Preclinical
NI-57	bromodomain inhibitor	BRD1, BRPF1, BRPF3			BRD-K03042257-001-01-2, BRD-K03042257-001-01-2, BRD-K03042257-001-02-0	Preclinical
niacin	NAD precursor, vitamin B	DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT	endocrinology	hypertriglyceridemia	BRD-K60237333-001-28-9, BRD-K60237333-001-26-3, BRD-K60237333-001-27-1, BRD-K60237333-001-27-1, BRD-K60237333-001-27-1	Launched
nialamide	monoamine oxidase inhibitor	COMT, MAOA, MAOB			BRD-K12102668-001-28-9, BRD-K12102668-001-25-5, BRD-K12102668-001-24-8	Withdrawn
nibentan	potassium channel blocker				BRD-A85876464-003-02-9, BRD-A85876464-001-01-5	Phase 2
nicainoprol	angiotensin converting enzyme inhibitor				BRD-K00003382-001-01-9	Preclinical
nicaraven	free radical scavenger				BRD-A86871940-001-02-9, BRD-A86871940-001-01-9	Phase 3
nicardipine	calcium channel blocker	ADORA3	cardiology	chronic stable angina, hypertension	BRD-A26711594-003-10-6, BRD-A26711594-003-10-6, BRD-A26711594-003-10-6, BRD-A26711594-003-08-0	Launched
niceritrol	NAD precursor		endocrinology	hyperlipidemia	BRD-K11256763-001-01-5, BRD-K11256763-001-01-5	Launched
niclosamide	DNA replication inhibitor, STAT inhibitor	STAT3	infectious disease	tapeworm	BRD-K35960502-001-20-0, BRD-K35960502-001-20-0, BRD-K35960502-001-20-0, BRD-K35960502-001-20-0, BRD-K35960502-001-19-2, BRD-K35960502-001-19-2	Launched
nicodicosapent	sterol regulatory element binding protein (SREBP) inhibitor				BRD-K00003262-001-01-9	Preclinical
nicorandil	nitric oxide donor, potassium channel activator	KCNJ11	cardiology	angina pectoris	BRD-K97752965-001-15-6, BRD-K97752965-001-14-9, BRD-K97752965-001-18-9, BRD-K97752965-001-18-9, BRD-K97752965-001-18-9, BRD-K97752965-001-13-1, BRD-K97752965-001-16-4, BRD-K97752965-001-16-4, BRD-K97752965-001-16-4	Launched
nicotinamide	protein synthesis stimulant	BST1, LDHA, PARP1, SIRT5	dermatology	acne vulgaris (AV)	BRD-K28912512-001-24-0, BRD-K28912512-001-25-7, BRD-K28912512-001-23-2	Launched
nicotine	acetylcholine receptor agonist	CHAT, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB2, CHRNB3, CHRNB4, CYP19A1, TBXAS1, TRPA1	neurology/psychiatry	smoking cessation	BRD-K05395900-322-05-4	Launched
nicotinyl-alcohol-tartrate			cardiology, neurology/psychiatry	vascular spasm, vertigo	BRD-K76600340-045-04-9, BRD-K76600340-001-06-9	Launched
NIDA-41020	cannabinoid receptor antagonist	CNR1			BRD-K17617556-001-01-3, BRD-K17617556-001-01-3, BRD-K17617556-001-02-9	Preclinical
nifedipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNB2, CALM1, GLRA1, GLRA3, GLRB, KCNA1, KCNA5, NR1I2, TRPM3	cardiology	vasospastic angina, chronic stable angina	BRD-K96354014-001-29-4, BRD-K96354014-001-29-4, BRD-K96354014-001-27-8, BRD-K96354014-001-15-3, BRD-K96354014-001-21-1, BRD-K96354014-001-17-9, BRD-K96354014-001-14-6	Launched
nifekalant	potassium channel blocker		cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	BRD-K32311154-001-01-0, BRD-K32311154-001-01-0	Launched
nifenalol	adrenergic receptor antagonist	ADRB1, ADRB2			BRD-A21280314-001-06-8	Launched
nifenazone	analgesic agent		neurology/psychiatry	pain relief	BRD-K47407372-001-16-3, BRD-K47407372-001-17-1, BRD-K47407372-001-19-9	Launched
niflumic-acid	cyclooxygenase inhibitor	ANO1, CLCN1, CLCNKA, CLCNKB, KCNQ1, PLA2G1B, PLA2G4A, PTGS1, PTGS2, UGT1A9	rheumatology, neurology/psychiatry	joint pain, muscle pain	BRD-K98763141-001-30-8, BRD-K98763141-001-29-0, BRD-K98763141-001-32-9	Launched
nifuroxazide	bacterial DNA inhibitor		gastroenterology	colitis, diarrhea	BRD-K68188368-001-09-4, BRD-K68188368-001-09-4, BRD-K68188368-001-09-4, BRD-K68188368-001-08-6, BRD-K68188368-001-11-0, BRD-K68188368-001-11-0, BRD-K68188368-001-11-0	Launched
nifursol	bacterial DNA inhibitor				BRD-K85757157-001-02-9, BRD-K85757157-001-02-9, BRD-K85757157-001-01-7	Launched
nifurtimox	DNA inhibitor		infectious disease	Chagas disease, African trypanosomiasis	BRD-A84020532-001-08-9	Launched
niguldipine-(R)-(-)					BRD-K01825503-003-03-9	Preclinical
niguldipine-(S)-(+)	adrenergic receptor antagonist	ADRA1A			BRD-K59333713-003-03-8, BRD-K59333713-003-03-8, BRD-K59333713-003-04-9, BRD-K59333713-003-04-9, BRD-K59333713-003-02-0, BRD-K59333713-003-02-0	Preclinical
nikethamide	immunostimulant				BRD-K91544578-001-04-9, BRD-K91544578-001-03-8	Withdrawn
nilotinib	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	ABL1, KIT	hematologic malignancy	chronic myeloid leukemia (CML)	BRD-K81528515-001-15-9, BRD-K81528515-001-13-8	Launched
nilutamide	androgen receptor antagonist	AR	oncology	prostate cancer	BRD-K23566484-001-15-1, BRD-K23566484-001-14-4, BRD-K23566484-001-16-9	Launched
nilvadipine	calcium channel blocker	CACNA1C, CACNA1D	cardiology	hypertension, cerebral artery occlusion	BRD-A84687895-001-05-9, BRD-A84687895-001-05-9, BRD-A84687895-001-05-9, BRD-A84687895-001-05-9, BRD-A84687895-001-03-2, BRD-A84687895-001-03-2, BRD-A84687895-001-03-2, BRD-A84687895-001-04-0	Launched
nimesulide	cyclooxygenase inhibitor	LTF, PLA2G2E, PTGS1, PTGS2	rheumatology, obstetrics/gynecology	osteoarthritis, menstrual pain	BRD-K76775527-001-30-2, BRD-K76775527-001-29-4, BRD-K76775527-001-28-6, BRD-K76775527-001-32-9, BRD-K76775527-001-32-9, BRD-K76775527-001-32-9	Launched
nimodipine	calcium channel blocker	CFTR, NR3C2	hematology	hemorrhage	BRD-A58048407-001-20-4, BRD-A58048407-001-17-0, BRD-A58048407-001-18-8	Launched
nimorazole	bacterial DNA inhibitor		oncology	head and neck squamous cell carcinoma (HNSCC)	BRD-K79145628-001-05-5, BRD-K79145628-001-07-9	Launched
nimustine	DNA alkylating agent				BRD-K13240081-001-06-1, BRD-K13240081-003-06-7	Launched
NIM811	mitochondrial permeability transition inhibitor				BRD-K00003331-001-01-9	Phase 2
ningetinib-tosylate	protein tyrosine kinase inhibitor				BRD-K00003476-075-01-9	Preclinical
nintedanib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	BRD-K49075727-001-09-3, BRD-K49075727-001-08-5, BRD-K49075727-001-08-5	Launched
niraparib	PARP inhibitor	PARP1	oncology	primary peritoneal cancer (PPC)	BRD-K54955827-001-02-2, BRD-K54955827-001-02-2, BRD-K54955827-001-02-2, BRD-K54955827-001-02-2, BRD-K54955827-001-02-2, BRD-K54955827-001-02-2, BRD-K54955827-001-01-4	Launched
niridazole	phosphofructokinase inhibitor		infectious disease	schistosomiasis	BRD-K53123955-001-10-5, BRD-K53123955-001-10-5, BRD-K53123955-001-10-5	Launched
nisin	bacterial cell wall synthesis inhibitor					Phase 1
nisoldipine	calcium channel blocker	CACNA1C, CACNA1D, CACNA1F, CACNA1S	cardiology	hypertension	BRD-A84465106-001-05-3, BRD-A84465106-001-09-5, BRD-A84465106-001-09-5, BRD-A84465106-001-09-5, BRD-A84465106-001-09-5, BRD-A84465106-001-09-5, BRD-A84465106-001-08-7, BRD-A84465106-001-03-8, BRD-A84465106-001-06-1	Launched
nisoxetine	norepinephrine reuptake inhibitor	SLC6A2, SLC6A3, SLC6A4			BRD-K01825513-003-03-9	Phase 1
nitarsone			dermatology	blackhead disease	BRD-K56707426-001-02-0, BRD-K56707426-001-01-2, BRD-K56707426-001-03-8	Launched
nitazoxanide	pyruvate ferredoxin oxidoreductase inhibitor		gastroenterology	diarrhea	BRD-K96471533-001-08-2, BRD-K96471533-001-10-8, BRD-K96471533-001-11-6, BRD-K96471533-001-09-0, BRD-K96471533-001-09-0, BRD-K96471533-001-07-4	Launched
nitecapone	catechol O methyltransferase inhibitor	COMT			BRD-K75551531-001-01-3	Phase 2
nitenpyram			infectious disease	flea control	BRD-K47887731-001-01-4	Launched
nithiamide	bacterial DNA inhibitor				BRD-K39467894-001-05-9, BRD-K39467894-001-04-2, BRD-K39467894-001-06-7	Preclinical
nitisinone	hydroxyphenylpyruvate dioxygenase inhibitor		metabolism	tyrosinemia	BRD-K01109406-001-03-7, BRD-K01109406-001-04-5, BRD-K01109406-001-04-5	Launched
nitrendipine	calcium channel blocker	CACNA1D, CACNA2D1, KCNN4	cardiology	hypertension	BRD-A02006392-001-19-8, BRD-A02006392-001-17-2, BRD-A02006392-001-15-6, BRD-A02006392-001-15-6, BRD-A02006392-001-16-4, BRD-A02006392-001-16-4	Launched
nitrocaramiphen	cholinergic receptor antagonist	CHRM1			BRD-K28453807-003-12-9, BRD-K28453807-003-11-2	Preclinical
nitroflurbiprofen	cyclooxygenase inhibitor				BRD-K00004737-001-01-9	Preclinical
nitrofurantoin	DNA inhibitor		infectious disease	urinary tract infections, pyelonephritis	BRD-K76927775-001-13-4, BRD-K76927775-001-11-8, BRD-K76927775-001-10-0	Launched
nitrofurazone	bacterial DNA inhibitor		infectious disease	first-aid antibiotic	BRD-K79092138-001-13-9, BRD-K79092138-001-10-2, BRD-K79092138-001-11-0, BRD-K79092138-001-11-0	Launched
nitromide			infectious disease	coccidiosis	BRD-K76381435-001-09-9, BRD-K76381435-001-09-9, BRD-K76381435-001-08-6	Launched
nitrosodimethylurea	DNA synthesis inhibitor				BRD-K08927448-001-01-9	Preclinical
nitroxoline	cathepsin inhibitor	METAP2	infectious disease	urinary tract infections	BRD-K97534525-001-24-3, BRD-K97534525-001-23-5	Launched
nizofenone	ion channel antagonist		neurology/psychiatry	stroke	BRD-K84011460-051-01-7	Launched
NK-252	nuclear factor erythroid derived, like (NRF2) activator	NFE2L2			BRD-K47441935-001-01-4, BRD-K47441935-001-02-9	Preclinical
NKY-80	adenylyl cyclase inhibitor	ADCY5			BRD-A75015151-001-08-9, BRD-A75015151-001-07-7	Preclinical
NLG919	indoleamine 2,3-dioxygenase inhibitor	IDO1			BRD-A62133859-001-03-7, BRD-A62133859-001-03-7, BRD-A62133859-001-04-5, BRD-A62133859-001-01-1, BRD-A62133859-001-02-9	Phase 1
NMS-P715	protein kinase inhibitor				BRD-K54170555-001-01-8	Preclinical
NMS-1286937	PLK inhibitor	FLT3, PLK1, PLK2, PLK3			BRD-K83699324-001-01-1, BRD-K83699324-001-01-1, BRD-K83699324-001-01-1, BRD-K83699324-001-01-1, BRD-K83699324-001-01-1, BRD-K83699324-001-01-1, BRD-K83699324-001-01-1, BRD-K83699324-001-01-1, BRD-K83699324-001-02-9	Phase 2
NMS-873	ATPase inhibitor	VCP			BRD-K26253904-001-03-1, BRD-K26253904-001-01-5	Preclinical
NM107	RNA polymerase inhibitor				BRD-K79424231-001-02-9	Phase 2
NN-DNJ	glucosidase inhibitor	GBA			BRD-K00004640-001-01-9	Preclinical
NNC-05-2090	GABA uptake inhibitor, GAT inhibitor	SLC6A12			BRD-K85015012-003-03-7, BRD-K85015012-003-02-9, BRD-K85015012-003-02-9, BRD-K85015012-003-02-9, BRD-K85015012-003-02-9, BRD-K85015012-003-02-9, BRD-K85015012-003-02-9, BRD-K85015012-003-02-9, BRD-K85015012-003-05-9	Preclinical
NNC-55-0396	T-type calcium channel blocker	CATSPER1, CATSPER2, CATSPER3, CATSPER4			BRD-K78122587-300-04-3, BRD-K78122587-300-04-3, BRD-K78122587-300-04-3, BRD-K78122587-300-04-3, BRD-K78122587-300-04-3, BRD-K78122587-300-02-7, BRD-K78122587-300-02-7, BRD-K78122587-300-02-7, BRD-K78122587-300-02-7	Preclinical
NNC-711	GABA uptake inhibitor	SIGMAR1, SLC6A1			BRD-K42221274-003-08-5, BRD-K42221274-003-09-9, BRD-K42221274-003-07-7	Preclinical
NO-ASA	cyclooxygenase inhibitor	PTGS2			BRD-K08807999-001-02-4, BRD-K08807999-001-03-9	Phase 2
nobiletin	MEK inhibitor	MAP2K1			BRD-K06753942-001-14-5, BRD-K06753942-001-14-5	Preclinical
nocodazole	tubulin polymerization inhibitor	HPGDS			BRD-K12539581-001-25-2, BRD-K12539581-001-25-2, BRD-K12539581-001-23-7, BRD-K12539581-001-21-1, BRD-K12539581-001-22-9	Preclinical
nolatrexed	thymidylate synthase inhibitor	TYMS			BRD-K36636143-001-01-0	Phase 3
nomegestrol-acetate	progesterone receptor agonist	PGR	endocrinology	contraceptive	BRD-K27351809-001-10-9, BRD-K27351809-001-09-5, BRD-K27351809-001-11-9, BRD-K27351809-001-11-9	Launched
nomifensine	dopamine reuptake inhibitor, noradrenaline uptake inhibitor	DRD2, SLC6A2, SLC6A3			BRD-A29644307-050-17-0, BRD-A29644307-050-16-2, BRD-A29644307-050-18-8	Withdrawn
nonivamide	TRPV agonist	TRPV1	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain	BRD-K05907307-001-08-9, BRD-K05907307-001-08-9, BRD-K05907307-001-07-1	Launched
nonoxynol-9	membrane integrity inhibitor		endocrinology	contraceptive	BRD-K88625236-001-04-2, BRD-K88625236-001-07-5, BRD-K88625236-001-05-9, BRD-K88625236-001-05-9, BRD-K88625236-001-05-9	Launched
nor-binaltorphimine	opioid receptor antagonist	OPRD1, OPRK1, OPRM1			BRD-K36381762-300-03-5, BRD-K36381762-300-02-7, BRD-K36381762-300-04-9	Preclinical
norcyclobenzaprine	adrenergic receptor agonist, serotonin receptor antagonist				BRD-K63165456-001-10-8, BRD-K63165456-001-10-8, BRD-K63165456-003-11-9, BRD-K63165456-003-11-9	Preclinical
norelgestromin		PGR	endocrinology	contraceptive	BRD-K42504537-001-01-6	Launched
norepinephrine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder	BRD-K87349682-347-08-9, BRD-K87349682-347-08-9, BRD-K87349682-347-02-0, BRD-K87349682-347-03-8, BRD-K87349682-001-04-9	Launched
norethindrone-acetate	progesterone receptor agonist	PGR	endocrinology, orthopedics, obstetrics/gynecology	menopause, osteoporosis, vaginal atrophy	BRD-K96037667-001-04-9	Launched
norethisterone-enanthate	contraceptive agent		endocrinology	contraceptive	BRD-K07625016-001-01-2, BRD-K07625016-001-01-2, BRD-K07625016-001-01-2	Launched
noretynodrel	progestogen hormone	PGR	endocrinology	contraceptive	BRD-A00758722-001-04-9, BRD-A00758722-001-04-9	Launched
norfloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis	BRD-K11196887-001-25-9, BRD-K11196887-001-22-0, BRD-K11196887-001-20-4, BRD-K11196887-001-21-2	Launched
norfluoxetine	selective serotonin reuptake inhibitor (SSRI)	HTR2B			BRD-A79769222-001-01-3, BRD-A79769222-001-01-3	Phase 1
norgestrel	progesterone receptor agonist	AR, ESR1, PGR, SRD5A1	endocrinology	contraceptive	BRD-A14886633-001-01-6, BRD-A14886633-001-01-6, BRD-A14886633-001-01-6	Launched
nornicotine	acetylcholine receptor agonist				BRD-K00003718-001-01-9	Preclinical
nortriptyline	tricyclic antidepressant	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR1A, HTR2A, HTR2C, HTR6, KCNJ10, PGRMC1, SIGMAR1, SLC6A2, SLC6A4	neurology/psychiatry	depression	BRD-K91263825-003-23-9, BRD-K91263825-003-21-4	Launched
norvancomycin					BRD-K00003706-003-01-9	Preclinical
NOV-002		GSR			BRD-K11411329-001-02-9, BRD-K11411329-001-01-3	Phase 3
novobiocin	bacterial DNA gyrase inhibitor		obstetrics/gynecology	mastitis	BRD-K85307935-236-11-9, BRD-K85307935-236-10-3, BRD-K85307935-236-10-3, BRD-K85307935-236-09-5, BRD-K85307935-236-09-5, BRD-K85307935-236-08-7	Launched
NPC-01	steroid				BRD-K58277159-001-01-7, BRD-K58277159-001-01-7	Phase 3
NPC-15199	ICAM1 antagonist	PPARG			BRD-K65275554-001-05-9, BRD-K65275554-001-04-7	Phase 2
NPPB	chloride channel blocker	ANO1, CLCN2, CLCN7, TRPA1			BRD-K89272762-001-13-5, BRD-K89272762-001-13-5, BRD-K89272762-001-14-9, BRD-K89272762-001-12-7	Preclinical
NPS-2143	calcium receptor antagonist	CASR			BRD-K75506300-003-01-2, BRD-K75506300-003-01-2, BRD-K75506300-001-01-6, BRD-K75506300-001-01-6, BRD-K75506300-001-01-6, BRD-K75506300-003-02-9, BRD-K75506300-003-02-9	Preclinical
NPS-2407	glutamate receptor antagonist				BRD-K00004686-001-01-9	Preclinical
NPY-5RA972	neuropeptide receptor antagonist	NPY5R			BRD-K95600043-001-02-3, BRD-K95600043-001-01-5, BRD-K95600043-001-03-9	Preclinical
NQDI-1	caspase inhibitor	CASP3			BRD-K61918008-001-07-1, BRD-K61918008-001-07-1	Preclinical
NS-018	JAK inhibitor	JAK1, JAK2, JAK3, TYK2			BRD-K21865955-003-01-5, BRD-K21865955-003-01-5, BRD-K21865955-003-01-5	Phase 1/Phase 2
NS-11021	calcium-activated potassium channel activator	KCNMA1			BRD-K94342292-001-02-9, BRD-K94342292-001-01-3	Preclinical
NS-11394	GABA receptor agonist				BRD-K00004548-001-01-9	Preclinical
NS-1643	voltage-gated potassium channel activator	KCNH2, KCNH6, KCNMA1			BRD-K73738482-001-02-5, BRD-K73738482-001-01-7, BRD-K73738482-001-01-7, BRD-K73738482-001-01-7, BRD-K73738482-001-01-7	Preclinical
NS-19504	calcium-activated potassium channel activator	KCNMA1			BRD-K03808106-001-01-9, BRD-K03808106-001-02-9, BRD-K03808106-001-02-9	Preclinical
NS-309	calcium-activated potassium channel activator	KCNN1, KCNN2, KCNN3, KCNN4			BRD-K00004295-001-01-9	Preclinical
NS-3623	voltage-gated potassium channel activator	KCNH2			BRD-K24434292-001-02-1, BRD-K24434292-001-01-3, BRD-K24434292-001-01-3, BRD-K24434292-001-01-3, BRD-K24434292-001-01-3, BRD-K24434292-001-01-3	Preclinical
NS-3861	acetylcholine receptor agonist	CHRNA3, CHRNB4			BRD-K00004309-051-01-9	Preclinical
NS-5806	voltage-gated potassium channel activator	KCND3			BRD-K93314017-001-01-7, BRD-K93314017-001-02-9, BRD-K93314017-001-02-9	Preclinical
NS-8	potassium channel agonist	KCNMA1			BRD-K22667752-001-01-3	Phase 2
NS-8593	calcium-activated potassium channel modulator	KCNN1, KCNN2, KCNN3			BRD-K34624869-003-02-9, BRD-K34624869-003-01-6	Preclinical
NS-9283	acetylcholine receptor allosteric modulator	CHRNA4			BRD-K40176866-001-02-9, BRD-K40176866-001-02-9, BRD-K40176866-001-01-6, BRD-K40176866-001-01-6	Preclinical
NSC-23766	Ras GTPase inhibitor				BRD-K01826800-305-08-9, BRD-K01826800-305-11-9, BRD-K01826800-305-13-9, BRD-K01826800-305-07-9	Preclinical
NSC-319726	p53 activator				BRD-K99170882-001-07-9, BRD-K99170882-001-04-3, BRD-K99170882-001-06-8, BRD-K99170882-001-05-0, BRD-K99170882-001-05-0, BRD-K99170882-001-05-0, BRD-K99170882-001-05-0, BRD-K99170882-001-05-0, BRD-K99170882-001-05-0	Preclinical
NSC-3852	HDAC inhibitor	HDAC1			BRD-K13169950-001-14-4, BRD-K13169950-001-14-4, BRD-K13169950-001-14-4, BRD-K13169950-001-14-4	Preclinical
NSC-405020	matrix metalloprotease inhibitor	MMP1			BRD-A67975844-001-03-9, BRD-A67975844-001-02-6, BRD-A67975844-001-01-8, BRD-A67975844-001-01-8, BRD-A67975844-001-01-8, BRD-A67975844-001-01-8	Preclinical
NSC-4644	ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor	PYGM			BRD-K64874225-001-05-9, BRD-K64874225-001-04-7	Phase 2
NSC-5844	CC chemokine receptor agonist	CCR1			BRD-K73799155-001-01-5	Preclinical
NSC-625987	CDK inhibitor	CDK2, CDK4			BRD-K62949423-001-03-1	Preclinical
NSC-632839	ubiquitin specific protease inhibitor	SENP2, USP1, USP2, USP7			BRD-K81197548-003-02-2, BRD-K81197548-003-01-4, BRD-K81197548-003-01-4, BRD-K81197548-003-01-4, BRD-K81197548-003-03-9	Preclinical
NSC-636819	histone demethylase inhibitor	KDM4A, KDM4B			BRD-K61120504-001-01-6	Preclinical
NSC-663284	CDC inhibitor	CDC25A, CDC25B, CDC25C			BRD-K03109492-001-03-0, BRD-K03109492-001-03-0, BRD-K03109492-001-02-2, BRD-K03109492-001-02-2, BRD-K03109492-001-02-2, BRD-K03109492-001-02-2, BRD-K03109492-001-02-2	Preclinical
NSC-697923	ubiquitin-conjugating enzyme inhibitor	UBE2N			BRD-K20605374-001-07-9, BRD-K20605374-001-05-4, BRD-K20605374-001-05-4, BRD-K20605374-001-06-2, BRD-K20605374-001-06-2	Preclinical
NSC-95397	CDC inhibitor	CDC25A, CDC25B			BRD-K68143200-001-11-7	Preclinical
NSC-9965	acetylcholine receptor antagonist	CHRNA4, CHRNB2			BRD-K49811169-004-06-6, BRD-K49811169-004-06-6, BRD-K49811169-004-08-9	Preclinical
NSI-189	neurotrophic agent				BRD-K74371986-001-01-7, BRD-K74371986-001-02-9	Phase 2
NSP-805	phosphodiesterase inhibitor				BRD-K00004733-001-01-9	Preclinical
NTNCB	neuropeptide receptor antagonist	NPY5R			BRD-A40413915-003-01-2, BRD-A40413915-003-01-2, BRD-A40413915-003-01-2, BRD-A40413915-003-02-9, BRD-A40413915-003-02-9	Preclinical
NTRC-824	neurotensin receptor antagonist	NTSR2			BRD-K07788774-001-01-0, BRD-K07788774-001-02-9	Preclinical
nTZDpa	PPAR receptor agonist	PPARG			BRD-K54708045-001-03-9, BRD-K54708045-001-02-1, BRD-K54708045-001-05-9	Preclinical
NT157	IGF-1 inhibitor	IGF1R			BRD-K54098378-001-02-4, BRD-K54098378-001-01-6	Preclinical
NU-1025	PARP inhibitor	PARP1			BRD-K48692744-001-03-8, BRD-K48692744-001-04-9, BRD-K48692744-001-02-0	Preclinical
NU-2058	cyclin D inhibitor	CCNA2, CDK2			BRD-K20976221-001-12-0	Preclinical
NU-6027	CDK inhibitor	CCNA2, CDK2			BRD-K03294269-001-08-0, BRD-K03294269-001-08-0, BRD-K03294269-001-09-8	Preclinical
NU-7026	DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor	PRKDC			BRD-K09537769-001-06-5, BRD-K09537769-001-06-5, BRD-K09537769-001-04-0, BRD-K09537769-001-03-2, BRD-K09537769-001-03-2	Preclinical
NU-7441	DNA dependent protein kinase inhibitor	PRKDC			BRD-K00337317-001-06-6, BRD-K00337317-001-06-6, BRD-K00337317-001-06-6, BRD-K00337317-001-06-6, BRD-K00337317-001-06-6, BRD-K00337317-001-06-6, BRD-K00337317-001-06-6, BRD-K00337317-001-08-2	Preclinical
nuclomedone	immunosuppressant				BRD-A96466199-001-01-4	Phase 3
nutlin-3	MDM inhibitor	MDM2, TP53			BRD-K00002882-001-02-9	Preclinical
nuvenzepine	acetylcholine receptor antagonist				BRD-K00004743-001-01-9	Preclinical
NVP-ADW742	insulin growth factor receptor inhibitor	IGF1R			BRD-K15179513-001-06-9, BRD-K15179513-001-05-9, BRD-K15179513-001-04-2, BRD-K15179513-001-04-2, BRD-K15179513-001-04-2, BRD-K15179513-001-04-2, BRD-K15179513-001-04-2, BRD-K15179513-001-04-2, BRD-K15179513-001-03-4	Preclinical
NVP-AEW541	IGF-1 inhibitor	IGF1R, INSR			BRD-K24696047-001-03-9, BRD-K24696047-001-02-3, BRD-K24696047-001-02-3, BRD-K24696047-001-02-3, BRD-K24696047-001-02-3	Preclinical
NVP-AUY922	HSP inhibitor	HSP90AA1, HSP90AB1			BRD-K41859756-001-09-2, BRD-K41859756-001-09-2, BRD-K41859756-001-09-2, BRD-K41859756-001-09-2, BRD-K41859756-001-09-2, BRD-K41859756-001-09-2, BRD-K41859756-001-08-4, BRD-K41859756-001-08-4, BRD-K41859756-001-06-8, BRD-K41859756-001-06-8, BRD-K41859756-001-06-8	Phase 2
NVP-BEZ235	mTOR inhibitor, PI3K inhibitor	ATR, MTOR, PIK3CA, PIK3CD, PIK3CG			BRD-K12184916-001-19-6, BRD-K12184916-001-19-6, BRD-K12184916-001-19-6, BRD-K12184916-001-15-4	Phase 3
NVP-BGJ398	FGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, KDR			BRD-K42728290-001-09-1, BRD-K42728290-001-09-1, BRD-K42728290-001-11-7, BRD-K42728290-001-06-7, BRD-K42728290-001-08-3, BRD-K42728290-001-07-5	Phase 3
NVP-BHG712	ephrin inhibitor	EPHB4			BRD-K79259477-001-06-9, BRD-K79259477-001-04-9, BRD-K79259477-001-04-9, BRD-K79259477-001-04-9	Preclinical
NVP-BSK805	JAK inhibitor	JAK2			BRD-K02017404-300-06-2, BRD-K02017404-300-07-0, BRD-K02017404-300-07-0, BRD-K02017404-300-07-0, BRD-K02017404-300-07-0, BRD-K02017404-300-07-0	Preclinical
NVP-BVU972	MET inhibitor	MET			BRD-K77943374-001-02-8, BRD-K77943374-001-03-9	Preclinical
NVP-DPP728	dipeptidyl peptidase inhibitor	DPP4			BRD-K77396579-300-01-0, BRD-K77396579-300-01-0, BRD-K77396579-300-01-0, BRD-K77396579-300-01-0, BRD-K77396579-300-01-0, BRD-K77396579-300-02-9	Phase 2
NVP-HSP990	HSP inhibitor	HSP90AA1, HSP90AB1			BRD-K67915505-001-01-2, BRD-K67915505-001-01-2, BRD-K67915505-001-01-2, BRD-K67915505-001-01-2	Phase 1
NVP-TAE226	protein tyrosine kinase inhibitor	PTK2			BRD-K21025364-001-04-9, BRD-K21025364-001-05-6, BRD-K21025364-001-05-6, BRD-K21025364-001-05-6, BRD-K21025364-001-05-6, BRD-K21025364-001-05-6	Preclinical
NVP-TAE684	ALK tyrosine kinase receptor inhibitor	ALK, INSR			BRD-K50140147-001-10-1, BRD-K50140147-001-10-1, BRD-K50140147-001-10-1, BRD-K50140147-001-10-1	Preclinical
NVP-TNKS656	tankyrase inhibitor	TNKS2			BRD-K87454346-001-01-1	Preclinical
NVP-231	ceramidase inhibitor	CERK			BRD-K01573278-001-03-9, BRD-K01573278-001-02-1, BRD-K01573278-001-02-1, BRD-K01573278-001-02-1	Preclinical
NVS-PAK1-1	p21 activated kinase inhibitor	PAK1			BRD-K28132190-001-02-0, BRD-K28132190-001-02-0	Preclinical
NXY-059	free radical scavenger				BRD-K46133855-304-04-9, BRD-K46133855-304-02-0, BRD-K46133855-304-03-8	Phase 3
N20C	glutamate receptor antagonist				BRD-K41143549-003-02-4, BRD-K41143549-003-06-9	Preclinical
N6-cyclopentyladenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, SLC29A1			BRD-K60150510-001-16-9, BRD-K60150510-001-15-6	Preclinical
N6-methyladenosine					BRD-K81807412-001-11-9, BRD-K81807412-001-10-6	Preclinical
N6022	alcohol dehydrogenase inhibitor	ADH5			BRD-K82522873-001-01-1, BRD-K82522873-001-01-1, BRD-K82522873-001-01-1, BRD-K82522873-001-01-1, BRD-K82522873-001-01-1, BRD-K82522873-001-02-9	Phase 1/Phase 2
O-acetyl-L-serine		PTGS1			BRD-K63247785-001-01-5	Preclinical
o-mercapto-benzoic-acid					BRD-K36998189-001-03-5	Preclinical
O-1918	cannabinoid receptor antagonist				BRD-K18316707-001-03-5, BRD-K18316707-001-02-7, BRD-K18316707-001-02-7, BRD-K18316707-001-04-9, BRD-K18316707-001-04-9	Preclinical
o-3M3FBS	phospholipase activator				BRD-K46384212-001-03-7, BRD-K46384212-001-04-9, BRD-K46384212-001-02-9	Preclinical
O-304	AMPK activator				BRD-K00003113-001-01-9	Preclinical
OAC1	Oct activator				BRD-K10878147-001-04-9, BRD-K10878147-001-03-0, BRD-K10878147-001-02-2	Preclinical
OAC2	Oct activator	POU5F1			BRD-K18305454-001-07-4, BRD-K18305454-001-07-4	Preclinical
obatoclax	BCL inhibitor	BCL2			BRD-K15600710-066-04-1, BRD-K15600710-066-04-1, BRD-K15600710-066-05-8, BRD-K15600710-066-05-8, BRD-K15600710-066-05-8, BRD-K15600710-066-05-8, BRD-K15600710-066-05-8, BRD-K15600710-066-05-8, BRD-K15600710-066-05-8, BRD-K15600710-066-05-8, BRD-K15600710-066-05-8	Phase 3
obeticholic-acid	FXR agonist	NR1H4	gastroenterology	primary biliary cholangitis	BRD-A75838038-001-01-4	Launched
obidoxime	cholinesterase reactivator	ACHE	critical care, neurology/psychiatry	poison antidote, nerve gas poisoning	BRD-K33588785-300-02-9, BRD-K33588785-001-01-9	Launched
ocaperidone	serotonin receptor antagonist				BRD-K00003399-001-01-9	Preclinical
ochromycinone	STAT inhibitor	STAT3			BRD-K92524032-001-02-1	Phase 1
ocinaplon	GABA receptor modulator	GABRA1, GABRA2, GABRA3, GABRA5			BRD-K92581468-001-01-6	Phase 3
OCO-1112	cholesterol inhibitor				BRD-K22097830-001-01-9, BRD-K22097830-001-01-9, BRD-K22097830-001-01-9, BRD-K22097830-001-01-9, BRD-K22097830-001-01-9	Phase 2
octadecan-1-ol					BRD-K20501889-001-02-0	Preclinical
octamethyltrisiloxane					BRD-K73201113-001-01-3	Preclinical
octenidine	membrane integrity inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-K04568635-300-01-4, BRD-K04568635-300-01-4, BRD-K04568635-300-01-4, BRD-K04568635-300-01-4, BRD-K04568635-300-01-4, BRD-K04568635-300-01-4, BRD-K04568635-300-01-4, BRD-K04568635-300-01-4	Launched
octinoxate			dermatology	sunscreen lotion	BRD-K00003688-001-01-9	Launched
octisalate			dermatology	sunscreen lotion	BRD-K00003664-001-01-9	Launched
octocrylene			dermatology	sunscreen lotion	BRD-K00003605-001-01-9	Launched
octodrine	antitumor agent				BRD-A37873789-001-01-9, BRD-A37873789-003-02-9	Preclinical
octopamine	trace amine associated receptor agonist	F10, TAAR1			BRD-A14240607-003-26-1, BRD-A14240607-003-25-3, BRD-A14240607-003-27-9, BRD-A14240607-003-27-9, BRD-A14240607-003-24-6	Preclinical
octreotide	somatostatin receptor agonist	SSTR2, SSTR3, SSTR5	gastroenterology, endocrinology, oncology	diarrhea, acromegaly, carcinoid tumors	BRD-A64173453-015-03-1, BRD-A64173453-015-02-3, BRD-A64173453-015-01-5	Launched
OC000459	CRTH receptor antagonist	PTGDR2			BRD-K36463073-001-03-9, BRD-K36463073-001-01-3, BRD-K36463073-001-02-1	Phase 2
odanacatib	cathepsin inhibitor	CTSK			BRD-K22822991-001-03-9, BRD-K22822991-001-02-3, BRD-K22822991-001-02-3, BRD-K22822991-001-02-3	Phase 3
ODQ	guanylyl cyclase inhibitor	GUCY1A2, GUCY1A3, GUCY1B3			BRD-K26015241-001-04-4, BRD-K26015241-001-03-6	Preclinical
OF-1	bromodomain inhibitor	BRD1			BRD-K92658264-001-01-8, BRD-K92658264-001-02-9	Preclinical
ofloxacin	bacterial DNA gyrase inhibitor		infectious disease, otolaryngology, gastroenterology, endocrinology	respiratory tract infections, sinusitis, skin infections, bone and joint infections, intra-abdominal infections, diarrhea, fever, urinary tract infections	BRD-K01826479-213-01-9	Launched
ogerin	G protein-coupled receptor modulator				BRD-K00005341-001-01-9	Preclinical
oglemilast	phosphodiesterase inhibitor				BRD-K92303087-001-01-6, BRD-K92303087-001-01-6, BRD-K92303087-001-01-6, BRD-K92303087-001-01-6, BRD-K92303087-001-01-6, BRD-K92303087-001-02-9	Phase 2
oglufanide	VEGF antagonist				BRD-K00003164-001-01-9	Phase 2
OICR-9429	WDR5/MLL interaction inhibitor	WDR5			BRD-K94083718-001-01-9, BRD-K94083718-001-03-9	Preclinical
olanzapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, HRH1, HRH2, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder	BRD-K18895904-001-16-1, BRD-K18895904-001-16-1, BRD-K18895904-001-19-5, BRD-K18895904-001-15-3, BRD-K18895904-001-17-9	Launched
olaparib	PARP inhibitor	PARP1, PARP2	oncology	ovarian cancer	BRD-K02113016-001-19-6, BRD-K02113016-001-19-6, BRD-K02113016-001-19-6, BRD-K02113016-001-15-4, BRD-K02113016-001-15-4	Launched
OLDA	TRPV agonist	GPR119			BRD-K95523387-001-10-9, BRD-K95523387-001-10-9, BRD-K95523387-001-09-6, BRD-K95523387-001-09-6, BRD-K95523387-001-09-6, BRD-K95523387-001-09-6	Preclinical
oleamide	cannabinoid receptor agonist	HTR7, PLA2G2A			BRD-K06644925-001-03-0, BRD-K06644925-001-03-0, BRD-K06644925-001-03-0	Preclinical
oleandrin	Na/K-ATPase inhibitor				BRD-K98006098-001-01-6, BRD-K98006098-001-01-6, BRD-K98006098-001-01-6	Phase 1
oleoylethanolamide	cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist	CNR1, GPR119, GPR55, PPARA			BRD-K66956375-001-11-3, BRD-K66956375-001-11-3	Preclinical
oleuropein	estrogen receptor agonist	GPER1			BRD-A00842753-001-01-9	Phase 2
oligomycin-A	ATP synthase inhibitor, ATPase inhibitor	ATP5A1			BRD-K00003580-001-01-9	Preclinical
olmesartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	BRD-K83144676-001-09-5, BRD-K83144676-001-08-7, BRD-K83144676-001-08-7, BRD-K83144676-001-06-1, BRD-K83144676-001-07-9	Launched
olmesartan-medoxomil	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	BRD-K78485176-001-07-8, BRD-K78485176-001-07-8, BRD-K78485176-001-09-4, BRD-K78485176-001-06-0, BRD-K78485176-001-10-9, BRD-K78485176-001-10-9	Launched
olmutinib	Bruton's tyrosine kinase (BTK) inhibitor, EGFR inhibitor	BTK, EGFR	oncology	non-small cell lung cancer (NSCLC)	BRD-K60421517-001-02-2, BRD-K60421517-001-02-2, BRD-K60421517-001-02-2, BRD-K60421517-001-01-4	Launched
olodanrigan	angiotensin antagonist				BRD-K00003151-001-01-9	Phase 2
olomoucine	CDK inhibitor	CDK1, CDK2, CDK5, MAPK1			BRD-K82731415-001-08-9, BRD-K82731415-001-07-0	Preclinical
olprinone	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	BRD-K20745393-003-01-0, BRD-K20745393-003-01-0, BRD-K20745393-003-01-0	Launched
olsalazine	cyclooxygenase inhibitor	IFNG, TPMT	gastroenterology	ulcerative colitis	BRD-K57853941-304-04-9, BRD-K57853941-304-03-3, BRD-K57853941-304-02-5	Launched
oltipraz	nuclear factor erythroid derived, like (NRF2) activator	ANG			BRD-K86972824-001-01-4, BRD-K86972824-001-01-4, BRD-K86972824-001-01-4, BRD-K86972824-001-01-4, BRD-K86972824-001-02-2	Phase 3
olumacostat-glasaretil	acetyl-CoA carboxylase inhibitor				BRD-K00004611-001-01-9	Phase 3
olvanil	TRPV agonist	CNR1, GPR119, TRPV1			BRD-K31560319-001-02-3, BRD-K31560319-001-02-3, BRD-K31560319-001-03-9, BRD-K31560319-001-01-5, BRD-K31560319-001-01-5, BRD-K31560319-001-01-5	Preclinical
omadacycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	pneumonia	BRD-K00003569-003-01-9	Launched
omapatrilat	metalloproteinase inhibitor	ACE, MME			BRD-K00003265-001-01-9	Preclinical
omarigliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	BRD-K14171291-001-01-4, BRD-K14171291-001-01-4, BRD-K14171291-001-02-2, BRD-K14171291-001-03-9	Launched
ombitasvir	HCV inhibitor		infectious disease	hepatitis C	BRD-K11072003-001-02-4, BRD-K11072003-001-01-6	Launched
ombrabulin	tubulin polymerization inhibitor				BRD-K00003267-003-01-9	Phase 3
OMDM-2	FAAH inhibitor	GPR119			BRD-K48830578-001-02-9, BRD-K48830578-001-01-9, BRD-K48830578-001-01-9	Preclinical
omecamtiv-mecarbil	cardiac myosin activator	MYBPC3			BRD-K36680103-001-01-6, BRD-K36680103-001-01-6, BRD-K36680103-001-02-9	Phase 3
omega-(4-iodophenyl)pentadecanoic-acid					BRD-K53156781-001-01-4	Preclinical
omega-3-acid-esters	cholesterol inhibitor				BRD-K31139048-001-02-4, BRD-K31139048-001-03-2, BRD-K31139048-001-03-2, BRD-K31139048-001-04-0	Launched
omeprazole	ATPase inhibitor	ATP4A, CLCN2	gastroenterology	heartburn	BRD-A55962179-001-23-9, BRD-A55962179-001-24-7, BRD-A55962179-001-22-1, BRD-A55962179-001-21-3	Launched
omeprazole-magnesium	proton pump inhibitor	ATP4A, ATP4B	gastroenterology	gastroesophageal reflux disease (GERD), heartburn	BRD-A56892734-001-09-4	Launched
omeprazole-sulfide	ATPase inhibitor				BRD-K69035426-001-01-3	Phase 1
omtriptolide	ERK1 and ERK2 phosphorylation inhibitor				BRD-K00003212-001-01-9	Preclinical
ON-01500	apoptosis stimulant				BRD-K55790047-001-02-9, BRD-K55790047-001-01-8	Preclinical
oncrasin-1	apoptosis stimulant				BRD-K43449605-001-01-0, BRD-K43449605-001-01-0, BRD-K43449605-001-01-0, BRD-K43449605-001-01-0, BRD-K43449605-001-01-0, BRD-K43449605-001-01-0, BRD-K43449605-001-02-8	Preclinical
ONC201	AKT inhibitor, MAP kinase inhibitor	TNFSF10			BRD-K58529924-001-02-3, BRD-K58529924-001-01-5, BRD-K58529924-001-01-5, BRD-K58529924-001-01-5	Phase 2
ondansetron	serotonin receptor antagonist	HTR3A, HTR3B	gastroenterology	nausea, vomiting	BRD-K01826546-001-06-9, BRD-K01826546-001-05-9	Launched
ONO-AE3-208	prostanoid receptor antagonist	PTGER4			BRD-A80567330-001-01-7, BRD-A80567330-001-02-9	Preclinical
ONO-4059	Bruton's tyrosine kinase (BTK) inhibitor	BTK			BRD-K00003197-001-02-9, BRD-K00003197-003-01-9	Phase 1
ONO-4817	matrix metalloprotease inhibitor	MMP8			BRD-K58894520-001-01-1, BRD-K58894520-001-01-1, BRD-K58894520-001-01-1	Phase 1
ONO-8130	prostanoid receptor antagonist	PTGER1			BRD-K76725781-001-01-9, BRD-K76725781-001-02-9	Preclinical
ONX-0914	proteasome inhibitor				BRD-K00003557-001-01-9	Preclinical
ON123300	CDK inhibitor	CDK4, NUAK1, PDGFRB			BRD-K88554883-001-01-6, BRD-K88554883-001-03-2	Preclinical
OP-0595	beta lactamase inhibitor				BRD-K00004708-001-01-9	Preclinical
OPC-21268	vasopressin receptor antagonist	AVPR1A, AVPR2, OXTR			BRD-K19426040-001-02-9, BRD-K19426040-001-01-1, BRD-K19426040-001-01-1, BRD-K19426040-001-01-1	Phase 1
opicapone	catechol O methyltransferase inhibitor	COMT			BRD-K66192203-001-01-4, BRD-K66192203-001-02-2	Phase 3
opipramol	sigma receptor agonist		neurology/psychiatry	generalized anxiety disorder (GAD)	BRD-K43786866-300-02-3, BRD-K43786866-300-02-3, BRD-K43786866-300-02-3	Launched
oprozomib	proteasome inhibitor				BRD-K91438851-001-02-9	Phase 1/Phase 2
OR-486	catechol O methyltransferase inhibitor	COMT			BRD-K18602506-001-09-9, BRD-K18602506-001-08-0	Preclinical
orantinib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB			BRD-K55966568-001-10-4, BRD-K55966568-001-09-6, BRD-K55966568-001-06-2, BRD-K55966568-001-05-4	Phase 3
ORE1001	angiotensin converting enzyme inhibitor	ACE2			BRD-K67068943-001-01-0, BRD-K67068943-001-01-0	Phase 1/Phase 2
ORG-12962	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			BRD-K07409305-001-01-1	Phase 2
ORG-25543	glycine transporter inhibitor	GLRB, SLC6A5			BRD-K32853922-003-02-9, BRD-K32853922-003-01-8	Preclinical
ORG-26576	glutamate receptor modulator				BRD-K40002998-001-01-5	Phase 2
ORG-27569	cannabinoid receptor modulator	CNR1			BRD-K57597776-001-01-2, BRD-K57597776-001-01-2, BRD-K57597776-001-02-9, BRD-K57597776-001-02-9, BRD-K57597776-001-02-9	Preclinical
ORG-9768	adrenergic receptor antagonist	ADRA2A			BRD-K41434598-003-01-9, BRD-K41434598-003-01-9	Phase 1
oridonin	BCL inhibitor	BCL2			BRD-K00003710-001-01-9	Preclinical
oritavancin	bacterial cell wall synthesis inhibitor		infectious disease	skin infections	BRD-K00003704-316-01-9	Launched
orlistat	lipase inhibitor	CNR1, DAGLA, DAGLB, FASN, LIPF, PNLIP	endocrinology	weight-loss aid	BRD-K63343048-001-13-0, BRD-K63343048-001-15-5, BRD-K63343048-001-17-9, BRD-K63343048-001-12-2, BRD-K63343048-001-12-2	Launched
ormeloxifene	selective estrogen receptor modulator (SERM)		endocrinology	contraceptive	BRD-K00004639-001-01-9	Launched
ornidazole	antiprotozoal agent		infectious disease	protozoan infection	BRD-A42759514-001-20-5, BRD-A42759514-001-23-9, BRD-A42759514-001-21-3, BRD-A42759514-001-19-7	Launched
ornipressin	vasoconstrictor				BRD-K00003333-001-01-9	Preclinical
ornithine	NFkB pathway modulator	GPRC6A			BRD-K01825132-003-02-9	Launched
orotic-acid		DHODH			BRD-K32572029-001-05-1, BRD-K32572029-001-04-4	Phase 2
orphanin-fq	opioid receptor agonist	OPRL1, OPRM1			BRD-K05717154-001-02-9, BRD-K05717154-001-01-1	Phase 1
orphenadrine	acetylcholine receptor antagonist		neurology/psychiatry	muscle pain	BRD-A53576514-048-14-3, BRD-A53576514-048-14-3, BRD-A53576514-048-13-5, BRD-A53576514-048-15-0, BRD-A53576514-048-15-0	Launched
ORY-1001	histone lysine demethylase inhibitor	KDM1A			BRD-K59711701-300-02-1, BRD-K59711701-300-02-1, BRD-K59711701-300-01-3	Phase 1/Phase 2
oseltamivir-carboxylate	neuraminidase inhibitor		infectious disease	influenza A virus infection	BRD-K93767137-001-01-1, BRD-K93767137-001-02-9	Launched
osemozotan	serotonin receptor agonist	HTR1A			BRD-K60371362-001-01-7	Phase 2/Phase 3
OSI-027	mTOR inhibitor	MTOR			BRD-K87124298-001-05-9, BRD-K87124298-001-03-4, BRD-K87124298-001-04-2	Phase 1
OSI-420	EGFR inhibitor	EGFR			BRD-K73309154-003-03-9, BRD-K73309154-003-02-8, BRD-K73309154-003-02-8	Preclinical
OSI-930	KIT inhibitor, VEGFR inhibitor	FLT1, KDR, KIT			BRD-K25340465-001-11-1, BRD-K25340465-001-11-1, BRD-K25340465-001-11-1, BRD-K25340465-001-07-9	Phase 1
osilodrostat	cytochrome P450 inhibitor				BRD-K00003210-001-01-9	Launched
osimertinib	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	BRD-K42805893-001-04-9, BRD-K42805893-001-04-9, BRD-K42805893-001-04-9, BRD-K42805893-001-04-9, BRD-K42805893-001-04-9, BRD-K42805893-001-08-9, BRD-K42805893-001-08-9	Launched
ospemifene	selective estrogen receptor modulator (SERM)	ESR1, ESR2	obstetrics/gynecology, endocrinology	vaginal atrophy, dyspareunia, menopause	BRD-K44184170-001-01-7, BRD-K44184170-001-01-7	Launched
ostarine	androgen receptor modulator	AR			BRD-K29735307-001-03-9, BRD-K29735307-001-02-9	Phase 3
osthol	calcium channel blocker				BRD-K78294846-001-13-9, BRD-K78294846-001-12-4	Preclinical
OT-R-antagonist-1	oxytocin receptor antagonist	AVPR1A, OXTR			BRD-K42009284-001-01-1	Preclinical
otamixaban	coagulation factor inhibitor	F10			BRD-K80082640-001-02-9, BRD-K80082640-001-01-0, BRD-K80082640-001-01-0, BRD-K80082640-001-01-0	Phase 3
otenzepad	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			BRD-A00520476-001-08-2, BRD-A00520476-001-09-9, BRD-A00520476-001-07-4	Phase 3
otilonium	acetylcholine receptor antagonist	CACNA1C	gastroenterology	irritable bowel syndrome	BRD-K85337334-004-03-9, BRD-K85337334-004-03-9, BRD-K85337334-004-03-9, BRD-K85337334-004-02-6, BRD-K85337334-004-02-6, BRD-K85337334-004-02-6	Launched
OTS167	maternal embryonic leucine zipper kinase inhibitor	MELK			BRD-K53417444-003-03-1, BRD-K53417444-003-03-1, BRD-K53417444-003-03-1, BRD-K53417444-003-03-1, BRD-K53417444-003-04-9, BRD-K53417444-003-04-9	Phase 1/Phase 2
OTS514	TOPK inhibitor				BRD-K38018935-001-01-1, BRD-K38018935-001-01-1, BRD-K38018935-001-01-1	Preclinical
OXA-06	rho associated kinase inhibitor	ROCK1, ROCK2			BRD-K98736329-300-02-9, BRD-K98736329-300-01-5	Preclinical
oxaceprol	anti-inflammatory agent				BRD-K65230684-001-06-9	Preclinical
oxacyclohexadecan-2-one	protein kinase inhibitor				BRD-K36982194-001-01-6	Preclinical
oxaloacetate	glutamate release inhibitor				BRD-K61279411-001-03-8, BRD-K61279411-001-02-0	Phase 2/Phase 3
oxantel	anthelmintic agent		infectious disease	gastrointestinal parasites	BRD-K66019333-096-02-0, BRD-K66019333-096-03-9	Launched
oxaprozin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	BRD-K25394294-001-14-9, BRD-K25394294-001-16-9, BRD-K25394294-001-13-1	Launched
oxatomide	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	BRD-K22556255-001-08-9, BRD-K22556255-001-06-9	Launched
oxcarbazepine	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	BRD-K04196797-001-24-4, BRD-K04196797-001-23-6, BRD-K04196797-001-25-1, BRD-K04196797-001-25-1, BRD-K04196797-001-25-1	Launched
oxethazaine	local anesthetic		neurology/psychiatry	local anesthetic	BRD-K56940463-001-14-6, BRD-K56940463-001-15-9, BRD-K56940463-001-13-8	Launched
OXF-BD-02	bromodomain inhibitor	BRD4			BRD-A73891132-001-02-9, BRD-A73891132-001-01-0	Preclinical
oxfendazole	anthelmintic agent		infectious disease	lungworms, tapeworm, gastrointestinal roundworms	BRD-A33447119-001-11-6, BRD-A33447119-001-10-8	Launched
oxfenicine	carnitine palmitoyltransferase inhibitor	CPT1A, CPT1B			BRD-K30373577-001-02-9, BRD-K30373577-001-01-1	Phase 1
oxibendazole	tubulin polymerization inhibitor	TUBB, TUBB4B	infectious disease	strongyles	BRD-K52075715-001-07-5, BRD-K52075715-001-06-7, BRD-K52075715-001-06-7, BRD-K52075715-001-06-7	Launched
oxiconazole	bacterial cell wall synthesis inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	BRD-K56104152-008-04-1, BRD-K56104152-008-05-9	Launched
oxidopamine	neurotoxin				BRD-K41809988-004-10-9, BRD-K41809988-003-09-3	Preclinical
oxiniacic-acid					BRD-K20417253-001-02-7, BRD-K20417253-001-02-7, BRD-K20417253-001-03-9, BRD-K20417253-001-01-9	Preclinical
oxiperomide	dopamine receptor antagonist				BRD-K78096648-001-05-7	Phase 2
oxiracetam	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	BRD-K50677762-001-02-9, BRD-K50677762-001-01-5, BRD-K50677762-001-01-5	Launched
oxolamine	antitussive		pulmonary	cough suppressant	BRD-K42596464-048-11-9, BRD-K42596464-048-12-9	Launched
oxolinic-acid	bacterial DNA gyrase inhibitor				BRD-K73394555-237-01-1, BRD-K73394555-001-10-9, BRD-K73394555-001-10-9	Preclinical
oxotremorine-M	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			BRD-K01942991-005-09-0, BRD-K01942991-005-09-0, BRD-K01942991-005-09-0, BRD-K01942991-005-08-2	Preclinical
oxybenzone	lipase inhibitor	LIPE	dermatology	sunscreen lotion	BRD-K59037100-001-15-9, BRD-K59037100-001-14-7	Launched
oxybuprocaine	local anesthetic	SCN10A	neurology/psychiatry	local anesthetic	BRD-K04185004-003-12-7, BRD-K04185004-003-11-9, BRD-K04185004-003-11-9, BRD-K04185004-003-14-3, BRD-K04185004-003-13-5	Launched
oxybutynin	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	urology	urinary incontinence	BRD-K01825580-001-03-9, BRD-K01825580-001-02-9	Launched
oxyfedrine	adrenergic receptor agonist		cardiology	angina pectoris	BRD-K73027814-003-01-0, BRD-K73027814-003-01-0	Launched
oxymatrine					BRD-K00003713-001-01-9	Launched
oxymetazoline	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR2C	otolaryngology	nasal congestion	BRD-K16195444-003-25-2, BRD-K16195444-003-26-0, BRD-K16195444-003-24-5	Launched
oxyphenbutazone	cyclooxygenase inhibitor				BRD-A33749298-001-18-3	Withdrawn
oxyphencyclimine	cholinergic receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	BRD-A58193911-003-18-7, BRD-A58193911-003-18-7	Launched
oxyphenonium	cholinergic receptor antagonist	CHRM1, CHRM3	gastroenterology	peptic ulcer disease (PUD)	BRD-A14208071-004-19-8	Launched
oxypurinol	xanthine oxidase inhibitor	XDH			BRD-K31841515-001-07-8, BRD-K31841515-001-07-8	Phase 2/Phase 3
oxyquinoline	chelating agent	METAP2	dermatology	cosmetic	BRD-K66808046-065-03-7, BRD-K66808046-065-03-7, BRD-K66808046-065-03-7, BRD-K66808046-065-03-7	Launched
ozagrel	thromboxane synthase inhibitor	TBXAS1	neurology/psychiatry	stroke	BRD-K53061490-003-15-9, BRD-K53061490-003-13-9, BRD-K53061490-003-13-9, BRD-K53061490-001-02-6, BRD-K53061490-003-14-7	Launched
ozanimod	sphingosine 1-phosphate receptor agonist	S1PR1			BRD-K46625559-001-01-8	Phase 3
ozenoxacin	antiinfective drug				BRD-K00003184-001-01-9	Phase 3
ozolinone	diuretic				BRD-A72297358-001-01-8	Phase 3
O4I1	Oct inducer	POU5F1			BRD-K53849769-001-02-9, BRD-K53849769-001-01-0	Preclinical
O6-benzylguanine	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			BRD-K92041145-001-09-5, BRD-K92041145-001-09-5, BRD-K92041145-001-09-5	Phase 3
p-dimethylinamyl-benzoate					BRD-K42336459-001-01-7, BRD-K42336459-001-02-9	Preclinical
PA-452	retinoid receptor antagonist	RXRA			BRD-K11428250-001-02-9, BRD-K11428250-001-02-9, BRD-K11428250-001-01-0, BRD-K11428250-001-01-0	Preclinical
PAC-1	caspase activator	CASP3			BRD-K92991072-001-06-4, BRD-K92991072-001-05-6, BRD-K92991072-001-05-6, BRD-K92991072-001-05-6, BRD-K92991072-001-07-9, BRD-K92991072-001-07-9, BRD-K92991072-001-07-9, BRD-K92991072-001-07-9, BRD-K92991072-001-04-9, BRD-K92991072-001-04-9, BRD-K92991072-001-04-9	Phase 1
PACOCF3	phospholipase inhibitor	PLA2G4A			BRD-K05677083-001-06-9, BRD-K05677083-001-06-9, BRD-K05677083-001-05-4	Preclinical
pacritinib	FLT3 inhibitor, JAK inhibitor	FLT3, JAK1, JAK2, JAK3			BRD-K19034817-001-04-8, BRD-K19034817-001-04-8, BRD-K19034817-001-04-8, BRD-K19034817-001-04-8, BRD-K19034817-001-01-4, BRD-K19034817-001-01-4, BRD-K19034817-001-02-2	Phase 3
padsevonil	antiepileptic				BRD-K00003493-001-01-9	Phase 3
paeonol	anti-inflammatory agent				BRD-K94239562-001-06-9, BRD-K94239562-001-05-5	Preclinical
pafuramidine	DNA synthesis inhibitor				BRD-K68805147-001-01-8, BRD-K68805147-001-02-9	Phase 3
pagoclone	GABA receptor agonist				BRD-K00003428-001-01-9	Phase 2/Phase 3
palbociclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	BRD-K51313569-001-07-8, BRD-K51313569-001-07-8, BRD-K51313569-001-07-8, BRD-K51313569-001-07-8, BRD-K51313569-001-07-8, BRD-K51313569-003-03-3, BRD-K51313569-003-03-3, BRD-K51313569-001-11-0, BRD-K51313569-001-11-0	Launched
palifosfamide	DNA alkylating agent				BRD-K12047401-001-02-3, BRD-K12047401-001-01-5	Phase 3
palmatine-chloride	dopamine synthesis inhibitor	CYP3A4			BRD-K58466253-003-15-9, BRD-K58466253-003-14-0, BRD-K58466253-003-14-0	Preclinical
palmitoleic-acid					BRD-K91356052-001-04-0, BRD-K91356052-001-04-0	Preclinical
palmitoylcarnitine	protein kinase inhibitor				BRD-K01826784-003-09-9, BRD-K01826784-003-08-9, BRD-K01826784-003-08-9	Preclinical
palmitoylethanolamide	cannabinoid receptor agonist	CNR2, GPR119, GPR55			BRD-K68095457-001-11-9, BRD-K68095457-001-10-1	Launched
palomid-529	AKT inhibitor, mTOR inhibitor	MTOR			BRD-A50998626-001-03-9, BRD-A50998626-001-02-1, BRD-A50998626-001-02-1	Phase 1
palonosetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	BRD-K08924299-003-07-9, BRD-K08924299-003-06-1	Launched
palosuran	urotensin receptor antagonist	UTS2R			BRD-K07682953-001-01-8	Phase 2
palovarotene	retinoid receptor agonist	RARG			BRD-K83794243-001-01-8, BRD-K83794243-001-01-8, BRD-K83794243-001-01-8, BRD-K83794243-001-02-9, BRD-K83794243-001-02-9	Phase 3
pamabrom	diuretic		gastroenterology	bloating	BRD-M67659203-001-01-9, BRD-M67659203-001-02-7	Launched
pamidronate	bone resorption inhibitor	FDPS	endocrinology, oncology, hematologic malignancy	hypercalcemia, Paget's disease, breast cancer, multiple myeloma	BRD-K58513245-304-03-5, BRD-K58513245-304-02-7	Launched
pamiparib	PARP inhibitor				BRD-K00003461-001-01-9	Phase 3
panipenem	antibacterial 				BRD-K00004671-001-01-9	Preclinical
panobinostat	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	multiple myeloma	BRD-K02130563-001-15-5, BRD-K02130563-001-15-5, BRD-K02130563-001-15-5, BRD-K02130563-001-14-8, BRD-K02130563-001-12-2, BRD-K02130563-001-12-2, BRD-K02130563-001-12-2, BRD-K02130563-001-11-4, BRD-K02130563-001-11-4, BRD-K02130563-001-11-4	Launched
pantethine	coenzyme A precursor				BRD-K68764924-001-03-2, BRD-K68764924-001-05-7, BRD-K68764924-001-06-9, BRD-K68764924-001-06-9, BRD-K68764924-001-04-0	Launched
pantoprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE), Zollinger-Ellison syndrome	BRD-K00003243-236-01-9	Launched
pantothenic-acid	coenzyme A precursor				BRD-K29392254-236-05-9, BRD-K29392254-236-01-6, BRD-K29392254-001-02-2, BRD-K29392254-001-03-0	Launched
PAOPA	dopamine receptor modulator	DRD2			BRD-K18573821-001-03-9, BRD-K18573821-001-02-4	Preclinical
papaverine	phosphodiesterase inhibitor	PDE10A, PDE4B, PDE5A	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm	BRD-K15567136-003-27-2, BRD-K15567136-003-27-2, BRD-K15567136-003-27-2	Launched
paquinimod	S100A9 inhibitor				BRD-K00003371-001-01-9	Phase 2
para-toluenesulfonamide		CA12, CA2, CA6, CA9			BRD-K62412084-001-08-9, BRD-K62412084-001-07-1, BRD-K62412084-001-07-1	Phase 3
paracetamol	cyclooxygenase inhibitor	FAAH, PTGS1, PTGS2, TRPV1	neurology/psychiatry, endocrinology	pain relief, fever	BRD-K41524689-001-25-0, BRD-K41524689-001-23-5, BRD-K41524689-001-22-7, BRD-K41524689-001-05-2, BRD-K41524689-001-05-2, BRD-K41524689-001-05-2, BRD-K41524689-001-05-2	Launched
parachlorophenol	antiinfective drug		infectious disease	first-aid antiseptic	BRD-K40992116-001-10-9, BRD-K40992116-001-10-9, BRD-K40992116-001-09-7, BRD-K40992116-001-09-7	Launched
paramethadione	anticonvulsant	CACNA1G	neurology/psychiatry	seizures	BRD-A22128695-001-02-6, BRD-A22128695-001-03-4	Launched
paraxanthine	adenosine receptor antagonist				BRD-K24084088-001-11-3, BRD-K24084088-001-11-3, BRD-K24084088-001-12-9	Phase 1
parbendazole	tubulin polymerization inhibitor	TUBB			BRD-K02407574-001-09-7, BRD-K02407574-001-09-7, BRD-K02407574-001-09-7	Preclinical
parcetasal	anti-inflammatory agent				BRD-K00004740-001-01-9	Preclinical
pardoprunox	dopamine receptor agonist, serotonin receptor agonist	DRD2, DRD3, DRD4, HTR1A, HTR7			BRD-K11851476-003-01-7, BRD-K11851476-003-01-7, BRD-K11851476-003-01-7	Phase 3
parecoxib	cyclooxygenase inhibitor	LTF	neurology/psychiatry	pain relief	BRD-K13800121-001-01-5, BRD-K13800121-001-03-9, BRD-K13800121-001-03-9	Launched
parethoxycaine	local anesthetic				BRD-K54799382-003-08-4	Preclinical
pargyline	monoamine oxidase inhibitor	MAOA, MAOB	cardiology	hypertension	BRD-K83597974-003-23-9, BRD-K83597974-003-22-2	Launched
paricalcitol	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperthyroidism	BRD-K60585088-001-03-9, BRD-K60585088-001-01-5, BRD-K60585088-001-01-5, BRD-K60585088-001-01-5	Launched
paritaprevir	HCV inhibitor		infectious disease	hepatitis C	BRD-K89920762-001-01-4, BRD-K89920762-001-01-4	Launched
paroxetine	selective serotonin reuptake inhibitor (SSRI)	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR2A, SLC6A2, SLC6A4	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorders, posttraumatic stress disorder, social anxiety disorder	BRD-K37991163-003-14-2, BRD-K37991163-050-18-4, BRD-K37991163-003-13-4, BRD-K37991163-003-13-4, BRD-K37991163-003-13-4, BRD-K37991163-003-13-4	Launched
paroxypropione	gonadotropin inhibitor				BRD-K07441213-001-20-9, BRD-K07441213-001-18-9	Launched
parsaclisib	PI3K inhibitor				BRD-K00004594-001-01-9	Phase 2
parthenolide	NFkB pathway inhibitor				BRD-K98548675-001-06-7, BRD-K98548675-001-09-9, BRD-K98548675-001-05-9	Phase 1
parthenolide-(-)	NFkB pathway inhibitor	HDAC1			BRD-K34851558-001-02-3, BRD-K34851558-001-02-3	Preclinical
parthenolide-(alternate-stereo)	NFkB pathway inhibitor	IKBKB, RELA			BRD-K28120222-001-09-9, BRD-K28120222-001-09-9, BRD-K28120222-001-08-4, BRD-K28120222-001-08-4, BRD-K28120222-001-08-4	Preclinical
pasireotide	somatostatin receptor agonist	SSTR1, SSTR2, SSTR3, SSTR5	endocrinology	Cushing's syndrome, acromegaly	BRD-K59715032-362-02-9, BRD-K59715032-362-01-4	Launched
PAT-1251	lysyl oxidase inhibitor				BRD-K00003481-001-01-9	Phase 1
pavinetant	neurokinin receptor antagonist				BRD-K00003170-001-01-9	Phase 2
pazopanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)	BRD-K74514084-003-09-2, BRD-K74514084-003-09-2, BRD-K74514084-003-09-2, BRD-K74514084-001-03-9, BRD-K74514084-001-03-9, BRD-K74514084-001-03-9, BRD-K74514084-001-03-9	Launched
pazufloxacin	topoisomerase inhibitor		infectious disease	pneumonia, peritonitis, bacterial septicemia	BRD-K66412701-066-09-9, BRD-K66412701-066-01-6	Launched
PBI-4050	free fatty acid receptor agonist				BRD-K00003391-236-01-9	Phase 2/Phase 3
PBT-1033	chelating agent				BRD-K00004615-001-01-9	Preclinical
PCA-4248	platelet activating factor receptor antagonist	PTAFR			BRD-A29289453-001-05-4, BRD-A29289453-001-05-4, BRD-A29289453-001-06-9, BRD-A29289453-001-04-7	Phase 1
PCI-24781	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC6			BRD-K12867552-001-04-7, BRD-K12867552-001-04-7, BRD-K12867552-001-04-7, BRD-K12867552-001-04-7	Phase 3
PCI-27483	ERK1 and ERK2 phosphorylation inhibitor				BRD-K00003213-001-01-9	Phase 2
PCI-29732	Bruton's tyrosine kinase (BTK) inhibitor	BTK			BRD-K71223042-001-03-9, BRD-K71223042-001-01-5	Preclinical
PCI-34051	HDAC inhibitor	HDAC1, HDAC10, HDAC6, HDAC8			BRD-K88742110-001-11-9, BRD-K88742110-001-11-9, BRD-K88742110-001-09-5, BRD-K88742110-001-07-9, BRD-K88742110-001-08-7	Preclinical
PCO-400	potassium channel activator	KCNJ8			BRD-K52721684-001-03-0, BRD-K52721684-001-04-8	Phase 1
PD-0325901	MEK inhibitor	MAP2K1			BRD-K49865102-001-08-4, BRD-K49865102-001-08-4	Phase 2
PD-102807	acetylcholine receptor antagonist	CHRM4			BRD-A89337244-001-03-7, BRD-A89337244-001-04-9, BRD-A89337244-001-02-9, BRD-A89337244-001-02-9	Preclinical
PD-118057	potassium channel activator	KCNH2			BRD-K34657753-001-01-9, BRD-K34657753-001-01-9, BRD-K34657753-001-01-9	Preclinical
PD-123319	angiotensin antagonist	AGTR2			BRD-K34713073-362-02-9, BRD-K34713073-001-01-3, BRD-K34713073-001-01-3, BRD-K34713073-362-01-9	Phase 1
PD-128907	dopamine receptor agonist	DRD2, DRD3			BRD-K62456038-003-08-9, BRD-K62456038-003-09-9, BRD-K62456038-003-07-1	Preclinical
PD-153035	EGFR inhibitor	EGFR, KDR			BRD-K26603252-003-04-9, BRD-K26603252-003-04-9	Phase 1
PD-156707	endothelin receptor antagonist	EDNRA, EDNRB			BRD-K13826399-236-01-7	Preclinical
PD-158780	EGFR inhibitor	EGFR			BRD-K48735772-001-04-8, BRD-K48735772-001-03-0, BRD-K48735772-001-01-4, BRD-K48735772-001-01-4, BRD-K48735772-001-01-4	Preclinical
PD-160170	neuropeptide receptor antagonist	NPY1R			BRD-K12079898-001-03-4, BRD-K12079898-001-02-6, BRD-K12079898-001-04-9	Preclinical
PD-161570	FGFR inhibitor	FGFR1			BRD-K97152684-001-02-7, BRD-K97152684-001-01-9, BRD-K97152684-001-03-9, BRD-K97152684-001-03-9	Preclinical
PD-166285	SRC inhibitor	EGFR, FGFR1, PDGFRB, PKMYT1, SRC, WEE1			BRD-K93217218-300-01-5, BRD-K93217218-300-01-5, BRD-K93217218-300-01-5, BRD-K93217218-300-03-9, BRD-K93217218-300-03-9, BRD-K93217218-300-03-9	Preclinical
PD-166793	collagenase inhibitor, metalloproteinase inhibitor	MMP13, MMP2, MMP3			BRD-K60984070-001-02-8, BRD-K60984070-001-01-0, BRD-K60984070-001-01-0, BRD-K60984070-001-03-9	Preclinical
PD-168077	dopamine receptor agonist	DRD2			BRD-K47761761-050-07-8	Preclinical
PD-168393	EGFR inhibitor	EGFR, ERBB2, SRC			BRD-K17702546-001-03-2, BRD-K17702546-001-03-2, BRD-K17702546-001-03-2, BRD-K17702546-001-03-2	Preclinical
PD-168568	dopamine receptor antagonist	DRD2, DRD4			BRD-A82013137-300-01-1, BRD-A82013137-300-01-1, BRD-A82013137-300-02-9	Preclinical
PD-173074	FGFR inhibitor, VEGFR inhibitor	FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB			BRD-K97764662-001-21-5, BRD-K97764662-001-20-7, BRD-K97764662-001-20-7, BRD-K97764662-001-20-7, BRD-K97764662-001-17-3, BRD-K97764662-001-23-9	Preclinical
PD-173212	calcium channel blocker	CACNA1B			BRD-K04426574-001-02-0, BRD-K04426574-001-02-0, BRD-K04426574-001-02-0, BRD-K04426574-001-03-9	Preclinical
PD-184352	MEK inhibitor	MAP2K1, MAP3K1, MAP3K2			BRD-K05104363-001-10-0, BRD-K05104363-001-10-0, BRD-K05104363-001-10-0, BRD-K05104363-001-10-0, BRD-K05104363-001-10-0, BRD-K05104363-001-01-9, BRD-K05104363-001-01-9, BRD-K05104363-001-01-9	Phase 2
PD-198306	MAP kinase inhibitor, MEK inhibitor	MAP2K1, MAP2K2			BRD-K88677950-001-03-9, BRD-K88677950-001-03-9, BRD-K88677950-001-03-9, BRD-K88677950-001-03-9, BRD-K88677950-001-03-9, BRD-K88677950-001-03-9, BRD-K88677950-001-04-9	Preclinical
PD-318088	MEK inhibitor				BRD-A57798112-001-04-9, BRD-A57798112-001-03-7, BRD-A57798112-001-03-7, BRD-A57798112-001-03-7	Preclinical
PD-407824	PKC inhibitor	WEE1			BRD-K82823804-001-04-1, BRD-K82823804-001-04-1, BRD-K82823804-001-04-1, BRD-K82823804-001-06-9, BRD-K82823804-001-06-9, BRD-K82823804-001-05-8	Preclinical
PD-81723	adenosine receptor agonist	ADORA1			BRD-K77951111-001-05-9, BRD-K77951111-001-04-5	Preclinical
PD-98059	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			BRD-K62810658-001-11-4, BRD-K62810658-001-15-5, BRD-K62810658-001-12-2	Preclinical
PDD-00017273	PARG inhibitor				BRD-K00021095-001-01-9, BRD-K00021095-001-01-9	Preclinical
PDE10-IN-1	phosphodiesterase inhibitor	PDE10A			BRD-K38145871-001-01-8	Preclinical
PDP-EA	FAAH activator	FAAH			BRD-K26358347-001-02-9, BRD-K26358347-001-01-7	Preclinical
PD1-PDL-inhibitor-1	programmed death ligand inhibitor	CD274			BRD-K04032780-001-01-8, BRD-K04032780-001-01-8	Preclinical
pefloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, urology	gastrointestinal infections, urethritis, gonorrhea, urinary tract infections	BRD-K55034111-066-18-9, BRD-K55034111-066-17-1, BRD-K55034111-066-16-3	Launched
pelanserin	serotonin receptor antagonist	HTR2A			BRD-K96436774-001-01-8	Phase 2
pelitinib	EGFR inhibitor	EGFR			BRD-K08799216-001-06-9, BRD-K08799216-001-05-3, BRD-K08799216-001-05-3, BRD-K08799216-001-05-3	Phase 2
pelrinone	phosphodiesterase inhibitor				BRD-K00004687-001-01-9	Phase 2
pemafibrate	PPAR receptor agonist				BRD-K00003251-001-01-9	Phase 3
pemirolast	mediator release inhibitor	HRH1	pulmonary	asthma	BRD-K31731454-237-04-9, BRD-K31731454-237-03-3, BRD-K31731454-237-02-5	Launched
pempidine	ganglionic blocker		cardiology	hypertension	BRD-K71075093-045-14-7, BRD-K71075093-045-14-7	Launched
penbutolol	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A, HTR1B	cardiology	hypertension	BRD-K55705469-065-01-0, BRD-K55705469-065-01-0, BRD-K55705469-065-01-0, BRD-K55705469-065-02-9, BRD-K55705469-065-02-9, BRD-K55705469-065-02-9	Launched
penciclovir	DNA directed DNA polymerase inhibitor		dental	cold sore	BRD-K47780086-001-07-9, BRD-K47780086-001-06-1, BRD-K47780086-001-10-9, BRD-K47780086-001-08-7	Launched
penfluridol	T-type calcium channel blocker	CACNA1G	neurology/psychiatry	schizophrenia	BRD-K15409150-001-07-4, BRD-K15409150-001-07-4, BRD-K15409150-001-07-4, BRD-K15409150-001-07-4, BRD-K15409150-001-05-8, BRD-K15409150-001-05-8	Launched
penicillamine-(D)	chelating agent		metabolism, rheumatology, nephrology	Wilson's disease, rheumatoid arthritis, cystinuria	BRD-K17518951-001-03-0, BRD-K17518951-001-14-9, BRD-K17518951-001-04-8	Launched
penicillamine-(racemic)					BRD-K01825697-213-01-9	Launched
penicillin-v-potassium	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, ear infections, skin infections, throat infections, cholera, scarlet fever	BRD-K43966364-237-06-9, BRD-K43966364-237-04-8	Launched
pentacosanoic-acid					BRD-K48996094-001-01-3, BRD-K48996094-001-01-3	Preclinical
pentamidine	anti-pneumocystis agent	TRDMT1	infectious disease	pneumonia	BRD-K13183738-317-10-2, BRD-K13183738-300-02-5	Launched
pentetic-acid	chelating agent				BRD-K40621224-001-07-9, BRD-K40621224-001-06-7	Phase 2
pentolinium	cholinergic receptor antagonist	CHRNA10, CHRNA3, CHRNA4, CHRNB4	cardiology	hypertension	BRD-K44942604-346-04-7, BRD-K44942604-346-05-4, BRD-K44942604-346-05-4	Launched
pentostatin	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	ADA	hematologic malignancy	hairy cell leukemia	BRD-K91543828-001-02-0, BRD-K91543828-001-02-0, BRD-K91543828-001-04-9	Launched
pentoxifylline	phosphodiesterase inhibitor	ADORA1, ADORA2A, ADORA2B, ADRA2B, NT5E, PDE10A, PDE1A, PDE1B, PDE1C, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE6D, PDE6G, PDE6H, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, TNF	cardiology	claudication	BRD-K57569181-001-27-5, BRD-K57569181-001-27-5, BRD-K57569181-001-27-5, BRD-K57569181-001-27-5, BRD-K57569181-001-26-7	Launched
pentylenetetrazol	GABA receptor antagonist				BRD-K57718010-001-12-7, BRD-K57718010-001-11-9, BRD-K57718010-001-11-9, BRD-K57718010-001-10-1	Withdrawn
peposertib	DNA dependent protein kinase inhibitor				BRD-K00003426-001-01-9	Phase 1/Phase 2
pepstatin	aspartic protease inhibitor	CTSB, CTSD, CTSL, REN			BRD-K13571841-201-16-9, BRD-K13571841-001-14-4	Preclinical
peramivir	neuraminidase inhibitor		infectious disease	influenza A virus infection	BRD-K00519864-341-02-5, BRD-K00519864-341-03-3, BRD-K00519864-341-04-9	Launched
perchlozone			infectious disease	tuberculosis	BRD-K00004530-001-01-9	Launched
peretinoin	retinoid receptor agonist	RXRA			BRD-K99431849-001-01-7, BRD-K99431849-001-01-7, BRD-K99431849-001-02-5	Phase 3
perfluamine					BRD-K16758059-001-01-8	Launched
perflubron	contrast agent		radiology	contrast agent	BRD-K92988025-001-02-7, BRD-K92988025-001-01-9	Launched
perfluorodecalin			dermatology	cosmetic	BRD-K55401595-001-01-8	Launched
perfluorohexyloctane					BRD-K00004546-001-01-9	Launched
perhexiline	carnitine palmitoyltransferase inhibitor	CPT1A	cardiology	angina pectoris	BRD-A19633847-050-32-1, BRD-A19633847-050-32-1, BRD-A19633847-050-32-1, BRD-A19633847-050-32-1, BRD-A19633847-050-32-1, BRD-A19633847-050-32-1, BRD-A19633847-050-32-1, BRD-A19633847-050-20-6, BRD-A19633847-050-20-6	Launched
perifosine	AKT inhibitor	AKT1			BRD-A89082344-001-07-9, BRD-A89082344-001-08-7, BRD-A89082344-001-08-7, BRD-A89082344-001-08-7, BRD-A89082344-001-06-1	Phase 3
perillyl-alcohol	apoptosis stimulant, farnesyltransferase inhibitor	FNTA			BRD-A13323580-001-05-5, BRD-A13323580-001-05-5, BRD-A13323580-001-04-8, BRD-A13323580-001-04-8	Phase 2
perindoprilat	angiotensin converting enzyme inhibitor	ACE			BRD-K00768353-001-01-8	Phase 2
permethrin			infectious disease	lice	BRD-A25366096-001-09-9, BRD-A25366096-001-07-3, BRD-A25366096-001-08-1	Launched
perospirone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, DRD3, DRD4	neurology/psychiatry	schizophrenia, bipolar disorder	BRD-K85503079-001-01-0, BRD-K85503079-001-02-8, BRD-K85503079-001-02-8, BRD-K85503079-001-02-8, BRD-K85503079-001-02-8	Launched
perphenazine	dopamine receptor antagonist	CALM1, DRD1, DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7	neurology/psychiatry, gastroenterology	schizophrenia, nausea, vomiting	BRD-K10995081-001-26-1, BRD-K10995081-001-28-7, BRD-K10995081-001-28-7, BRD-K10995081-001-27-9	Launched
peruvoside	cardiac glycoside				BRD-A72716251-001-01-5	Phase 1
perzinfotel	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B			BRD-K04643877-001-03-2, BRD-K04643877-001-03-2, BRD-K04643877-001-03-2	Phase 2
PETCM	caspase activator	CASP3			BRD-A93477898-001-04-2, BRD-A93477898-001-04-2	Preclinical
pevonedistat	nedd activating enzyme inhibitor	NAE1, UBA3			BRD-K67844266-003-01-9, BRD-K67844266-003-01-9, BRD-K67844266-003-01-9, BRD-K67844266-003-01-9, BRD-K67844266-003-01-9, BRD-K67844266-001-02-1, BRD-K67844266-001-02-1, BRD-K67844266-001-02-1	Phase 3
pexidartinib	tyrosine kinase inhibitor	CSF1R, FLT3, KIT			BRD-K54519451-001-02-9, BRD-K54519451-001-02-9, BRD-K54519451-001-02-9	Launched
pexmetinib	MAP kinase inhibitor, TIE tyrosine kinase inhibitor	MAPK14, TEK			BRD-K53405000-001-01-0, BRD-K53405000-001-02-8, BRD-K53405000-001-02-8, BRD-K53405000-001-02-8	Phase 1
PF-02413873	progesterone receptor antagonist				BRD-K00004632-001-01-9	Phase 1
PF-02545920	phosphodiesterase inhibitor	PDE10A			BRD-K31519811-001-02-2, BRD-K31519811-001-02-2, BRD-K31519811-001-02-2	Phase 2
PF-03049423	phosphodiesterase inhibitor	PDE5A			BRD-K07070922-001-01-4, BRD-K07070922-001-01-4	Phase 2
PF-03084014	gamma secretase inhibitor				BRD-K61691541-303-02-9, BRD-K61691541-001-01-1, BRD-K61691541-001-01-1	Phase 3
PF-03758309	p21 activated kinase inhibitor	PAK4			BRD-K37764012-001-04-1, BRD-K37764012-001-04-1, BRD-K37764012-001-04-1, BRD-K37764012-001-04-1, BRD-K37764012-001-01-7, BRD-K37764012-001-01-7, BRD-K37764012-001-01-7, BRD-K37764012-001-01-7, BRD-K37764012-001-01-7, BRD-K37764012-001-01-7, BRD-K37764012-001-01-7, BRD-K37764012-001-01-7	Phase 1
PF-03814735	Aurora kinase inhibitor	AURKA, AURKB			BRD-K68747584-001-06-9, BRD-K68747584-001-03-8, BRD-K68747584-001-03-8, BRD-K68747584-001-02-0	Phase 1
PF-03882845	mineralocorticoid receptor antagonist				BRD-K51041191-001-02-9, BRD-K51041191-001-01-4, BRD-K51041191-001-01-4, BRD-K51041191-001-01-4	Phase 1
PF-04136309	CC chemokine receptor antagonist				BRD-K94420399-001-01-9, BRD-K94420399-001-01-9, BRD-K94420399-001-02-9, BRD-K94420399-001-02-9, BRD-K94420399-001-02-9	Phase 2
PF-04217903	c-Met inhibitor	MET			BRD-K73319509-001-08-0, BRD-K73319509-001-08-0, BRD-K73319509-001-08-0, BRD-K73319509-001-06-4	Phase 1
PF-04418948	prostaglandin inhibitor	PTGER2			BRD-K54871792-001-01-4, BRD-K54871792-001-02-2, BRD-K54871792-001-02-2	Phase 1
PF-04447943	phosphodiesterase inhibitor	PDE9A			BRD-K50031829-001-01-6, BRD-K50031829-001-01-6, BRD-K50031829-001-02-9	Phase 2
PF-04457845	FAAH inhibitor	FAAH			BRD-K86816506-001-02-9, BRD-K86816506-001-01-8, BRD-K86816506-001-01-8	Phase 2
PF-04620110	diacylglycerol O acyltransferase inhibitor	DGAT1			BRD-K30550578-001-02-9, BRD-K30550578-001-01-3, BRD-K30550578-001-01-3	Phase 1
PF-04691502	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			BRD-K07310275-001-02-5, BRD-K07310275-001-02-5, BRD-K07310275-001-02-5	Phase 2
PF-04885614	voltage-gated sodium channel blocker	SCN10A			BRD-K92435527-001-03-9, BRD-K92435527-001-01-4	Preclinical
PF-04937319	glucokinase activator	GCK			BRD-K27755542-001-01-6	Phase 2
PF-04995274	serotonin receptor agonist				BRD-K00004635-001-01-9	Phase 1
PF-05089771	sodium channel blocker				BRD-K00003145-001-01-9	Preclinical
PF-05175157	acetyl-CoA carboxylase inhibitor				BRD-K00002423-001-02-9	Phase 2
PF-05180999	phosphodiesterase inhibitor				BRD-K00003097-001-01-9	Phase 1
PF-05190457	growth hormone secretagogue receptor inverse agonist	GHSR			BRD-K02554563-001-01-6	Phase 2
PF-05212384	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			BRD-K07955840-001-04-9, BRD-K07955840-001-02-3, BRD-K07955840-001-03-1	Phase 2
PF-06260414	androgen receptor modulator				BRD-K00004644-001-01-9	Phase 1
PF-06273340	tyrosine kinase receptor inhibitor				BRD-K00004638-001-01-9	Phase 1
PF-06282999	myeloperoxidase inhibitor				BRD-K00003279-001-01-9	Phase 1
PF-06305591	sodium channel blocker				BRD-K00004712-001-01-9	Phase 1
PF-06409577	protein kinase activator				BRD-K00003731-001-01-9	Phase 1
PF-06412562	dopamine receptor partial agonist				BRD-K00004652-001-01-9	Phase 1
PF-06447475	serine/threonine kinase inhibitor	LRRK2			BRD-K83114366-001-02-8, BRD-K83114366-001-01-0	Preclinical
PF-06459988	receptor tyrosine protein kinase inhibitor				BRD-K00003311-001-01-9	Phase 2
PF-06463922	ALK tyrosine kinase receptor inhibitor	ALK, FES, ROS1	oncology	non-small cell lung cancer (NSCLC)	BRD-A23124853-001-01-4	Launched
PF-06650833	kinase inhibitor				BRD-K00003296-001-01-9	Phase 1
PF-06651600	JAK inhibitor				BRD-K47084954-001-02-9	Phase 2/Phase 3
PF-06747775	EGFR inhibitor				BRD-K00004648-001-01-9	Phase 2
PF-06751979	beta secretase inhibitor				BRD-K00004598-001-01-9	Phase 1
PF-06840003	indoleamine 2,3-dioxygenase inhibitor				BRD-K00003400-001-01-9	Phase 1
PF-06873600	CDK inhibitor				BRD-K00004750-001-01-9	Phase 2
PF-06928215	cyclic GMP-AMP synthase inhibitor				BRD-K00005326-001-01-9	Preclinical
PF-3274167	oxytocin receptor antagonist	AVPR1A, OXTR			BRD-K31417912-001-01-9	Phase 2
PF-3845	FAAH inhibitor	FAAH			BRD-K68997413-001-06-9, BRD-K68997413-001-05-1, BRD-K68997413-001-05-1	Preclinical
PF-4191834	lipoxygenase inhibitor				BRD-K00004633-001-01-9	Preclinical
PF-429242	SREBP inhibitor	MBTPS1			BRD-K11821338-300-01-8, BRD-K11821338-300-02-9	Preclinical
PF-431396	focal adhesion kinase inhibitor	PTK2, PTK2B			BRD-K93788137-001-04-1, BRD-K93788137-001-04-1, BRD-K93788137-001-04-1, BRD-K93788137-001-05-9	Preclinical
PF-4708671	ribosomal protein inhibitor	RPS6KB1			BRD-K14711741-001-02-1, BRD-K14711741-001-02-1, BRD-K14711741-001-05-4	Preclinical
PF-477736	CHK inhibitor	CHEK1, CHEK2			BRD-K03063480-001-06-6, BRD-K03063480-001-06-6, BRD-K03063480-001-06-6, BRD-K03063480-001-06-6, BRD-K03063480-001-07-4, BRD-K03063480-001-08-9, BRD-K03063480-001-05-8, BRD-K03063480-001-05-8	Phase 1
PF-4800567	casein kinase inhibitor	CSNK1D, CSNK1E			BRD-K43428468-003-04-0, BRD-K43428468-003-01-6, BRD-K43428468-003-01-6, BRD-K43428468-003-01-6, BRD-K43428468-003-01-6, BRD-K43428468-003-01-6, BRD-K43428468-003-01-6, BRD-K43428468-003-01-6, BRD-K43428468-003-01-6	Preclinical
PF-4981517	cytochrome P450 inhibitor	CYP3A4			BRD-K78318619-001-03-9, BRD-K78318619-001-02-7	Preclinical
PF-514273	cannabinoid receptor antagonist				BRD-K00004642-001-01-9	Preclinical
PF-5274857	smoothened receptor antagonist	SMO			BRD-K40302533-003-03-9, BRD-K40302533-003-03-9, BRD-K40302533-003-01-7, BRD-K40302533-001-02-9, BRD-K40302533-001-02-9, BRD-K40302533-001-02-9	Preclinical
PF-562271	focal adhesion kinase inhibitor	PTK2, PTK2B			BRD-K99545815-001-07-9, BRD-K99545815-074-02-9, BRD-K99545815-074-02-9, BRD-K99545815-074-02-9, BRD-K99545815-003-01-0, BRD-K99545815-074-03-7, BRD-K99545815-001-06-3, BRD-K99545815-001-06-3, BRD-K99545815-001-06-3, BRD-K99545815-001-06-3	Phase 1
PF-573228	focal adhesion kinase inhibitor	CDK1, CDK2, CDK7, GSK3B, IKBKB			BRD-K79239947-001-06-8, BRD-K79239947-001-06-8, BRD-K79239947-001-06-8, BRD-K79239947-001-08-9, BRD-K79239947-001-07-6, BRD-K79239947-001-07-6	Preclinical
PF-670462	casein kinase inhibitor	CSNK1D, CSNK1E			BRD-K96295391-300-01-7, BRD-K96295391-300-01-7, BRD-K96295391-300-02-5, BRD-K96295391-300-02-5, BRD-K96295391-300-02-5	Preclinical
PF-750	FAAH inhibitor	FAAH			BRD-K83213911-001-07-7, BRD-K83213911-001-08-9	Preclinical
PF-8380	autotaxin inhibitor	ENPP2			BRD-K50865540-001-02-3, BRD-K50865540-001-01-5	Preclinical
PF-915275	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1			BRD-K18289362-001-02-2, BRD-K18289362-001-02-2, BRD-K18289362-001-01-4, BRD-K18289362-001-03-9	Phase 1
PFI-1	bromodomain inhibitor	BRD4			BRD-K13094524-001-04-2, BRD-K13094524-001-04-2, BRD-K13094524-001-09-1, BRD-K13094524-001-09-1, BRD-K13094524-001-07-5, BRD-K13094524-001-07-5, BRD-K13094524-001-07-5	Preclinical
PFI-3	bromodomain inhibitor	PBRM1, SMARCA4			BRD-K61524559-001-01-3, BRD-K61524559-001-01-3, BRD-K61524559-001-03-9	Preclinical
PFI-4	bromodomain inhibitor	BRPF1			BRD-K13106865-001-01-7, BRD-K13106865-001-01-7, BRD-K13106865-001-02-9	Preclinical
PFK-015	phosphofructokinase inhibitor	PFKFB3			BRD-K95573441-001-02-0, BRD-K95573441-001-01-2, BRD-K95573441-001-01-2, BRD-K95573441-001-01-2, BRD-K95573441-001-01-2	Phase 1
PFK-158	phosphofructokinase inhibitor	PFKFB3			BRD-K28010364-001-01-0, BRD-K28010364-001-01-0, BRD-K28010364-001-02-9	Phase 1
PG-9	acetylcholine receptor agonist				BRD-K00004212-001-01-9	Preclinical
PGL5001	JNK inhibitor	MAPK10, MAPK8, MAPK9			BRD-A53813595-001-03-4, BRD-A53813595-001-03-4, BRD-A53813595-001-01-8, BRD-A53813595-001-01-8, BRD-A53813595-001-01-8, BRD-A53813595-001-01-8, BRD-A53813595-001-02-6, BRD-A53813595-001-02-6, BRD-A53813595-001-02-6, BRD-A53813595-001-02-6	Phase 2
PH-797804	p38 MAPK inhibitor	MAPK11, MAPK14			BRD-K95880107-001-03-9, BRD-K95880107-001-02-4, BRD-K95880107-001-02-4	Phase 2
PHA-543613	nicotinic receptor agonist				BRD-K00004641-001-01-9	Preclinical
PHA-568487	nicotinic receptor agonist	CHRNA7			BRD-K48053228-051-01-7, BRD-K48053228-051-02-9	Preclinical
PHA-680632	Aurora kinase inhibitor	AURKA, AURKB, AURKC			BRD-K09443272-001-04-9, BRD-K09443272-001-04-9, BRD-K09443272-001-03-3, BRD-K09443272-001-03-3	Preclinical
PHA-767491	CDC inhibitor	CDK1, RPS6KB1			BRD-K50000283-001-04-4, BRD-K50000283-001-04-4, BRD-K50000283-003-02-4, BRD-K50000283-003-02-4, BRD-K50000283-003-02-4	Preclinical
PHA-793887	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CDK7, CDK9			BRD-K64800655-001-11-9, BRD-K64800655-001-09-0, BRD-K64800655-001-09-0, BRD-K64800655-001-09-0, BRD-K64800655-001-09-0, BRD-K64800655-001-09-0, BRD-K64800655-001-09-0, BRD-K64800655-001-09-0, BRD-K64800655-001-09-0, BRD-K64800655-001-09-0, BRD-K64800655-001-09-0, BRD-K64800655-001-07-4, BRD-K64800655-001-07-4	Phase 1
PHA-848125	CDK inhibitor, growth factor receptor inhibitor	CDK2, CDK4, CDK7, NTRK1			BRD-K60997853-001-03-9, BRD-K60997853-001-02-3, BRD-K60997853-001-02-3, BRD-K60997853-001-02-3, BRD-K60997853-001-02-3, BRD-K60997853-001-02-3, BRD-K60997853-001-02-3, BRD-K60997853-001-02-3, BRD-K60997853-001-02-3	Phase 2
PHCCC	glutamate receptor agonist	GRM1, GRM4			BRD-K00004222-001-01-9	Preclinical
phenacaine	local anesthetic		neurology/psychiatry	local anesthetic	BRD-K81092066-311-01-6, BRD-K81092066-311-01-6	Launched
phenacemide	sodium channel blocker	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, seizures	BRD-K40905133-001-05-9, BRD-K40905133-001-04-9	Launched
phenacetin	cyclooxygenase inhibitor	PTGS1			BRD-K38323065-001-22-9, BRD-K38323065-001-19-9, BRD-K38323065-001-18-1	Withdrawn
phenazone	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-K46937689-001-16-9, BRD-K46937689-001-15-0, BRD-K46937689-001-14-3	Launched
phenazopyridine	local anesthetic	SCN1A	infectious disease	urinary tract infections	BRD-K76304753-003-22-9, BRD-K76304753-003-19-5, BRD-K76304753-003-20-3, BRD-K76304753-003-21-1, BRD-K76304753-003-21-1	Launched
phenelzine	monoamine oxidase inhibitor	ABAT, AOC3, GAD2, GPT, GPT2, MAOA, MAOB, SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	BRD-K87024524-001-04-0, BRD-K87024524-001-04-0, BRD-K87024524-065-17-7, BRD-K87024524-065-18-5, BRD-K87024524-065-18-5	Launched
phenethicillin	bacterial cell wall synthesis inhibitor				BRD-A66025870-237-06-9	Launched
phenethyl-isothiocyanate	anticancer agent	CYP2E1			BRD-K56700933-001-03-9	Phase 2
phenformin	AMPK activator	KCNJ8, PRKAA1			BRD-K11399644-003-10-5, BRD-K11399644-003-11-3, BRD-K11399644-003-19-9, BRD-K11399644-003-19-9, BRD-K11399644-003-09-7	Withdrawn
phenindamine	histamine receptor antagonist	HRH1	allergy, otolaryngology	allergic rhinitis, common cold	BRD-A33178345-001-01-4, BRD-A33178345-001-02-2	Launched
phenindione	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	BRD-K70592963-001-33-2, BRD-K70592963-001-33-2, BRD-K70592963-001-33-2, BRD-K70592963-001-31-6, BRD-K70592963-001-29-0, BRD-K70592963-001-27-4, BRD-K70592963-001-32-4, BRD-K70592963-001-28-2	Launched
pheniramine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	BRD-A23072235-050-17-7, BRD-A23072235-050-17-7, BRD-A23072235-050-18-5, BRD-A23072235-050-19-9	Launched
phenol		CA1, CA12, CA14, CA2, CA4, CA9	otolaryngology	pharyngitis	BRD-K76549667-001-04-6	Preclinical
phenolphthalein	indicator dye	UGT1A9			BRD-K19227686-001-19-9, BRD-K19227686-001-18-6	Withdrawn
phenolsulfonphthalein					BRD-K79892937-236-04-9, BRD-K79892937-001-02-5	Launched
phenothiazine	dopamine receptor antagonist				BRD-K59597909-001-19-2, BRD-K59597909-001-17-6, BRD-K59597909-001-20-0, BRD-K59597909-001-20-0	Preclinical
phenothrin			infectious disease	lice	BRD-A22106989-001-06-8, BRD-A22106989-001-05-0, BRD-A22106989-001-08-9	Launched
phenoxybenzamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	cardiology, endocrinology	hypertension, pheochromocytoma	BRD-A67799922-003-28-6, BRD-A67799922-003-26-0, BRD-A67799922-003-29-4, BRD-A67799922-003-29-4, BRD-A67799922-003-27-8	Launched
phenprobamate	muscle relaxant		neurology/psychiatry	anxiety, muscle relaxant	BRD-K22009844-001-12-5	Launched
phenprocoumon	vitamin K antagonist	VKORC1	hematology	thrombosis, pulmonary embolism (PE)	BRD-A49838158-001-01-1	Launched
phenserine	acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor	ACHE, BCHE			BRD-K46580984-001-03-6, BRD-K46580984-001-03-6, BRD-K46580984-001-02-8	Phase 3
phensuximide	succinimide antiepileptic		neurology/psychiatry	seizures	BRD-A18043272-001-09-9, BRD-A18043272-001-10-7	Launched
phentolamine	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	endocrinology, cardiology	pheochromocytoma, hypertension	BRD-K90333595-066-24-9, BRD-K90333595-066-24-9, BRD-K90333595-003-22-2, BRD-K90333595-003-22-2, BRD-K90333595-066-17-9, BRD-K90333595-003-21-4, BRD-K90333595-066-16-1	Launched
phenyl-aminosalicylate			infectious disease	tuberculosis	BRD-K73157543-001-04-1, BRD-K73157543-001-05-9	Launched
phenyl-salicylate	antiseptic		urology	interstitial cystitis (IC)	BRD-K44091963-001-04-9, BRD-K44091963-001-01-5	Launched
phenylacetylglutamine	DNA methylase inhibitor, protein synthesis inhibitor				BRD-K70592483-001-01-0	Phase 2
phenylbenzimidazole-sulfonic-acid			dermatology	sunscreen lotion	BRD-K02729857-001-01-9, BRD-K02729857-001-01-9	Launched
phenylbutazone	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGIS, PTGS1, PTGS2			BRD-K10843433-001-26-9, BRD-K10843433-001-23-5, BRD-K10843433-001-21-9, BRD-K10843433-001-22-7	Withdrawn
phenylbutyrate	HDAC inhibitor	HDAC1	metabolism	urea cycle disorders	BRD-K67102207-236-08-5, BRD-K67102207-236-08-5, BRD-K67102207-236-10-1, BRD-K67102207-236-07-7, BRD-K67102207-236-07-7, BRD-K67102207-236-06-9	Launched
phenylephrine	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D	otolaryngology, gastroenterology, cardiology	nasal congestion, hemorrhoids, hypotension	BRD-K73381542-003-22-6, BRD-K73381542-003-24-2, BRD-K73381542-003-24-2, BRD-K73381542-003-24-2, BRD-K73381542-003-23-4	Launched
phenylethyl-alcohol					BRD-K42371134-001-06-6, BRD-K42371134-001-09-9	Preclinical
phenylmercuric-acetate	other antifungal				BRD-K74193284-001-05-9, BRD-K74193284-001-04-8, BRD-K74193284-001-04-8, BRD-K74193284-001-04-8	Preclinical
phenylmethylsulfonyl-fluoride	serine protease inhibitor				BRD-K33422401-001-06-4, BRD-K33422401-001-06-4, BRD-K33422401-001-06-4, BRD-K33422401-001-05-6	Preclinical
phenylpiracetam	noradrenaline uptake inhibitor		neurology/psychiatry	anxiety, fatigue, depression	BRD-A65683612-001-07-7	Launched
phenytoin	hydantoin antiepileptic	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	BRD-K55930204-236-23-5, BRD-K55930204-236-24-3, BRD-K55930204-001-20-9	Launched
PhiKan-083	p53 stabilizing agent	TP53			BRD-K44400149-003-01-1, BRD-K44400149-003-02-9	Preclinical
phloretin	sodium/glucose cotransporter inhibitor	AQP9, CLCN3, SLC23A1			BRD-K15563106-001-18-0, BRD-K15563106-001-18-0	Launched
phlorizin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A11, SLC5A2, SLC5A3			BRD-K73756878-001-07-9	Preclinical
phloroglucin			neurology/psychiatry	spasms	BRD-K00405906-001-03-9, BRD-K00405906-001-01-9	Launched
phortress	aryl hydrocarbon receptor ligand	AHR			BRD-K74558903-300-01-5, BRD-K74558903-300-01-5, BRD-K74558903-300-01-5	Phase 1
phosphatidylcholine			infectious disease, dermatology, gastroenterology, cardiology, obstetrics/gynecology	hepatitis B, hepatitis C, eczema, gallbladder disease, cholesterol, premenstrual syndrome	BRD-A10131665-001-02-0, BRD-A10131665-001-03-8, BRD-A10131665-001-03-8	Launched
PHP-501	GABA receptor antagonist	GABRA1, GABRB2, GABRG2			BRD-K07460388-019-02-9, BRD-K07460388-019-02-9, BRD-K07460388-019-01-6	Preclinical
PHT-427	AKT inhibitor, pyruvate dehydrogenase inhibitor	AKT2, PDPK1			BRD-K59745944-001-05-9, BRD-K59745944-001-04-6, BRD-K59745944-001-04-6, BRD-K59745944-001-03-8, BRD-K59745944-001-02-0	Preclinical
phthalylsulfacetamide					BRD-K77115421-001-02-6, BRD-K77115421-001-03-4, BRD-K77115421-001-05-9, BRD-K77115421-001-04-2	Preclinical
phthalylsulfathiazole	dihydropteroate synthetase inhibitor		infectious disease, gastroenterology	dysentry, colitis	BRD-K64659768-001-13-6, BRD-K64659768-001-12-8	Launched
PHTPP	estrogen receptor antagonist	ESR2			BRD-K76568384-001-03-0, BRD-K76568384-001-02-2, BRD-K76568384-001-04-9	Preclinical
phytonadione		BGLAP, GGCX	hematology	vitamin K deficiency, anticoagulation reversal	BRD-K76661572-001-07-6, BRD-K76661572-001-08-4	Launched
phytosphingosine					BRD-K05048137-001-03-9, BRD-K05048137-001-01-3, BRD-K05048137-001-01-3, BRD-K05048137-001-01-3, BRD-K05048137-001-01-3, BRD-K05048137-001-01-3	Phase 1
PI-103	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC			BRD-K67868012-003-02-3, BRD-K67868012-003-02-3, BRD-K67868012-001-07-6, BRD-K67868012-001-07-6, BRD-K67868012-001-07-6, BRD-K67868012-001-07-6, BRD-K67868012-001-07-6, BRD-K67868012-001-14-2, BRD-K67868012-001-14-2	Preclinical
PI-828	PI3K inhibitor				BRD-K97365803-001-04-7, BRD-K97365803-001-04-7, BRD-K97365803-001-04-7, BRD-K97365803-001-04-7, BRD-K97365803-001-04-7, BRD-K97365803-001-04-7, BRD-K97365803-001-04-7, BRD-K97365803-001-04-7, BRD-K97365803-001-02-1, BRD-K97365803-001-03-9, BRD-K97365803-001-03-9	Preclinical
pibenzimol	DNA inhibitor				BRD-K17026858-305-02-9, BRD-K17026858-001-01-2	Phase 2
piboserod	serotonin receptor antagonist	HTR2B, HTR4			BRD-K02750403-001-02-2, BRD-K02750403-001-01-4	Phase 2
picartamide	H+/K+-ATPase inhibitor	ATP4A			BRD-A71765060-001-01-4	Phase 2
piceatannol	SYK inhibitor	ATP5A1, ATP5B, ATP5C1, IRF3			BRD-K91509126-001-26-9, BRD-K91509126-001-25-1, BRD-K91509126-001-25-1, BRD-K91509126-001-25-1, BRD-K91509126-001-25-1, BRD-K91509126-001-23-6, BRD-K91509126-001-23-6, BRD-K91509126-001-24-4	Preclinical
piclamilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D			BRD-K47642186-001-04-9, BRD-K47642186-001-02-1, BRD-K47642186-001-01-3, BRD-K47642186-001-01-3	Phase 2
picolamine					BRD-K68653965-001-02-9, BRD-K68653965-001-01-1	Preclinical
picolinic-acid	chelating agent				BRD-K60612034-001-08-7, BRD-K60612034-001-07-9	Phase 2
piconol					BRD-K28492574-001-02-9, BRD-K28492574-001-01-6	Preclinical
picotamide	thromboxane receptor antagonist, thromboxane synthase inhibitor	TBXA2R	hematology	thrombosis	BRD-K67277431-001-11-9, BRD-K67277431-002-10-5, BRD-K67277431-002-10-5, BRD-K67277431-002-10-5, BRD-K67277431-002-10-5, BRD-K67277431-002-10-5	Launched
picrotin	GABA receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB			BRD-A91822151-001-05-0, BRD-A91822151-001-05-0, BRD-A91822151-001-05-0, BRD-A91822151-001-05-0	Phase 2
picrotoxinin	GABA receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B			BRD-K36461289-001-05-8, BRD-K36461289-001-06-6	Preclinical
pidolic-acid		ADAM28, AMY1A, AMY2A, AMY2B, ANG, CCL8, HCRT, IGLC1, KRTAP5-2, TFF2, VEGFA	dermatology	xerosis cutis	BRD-K57313110-001-06-8	Launched
pidotimod	interferon receptor agonist, interleukin receptor agonist		infectious disease	immune adjuvant	BRD-K44442813-001-13-9, BRD-K44442813-001-12-9, BRD-K44442813-001-11-1, BRD-K44442813-001-11-1	Launched
pifithrin-alpha	TP53 inhibitor	TP53			BRD-K66874953-004-07-0, BRD-K66874953-004-09-6, BRD-K66874953-004-08-8	Preclinical
pifithrin-cyclic	TP53 inhibitor	TP53			BRD-K31792052-004-02-7, BRD-K31792052-004-02-7, BRD-K31792052-004-03-9, BRD-K31792052-004-03-9	Preclinical
pifithrin-mu	HSP inhibitor	HSPA1A, TP53			BRD-K96799727-001-06-6, BRD-K96799727-001-05-8, BRD-K96799727-001-07-4, BRD-K96799727-001-07-4, BRD-K96799727-001-07-4, BRD-K96799727-001-07-4, BRD-K96799727-001-07-4, BRD-K96799727-001-07-4, BRD-K96799727-001-07-4	Preclinical
PIK-293	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			BRD-K30977212-001-02-8, BRD-K30977212-001-03-6	Preclinical
PIK-294	PI3K inhibitor	PIK3CB, PIK3CD, PIK3CG			BRD-K50631926-001-03-9, BRD-K50631926-001-02-3	Preclinical
PIK-75	DNA protein kinase inhibitor, PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC			BRD-K49371609-003-03-8, BRD-K49371609-003-03-8, BRD-K49371609-003-03-8	Preclinical
PIK-93	PI3K inhibitor	PI4KB, PIK3C3, PIK3CG			BRD-K29395450-001-06-8, BRD-K29395450-001-06-8, BRD-K29395450-001-06-8, BRD-K29395450-001-06-8	Preclinical
pikamilone					BRD-K56691760-001-01-2	Phase 1
piketoprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	BRD-A85548292-001-01-8, BRD-A85548292-001-01-8, BRD-A85548292-001-01-8, BRD-A85548292-001-01-8	Launched
pilaralisib	PI3K inhibitor				BRD-K49456274-001-01-9, BRD-K49456274-001-01-9, BRD-K49456274-001-01-9, BRD-K49456274-001-01-9, BRD-K49456274-001-03-9, BRD-K49456274-001-03-9	Phase 2
pilocarpine	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	ophthalmology, cardiology	glaucoma, hypertension	BRD-K85090592-003-20-2, BRD-K85090592-003-20-2, BRD-K85090592-003-23-9, BRD-K85090592-003-23-9, BRD-K85090592-003-23-9, BRD-K85090592-003-23-9, BRD-K85090592-008-22-7, BRD-K85090592-003-19-4, BRD-K85090592-003-18-6	Launched
pilsicainide	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	BRD-K83245588-001-01-4, BRD-K83245588-001-01-4	Launched
PIM-1-Inhibitor-2	Pim kinase inhibitor	PIM1			BRD-K48832421-001-02-2, BRD-K48832421-001-01-4, BRD-K48832421-001-03-9	Preclinical
PIM-447	Pim kinase inhibitor				BRD-K00003280-300-01-9	Phase 1
pimavanserin	serotonin receptor inverse agonist	DRD2, HTR2A	neurology/psychiatry	Parkinson's Disease	BRD-K83405785-001-01-5, BRD-K83405785-001-03-9	Launched
pimethixene	antihistamine		neurology/psychiatry, allergy	attention-deficit/hyperactivity disorder (ADHD), anxiety, sleep cycle support, allergic rhinitis	BRD-K88090157-050-10-8, BRD-K88090157-050-11-9	Launched
pimobendan	calcium sensitizer, phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	BRD-K01826269-001-04-9, BRD-K01826269-001-04-9	Launched
pimodivir	antiviral				BRD-K00003127-001-01-9	Phase 3
pimonidazole					BRD-A67521319-001-01-6, BRD-A67521319-001-01-6	Phase 3
pimozide	dopamine receptor antagonist	CACNA1I, CALM1, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, KCNA10, KCNH2	neurology/psychiatry	Tourette's disorder	BRD-K01292756-001-27-6, BRD-K01292756-001-23-5, BRD-K01292756-001-25-0, BRD-K01292756-001-24-3	Launched
pinacidil	ATP channel activator, potassium channel activator	ABCC8, ABCC9	cardiology	hypertension	BRD-A43882281-001-14-8, BRD-A43882281-001-15-5, BRD-A43882281-002-18-9, BRD-A43882281-002-18-9, BRD-A43882281-002-18-9	Launched
pinanediol					BRD-K32485706-001-01-5	Preclinical
pinaverium	T-type calcium channel blocker	CACNA1C	gastroenterology	irritable bowel syndrome	BRD-A13175897-004-01-0	Launched
pincainide	antiarrhythmic				BRD-K90727284-001-05-0	Phase 1
pindolol	adrenergic receptor antagonist	ADRB1, ADRB2, HTR1A, HTR2A, HTR2B	cardiology	hypertension	BRD-A97701745-001-14-5, BRD-A97701745-001-18-9, BRD-A97701745-001-18-9, BRD-A97701745-001-15-2, BRD-A97701745-001-16-0	Launched
pindolol-(-)	adrenergic receptor antagonist, serotonin receptor antagonist	HTR1A			BRD-K95598440-001-10-9, BRD-K95598440-001-09-3	Phase 2
pinitol	gamma secretase inhibitor					Phase 2
pinocembrin	cytochrome P450 inhibitor	CYP1B1			BRD-K94689771-001-09-0, BRD-K94689771-001-10-9	Phase 2
pioglitazone	insulin sensitizer, PPAR receptor agonist	PPARG, TRPM3	endocrinology	diabetes mellitus	BRD-K01826904-001-08-9	Launched
pipamperone	dopamine receptor antagonist	DRD2, HRH1, HTR1A, HTR1B, HTR1D, HTR2A	neurology/psychiatry	schizophrenia	BRD-K26801045-001-02-9, BRD-K26801045-001-02-9, BRD-K26801045-300-01-7	Launched
pipecuronium	neuromuscular blocker	CHRM2, CHRM3, CHRNA2	neurology/psychiatry	anesthetic		Launched
pipemidic-acid	topoisomerase inhibitor		infectious disease	gram-negative bacterial infections	BRD-K08999871-001-16-9, BRD-K08999871-213-01-5	Launched
pipenzolate	cholinergic receptor antagonist	CHRM1	neurology/psychiatry	spasms	BRD-A53561827-004-22-3, BRD-A53561827-004-23-1, BRD-A53561827-004-24-9	Launched
piperacetazine	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	BRD-K16277217-001-10-9, BRD-K16277217-001-11-9	Launched
piperaquine-phosphate	antimalarial agent		infectious disease	malaria	BRD-K27382019-418-01-9, BRD-K27382019-418-01-9	Launched
piperazine	benzodiazepine receptor agonist	GABRB3	infectious disease	gastrointestinal roundworms	BRD-K13249881-001-05-9, BRD-K13249881-001-02-3, BRD-K13249881-001-02-3	Launched
piperazinedione	DNA synthesis inhibitor				BRD-K95941975-001-01-5	Phase 2
piperidolate	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	spasms	BRD-A97479839-003-13-3, BRD-A97479839-001-14-9	Launched
piperine	monoamine oxidase inhibitor	MAOA, MAOB, TRPV1			BRD-K59522102-001-13-8, BRD-K59522102-001-18-9, BRD-K59522102-001-18-9, BRD-K59522102-001-14-6, BRD-K59522102-001-14-6, BRD-K59522102-001-15-3	Phase 1
piperonyl-butoxide	cytochrome P450 inhibitor		infectious disease	lice	BRD-K76452401-001-05-9, BRD-K76452401-001-03-6, BRD-K76452401-001-03-6	Launched
pipobroman	DNA alkylating agent		hematology	polycythemia vera, thrombocythemia	BRD-K15656090-001-04-0, BRD-K15656090-001-06-5, BRD-K15656090-001-07-3	Launched
pipofezine	selective serotonin reuptake inhibitor (SSRI)				BRD-K00003317-312-01-9	Preclinical
pipotiazine	dopamine receptor antagonist	DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	BRD-K00004560-001-01-9	Launched
pipotiazine-palmitate	dopamine receptor antagonist, serotonin receptor antagonist	DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	BRD-K48429278-001-01-3	Launched
piracetam	acetylcholine receptor agonist	GRIA1, GRIA2, GRIA3, GRIA4	neurology/psychiatry	senile dementia	BRD-K19456237-001-27-6, BRD-K19456237-001-27-6, BRD-K19456237-001-26-8	Launched
pirarubicin	topoisomerase inhibitor	TOP2A	oncology	breast cancer	BRD-K83794624-003-02-1, BRD-K83794624-003-01-3, BRD-K83794624-001-02-5, BRD-K83794624-001-03-3	Launched
pirenoxine	AGE inhibitor		ophthalmology	cataracts	BRD-K65992024-001-01-5	Launched
pirenperone	serotonin receptor antagonist	HTR2A, HTR7			BRD-K25224017-001-26-9, BRD-K25224017-001-25-0, BRD-K25224017-001-25-0	Preclinical
pirenzepine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	gastroenterology	peptic ulcer disease (PUD)	BRD-K89375097-300-08-8, BRD-K89375097-300-09-9, BRD-K89375097-300-09-9	Launched
piretanide	glucocorticoid receptor agonist	SLC12A1, SLC12A2	cardiology	hypertension, edema	BRD-K87990216-001-10-2, BRD-K87990216-001-10-2	Launched
pirfenidone	TGF beta receptor inhibitor	FURIN, TNF	pulmonary	idiopathic pulmonary fibrosis (IPF)	BRD-K96862998-001-17-9, BRD-K96862998-001-14-8, BRD-K96862998-001-14-8, BRD-K96862998-001-15-5	Launched
piribedil	dopamine receptor agonist	ADRA1A, ADRA2A, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR2B	neurology/psychiatry	Parkinson's Disease, dizziness	BRD-K47936004-003-11-4	Launched
piricapiron	dopamine receptor antagonist, serotonin receptor antagonist	HTR2A			BRD-K00004544-001-01-9	Phase 2
pirinixic-acid	PPAR receptor agonist	PPARA			BRD-K01902415-001-13-3, BRD-K01902415-001-13-3, BRD-K01902415-001-14-9, BRD-K01902415-001-10-9, BRD-K01902415-001-11-7	Preclinical
pirlindole	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	BRD-K01826702-066-07-9	Launched
pirmenol	acetylcholine receptor inhibitor				BRD-K00003530-003-01-9	Preclinical
pirodavir					BRD-K22261391-001-01-2, BRD-K22261391-001-01-2, BRD-K22261391-001-02-9	Phase 2
piromidic-acid	bacterial DNA gyrase inhibitor				BRD-K37682401-001-10-9, BRD-K37682401-213-01-1, BRD-K37682401-001-08-5, BRD-K37682401-001-09-3	Phase 2
piroxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	BRD-K01826746-001-05-9	Launched
piroximone	phosphodiesterase inhibitor	PDE3A			BRD-K71977764-001-01-2, BRD-K71977764-001-01-2	Phase 2
pirozadil	hypolipidemic				BRD-K00004581-001-01-9	Preclinical
pirquinozol	histamine release inhibitor				BRD-K63651590-001-01-3	Phase 1
PIT	purinergic receptor antagonist	P2RY1			BRD-K43978949-075-03-9, BRD-K43978949-075-02-5	Preclinical
pitolisant	histamine receptor antagonist	HRH3			BRD-K21673112-003-02-1, BRD-K21673112-003-01-3, BRD-K21673112-003-03-9, BRD-K21673112-003-03-9, BRD-K21673112-003-03-9	Launched
pivagabine	corticotropin releasing factor receptor antagonist	CRHR1, CRHR2	neurology/psychiatry	depression	BRD-K62264492-001-02-3, BRD-K62264492-001-01-5	Launched
pivampicillin	bacterial cell wall synthesis inhibitor		pulmonary, infectious disease	bronchitis, pneumonia, gynecologic infections	BRD-K32791151-001-04-0	Launched
pivanex	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			BRD-K20504455-001-01-0, BRD-K20504455-001-01-0	Phase 2
pivmecillinam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, gram-negative bacterial infections	BRD-K67100011-001-01-8, BRD-K67100011-003-07-1, BRD-K67100011-003-06-3	Launched
pixantrone	topoisomerase inhibitor	TOP2A	hematologic malignancy	non-Hodgkin lymphoma (NHL)	BRD-K48304345-332-02-4, BRD-K48304345-332-01-6	Launched
pizotifen	serotonin receptor antagonist	HTR1A, HTR2A, HTR2C	neurology/psychiatry	migraine headache	BRD-K75958195-001-10-9, BRD-K75958195-037-09-4, BRD-K75958195-037-08-6, BRD-K75958195-037-08-6	Launched
PI3K-IN-2	PI3K inhibitor				BRD-K62374002-001-01-5, BRD-K62374002-001-01-5, BRD-K62374002-001-01-5	Phase 2
PI3Kd-IN-2	PI3K inhibitor				BRD-K00004592-001-01-9	Preclinical
PI4KIII-beta-inhibitor-1	PI4K inhibitor	PI4K2B			BRD-K75528696-001-01-2, BRD-K75528696-001-01-2	Preclinical
PJ-34	PARP inhibitor	EEF2, PARP1, PARP15, PARP3			BRD-K11853856-003-02-1, BRD-K11853856-001-01-7, BRD-K11853856-001-01-7, BRD-K11853856-001-01-7, BRD-K11853856-001-02-5, BRD-K11853856-001-02-5, BRD-K11853856-001-02-5, BRD-K11853856-001-02-5	Preclinical
PK-THPP	potassium channel blocker	KCNK9			BRD-K44043890-001-01-4, BRD-K44043890-001-02-9, BRD-K44043890-001-02-9	Preclinical
PK-11195	benzodiazepine receptor antagonist	TSPO			BRD-A41451487-001-12-0, BRD-A41451487-001-11-2	Phase 1
PK-44	dipeptidyl peptidase inhibitor	DPP4			BRD-K04035716-011-01-9, BRD-K04035716-011-02-9	Preclinical
PKI-166	EGFR inhibitor	EGFR			BRD-K10115470-001-01-8, BRD-K10115470-001-01-8	Phase 1
PKI-179	mTOR inhibitor, PI3K inhibitor	MTOR			BRD-A28467416-002-01-0, BRD-A28467416-002-01-0, BRD-A28467416-002-01-0, BRD-A28467416-002-01-0, BRD-A28467416-002-01-0	Phase 1
pleconaril					BRD-K27625831-001-02-9, BRD-K27625831-001-01-1	Phase 3
plerixafor	CC chemokine receptor antagonist	ACKR3, CCR4, CXCR4	hematologic malignancy	non-Hodgkin lymphoma (NHL), multiple myeloma	BRD-K33240821-001-06-2, BRD-K33240821-001-06-2, BRD-K33240821-001-03-9, BRD-K33240821-400-02-5, BRD-K33240821-400-02-5, BRD-K33240821-001-05-4	Launched
plicamycin	alcohol dehydrogenase inhibitor		oncology, endocrinology	testicular carcinoma, Paget's disease, hypercalcemia	BRD-K36368047-001-01-7, BRD-K36368047-001-02-9	Launched
plinabulin	tubulin polymerization inhibitor				BRD-K99498722-001-04-2, BRD-K99498722-001-02-6, BRD-K99498722-001-03-4	Phase 3
plovamer-acetate		TAT, TH, YARS, YARS2			BRD-A20781140-001-02-5, BRD-A20781140-001-01-7	Phase 2
plumbagin	anticancer agent				BRD-K36137799-001-06-9	Preclinical
plurisin-1	stearoyl-CoA desaturase inhibitor	SCD			BRD-K99149715-001-04-9, BRD-K99149715-001-03-2, BRD-K99149715-001-01-6, BRD-K99149715-001-02-4, BRD-K99149715-001-02-4, BRD-K99149715-001-02-4, BRD-K99149715-001-02-4	Preclinical
PLX4720	RAF inhibitor	BRAF, KDR			BRD-K16478699-001-09-2, BRD-K16478699-001-09-2	Preclinical
PLX51107	bromodomain inhibitor				BRD-K00003099-001-01-9	Phase 1
PLX647	receptor tyrosine protein kinase inhibitor	CSF1R, KIT			BRD-K79294107-300-02-9, BRD-K79294107-300-01-6	Preclinical
PLX8394	serine/threonine kinase inhibitor	BRAF			BRD-K53723268-001-01-3, BRD-K53723268-001-01-3	Phase 1/Phase 2
PMPA	glutamate receptor antagonist	FOLH1			BRD-A74387232-001-03-9, BRD-A74387232-001-03-9, BRD-A74387232-001-02-5	Preclinical
PNU-120596	acetylcholine receptor agonist	CHRNA7			BRD-K71731651-001-05-0, BRD-K71731651-001-04-3, BRD-K71731651-001-04-3, BRD-K71731651-001-04-3, BRD-K71731651-001-06-9, BRD-K71731651-001-06-9, BRD-K71731651-001-03-5	Preclinical
PNU-142633	serotonin receptor agonist	HTR1D			BRD-K81616657-001-01-4	Phase 2
PNU-177864	dopamine receptor antagonist	DRD3			BRD-K04635846-003-01-6, BRD-K04635846-003-02-9	Preclinical
PNU-22394	serotonin receptor agonist	HTR2A, HTR2B, HTR2C, MAOA, MAOB			BRD-K16551401-003-03-4, BRD-K16551401-003-04-9	Phase 2
PNU-282987	cholinergic receptor agonist	CHRNA7			BRD-K28863208-001-03-8, BRD-K28863208-001-02-0, BRD-K28863208-001-04-9, BRD-K28863208-001-04-9	Preclinical
PNU-37883	ATP-sensitive potassium channel antagonist				BRD-K06341478-003-02-9	Preclinical
PNU-74654	beta-catenin inhibitor	CTNNB1, TCF4			BRD-K30707190-001-05-8, BRD-K30707190-001-04-1, BRD-K30707190-001-04-1, BRD-K30707190-001-04-1, BRD-K30707190-001-01-7	Preclinical
PNU-89843	benzodiazepine receptor agonist	GABBR1			BRD-K84507776-003-01-4	Preclinical
pocapavir	Enterovirus capsid inhibitor				BRD-K00003464-001-01-9	Preclinical
podophyllotoxin	microtubule inhibitor, tubulin polymerization inhibitor	IGF1R, TOP2A, TUBA4A, TUBB	infectious disease	genital warts	BRD-K47869605-001-32-0, BRD-K47869605-001-32-0, BRD-K47869605-001-32-0, BRD-K47869605-001-32-0, BRD-K47869605-001-34-9	Launched
polaprezinc	chelating agent				BRD-K00003535-001-01-9	Preclinical
polidocanol	local anesthetic		dermatology	varicose veins	BRD-K35798650-001-01-4	Launched
polyinosine	immunostimulant	HPRT1, IMPDH2, PYGM			BRD-A67531813-001-01-6	Preclinical
polymyxin-B-sulfate	bacterial permeability inducer		ophthalmology	eye infection	BRD-A08641215-065-05-5, BRD-A08641215-065-04-8	Launched
polythiazide	sodium/chloride cotransporter inhibitor	SLC12A3	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure, hypertension	BRD-A15739803-001-01-0, BRD-A15739803-001-01-0	Launched
pomalidomide	angiogenesis inhibitor, tumor necrosis factor production inhibitor		hematologic malignancy	multiple myeloma	BRD-A12994259-001-02-1, BRD-A12994259-001-02-1, BRD-A12994259-001-02-1, BRD-A12994259-001-04-7	Launched
ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)	BRD-K44227013-001-08-0, BRD-K44227013-001-08-0, BRD-K44227013-001-08-0, BRD-K44227013-001-08-0, BRD-K44227013-001-06-4, BRD-K44227013-001-06-4, BRD-K44227013-001-06-4, BRD-K44227013-001-06-4, BRD-K44227013-001-06-4	Launched
ponesimod	sphingosine 1-phosphate receptor agonist	S1PR1			BRD-K44030614-001-01-6, BRD-K44030614-001-01-6	Phase 3
posaconazole	sterol demethylase inhibitor	CYP3A4	infectious disease	oropharyngeal candidiasis	BRD-K06222852-001-05-7, BRD-K06222852-001-05-7, BRD-K06222852-001-05-7, BRD-K06222852-001-05-7, BRD-K06222852-001-05-7, BRD-K06222852-001-03-2	Launched
potassium-iodide			pulmonary	asthma, bronchitis, emphysema	BRD-M55321172-001-03-3, BRD-M55321172-001-02-5	Launched
potassium-p-aminobenzoate			rheumatology, urology	scleroderma, dermatomyositis, Peyronie's disease	BRD-K58497451-001-11-9, BRD-K58497451-237-10-7, BRD-K58497451-237-10-7, BRD-K58497451-237-10-7	Launched
pozanicline	acetylcholine receptor antagonist	CHRNA4, CHRNB2			BRD-K79803033-300-01-3	Phase 2
poziotinib	EGFR inhibitor	EGFR, ERBB2, ERBB4			BRD-K50010139-001-02-3, BRD-K50010139-001-02-3, BRD-K50010139-001-02-3, BRD-K50010139-001-01-5, BRD-K50010139-001-01-5	Phase 2
PP-1	SRC inhibitor	HCK, RET			BRD-K47598052-001-14-1, BRD-K47598052-001-17-9, BRD-K47598052-001-15-8, BRD-K47598052-001-15-8	Preclinical
PP-121	protein tyrosine kinase inhibitor	ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC			BRD-K81801188-001-02-8, BRD-K81801188-001-05-1, BRD-K81801188-001-05-1, BRD-K81801188-001-06-9	Preclinical
PP-2	SRC inhibitor	ABL1, LCK, RIPK2, SRC			BRD-K95785537-001-22-3, BRD-K95785537-001-26-9, BRD-K95785537-001-24-9, BRD-K95785537-001-23-1, BRD-K95785537-001-23-1	Preclinical
PPT	estrogen receptor agonist	ESR1			BRD-K00312224-001-10-3, BRD-K00312224-001-10-3, BRD-K00312224-001-11-9, BRD-K00312224-001-09-5	Preclinical
PPY-A	Abl kinase inhibitor	ABL1, BCR			BRD-K72514671-001-02-9, BRD-K72514671-001-02-9, BRD-K72514671-001-01-4, BRD-K72514671-001-01-4, BRD-K72514671-001-01-4	Preclinical
PP242	mTOR inhibitor	MTOR, PASK			BRD-K87112191-001-04-5, BRD-K87112191-001-06-0, BRD-K87112191-001-06-0, BRD-K87112191-001-05-2	Preclinical
PQ-401	IGF-1 inhibitor	IGF1R			BRD-K67537649-001-03-7, BRD-K67537649-001-04-5, BRD-K67537649-001-04-5, BRD-K67537649-001-04-5, BRD-K67537649-001-04-5, BRD-K67537649-001-04-5, BRD-K67537649-001-04-5, BRD-K67537649-001-04-5, BRD-K67537649-001-06-9, BRD-K67537649-001-05-2	Preclinical
PR-619	DUB inhibitor				BRD-K54395039-001-03-9, BRD-K54395039-001-01-7, BRD-K54395039-001-02-5, BRD-K54395039-001-02-5, BRD-K54395039-001-02-5, BRD-K54395039-001-02-5, BRD-K54395039-001-02-5	Preclinical
practolol	adrenergic receptor antagonist	ADRB1			BRD-A41304429-001-17-1, BRD-A41304429-001-14-8	Withdrawn
pradefovir	cytochrome P450 activator				BRD-K00003119-066-01-9	Phase 2
pralatrexate	dihydrofolate reductase inhibitor	DHFR	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	BRD-A74914197-001-02-9, BRD-A74914197-001-02-9, BRD-A74914197-001-02-9, BRD-A74914197-001-02-9, BRD-A74914197-001-02-9, BRD-A74914197-001-01-1, BRD-A74914197-001-01-1	Launched
pralidoxime-chloride	acetylcholinesterase inhibitor	ACHE, BCHE	pulmonary	respiratory depression	BRD-K24221957-003-01-6, BRD-K24221957-003-01-6	Launched
pralmorelin	growth hormone releasing peptide ligand agonist				BRD-K00004629-001-01-9	Launched
pramipexole	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease	BRD-K06388322-300-01-3, BRD-K06388322-300-10-9, BRD-K06388322-001-07-4, BRD-K06388322-312-02-6	Launched
pramiracetam	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	BRD-K21123171-001-02-9, BRD-K21123171-001-03-9	Launched
pramoxine	topical anesthetic		dermatology	corticosteroid-responsive dermatoses	BRD-K46523383-003-23-9, BRD-K46523383-003-21-1, BRD-K46523383-003-22-9	Launched
pranidipine	calcium channel blocker	CACNA1C			BRD-A68083442-001-01-6, BRD-A68083442-001-01-6, BRD-A68083442-001-01-6, BRD-A68083442-001-01-6, BRD-A68083442-001-01-6	Phase 2
pranoprofen	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	BRD-A64610707-001-04-4, BRD-A64610707-001-03-6, BRD-A64610707-001-07-9, BRD-A64610707-001-05-1	Launched
prasterone-acetate					BRD-K96527333-001-09-9	Preclinical
prasugrel	purinergic receptor antagonist	P2RY12	cardiology	myocardial infarction, acute coronary syndrome (ACS)	BRD-A83029242-001-08-7, BRD-A83029242-001-08-7, BRD-A83029242-001-08-7, BRD-A83029242-001-06-1, BRD-A83029242-001-05-3, BRD-A83029242-001-05-3, BRD-A83029242-001-07-9	Launched
pravadoline	cyclooxygenase inhibitor	CNR1, CNR2			BRD-K46209126-001-06-4	Preclinical
praziquantel	anthelmintic agent		infectious disease	gastrointestinal parasites, cystic hydatid disease, schistosomiasis	BRD-A21858158-001-22-7, BRD-A21858158-001-23-5	Launched
prazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7	cardiology	hypertension	BRD-K49111258-003-30-5, BRD-K49111258-003-30-5, BRD-K49111258-003-29-7, BRD-K49111258-003-27-1, BRD-K49111258-003-27-1, BRD-K49111258-003-28-9	Launched
PRE-084	sigma receptor agonist	SIGMAR1			BRD-K57304726-003-07-7, BRD-K57304726-003-07-7, BRD-K57304726-003-08-9, BRD-K57304726-003-06-9	Preclinical
preclamol	dopamine receptor agonist	DRD2			BRD-K02908048-003-06-4, BRD-K02908048-003-06-4	Phase 2
prednicarbate	phospholipase activator	PLA2G1B	dermatology, ophthalmology, neurology/psychiatry	eczema, contact dermatitis, itching	BRD-A93963402-001-01-6	Launched
prednisolone-hemisuccinate	glucocorticoid receptor agonist	NR3C1			BRD-A78391468-001-02-8	Preclinical
prednisolone-sodium-phosphate	glucocorticoid receptor agonist	NR3C1	allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology	allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, meningitis, psoriatic arthritis, rheumatoid arthritis	BRD-K00003654-304-01-9	Launched
prednisolone-tebutate	anti-inflammatory agent				BRD-A53151380-001-01-2	Launched
pregnenolone-succinate	GABA receptor negative allosteric modulator	CYP17A1			BRD-A35912562-001-02-8, BRD-A35912562-001-02-8	Preclinical
preladenant	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K46290096-001-02-9, BRD-K46290096-001-01-1, BRD-K46290096-001-01-1, BRD-K46290096-001-01-1, BRD-K46290096-001-01-1	Phase 3
prenylamine	calcium channel blocker				BRD-A10662413-043-11-2, BRD-A10662413-043-11-2, BRD-A10662413-043-11-2, BRD-A10662413-043-11-2	Withdrawn
presatovir	RSV fusion inhibitor				BRD-K45906612-001-01-8, BRD-K45906612-001-01-8	Phase 2
pretomanid	nitric oxide donor	FASN			BRD-K96671969-001-05-9, BRD-K96671969-001-03-1	Launched
pridinol	muscle relaxant		neurology/psychiatry	muscle relaxant	BRD-K17565903-066-22-3, BRD-K17565903-066-23-1, BRD-K17565903-066-24-9, BRD-K17565903-066-24-9	Launched
pridopidine	dopamine receptor antagonist				BRD-K00003473-001-01-9	Phase 2
prilocaine	local anesthetic	SCN5A	neurology/psychiatry	anesthetic	BRD-K01825595-001-03-9, BRD-K01825595-001-02-9	Launched
primaquine	antimalarial agent, DNA inhibitor		infectious disease	malaria	BRD-K00003556-316-01-9	Launched
PRIMA1	TP53 inhibitor	ACHE			BRD-K15318909-001-12-1, BRD-K15318909-001-12-1, BRD-K15318909-001-10-5	Preclinical
primidone	GABA receptor antagonist	CHRNA4, CHRNA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA2, GRIK2, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	BRD-K32247306-001-27-8, BRD-K32247306-001-27-8, BRD-K32247306-001-30-9, BRD-K32247306-001-30-9, BRD-K32247306-001-28-6, BRD-K32247306-001-29-4	Launched
prinaberel	estrogen receptor agonist	ESR2, NCOA1			BRD-K87316765-001-01-4	Phase 2
prinomastat	matrix metalloprotease inhibitor				BRD-K00003122-001-01-9	Phase 3
priralfinamide	sodium channel blocker	CACNA1B			BRD-K01662324-066-01-1, BRD-K01662324-001-01-8	Phase 3
prisotinol					BRD-K00004547-001-01-9	Phase 2
pritelivir	helicase primase inhibitor				BRD-K25204779-001-01-1, BRD-K25204779-001-02-9	Phase 2
PRLX-93936	voltage-dependent anion selective channel protein inhibitor				BRD-K00004604-001-01-9	Phase 1/Phase 2
PRN1008	Bruton's tyrosine kinase (BTK) inhibitor				BRD-K00004599-001-01-9	Preclinical
PRN1371	protein tyrosine kinase inhibitor				BRD-K00003430-001-01-9	Phase 1
proacipimox	cholesterol inhibitor				BRD-K53605365-001-01-4, BRD-K53605365-001-01-4	Phase 1
proadifen	nitric oxide synthase inhibitor	NOS1			BRD-K46317332-003-16-0, BRD-K46317332-003-17-8, BRD-K46317332-003-18-6	Preclinical
probenecid	uricosuric blocker	PANX1, SLC22A11, SLC22A6, SLC22A8, SLCO1C1	nephrology, rheumatology	hyperuricemia, gout	BRD-K95237249-001-27-3, BRD-K95237249-001-26-5, BRD-K95237249-001-28-9, BRD-K95237249-001-28-9, BRD-K95237249-001-25-7	Launched
probucol	atherogenesis inhibitor	ABCA1, ABCB11, CES1	cardiology	coronary artery disease (CAD)	BRD-K72029282-001-23-8, BRD-K72029282-001-25-9, BRD-K72029282-001-25-9, BRD-K72029282-001-22-0, BRD-K72029282-001-22-0	Launched
procainamide	sodium channel blocker	DNMT1, SCN5A	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)	BRD-K75089421-003-26-9, BRD-K75089421-003-26-9, BRD-K75089421-003-24-5, BRD-K75089421-003-24-5	Launched
procaine	HMGCR inhibitor	CHRNA2, GRIN3A, HTR3A, KCNMA1, KCNMB1, KCNMB2, KCNMB3, KCNMB4, KCNN1, KCNN2, KCNN3, KCNN4, MAOA, MAOB, RYR1, RYR2, SCN10A, SLC6A3	neurology/psychiatry	anesthetic	BRD-K24616672-003-20-1, BRD-K24616672-003-19-3	Launched
procarbazine	monoamine oxidase inhibitor		hematologic malignancy	Hodgkin's lymphoma	BRD-K13032584-001-01-5, BRD-K13032584-003-19-3, BRD-K13032584-003-18-5, BRD-K13032584-003-21-9	Launched
procaterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	BRD-K78666826-003-02-4, BRD-K78666826-003-03-9, BRD-K78666826-003-03-9, BRD-K78666826-003-01-6	Launched
prochlorperazine	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4	gastroenterology	nausea, vomiting	BRD-K19352500-332-09-4, BRD-K19352500-332-07-8, BRD-K19352500-332-07-8, BRD-K19352500-070-12-4, BRD-K19352500-070-12-4, BRD-K19352500-332-08-6	Launched
procodazole	immunostimulant				BRD-K54824716-001-04-0, BRD-K54824716-001-03-2	Preclinical
procyanidin-B-2					BRD-K72093555-001-03-9, BRD-K72093555-001-02-8, BRD-K72093555-001-01-0	Phase 2
procyclidine	acetylcholine receptor antagonist		neurology/psychiatry	parkinsonism, Parkinson's Disease, akathisia, dystonia	BRD-K01826750-003-15-9	Launched
procysteine	glutathione synthase stimulant				BRD-K92413528-001-06-9, BRD-K92413528-001-06-9	Phase 3
profenamine	butyrylcholinesterase inhibitor, cholinergic receptor antagonist	CHRM1	neurology/psychiatry	Parkinson's Disease	BRD-A16311756-003-08-5, BRD-A16311756-003-09-3	Launched
proflavine-hemisulfate	topical anesthetic	F2			BRD-K68408467-065-01-8, BRD-K68408467-065-01-8, BRD-K68408467-065-01-8, BRD-K68408467-065-02-9	Phase 2
proglumetacin	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-A19458515-001-01-2	Launched
proglumide	CCK receptor antagonist	CCKAR, CCKBR			BRD-K01826553-236-10-9	Withdrawn
proguanil	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	BRD-K28183345-003-11-4, BRD-K28183345-003-11-4	Launched
prolylleucylglycinamide	melanocyte-stimulating hormone release inhibitor				BRD-A09911125-001-01-4	Phase 2
promazine	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C	neurology/psychiatry	schizophrenia	BRD-K06980535-003-26-7, BRD-K06980535-003-25-9	Launched
promestriene	estrogen receptor agonist	ESR1	endocrinology	androgenetic alopecia	BRD-K75097983-001-01-0	Launched
promethazine	histamine receptor antagonist	HRH1	neurology/psychiatry, allergy	sedative, allergic rhinitis	BRD-A46335897-003-27-8, BRD-A46335897-003-27-8, BRD-A46335897-003-27-8, BRD-A46335897-003-26-0	Launched
pronethalol	adrenergic receptor antagonist				BRD-K01825804-003-02-9	Withdrawn
propacetamol	cyclooxygenase inhibitor	PTGS2	endocrinology, neurology/psychiatry	fever, pain relief	BRD-K54496168-003-01-2	Launched
propafenone	antiarrhythmic	ADRB1, ADRB2, KCNA5, KCNH2	cardiology	atrial fibrillation (AF), ventricular tachycardia (VT), ventricular arrhythmias	BRD-K01826541-003-08-9, BRD-K01826541-003-08-9, BRD-K01826541-001-06-9	Launched
propagermanium	CCR agonist, interferon receptor agonist	CCR2	infectious disease	hepatitis B	BRD-K53382462-001-02-0	Launched
propantheline	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology	peptic ulcer disease (PUD)	BRD-K90885812-004-25-9, BRD-K90885812-004-25-9, BRD-K90885812-004-24-2	Launched
propatylnitrate			cardiology	angina pectoris	BRD-K56276053-001-01-8, BRD-K56276053-001-01-8	Launched
propentofylline	adenosine reuptake inhibitor, phosphodiesterase inhibitor	PDE1A	neurology/psychiatry	stroke	BRD-K59273480-001-10-6, BRD-K59273480-001-11-9	Launched
propidium-iodide		ACHE			BRD-K14821965-302-06-9, BRD-K14821965-302-05-2	Preclinical
propiolactone			infectious disease	antiseptic	BRD-K76867903-001-03-8, BRD-K76867903-001-04-9	Launched
propiverine	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence	BRD-K91244729-003-01-3	Launched
propofol	benzodiazepine receptor agonist	FAAH, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, SCN2A, SCN4A	neurology/psychiatry	anesthetic	BRD-K82255054-001-15-9, BRD-K82255054-001-17-5	Launched
propoxur			infectious disease	flea control	BRD-K08231299-001-09-9, BRD-K08231299-001-08-1	Launched
propoxycaine	local anesthetic		neurology/psychiatry	anesthetic	BRD-K18250272-003-12-9, BRD-K18250272-003-11-0, BRD-K18250272-003-11-0, BRD-K18250272-003-11-0	Launched
propranolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology, neurology/psychiatry	hypertension, angina pectoris, migraine headache	BRD-A10070317-003-30-9, BRD-A10070317-003-30-9, BRD-A10070317-003-28-3, BRD-A10070317-003-29-1	Launched
propranolol-(R)	adrenergic receptor antagonist	ADRB2, ADRB3			BRD-K92830582-003-11-9, BRD-K92830582-003-10-5, BRD-K92830582-003-10-5	Preclinical
propranolol-(S)	adrenergic receptor antagonist	ADRB1, HTR1A, HTR5A, SLC10A1			BRD-K13994703-003-17-9, BRD-K13994703-003-15-8, BRD-K13994703-003-15-8, BRD-K13994703-003-16-6	Preclinical
propyl-benzoate					BRD-K15329706-001-01-6, BRD-K15329706-001-02-9	Launched
propylene-glycol					BRD-A19232309-001-08-6	Launched
propylhexedrine	adrenergic receptor agonist		otolaryngology, endocrinology, allergy	nasal congestion, fever, allergic rhinitis	BRD-K01825844-001-01-9	Launched
propylparaben					BRD-K60783397-001-12-9, BRD-K60783397-001-09-5	Launched
propylthiouracil	thyroid peroxidase inhibitor	DIO1, TPO	endocrinology	hyperthyroidism, Grave's disease, goiter	BRD-K48168960-001-19-2, BRD-K48168960-001-18-4	Launched
propyphenazone	anti-inflammatory agent				BRD-K06520168-001-03-9	Preclinical
proquazone	cyclooxygenase inhibitor	PTGS1, PTGS2	neurology/psychiatry	pain relief	BRD-K54339150-001-01-8, BRD-K54339150-001-01-8	Launched
proscillaridin-A			cardiology	congestive heart failure, cardiac arrythmia	BRD-K00005354-001-01-9, BRD-K00005354-001-01-9, BRD-K00005354-001-01-9	Launched
protionamide			infectious disease	tuberculosis	BRD-K97863768-001-06-9, BRD-K97863768-001-24-9, BRD-K97863768-001-07-9	Launched
protirelin	thyrotropin releasing hormone receptor agonist	TRHR	radiology	thyroid function diagnostic	BRD-K00003716-015-01-9	Launched
protoporphyrin-IX	heme oxygenase inhibitor	HMOX1			BRD-K26813314-001-12-9, BRD-K26813314-001-08-5	Preclinical
protriptyline	tricyclic antidepressant	SLC6A2, SLC6A4	neurology/psychiatry	depression	BRD-K42098891-003-21-9, BRD-K42098891-003-20-5, BRD-K42098891-003-20-5, BRD-K42098891-003-20-5	Launched
proxodolol	adrenergic receptor antagonist				BRD-A29944538-003-09-9, BRD-A29944538-003-08-3	Launched
proxyfan	histamine receptor modulator	HRH3			BRD-K77171813-034-02-6, BRD-K77171813-034-01-8, BRD-K77171813-034-03-9	Preclinical
proxymetacaine	sodium channel blocker	SCN10A, SCN5A	neurology/psychiatry	anesthetic	BRD-K79116891-003-15-1, BRD-K79116891-003-16-9, BRD-K79116891-003-14-4	Launched
Proxyphylline			pulmonary	asthma	BRD-A28887267-001-19-3, BRD-A28887267-001-20-9	Launched
PRT062070	JAK inhibitor, SYK inhibitor	SYK			BRD-K25835157-001-02-2, BRD-K25835157-001-02-2, BRD-K25835157-001-02-2, BRD-K25835157-001-04-8, BRD-K25835157-001-01-4, BRD-K25835157-001-01-4	Phase 2/Phase 3
PRT4165	polycomb repressive complex inhibitor	PRC1			BRD-K32456483-001-02-3, BRD-K32456483-001-04-9, BRD-K32456483-001-03-1	Preclinical
prucalopride	serotonin receptor agonist	HTR4	gastroenterology	constipation	BRD-K33681278-001-03-9, BRD-K33681278-001-03-9, BRD-K33681278-036-01-2, BRD-K33681278-001-02-4	Launched
pruvanserin	serotonin receptor antagonist	HTR2A, HTR2C			BRD-K43837174-003-02-1, BRD-K43837174-003-02-1, BRD-K43837174-003-01-3	Phase 2
PRX-07034	serotonin receptor antagonist				BRD-K00004616-001-01-9	Phase 1
PRX-08066	serotonin receptor antagonist	HTR2B			BRD-K16757695-050-02-5, BRD-K16757695-001-03-9, BRD-K16757695-001-03-9	Phase 2
PSB-06126	NTPDase inhibitor	ENTPD3			BRD-K71266197-236-02-7, BRD-K71266197-236-02-7, BRD-K71266197-236-02-7, BRD-K71266197-236-02-7, BRD-K71266197-236-02-7, BRD-K71266197-236-02-7, BRD-K71266197-236-03-9, BRD-K71266197-236-03-9	Preclinical
PSB-11	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA3			BRD-K10177585-003-03-2, BRD-K10177585-003-04-9, BRD-K10177585-003-02-4, BRD-K10177585-003-02-4, BRD-K10177585-003-02-4	Preclinical
PSB-1115	adenosine receptor antagonist	ADORA1, ADORA2B, ADORA3			BRD-K49027941-001-02-9, BRD-K49027941-001-03-9, BRD-K49027941-001-01-1, BRD-K49027941-001-01-1	Preclinical
PSB-36	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K00004243-001-01-9	Preclinical
PSB-603	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K05419687-001-01-0, BRD-K05419687-001-01-0, BRD-K05419687-001-01-0, BRD-K05419687-001-02-9	Preclinical
PSI-6130	RNA polymerase inhibitor				BRD-K07798980-001-02-9, BRD-K07798980-001-01-9	Phase 1
PSI-697	P selectin inhibitor				BRD-K00003192-001-01-9	Phase 1
PSI-7976	HCV inhibitor				BRD-K05674516-001-01-7, BRD-K05674516-001-01-7, BRD-K05674516-001-03-9	Preclinical
PSN-375963	glucose dependent insulinotropic receptor agonist	GPR119			BRD-K25524093-003-02-5, BRD-K25524093-003-01-7, BRD-K25524093-003-03-9	Preclinical
PSNCBAM-1	cannabinoid receptor modulator	CNR1			BRD-K33502629-001-01-0, BRD-K33502629-001-02-9	Preclinical
psoralen		MAOA, MAOB	dermatology	psoriasis, eczema, vitiligo	BRD-K47264279-001-08-9	Launched
PS178990	androgen receptor modulator	AR			BRD-K99092662-001-02-9, BRD-K99092662-001-01-1, BRD-K99092662-001-01-1, BRD-K99092662-001-01-1, BRD-K99092662-001-01-1	Phase 1
PT-2385	hypoxia inducible factor inhibitor	EPAS1			BRD-K20850787-001-01-6, BRD-K20850787-001-01-6, BRD-K20850787-001-01-6	Phase 1
PTC-028	BMI-1 inhibitor				BRD-K00010388-001-01-9	Preclinical
PTC-209	BMI-1 inhibitor				BRD-K83834509-001-01-1, BRD-K83834509-001-01-1, BRD-K83834509-001-04-9, BRD-K83834509-001-03-7, BRD-K83834509-001-03-7, BRD-K83834509-001-02-9	Preclinical
pterostilbene	cyclooxygenase inhibitor, PPAR receptor agonist	PTGS2			BRD-K92870997-001-16-9	Phase 2/Phase 3
PU-H71	HSP inhibitor	HSP90AA1			BRD-K36529613-001-02-6, BRD-K36529613-001-02-6, BRD-K36529613-001-02-6	Phase 1
pumosetrag	serotonin receptor agonist	HTR3A, HTR4			BRD-K44164034-003-01-1	Phase 2
purmorphamine	smoothened receptor agonist	SMO			BRD-K73397362-001-08-2, BRD-K73397362-001-06-6, BRD-K73397362-001-06-6, BRD-K73397362-001-06-6, BRD-K73397362-001-07-4, BRD-K73397362-001-07-4	Preclinical
puromycin	protein synthesis inhibitor	NHP2L1, RPL10L, RPL11, RPL13A, RPL15, RPL19, RPL23, RPL23A, RPL26L1, RPL3, RPL37, RPL8, RSL24D1			BRD-K36007650-300-09-9	Preclinical
purvalanol-A	CDK inhibitor	CDK1, CDK2, CDK4, CDK5, CSNK1G3, RPS6KA1, SRC			BRD-K50836978-001-04-9, BRD-K50836978-001-03-3, BRD-K50836978-001-02-5, BRD-K50836978-001-02-5, BRD-K50836978-001-02-5	Preclinical
purvalanol-B	tyrosine kinase inhibitor	CDK2, CDK4, CDK5, MAPK1, MAPK3, SRPK2			BRD-K41564320-001-04-9, BRD-K41564320-001-03-8, BRD-K41564320-001-03-8, BRD-K41564320-001-02-0	Preclinical
putrescine	tissue transglutaminase inhibitor	AMD1, KCNJ4, ODC1			BRD-K75282878-300-05-3	Phase 2
PX-12	thioredoxin inhibitor	CNR1, TXN			BRD-A56592690-001-04-3	Phase 2
PX-478	hypoxia inducible factor inhibitor				BRD-A26835809-300-01-3, BRD-A26835809-300-01-3, BRD-A26835809-300-01-3	Phase 1
PYM50028	neurotrophic agent				BRD-K62277907-001-02-9, BRD-K62277907-001-01-6	Phase 2
PYR-41	ubiquitin activating enzyme inhibitor				BRD-K66101666-001-01-5, BRD-K66101666-001-02-3, BRD-K66101666-001-02-3	Preclinical
pyrantel	acetylcholine receptor agonist, nicotinic receptor agonist		infectious disease	gastrointestinal roundworms	BRD-K82118441-001-03-7	Launched
pyrantel-pamoate	neuromuscular blocker		infectious disease	hookworm, tapeworm	BRD-K20672254-096-06-7, BRD-K20672254-046-05-4, BRD-K20672254-096-05-9, BRD-K20672254-046-04-7, BRD-K20672254-046-03-9, BRD-K20672254-096-03-4	Launched
pyrazinamide	fatty acid synthase inhibitor	FASN	infectious disease	tuberculosis	BRD-K28667793-001-27-3, BRD-K28667793-001-28-1	Launched
pyrazinoylguanidine	diuretic				BRD-K61693562-300-01-7	Phase 1
pyrazolanthrone	JNK inhibitor	MAPK10, MAPK8, MAPK8IP1, MAPK9, TTK			BRD-K01567962-001-30-9, BRD-K01567962-001-23-0, BRD-K01567962-001-23-0, BRD-K01567962-001-23-0, BRD-K01567962-001-24-8	Preclinical
pyrazoloacridine	topoisomerase inhibitor	TOP1, TOP2A			BRD-K42607789-001-01-2	Phase 2
pyrethrins			infectious disease	flea control	BRD-K00010129-001-01-9	Launched
pyridoxal		PDXK	neurology/psychiatry	epilepsy	BRD-K76204040-001-03-8	Launched
pyridoxal-isonicotinoyl-hydrazone	apoptosis stimulant				BRD-K42019693-001-01-5, BRD-K42019693-001-01-5	Phase 2
pyridoxamine	AGE inhibitor				BRD-K96669468-300-01-1	Phase 3
pyridoxine	vitamin B	DDC, PDXK	metabolism	vitamin B6 deficiency	BRD-K14349461-001-04-4, BRD-K14349461-003-13-1	Launched
pyrimethamine	dihydrofolate reductase inhibitor	DHFR, SLC47A1	infectious disease	malaria	BRD-K88429204-001-38-5, BRD-K88429204-001-33-6, BRD-K88429204-001-33-6, BRD-K88429204-001-34-4, BRD-K88429204-001-35-1, BRD-K88429204-001-35-1, BRD-K88429204-001-35-1, BRD-K88429204-001-40-9	Launched
pyrintegrin	integrin signaling activator				BRD-K94659840-001-02-9, BRD-K94659840-001-01-7	Preclinical
pyrithyldione	psychoactive drug				BRD-K36116267-001-15-3	Withdrawn
pyritinol			rheumatology, neurology/psychiatry	rheumatoid arthritis, senile dementia	BRD-K82181219-300-05-9, BRD-K82181219-001-04-3	Launched
pyronaridine	antimalarial agent				BRD-K73132780-411-01-3, BRD-K73132780-001-01-2	Phase 3
pyrotinib	kinase inhibitor				BRD-K00003463-001-01-9	Phase 3
pyroxamide	HDAC inhibitor	HDAC1			BRD-K11663430-001-04-9, BRD-K11663430-001-04-9, BRD-K11663430-001-03-1, BRD-K11663430-001-02-3, BRD-K11663430-001-02-3, BRD-K11663430-001-02-3, BRD-K11663430-001-02-3	Phase 1
pyrrolidine-dithiocarbamate	NFkB pathway inhibitor	HSD11B1, RELA			BRD-K80970344-201-10-9, BRD-K80970344-201-08-6	Preclinical
PZ-2891	pantothenate kinase activator				BRD-K00005336-001-01-9	Preclinical
P22077	ubiquitin specific protease inhibitor	USP7			BRD-K97714174-001-04-9, BRD-K97714174-001-02-1, BRD-K97714174-001-02-1, BRD-K97714174-001-01-3, BRD-K97714174-001-01-3, BRD-K97714174-001-01-3, BRD-K97714174-001-01-3, BRD-K97714174-001-01-3, BRD-K97714174-001-01-3, BRD-K97714174-001-01-3	Preclinical
P276-00	CDK inhibitor	CDK1, CDK4, CDK9			BRD-K51791723-003-01-7, BRD-K51791723-003-01-7, BRD-K51791723-003-01-7, BRD-K51791723-003-02-5	Phase 2
P5091	ubiquitin specific protease inhibitor	USP7			BRD-K13606314-001-02-9, BRD-K13606314-001-01-3, BRD-K13606314-001-01-3, BRD-K13606314-001-01-3, BRD-K13606314-001-01-3, BRD-K13606314-001-01-3, BRD-K13606314-001-01-3, BRD-K13606314-001-01-3	Preclinical
P7C3	NAMPT inhibitor	NAMPT			BRD-A09487507-001-02-1, BRD-A09487507-001-03-9	Preclinical
Q-203	ATP synthase inhibitor				BRD-K59853741-001-01-9, BRD-K59853741-001-01-9	Phase 2
quazinone	phosphodiesterase inhibitor	PDE3A, PDE3B			BRD-K63631219-001-01-6, BRD-K63631219-001-01-6, BRD-K63631219-001-01-6	Phase 2
quercetin	polar auxin transport inhibitor	ATP5A1, ATP5B, ATP5C1, HCK, HIBCH, PIK3CG, PIM1, STK17B, UGT3A1	neurology/psychiatry, allergy	fatigue, allergic rhinitis, drowsiness	BRD-K97399794-001-15-3, BRD-K97399794-001-15-3, BRD-K97399794-001-15-3, BRD-K97399794-001-14-6, BRD-K97399794-335-05-6, BRD-K97399794-001-16-1, BRD-K97399794-335-06-4	Launched
quiflapon	leukotriene synthesis inhibitor	ALOX5, ALOX5AP			BRD-K39503511-001-03-9	Phase 2
quinagolide	dopamine receptor agonist	DRD2	endocrinology	hyperprolactinemia	BRD-K02995728-003-01-9	Launched
quinapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, congestive heart failure, angioedema	BRD-K72222507-003-16-8, BRD-K72222507-003-15-0, BRD-K72222507-003-17-6, BRD-K72222507-003-20-0, BRD-K72222507-003-20-0	Launched
quinaprilat	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, angioedema	BRD-K42317111-001-01-7, BRD-K42317111-001-01-7	Launched
quinelorane	dopamine receptor agonist	DRD2, DRD3			BRD-K13261168-300-01-0	Phase 3
quinestrol	estrogen receptor agonist	ESR1, ESR2	endocrinology	menopause	BRD-K63794707-001-20-9	Launched
quinethazone	thiazide diuretic		cardiology	hypertension	BRD-A59303141-001-11-9, BRD-A59303141-001-11-9, BRD-A59303141-001-11-9, BRD-A59303141-001-10-4, BRD-A59303141-001-10-4, BRD-A59303141-001-10-4, BRD-A59303141-001-10-4, BRD-A59303141-001-10-4	Launched
quinidine	sodium channel blocker	KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias	BRD-K59632282-001-04-9, BRD-K59632282-001-04-9, BRD-K59632282-052-03-1, BRD-K59632282-052-03-1	Launched
quinine-ethyl-carbonate			infectious disease	malaria	BRD-K97028990-001-04-4	Launched
quinolinic-acid	glutamate receptor agonist				BRD-K51885093-001-11-2	Preclinical
quinpirol-(-)	dopamine receptor agonist	DRD1, DRD2, DRD3, DRD4, HTR1A, HTR2A, HTR2B, HTR2C			BRD-K26548821-003-11-3, BRD-K26548821-003-11-3, BRD-K26548821-003-14-9, BRD-K26548821-003-14-9, BRD-K26548821-003-10-5	Phase 2
quipazine	serotonin receptor agonist	HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR6, SLC6A4			BRD-K77925998-050-14-3, BRD-K77925998-364-01-5, BRD-K77925998-332-15-9, BRD-K77925998-332-04-6	Preclinical
quizartinib	FLT3 inhibitor	CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET			BRD-K93918653-001-12-9, BRD-K93918653-001-08-9, BRD-K93918653-001-08-9, BRD-K93918653-001-08-9, BRD-K93918653-001-08-9	Phase 3
QX-222	sodium channel blocker				BRD-K40782193-003-02-9	Preclinical
QX-314	sodium channel blocker	MAPK14, TGFBR1			BRD-K56596464-003-02-6, BRD-K56596464-003-11-9, BRD-K56596464-003-11-9, BRD-K56596464-004-10-7	Preclinical
R-121919	CRF receptor antagonist				BRD-K00004717-001-01-9	Preclinical
R-1479	HCV inhibitor				BRD-K28442028-001-02-9, BRD-K28442028-001-01-3	Phase 1
R-1485	serotonin receptor antagonist	HTR6			BRD-K96418224-300-02-9, BRD-K96418224-300-01-8, BRD-K96418224-300-01-8	Phase 1
R-1487	p38 MAPK inhibitor				BRD-K00004710-001-01-9	Phase 1
R-268712	serine/threonine kinase inhibitor	TGFBR1			BRD-K83904070-001-01-1, BRD-K83904070-001-01-1, BRD-K83904070-001-02-9, BRD-K83904070-001-02-9	Preclinical
R-428	AXL kinase inhibitor	AXL			BRD-K14870255-001-02-3, BRD-K14870255-001-02-3, BRD-K14870255-001-02-3	Phase 2
R-59022	diacylglycerol kinase inhibitor, protein kinase inhibitor	DGKA			BRD-K54665485-001-08-7, BRD-K54665485-001-07-9	Preclinical
R-96544	serotonin receptor antagonist	HTR2A			BRD-K15588452-003-03-5, BRD-K15588452-003-04-9, BRD-K15588452-003-02-7	Preclinical
rabeprazole	ATPase inhibitor, gastrin inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome	BRD-K01826765-236-11-9, BRD-K01826765-236-09-9, BRD-K01826765-236-10-9, BRD-K01826765-236-12-9	Launched
rac-BHFF	GABA receptor positive allosteric modulator	GABBR1			BRD-A11069678-001-01-8, BRD-A11069678-001-02-9	Preclinical
racecadotril	enkephalinase inhibitor	MME	gastroenterology	diarrhea	BRD-A08187463-001-12-9, BRD-A08187463-001-12-9, BRD-A08187463-001-12-9, BRD-A08187463-001-14-9, BRD-A08187463-001-14-9, BRD-A08187463-001-11-1, BRD-A08187463-001-11-1	Launched
raclopride	dopamine receptor antagonist	DRD2, DRD3, HTR1A			BRD-K04111260-001-12-6, BRD-K04111260-001-10-0, BRD-K04111260-001-10-0	Launched
ractopamine	adrenergic receptor agonist		endocrinology	weight-gain aid	BRD-K01825837-003-02-9	Launched
radafaxine	dopamine-norepinephrine reuptake inhibitor	SLC6A3			BRD-K13394247-003-01-4	Phase 2
radezolid	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor				BRD-K84683831-001-01-0, BRD-K84683831-001-01-0, BRD-K84683831-001-01-0, BRD-K84683831-001-02-9	Phase 2
radiprodil	acetylcholine receptor antagonist				BRD-K00005328-001-01-9	Phase 2
radotinib	Bcr-Abl kinase inhibitor				BRD-K00004716-001-01-9	Phase 3
RAD140	androgen receptor modulator				BRD-K00003169-001-01-9	Phase 1
RAF265	RAF inhibitor, VEGFR inhibitor	BRAF			BRD-K93123848-001-06-9, BRD-K93123848-001-04-1, BRD-K93123848-001-04-1, BRD-K93123848-001-04-1	Phase 2
RAF709	RAF inhibitor				BRD-K00010389-001-01-9	Preclinical
ralinepag	IP1 prostacyclin receptor agonist				BRD-K00003227-001-01-9	Phase 3
raloxifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	ESR1, ESR2	orthopedics, oncology	osteoporosis, breast cancer	BRD-K63828191-003-34-7, BRD-K63828191-003-34-7, BRD-K63828191-003-35-4, BRD-K63828191-003-33-9, BRD-K63828191-003-33-9, BRD-K63828191-003-32-1	Launched
raltegravir	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K05658747-001-02-9, BRD-K05658747-001-02-9, BRD-K05658747-001-03-7	Launched
raltitrexed	thymidylate synthase inhibitor	FPGS, TYMS	oncology	mesothelioma	BRD-K08151102-001-11-9, BRD-K08151102-001-05-9, BRD-K08151102-001-05-9, BRD-K08151102-001-06-9	Launched
ramatroban	prostanoid receptor antagonist	PTGDR2, TBXA2R	cardiology, pulmonary	coronary artery disease (CAD), asthma	BRD-K08586861-001-01-1, BRD-K08586861-001-01-1, BRD-K08586861-001-02-9, BRD-K08586861-001-02-9	Launched
ramelteon	melatonin receptor agonist	MTNR1A, MTNR1B	neurology/psychiatry	insomnia	BRD-K28761891-001-10-1, BRD-K28761891-001-09-3	Launched
ramifenazone	cyclooxygenase inhibitor		neurology/psychiatry, endocrinology	pain relief, fever	BRD-K85333151-001-01-3, BRD-K85333151-001-01-3, BRD-K85333151-003-13-4	Launched
ramosetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting, irritable bowel syndrome	BRD-K85046107-003-03-9, BRD-K85046107-003-01-2	Launched
ranirestat	aldose reductase inhibitor	AKR1B1			BRD-K50489389-001-01-8, BRD-K50489389-001-01-8	Phase 3
ranitidine	histamine receptor antagonist	HRH2	gastroenterology	heartburn	BRD-K30816563-003-03-9	Launched
ranolazine	sodium channel blocker	SCN10A, SCN9A	cardiology	chronic stable angina	BRD-K01825102-300-04-9, BRD-K01825102-300-03-9, BRD-K01825102-300-03-9	Launched
rapastinel	glutamate receptor agonist				BRD-K02206208-001-01-4	Phase 2
ravoxertinib	ERK1 and ERK2 phosphorylation inhibitor	MAPK1, MAPK3			BRD-K86309810-001-02-9, BRD-K86309810-001-02-9, BRD-K86309810-001-01-5, BRD-K86309810-001-01-5	Phase 1
ravuconazole	sterol demethylase inhibitor				BRD-K03503561-001-01-4, BRD-K03503561-001-01-4, BRD-K03503561-001-01-4	Phase 2
RBC8	Ral GTPase inhibitor	RALA, RALB			BRD-A67036568-001-02-1, BRD-A67036568-001-03-9, BRD-A67036568-001-01-3	Preclinical
rebamipide	free radical scavenger	FPR1	gastroenterology	peptic ulcer disease (PUD), gastritis	BRD-A15909516-001-07-4, BRD-A15909516-001-09-9, BRD-A15909516-001-06-6	Launched
rebastinib	Bcr-Abl kinase inhibitor, TIE tyrosine kinase inhibitor, VEGFR inhibitor	ABL1, BCR, FGR, FLT3, HCK, LYN, SRC			BRD-K76694128-001-06-8, BRD-K76694128-001-07-6, BRD-K76694128-001-07-6, BRD-K76694128-001-05-0, BRD-K76694128-001-05-0, BRD-K76694128-001-05-0, BRD-K76694128-001-04-3	Phase 1/Phase 2
reboxetine	adrenergic receptor antagonist	SLC6A2	neurology/psychiatry	depression	BRD-K77224738-066-02-7, BRD-K77224738-066-09-9, BRD-K77224738-066-08-9	Launched
Rec-15/2615	adrenergic receptor antagonist	ADRA1A			BRD-K84924479-300-01-1, BRD-K84924479-300-02-9	Phase 2
refametinib	MEK inhibitor	MAP2K1, MAP2K2			BRD-K85751432-001-03-3, BRD-K85751432-001-03-3, BRD-K85751432-001-03-3, BRD-K85751432-001-03-3, BRD-K85751432-001-03-3, BRD-K85751432-001-04-9	Phase 2
regadenoson	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3	radiology	myocardial perfusion imaging (MPI)	BRD-K00003609-001-01-9	Launched
regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)	BRD-K16730910-001-07-3, BRD-K16730910-001-07-3, BRD-K16730910-001-10-7, BRD-K16730910-001-10-7, BRD-K16730910-001-10-7, BRD-K16730910-001-10-7	Launched
relcovaptan	vasopressin receptor antagonist	AVPR1A, AVPR1B, AVPR2, OXTR			BRD-K96720755-001-03-4, BRD-K96720755-001-02-6, BRD-K96720755-001-04-9	Phase 2
relebactam	beta lactamase inhibitor				BRD-K63018010-001-01-7	Launched
relugolix	gonadotropin releasing factor hormone receptor antagonist				BRD-K00003216-001-01-9	Phase 3
remacemide	glutamate receptor antagonist	GRIN1			BRD-A36074203-003-08-9, BRD-A36074203-003-07-6	Phase 3
remetinostat	HDAC inhibitor				BRD-K00004584-001-01-9	Phase 2
remimazolam	benzodiazepine receptor agonist	GABBR1			BRD-K89413285-074-01-5, BRD-K89413285-074-01-5	Phase 3
remodelin	transferase inhibitor	NAT10			BRD-K75349868-001-03-9, BRD-K75349868-001-01-5	Preclinical
remoxipride	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR2A, SIGMAR1			BRD-K54094468-003-12-9, BRD-K54094468-003-12-9, BRD-K54094468-003-11-1, BRD-K54094468-003-11-1, BRD-K54094468-003-11-1	Withdrawn
repaglinide	insulin secretagogue	ABCC8, KCNJ11, PPARG	endocrinology	diabetes mellitus	BRD-K82846253-001-17-0, BRD-K82846253-001-16-2, BRD-K82846253-001-15-4, BRD-K82846253-001-14-7, BRD-K82846253-001-20-9	Launched
reparixin	CC chemokine receptor antagonist	CXCR1, CXCR2			BRD-K58486055-001-02-7, BRD-K58486055-001-02-7, BRD-K58486055-001-02-7, BRD-K58486055-001-03-9	Phase 3
repotrectinib	receptor tyrosine protein kinase inhibitor				BRD-K00003447-001-01-9	Phase 1/Phase 2
repsox	TGF beta receptor inhibitor	TGFBR1			BRD-K80480517-001-04-0, BRD-K80480517-001-04-0, BRD-K80480517-001-04-0, BRD-K80480517-001-02-4, BRD-K80480517-001-02-4, BRD-K80480517-001-02-4, BRD-K80480517-001-02-4, BRD-K80480517-001-05-9	Preclinical
resatorvid	toll-like receptor inhibitor	TLR4			BRD-K61567297-001-02-7, BRD-K61567297-001-01-9, BRD-K61567297-001-01-9	Phase 3
reserpine	vesicular monoamine transporter inhibitor	SLC18A1, SLC18A2	cardiology	hypertension	BRD-K95921201-001-15-3, BRD-K95921201-001-15-3, BRD-K95921201-001-13-8, BRD-K95921201-001-19-9, BRD-K95921201-001-19-9, BRD-K95921201-001-12-0, BRD-K95921201-001-14-6	Launched
resibufogenin	Na/K-ATPase inhibitor				BRD-K25970317-001-01-6	Phase 2
resiquimod	toll-like receptor agonist	TLR7, TLR8			BRD-K76210423-001-03-9, BRD-K76210423-001-02-4, BRD-K76210423-001-01-6, BRD-K76210423-001-01-6	Phase 3
resmetirom	thyroid hormone receptor agonist				BRD-K00003123-001-01-9	Phase 3
resminostat	HDAC inhibitor	HDAC1, HDAC3, HDAC6, HDAC8			BRD-K28822270-003-04-9, BRD-K28822270-003-04-9, BRD-K28822270-003-04-9, BRD-K28822270-001-01-1, BRD-K28822270-001-01-1, BRD-K28822270-001-01-1, BRD-K28822270-001-03-7, BRD-K28822270-001-03-7, BRD-K28822270-001-03-7, BRD-K28822270-001-03-7, BRD-K28822270-001-03-7	Phase 2
resorcinol	phosphodiesterase inhibitor	CA12, CA14, CA2, PTGS1	dermatology	acne vulgaris (AV), eczema, psoriasis, seborrheic dermatitis	BRD-K74190368-001-08-9, BRD-K74190368-001-04-3, BRD-K74190368-001-04-3	Launched
resorcinol-monoacetate	antiseptic				BRD-K85603128-001-03-5, BRD-K85603128-001-04-3	Launched
resveratrol	cytochrome P450 inhibitor, SIRT activator	CSNK2A1, NQO2, PTGS1, PTGS2			BRD-K80738081-001-46-8, BRD-K80738081-001-47-6, BRD-K80738081-001-44-3, BRD-K80738081-001-42-7, BRD-K80738081-001-43-5	Launched
retagliptin	dipeptidyl peptidase inhibitor				BRD-K00003118-011-01-9	Phase 1
retaspimycin	HSP inhibitor	HSP90AA1			BRD-K67935717-003-02-8, BRD-K67935717-003-01-0	Phase 3
retinaldehyde			dermatology	cosmetic	BRD-K79884267-001-01-4	Launched
retinol	retinoid receptor ligand	ALDH1A1, ALDH1A2, ALDH1A3, DHRS3, DHRS4, LRAT, NR2C2, RBP1, RBP3, RDH11, RDH12, RDH13, RDH14, RDH5, RDH8, RETSAT, RHO, RLBP1, RXRA, RXRB, RXRG	dermatology	cosmetic, acne vulgaris (AV), keratosis	BRD-K22429181-001-15-9, BRD-K22429181-001-14-2	Launched
retinyl-acetate					BRD-K65331431-001-06-2, BRD-K65331431-001-08-8	Launched
retinyl-palmitate					BRD-K80595380-001-07-2, BRD-K80595380-001-09-8	Launched
REV-5901	leukotriene receptor antagonist, lipoxygenase inhibitor	ALOX5			BRD-A68281735-001-19-9, BRD-A68281735-001-19-9, BRD-A68281735-001-18-6, BRD-A68281735-001-18-6	Phase 2
revaprazan	potassium-competitive acid antagonist	ATP4A	gastroenterology	gastritis	BRD-A51497544-001-01-4	Launched
revefenacin	cholinergic receptor antagonist				BRD-K00003198-001-01-9	Launched
reversan	MRP inhibitor	ABCC1			BRD-K79700588-001-09-7, BRD-K79700588-001-09-7, BRD-K79700588-001-10-9	Preclinical
reversine	Aurora kinase inhibitor	AURKB, INCENP, MAP2K1			BRD-K77286328-001-03-7, BRD-K77286328-001-06-0, BRD-K77286328-001-06-0	Preclinical
reynoutrin	antioxidant				BRD-K00005343-001-01-9, BRD-K00005343-001-01-9	Preclinical
RGB-286638	CDK inhibitor	CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK9, FLT3, GSK3B, JAK2, MAP3K7, MAPK9			BRD-K20986415-001-02-6, BRD-K20986415-001-02-6, BRD-K20986415-001-01-8, BRD-K20986415-001-01-8	Phase 1
RGFP966	HDAC inhibitor	HDAC3			BRD-K61688984-001-02-9, BRD-K61688984-001-02-9, BRD-K61688984-001-02-9	Preclinical
RGX-104	LXR agonist				BRD-K00004597-001-01-9	Phase 1
RG108	DNA methyltransferase inhibitor	DNMT1, DNMT3B			BRD-K89391146-001-09-8, BRD-K89391146-001-09-8, BRD-K89391146-001-12-9, BRD-K89391146-001-08-0	Preclinical
RG1530	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	FGFR1, FGFR2			BRD-K32942258-001-04-1, BRD-K32942258-001-02-5, BRD-K32942258-001-01-7, BRD-K32942258-001-03-3	Phase 1
RG2833	HDAC inhibitor	HDAC1, HDAC3			BRD-K02389548-001-04-1, BRD-K02389548-001-04-1, BRD-K02389548-001-04-1, BRD-K02389548-001-04-1, BRD-K02389548-001-02-5	Phase 1
RG4733	gamma secretase inhibitor	PSEN1			BRD-K22024824-001-03-7, BRD-K22024824-001-03-7, BRD-K22024824-001-04-9, BRD-K22024824-001-04-9	Phase 2
RG7112	MDM inhibitor	MDM2			BRD-K13178532-001-01-9	Phase 1
RG7800	RNA splicing modifier				BRD-K00004590-001-01-9	Preclinical
RG7834	antiviral				BRD-K00004573-001-01-9	Preclinical
RHC-80267	triacylglycerol lipase inhibitor	DAGLA, DAGLB			BRD-K56047318-001-07-1, BRD-K56047318-001-08-9, BRD-K56047318-001-06-3	Preclinical
rhein		HSP90AA1			BRD-K27335680-001-11-9, BRD-K27335680-001-10-0, BRD-K27335680-001-10-0	Phase 1
rheochrysidin	protein tyrosine kinase inhibitor	PTPN1			BRD-K67772619-001-05-1, BRD-K67772619-001-05-1, BRD-K67772619-001-06-9	Preclinical
rhodamine-123					BRD-K47169076-003-01-6, BRD-K47169076-003-01-6, BRD-K47169076-003-01-6	Phase 1
RI-1		RAD51			BRD-K79555887-001-02-9, BRD-K79555887-001-01-0	Preclinical
ribitol					BRD-K49313711-001-06-9, BRD-K49313711-001-05-4	Preclinical
ribociclib	CDK inhibitor	CDK4, CDK6	oncology	breast cancer	BRD-K36788280-001-04-6, BRD-K36788280-001-04-6, BRD-K36788280-001-04-6, BRD-K36788280-001-04-6, BRD-K36788280-001-04-6, BRD-K36788280-001-01-2, BRD-K36788280-001-01-2, BRD-K36788280-001-03-8	Launched
riboflavin	vitamin B	BLVRB, RFK	gastroenterology	jaundice	BRD-K92760278-001-07-3, BRD-K92760278-001-06-5, BRD-K92760278-001-09-9, BRD-K92760278-001-08-1	Launched
riboflavin-tetrabutyrate	antioxidant				BRD-K74227494-001-03-9	Preclinical
riboflavin-5-phosphate-sodium		BLVRB, DHODH, DPYD, HAO1, HAO2, MT-ND1, NOS1, PNPO, POR, PPCDC, RFK, RPS6KA4, SGK1			BRD-K09229706-236-02-6, BRD-K09229706-236-01-8, BRD-K09229706-325-01-9	Launched
ribostamycin	bacterial 30S ribosomal subunit inhibitor	P4HB	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K55188888-065-01-2, BRD-K55188888-065-01-2, BRD-K55188888-065-02-9	Launched
ribostamycin-sulfate	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	BRD-K01826536-065-03-9	Launched
ricinoleic-acid	prostanoid receptor agonist	PTGER3			BRD-K33682646-001-02-7	Launched
ridinilazole	antibacterial				BRD-K77897005-001-02-9	Phase 3
rifabutin	protein synthesis inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K31484631-001-12-9	Launched
rifamycin	DNA directed RNA polymerase inhibitor	SLCO1A2, SLCO1B1, SLCO1B3, SLCO2B1	infectious disease	tuberculosis, leprosy	BRD-K38512030-001-01-7	Launched
rifamycin-sv	RNA synthesis inhibitor				BRD-K66048476-236-01-0	Phase 3
rifaximin	RNA synthesis inhibitor		gastroenterology	diarrhea, irritable bowel syndrome, hepatic encephalopathy (HE)	BRD-K53484294-001-03-9, BRD-K53484294-001-03-9	Launched
rigosertib	cell cycle inhibitor, PLK inhibitor	PLK1			BRD-K55187425-236-06-0, BRD-K55187425-236-07-8, BRD-K55187425-236-05-2, BRD-K55187425-236-05-2, BRD-K55187425-236-05-2, BRD-K55187425-236-05-2, BRD-K55187425-236-05-2	Phase 3
rilapladib	phospholipase inhibitor				BRD-K00004676-001-01-9	Phase 2
rilpivirine	non-nucleoside reverse transcriptase inhibitor	NR1I2, SCN10A	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K06240250-001-02-9, BRD-K06240250-001-02-9, BRD-K06240250-001-01-6	Launched
riluzole	glutamate inhibitor	KCNK10, KCNK2, KCNK4, KCNN4, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A, SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	BRD-K21283037-003-11-2, BRD-K21283037-001-21-5, BRD-K21283037-001-20-7, BRD-K21283037-001-20-7	Launched
rimantadine	antiviral, RNA synthesis inhibitor		infectious disease	influenza A virus infection	BRD-K01825586-001-02-9, BRD-K01825586-001-02-9, BRD-K01825586-001-04-9	Launched
rimcazole	sigma receptor antagonist	SIGMAR1			BRD-K70490179-300-01-2, BRD-K70490179-300-01-2	Phase 1
rimegepant	calcitonin antagonist	CALCA			BRD-K55781385-001-01-7, BRD-K55781385-001-01-7, BRD-K55781385-001-02-9	Launched
rimeporide	sodium/hydrogen exchanger inhibitor				BRD-K00004645-001-01-9	Phase 1
rimexolone	glucocorticoid receptor agonist	NR3C1, SERPINA6	ophthalmology	anterior uveitis	BRD-K31627533-001-09-5, BRD-K31627533-001-09-5, BRD-K31627533-001-10-3	Launched
rimonabant	cannabinoid receptor antagonist	CNR1, GPR55			BRD-K13296708-001-05-8, BRD-K13296708-001-05-8, BRD-K13296708-003-06-9	Withdrawn
riociguat	guanylate cyclase stimulant	GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3	cardiology	hypertension	BRD-K84783599-001-01-0, BRD-K84783599-001-02-9, BRD-K84783599-001-02-9	Launched
riodipine	calcium channel blocker				BRD-K36379990-001-01-1, BRD-K36379990-001-01-1	Phase 2
riodoxol	other antibiotic				BRD-K48963429-001-02-7, BRD-K48963429-001-01-9, BRD-K48963429-001-01-9	Launched
ripasudil	rho associated kinase inhibitor	ROCK1, ROCK2	ophthalmology	glaucoma, ocular hypertension	BRD-K53814070-310-01-3, BRD-K53814070-310-01-3, BRD-K53814070-310-01-3, BRD-K53814070-310-01-3, BRD-K53814070-310-02-9, BRD-K53814070-310-02-9	Launched
ripazepam	benzodiazepine receptor agonist	GABRA1			BRD-K57427145-001-01-6, BRD-K57427145-001-01-6	Phase 2
ripretinib	receptor tyrosine protein kinase inhibitor				BRD-K00005241-001-01-9	Phase 3
risdiplam	RNA splicing inhibitor				BRD-K00003506-001-01-9	Phase 2/Phase 3
risedronate	osteoclast inhibitor	FDPS	orthopedics, endocrinology	osteoporosis, Paget's disease	BRD-K05185389-236-04-4, BRD-K05185389-236-05-1, BRD-K05185389-001-02-6, BRD-K05185389-001-03-4, BRD-K05185389-236-03-6	Launched
rislenemdaz	ionotropic glutamate receptor antagonist				BRD-K00003471-001-01-9	Preclinical
risperidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, HTR7	neurology/psychiatry	schizophrenia, bipolar disorder, irritability	BRD-K53857191-001-22-7, BRD-K53857191-001-21-9	Launched
RITA	MDM inhibitor	MDM2			BRD-K00317371-001-05-3, BRD-K00317371-001-06-1, BRD-K00317371-001-06-1	Preclinical
ritanserin	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			BRD-K40887525-001-23-5, BRD-K40887525-001-23-5, BRD-K40887525-001-22-7, BRD-K40887525-001-24-9, BRD-K40887525-001-21-9, BRD-K40887525-001-21-9	Phase 3
ritodrine	adrenergic receptor agonist		obstetrics/gynecology	premature labor	BRD-K14003026-003-09-0, BRD-K14003026-003-08-2, BRD-K14003026-003-10-9, BRD-K14003026-003-10-9	Withdrawn
ritonavir	HIV protease inhibitor	CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K51485625-001-08-4, BRD-K51485625-001-08-4, BRD-K51485625-001-08-4	Launched
rivanicline	acetylcholine receptor agonist	CHRNA4, CHRNB2, CXCL8			BRD-K79966802-034-02-9, BRD-K79966802-034-01-2	Phase 2
rivastigmine	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	Alzheimer's disease, Parkinson's Disease, senile dementia	BRD-K10706131-046-06-9, BRD-K10706131-046-04-4, BRD-K10706131-046-04-4, BRD-K10706131-046-04-4, BRD-K10706131-046-05-1, BRD-K10706131-046-02-8, BRD-K10706131-046-03-6	Launched
rizatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	BRD-K75699339-057-10-7, BRD-K75699339-057-08-1, BRD-K75699339-057-09-9, BRD-K75699339-057-07-3	Launched
RKI-1447	rho associated kinase inhibitor	CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2			BRD-K19333160-300-02-9, BRD-K19333160-300-01-9, BRD-K19333160-001-01-3, BRD-K19333160-001-01-3	Preclinical
RLX					BRD-K28773847-001-08-9, BRD-K28773847-001-07-7	Preclinical
RMC-4550	SHIP2 phosphatase inhibitor				BRD-K00010386-001-01-9, BRD-K00010386-001-01-9	Preclinical
RN-1	histone demethylase inhibitor	KDM1A			BRD-K41415459-300-02-9, BRD-K41415459-300-01-6	Preclinical
RN-1734	TRPV antagonist	TRPV4			BRD-K95581532-001-02-3, BRD-K95581532-001-02-3, BRD-K95581532-001-01-5, BRD-K95581532-001-01-5, BRD-K95581532-001-01-5, BRD-K95581532-001-01-5, BRD-K95581532-001-03-9	Preclinical
RN-1747	TRPV agonist	TRPV4			BRD-K45519571-001-02-6, BRD-K45519571-001-01-8, BRD-K45519571-001-03-9, BRD-K45519571-001-03-9	Preclinical
Ro-04-5595	glutamate receptor antagonist	GRIN2B			BRD-A63546914-003-03-8, BRD-A63546914-003-04-9, BRD-A63546914-003-02-0	Preclinical
Ro-08-2750	NGF binding inhibitor	NGF, NGFR			BRD-K00486786-001-02-2, BRD-K00486786-001-02-2, BRD-K00486786-001-03-9	Preclinical
Ro-10-5824	dopamine receptor agonist	DRD4			BRD-K79684402-300-03-6, BRD-K79684402-300-03-6, BRD-K79684402-300-02-8, BRD-K79684402-300-04-9	Preclinical
Ro-106-9920	NFkB pathway inhibitor				BRD-A53134341-001-04-0, BRD-A53134341-001-04-0, BRD-A53134341-001-04-0, BRD-A53134341-001-04-0, BRD-A53134341-001-03-2, BRD-A53134341-001-03-2, BRD-A53134341-001-03-2, BRD-A53134341-001-03-2, BRD-A53134341-001-03-2	Preclinical
Ro-1138452	prostanoid receptor antagonist	PTGIR			BRD-K77220725-003-01-5, BRD-K77220725-003-01-5, BRD-K77220725-003-01-5, BRD-K77220725-003-02-9	Preclinical
Ro-15-4513	GABA benzodiazepine site receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB2, GABRG2			BRD-K82823076-001-03-9, BRD-K82823076-001-02-6	Preclinical
Ro-19-4605	GABA benzodiazepine site receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			BRD-K80778372-001-03-3, BRD-K80778372-001-04-9, BRD-K80778372-001-02-5, BRD-K80778372-001-02-5	Preclinical
Ro-20-1724	phosphodiesterase inhibitor	PDE3A, PDE4A, PDE4B, PDE4C, PDE4D			BRD-A07207424-001-14-0, BRD-A07207424-001-14-0, BRD-A07207424-001-13-2, BRD-A07207424-001-13-2, BRD-A07207424-001-15-9	Preclinical
Ro-25-6981	glutamate receptor antagonist, monamine transporter modulator	GRIN2B			BRD-K51541829-050-02-8, BRD-K51541829-050-06-9, BRD-K51541829-050-01-0, BRD-K51541829-050-01-0	Preclinical
Ro-28-1675	glucokinase activator	GCK			BRD-K21672174-001-03-0	Preclinical
Ro-3	purinergic receptor antagonist	P2RX3			BRD-K00354853-001-01-2, BRD-K00354853-001-01-2, BRD-K00354853-001-02-9, BRD-K00354853-001-02-9	Preclinical
Ro-3306	CDK inhibitor	CDK1			BRD-K78373679-001-03-7, BRD-K78373679-001-03-7, BRD-K78373679-001-04-9	Preclinical
Ro-48-6791	GABA receptor modulator				BRD-K00004572-001-01-9	Preclinical
Ro-48-8071	oxidosqualene cyclase inhibitor	LSS			BRD-K55192287-051-02-9, BRD-K55192287-051-02-9, BRD-K55192287-051-01-1	Preclinical
Ro-4987655	MEK inhibitor	MAP2K1			BRD-K64538373-001-01-4, BRD-K64538373-001-01-4, BRD-K64538373-001-02-9	Phase 1
Ro-5028442	vasopressin receptor antagonist				BRD-K00003149-001-01-9	Phase 1
Ro-5126766	MEK inhibitor, RAF inhibitor	BRAF, MAP2K1, MAP2K2, RAF1			BRD-K82804538-001-03-6, BRD-K82804538-001-01-0, BRD-K82804538-001-02-8	Phase 1
Ro-5263397	trace amine associated receptor agonist				BRD-K00004623-001-01-9	Preclinical
Ro-60-0175	serotonin receptor agonist	HTR2A, HTR2B, HTR2C			BRD-K28007504-051-02-0, BRD-K28007504-051-03-9, BRD-K28007504-051-03-9, BRD-K28007504-051-01-2, BRD-K28007504-051-01-2	Preclinical
Ro-61-8048	kynurenine 3-monooxygenase inhibitor	KMO			BRD-K12639498-001-02-1, BRD-K12639498-001-01-3, BRD-K12639498-001-03-9	Preclinical
Ro-67-7476	glutamate receptor positive allosteric modulator	GRM1			BRD-K91333421-001-01-9, BRD-K91333421-001-02-9	Preclinical
Ro-90-7501	beta amyloid protein neurotoxicity inhibitor	APP			BRD-K58299615-001-04-3, BRD-K58299615-001-03-5, BRD-K58299615-001-03-5, BRD-K58299615-001-05-9	Preclinical
Ro-9187	HCV inhibitor				BRD-K57284066-001-02-9, BRD-K57284066-001-01-6, BRD-K57284066-001-01-6	Preclinical
robalzotan	serotonin receptor antagonist	HTR1A			BRD-K26169680-003-01-9, BRD-K26169680-003-01-9, BRD-K26169680-003-02-9	Phase 2
roblitinib	FGFR inhibitor				BRD-K00003424-001-01-9	Preclinical
rociletinib	EGFR inhibitor	EGFR			BRD-K33610132-001-02-9, BRD-K33610132-001-02-9, BRD-K33610132-001-02-9, BRD-K33610132-001-02-9, BRD-K33610132-001-02-9, BRD-K33610132-001-04-5, BRD-K33610132-001-04-5, BRD-K33610132-001-04-5, BRD-K33610132-001-04-5, BRD-K33610132-001-04-5, BRD-K33610132-001-04-5, BRD-K33610132-001-04-5	Phase 3
rofecoxib	cyclooxygenase inhibitor	ELN, PTGS2			BRD-K21733600-001-15-8, BRD-K21733600-001-24-0, BRD-K21733600-001-24-0, BRD-K21733600-001-23-2, BRD-K21733600-001-19-0, BRD-K21733600-001-14-1	Withdrawn
roflumilast	phosphodiesterase inhibitor	PDE4A, PDE4B, PDE4C, PDE4D	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis	BRD-K03194791-001-04-8, BRD-K03194791-001-04-8	Launched
rogaratinib	FGFR inhibitor				BRD-K00003358-001-01-9	Phase 2/Phase 3
rolapitant	neurokinin receptor antagonist				BRD-K00003175-001-01-9	Phase 3
rolipram	phosphodiesterase inhibitor				BRD-A34255068-001-38-6, BRD-A34255068-001-34-5, BRD-A34255068-001-34-5, BRD-A34255068-001-33-7, BRD-A34255068-001-32-9	Phase 3
rolitetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-A62336573-001-03-1, BRD-A62336573-001-04-9, BRD-A62336573-001-02-3, BRD-A62336573-001-06-4	Launched
roluperidone					BRD-K00003283-001-01-9	Phase 2
rolziracetam					BRD-K38564664-001-01-1	Phase 2
romidepsin	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	BRD-K61397605-001-03-4, BRD-K61397605-001-03-4, BRD-K61397605-001-03-4, BRD-K61397605-001-03-4, BRD-K61397605-001-01-8, BRD-K61397605-001-01-8, BRD-K61397605-001-01-8	Launched
ronidazole	antiprotozoal agent		infectious disease	histomoniasis, dysentry	BRD-K94266545-001-25-9, BRD-K94266545-001-24-1, BRD-K94266545-001-23-3	Launched
ropinirole	dopamine receptor agonist	ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease, restless leg syndrome	BRD-K15933101-003-07-9, BRD-K15933101-003-06-1, BRD-K15933101-003-06-1, BRD-K15933101-003-08-9	Launched
ropivacaine	sodium channel blocker	SCN10A	neurology/psychiatry	anesthetic	BRD-K50938786-311-12-9, BRD-K50938786-311-12-9, BRD-K50938786-003-11-8	Launched
roquinimex	angiogenesis inhibitor, tumor necrosis factor production inhibitor				BRD-K03384561-001-03-9, BRD-K03384561-001-02-7, BRD-K03384561-001-02-7	Phase 3
rosamicin	protein synthesis inhibitor				BRD-K00004538-001-01-9	Phase 2
roscovitine	CDK inhibitor	CDK2, CDK9			BRD-K07691486-001-19-7, BRD-K07691486-001-19-7, BRD-K07691486-001-15-5, BRD-K07691486-001-15-5	Phase 2
rose-bengal-lactone	coloring agent		ophthalmology	staining agent	BRD-K36163066-304-02-4, BRD-K36163066-304-02-4	Launched
rosiglitazone	insulin sensitizer, PPAR receptor agonist	FFAR1, PPARG, TRPC5, TRPM3			BRD-K01826734-003-14-9, BRD-K01826734-003-14-9	Withdrawn
rosiptor	SHIP1 phosphatase activator				BRD-K00003494-001-01-9	Phase 2
rosmarinic-acid	GABA transaminase inhibitor	MCL1, TYR			BRD-K20313525-001-05-9, BRD-K20313525-001-04-6, BRD-K20313525-001-04-6, BRD-K20313525-001-04-6	Launched
rosoxacin	topoisomerase inhibitor		infectious disease	urinary tract infections	BRD-K49841478-001-01-6	Launched
rostafuroxine	ATPase inhibitor	ATP1A1			BRD-K11672787-001-02-3, BRD-K11672787-001-03-9, BRD-K11672787-001-01-5	Phase 2
rotigotine	dopamine receptor agonist	ADRA2B, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A	neurology/psychiatry	Parkinson's Disease, restless leg syndrome	BRD-K91111634-003-01-8, BRD-K91111634-001-01-2, BRD-K91111634-003-02-9	Launched
rotundine	serotonin receptor agonist	DRD1, DRD2, DRD3, HTR1A	neurology/psychiatry	anxiety, sedative	BRD-K35719256-001-09-9, BRD-K35719256-001-02-6	Launched
rovazolac	LXR agonist				BRD-K00003502-001-01-9	Preclinical
roxarsone	antiprotozoal agent		endocrinology	weight-gain aid	BRD-K22685337-001-15-9, BRD-K22685337-001-15-9, BRD-K22685337-001-13-4	Launched
roxatidine-acetate	histamine receptor antagonist	HRH2	gastroenterology	Zollinger-Ellison syndrome, erosive esophagitis (EE), gastroesophageal reflux disease (GERD), gastritis	BRD-K81855038-003-14-7, BRD-K81855038-003-13-9, BRD-K81855038-003-12-1	Launched
RP-001	sphingosine 1-phosphate receptor agonist	S1PR1			BRD-A29148886-003-01-4, BRD-A29148886-003-02-9, BRD-A29148886-003-02-9	Preclinical
RP67580					BRD-K40767677-001-01-1	Preclinical
RQ-00203078	transient receptor potential channel antagonist	TRPM8			BRD-K87973152-001-01-3, BRD-K87973152-001-02-9	Preclinical
RRx-001	glucose 6-phosphate dehydrogenase inhibitor	G6PD			BRD-K06894065-001-02-3, BRD-K06894065-001-01-5	Phase 3
RS-0481	immunostimulant					Phase 2
RS-100329	adrenergic receptor antagonist	ADRA1A, ADRA1D			BRD-K08640512-003-03-9, BRD-K08640512-003-02-3	Preclinical
RS-102221	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			BRD-K87048468-003-03-5, BRD-K87048468-003-03-5, BRD-K87048468-003-04-3, BRD-K87048468-003-04-3, BRD-K87048468-003-02-7	Preclinical
RS-102895	CCR antagonist	CCR2			BRD-K83063356-003-03-3, BRD-K83063356-003-04-9, BRD-K83063356-003-02-5	Preclinical
RS-127445	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			BRD-K90825648-001-02-0, BRD-K90825648-003-03-9, BRD-K90825648-003-03-9	Phase 1
RS-16566	serotonin receptor antagonist				BRD-K00004221-300-01-9	Preclinical
RS-17053	adrenergic receptor antagonist	ADRA1A, ADRA1D			BRD-K76840893-003-03-3, BRD-K76840893-003-03-3, BRD-K76840893-003-04-9, BRD-K76840893-003-04-9, BRD-K76840893-003-02-5, BRD-K76840893-003-02-5, BRD-K76840893-003-02-5, BRD-K76840893-003-02-5	Preclinical
RS-23597-190	serotonin receptor antagonist	HTR4			BRD-K01868942-003-02-7	Preclinical
RS-39604	serotonin receptor antagonist	HTR4			BRD-K20742498-003-03-9, BRD-K20742498-003-02-9, BRD-K20742498-003-02-9, BRD-K20742498-003-02-9	Preclinical
RS-45041-190	imidazoline receptor agonist				BRD-K26160755-003-03-9, BRD-K26160755-003-03-9, BRD-K26160755-003-02-6	Preclinical
RS-504393	CC chemokine receptor antagonist	CCL2, CCR2			BRD-K87510569-001-02-8, BRD-K87510569-001-03-9	Preclinical
RS-56812	serotonin receptor partial agonist	HTR3A			BRD-K00004219-003-01-9	Preclinical
RS-67333	serotonin receptor partial agonist	HTR4			BRD-K46142322-003-03-9, BRD-K46142322-003-02-4, BRD-K46142322-003-02-4	Preclinical
RS-67506	serotonin receptor partial agonist	HTR4			BRD-K50018155-003-03-9, BRD-K50018155-003-02-1, BRD-K50018155-003-02-1, BRD-K50018155-003-02-1	Preclinical
RS-79948	adrenergic receptor antagonist	ADRA2A			BRD-K86600316-003-03-9, BRD-K86600316-003-02-0	Preclinical
RSV604	RSV replication inhibitor				BRD-K30159788-001-01-9	Phase 2
RU-SKI-43	hedgehog pathway inhibitor	HHAT			BRD-A33603104-003-02-9, BRD-A33603104-003-01-8	Preclinical
RU-28318	cytochrome P450 inhibitor	NR3C2			BRD-K37687387-237-02-9, BRD-K37687387-237-01-7	Phase 2
RU-42173	adrenergic receptor agonist	ADRB2			BRD-K85285268-003-01-1	Phase 2
RU-58841	androgen receptor antagonist	AR			BRD-K62762455-001-02-9, BRD-K62762455-001-01-3	Phase 2
rubitecan	topoisomerase inhibitor	TOP1			BRD-K79821389-001-03-5, BRD-K79821389-001-03-5, BRD-K79821389-001-03-5	Phase 3
ruboxistaurin	PKC inhibitor				BRD-K27677357-003-04-9	Phase 3
rucaparib	PARP inhibitor	PARP1, PARP2			BRD-K88560311-001-08-9, BRD-K88560311-001-08-9, BRD-K88560311-011-07-1, BRD-K88560311-011-07-1, BRD-K88560311-011-07-1, BRD-K88560311-011-07-1, BRD-K88560311-011-07-1, BRD-K88560311-011-07-1, BRD-K88560311-011-07-1, BRD-K88560311-011-06-3, BRD-K88560311-011-06-3, BRD-K88560311-011-06-3	Phase 3
rucinol	tyrosinase inhibitor	TYR			BRD-K61036791-001-01-6, BRD-K61036791-001-01-6	Phase 1
rufinamide	voltage-gated sodium channel blocker	GRM5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures	BRD-K20079257-001-09-6	Launched
rufloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	BRD-K62374253-001-07-8, BRD-K62374253-003-10-9, BRD-K62374253-003-10-9	Launched
rupatadine	histamine receptor antagonist, platelet activating factor receptor antagonist	HRH1, PTAFR	allergy	allergic rhinitis, urticaria	BRD-K98004573-051-03-9, BRD-K98004573-051-02-8	Launched
rutaecarpine	cyclooxygenase inhibitor	PTGS2			BRD-K94723713-001-12-9, BRD-K94723713-001-10-6, BRD-K94723713-001-10-6	Preclinical
ruxolitinib-(S)	JAK inhibitor	JAK1, JAK2			BRD-K19601669-001-04-9, BRD-K19601669-001-03-5, BRD-K19601669-001-03-5	Preclinical
RV1729	PI3K inhibitor				BRD-K00004579-001-01-9	Phase 1
RWJ-21757	toll-like receptor agonist	TLR7			BRD-K00091711-001-03-8, BRD-K00091711-001-02-0, BRD-K00091711-001-02-0, BRD-K00091711-001-01-2	Phase 2
RWJ-50271	integrin inhibitor	ICAM1			BRD-K94623186-001-01-5, BRD-K94623186-001-01-5, BRD-K94623186-001-02-9	Preclinical
RWJ-67657	MAP kinase inhibitor	MAPK14, PTGS2			BRD-K07074923-001-01-5, BRD-K07074923-001-01-5, BRD-K07074923-001-02-3, BRD-K07074923-001-02-3	Phase 1
RX-3117	CDK inhibitor, DNA synthesis inhibitor	CDK2, DNMT1			BRD-K66213167-001-02-0, BRD-K66213167-001-01-2, BRD-K66213167-001-01-2	Phase 1/Phase 2
RX-821002	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C			BRD-A65597028-003-08-1, BRD-A65597028-003-09-9, BRD-A65597028-003-07-3	Preclinical
ryuvidine	histone lysine methyltransferase inhibitor	CDK2, CDK4			BRD-K06426971-001-02-7, BRD-K06426971-001-02-7, BRD-K06426971-001-02-7, BRD-K06426971-001-02-7, BRD-K06426971-001-02-7, BRD-K06426971-001-04-9, BRD-K06426971-001-03-5	Preclinical
R112	SYK inhibitor	SYK			BRD-K23902832-001-01-7, BRD-K23902832-001-01-7, BRD-K23902832-001-01-7, BRD-K23902832-001-01-7, BRD-K23902832-001-01-7	Phase 1
R306465	HDAC inhibitor				BRD-K86687746-001-01-3, BRD-K86687746-001-01-3, BRD-K86687746-001-01-3, BRD-K86687746-001-01-3	Phase 1
R406	SYK inhibitor	RET, SYK			BRD-K20285085-074-04-5, BRD-K20285085-074-04-5, BRD-K20285085-074-03-7, BRD-K20285085-074-03-7, BRD-K20285085-074-03-7, BRD-K20285085-074-03-7, BRD-K20285085-074-03-7, BRD-K20285085-074-03-7, BRD-K20285085-074-03-7, BRD-K20285085-074-03-7, BRD-K20285085-001-07-1, BRD-K20285085-001-07-1, BRD-K20285085-001-07-1, BRD-K20285085-001-07-1	Phase 1
R547	CDK inhibitor	CDK1, CDK2, CDK4, CDK7			BRD-K52233191-001-03-9, BRD-K52233191-001-02-4, BRD-K52233191-001-02-4, BRD-K52233191-001-02-4	Phase 1
S-isopropylisothiourea	nitric oxide synthase inhibitor	NOS3			BRD-K10673031-004-03-9, BRD-K10673031-004-02-0	Preclinical
S-methylcysteine		CTSD, MGMT			BRD-K63123526-001-02-0, BRD-K63123526-001-02-0, BRD-K63123526-001-01-2	Phase 1
S-nitrosoglutathione	nitric oxide stimulant	PTPN1				Phase 1
S-sulfo-L-cysteine	glutamate receptor agonist				BRD-K59527975-236-01-8	Preclinical
S-trityl-L-cysteine	mitotic kinesin inhibitor				BRD-K09774593-001-03-9, BRD-K09774593-001-01-7, BRD-K09774593-001-02-9	Preclinical
S-07662	CAR antagonist	NR1I3			BRD-K37635256-001-02-9, BRD-K37635256-001-02-9, BRD-K37635256-001-02-9, BRD-K37635256-001-01-4	Preclinical
S-111	PARP inhibitor	PARP1			BRD-K60005752-001-02-9, BRD-K60005752-001-01-9, BRD-K60005752-001-01-9, BRD-K60005752-001-01-9, BRD-K60005752-001-01-9, BRD-K60005752-001-01-9	Phase 2
S-14506	serotonin receptor agonist	HTR1A			BRD-K46766488-003-03-8, BRD-K46766488-003-03-8, BRD-K46766488-003-04-9, BRD-K46766488-003-02-0, BRD-K46766488-003-02-0, BRD-K46766488-003-02-0	Preclinical
S-17092	prolyl endopeptidase inhibitor				BRD-K00004618-001-01-9	Preclinical
S-3304	matrix metalloprotease inhibitor				BRD-K00003475-001-01-9	Phase 1/Phase 2
S-38093	histamine receptor antagonist				BRD-K00003455-001-01-9	Preclinical
SA-47	FAAH inhibitor	FAAH			BRD-K99819791-001-02-9, BRD-K99819791-001-01-1	Preclinical
saccharin	DNA polymerase inhibitor	CA1, CA12, CA2, CA9			BRD-K46493214-001-06-7	Launched
saclofen	GABA receptor antagonist	GABBR1, GABBR2, KCTD12, KCTD16, KCTD8			BRD-A24122750-001-03-7, BRD-A24122750-001-03-7, BRD-A24122750-001-04-9	Preclinical
sacubitrilat	neprilysin inhibitor				BRD-K00003252-001-01-9	Preclinical
safflower-yellow	anti-inflammatory agent				BRD-A96503329-001-01-7	Preclinical
safinamide	dopamine reuptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor	MAOB	neurology/psychiatry	Parkinson's Disease	BRD-K92613113-001-03-9, BRD-K92613113-066-02-7	Launched
safingol	PKC inhibitor	TRPM3			BRD-K93944989-001-08-0, BRD-K93944989-001-10-9, BRD-K93944989-001-10-9	Phase 1
safranal	benzodiazepine receptor agonist	GABBR1			BRD-K90582192-001-01-9	Phase 2
SAG	smoothened receptor agonist	SMO, TRPC6			BRD-K99433989-001-02-9, BRD-K99433989-001-02-9, BRD-K99433989-001-02-9, BRD-K99433989-001-01-3, BRD-K99433989-001-01-3	Preclinical
salazodine					BRD-K15045219-001-01-8	Phase 2
salicin	anti-inflammatory agent				BRD-K64614248-001-13-9, BRD-K64614248-001-12-3, BRD-K64614248-001-11-5	Phase 1
salicyl-alcohol					BRD-K08493205-001-05-9, BRD-K08493205-001-04-9, BRD-K08493205-001-04-9	Preclinical
salicylamide	analgesic agent		neurology/psychiatry, endocrinology	pain relief, fever	BRD-K81130846-001-18-9, BRD-K81130846-001-17-4	Launched
salicylanilide	other antibiotic				BRD-K83036479-001-11-9, BRD-K83036479-001-09-2, BRD-K83036479-001-08-4	Preclinical
salidroside	beta amyloid protein neurotoxicity inhibitor	APP			BRD-K66030860-001-04-4, BRD-K66030860-001-03-6	Preclinical
salinomycin			infectious disease	coccidiosis	BRD-K23414042-236-05-9	Launched
salirasib	mTOR inhibitor	TRPA1			BRD-K98453471-001-03-9, BRD-K98453471-001-03-9, BRD-K98453471-001-01-7, BRD-K98453471-001-01-7	Phase 2
salmeterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm	BRD-K01826763-104-12-9, BRD-K01826763-104-11-9, BRD-K01826763-104-14-9, BRD-K01826763-104-13-9, BRD-K01826763-104-10-9	Launched
salsolinol-1-carboxylic-acid					BRD-A49952467-001-03-9, BRD-A49952467-001-02-4	Preclinical
salubrinal	eukaryotic translation initiation factor inhibitor	EIF2S1			BRD-A45107007-001-06-7, BRD-A45107007-001-03-4, BRD-A45107007-001-05-9, BRD-A45107007-001-05-9, BRD-A45107007-001-02-6, BRD-A45107007-001-02-6	Preclinical
salvianolic-acid-A	matrix metalloprotease inhibitor				BRD-K00005247-001-01-9	Phase 1
salvianolic-acid-B	EGFR inhibitor, metalloproteinase inhibitor	MMP9			BRD-K18898553-001-01-1, BRD-K18898553-001-01-1	Phase 2
salvinorin-A	opioid receptor agonist	OPRD1, OPRK1, OPRM1			BRD-K19284129-001-04-9, BRD-K19284129-001-02-6	Phase 1
sal003	eukaryotic translation initiation factor inhibitor	EIF2A			BRD-K01828772-001-06-9, BRD-K01828772-001-07-9, BRD-K01828772-001-07-9, BRD-K01828772-001-08-9, BRD-K01828772-001-13-9	Preclinical
SAM-315	serotonin receptor antagonist				BRD-K00004553-001-01-9	Preclinical
sameridine	opioid receptor modulator				BRD-K00004552-001-01-9	Preclinical
sanazole					BRD-K37747025-001-08-2	Phase 1
sancycline	antitumor agent				BRD-K00003242-001-01-9	Preclinical
sangivamycin	DNA inhibitor				BRD-K36169695-001-02-9, BRD-K36169695-001-02-9	Phase 1
sanguinarium-chloride	apoptosis stimulant	CASP3			BRD-K66898851-003-02-5, BRD-K66898851-003-02-5, BRD-K66898851-003-02-5, BRD-K66898851-003-03-3, BRD-K66898851-003-03-3, BRD-K66898851-003-03-3, BRD-K66898851-003-03-3, BRD-K66898851-003-03-3	Phase 1
SANT-1	smoothened receptor antagonist	SHH, SMO			BRD-K99741577-001-03-3, BRD-K99741577-001-04-9, BRD-K99741577-001-01-7, BRD-K99741577-001-01-7, BRD-K99741577-001-01-7, BRD-K99741577-001-02-5, BRD-K99741577-001-02-5	Preclinical
SANT-2	smoothened receptor antagonist	SHH, SMO			BRD-K35781423-001-02-4, BRD-K35781423-001-01-6, BRD-K35781423-001-01-6, BRD-K35781423-001-01-6, BRD-K35781423-001-01-6, BRD-K35781423-001-03-9	Preclinical
sapacitabine	DNA synthesis inhibitor				BRD-K00003214-001-01-9	Phase 3
sapropterin	phenylalanine 4-hydroxylase stimulant	NOS3, PAH, TH, TPH1	metabolism	hyperphenylalaninemia (HPA)	BRD-K36859431-300-04-9, BRD-K36859431-300-03-1, BRD-K36859431-300-02-3	Launched
saquinavir	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K09963420-066-14-9, BRD-K09963420-066-14-9, BRD-K09963420-066-12-5, BRD-K09963420-066-12-5, BRD-K09963420-066-13-9, BRD-K09963420-066-13-9	Launched
SAR-245409	PI3K inhibitor	MTOR, PIK3CG			BRD-K75308783-001-07-0	Phase 1/Phase 2
saracatinib	SRC inhibitor	ABL1, LCK, SRC, YES1			BRD-K19540840-001-09-4, BRD-K19540840-001-09-4, BRD-K19540840-001-09-4, BRD-K19540840-001-09-4, BRD-K19540840-001-09-4, BRD-K19540840-001-09-4, BRD-K19540840-001-09-4, BRD-K19540840-001-14-4, BRD-K19540840-001-14-4, BRD-K19540840-001-14-4, BRD-K19540840-001-14-4, BRD-K19540840-001-14-4, BRD-K19540840-001-14-4, BRD-K19540840-001-14-4, BRD-K19540840-001-14-4, BRD-K19540840-001-14-4	Phase 2/Phase 3
sarafloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-K08525451-003-06-0, BRD-K08525451-003-07-9, BRD-K08525451-003-05-2	Launched
sarcosine	glycine transporter inhibitor	SLC6A9			BRD-K51263939-001-08-6	Phase 2
sardomozide	S-adenosylmethionine decarboxylase inhibitor				BRD-K00003165-300-01-9	Preclinical
sari-59-801					BRD-A92448440-001-01-3, BRD-A92448440-001-01-3	Phase 1
saroglitazar	PPAR receptor agonist	PPARA, PPARG	endocrinology, cardiology, gastroenterology	diabetes mellitus, dyslipidemia, non-alcoholic steatohepatitis (NASH)	BRD-K79878800-239-02-9, BRD-K79878800-001-01-0	Launched
sarpogrelate	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C	endocrinology, cardiology, rheumatology	diabetes mellitus, angina pectoris, Raynaud's disease, atherosclerosis, Buerger's disease	BRD-A34358106-003-02-4, BRD-A34358106-003-01-6, BRD-A34358106-003-03-9, BRD-A34358106-003-03-9	Launched
SAR131675	VEGFR inhibitor	FLT4			BRD-K38904395-001-02-3, BRD-K38904395-001-03-9	Preclinical
SAR405	PI3K inhibitor	PIK3C3			BRD-K72868067-001-02-4, BRD-K72868067-001-02-4, BRD-K72868067-001-02-4, BRD-K72868067-001-02-4	Preclinical
SAR405838	MDM inhibitor	MDM2			BRD-K45349653-001-03-9, BRD-K45349653-001-03-9, BRD-K45349653-001-01-1, BRD-K45349653-001-01-1, BRD-K45349653-001-01-1, BRD-K45349653-001-01-1, BRD-K45349653-001-02-9, BRD-K45349653-001-02-9	Phase 1
SAR407899	rho associated kinase inhibitor	ROCK1			BRD-K56912469-003-02-0, BRD-K56912469-003-02-0, BRD-K56912469-003-01-2	Phase 2
sasapyrine	NFkB pathway inhibitor	PTGS1, PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	BRD-K48892307-001-05-8, BRD-K48892307-001-06-9, BRD-K48892307-001-04-1	Launched
savolitinib	c-Met inhibitor	MET			BRD-K98028353-001-02-8, BRD-K98028353-001-02-8, BRD-K98028353-001-01-0	Phase 3
saxagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	BRD-K00003546-001-01-9	Launched
SB-200646	serotonin receptor antagonist	HTR2B, HTR2C			BRD-K77677632-003-03-4, BRD-K77677632-003-03-4, BRD-K77677632-003-07-9, BRD-K77677632-003-02-6, BRD-K77677632-003-02-6	Preclinical
SB-202190	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1			BRD-K54330070-001-19-6, BRD-K54330070-001-16-2, BRD-K54330070-001-15-4	Preclinical
SB-203186	serotonin receptor antagonist	HTR4			BRD-K27141178-003-08-9, BRD-K27141178-003-07-3	Preclinical
SB-203580	p38 MAPK inhibitor	AKT1, ALOX5, CHEK1, CYP2D6, CYP3A4, GAK, GSK3B, LCK, MAPK1, MAPK10, MAPK11, MAPK12, MAPK14, MAPK8, MAPK9, PRKCA, RAF1, RIPK2, ROCK1, RPS6KB1, SGK1, SRC, TNF			BRD-K01826796-001-03-9, BRD-K01826796-003-02-9	Preclinical
SB-205384	GABA receptor modulator	GABRA3, GABRA5, GABRA6			BRD-A22707317-001-11-6, BRD-A22707317-001-11-6, BRD-A22707317-001-12-9, BRD-A22707317-001-12-9, BRD-A22707317-001-10-8, BRD-A22707317-001-10-8, BRD-A22707317-001-10-8	Preclinical
SB-206553	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			BRD-K36395411-003-03-0, BRD-K36395411-003-06-9, BRD-K36395411-003-02-2	Preclinical
SB-216641	serotonin receptor antagonist	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			BRD-K30867024-003-03-3, BRD-K30867024-003-03-3	Preclinical
SB-216763	glycogen synthase kinase inhibitor	CCNA2, CDK2, GSK3A, GSK3B			BRD-K59184148-001-21-6, BRD-K59184148-001-22-4	Preclinical
SB-218078	CHK inhibitor	CHEK1				Preclinical
SB-218795	tachykinin antagonist	TACR3			BRD-K61097567-001-09-3, BRD-K61097567-001-10-9, BRD-K61097567-001-08-5	Preclinical
SB-221284	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			BRD-K14807180-001-03-9, BRD-K14807180-001-02-5, BRD-K14807180-001-02-5	Preclinical
SB-222200	tachykinin antagonist	TACR3			BRD-K04414442-001-09-1, BRD-K04414442-001-09-1, BRD-K04414442-001-10-9, BRD-K04414442-001-08-3	Preclinical
SB-225002	CC chemokine receptor antagonist	CXCR2			BRD-K61323504-001-06-5, BRD-K61323504-001-06-5, BRD-K61323504-001-04-0, BRD-K61323504-001-04-0, BRD-K61323504-001-04-0, BRD-K61323504-001-04-0, BRD-K61323504-001-04-0	Preclinical
SB-228357	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			BRD-K15424032-001-04-4, BRD-K15424032-001-04-4, BRD-K15424032-001-03-6, BRD-K15424032-001-03-6	Preclinical
SB-2343	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG			BRD-K98795921-001-01-7, BRD-K98795921-001-01-7, BRD-K98795921-001-01-7, BRD-K98795921-001-01-7, BRD-K98795921-001-02-9	Phase 1
SB-239063	p38 MAPK inhibitor	MAPK11, MAPK14, PTGS2			BRD-K82091397-001-04-9, BRD-K82091397-001-03-0, BRD-K82091397-001-03-0, BRD-K82091397-001-03-0, BRD-K82091397-001-03-0, BRD-K82091397-001-03-0, BRD-K82091397-001-03-0	Preclinical
SB-242235	p38 MAPK inhibitor	HSPB1, MAPK14			BRD-K19412355-001-02-9, BRD-K19412355-001-01-0, BRD-K19412355-001-01-0, BRD-K19412355-001-01-0	Phase 1
SB-243213	serotonin receptor inverse agonist	HTR2A, HTR2B, HTR2C, HTR6			BRD-K99968849-300-01-4, BRD-K99968849-300-01-4, BRD-K99968849-300-01-4, BRD-K99968849-300-02-9	Phase 1
SB-258585	serotonin receptor antagonist	HTR6			BRD-K80639402-003-03-9, BRD-K80639402-003-02-9	Preclinical
SB-268262	calcitonin antagonist	CALCA			BRD-A91031770-001-01-8, BRD-A91031770-001-01-8, BRD-A91031770-001-01-8, BRD-A91031770-001-02-9, BRD-A91031770-001-02-9	Preclinical
SB-269970	serotonin receptor antagonist	HTR7			BRD-K24201553-003-12-3, BRD-K24201553-003-10-7, BRD-K24201553-003-13-9, BRD-K24201553-003-13-9, BRD-K24201553-003-11-5	Preclinical
SB-271046	serotonin receptor antagonist	HTR6			BRD-K82467063-003-01-5, BRD-K82467063-003-01-5, BRD-K82467063-003-04-9, BRD-K82467063-003-04-9, BRD-K82467063-003-04-9, BRD-K82467063-001-02-7, BRD-K82467063-001-02-7, BRD-K82467063-001-02-7	Phase 1
SB-297006	CC chemokine receptor antagonist	CCR3			BRD-K16107558-001-01-4, BRD-K16107558-001-02-9	Preclinical
SB-328437	CCR antagonist				BRD-K78720403-001-02-4, BRD-K78720403-001-01-6, BRD-K78720403-001-03-9	Preclinical
SB-334867	orexin receptor antagonist	HCRTR1, HCRTR2			BRD-K41567364-001-05-3, BRD-K41567364-001-04-6, BRD-K41567364-001-04-6, BRD-K41567364-001-04-6	Preclinical
SB-366791	TRPV antagonist	TRPV1			BRD-K61536336-001-02-5, BRD-K61536336-001-03-9, BRD-K61536336-001-03-9, BRD-K61536336-001-01-7, BRD-K61536336-001-01-7	Preclinical
SB-399885	serotonin receptor antagonist	HTR6			BRD-K03988082-001-01-7, BRD-K03988082-003-02-9	Preclinical
SB-408124	orexin receptor antagonist	HCRTR1, HCRTR2			BRD-K53913732-001-07-5, BRD-K53913732-001-06-7, BRD-K53913732-001-06-7, BRD-K53913732-001-05-9, BRD-K53913732-001-04-2	Preclinical
SB-415286	glycogen synthase kinase inhibitor	GSK3A, GSK3B, RPS6KB1			BRD-K76805682-001-18-9, BRD-K76805682-001-17-5, BRD-K76805682-001-17-5, BRD-K76805682-001-17-5, BRD-K76805682-001-15-9, BRD-K76805682-001-16-7	Preclinical
SB-431542	TGF beta receptor inhibitor	ACVR1C, TGFBR1			BRD-K67298865-001-08-2, BRD-K67298865-001-08-2, BRD-K67298865-001-10-8, BRD-K67298865-001-10-8, BRD-K67298865-001-09-0, BRD-K67298865-001-09-0	Preclinical
SB-452533	TRPV antagonist	TRPV1			BRD-K03665769-001-01-1, BRD-K03665769-001-02-9	Preclinical
SB-505124	ALK tyrosine kinase receptor inhibitor	TGFBR1			BRD-K40109029-001-02-9, BRD-K40109029-001-02-9, BRD-K40109029-001-02-9	Preclinical
SB-525334	TGF beta receptor inhibitor	TGFBR1			BRD-K37720887-001-07-8, BRD-K37720887-001-07-8, BRD-K37720887-001-08-6, BRD-K37720887-001-08-6	Preclinical
SB-612111	nociceptin/orphanin FQ receptor antagonist	OPRL1			BRD-K08333979-003-01-3, BRD-K08333979-003-02-9, BRD-K08333979-003-02-9	Preclinical
SB-649868	orexin receptor antagonist				BRD-K00003485-001-01-9	Phase 2
SB-657510	urotensin receptor antagonist	UTS2R			BRD-K95292280-001-02-1, BRD-K95292280-001-01-3, BRD-K95292280-001-01-3, BRD-K95292280-001-03-9	Preclinical
SB-683698	integrin antagonist	ITGA4, ITGAV, ITGB1, ITGB7			BRD-K24968862-001-01-0, BRD-K24968862-001-01-0, BRD-K24968862-001-01-0, BRD-K24968862-001-01-0, BRD-K24968862-001-02-9	Phase 1
SB-705498	TRPV antagonist	TRPV1			BRD-K65991129-001-02-9, BRD-K65991129-001-02-9, BRD-K65991129-001-02-9, BRD-K65991129-001-02-9, BRD-K65991129-001-03-9	Phase 2
SB-706375	urotensin receptor antagonist	UTS2R			BRD-K68633027-001-02-9, BRD-K68633027-001-01-9	Preclinical
SB-742457	serotonin receptor antagonist	HTR6			BRD-K78941306-001-03-2, BRD-K78941306-001-04-9, BRD-K78941306-001-02-4	Phase 3
SB-743921	kinesin-like spindle protein inhibitor	KIF11			BRD-K68532323-003-02-8, BRD-K68532323-003-02-8, BRD-K68532323-003-05-1	Phase 1/Phase 2
SB-747651A	kinase inhibitor	AKT1, AKT3, ROCK1, RPS6KA5, RPS6KB1			BRD-K49597925-300-02-9, BRD-K49597925-300-02-9, BRD-K49597925-300-02-9, BRD-K49597925-300-01-9	Preclinical
SB-756050	G protein-coupled receptor agonist	GPBAR1			BRD-K45168550-001-02-9, BRD-K45168550-001-01-9, BRD-K45168550-001-01-9	Phase 1
SB-772077B	rho associated kinase inhibitor	ROCK1, ROCK2			BRD-K49110935-300-01-9, BRD-K49110935-300-02-9	Preclinical
SB-939	HDAC inhibitor	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC9			BRD-K86797399-001-04-4, BRD-K86797399-001-04-4, BRD-K86797399-001-05-1, BRD-K86797399-001-05-1, BRD-K86797399-001-06-9, BRD-K86797399-001-06-9, BRD-K86797399-001-06-9	Phase 3
SBE-13	PLK inhibitor	PLK1			BRD-K71667152-003-09-8, BRD-K71667152-003-10-9	Preclinical
SBHA	HDAC inhibitor	HDAC1, HDAC3			BRD-K54729176-001-02-8, BRD-K54729176-001-03-9, BRD-K54729176-001-03-9	Preclinical
SBI-115	G protein-coupled receptor antagonist				BRD-K00005340-001-01-9	Preclinical
SC-10	protein kinase activator	PRKCA			BRD-K05361803-001-03-9, BRD-K05361803-001-04-9	Preclinical
SC-12267	dihydroorotate dehydrogenase inhibitor	IL17A			BRD-K40797222-001-01-8, BRD-K40797222-001-01-8, BRD-K40797222-001-01-8, BRD-K40797222-001-01-8, BRD-K40797222-001-01-8, BRD-K40797222-001-02-9	Phase 2
SC-144	P glycoprotein inhibitor				BRD-K55305701-003-03-9, BRD-K55305701-001-01-2, BRD-K55305701-001-01-2, BRD-K55305701-001-01-2, BRD-K55305701-001-01-2, BRD-K55305701-003-01-8, BRD-K55305701-001-02-0	Preclinical
SC-19220	prostanoid receptor antagonist	PTGER1			BRD-K52512893-001-09-7, BRD-K52512893-001-09-7, BRD-K52512893-001-10-9, BRD-K52512893-001-08-9	Preclinical
SC-236	cyclooxygenase inhibitor	PTGS2			BRD-K76365178-001-01-5, BRD-K76365178-001-01-5, BRD-K76365178-001-02-9	Preclinical
SC-51089	prostanoid receptor antagonist	PTGER1			BRD-K62715847-003-01-4, BRD-K62715847-003-02-9	Preclinical
SC-560	cyclooxygenase inhibitor	PTGS1			BRD-K14767410-001-03-1, BRD-K14767410-001-03-1, BRD-K14767410-001-04-9, BRD-K14767410-001-02-3	Preclinical
SC-9	protein tyrosine kinase activator	PRKCA			BRD-K25875056-001-03-8, BRD-K25875056-001-03-8, BRD-K25875056-001-03-8, BRD-K25875056-001-04-9, BRD-K25875056-001-02-0	Preclinical
scabertopin	anticancer agent				BRD-K00005327-001-01-9	Preclinical
SCH-202676	G protein-coupled receptor modulator	CHRM1, CHRM2, DRD1, DRD2			BRD-K29562203-004-09-1, BRD-K29562203-004-12-9, BRD-K29562203-004-08-3	Preclinical
SCH-221510	nociceptin/orphanin FQ receptor agonist	OPRL1			BRD-K00004286-001-01-9	Preclinical
SCH-23390	dopamine receptor antagonist	DRD1, DRD5, HTR2C, KCNJ4, KCNJ6			BRD-K45435259-003-12-9, BRD-K45435259-003-11-1	Preclinical
SCH-28080	ATPase inhibitor	ATP4A			BRD-K55748775-001-02-2, BRD-K55748775-001-03-9	Phase 1
SCH-51344	MTH1 inhibitor	NUDT1			BRD-K02460719-001-01-9, BRD-K02460719-001-02-9	Preclinical
SCH-58261	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K81225797-001-03-1, BRD-K81225797-001-02-3, BRD-K81225797-001-02-3, BRD-K81225797-001-02-3, BRD-K81225797-001-02-3, BRD-K81225797-001-02-3, BRD-K81225797-001-05-9	Preclinical
SCH-900776	CHK inhibitor	CDK2, CHEK1			BRD-K75009076-001-02-1, BRD-K75009076-001-02-1, BRD-K75009076-001-02-1, BRD-K75009076-001-02-1, BRD-K75009076-001-01-3	Phase 2
schisandrin-B	antioxidant	ATR			BRD-K00003711-001-01-9	Preclinical
schisandrol-B	lipid peroxidase inhibitor				BRD-K18878288-001-06-4, BRD-K18878288-001-07-2	Phase 3
sclareol					BRD-A23127772-001-02-3, BRD-A23127772-001-03-1	Preclinical
SCMC-Lys	mucolytic agent	GSTP1	pulmonary	chronic obstructive pulmonary disease (COPD)	BRD-K33809398-001-02-6, BRD-K33809398-001-01-8	Launched
scopine					BRD-K75923785-003-03-9, BRD-K75923785-003-02-1, BRD-K75923785-001-02-5, BRD-K75923785-001-02-5	Launched
scopolamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, SI	neurology/psychiatry, gastroenterology	motion sickness, vomiting, nausea	BRD-K89923877-004-15-4, BRD-K89923877-004-21-9, BRD-K89923877-004-20-9, BRD-K89923877-004-16-2	Launched
scopolamine-N-oxide	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4			BRD-A49906757-004-09-8, BRD-A49906757-004-10-6	Preclinical
SCP-1	analgesic agent				BRD-K20548681-001-02-9, BRD-K20548681-001-01-3	Phase 1
scriptaid	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			BRD-K22503835-001-12-8, BRD-K22503835-001-12-8, BRD-K22503835-001-11-0	Preclinical
SCS					BRD-K78496197-001-04-7, BRD-K78496197-001-03-9, BRD-K78496197-001-03-9, BRD-K78496197-001-05-9	Preclinical
SD-0006	p38 MAPK inhibitor				BRD-K00003093-001-01-9	Phase 2
SD-169	p38 MAPK inhibitor	MAPK14			BRD-K91904471-001-02-4	Preclinical
SD-208	TGF beta receptor inhibitor	TGFBR1			BRD-K24566386-001-01-9, BRD-K24566386-001-01-9, BRD-K24566386-001-03-5	Preclinical
SD-2590	matrix metalloprotease inhibitor	MMP1, MMP13, MMP2			BRD-K51102532-003-02-9, BRD-K51102532-003-01-8, BRD-K51102532-003-01-8	Preclinical
SDM25N	opioid receptor antagonist	OPRD1			BRD-K01826797-003-04-9, BRD-K01826797-003-03-9, BRD-K01826797-003-02-9, BRD-K01826797-003-02-9, BRD-K01826797-003-02-9	Preclinical
SDZ-NKT-343	tachykinin antagonist	TACR1			BRD-K65820248-001-02-6, BRD-K65820248-001-02-6, BRD-K65820248-001-01-8, BRD-K65820248-001-01-8, BRD-K65820248-001-03-9	Phase 1
SDZ-SER-082	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C			BRD-K31339597-051-03-9, BRD-K31339597-051-02-0	Preclinical
SDZ-WAG-994	adenosine receptor agonist	ADORA1			BRD-K39558284-001-02-0, BRD-K39558284-001-01-2, BRD-K39558284-001-01-2, BRD-K39558284-001-03-9	Phase 2
SDZ-205-557	serotonin receptor antagonist	HTR3A, HTR3B			BRD-K15868788-003-08-9, BRD-K15868788-003-07-7	Preclinical
SDZ-21009	adrenergic receptor antagonist, serotonin receptor antagonist	HTR1A, HTR1B			BRD-A15530910-001-03-9, BRD-A15530910-001-02-1, BRD-A15530910-001-02-1	Preclinical
SDZ-220-040	glutamate receptor antagonist	GRIN1			BRD-K82266792-001-03-9, BRD-K82266792-001-02-1	Preclinical
SDZ-220-581	glutamate receptor antagonist	GRIN1			BRD-K27168049-001-03-6, BRD-K27168049-001-03-6, BRD-K27168049-001-04-9, BRD-K27168049-001-02-8	Preclinical
Se-methylselenocysteine					BRD-K74227499-001-02-9, BRD-K74227499-001-01-1	Phase 2
secalciferol	vitamin D receptor agonist	VDR	critical care	bone fracture	BRD-K02965577-001-04-9, BRD-K02965577-001-04-9, BRD-K02965577-001-03-4, BRD-K02965577-001-03-4	Launched
seclazone	anti-inflammatory agent				BRD-A53472930-001-01-7	Phase 1
seclidemstat	histone demethylase inhibitor				BRD-K00003454-001-01-9	Phase 1
secnidazole	acetylcholinesterase inhibitor, microtubule inhibitor		infectious disease	protozoan infection	BRD-A70083328-001-23-5, BRD-A70083328-001-22-7, BRD-A70083328-001-22-7, BRD-A70083328-001-22-7, BRD-A70083328-001-24-3	Launched
secoisolariciresinol-(-)					BRD-K91733562-001-05-0, BRD-K91733562-001-05-0, BRD-K91733562-001-06-9	Phase 2
secoisolariciresinol-diglucoside	antioxidant				BRD-K77320845-001-01-2	Phase 2
securinine	GABA receptor antagonist, TP53 activator	GABRA1			BRD-K49071277-001-05-9, BRD-K49071277-001-05-9, BRD-K49071277-001-04-7, BRD-K49071277-001-04-7	Preclinical
segesterone-acetate	progesterone receptor agonist	PGR			BRD-K00003150-001-01-9	Launched
seladelpar	PPAR receptor agonist				BRD-K00003284-236-01-9	Phase 3
selamectin	nematocide		infectious disease	flea control	BRD-K00003549-001-01-9	Launched
selegiline	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	Parkinson's Disease	BRD-K86434416-003-16-9	Launched
selenomethionine					BRD-K74664543-001-01-1, BRD-K74664543-213-01-2	Launched
seletalisib	PI3K inhibitor				BRD-K00003228-001-01-9	Preclinical
selexipag	IP1 prostacyclin receptor agonist, platelet aggregation inhibitor	PTGIR	pulmonary	pulmonary arterial hypertension (PAH)	BRD-K21191422-001-02-3, BRD-K21191422-001-01-5	Launched
selfotel	glutamate receptor antagonist	GRIN2A, GRIN2B, GRIN2C, GRIN2D			BRD-K48738253-001-02-4, BRD-K48738253-001-03-9, BRD-K48738253-001-03-9	Phase 3
selinexor	exportin antagonist	XPO1	hematologic malignancy	multiple myeloma	BRD-K21361524-001-04-9, BRD-K21361524-001-01-1, BRD-K21361524-001-01-1, BRD-K21361524-001-01-1, BRD-K21361524-001-01-1	Launched
selitrectinib	protein tyrosine kinase inhibitor				BRD-K00003441-001-01-9	Phase 1/Phase 2
selonsertib	MAP kinase activator				BRD-K00003274-001-01-9	Phase 2
selumetinib	MEK inhibitor	MAP2K1			BRD-K57080016-001-19-1, BRD-K57080016-001-19-1, BRD-K57080016-001-19-1, BRD-K57080016-001-15-9, BRD-K57080016-001-15-9, BRD-K57080016-001-15-9, BRD-K57080016-001-15-9, BRD-K57080016-001-15-9	Phase 3
semagacestat	gamma secretase inhibitor	PSEN1			BRD-K65592642-001-05-9	Phase 3
semapimod	cytokine production inhibitor, p38 MAPK inhibitor	MAPK14			BRD-K21237892-376-01-3, BRD-K21237892-376-01-3, BRD-K21237892-376-01-3	Phase 2
semaxanib	VEGFR inhibitor	FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET			BRD-K63504947-001-15-4, BRD-K63504947-001-15-4, BRD-K63504947-001-14-7, BRD-K63504947-001-14-7, BRD-K63504947-001-16-2, BRD-K63504947-001-16-2, BRD-K63504947-001-18-9, BRD-K63504947-001-17-0, BRD-K63504947-001-17-0	Phase 3
semustine	DNA alkylating agent				BRD-K13281575-001-13-4, BRD-K13281575-001-14-2	Phase 3
SEN-1269	beta amyloid inhibitor	APP			BRD-K70614402-001-02-9, BRD-K70614402-001-01-0	Preclinical
senicapoc	intermediate conductance potassium channel blocker	KCNN4			BRD-K21295289-001-02-9, BRD-K21295289-001-02-9, BRD-K21295289-001-01-6	Phase 3
sennoside-A	glycoside agonist		gastroenterology	constipation	BRD-A30370660-001-04-1, BRD-A30370660-001-04-1	Launched
sennoside-protonated					BRD-A53504839-001-01-9, BRD-A53504839-001-01-9	Preclinical
seocalcitol	vitamin D receptor agonist	VDR			BRD-K28456624-001-03-9, BRD-K28456624-001-02-9, BRD-K28456624-001-02-9, BRD-K28456624-001-02-9, BRD-K28456624-001-01-1, BRD-K28456624-001-01-1	Phase 3
SEP-227900	D-amino acid oxidase Inhibitor	DAO			BRD-K49504902-001-02-9, BRD-K49504902-001-01-6	Phase 1
seratrodast	prostanoid receptor antagonist	TBXA2R	pulmonary	asthma	BRD-A60765580-001-03-4, BRD-A60765580-001-01-8, BRD-A60765580-001-02-6	Launched
serdemetan	MDM inhibitor	MDM2			BRD-K65924316-001-07-2, BRD-K65924316-001-07-2, BRD-K65924316-001-07-2, BRD-K65924316-001-07-2, BRD-K65924316-001-07-2, BRD-K65924316-001-03-1	Phase 1
serotonin	growth factor receptor activator	DRD1, DRD5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR3B, HTR4, HTR5A, HTR6, HTR7, SLC36A1	neurology/psychiatry	anxiety, depression, sleeplessness	BRD-K38580127-003-15-4, BRD-K38580127-003-16-2, BRD-K38580127-003-17-0	Launched
sertindole	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2			BRD-K69116396-001-04-1, BRD-K69116396-001-04-1, BRD-K69116396-001-04-1, BRD-K69116396-001-04-1, BRD-K69116396-001-05-9	Withdrawn
setipiprant	prostaglandin inhibitor	PTGDR2			BRD-K24497734-001-01-6	Phase 3
setiptiline	adrenergic receptor antagonist	HRH1, HTR2A, HTR2C	neurology/psychiatry	depression	BRD-K36732695-001-02-9, BRD-K36732695-001-01-9	Launched
setmelanotide	melanocortin receptor agonist				BRD-K00003298-001-01-9	Phase 3
sevoflurane	membrane integrity inhibitor	ATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GLRA1, GLRB, GRIA1, KCNA1, KCNK10, KCNK18, KCNK2, KCNK3, KCNK9, MT-ND1	neurology/psychiatry	anesthetic	BRD-K05638300-001-02-0, BRD-K05638300-001-01-2	Launched
SEW-2871	lysophospholipid receptor agonist	S1PR1			BRD-K15601958-001-03-9, BRD-K15601958-001-05-9	Preclinical
SF-11	neuropeptide receptor antagonist	MCOLN3, NPY2R			BRD-K42629487-001-08-6, BRD-K42629487-001-09-9	Preclinical
SGC-CBP30	bromodomain inhibitor	CREBBP, EP300			BRD-K24821794-001-04-8, BRD-K24821794-001-04-8, BRD-K24821794-001-01-4, BRD-K24821794-001-01-4, BRD-K24821794-001-01-4, BRD-K24821794-001-01-4	Preclinical
SGC-0946	histone lysine methyltransferase inhibitor				BRD-K69577666-001-03-9, BRD-K69577666-001-01-3, BRD-K69577666-001-01-3, BRD-K69577666-001-01-3, BRD-K69577666-001-01-3	Preclinical
SGC-707	protein arginine N-methyltransferase inhibitor	PRMT3			BRD-K86718786-001-01-7, BRD-K86718786-001-03-9, BRD-K86718786-001-03-9	Preclinical
SGI-1027	DNA methyltransferase inhibitor	DNMT1, DNMT3A, DNMT3B			BRD-K61228301-001-03-9, BRD-K61228301-001-01-2, BRD-K61228301-001-01-2, BRD-K61228301-001-01-2	Preclinical
SGI-1776	Pim kinase inhibitor	FLT3, PIM1, PIM2, PIM3			BRD-K80700417-001-07-9, BRD-K80700417-001-07-9, BRD-K80700417-001-04-2, BRD-K80700417-001-04-2, BRD-K80700417-001-04-2, BRD-K80700417-001-04-2, BRD-K80700417-001-04-2, BRD-K80700417-001-04-2	Phase 1
SGS-742	GABA receptor antagonist	GABBR1, GABBR2			BRD-K00004650-001-01-9	Preclinical
SGX523	hepatocyte growth factor receptor inhibitor	MET			BRD-K19477839-001-07-6, BRD-K19477839-001-07-6, BRD-K19477839-001-07-6	Phase 1
SHA-68	neuropeptide receptor antagonist	NPSR1			BRD-A63344375-001-02-9, BRD-A63344375-001-01-8	Preclinical
shikimic-acid					BRD-A92096630-001-02-8, BRD-A92096630-001-03-6	Preclinical
SHP099	protein tyrosine kinase inhibitor	PTPN11			BRD-K00818915-001-02-9, BRD-K00818915-003-01-8, BRD-K00818915-003-01-8, BRD-K00818915-003-01-8	Preclinical
SIB-1553A	acetylcholine receptor agonist	CHRNB4			BRD-K01826006-003-01-9	Phase 2
SIB-1757	glutamate receptor antagonist	GRM5			BRD-K98157055-001-11-9, BRD-K98157055-001-10-9, BRD-K98157055-001-10-9, BRD-K98157055-001-10-9, BRD-K98157055-001-10-9, BRD-K98157055-001-10-9	Preclinical
SIB-1893	glutamate receptor antagonist	GRM4, GRM5			BRD-K14561059-001-06-9, BRD-K14561059-001-05-9	Preclinical
SID-7969543	steroidogenic factor antagonist	NR5A1			BRD-A43885598-001-09-9, BRD-A43885598-001-08-1, BRD-A43885598-001-10-9	Preclinical
siguazodan	phosphodiesterase inhibitor	PDE3A			BRD-A62071884-001-06-1, BRD-A62071884-001-04-6, BRD-A62071884-001-04-6	Phase 1
sildenafil	phosphodiesterase inhibitor	PDE5A, PDE6G, PDE6H, SLCO1B1, SLCO1B3	urology	erectile dysfunction	BRD-K79759585-048-07-1, BRD-K79759585-048-04-8, BRD-K79759585-048-04-8, BRD-K79759585-048-03-0, BRD-K79759585-048-12-9, BRD-K79759585-048-12-9	Launched
silodosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology	benign prostatic hyperplasia (BPH)	BRD-K10906636-001-03-9, BRD-K10906636-001-01-1, BRD-K10906636-001-02-9	Launched
silymarin					BRD-A06629414-001-02-3, BRD-A06629414-001-03-1, BRD-A06629414-001-04-9	Launched
simeprevir	HCV inhibitor	CYP1A2, CYP3A4	infectious disease	hepatitis C	BRD-K00003545-001-01-9, BRD-K00003545-001-01-9	Launched
simurosertib	kinase inhibitor				BRD-K00004727-001-01-9	Preclinical
sincalide	cholecystokinin agonist				BRD-K00003334-001-01-9	Preclinical
sinefungin	DNA methyltransferase inhibitor, RNA synthesis inhibitor	CARM1			BRD-K91100918-001-03-8, BRD-K91100918-001-03-8	Preclinical
sinomenine	angiogenesis inhibitor				BRD-K83459933-001-05-4, BRD-K83459933-003-06-9	Preclinical
sipatrigine	voltage-gated sodium channel blocker	CACNA1D, SCN10A, SCN1A, SCN3A, SCN4A, SCN5A, SCN9A			BRD-K53195974-001-02-7, BRD-K53195974-001-01-9	Phase 2
siponimod	sphingosine 1-phosphate receptor modulator	S1PR1	neurology/psychiatry	multiple sclerosis	BRD-K62384160-001-02-0, BRD-K62384160-001-02-0, BRD-K62384160-001-02-0, BRD-K62384160-001-02-0, BRD-K62384160-001-01-2	Launched
siramesine	sigma receptor antagonist	ADRA1A, ADRA1B, ADRA1D			BRD-K51333959-003-01-3, BRD-K51333959-003-01-3, BRD-K51333959-003-02-9	Phase 2
siremadlin	MDM inhibitor				BRD-K65480835-001-02-9	Preclinical
SirReal-2	SIRT inhibitor	SIRT2			BRD-K16472653-001-01-6, BRD-K16472653-001-01-6, BRD-K16472653-001-02-4	Preclinical
sirtinol	SIRT inhibitor	SIRT1, SIRT2			BRD-A23747351-001-06-8, BRD-A23747351-001-07-6, BRD-A23747351-001-08-9, BRD-A23747351-001-05-0	Preclinical
sisomicin-sulfate	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	BRD-A68997559-065-04-5	Launched
SIS3	serine/threonine kinase inhibitor	SMAD3, TGFBR1			BRD-K38905597-003-01-4, BRD-K38905597-003-02-9	Preclinical
sitaxentan	endothelin receptor antagonist	EDNRA, EDNRB			BRD-K63806092-236-05-9, BRD-K63806092-236-06-9, BRD-K63806092-236-03-4, BRD-K63806092-236-02-6, BRD-K63806092-236-04-2	Withdrawn
sitravatinib	receptor tyrosine protein kinase inhibitor				BRD-K00003238-001-01-9	Phase 3
sivelestat	elastase inhibitor	CELA1, ELANE	pulmonary	acute lung injury	BRD-K02152879-236-01-0, BRD-K02152879-414-02-1, BRD-K02152879-414-01-3, BRD-K02152879-414-01-3	Launched
SJ-172550	MDM inhibitor	MDM4			BRD-K35945299-001-04-2, BRD-K35945299-001-03-4, BRD-K35945299-001-02-6	Preclinical
SJ-733	ATPase inhibitor				BRD-K34798115-001-02-9	Phase 1
SJG-136	DNA intercalating agent				BRD-K00003173-001-01-9	Phase 2
SK&F-10047-(+)	sigma receptor agonist	SIGMAR1			BRD-K00004226-003-01-9, BRD-K00004226-003-01-9	Phase 1
SKA-31	potassium channel activator	KCNN4			BRD-K67304264-001-10-1, BRD-K67304264-001-08-5, BRD-K67304264-001-11-9, BRD-K67304264-001-11-9	Preclinical
skepinone-L	p38 MAPK inhibitor	MAPK14			BRD-K83607951-001-02-2, BRD-K83607951-001-02-2, BRD-K83607951-001-02-2, BRD-K83607951-001-04-9	Preclinical
SKF-38393	dopamine receptor agonist	CALY, DRD1, DRD5			BRD-K01826815-004-03-9, BRD-K01826815-004-03-9, BRD-K01826815-004-02-9, BRD-K01826815-004-02-9	Preclinical
SKF-77434	dopamine receptor agonist	DRD1			BRD-A64227845-004-10-9, BRD-A64227845-004-10-9, BRD-A64227845-004-09-3	Preclinical
SKF-81297	dopamine receptor agonist	DRD1, DRD5			BRD-A09828896-004-12-8, BRD-A09828896-004-12-8, BRD-A09828896-004-11-0, BRD-A09828896-004-11-0, BRD-A09828896-004-11-0	Preclinical
SKF-83566	dopamine receptor antagonist	DRD1, DRD5			BRD-A52588987-004-09-0, BRD-A52588987-004-08-2, BRD-A52588987-004-08-2	Preclinical
SKF-86002	p38 MAPK inhibitor	ALOX5, MAPK14			BRD-K96809896-300-03-9, BRD-K96809896-300-02-3, BRD-K96809896-300-02-3	Preclinical
SKF-89976A	GABA uptake inhibitor	SLC6A1			BRD-K01826728-003-08-9, BRD-K01826728-003-10-9, BRD-K01826728-003-07-9, BRD-K01826728-003-07-9	Preclinical
SKF-91488	histamine N-methyltransferase inhibitor	HNMT			BRD-K49776472-300-03-2, BRD-K49776472-300-04-9, BRD-K49776472-300-02-4	Preclinical
SKF-96365	calcium channel blocker	CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2			BRD-K01826819-003-04-9, BRD-K01826819-003-04-9, BRD-K01826819-003-04-9, BRD-K01826819-003-04-9	Preclinical
SKI-II	sphingosine kinase inhibitor	SPHK1			BRD-K20755323-001-06-7, BRD-K20755323-001-06-7, BRD-K20755323-001-05-9, BRD-K20755323-001-07-5, BRD-K20755323-001-07-5, BRD-K20755323-001-07-5	Preclinical
SKLB-1028	Abl kinase inhibitor, EGFR inhibitor, FLT3 inhibitor				BRD-K00004690-001-01-9	Preclinical
SKLB1002	VEGFR inhibitor	KDR			BRD-K29895144-001-01-0, BRD-K29895144-001-02-9, BRD-K29895144-001-02-9	Preclinical
SLV-319-(+/-)	cannabinoid receptor antagonist	CNR1, DRD2, HTR1A			BRD-K00004304-001-01-9	Phase 2
SLV-320	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K34445261-001-02-2, BRD-K34445261-001-02-2, BRD-K34445261-001-02-2, BRD-K34445261-001-01-4	Phase 2
SM-108					BRD-K70053378-001-02-9, BRD-K70053378-001-01-1	Phase 2
SM-164	XIAP inhibitor	BIRC2, BIRC3, XIAP			BRD-K06191411-001-02-5, BRD-K06191411-001-01-7	Preclinical
SM-21	sigma receptor antagonist	PGRMC1			BRD-K00004213-050-01-9	Preclinical
SMER-28	autophagy inducer	SNCA			BRD-K08478539-001-13-8, BRD-K08478539-001-13-8, BRD-K08478539-001-06-2, BRD-K08478539-001-06-2, BRD-K08478539-001-06-2	Preclinical
SMI-4a	Pim kinase inhibitor	PIM1			BRD-K98396737-001-05-9	Preclinical
SN-2	transient receptor potential channel agonist	MCOLN3			BRD-K00004310-001-01-9	Preclinical
SN-38	topoisomerase inhibitor	TOP1	oncology	colorectal cancer	BRD-K89561498-001-03-3, BRD-K89561498-001-02-5, BRD-K89561498-001-02-5, BRD-K89561498-001-04-9, BRD-K89561498-001-01-7, BRD-K89561498-001-01-7, BRD-K89561498-001-01-7	Launched
SN-6	sodium/calcium exchange inhibitor				BRD-K01825672-001-01-9, BRD-K01825672-001-02-9, BRD-K01825672-001-04-9	Preclinical
SNAP	nitric oxide donor	PTPN1			BRD-A67006024-001-05-5, BRD-A67006024-001-04-8	Phase 2
SNAP-5089	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CACNA1C, CACNA1D			BRD-A21428877-003-02-7, BRD-A21428877-003-03-9	Preclinical
SNAP-94847		ADRA1A, DRD2			BRD-K49702221-003-02-4, BRD-K49702221-003-02-4, BRD-K49702221-003-02-4, BRD-K49702221-003-01-6, BRD-K49702221-003-03-9	Preclinical
SNC-80		OPRD1			BRD-K29546239-001-04-9, BRD-K29546239-001-05-9, BRD-K29546239-001-02-3	Preclinical
SNG-1153	selective estrogen receptor modulator (SERM)	ESR1			BRD-K75016267-001-02-9, BRD-K75016267-001-01-7	Preclinical
SNS-314	Aurora kinase inhibitor	AURKA, AURKB, AURKC			BRD-K71512533-066-03-6, BRD-K71512533-066-03-6, BRD-K71512533-066-03-6, BRD-K71512533-066-02-8	Phase 1
SNX-2112	HSP inhibitor				BRD-K71281111-001-04-3, BRD-K71281111-001-04-3	Phase 1
SNX-5422	HSP inhibitor	HSP90AA1, HSP90AB1			BRD-K73197500-001-04-8, BRD-K73197500-001-04-8, BRD-K73197500-001-02-2, BRD-K73197500-001-02-2, BRD-K73197500-001-03-0	Phase 1/Phase 2
sobetirome	thyroid hormone receptor agonist	THRA, THRB			BRD-K85406984-001-03-9, BRD-K85406984-001-03-9, BRD-K85406984-001-02-8, BRD-K85406984-001-02-8, BRD-K85406984-001-01-0, BRD-K85406984-001-01-0, BRD-K85406984-001-01-0	Phase 1/Phase 2
soblidotin	microtubule inhibitor				BRD-K00003174-001-01-9	Phase 2
sobrepin	mucolytic agent		pulmonary	chest congestion	BRD-K58262380-001-01-0	Launched
sobuzoxane	topoisomerase inhibitor		hematologic malignancy	peripheral T-cell lymphoma (PTCL)	BRD-K87595680-001-05-9	Launched
sodium-ascorbate					BRD-A67265925-236-01-8, BRD-A67265925-236-02-6	Launched
sodium-butyrate	HDAC inhibitor	BCHE, FFAR2, FFAR3, HDAC1, HDAC2, HDAC3, HDAC8			BRD-K05878375-236-05-7, BRD-K05878375-236-06-5, BRD-K05878375-236-06-5	Phase 2
sodium-danshensu					BRD-A93699261-236-02-6, BRD-A93699261-236-03-4, BRD-A93699261-236-04-2	Preclinical
sodium-dodecyl-sulfate		ALB			BRD-M58433298-001-02-4, BRD-M58433298-001-01-6	Launched
sodium-gualenate	antacid		gastroenterology, otolaryngology	peptic ulcer disease (PUD), pharyngitis	BRD-K80043866-236-01-1	Launched
sodium-monofluorophosphate		PYGM	dental	cavities	BRD-K99308954-304-03-2, BRD-K99308954-304-02-4, BRD-K99308954-304-04-0	Launched
sodium-nitrite	nitric oxide donor		critical care	poison antidote, cyanide poisoning	BRD-K61230716-236-02-7, BRD-K61230716-236-03-5	Launched
sodium-nitroprusside	nitric oxide donor		cardiology	hypertension, congestive heart failure	BRD-K00003606-380-01-9, BRD-K00003606-380-01-9	Launched
sodium-orthovanadate					BRD-K60600693-314-02-4, BRD-K60600693-314-03-2	Preclinical
sodium-picosulfate			gastroenterology	constipation	BRD-K77251551-304-03-9, BRD-K77251551-304-02-9	Launched
sodium-stibogluconate	tyrosine phosphatase inhibitor	PTPN6	infectious disease	leishmaniasis	BRD-K00003543-412-01-9	Launched
sodium-tanshinone-II-A-sulfonate	potassium channel activator				BRD-K84798689-236-02-9	Phase 2
sodium-tetradecyl-sulfate		PROC	dermatology	varicose veins	BRD-A55664972-236-02-6, BRD-A55664972-236-02-6, BRD-A55664972-236-02-6	Launched
sofalcone	mucus protecting agent	CBR1	gastroenterology	peptic ulcer disease (PUD)	BRD-K01039503-001-01-2, BRD-K01039503-001-01-2	Launched
sofosbuvir-impurity-m	antiviral				BRD-K00003527-001-01-9	Preclinical
sograzepide	gastrin inhibitor				BRD-K00004608-001-01-9	Phase 2
solamargine	apoptosis inhibitor				BRD-A65562236-001-01-2, BRD-A65562236-001-01-2, BRD-A65562236-001-01-2, BRD-A65562236-001-01-2	Phase 3
solcitinib	JAK inhibitor	JAK1			BRD-K69215269-001-01-1, BRD-K69215269-001-01-1	Phase 1
solifenacin-succinate	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence, urinary frequency	BRD-K00003600-001-01-9	Launched
solithromycin	protein synthesis inhibitor				BRD-K32256160-001-01-9	Phase 3
solriamfetol	dopamine reuptake inhibitor		neurology/psychiatry	narcolepsy	BRD-K00004707-001-01-9	Launched
somantadine	antiviral				BRD-K85764479-003-01-0	Phase 1
somatostatin	somatostatin receptor agonist	OPRD1, OPRM1, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5	hematology	hemorrhage	BRD-K14681867-001-01-6, BRD-K14681867-001-02-9	Launched
sonepiprazole	dopamine receptor antagonist				BRD-K69857269-001-03-9	Phase 2
sonidegib	smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	BRD-K19796430-001-05-6, BRD-K19796430-001-05-6, BRD-K19796430-001-09-8, BRD-K19796430-001-09-8	Launched
sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)	BRD-K23984367-075-15-2, BRD-K23984367-075-15-2, BRD-K23984367-075-15-2, BRD-K23984367-075-15-2, BRD-K23984367-001-07-5, BRD-K23984367-001-07-5, BRD-K23984367-001-07-5, BRD-K23984367-001-07-5	Launched
soraprazan	proton pump inhibitor				BRD-K00004585-001-01-9	Preclinical
sorbic-acid					BRD-K88734090-001-07-9	Launched
sorbinil	aldose reductase inhibitor	AKR1B1			BRD-A89164055-001-04-9, BRD-A89164055-001-03-3, BRD-A89164055-001-03-3, BRD-A89164055-001-03-3, BRD-A89164055-001-03-3	Phase 3
sorbitan-monostearate					BRD-A70197423-001-01-3, BRD-A70197423-001-02-9	Preclinical
sorbitol	mucolytic agent		gastroenterology	constipation	BRD-K66035042-001-15-9, BRD-K66035042-001-11-9, BRD-K66035042-001-10-1, BRD-K66035042-001-14-3	Launched
sotagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2			BRD-K05850076-001-01-5, BRD-K05850076-001-01-5, BRD-K05850076-001-02-9	Phase 3
sotalol	adrenergic receptor antagonist	ADRB1, ADRB2, KCNH2	cardiology	atrial fibrillation (AF), ventricular arrhythmias	BRD-A33168282-003-18-0, BRD-A33168282-003-18-0, BRD-A33168282-003-16-4, BRD-A33168282-003-17-2	Launched
sotrastaurin	PKC inhibitor	PRKCA, PRKCB, PRKCD, PRKCE, PRKCH, PRKCQ			BRD-K16761703-001-05-9, BRD-K16761703-001-05-9, BRD-K16761703-001-03-8	Phase 2
SP-100030	NFkB pathway inhibitor	JUN, NFKB1			BRD-K71900389-001-01-9, BRD-K71900389-001-02-9	Preclinical
SP-141	ubiquitin ligase inhibitor	MDM2			BRD-K28571773-001-01-6, BRD-K28571773-001-01-6, BRD-K28571773-001-02-9, BRD-K28571773-001-02-9, BRD-K28571773-001-02-9	Preclinical
SP-420					BRD-K23005288-001-01-8, BRD-K23005288-001-01-8	Phase 1
sparfosate	aspartate carbamoyltransferase inhibitor	CA2, CA4			BRD-A81539525-433-01-5	Phase 3
sparsentan	angiotensin receptor antagonist				BRD-K00003253-001-01-9	Phase 3
sparteine-(+)					BRD-K38203080-001-01-2	Launched
sparteine-(-)					BRD-K86872788-065-01-5	Launched
sparteine-sulfate					BRD-K32847234-065-04-6	Launched
spautin-1	deubiquitinase inhibitor	USP10, USP13			BRD-K84964099-001-03-9, BRD-K84964099-001-03-9, BRD-K84964099-001-02-9	Preclinical
spermidine	glutamate receptor modulator	KCNJ4, TXNRD1			BRD-K40438880-305-06-6, BRD-K40438880-305-06-6	Preclinical
spermine		CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5			BRD-K18375018-376-02-3	Preclinical
sphingosylphosphorylcholine	gene expression stimulant	GPR12			BRD-K01825110-001-02-9	Preclinical
spiperone	dopamine receptor antagonist	ADRA1A, ADRA1B, ADRA1D, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7	neurology/psychiatry	schizophrenia	BRD-K55468218-001-26-1, BRD-K55468218-003-02-8	Launched
spiradoline	opioid receptor agonist	OPRK1			BRD-K28192623-066-08-1, BRD-K28192623-066-08-1, BRD-K28192623-066-08-1, BRD-K28192623-066-08-1, BRD-K28192623-001-01-3	Phase 2
spiramycin	bacterial 50S ribosomal subunit inhibitor		infectious disease	toxoplasmosis, soft tissue infection	BRD-K00003542-001-01-9	Launched
spirobromin					BRD-K96684644-300-01-7	Phase 1
spiroxatrine	serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A, HTR2B			BRD-A72483914-001-05-9, BRD-A72483914-001-03-7	Preclinical
spizofurone					BRD-K94934625-001-01-5	Withdrawn
splitomycin	SIRT inhibitor	SIRT1			BRD-K27710560-001-07-5	Preclinical
SPP301	endothelin receptor antagonist	EDNRA			BRD-K19203487-001-01-4, BRD-K19203487-001-01-4	Phase 3
SPP86	receptor tyrosine protein kinase inhibitor	RET			BRD-K63253858-001-02-9, BRD-K63253858-001-01-5	Preclinical
SQ-109	bacterial cell wall synthesis inhibitor	FDFT1			BRD-A08772153-001-01-6, BRD-A08772153-001-02-4	Phase 3
SQ-22536	adenylyl cyclase inhibitor	ADCY1			BRD-A56987319-001-13-7, BRD-A56987319-001-12-9	Preclinical
squalamine	antiviral				BRD-K00003215-043-01-9	Phase 3
squaric-acid-dibutyl-ester	oxidative stress inducer				BRD-K00004684-001-01-9	Preclinical
SR-1078	retinoid receptor agonist	RORA, RORC			BRD-K26501486-001-02-9, BRD-K26501486-001-01-3	Preclinical
SR-11302					BRD-K16229414-001-02-9, BRD-K16229414-001-01-0	Preclinical
SR-140333	neurokinin receptor antagonist	TACR1			BRD-K60931454-003-01-3, BRD-K60931454-003-01-3, BRD-K60931454-003-02-9	Phase 2
SR-1664	PPAR receptor ligand	PPARG			BRD-K62814487-001-03-0, BRD-K62814487-001-04-8	Preclinical
SR-2211	retinoid receptor inverse agonist	RORC			BRD-K11641193-001-03-9, BRD-K11641193-001-02-6, BRD-K11641193-001-02-6	Preclinical
SR-2640	leukotriene receptor antagonist	CYSLTR1			BRD-K62562723-003-03-5, BRD-K62562723-003-08-9, BRD-K62562723-003-02-7	Phase 2
SR-27897	CCK receptor antagonist	CCKAR			BRD-K35629949-001-03-8, BRD-K35629949-001-02-0, BRD-K35629949-001-02-0, BRD-K35629949-001-02-0	Phase 2
SR-3306	JNK inhibitor	MAPK10, MAPK8, MAPK9			BRD-K60952143-001-01-0, BRD-K60952143-001-01-0, BRD-K60952143-001-01-0, BRD-K60952143-001-01-0	Preclinical
SR-33805	calcium channel blocker				BRD-K43002771-034-02-4, BRD-K43002771-034-02-4, BRD-K43002771-034-02-4, BRD-K43002771-034-01-6, BRD-K43002771-034-03-9	Phase 1
SR-3576	JNK inhibitor	MAPK10			BRD-K50378376-001-02-9, BRD-K50378376-001-02-9, BRD-K50378376-001-01-8	Preclinical
SR-3677	rho associated kinase inhibitor	ROCK2			BRD-A86468475-300-01-3, BRD-A86468475-300-02-9	Preclinical
SR-57227A	serotonin receptor agonist	HTR3A			BRD-K09397065-003-06-1, BRD-K09397065-003-07-9	Phase 2
SR-59230A	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			BRD-K35430135-003-03-1, BRD-K35430135-003-06-9, BRD-K35430135-003-02-3, BRD-K35430135-003-02-3	Preclinical
SR-95639A	acetylcholine receptor agonist	CHRM1			BRD-K19309090-300-05-5, BRD-K19309090-300-05-5	Preclinical
SRC-kinase-inhibitor-I	SRC inhibitor	CSK, LCK, RIPK2			BRD-K50495309-001-03-8, BRD-K50495309-001-03-8, BRD-K50495309-001-02-0	Preclinical
SRPIN340	serine arginine protein kinase inhibitor	SRPK1, SRPK2			BRD-K62621335-001-03-9, BRD-K62621335-001-02-5, BRD-K62621335-001-01-7, BRD-K62621335-001-01-7	Preclinical
SRT1720	SIRT activator	SIRT1			BRD-K95926480-003-03-6, BRD-K95926480-003-03-6, BRD-K95926480-003-03-6, BRD-K95926480-003-03-6, BRD-K95926480-003-06-9, BRD-K95926480-003-06-9	Preclinical
SRT2104	SIRT activator	SIRT1			BRD-K48452630-001-01-8, BRD-K48452630-001-02-6	Phase 2
SRT3190	CC chemokine receptor antagonist				BRD-K34801930-001-02-9, BRD-K34801930-001-01-9, BRD-K34801930-001-01-9	Preclinical
SSR128129E					BRD-K65890018-236-01-1, BRD-K65890018-236-02-9	Preclinical
SSR180711	acetylcholine receptor agonist	CHRNA7			BRD-K00004316-003-01-9	Phase 2
SSR240612	bradykinin receptor antagonist				BRD-K00003186-003-01-9	Preclinical
ST-1535	adenosine receptor antagonist				BRD-K00004706-001-01-9	Preclinical
ST-1859	antiamyloidogenic agent				BRD-K73524797-001-02-9, BRD-K73524797-001-01-1, BRD-K73524797-001-01-1, BRD-K73524797-001-01-1	Phase 1
ST-2825	myeloid differentiation primary response inhibitor	MYD88			BRD-K68470841-001-01-0	Preclinical
ST-91	adrenergic receptor agonist				BRD-K18905250-003-03-2, BRD-K18905250-003-02-4, BRD-K18905250-003-04-9, BRD-K18905250-003-04-9	Preclinical
STA-5326	interleukin synthesis inhibitor	IL12A			BRD-K41783120-001-02-8, BRD-K41783120-001-02-8, BRD-K41783120-001-02-8, BRD-K41783120-001-02-8, BRD-K41783120-001-04-4, BRD-K41783120-001-04-4, BRD-K41783120-001-04-4	Phase 2
statil	aldose reductase inhibitor				BRD-K68332390-001-04-9	Preclinical
stattic					BRD-K17061841-001-03-5	Preclinical
STAT3-inhibitor-VI	STAT inhibitor	STAT3			BRD-K40853697-001-20-5, BRD-K40853697-001-20-5, BRD-K40853697-001-19-7, BRD-K40853697-001-12-2, BRD-K40853697-001-17-1, BRD-K40853697-001-18-9	Preclinical
stemregenin-1	aryl hydrocarbon receptor antagonist	AHR			BRD-K36739687-001-03-0, BRD-K36739687-001-03-0, BRD-K36739687-001-03-0	Preclinical
stepronin	mucolytic agent				BRD-A04506385-001-01-2	Launched
stetaderm					BRD-K93900986-001-15-0, BRD-K93900986-001-15-0	Launched
STF-083010	serine/threonine kinase inhibitor	ERN1			BRD-K13049524-001-04-6, BRD-K13049524-001-03-8	Preclinical
STF-118804	NAMPT inhibitor	NAMPT			BRD-K39171998-001-05-9, BRD-K39171998-001-04-5, BRD-K39171998-001-04-5, BRD-K39171998-001-04-5, BRD-K39171998-001-01-1, BRD-K39171998-001-01-1	Preclinical
STF-31	NAMPT inhibitor	NAMPT, SLC2A1			BRD-K22477529-001-02-7, BRD-K22477529-001-02-7, BRD-K22477529-001-01-9, BRD-K22477529-001-01-9, BRD-K22477529-001-01-9, BRD-K22477529-001-01-9, BRD-K22477529-001-01-9, BRD-K22477529-001-01-9, BRD-K22477529-001-01-9, BRD-K22477529-001-01-9, BRD-K22477529-001-01-9, BRD-K22477529-001-01-9	Preclinical
STF-62247	autophagy inducer				BRD-K85479953-001-12-1, BRD-K85479953-001-11-3	Preclinical
stiripentol	GABA uptake inhibitor	GABRA3	neurology/psychiatry	epilepsy	BRD-A72441487-001-05-7, BRD-A72441487-001-05-7	Launched
stobadine	adrenergic receptor antagonist	ADRA1A			BRD-K33839500-001-01-0	Phase 2
strychnine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHRNA10, CHRNA9, GLRA1, GLRA2, GLRA3, GLRB			BRD-K72572686-001-02-9	Preclinical
substance-P	neurokinin receptor antagonist	TACR1, TACR2, TACR3			BRD-K23106423-001-01-0, BRD-K23106423-001-01-0, BRD-K23106423-001-01-0, BRD-K23106423-001-01-0	Phase 1
succinic-acid		ALDH5A1, ASPH, BBOX1, HSD17B6, OXCT1, OXCT2, P3H1, P3H2, P3H3, P4HA1, P4HA2, PLOD1, PLOD3, SDHA, SDHB, SDHC, SDHD, SLC13A1, SLC13A2, SLC13A3, SLC25A10, SUCLA2, SUCLG1, SUCLG2, SUCNR1, TMLHE			BRD-K45238818-001-02-6	Launched
succinobucol	antioxidant	VCAM1			BRD-K00003183-001-01-9	Phase 2/Phase 3
succinylcholine-chloride		CHRFAM7A, CHRM1, CHRM2, CHRM3, CHRNA1, CHRNA10	neurology/psychiatry	muscle relaxant	BRD-K45497762-336-03-2, BRD-K45497762-300-01-2, BRD-K45497762-336-01-6, BRD-K45497762-336-02-4	Launched
succinylsulfathiazole	dihydrofolate reductase inhibitor	DHFR			BRD-K01950558-001-15-9, BRD-K01950558-001-14-7	Phase 2
sucralfate	antacid		gastroenterology	duodenal ulcer disease	BRD-M71167108-001-01-3, BRD-M71167108-001-02-1	Launched
sucrose		ACTA1, ATOX1, C22orf28, LYZ			BRD-K74724920-001-02-4	Launched
sucrose-octaacetate					BRD-K01294196-001-01-5	Preclinical
sudan-IV					BRD-K00004524-001-01-9	Preclinical
sufugolix	gonadotropin releasing factor hormone receptor antagonist				BRD-K00004582-001-01-9	Preclinical
sugammadex	neuromuscular blockade reversal agent				BRD-K00003322-363-01-9	Launched
sulbactam-pivoxil	beta lactamase inhibitor		infectious disease	skin infections	BRD-A63431791-001-01-9	Launched
sulbutiamine	acetylcholine receptor antagonist		neurology/psychiatry	asthenia	BRD-K12539416-001-01-4	Launched
sulconazole	sterol demethylase inhibitor		infectious disease	tinea pedis, tinea cruris, tinea corporis	BRD-A70649075-008-30-8, BRD-A70649075-008-30-8, BRD-A70649075-008-30-8, BRD-A70649075-008-30-8, BRD-A70649075-008-30-8, BRD-A70649075-008-32-9, BRD-A70649075-008-29-0	Launched
sulfabenzamide	bacterial antifolate		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-K59983611-001-21-9, BRD-K59983611-001-21-9, BRD-K59983611-001-21-9	Launched
sulfacarbamide					BRD-K13486660-001-02-9, BRD-K13486660-001-01-0	Withdrawn
sulfacetamide	PABA antagonist		ophthalmology	conjunctivitis	BRD-K21520694-236-02-6, BRD-K21520694-001-21-4, BRD-K21520694-236-03-4	Launched
sulfachlorpyridazine	bacterial antifolate		infectious disease	urinary tract infections	BRD-K32021043-001-15-9, BRD-K32021043-001-14-3	Launched
sulfadiazine	bacterial antifolate		infectious disease, ophthalmology	malaria, meningitis, urinary tract infections, conjunctivitis, trachoma, chancroid	BRD-K32273377-001-20-9, BRD-K32273377-001-17-9, BRD-K32273377-001-15-3, BRD-K32273377-001-16-1	Launched
sulfadoxine	dihydropteroate synthase inhibitor		infectious disease	malaria	BRD-K55250441-001-17-9, BRD-K55250441-001-13-0, BRD-K55250441-001-13-0, BRD-K55250441-001-12-2	Launched
sulfafurazole	bacterial antifolate		infectious disease	urinary tract infections	BRD-K50859149-001-24-9, BRD-K50859149-001-24-9, BRD-K50859149-001-18-7, BRD-K50859149-001-19-5, BRD-K50859149-001-23-7, BRD-K50859149-001-17-9	Launched
sulfaguanidine	bacterial antifolate		infectious disease	urinary tract infections	BRD-K45086103-001-17-9, BRD-K45086103-001-15-5, BRD-K45086103-001-14-8, BRD-K45086103-001-16-3	Launched
sulfamerazine	bacterial antifolate		infectious disease	coccidiosis, cholera	BRD-K93524252-001-27-9, BRD-K93524252-001-24-7, BRD-K93524252-001-23-9, BRD-K93524252-001-23-9	Launched
sulfameter	dihydrofolate reductase inhibitor	DHFR	infectious disease	urinary tract infections	BRD-K87492696-001-18-9, BRD-K87492696-001-15-7, BRD-K87492696-001-16-5	Launched
sulfamethazine	PABA antagonist		gastroenterology	enteritis	BRD-K11640013-001-17-9, BRD-K11640013-236-10-1, BRD-K11640013-001-15-8, BRD-K11640013-001-14-1	Launched
sulfamethizole	bacterial antifolate		infectious disease	urinary tract infections	BRD-K31682896-001-26-9, BRD-K31682896-001-24-0, BRD-K31682896-001-23-2	Launched
sulfamethoxazole	PABA antagonist		infectious disease, gastroenterology	pneumonia, enteritis, urinary tract infections	BRD-K28494619-001-31-9, BRD-K28494619-001-28-2, BRD-K28494619-001-27-4	Launched
sulfamethoxypyridazine	bacterial antifolate				BRD-K00938507-001-18-9, BRD-K00938507-001-17-8, BRD-K00938507-001-16-0	Withdrawn
sulfametopyrazine	PABA antagonist		infectious disease	malaria, urinary tract infections, respiratory tract infections	BRD-K17205817-001-08-9, BRD-K17205817-001-06-1, BRD-K17205817-001-06-1, BRD-K17205817-001-06-1, BRD-K17205817-001-06-1	Launched
sulfamonomethoxine	bacterial antifolate		infectious disease	urinary tract infections	BRD-K14116214-001-12-9, BRD-K14116214-001-09-6	Launched
sulfamoxole	PABA antagonist		infectious disease	urinary tract infections	BRD-K19742012-001-02-3, BRD-K19742012-001-02-3, BRD-K19742012-001-01-5	Launched
sulfanilamide	carbonic anhydrase inhibitor	CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4	infectious disease	vulvovaginal candidiasis	BRD-K02594908-001-16-4, BRD-K02594908-001-15-6	Launched
sulfanitran			infectious disease	coccidiosis	BRD-K76845197-001-05-4, BRD-K76845197-001-07-9	Launched
sulfaphenazole	dihydropteroate synthetase inhibitor	DHPS	infectious disease	urinary tract infections	BRD-K10671814-001-17-9, BRD-K10671814-001-14-8, BRD-K10671814-001-14-8	Launched
sulfapyridine	PABA antagonist		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-K41406082-001-17-9, BRD-K41406082-001-15-4, BRD-K41406082-001-16-2, BRD-K41406082-001-16-2, BRD-K41406082-001-16-2, BRD-K41406082-001-16-2	Launched
sulfaquinoxaline	vitamin K antagonist		infectious disease	coccidiosis	BRD-K71133585-236-14-4, BRD-K71133585-236-14-4	Launched
sulfasalazine	cyclooxygenase inhibitor	ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1	gastroenterology	ulcerative colitis	BRD-K10670311-001-17-1, BRD-K10670311-001-15-5, BRD-K10670311-001-14-8, BRD-K10670311-001-14-8	Launched
sulfathiazole	dihydropteroate synthase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-K14705039-236-19-9, BRD-K14705039-001-16-4, BRD-K14705039-001-15-6	Launched
sulfatinib	tyrosine kinase inhibitor				BRD-K00003125-001-01-9	Phase 1
sulfinpyrazone	uricosuric blocker	ABCC1, FPR1, SLC22A12	rheumatology	gout	BRD-K00004525-001-01-9	Launched
sulfisomidin	antibacterial				BRD-K52416806-001-05-9	Preclinical
sulforaphane	anticancer agent, aryl hydrocarbon receptor antagonist	NFE2L2			BRD-A58955223-001-03-8, BRD-A58955223-001-03-8, BRD-A58955223-001-03-8	Phase 2
sulindac	cyclooxygenase inhibitor	AKR1B1	rheumatology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis	BRD-K01827279-001-20-9, BRD-K01827279-001-11-9, BRD-K01827279-001-10-9, BRD-K01827279-001-13-9, BRD-K01827279-001-12-9	Launched
sulmazole	adenosine receptor antagonist				BRD-K01824719-001-08-9, BRD-K01824719-001-07-9, BRD-K01824719-001-07-9	Phase 1
sulmetozine	gastrin inhibitor	GAST	gastroenterology	peptic ulcer disease (PUD)	BRD-K29570907-001-07-3, BRD-K29570907-001-07-3	Launched
suloctidil	adrenergic receptor antagonist				BRD-K42635745-001-26-9	Withdrawn
sulopenem	antibacterial				BRD-K00004713-001-01-9	Phase 3
sulphadimethoxine	dihydropteroate synthetase inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-K71125014-001-31-9, BRD-K71125014-001-31-9, BRD-K71125014-001-26-3, BRD-K71125014-001-27-1	Launched
sultamicillin	antibacterial 		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-K00004694-001-01-9	Launched
sultiame	carbonic anhydrase inhibitor	CA2			BRD-K00003488-001-01-9	Phase 3
sultopride	dopamine receptor antagonist				BRD-K00003312-003-01-9	Preclinical
sumanirole	dopamine receptor agonist	DRD2			BRD-K30485548-050-01-6	Phase 3
sumatriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR5A, HTR6, HTR7	neurology/psychiatry	migraine headache	BRD-K50938287-001-09-0, BRD-K50938287-036-16-1, BRD-K50938287-036-12-0, BRD-K50938287-036-13-8	Launched
SUN-B-8155	calcitonin agonist	CALCR			BRD-K36274133-001-02-0, BRD-K36274133-001-01-2, BRD-K36274133-001-03-9	Preclinical
SUN-11602	fibroblast growth factor mimetic	FGFR1			BRD-K71250460-001-02-9, BRD-K71250460-001-02-9, BRD-K71250460-001-01-1	Preclinical
sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)	BRD-K42828737-001-03-3, BRD-K42828737-001-03-3, BRD-K42828737-001-03-3, BRD-K42828737-001-03-3, BRD-K42828737-044-09-0, BRD-K42828737-044-09-0, BRD-K42828737-044-10-8, BRD-K42828737-044-10-8, BRD-K42828737-044-10-8, BRD-K42828737-044-10-8, BRD-K42828737-044-10-8, BRD-K42828737-044-12-4	Launched
suplatast	histamine release inhibitor, immunoglobulin inhibitor		rheumatology	Kimura's disease	BRD-A98427211-075-06-1, BRD-A98427211-075-03-8, BRD-A98427211-075-04-6, BRD-A98427211-075-05-3, BRD-A98427211-075-02-0	Launched
suprofen	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-A34006693-001-15-4, BRD-A34006693-001-14-7, BRD-A34006693-001-16-9	Withdrawn
suramin	DNA synthesis inhibitor	F2, FSHR, P2RY1, P2RY11, P2RY13, P2RY2, PLA2G2A, RYR1, RYR2, SIRT5	infectious disease	African trypanosomiasis, onchocerciasis	BRD-K70327167-348-13-4, BRD-K70327167-348-12-6	Launched
suritozole	GABA receptor inverse agonist	GABBR1			BRD-K98557884-001-01-6, BRD-K98557884-001-01-6	Phase 2
sutezolid	protein synthesis inhibitor				BRD-K86670086-001-02-5	Phase 2
suxibuzone	cyclooxygenase inhibitor		rheumatology, neurology/psychiatry	joint pain, muscle pain	BRD-K78815826-001-15-9, BRD-K78815826-001-13-8, BRD-K78815826-001-13-8, BRD-K78815826-001-14-6	Launched
SU014813	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			BRD-K00003547-001-01-9	Phase 2
SU16f	PDGFR tyrosine kinase receptor inhibitor	PDGFRB			BRD-K91106808-001-03-9, BRD-K91106808-001-02-0, BRD-K91106808-001-02-0	Preclinical
SU3327	JNK inhibitor	MAPK8			BRD-K32730239-001-02-8, BRD-K32730239-001-02-8, BRD-K32730239-001-02-8, BRD-K32730239-001-01-0, BRD-K32730239-001-01-0, BRD-K32730239-001-03-9	Preclinical
SU4312	PDGFR tyrosine kinase receptor inhibitor, tyrosine kinase inhibitor, VEGFR inhibitor	KDR, PDGFRB			BRD-K20287671-001-07-9, BRD-K20287671-001-06-9	Preclinical
SU9516	CDK inhibitor	CDK1, CDK2, CDK4, CDK5			BRD-K94883909-001-18-5, BRD-K94883909-001-17-7, BRD-K94883909-001-17-7	Preclinical
swainsonine	alpha mannosidase inhibitor	MAN2A1			BRD-K15170068-001-03-2	Phase 2
SX-011	MAP kinase inhibitor	MAPK14			BRD-K45385835-001-03-2, BRD-K45385835-001-03-2, BRD-K45385835-001-02-4	Preclinical
SY-640					BRD-K00004665-001-01-9	Phase 2
SYM-2081	kainate receptor antagonist	GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SLC1A2			BRD-K72106461-001-02-1, BRD-K72106461-001-03-9	Preclinical
SYM-2206	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			BRD-A77218119-001-04-3, BRD-A77218119-001-04-3, BRD-A77218119-001-03-5	Preclinical
symclosene					BRD-K33642804-001-01-1, BRD-K33642804-001-02-9	Preclinical
synephrine	adrenergic receptor agonist	ADRA1A	otolaryngology	sinusitis	BRD-K01825585-003-03-9, BRD-K01825585-003-02-9	Launched
S1P1-agonist-III	sphingosine kinase inhibitor	S1PR1			BRD-K12745498-001-02-6, BRD-K12745498-001-03-4, BRD-K12745498-001-01-8, BRD-K12745498-001-01-8	Preclinical
S15535	serotonin receptor agonist				BRD-K00004653-001-01-9	Preclinical
S18986	glutamate receptor modulator	GRIA1, GRIA2, GRIA3, GRIA4			BRD-K02501528-001-01-1, BRD-K02501528-001-01-1	Phase 2
S26948	PPAR receptor agonist	PPARG			BRD-K48826825-001-02-6, BRD-K48826825-001-01-8, BRD-K48826825-001-04-9	Preclinical
S4	carbonic anhydrase inhibitor	CA12, CA9			BRD-K96798615-001-01-4, BRD-K96798615-001-02-9	Preclinical
S49076	tyrosine kinase inhibitor				BRD-K00003147-001-01-9	Preclinical
S63845	MCL1 inhibitor				BRD-K91876515-001-03-9, BRD-K91876515-001-03-9	Preclinical
T-0070907	PPAR receptor antagonist	PPARG			BRD-K31843556-001-05-8, BRD-K31843556-001-04-1, BRD-K31843556-001-07-9, BRD-K31843556-001-07-9, BRD-K31843556-001-03-3	Preclinical
T-0156	phosphodiesterase inhibitor	PDE5A			BRD-K63516691-003-03-8, BRD-K63516691-003-04-9, BRD-K63516691-003-02-0, BRD-K63516691-003-02-0, BRD-K63516691-003-02-0	Preclinical
T-025	CLK inhibitor					Preclinical
T-0901317	LXR agonist	NCOA1, NCOA2, NR1H2, NR1H3, NR1I2, RXRB			BRD-K23383398-001-10-7, BRD-K23383398-001-10-7, BRD-K23383398-001-09-9, BRD-K23383398-001-09-9, BRD-K23383398-001-09-9, BRD-K23383398-001-09-9, BRD-K23383398-001-08-1, BRD-K23383398-001-11-9	Preclinical
T-1095	sodium/glucose cotransporter inhibitor				BRD-K00004631-001-01-9	Preclinical
T-5224	AP inhibitor	JUN			BRD-K84925803-001-01-9, BRD-K84925803-001-01-9, BRD-K84925803-001-02-9	Phase 2
T-5601640	LIM kinase inhibitor	LIMK2			BRD-K83492904-001-03-9, BRD-K83492904-001-01-9	Preclinical
T-62	adenosine receptor modulator	ADORA2A			BRD-K09001147-001-02-4, BRD-K09001147-001-01-6	Phase 2
T-807	PET radiotracer				BRD-K00003402-001-01-9	Phase 2
TA-01	casein kinase inhibitor, MAP kinase inhibitor	CSNK1D, CSNK1E, MAPK14			BRD-K79856806-001-01-0, BRD-K79856806-001-01-0, BRD-K79856806-001-01-0, BRD-K79856806-001-01-0	Preclinical
tacalcitol	vitamin D receptor agonist	VDR	dermatology	psoriasis, chapped lips	BRD-K73237276-001-02-9, BRD-K73237276-001-01-0, BRD-K73237276-001-01-0, BRD-K73237276-001-01-0, BRD-K73237276-001-01-0, BRD-K73237276-001-01-0, BRD-K73237276-001-01-0	Launched
tacedinaline	HDAC inhibitor	HDAC1			BRD-K52313696-001-14-9, BRD-K52313696-001-14-9, BRD-K52313696-001-12-3, BRD-K52313696-001-12-3, BRD-K52313696-001-12-3, BRD-K52313696-001-12-3, BRD-K52313696-001-12-3	Phase 3
tacrine	acetylcholinesterase inhibitor	ACHE, BCHE	neurology/psychiatry	Alzheimer's disease	BRD-K81473089-003-24-6, BRD-K81473089-003-24-6, BRD-K81473089-003-24-6, BRD-K81473089-003-26-1, BRD-K81473089-003-27-9, BRD-K81473089-003-25-3	Launched
tadalafil	phosphodiesterase inhibitor	PDE11A, PDE5A	urology	erectile dysfunction	BRD-K93645900-001-12-1, BRD-K93645900-001-12-1, BRD-K93645900-001-12-1, BRD-K93645900-001-14-9, BRD-K93645900-001-14-9, BRD-K93645900-001-11-3	Launched
tafamidis-meglumine	transthyretin amyloid inhibitor	TTR	neurology/psychiatry	familial amyloid polyneuropathy (FAP)	BRD-K23728141-001-01-2, BRD-K23728141-001-02-9	Launched
tafenoquine	antimalarial agent		infectious disease	malaria	BRD-A78965079-036-01-8	Launched
tafluprost	prostaglandin inhibitor	PTGFR	ophthalmology	glaucoma, ocular hypertension	BRD-K65059905-001-02-9	Launched
tagatose	phosphorylase inhibitor	PYGL			BRD-K18320600-001-01-9	Launched
TAK-063	phosphodiesterase inhibitor	PDE10A			BRD-K57155378-001-01-1	Phase 2
TAK-220	CC chemokine receptor antagonist	CCR5			BRD-K38793468-001-01-4, BRD-K38793468-001-01-4, BRD-K38793468-001-01-4	Phase 1
TAK-243	ubiquitin activating enzyme inhibitor				BRD-K00003376-001-01-9	Phase 1
TAK-285	EGFR inhibitor	ERBB2			BRD-K80343549-001-03-9, BRD-K80343549-001-02-6, BRD-K80343549-001-02-6, BRD-K80343549-001-02-6	Phase 1
TAK-593	VEGFR inhibitor	PDGFRA			BRD-K67262033-001-01-0, BRD-K67262033-001-01-0	Phase 1
TAK-632	RAF inhibitor	BRAF			BRD-K31866293-001-01-6, BRD-K31866293-001-01-6, BRD-K31866293-001-01-6, BRD-K31866293-001-01-6	Preclinical
TAK-659	spleen associated tyrosine kinase inhibitor				BRD-K71500795-003-02-9, BRD-K71500795-003-02-9	Phase 2
TAK-733	MEK inhibitor	MAP2K1			BRD-K26667523-001-02-5, BRD-K26667523-001-04-9, BRD-K26667523-001-03-3, BRD-K26667523-001-03-3	Phase 1
TAK-779	CC chemokine receptor antagonist				BRD-K00003155-003-01-9	Preclinical
TAK-901	Aurora kinase inhibitor	AURKB			BRD-K01683783-001-02-6, BRD-K01683783-001-02-6, BRD-K01683783-001-03-9	Phase 1
TAK-960	PLK inhibitor	PLK1			BRD-K48059512-003-01-0, BRD-K48059512-001-01-4, BRD-K48059512-001-01-4, BRD-K48059512-001-01-4	Phase 1
talabostat	dipeptidyl peptidase inhibitor, fibroblast activation protein inhibitor	DPP4			BRD-K37419961-066-03-8, BRD-K37419961-066-02-0, BRD-K37419961-066-01-2	Phase 3
taladegib	smoothened receptor antagonist	DHH, IHH, SMO			BRD-K50498985-001-03-3, BRD-K50498985-001-03-3, BRD-K50498985-001-03-3, BRD-K50498985-001-03-3, BRD-K50498985-001-03-3, BRD-K50498985-001-04-9	Phase 2
talampanel	glutamate receptor antagonist	GRIA1, GRIA2, GRIA3, GRIA4			BRD-K80359953-001-01-3, BRD-K80359953-001-01-3, BRD-K80359953-001-02-1	Phase 2
talaporfin	photosensitizing agent				BRD-K00004965-342-01-9	Phase 3
talarozole	cytochrome P450 inhibitor	CYP26A1			BRD-A95755460-001-02-9, BRD-A95755460-001-01-3, BRD-A95755460-001-01-3	Phase 2
talazoparib	PARP inhibitor	PARP2	oncology	breast cancer	BRD-K95142244-001-01-5, BRD-K95142244-001-01-5, BRD-K95142244-001-01-5, BRD-K95142244-001-01-5, BRD-K95142244-001-01-5, BRD-K95142244-001-01-5, BRD-K95142244-001-03-9	Launched
talinolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	BRD-A94276798-001-01-4, BRD-A94276798-001-01-4, BRD-A94276798-001-01-4	Launched
talipexole	adrenergic receptor agonist, dopamine receptor agonist	ADRA2A, DRD2, HTR3A	infectious disease	genitial herpes	BRD-K75615183-300-04-7, BRD-K75615183-300-05-4, BRD-K75615183-300-06-2, BRD-K75615183-300-03-9	Launched
talmapimod	p38 MAPK inhibitor	IL1B, MAPK11, MAPK14, MT-CO2, TNF			BRD-K17555800-003-02-3, BRD-K17555800-003-02-3, BRD-K17555800-003-01-5, BRD-K17555800-003-01-5, BRD-K17555800-003-01-5, BRD-K17555800-003-01-5, BRD-K17555800-001-01-9, BRD-K17555800-001-01-9, BRD-K17555800-001-01-9	Phase 2
talnetant	tachykinin antagonist	TACR2, TACR3			BRD-K47095176-001-02-9, BRD-K47095176-001-01-6	Phase 2
talniflumate	cyclooxygenase inhibitor	CLCA1	neurology/psychiatry	pain relief	BRD-A98378129-001-03-0, BRD-A98378129-001-03-0, BRD-A98378129-001-02-2, BRD-A98378129-001-04-9, BRD-A98378129-001-04-9	Launched
talopram	adrenergic inhibitor	SLC6A2			BRD-A02532772-003-01-7, BRD-A02532772-003-01-7, BRD-A02532772-003-02-9	Phase 2
talsaclidine	acetylcholine receptor agonist				BRD-K00004651-001-01-9	Phase 2/Phase 3
taltirelin	thyrotropin releasing hormone receptor agonist	TRHR	neurology/psychiatry	spinocerebellar ataxia	BRD-K93869735-001-03-9, BRD-K93869735-001-01-1	Launched
taltobulin	tubulin polymerization inhibitor				BRD-K87512222-019-01-7, BRD-K87512222-019-01-7, BRD-K87512222-019-01-7, BRD-K87512222-019-01-7, BRD-K87512222-019-01-7, BRD-K87512222-019-02-9	Phase 1
TAME					BRD-K72231366-001-03-9, BRD-K72231366-001-02-3	Preclinical
tamibarotene	retinoid receptor agonist	RARA, RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	BRD-K36627727-001-05-4, BRD-K36627727-001-05-4, BRD-K36627727-001-05-4, BRD-K36627727-001-06-2	Launched
taminadenant	adenosine receptor antagonist				BRD-K00004682-001-01-9	Phase 1/Phase 2
tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	EBP, ESR1, ESR2, GPER1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCI, PRKCQ, PRKCZ	oncology	breast cancer	BRD-K93754473-048-23-6, BRD-K93754473-048-23-6, BRD-K93754473-048-27-9, BRD-K93754473-048-18-6, BRD-K93754473-048-19-4, BRD-K93754473-048-20-2, BRD-K93754473-048-21-0	Launched
tamsulosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology	benign prostatic hyperplasia (BPH)	BRD-K74339692-003-03-1, BRD-K74339692-001-01-9	Launched
tanaproget	progesterone receptor agonist	PGR			BRD-K99604664-001-02-9, BRD-K99604664-001-02-9, BRD-K99604664-001-02-9, BRD-K99604664-001-02-9, BRD-K99604664-001-01-1	Phase 2
tandospirone	serotonin receptor agonist	HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD), dysthymic disorder	BRD-K65904673-003-01-0, BRD-K65904673-003-01-0, BRD-K65904673-001-01-4, BRD-K65904673-003-02-9	Launched
tandutinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	CSF1R, FLT3, KIT, PDGFD, PDGFRB			BRD-K89162000-001-12-9, BRD-K89162000-001-07-2, BRD-K89162000-001-07-2, BRD-K89162000-001-07-2, BRD-K89162000-001-06-4, BRD-K89162000-001-06-4	Phase 2
tangeritin	cell cycle inhibitor				BRD-K25186396-001-10-9, BRD-K25186396-001-09-6	Preclinical
tannic-acid	PARG inhibitor	ANO1	gastroenterology	constipation	BRD-K01584643-001-04-9	Launched
tanshinone-I	AP inhibitor	IFNG			BRD-K34073885-001-10-9, BRD-K34073885-001-07-7, BRD-K34073885-001-09-3, BRD-K34073885-001-09-3	Phase 2
tanshinone-IIA	anti-inflammatory agent, interleukin inhibitor	IL1B, NR1I2, TNF			BRD-K00141480-001-17-9, BRD-K00141480-001-15-4, BRD-K00141480-001-15-4, BRD-K00141480-001-14-7	Phase 2/Phase 3
tapinarof	aryl hydrocarbon receptor agonist				BRD-K00003498-001-01-9	Phase 3
taprenepag	prostaglandin receptor agonist	PTGER2			BRD-K88854110-001-01-5	Phase 2
tarafenacin	acetylcholine receptor antagonist	CHRM3			BRD-K00003568-001-01-9	Phase 2
taranabant	cannabinoid receptor inverse agonist	CNR1			BRD-K35169477-001-02-9, BRD-K35169477-001-02-9, BRD-K35169477-001-01-9, BRD-K35169477-001-01-9, BRD-K35169477-001-01-9	Phase 3
targinine	nitric oxide synthase inhibitor	NOS3			BRD-K22227508-015-05-4	Phase 3
tariquidar	P glycoprotein inhibitor	ABCB1			BRD-K09353376-001-02-1, BRD-K09353376-001-02-1, BRD-K09353376-001-03-9, BRD-K09353376-001-03-9, BRD-K09353376-001-05-4, BRD-K09353376-001-05-4, BRD-K09353376-001-05-4	Phase 3
tartaric-acid	antioxidant				BRD-K36474365-001-09-9, BRD-K36474365-001-06-6	Launched
TAS-103	topoisomerase inhibitor	TOP1			BRD-K09426783-300-01-0, BRD-K09426783-300-01-0, BRD-K09426783-300-03-9	Phase 1
taselisib	PI3K inhibitor	PIK3CA			BRD-K44844162-001-01-6, BRD-K44844162-001-01-6, BRD-K44844162-001-01-6, BRD-K44844162-001-01-6, BRD-K44844162-001-01-6, BRD-K44844162-001-04-0, BRD-K44844162-001-04-0, BRD-K44844162-001-04-0, BRD-K44844162-001-04-0, BRD-K44844162-001-04-0, BRD-K44844162-001-04-0	Phase 3
tasimelteon	melatonin receptor agonist	MTNR1A, MTNR1B	neurology/psychiatry	Non-24-Hour Sleep-Wake Disorder	BRD-K62971431-001-01-9	Launched
tasisulam	apoptosis stimulant				BRD-K42495768-001-01-7, BRD-K42495768-001-01-7, BRD-K42495768-001-01-7, BRD-K42495768-001-01-7, BRD-K42495768-001-01-7, BRD-K42495768-001-01-7, BRD-K42495768-001-02-5	Phase 3
tasquinimod	angiogenesis inhibitor, S100A9 inhibitor	HDAC4			BRD-K14653796-001-02-9, BRD-K14653796-001-02-9, BRD-K14653796-001-01-1, BRD-K14653796-001-01-1	Phase 3
tasuldine	mucolytic agent				BRD-K10415035-001-04-4, BRD-K10415035-001-03-6	Phase 3
taurine	antioxidant		neurology/psychiatry	anxiety, irritability, sleeplessness	BRD-K51474575-001-11-2, BRD-K51474575-001-10-4	Launched
taurocholate	G protein-coupled receptor agonist	CEL, FABP6, SLCO1C1			BRD-K81062487-001-05-8, BRD-K81062487-236-01-9	Phase 1
tauroglycocholate	membrane permeability enhancer				BRD-K00003523-236-01-9	Preclinical
taurolidine	apoptosis stimulant		infectious disease	catheter-related bloodstream infection	BRD-K98765504-001-01-5	Launched
tavaborole	leucyl-tRNA synthetase inhibitor		infectious disease	onychomycosis	BRD-K76713213-001-02-1, BRD-K76713213-001-02-1, BRD-K76713213-001-01-3	Launched
tavilermide	tyrosine kinase partial agonist				BRD-K00003254-001-01-9	Phase 3
taxifolin	opioid receptor antagonist	ADIPOR2			BRD-K94649603-001-14-9, BRD-K94649603-001-14-9, BRD-K94649603-001-10-6, BRD-K94649603-001-11-4, BRD-K94649603-001-11-4, BRD-K94649603-001-11-4	Phase 2
tazarotene	retinoid receptor agonist	RARA, RARB, RARG, RXRB	dermatology	cosmetic, sunscreen lotion	BRD-K76841105-001-04-7, BRD-K76841105-001-04-7, BRD-K76841105-001-05-9	Launched
tazemetostat	histone lysine methyltransferase inhibitor	EZH2			BRD-K11215326-001-02-9, BRD-K11215326-001-03-7, BRD-K11215326-001-03-7, BRD-K11215326-001-03-7	Launched
tazobactam	beta lactamase inhibitor		infectious disease	pneumonia	BRD-K14312455-001-03-9	Launched
TBA-354					BRD-K56405978-001-01-5, BRD-K56405978-001-01-5	Phase 1
TBOA-(DL)	excitatory amino acid transporter inhibitor	SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7			BRD-M77041484-001-03-4, BRD-M77041484-001-03-4, BRD-M77041484-001-02-6, BRD-M77041484-001-02-6, BRD-M77041484-001-01-8	Preclinical
TC-A-2317	Aurora kinase inhibitor	AURKA			BRD-A12147465-003-01-4, BRD-A12147465-003-01-4, BRD-A12147465-003-02-9, BRD-A12147465-003-02-9	Preclinical
TC-ASK-10	MAP kinase inhibitor	MAP3K5, MAP3K6			BRD-K29660062-300-01-2, BRD-K29660062-300-01-2, BRD-K29660062-300-01-2, BRD-K29660062-001-01-6	Preclinical
TC-E-5002	histone demethylase inhibitor	KDM2A, KDM4A, KDM4C, KDM5A, KDM6A, KDM7A, PHF8			BRD-K15256258-001-03-9, BRD-K15256258-001-01-3, BRD-K15256258-001-02-1	Preclinical
TC-E-5006	gamma secretase modulator	APP			BRD-A66521565-001-03-9, BRD-A66521565-001-03-9, BRD-A66521565-001-01-8, BRD-A66521565-001-01-8	Preclinical
TC-F-2	FAAH inhibitor	FAAH			BRD-K26041695-001-02-5, BRD-K26041695-001-01-7	Preclinical
TC-FPR-43	formyl peptide receptor agonist	FPR2			BRD-K16497916-001-02-9, BRD-K16497916-001-01-6	Preclinical
TC-G-1000	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C			BRD-K27010807-050-02-9, BRD-K27010807-050-01-3	Preclinical
TC-G-1004	adenosine receptor antagonist	ADORA2A			BRD-K76989898-001-02-9, BRD-K76989898-001-02-9, BRD-K76989898-001-01-1	Preclinical
TC-G-1005	G protein-coupled receptor agonist	GPBAR1			BRD-K16939217-001-02-9, BRD-K16939217-001-01-3	Preclinical
TC-G-1008	G protein-coupled receptor agonist	GPR39			BRD-K87199310-001-01-4, BRD-K87199310-001-02-9	Preclinical
TC-H-106	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			BRD-K45044657-001-02-2, BRD-K45044657-001-02-2, BRD-K45044657-001-01-4, BRD-K45044657-001-01-4, BRD-K45044657-001-01-4, BRD-K45044657-001-01-4	Preclinical
TC-I-15	integrin inhibitor	ITGA2, ITGB1			BRD-K17621556-001-02-9, BRD-K17621556-001-01-5, BRD-K17621556-001-01-5	Preclinical
TC-I-2000	transient receptor potential channel antagonist	TRPM8			BRD-A83792282-001-02-9, BRD-A83792282-001-02-9, BRD-A83792282-001-01-6, BRD-A83792282-001-01-6	Preclinical
TC-I-2014	transient receptor potential channel antagonist	TRPM8			BRD-K05262258-001-01-3, BRD-K05262258-001-02-9, BRD-K05262258-001-02-9	Preclinical
TC-LPA5-4	lysophosphatidic acid receptor antagonist	LPAR5			BRD-K32031961-001-02-9, BRD-K32031961-001-02-9, BRD-K32031961-001-02-9, BRD-K32031961-001-01-7, BRD-K32031961-001-01-7	Preclinical
TC-Mps1-12	monopolar spindle 1 kinase inhibitor	TTK			BRD-K76792630-001-02-9, BRD-K76792630-001-01-2	Preclinical
TC-N-1752	sodium channel blocker	SCN9A			BRD-K78161388-001-02-9, BRD-K78161388-001-02-9, BRD-K78161388-001-01-2	Preclinical
TC-NTR1-17	neurotensin agonist	NTSR1			BRD-K79608170-001-03-9, BRD-K79608170-001-02-1	Preclinical
TC-O-9311	G protein-coupled receptor agonist	GPR139			BRD-K54297077-001-01-8, BRD-K54297077-001-01-8, BRD-K54297077-001-02-9	Preclinical
TC-OT-39	oxytocin receptor agonist, vasopressin receptor agonist	AVPR1A, OXT			BRD-K55013981-001-02-9, BRD-K55013981-001-01-3, BRD-K55013981-001-01-3	Preclinical
TC-S-7003	SRC inhibitor	LCK			BRD-K34362291-001-02-9, BRD-K34362291-001-01-5	Preclinical
TC-S-7004	DYRK inhibitor	DYRK1A, DYRK1B			BRD-K89517477-001-03-9, BRD-K89517477-001-01-4, BRD-K89517477-001-01-4, BRD-K89517477-001-01-4	Preclinical
TC-S-7005	PLK inhibitor	PLK2			BRD-K89584803-001-02-9, BRD-K89584803-001-01-9	Preclinical
TC-S-7006	MAP kinase inhibitor	MAP3K8			BRD-K51776215-001-03-9, BRD-K51776215-001-02-5	Preclinical
TC-S-7009	hypoxia inducible factor inhibitor	EPAS1			BRD-K21894922-001-01-9, BRD-K21894922-001-02-9	Preclinical
TC-SP-14	sphingosine 1-phosphate receptor agonist	S1PR1			BRD-K87461578-001-02-9, BRD-K87461578-001-01-5	Preclinical
TCID					BRD-K27536248-001-03-9, BRD-K27536248-001-03-9, BRD-K27536248-001-01-7, BRD-K27536248-001-02-5, BRD-K27536248-001-02-5	Preclinical
TCN201	glutamate receptor antagonist	GRIN2A			BRD-K09787262-001-02-7, BRD-K09787262-001-01-9, BRD-K09787262-001-03-9, BRD-K09787262-001-03-9	Preclinical
TCN238	glutamate receptor positive allosteric modulator	GRM4			BRD-K77915400-001-01-6, BRD-K77915400-001-02-9	Preclinical
TCS-HDAC6-20b	HDAC inhibitor	HDAC6			BRD-K68358632-001-02-9, BRD-K68358632-001-02-9, BRD-K68358632-001-01-0	Preclinical
TCS-OX2-29	orexin receptor antagonist	HCRTR2			BRD-K29424831-003-02-1, BRD-K29424831-003-01-3	Preclinical
TCS-PIM-1-1	Pim kinase inhibitor	PIM1			BRD-K08902330-001-01-3, BRD-K08902330-001-02-9	Preclinical
TCS-2002	glycogen synthase kinase inhibitor	GSK3B			BRD-K00004294-001-01-9	Preclinical
TCS-21311	JAK inhibitor	JAK3			BRD-K49461364-001-02-8, BRD-K49461364-001-02-8, BRD-K49461364-001-02-8, BRD-K49461364-001-01-0, BRD-K49461364-001-01-0	Preclinical
TCS-2210	neural stem cell inducer				BRD-K19958299-001-01-1, BRD-K19958299-001-02-9	Preclinical
TCS-2314	integrin inhibitor	ITGA4, ITGB1			BRD-K55216666-001-01-4, BRD-K55216666-001-01-4, BRD-K55216666-001-02-9	Preclinical
TCS-3035	G protein-coupled receptor agonist	GPR35			BRD-K81935556-001-01-0, BRD-K81935556-001-02-9	Preclinical
TCS-359	FLT3 inhibitor	FLT3			BRD-K81376179-001-04-8, BRD-K81376179-001-04-8, BRD-K81376179-001-07-9, BRD-K81376179-001-03-0, BRD-K81376179-001-03-0, BRD-K81376179-001-06-3, BRD-K81376179-001-05-5	Preclinical
TCS-5861528	transient receptor potential channel antagonist	TRPA1			BRD-A16560607-001-02-5, BRD-A16560607-001-02-5, BRD-A16560607-001-04-9, BRD-A16560607-001-04-9	Preclinical
TCV-309	platelet activating factor receptor antagonist				BRD-K00003278-003-01-9	Preclinical
TC1	beta-secretase inhibitor	BACE1			BRD-K01825674-001-01-9, BRD-K01825674-001-01-9, BRD-K01825674-001-01-9, BRD-K01825674-001-01-9, BRD-K01825674-001-01-9, BRD-K01825674-001-02-9	Preclinical
TC2559	acetylcholine receptor agonist	CHRNA4			BRD-K24227647-364-02-3, BRD-K24227647-364-01-5	Preclinical
TD139	anti-inflammatory agent				BRD-K00003308-001-01-9	Phase 2
tebipenem	bacterial cell wall synthesis inhibitor	CNR1	infectious disease, otolaryngology	pneumonia, otitis	BRD-K28224173-001-03-9	Launched
tecadenoson	adenosine receptor agonist	ADORA1			BRD-K00003289-001-01-9	Phase 2
tecalcet	calcium-sensing receptor agonist	CASR			BRD-K41662846-003-02-3, BRD-K41662846-003-01-5	Phase 2
tecastemizole	histamine receptor antagonist	KCNH2			BRD-K48195801-001-01-6, BRD-K48195801-001-01-6, BRD-K48195801-001-01-6, BRD-K48195801-001-01-6	Phase 3
tecovirimat	orthopoxvirus egress inhibitor		infectious disease	smallpox	BRD-K24312986-001-01-2, BRD-K24312986-001-02-9	Launched
tedizolid	bacterial 50S ribosomal subunit inhibitor		infectious disease	skin infections	BRD-K59436580-001-01-7, BRD-K59436580-001-01-7, BRD-K59436580-001-01-7, BRD-K59436580-001-03-9, BRD-K59436580-001-03-9	Launched
tedizolid-phosphate	protein synthesis inhibitor		infectious disease	skin infections	BRD-K89121095-001-02-5, BRD-K89121095-304-01-5, BRD-K89121095-001-01-7, BRD-K89121095-001-01-7	Launched
tegaserod	serotonin receptor partial agonist	HTR2A, HTR2B, HTR2C, HTR4			BRD-K88743730-050-03-3, BRD-K88743730-050-04-1, BRD-K88743730-050-04-1, BRD-K88743730-050-05-8	Withdrawn
tegobuvir	HCV inhibitor, protease inhibitor				BRD-K26701552-001-02-9, BRD-K26701552-001-01-8	Phase 3
teicoplanin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	BRD-K07712545-001-02-9, BRD-K07712545-001-01-8	Launched
teicoplanin-A2-1	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	BRD-A09761158-001-02-1, BRD-A09761158-001-03-9	Launched
teicoplanin-A2-3	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	BRD-K96571715-001-01-4	Launched
teijin-compound-1	CC chemokine receptor antagonist	CCR2			BRD-K51528698-003-01-4, BRD-K51528698-003-02-9	Preclinical
telatinib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	KDR			BRD-K84564571-001-03-9, BRD-K84564571-001-02-4, BRD-K84564571-001-02-4	Phase 2
telbivudine	DNA polymerase inhibitor		infectious disease	hepatitis B	BRD-K15976406-001-03-3, BRD-K15976406-001-04-1	Launched
telcagepant	calcitonin antagonist	CALCRL, RAMP1			BRD-K91159026-001-02-9, BRD-K91159026-001-01-7, BRD-K91159026-001-01-7, BRD-K91159026-001-01-7	Phase 3
telenzepine	acetylcholine receptor antagonist	CHRM1			BRD-K06147391-003-03-5, BRD-K06147391-300-06-8	Phase 3
telithromycin	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor	CYP1A2, CYP2D6, CYP3A4, CYP3A5, CYP3A7	infectious disease	pneumonia	BRD-K82240271-001-02-9, BRD-K82240271-001-01-8	Launched
telmesteine	mucolytic agent		pulmonary	cough suppressant	BRD-A05523972-001-01-5	Launched
telmisartan	angiotensin receptor antagonist	AGTR1, PPARG	cardiology	hypertension	BRD-K73999723-001-11-3, BRD-K73999723-001-11-3, BRD-K73999723-001-13-9, BRD-K73999723-001-14-9, BRD-K73999723-001-14-9, BRD-K73999723-001-10-5, BRD-K73999723-001-10-5, BRD-K73999723-001-10-5, BRD-K73999723-001-10-5	Launched
telotristat	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	BRD-K63178091-001-01-1, BRD-K63178091-001-02-9	Launched
telotristat-ethyl	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	BRD-K94559059-091-03-2, BRD-K94559059-091-03-2, BRD-K94559059-091-02-4, BRD-K94559059-091-01-6	Launched
telratolimod	toll-like receptor agonist				BRD-K00004596-001-01-9	Preclinical
temanogrel	serotonin receptor antagonist				BRD-K00003467-001-01-9	Preclinical
temefos	cholinesterase inhibitor				BRD-K51805276-001-09-3, BRD-K51805276-001-10-9	Launched
temocapril	angiotensin converting enzyme inhibitor	ACE	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)	BRD-K10784860-003-02-3, BRD-K10784860-003-03-9, BRD-K10784860-003-03-9, BRD-K10784860-003-03-9	Launched
temoporfin	radical formation stimulant		oncology	head and neck squamous cell carcinoma (HNSCC)	BRD-K63712959-001-02-9, BRD-K63712959-001-01-8, BRD-K63712959-001-01-8	Launched
temozolomide	DNA alkylating agent	MGMT	oncology	glioblastoma, astrocytoma	BRD-K32107296-001-20-1, BRD-K32107296-001-16-9, BRD-K32107296-001-15-1, BRD-K32107296-001-14-4	Launched
temsirolimus	mTOR inhibitor	MTOR	oncology	renal cell carcinoma (RCC)	BRD-K08177763-001-05-9, BRD-K08177763-001-05-9	Launched
TEN-010	bromodomain inhibitor				BRD-K00005242-001-01-9	Preclinical
tenalisib	PI3K inhibitor				BRD-K00003263-001-01-9	Phase 2
tenapanor	sodium/hydrogen exchanger inhibitor				BRD-K00003201-001-01-9	Launched
tenatoprazole	ATPase inhibitor	IDO1			BRD-A42270467-001-04-4	Phase 2
teneligliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	BRD-K48068743-001-01-6, BRD-K48068743-001-01-6, BRD-K48068743-001-01-6, BRD-K48068743-001-01-6, BRD-K48068743-001-01-6, BRD-K48068743-001-02-9	Launched
tenidap	cyclooxygenase inhibitor	KCNJ4, PTGS1			BRD-K00004279-001-01-9	Phase 3
tenilsetam	AGE inhibitor				BRD-A41835910-001-02-2, BRD-A41835910-001-01-4	Phase 3
tenofovir	HIV integrase inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1), hepatitis B	BRD-K15891719-213-01-1, BRD-K15891719-001-05-1, BRD-K15891719-001-04-4	Launched
tenofovir-alafenamide	nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	BRD-A25988899-001-01-6	Launched
tenofovir-disoproxil	nucleoside reverse transcriptase inhibitor	CYP1A2	infectious disease	human immunodeficiency virus (HIV-1), hepatitis B	BRD-K61868322-051-06-4, BRD-K61868322-051-06-4, BRD-K61868322-051-06-4, BRD-K61868322-050-01-7	Launched
tenovin-1	SIRT inhibitor, TP53 activator	SIRT1			BRD-K05977823-001-05-3, BRD-K05977823-001-05-3, BRD-K05977823-001-06-9, BRD-K05977823-001-06-9, BRD-K05977823-001-06-9, BRD-K05977823-001-04-6, BRD-K05977823-001-03-8	Preclinical
tenovin-6	SIRT inhibitor	SIRT1, SIRT2, SIRT3			BRD-K13949769-001-01-7, BRD-K13949769-001-01-7, BRD-K13949769-003-01-3, BRD-K13949769-003-01-3, BRD-K13949769-001-02-9	Preclinical
tenoxicam	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology, orthopedics	rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, periarthritis	BRD-A22844106-001-29-9, BRD-A22844106-001-26-0, BRD-A22844106-001-25-2	Launched
tenylidone					BRD-K91298281-001-01-3, BRD-K91298281-001-09-9	Preclinical
tepoxalin	cyclooxygenase inhibitor, lipoxygenase inhibitor	ALOX5	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia	BRD-K89714990-001-01-5, BRD-K89714990-001-01-5, BRD-K89714990-001-01-5, BRD-K89714990-001-02-3, BRD-K89714990-001-02-3	Launched
TEPP-46	pyruvate kinase isozyme activator	PKM			BRD-K01826017-001-02-9, BRD-K01826017-001-01-9, BRD-K01826017-001-01-9	Preclinical
teprenone	mucus protecting agent		dermatology	cosmetic	BRD-K11510141-001-04-2, BRD-K11510141-001-03-4, BRD-K11510141-001-02-6, BRD-K11510141-001-01-8	Launched
terameprocol	lipoxygenase inhibitor	BIRC5, CDK1			BRD-K76788410-001-01-6	Phase 1/Phase 2
terazosin	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension	BRD-K01826569-003-19-9, BRD-K01826569-003-19-9	Launched
terbinafine	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis, tinea cruris, tinea corporis	BRD-K68132782-003-14-6, BRD-K68132782-003-13-8, BRD-K68132782-003-13-8, BRD-K68132782-003-13-8, BRD-K68132782-001-03-3	Launched
terciprazine					BRD-K01826018-001-01-9, BRD-K01826018-001-01-9	Phase 1
terconazole	sterol demethylase inhibitor		infectious disease	vulvovaginal candidiasis	BRD-K86204871-001-17-9, BRD-K86204871-001-16-2	Launched
terfenadine	histamine receptor antagonist	HRH1, KCNH1, KCNH2			BRD-A06352418-001-25-9, BRD-A06352418-001-25-9, BRD-A06352418-001-27-5, BRD-A06352418-001-27-5, BRD-A06352418-001-24-2, BRD-A06352418-001-28-9	Withdrawn
terguride	dopamine receptor agonist, serotonin receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, DRD4, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C	neurology/psychiatry	Parkinson's Disease	BRD-A89207210-001-01-6	Launched
teriflunomide	dihydroorotate dehydrogenase inhibitor	DHODH	neurology/psychiatry	multiple sclerosis	BRD-A42699921-001-02-8, BRD-A42699921-001-04-4, BRD-A42699921-001-03-6	Launched
terlipressin	vasopressin receptor agonist	AVPR1A	cardiology	hypotension	BRD-K73451719-001-01-2, BRD-K73451719-001-01-2	Launched
terodiline	cholinergic receptor antagonist				BRD-A33479817-003-03-7	Withdrawn
teroxirone	DNA inhibitor				BRD-A39935389-001-06-9, BRD-A39935389-001-05-9, BRD-A39935389-001-05-9	Phase 1
terpene					BRD-K00003674-002-01-9	Preclinical
terreic-acid-(-)	Bruton's tyrosine kinase (BTK) inhibitor	BTK				Preclinical
terutroban	prostanoid receptor antagonist	TBXA2R			BRD-K43975632-001-01-1, BRD-K43975632-001-01-1	Phase 3
tesaglitazar	insulin sensitizer, PPAR receptor agonist	PPARA, PPARG			BRD-K15507868-001-04-5, BRD-K15507868-001-03-7	Phase 3
tetomilast	phosphodiesterase inhibitor	PDE4D			BRD-K00004564-001-01-9	Phase 2
tetrabenazine	vesicular monoamine transporter inhibitor	SLC18A1, SLC18A2	infectious disease, neurology/psychiatry	cholera, Huntington's disease	BRD-K95739795-001-04-5, BRD-K95739795-001-03-7, BRD-K95739795-001-03-7, BRD-K95739795-001-03-7, BRD-K95739795-001-05-9	Launched
tetracaine	membrane integrity inhibitor	SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	anesthetic	BRD-K45071273-003-24-9, BRD-K45071273-003-25-6	Launched
tetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease, dermatology	respiratory tract infections, pneumonia, skin infections, urinary tract infections, acne vulgaris (AV), plague, psittacosis	BRD-K00003352-003-01-9	Launched
tetradecylthioacetic-acid	lipid peroxidase inhibitor				BRD-K47539947-001-03-7, BRD-K47539947-001-03-7, BRD-K47539947-001-04-9	Phase 2
tetraethylenepentamine	superoxide dismutase inhibitor	SOD1, SOD2			BRD-K41298358-395-02-6, BRD-K41298358-395-03-4, BRD-K41298358-395-03-4, BRD-K41298358-395-03-4, BRD-K41298358-395-04-2	Phase 2/Phase 3
tetrahydrofolic-acid		FOLR2			BRD-A36978621-001-01-9	Launched
tetrahydropapaverine					BRD-K01825583-003-03-9, BRD-K01825583-003-02-9	Preclinical
tetrahydrouridine	cytidine deaminase inhibitor	CDA			BRD-A86248581-001-01-4	Phase 2
tetrahydrozoline	adrenergic receptor agonist		ophthalmology	eye irritation	BRD-A28856712-003-25-2, BRD-A28856712-003-26-0, BRD-A28856712-003-26-0, BRD-A28856712-003-27-9	Launched
tetramethylthiuram-monosulfide					BRD-K36889451-001-01-1	Preclinical
tetramisole	immunostimulant	ALPPL2, CHRNA3	infectious disease	gastrointestinal parasites	BRD-A46393198-003-16-6, BRD-A46393198-003-16-6, BRD-A46393198-003-16-6, BRD-A46393198-003-15-8	Launched
tetrazol-5-yl-glycine-(RS)	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			BRD-A14757586-001-03-2, BRD-A14757586-001-04-9	Preclinical
tetrindole	monoamine oxidase inhibitor	MAOA			BRD-A52660433-066-03-9, BRD-A52660433-066-03-9, BRD-A52660433-066-02-1, BRD-A52660433-066-02-1, BRD-A52660433-066-02-1, BRD-A52660433-066-02-1, BRD-A52660433-066-02-1	Phase 3
tetroquinone					BRD-K90177246-001-05-5, BRD-K90177246-001-05-5, BRD-K90177246-001-06-3	Preclinical
tezacaftor	CFTR channel agonist		pulmonary	cystic fibrosis	BRD-K97101532-001-02-8, BRD-K97101532-001-03-9	Launched
TFC-007	prostaglandin inhibitor	HPGDS			BRD-K57708067-001-02-9, BRD-K57708067-001-01-3, BRD-K57708067-001-01-3	Preclinical
TG-003	CLK inhibitor	CLK1, CLK4, DYRK1A, DYRK1B			BRD-K97072811-001-11-4, BRD-K97072811-001-11-4, BRD-K97072811-001-13-9	Preclinical
TG-02	CDK inhibitor, FLT3 inhibitor, JAK inhibitor	CDK1, CDK2, CDK7, CDK9, FLT3, JAK2			BRD-K14560436-001-01-4, BRD-K14560436-001-01-4, BRD-K14560436-001-01-4, BRD-K14560436-001-01-4, BRD-K14560436-001-01-4, BRD-K14560436-001-01-4, BRD-K14560436-001-01-4, BRD-K14560436-001-02-9	Phase 1/Phase 2
TG-100572	SRC inhibitor, VEGFR inhibitor	KDR, SRC			BRD-K18424115-003-02-9, BRD-K18424115-003-02-9, BRD-K18424115-003-01-3, BRD-K18424115-003-01-3, BRD-K18424115-003-01-3	Preclinical
TG-100713	PI3K inhibitor				BRD-K46392623-001-03-9, BRD-K46392623-001-02-5	Preclinical
TG-100801	SRC inhibitor, VEGFR inhibitor	CSK, FGFR1, FLT1, FLT4, KDR, SRC			BRD-K12735121-001-02-9, BRD-K12735121-001-01-4, BRD-K12735121-001-01-4	Phase 2
TG-101209	JAK inhibitor	JAK2, JAK3			BRD-K39841531-001-04-9, BRD-K39841531-001-02-1, BRD-K39841531-001-02-1, BRD-K39841531-001-02-1, BRD-K39841531-001-02-1, BRD-K39841531-001-02-1, BRD-K39841531-001-02-1	Preclinical
TGR-1202	PI3K inhibitor				BRD-K52579889-001-01-9, BRD-K52579889-001-01-9	Phase 3
TGX-221	PI3K inhibitor	PIK3CB, PIK3CD			BRD-A41692738-001-10-0, BRD-A41692738-001-07-6, BRD-A41692738-001-07-6	Preclinical
TG100-115	PI3K inhibitor	PIK3CA, PIK3CB, PIK3CD, PIK3CG			BRD-K64785675-001-04-0	Phase 1/Phase 2
TH-302	DNA alkylating agent				BRD-K20958582-001-02-9, BRD-K20958582-001-02-9, BRD-K20958582-001-01-4	Phase 3
TH-588	MTH1 inhibitor	NUDT1			BRD-K01054709-001-01-3, BRD-K01054709-001-01-3, BRD-K01054709-001-01-3, BRD-K01054709-001-01-3, BRD-K01054709-001-01-3, BRD-K01054709-001-01-3	Preclinical
thaliblastine	DNA inhibitor				BRD-K87548127-300-01-1	Phase 2
thalidomide	tumor necrosis factor production inhibitor	TNF	oncology	myeloma	BRD-A93255169-001-28-3, BRD-A93255169-001-28-3, BRD-A93255169-001-27-5	Launched
theaflavin	antiviral				BRD-K60842365-001-03-9	Preclinical
theobromine	phosphodiesterase inhibitor	ADORA1, ADORA2A, PDE4B			BRD-K34888156-213-01-4, BRD-K34888156-001-12-9, BRD-K34888156-001-11-2, BRD-K34888156-001-11-2, BRD-K34888156-001-11-2	Launched
thiamet-g	GLCNAC phosphotransferase inhibitor	MGEA5			BRD-K38380126-001-04-9, BRD-K38380126-001-02-2, BRD-K38380126-001-01-4	Preclinical
thiamine	vitamin B	SLC19A2, SLC19A3, TPK1	metabolism	thiamine deficiency	BRD-K95785345-003-16-9, BRD-K95785345-300-15-5, BRD-K95785345-300-14-8	Launched
thiamine-pyrophosphate			hematology	anemia	BRD-A09994331-003-02-4	Launched
thiamphenicol	bacterial 50S ribosomal subunit inhibitor		infectious disease	pelvic inflammatory disease	BRD-K79711234-001-18-3, BRD-K79711234-001-20-9, BRD-K79711234-001-17-5	Launched
thiamylal	glutamate receptor antagonist	GABRA1	neurology/psychiatry	sedative	BRD-A23970436-236-04-2	Launched
thiazovivin	rho associated kinase inhibitor				BRD-K03164761-001-04-9, BRD-K03164761-001-04-9, BRD-K03164761-001-02-1, BRD-K03164761-001-02-1	Preclinical
thiethylperazine	dopamine receptor antagonist	DRD1, DRD2, DRD4	gastroenterology	nausea	BRD-K69600043-001-08-9, BRD-K69600043-328-05-5, BRD-K69600043-328-05-5, BRD-K69600043-328-09-9, BRD-K69600043-328-09-9	Launched
thiocolchicoside	GABA receptor antagonist	GABRA1, GABRB2, GABRG2, GLRA1, GLRB	neurology/psychiatry	muscle relaxant	BRD-K26619122-001-02-1, BRD-K26619122-001-02-1, BRD-K26619122-001-02-1, BRD-K26619122-001-03-9, BRD-K26619122-001-03-9	Launched
thioctic-acid	reducing agent	ACHE, PTGS2	nephrology	diabetic nephropathy	BRD-A16347691-001-13-1	Launched
thiodiglycol					BRD-K54521836-001-02-1, BRD-K54521836-001-03-9	Preclinical
thioguanine	purine antagonist	IMPDH1, IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	BRD-K49350383-001-15-2, BRD-K49350383-001-13-7, BRD-K49350383-001-14-5, BRD-K49350383-001-14-5	Launched
thiomersal	other antibiotic	OXCT1	infectious disease	preservative	BRD-K61443650-236-14-9, BRD-K61443650-236-14-9, BRD-K61443650-236-14-9, BRD-K61443650-236-13-1, BRD-K61443650-236-13-1, BRD-K61443650-236-13-1, BRD-K61443650-236-13-1, BRD-K61443650-236-13-1	Launched
thiopental	GABA receptor antagonist	FAAH	neurology/psychiatry	anesthetic	BRD-A72603112-236-05-7, BRD-A72603112-236-04-0	Launched
thioperamide	histamine receptor antagonist	HRH3, HRH4			BRD-A85424553-001-07-9	Preclinical
thiophanate					BRD-K90168339-001-09-4, BRD-K90168339-001-09-4, BRD-K90168339-001-09-4, BRD-K90168339-001-08-6	Preclinical
thioproperazine	dopamine receptor antagonist	ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A	neurology/psychiatry	schizophrenia	BRD-K08619574-001-07-9, BRD-K08619574-334-05-4	Launched
thioridazine	dopamine receptor antagonist	DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR2A, HTR2C, HTR6, HTR7			BRD-A84481105-003-31-3, BRD-A84481105-003-31-3, BRD-A84481105-003-31-3, BRD-A84481105-003-32-1	Withdrawn
thiorphan	membrane metalloendopeptidase inhibitor	MME			BRD-A56012032-001-14-8, BRD-A56012032-001-15-5	Phase 1
thiotepa	cytochrome P450 inhibitor	CYP2B6, CYP3A4	oncology	breast cancer, ovarian cancer, bladder cancer	BRD-K09631521-001-12-3, BRD-K09631521-001-12-3, BRD-K09631521-001-09-9, BRD-K09631521-001-11-5	Launched
thiothixene	dopamine receptor antagonist	DRD1, DRD2, HRH1, HTR2A	neurology/psychiatry	schizophrenia	BRD-K04175245-001-14-9	Launched
thiram		JAK2	ophthalmology	contact dermatitis	BRD-K29254801-001-14-7, BRD-K29254801-001-14-7	Launched
THK5351	PET radiotracer 				BRD-K00003401-001-01-9	Phase 2
thonzonium	ATPase inhibitor		infectious disease	ear infections	BRD-K13387373-004-16-9, BRD-K13387373-004-15-2, BRD-K13387373-004-14-5, BRD-K13387373-004-14-5, BRD-K13387373-004-14-5, BRD-K13387373-004-14-5, BRD-K13387373-004-14-5	Launched
thonzylamine	antihistamine		neurology/psychiatry	itching	BRD-K88405679-003-03-1	Launched
threo-2-methylisocitrate-(DL)	isocitrate lyase substrate				BRD-M01344114-348-01-0, BRD-M01344114-348-01-0	Preclinical
thymalfasin	immune response modulator		infectious disease	hepatitis B, hepatitis C	BRD-K00004602-001-01-9	Launched
thymol	GABA receptor positive allosteric modulator	TRPA1	infectious disease	ringworm, antiseptic	BRD-K17458574-001-07-7, BRD-K17458574-001-08-9	Launched
thymol-iodide					BRD-K36617478-001-01-5	Preclinical
thymopentin	immune response stimulator				BRD-K43977121-001-06-9	Launched
THZ1	CDK inhibitor	CDK7			BRD-K66401437-001-03-3, BRD-K66401437-001-03-3, BRD-K66401437-001-03-3, BRD-K66401437-001-03-3, BRD-K66401437-001-03-3, BRD-K66401437-001-03-3, BRD-K66401437-001-03-3, BRD-K66401437-001-03-3	Preclinical
THZ1-R	CDK inhibitor	CDK7			BRD-K02135007-001-01-8, BRD-K02135007-001-01-8	Preclinical
THZ2	CDK inhibitor	CDK7			BRD-K95902121-001-01-0, BRD-K95902121-001-01-0, BRD-K95902121-001-01-0, BRD-K95902121-001-01-0, BRD-K95902121-001-01-0	Preclinical
tiabendazole	angiogenesis inhibitor		infectious disease	gastrointestinal roundworms, hookworm	BRD-K77695569-001-33-9, BRD-K77695569-001-33-9, BRD-K77695569-001-29-2, BRD-K77695569-001-30-0	Launched
tiagabine	GABA uptake inhibitor	SLC6A1	neurology/psychiatry	seizures	BRD-K60160658-003-12-0, BRD-K60160658-003-11-2, BRD-K60160658-003-11-2	Launched
tianeptine	selective serotonin reuptake enhancer (SSRE)	OPRD1, OPRK1, OPRM1	neurology/psychiatry, pulmonary, gastroenterology	depression, asthma, irritable bowel syndrome	BRD-K01826304-001-01-9, BRD-K01826304-001-02-9	Launched
tiapride	dopamine receptor antagonist	DRD2, DRD3	neurology/psychiatry	dyskinesia, abstinence from alcohol, psychosis	BRD-K57432881-003-21-8, BRD-K57432881-003-22-9, BRD-K57432881-003-22-9	Launched
tiaprofenic-acid	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis	BRD-A72988804-001-11-1, BRD-A72988804-001-11-1, BRD-A72988804-001-10-3	Launched
tiaramide	anti-inflammatory agent		pulmonary	asthma	BRD-K27293958-001-01-5	Launched
tibolone	androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist	ESR1	obstetrics/gynecology	endometriosis	BRD-A82522119-001-01-7, BRD-A82522119-001-01-7, BRD-A82522119-001-01-7	Launched
ticagrelor	purinergic receptor antagonist	P2RY12	cardiology	acute coronary syndrome (ACS), myocardial infarction	BRD-K25838957-001-02-9, BRD-K25838957-001-02-9	Launched
ticlopidine	purinergic receptor antagonist	P2RY12	hematology, neurology/psychiatry	thrombosis, stroke	BRD-K00603606-003-24-0, BRD-K00603606-003-24-0, BRD-K00603606-003-24-0, BRD-K00603606-003-23-2, BRD-K00603606-003-25-9	Launched
TIC10	AKT inhibitor, TRAIL modulator	AKT1, MAPK1			BRD-K19939891-001-05-4, BRD-K19939891-001-06-9	Phase 2
tideglusib	glycogen synthase kinase inhibitor	GSK3B			BRD-K81330143-001-02-2, BRD-K81330143-001-04-8, BRD-K81330143-001-04-8, BRD-K81330143-001-04-8, BRD-K81330143-001-06-9, BRD-K81330143-001-06-9	Phase 2
tienilic-acid	cytochrome P450 inhibitor, sodium/potassium/chloride transporter inhibitor	CYP2C9, SLC12A1			BRD-K34098590-001-02-1, BRD-K34098590-001-02-1	Withdrawn
tie2-kinase-inhibitor	TIE tyrosine kinase inhibitor	KDR, MAPK14			BRD-A92800748-001-05-5, BRD-A92800748-001-05-5, BRD-A92800748-001-05-5	Preclinical
tifenazoxide	ATP-sensitive potassium channel agonist	ABCC8, KCNJ11			BRD-K20568871-001-01-1, BRD-K20568871-001-01-1, BRD-K20568871-001-01-1	Phase 1
tigecycline	bacterial 30S ribosomal subunit inhibitor		infectious disease	skin infections, pneumonia, intra-abdominal infections	BRD-K00003349-001-01-9	Launched
tilmicosin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bovine respiratory disease (BRD)	BRD-K36796419-011-03-9	Launched
tilorone	interferon inducer		infectious disease, gastroenterology, neurology/psychiatry	influenza A virus infection, diarrhea, hepatitis B, multiple sclerosis, urinary tract infections, virus herpes simplex (HSV), hepatitis C	BRD-K34568562-300-05-9, BRD-K34568562-300-05-9, BRD-K34568562-001-04-3	Launched
tiludronate	bone resorption inhibitor, osteoclast inhibitor	ATP6V1A, MMP2, PTPN1	orthopedics	navicular syndrome	BRD-K10845183-304-01-6, BRD-K10845183-304-01-6	Launched
timofibrate	cholesterol inhibitor, lipase clearing factor inhibitor	LPL			BRD-A64406146-001-01-2, BRD-A64406146-001-01-2, BRD-A64406146-001-01-2, BRD-A64406146-001-01-2, BRD-A64406146-001-01-2	Phase 2
timolol	adrenergic receptor antagonist	ADRB1, ADRB2	ophthalmology	ocular hypertension, glaucoma	BRD-K08806317-050-30-9, BRD-K08806317-050-29-1, BRD-K08806317-051-01-8	Launched
timonacic	antioxidant				BRD-K00003683-001-01-9	Launched
tinazoline	adrenergic receptor agonist				BRD-K00004663-001-01-9	Launched
tinidazole	antiprotozoal agent		infectious disease, obstetrics/gynecology	giardiasis, amebiasis, bacterial vaginosis, trichomoniasis	BRD-K89125793-001-31-9, BRD-K89125793-001-25-2, BRD-K89125793-001-26-0, BRD-K89125793-001-27-8, BRD-K89125793-001-27-8	Launched
tinoridine	anti-inflammatory agent		neurology/psychiatry	pain relief	BRD-K84313779-003-03-9	Launched
tioconazole	sterol demethylase inhibitor		infectious disease	yeast infection	BRD-K00003630-001-01-9	Launched
tioguanine	purine antagonist		hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML)	BRD-K75649340-001-13-1, BRD-K75649340-001-13-1, BRD-K75649340-001-13-1, BRD-K75649340-002-14-9, BRD-K75649340-002-14-9	Launched
tiopronin	chelating agent, reducing agent		urology	kidney stones	BRD-A85295731-001-06-4, BRD-A85295731-001-05-6, BRD-A85295731-001-03-1, BRD-A85295731-001-02-3, BRD-A85295731-001-04-9	Launched
tiotidine	histamine receptor antagonist	HRH2			BRD-K11107424-001-02-9	Phase 2
tiotropium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	BRD-K62782754-337-02-5, BRD-K62782754-337-03-3	Launched
tioxolone	carbonic anhydrase inhibitor	CA2			BRD-K41876534-001-14-9, BRD-K41876534-001-13-7, BRD-K41876534-001-12-9	Preclinical
tipelukast	leukotriene receptor antagonist				BRD-K00004627-001-01-9	Phase 2
tipifarnib	farnesyltransferase inhibitor	FNTA, FNTB			BRD-K62965247-001-04-9, BRD-K62965247-001-04-9, BRD-K62965247-001-04-9, BRD-K62965247-001-04-9, BRD-K62965247-001-04-9, BRD-K62965247-001-05-6	Phase 3
tipiracil	thymidine phosphorylase inhibitor		oncology	colorectal cancer	BRD-K11973162-003-02-9, BRD-K11973162-003-01-8, BRD-K11973162-003-01-8	Launched
tiplaxtinin	plasminogen activator inhibitor	SERPINE1			BRD-K30882994-001-02-4, BRD-K30882994-001-01-6, BRD-K30882994-001-01-6, BRD-K30882994-001-01-6	Phase 1
tipranavir	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-A10039652-001-02-0, BRD-A10039652-001-01-2, BRD-A10039652-001-01-2, BRD-A10039652-001-03-9	Launched
tiprenolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			BRD-A73566563-001-01-6	Phase 2
tiquizium	acetylcholine receptor antagonist		neurology/psychiatry	spasms	BRD-K77552740-004-01-0	Launched
tiracizine	sodium channel blocker	SCN5A			BRD-K75250001-001-01-3	Withdrawn
tirasemtiv	troponin activator				BRD-K51087630-001-01-6, BRD-K51087630-001-02-9	Phase 2
tiratricol	thyroid hormone stimulant	THRA, THRB	endocrinology	Refetoff syndrome	BRD-K61236135-001-08-2, BRD-K61236135-001-09-0, BRD-K61236135-001-10-8	Launched
tirofiban	platelet aggregation inhibitor, structural glycoprotein antagonist	ITGA2B, ITGB3	cardiology	myocardial infarction, refactory angina	BRD-K37872686-003-01-9, BRD-K37872686-003-01-9	Launched
titanocene-dichloride	apoptosis stimulant				BRD-K60284353-001-02-9, BRD-K60284353-001-01-3	Phase 2
tivantinib	tyrosine kinase inhibitor	MET			BRD-K33379087-001-07-5, BRD-K33379087-001-07-5, BRD-K33379087-001-07-5, BRD-K33379087-001-07-5	Phase 3
tivozanib	VEGFR inhibitor	FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB	oncology	renal cell carcinoma (RCC)	BRD-K53414658-001-08-2, BRD-K53414658-001-08-2, BRD-K53414658-001-08-2, BRD-K53414658-001-08-2, BRD-K53414658-001-08-2, BRD-K53414658-001-08-2	Launched
tizanidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C, NISCH	neurology/psychiatry	spasms	BRD-K06335600-003-22-3, BRD-K06335600-003-20-7, BRD-K06335600-003-19-9, BRD-K06335600-003-19-9, BRD-K06335600-003-19-9	Launched
TMC-353121	RSV fusion inhibitor				BRD-K66097663-001-01-8, BRD-K66097663-001-02-9	Phase 2
TMC647055	RNA polymerase inhibitor				BRD-K49659468-436-01-2	Phase 2
TMN-355	cyclophilin inhibitor	PPIA			BRD-K24527118-001-01-6, BRD-K24527118-001-02-9	Preclinical
TMPH					BRD-K49119234-003-03-4, BRD-K49119234-003-02-6, BRD-K49119234-003-04-9	Preclinical
TMS					BRD-K96233303-001-02-7, BRD-K96233303-001-02-7, BRD-K96233303-001-02-7, BRD-K96233303-001-03-9, BRD-K96233303-001-01-9	Preclinical
TNP-470	methionine aminopeptidase inhibitor	METAP2			BRD-K53597484-001-02-7, BRD-K53597484-001-02-7, BRD-K53597484-001-02-7	Phase 2
tocainide	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	BRD-K01826767-001-05-9, BRD-K01826767-001-05-9	Launched
toceranib	protein tyrosine kinase inhibitor	FLT1, FLT3, KDR, PDGFRA, PDGFRB	oncology	cutaneous mast cell tumors	BRD-K62040061-001-01-0, BRD-K62040061-011-02-7, BRD-K62040061-011-02-7, BRD-K62040061-011-01-9	Launched
todralazine	antihypertensive agent		cardiology	hypertension	BRD-K68553471-003-12-3	Launched
tofisopam	cytochrome P450 inhibitor, phosphodiesterase inhibitor	CYP3A4	neurology/psychiatry	anxiety, abstinence from alcohol	BRD-K94830213-001-01-3, BRD-K94830213-001-01-3	Launched
tofogliflozin	sodium/glucose cotransporter inhibitor	GCK	endocrinology	diabetes mellitus	BRD-K96344439-002-02-7, BRD-K96344439-002-02-7, BRD-K96344439-002-02-7, BRD-K96344439-002-02-7, BRD-K96344439-002-01-9	Launched
tolamolol	adrenergic receptor antagonist	ADRB1, ADRB2, ADRB3			BRD-A60498477-001-01-2	Phase 3
tolazamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ10, KCNJ11	endocrinology	diabetes mellitus	BRD-K32164935-001-29-0, BRD-K32164935-001-30-8, BRD-K32164935-001-31-6	Launched
tolazoline	adrenergic receptor antagonist	ADRA1A, ADRA2A, ADRA2B, ADRA2C, HRH1, HRH2	neurology/psychiatry	reverse sedative	BRD-K46211610-003-27-9, BRD-K46211610-003-26-7, BRD-K46211610-003-25-9	Launched
tolbutamide	ATP channel blocker	ABCC8, KCNJ1, KCNJ11, KCNJ8	endocrinology	diabetes mellitus	BRD-K85119730-001-31-9, BRD-K85119730-001-28-9, BRD-K85119730-001-27-1	Launched
tolcapone	catechol O methyltransferase inhibitor	COMT			BRD-K10852020-001-07-9, BRD-K10852020-001-07-9, BRD-K10852020-001-04-5, BRD-K10852020-001-04-5, BRD-K10852020-001-05-2, BRD-K10852020-001-05-2, BRD-K10852020-001-05-2	Withdrawn
tolfenamic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist		neurology/psychiatry	migraine headache	BRD-K50133271-001-20-9, BRD-K50133271-001-18-7, BRD-K50133271-001-17-9	Launched
tolimidone	SRC activator	LYN, SRC			BRD-K41772907-001-02-0, BRD-K41772907-001-02-0, BRD-K41772907-001-01-2	Phase 2
tolmetin	cyclooxygenase inhibitor	PTGS1, PTGS2	rheumatology	rheumatoid arthritis, osteoarthritis	BRD-K82562631-325-06-9, BRD-K82562631-325-04-7, BRD-K82562631-236-04-6	Launched
tolnaftate	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis, tinea corporis	BRD-K44273375-001-27-9, BRD-K44273375-001-25-0, BRD-K44273375-001-24-3	Launched
tolonidine	adrenergic receptor antagonist	ADRA2A			BRD-K82687598-001-01-6	Launched
tolonium			hematology	methemoglobinemia	BRD-K94882685-003-09-2, BRD-K94882685-003-10-0	Launched
toloxatone	monoamine oxidase inhibitor	MAOA, MAOB	neurology/psychiatry	depression	BRD-A67182178-001-01-7, BRD-A67182178-001-01-7	Launched
tolperisone	voltage-gated sodium channel blocker	CYP2C19, CYP2D6	neurology/psychiatry, infectious disease, rheumatology, cardiology	muscle relaxant, multiple sclerosis, encephalomyelitis, ankylosing spondylitis, atherosclerosis, Raynaud's disease	BRD-A27732521-003-08-3, BRD-A27732521-003-08-3, BRD-A27732521-003-08-3, BRD-A27732521-003-07-5	Launched
tolrestat	aldose reductase inhibitor	AKR1A1, AKR1B1, AKR1B10			BRD-K85693895-001-02-9, BRD-K85693895-001-02-9, BRD-K85693895-001-02-9, BRD-K85693895-001-03-7, BRD-K85693895-001-01-1	Withdrawn
tolterodine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence, urinary frequency	BRD-K54316499-046-06-0, BRD-K54316499-046-05-2, BRD-K54316499-046-09-9, BRD-K54316499-046-04-5	Launched
toltrazuril	antiprotozoal agent		infectious disease	coccidiosis	BRD-K64514229-001-07-9, BRD-K64514229-001-07-9, BRD-K64514229-001-05-2, BRD-K64514229-001-04-5	Launched
tolvaptan	vasopressin receptor antagonist	AVPR1A, AVPR2	endocrinology, cardiology, gastroenterology	hyponatremia, congestive heart failure, hepatic cirrhosis	BRD-A82035391-001-03-5, BRD-A82035391-001-04-9, BRD-A82035391-001-04-9, BRD-A82035391-001-02-7	Launched
tomeglovir	antiviral				BRD-K00003487-001-01-9	Preclinical
tomelukast	leukotriene receptor antagonist	CYSLTR1			BRD-K74765201-001-16-7	Phase 3
tomivosertib	MAPK-interacting kinase inhibitor				BRD-K00003361-001-01-9	Phase 2
tonabersat	gap junction modulator, nitric oxide production inhibitor				BRD-K36970462-001-01-6, BRD-K36970462-001-02-9	Phase 2
topilutamide	androgen receptor antagonist				BRD-K00003325-001-01-9	Preclinical
topiramate	carbonic anhydrase inhibitor, glutamate receptor antagonist, kainate receptor antagonist	CA1, CA12, CA2, CA4, CA7, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, migraine headache	BRD-K29653726-001-16-7, BRD-K29653726-001-15-9, BRD-K29653726-001-14-2, BRD-K29653726-001-13-4, BRD-K29653726-001-13-4, BRD-K29653726-001-13-4	Launched
topiroxostat	xanthine oxidase inhibitor	XDH	rheumatology, nephrology	gout, hyperuricemia	BRD-K77561571-001-01-1, BRD-K77561571-001-01-1, BRD-K77561571-001-01-1, BRD-K77561571-001-01-1, BRD-K77561571-001-02-9	Launched
topotecan	topoisomerase inhibitor	TOP1, TOP1MT	oncology	small cell lung cancer, cervical cancer	BRD-K55696337-003-25-1, BRD-K55696337-003-21-0, BRD-K55696337-003-23-6, BRD-K55696337-003-22-8, BRD-K55696337-003-24-4, BRD-K55696337-003-24-4, BRD-K55696337-003-20-2	Launched
torasemide	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	SLC12A1	cardiology	edema, congestive heart failure, hypertension	BRD-K30480208-001-18-5, BRD-K30480208-001-19-9, BRD-K30480208-001-19-9, BRD-K30480208-001-17-7	Launched
torcitabine	DNA polymerase inhibitor	DCK, TK2			BRD-K91822704-003-08-9, BRD-K91822704-003-07-2	Phase 2
toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	ESR1	oncology	breast cancer	BRD-K51350053-048-16-5, BRD-K51350053-048-18-9, BRD-K51350053-048-18-9, BRD-K51350053-048-17-3, BRD-K51350053-048-17-3, BRD-K51350053-048-17-3, BRD-K51350053-048-17-3, BRD-K51350053-048-17-3, BRD-K51350053-048-15-7, BRD-K51350053-048-15-7	Launched
torin-1	mTOR inhibitor	MTOR			BRD-K40175214-001-11-6, BRD-K40175214-001-11-6, BRD-K40175214-001-13-2, BRD-K40175214-001-13-2, BRD-K40175214-001-15-9	Preclinical
torin-2	mTOR inhibitor	MTOR			BRD-K68174511-001-06-6, BRD-K68174511-001-06-6, BRD-K68174511-001-08-2, BRD-K68174511-001-08-2, BRD-K68174511-001-08-2, BRD-K68174511-001-09-9	Preclinical
tosedostat	peptidase inhibitor	ANPEP, LAP3, NPEPPS			BRD-K92241597-001-11-0, BRD-K92241597-001-09-4, BRD-K92241597-001-06-0, BRD-K92241597-001-06-0, BRD-K92241597-001-06-0, BRD-K92241597-001-06-0, BRD-K92241597-001-12-9, BRD-K92241597-001-05-2	Phase 2
tosufloxacin	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	BRD-K01825158-003-02-9	Launched
toyocamycin	serine/threonine kinase inhibitor	ERN1			BRD-K26420709-001-01-7, BRD-K26420709-001-01-7, BRD-K26420709-001-01-7	Phase 1
tozadenant	adenosine receptor antagonist	ADORA2A			BRD-K93045741-001-02-9, BRD-K93045741-001-01-0, BRD-K93045741-001-01-0, BRD-K93045741-001-01-0	Phase 3
tozasertib	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor	AURKA, AURKB, AURKC, LCK			BRD-K59369769-001-23-7, BRD-K59369769-001-20-3, BRD-K59369769-001-20-3, BRD-K59369769-001-20-3, BRD-K59369769-001-20-3	Phase 2
TP-003	GABA receptor inverse agonist	GABRA1, GABRA2, GABRA3, GABRA5			BRD-K87941707-001-02-9, BRD-K87941707-001-01-0	Preclinical
TP-0903	AXL kinase inhibitor	AXL			BRD-K84034737-001-01-1, BRD-K84034737-001-01-1, BRD-K84034737-001-01-1, BRD-K84034737-001-01-1, BRD-K84034737-001-01-1	Phase 1/Phase 2
TP-3654	1,4,5-trisphosphate inhibitor				BRD-K00005239-001-01-9	Phase 1
TPCA-1	IKK inhibitor	IKBKB			BRD-K51575138-001-15-7, BRD-K51575138-001-13-2, BRD-K51575138-001-13-2, BRD-K51575138-001-13-2, BRD-K51575138-001-13-2, BRD-K51575138-001-12-4	Preclinical
TPPS4					BRD-K00004542-001-01-9	Phase 1
trabectedin	antitumor agent				BRD-K00003313-001-01-9	Phase 3
trabodenoson	adenosine receptor agonist				BRD-K00004698-001-01-9	Phase 3
tracazolate	GABA receptor modulator	GABRA1			BRD-K34154330-003-07-9, BRD-K34154330-003-06-4, BRD-K34154330-003-06-4, BRD-K34154330-003-06-4	Phase 2
tradipitant	neurokinin receptor antagonist				BRD-K00003222-001-01-9	Phase 3
TRAM-34	potassium channel antagonist	KCNN4			BRD-K30071764-001-03-0, BRD-K30071764-001-02-2	Preclinical
TRAM-39	calcium-activated potassium channel activator	KCNN4			BRD-K81341251-001-02-9, BRD-K81341251-001-02-9, BRD-K81341251-001-01-9	Preclinical
trametinib	MEK inhibitor	MAP2K1, MAP2K2	oncology	melanoma	BRD-K12343256-001-18-8, BRD-K12343256-001-18-8, BRD-K12343256-001-18-8, BRD-K12343256-001-18-8, BRD-K12343256-001-14-7, BRD-K12343256-001-14-7, BRD-K12343256-001-14-7, BRD-K12343256-001-11-3, BRD-K12343256-001-11-3, BRD-K12343256-001-08-9, BRD-K12343256-001-08-9	Launched
tramiprosate	beta amyloid protein neurotoxicity inhibitor	APP			BRD-K82234479-001-09-4, BRD-K82234479-001-10-9	Phase 3
trandolapril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction	BRD-K28550399-001-03-9, BRD-K28550399-001-03-9	Launched
tranilast	angiogenesis inhibitor	HPGDS, HRH1	pulmonary	asthma	BRD-K17849083-001-34-5, BRD-K17849083-001-34-5, BRD-K17849083-001-31-1, BRD-K17849083-001-32-9, BRD-K17849083-001-29-5, BRD-K17849083-001-30-3	Launched
trans-10,cis-12-conjugated-linoleic-acid					BRD-K26222048-001-02-9, BRD-K26222048-001-01-7	Launched
trans-2-undecenoic-acid					BRD-K42959922-001-01-5	Preclinical
trans-4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid					BRD-K75080769-001-02-9, BRD-K75080769-001-01-6	Preclinical
trans-4-hydroxycrotonic-acid	gamma hydroxybutyric acid ligand				BRD-K91614056-001-03-9, BRD-K91614056-001-02-2	Preclinical
trans-4-methoxycinnamic-acid					BRD-K26273521-001-08-9, BRD-K26273521-001-07-3, BRD-K26273521-001-07-3	Preclinical
transcrocetinate	glutamate receptor antagonist				BRD-K00003217-304-01-9	Preclinical
tranylcypromine	monoamine oxidase inhibitor	KDM1A, MAOA, MAOB	neurology/psychiatry	depression	BRD-K00003699-065-01-9	Launched
trap-101	nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist	OPRL1			BRD-K69837166-003-03-8, BRD-K69837166-003-03-8, BRD-K69837166-003-02-0, BRD-K69837166-003-04-9	Preclinical
trapidil	PDGFR tyrosine kinase receptor inhibitor	PDGFRA	cardiology	coronary artery disease (CAD)	BRD-K95763993-001-20-9, BRD-K95763993-001-20-9, BRD-K95763993-001-19-3	Launched
travoprost	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension, glaucoma	BRD-K23976833-001-02-9, BRD-K23976833-001-01-0	Launched
traxoprodil	glutamate receptor antagonist	GRIN2B			BRD-K38158531-001-02-1, BRD-K38158531-001-02-1	Phase 2
trazodone	adrenergic receptor antagonist, serotonin receptor antagonist, serotonin reuptake inhibitor	ADRA1A, ADRA2A, HRH1, HTR1A, HTR2A, HTR2B, HTR2C, SLC6A4	neurology/psychiatry	depression	BRD-K70778732-003-27-5, BRD-K70778732-003-26-7	Launched
trebenzomine					BRD-A20686268-001-01-4	Phase 2
trelagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	BRD-K36407194-001-02-9	Launched
tremorine	acetylcholine receptor agonist				BRD-K08619838-303-06-9, BRD-K08619838-300-05-7, BRD-K08619838-300-05-7	Preclinical
treosulfan	DNA synthesis inhibitor		oncology	ovarian cancer	BRD-K20902145-001-01-2, BRD-K20902145-001-02-0	Launched
trepibutone	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology	irritable bowel syndrome	BRD-K37543758-001-01-3	Launched
treprostinil	prostanoid receptor agonist	P2RY12, PPARD, PTGIR	pulmonary	pulmonary arterial hypertension (PAH)	BRD-K19706299-236-02-9	Launched
trequinsin	phosphodiesterase inhibitor	PDE5A			BRD-K84663978-003-03-7, BRD-K84663978-003-02-9, BRD-K84663978-003-02-9, BRD-K84663978-003-05-9	Phase 1
tretazicar	DNA replication inhibitor	NQO2			BRD-K08748705-001-08-2, BRD-K08748705-001-08-2, BRD-K08748705-001-08-2	Phase 2
tretinoin	retinoid receptor agonist, retinoid receptor ligand	ALDH1A1, ALDH1A2, GPRC5A, NR0B1, NR2C2, PPARD, RARA, RARB, RARG, RARRES1, RORB, RORC, RXRB, RXRG	hematologic malignancy	acute promyelocytic leukemia (APL)	BRD-K71879491-001-51-5, BRD-K71879491-001-51-5, BRD-K71879491-001-51-5, BRD-K71879491-001-47-3, BRD-K71879491-001-39-0, BRD-K71879491-001-44-0, BRD-K71879491-001-48-1, BRD-K71879491-001-38-2, BRD-K71879491-001-37-4	Launched
triacetin					BRD-K92844263-001-12-9, BRD-K92844263-001-09-8	Launched
triamcinolone-acetonide	glucocorticoid receptor agonist, immunosuppressant	NR3C1, SERPINA6	dermatology	corticosteroid-responsive dermatoses	BRD-K53790871-001-20-9	Launched
triamcinolone-hexacetonide	anti-inflammatory agent				BRD-K00003338-001-01-9	Launched
triamterene	sodium channel blocker	SCNN1A, SCNN1B, SCNN1D, SCNN1G	endocrinology, cardiology	hypokalemia, hypertension, edema	BRD-K92049597-001-21-9, BRD-K92049597-001-21-9, BRD-K92049597-001-20-8, BRD-K92049597-001-20-8, BRD-K92049597-001-20-8, BRD-K92049597-001-20-8, BRD-K92049597-001-19-0	Launched
triapine	ribonucleotide reductase inhibitor	RRM1, RRM2			BRD-K01669786-001-03-0, BRD-K01669786-001-01-4, BRD-K01669786-001-02-2	Phase 2
tribenoside	anti-inflammatory agent, capillary stabilizing agent				BRD-A60294240-001-04-9, BRD-A60294240-001-03-7	Launched
tribomsalan					BRD-K09118247-001-04-9, BRD-K09118247-001-03-3, BRD-K09118247-001-03-3, BRD-K09118247-001-03-3	Preclinical
tribromoethanol	analgesic agent				BRD-K69632891-001-02-9, BRD-K69632891-001-01-3	Preclinical
tributyrin	HDAC inhibitor				BRD-K38969488-001-01-6, BRD-K38969488-001-01-6	Phase 1
tricaprylin			dermatology	cosmetic	BRD-K24790130-001-07-1, BRD-K24790130-001-09-9	Launched
trichlormethiazide	chloride channel blocker	PTGS1, PTGS2, SLC12A1	cardiology	hypertension, edema	BRD-A28940325-001-23-2, BRD-A28940325-001-24-0, BRD-A28940325-001-25-7, BRD-A28940325-001-25-7, BRD-A28940325-001-25-7	Launched
trichloroacetic-acid			dermatology	warts	BRD-K42090719-001-07-3, BRD-K42090719-001-06-5, BRD-K42090719-001-06-5	Launched
trichloroethylene					BRD-K46435528-001-05-1, BRD-K46435528-001-04-4	Preclinical
trichostatin-a	HDAC inhibitor	HDAC1, HDAC10, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9			BRD-K68202742-001-16-5, BRD-K68202742-001-16-5, BRD-K68202742-001-16-5, BRD-K68202742-001-16-5, BRD-K68202742-001-16-5, BRD-K68202742-001-13-2	Phase 1
triciribine-phosphate	AKT inhibitor				BRD-K00004666-001-01-9	Phase 1/Phase 2
triclabendazole	microtubule inhibitor	DNMT1	infectious disease	tapeworm	BRD-K81916719-001-15-9, BRD-K81916719-001-14-7, BRD-K81916719-001-13-9, BRD-K81916719-001-13-9, BRD-K81916719-001-13-9, BRD-K81916719-001-13-9, BRD-K81916719-001-13-9, BRD-K81916719-001-13-9, BRD-K81916719-001-13-9	Launched
triclocarban	other antibiotic		infectious disease	first-aid antiseptic	BRD-K25029121-001-07-9, BRD-K25029121-001-05-8, BRD-K25029121-001-05-8, BRD-K25029121-001-05-8, BRD-K25029121-001-05-8, BRD-K25029121-001-05-8	Launched
triclosan	antibacterial agent	DNMT1	infectious disease	first-aid antiseptic	BRD-K41731458-001-15-1, BRD-K41731458-001-15-1, BRD-K41731458-001-15-1, BRD-K41731458-001-15-1	Launched
tridihexethyl	acetylcholine receptor antagonist		gastroenterology, ophthalmology	peptic ulcer disease (PUD), nystagmus	BRD-A22152765-003-10-0	Launched
trientine	chelating agent	CA14	metabolism	Wilson's disease	BRD-K37111771-300-02-6, BRD-K37111771-001-09-9	Launched
trifloxystrobin	mitochondrial electron transport inhibitor				BRD-K00005342-001-01-9	Preclinical
trifluoperazine	dopamine receptor antagonist	ADRA1A, CALM1, CALY, DRD2, DRD4, HRH1, HTR2A, HTR2C, S100A4, TNNC1	neurology/psychiatry	schizophrenia	BRD-K89732114-300-20-9, BRD-K89732114-300-15-4, BRD-K89732114-300-15-4, BRD-K89732114-300-15-4, BRD-K89732114-300-14-7, BRD-K89732114-300-14-7, BRD-K89732114-300-13-9	Launched
triflupromazine	dopamine receptor antagonist	CHRM1, CHRM2, DRD1, DRD2, HTR2B	neurology/psychiatry, gastroenterology	psychosis, nausea, vomiting	BRD-K63675182-003-25-9, BRD-K63675182-003-25-9, BRD-K63675182-003-23-6, BRD-K63675182-003-23-6, BRD-K63675182-003-22-8, BRD-K63675182-003-22-8, BRD-K63675182-003-22-8	Launched
triflusal	cyclooxygenase inhibitor, platelet aggregation inhibitor, thromboxane synthase inhibitor	NFKB1, NOS2, PDE10A, PTGS1	neurology/psychiatry, cardiology	stroke, myocardial infarction, atrial fibrillation (AF)	BRD-K71696703-001-08-7, BRD-K71696703-001-11-1, BRD-K71696703-001-11-1, BRD-K71696703-001-07-9, BRD-K71696703-001-07-9, BRD-K71696703-001-09-5, BRD-K71696703-001-06-1	Launched
trigonelline					BRD-K69231085-003-05-7, BRD-K69231085-003-05-7	Phase 1
trihexyphenidyl	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	parkinsonism	BRD-K00003691-003-01-9	Launched
trilaciclib	CDK inhibitor				BRD-K00003412-300-01-9	Phase 2
TRIM					BRD-K36851334-001-12-1	Preclinical
trimebutine	opioid receptor agonist	OPRD1, OPRK1, OPRM1	gastroenterology	irritable bowel syndrome	BRD-K00003635-050-01-9	Launched
trimetazidine	3-ketoacyl CoA thiolase inhibitor	ACAA2	cardiology	angina pectoris	BRD-K88366685-300-07-9, BRD-K88366685-300-07-9, BRD-K88366685-300-06-0	Launched
trimethadione	oxazolidine antiepileptic	CACNA1G, CACNA1H, CACNA1I	neurology/psychiatry	seizures	BRD-K16606819-001-10-1, BRD-K16606819-001-13-5, BRD-K16606819-001-11-9, BRD-K16606819-001-12-7	Launched
trimethobenzamide	histamine receptor antagonist	DRD2	gastroenterology	vomiting, nausea, gastroenteritis	BRD-K34415467-003-13-0, BRD-K34415467-003-13-0, BRD-K34415467-003-14-8, BRD-K34415467-003-14-8	Launched
trimethoprim	dihydrofolate reductase inhibitor	DHFR, TYMS	infectious disease, gastroenterology	urinary tract infections, ear infections, diarrhea	BRD-K07208025-001-31-3, BRD-K07208025-001-29-7	Launched
trimethoquinol	adrenergic receptor antagonist	ADRB2, ADRB3	pulmonary	asthma	BRD-A56241705-003-01-2	Launched
trimethylolpropane-triacrylate					BRD-K24483849-001-01-8	Preclinical
trimetozine	sedative		neurology/psychiatry	sedative	BRD-K53220666-001-02-6, BRD-K53220666-001-03-9	Launched
trimetrexate	dihydrofolate reductase inhibitor	DHFR			BRD-K13642819-001-02-9	Phase 3
trimipramine	norepinephrine reputake inhibitor, tricyclic antidepressant	SLC6A2, SLC6A3, SLC6A4	neurology/psychiatry	depression	BRD-K01825162-050-02-9	Launched
trioxsalen	DNA synthesis inhibitor		dermatology	vitiligo, eczema	BRD-K54790157-001-16-9, BRD-K54790157-001-15-5	Launched
tripelennamine	histamine receptor antagonist	HRH1	pulmonary, allergy	asthma, allergic rhinitis, urticaria	BRD-K57033106-048-04-4, BRD-K57033106-003-19-7, BRD-K57033106-003-20-9	Launched
triprolidine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	BRD-K11742128-003-23-4, BRD-K11742128-003-22-6	Launched
triptan	serotonin receptor agonist	HTR1B, HTR1D			BRD-K19427720-001-01-6	Phase 1
triptorelin	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology, endocrinology, obstetrics/gynecology	prostate cancer, breast cancer, precocious puberty, endometriosis, myoma, gender dysphoria	BRD-K62685538-001-01-7, BRD-K62685538-001-02-9	Launched
troclosene					BRD-K76375510-237-01-1, BRD-K76375510-001-02-9	Launched
trodusquemine	tyrosine phosphatase inhibitor				BRD-K00003124-389-01-9	Phase 1
trofinetide	cytokine production inhibitor	IFNG, IL6, TNF			BRD-K83502127-001-01-6	Phase 2
trofosfamide	DNA alkylating agent		oncology	medulloblastoma	BRD-A91386192-001-07-9	Launched
troglitazone	insulin sensitizer, PPAR receptor agonist	CYP2C8, PPARG, TRPM3			BRD-A13084692-001-20-7, BRD-A13084692-001-20-7, BRD-A13084692-001-17-3	Withdrawn
troleandomycin	protein synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, tonsillitis, sinusitis	BRD-K38310698-001-05-0	Launched
trolox	antioxidant				BRD-A17846016-001-14-9, BRD-A17846016-001-14-9, BRD-A17846016-001-13-9	Launched
tromaril	prostanoid receptor antagonist		ophthalmology	eye inflammation	BRD-K91422571-001-02-9, BRD-K91422571-001-01-8, BRD-K91422571-001-01-8, BRD-K91422571-001-01-8	Launched
trometamol		AMD1, CANT1, DCN, NEIL1, VEGFA			BRD-K47978074-001-04-9, BRD-K47978074-001-04-9, BRD-K47978074-001-03-2, BRD-K47978074-001-02-4	Launched
tropanyl-3,5-dimethylbenzoate	serotonin receptor antagonist	HTR3A, HTR3B			BRD-A84389633-001-05-7	Preclinical
tropesin	cyclooxygenase inhibitor	PTGS1, PTGS2			BRD-A34603619-001-01-9	Launched
tropicamide	acetylcholine receptor antagonist	CHRM3, CHRM4	ophthalmology	mydriasis diagnostic, cycloplegia diagnostic	BRD-A79672927-001-22-3, BRD-A79672927-001-23-9, BRD-A79672927-001-19-9, BRD-A79672927-001-20-7, BRD-A79672927-001-18-1, BRD-A79672927-001-18-1	Launched
tropifexor	FXR agonist				BRD-K00003480-001-01-9	Phase 2
trospium	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence, urinary frequency	BRD-K00003641-003-01-9	Launched
trovafloxacin	bacterial DNA gyrase inhibitor	TOP2A			BRD-K00494077-066-02-7, BRD-K00494077-066-02-7, BRD-K00494077-066-02-7, BRD-K00494077-066-01-9, BRD-K00494077-066-03-9	Withdrawn
troventol					BRD-A35868371-005-01-6	Phase 1
trovirdine	non-nucleoside reverse transcriptase inhibitor				BRD-K00989047-001-01-2, BRD-K00989047-001-01-2, BRD-K00989047-001-01-2	Phase 1
troxipide	glucosamine synthetase stimulant		gastroenterology	gastroesophageal reflux disease (GERD)	BRD-A68589262-001-04-3, BRD-A68589262-001-04-3, BRD-A68589262-001-06-9, BRD-A68589262-001-05-0	Launched
TRV130	opioid receptor agonist	OPRM1			BRD-K35626314-003-01-1	Phase 3
tryptanthrin	cyclooxygenase inhibitor	IDO1			BRD-K76973696-001-12-6, BRD-K76973696-001-14-2	Preclinical
tryptophan	serotonin receptor partial agonist	CASR, IDO1, SLC36A1, WARS, WARS2	neurology/psychiatry, gastroenterology	anxiety, bloating, constipation, fatigue, sleeplessness	BRD-K83776863-001-08-9, BRD-K83776863-001-08-9, BRD-K83776863-001-05-5	Launched
TS-011	delayed vasospasm antagonist				BRD-K00004685-001-01-9	Preclinical
TTNPB	retinoid receptor agonist	RARA, RARB, RARG			BRD-K49685476-001-15-9, BRD-K49685476-001-14-2, BRD-K49685476-001-16-7	Phase 1
TTP-22	casein kinase inhibitor	CSNK2A1			BRD-K64852730-001-02-9, BRD-K64852730-001-01-7	Preclinical
TU-2100					BRD-K44590731-001-02-9, BRD-K44590731-001-01-7	Phase 2
tuaminoheptane			otolaryngology	nasal congestion	BRD-A19958636-065-04-4, BRD-A19958636-001-05-9	Launched
tubastatin-A	HDAC inhibitor	HDAC6			BRD-K00627859-003-03-7, BRD-K00627859-003-03-7, BRD-K00627859-003-03-7, BRD-K00627859-001-07-2, BRD-K00627859-001-07-2, BRD-K00627859-001-06-4	Preclinical
tubocurarine	acetylcholine receptor antagonist	ACHE, CHRNA2, HTR3A, HTR3B, KCNN1, KCNN2, KCNN3, ZACN	neurology/psychiatry	anesthetic	BRD-K99621550-300-01-8, BRD-K99621550-300-04-9, BRD-K99621550-300-04-9	Launched
tucatinib	EGFR inhibitor	ERBB2			BRD-K26026438-001-01-0, BRD-K26026438-001-01-0, BRD-K26026438-001-01-0, BRD-K26026438-001-01-0	Phase 3
tucidinostat	HDAC inhibitor				BRD-K95216408-001-02-9	Phase 3
tuftsin	macrophage activator				BRD-K00003336-001-01-9	Preclinical
TUG-770	free fatty acid receptor agonist	FFAR1			BRD-K56086081-001-01-7	Preclinical
TUG-891	free fatty acid receptor agonist	FFAR4			BRD-K24282351-001-02-9, BRD-K24282351-001-02-9, BRD-K24282351-001-02-9, BRD-K24282351-001-01-4	Preclinical
tulobuterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma	BRD-K00003719-003-01-9	Launched
tulrampator	antidepressant 				BRD-K00005240-001-01-9	Phase 2
TW-37	BCL inhibitor	BCL2, BCL2L1, MCL1			BRD-K28360340-001-08-3, BRD-K28360340-001-08-3, BRD-K28360340-001-08-3, BRD-K28360340-001-05-9	Preclinical
TWS-119	glycogen synthase kinase inhibitor	GSK3B, JUN, MYC			BRD-K94176593-001-09-4, BRD-K94176593-001-09-4, BRD-K94176593-001-09-4, BRD-K94176593-362-01-7, BRD-K94176593-362-10-9	Preclinical
TXA127	angiotensin receptor agonist				BRD-K36040345-001-02-9, BRD-K36040345-001-02-9, BRD-K36040345-001-01-1	Phase 2
TY-52156	sphingosine 1-phosphate receptor antagonist	S1PR3			BRD-K66584608-001-02-1, BRD-K66584608-001-03-9, BRD-K66584608-001-01-3	Preclinical
tymazoline			allergy	allergic rhinitis	BRD-K64414150-001-01-7	Launched
tyrphostin-AG-1296	FLT3 inhibitor	FLT3			BRD-K76064317-001-08-1, BRD-K76064317-001-08-1, BRD-K76064317-001-07-3, BRD-K76064317-001-07-3, BRD-K76064317-001-07-3, BRD-K76064317-001-07-3	Preclinical
tyrphostin-AG-1478	EGFR inhibitor	EGFR, MAPK14			BRD-K68336408-001-10-9, BRD-K68336408-001-10-9	Preclinical
tyrphostin-AG-18	EGFR inhibitor, tyrosine kinase inhibitor	EGFR			BRD-K49657628-001-14-8, BRD-K49657628-001-14-8, BRD-K49657628-001-13-0, BRD-K49657628-001-15-5	Preclinical
tyrphostin-AG-494	EGFR inhibitor	EGFR			BRD-K34533029-001-09-9, BRD-K34533029-001-08-5, BRD-K34533029-001-08-5, BRD-K34533029-001-08-5	Preclinical
tyrphostin-AG-825	protein tyrosine kinase inhibitor	ERBB2			BRD-K87919739-001-07-5, BRD-K87919739-001-08-9	Preclinical
tyrphostin-AG-835	protein tyrosine kinase inhibitor	EGFR			BRD-K17415526-001-04-9, BRD-K17415526-001-03-5	Preclinical
tyrphostin-AG-879	tyrosine kinase inhibitor	ERBB2, KDR, NTRK1			BRD-K59469039-001-09-8, BRD-K59469039-001-09-8, BRD-K59469039-001-09-8, BRD-K59469039-001-08-0, BRD-K59469039-001-08-0, BRD-K59469039-001-08-0, BRD-K59469039-001-08-0, BRD-K59469039-001-08-0, BRD-K59469039-001-08-0, BRD-K59469039-001-08-0	Preclinical
tyrphostin-AG-99	tyrosine kinase inhibitor	EGFR			BRD-K60184833-001-06-9, BRD-K60184833-001-05-6, BRD-K60184833-001-05-6	Preclinical
tyrphostin-A9	protein tyrosine kinase inhibitor, tyrosine kinase inhibitor				BRD-K40255344-001-17-6, BRD-K40255344-001-17-6, BRD-K40255344-001-17-6, BRD-K40255344-001-17-6, BRD-K40255344-001-17-6, BRD-K40255344-001-17-6, BRD-K40255344-001-17-6, BRD-K40255344-001-17-6, BRD-K40255344-001-13-5	Preclinical
U-0124	MEK inhibitor				BRD-K03635852-001-02-0, BRD-K03635852-001-03-9	Preclinical
U-0521	catechol O methyltransferase inhibitor	COMT			BRD-K08953028-001-09-6	Preclinical
U-104	carbonic anhydrase inhibitor	CA1, CA12, CA2, CA9			BRD-K77867004-001-04-9, BRD-K77867004-001-02-7, BRD-K77867004-001-03-5, BRD-K77867004-001-03-5, BRD-K77867004-001-03-5	Phase 1/Phase 2
U-18666A	oxidosqualene cyclase inhibitor				BRD-K22025381-003-02-9, BRD-K22025381-003-01-9, BRD-K22025381-003-01-9, BRD-K22025381-003-01-9, BRD-K22025381-003-01-9	Preclinical
U-54494A	opioid receptor agonist	OPRK1			BRD-K20995441-001-03-9, BRD-K20995441-001-02-5	Preclinical
U-75799E	growth hormone releasing factor agonist	GHSR			BRD-K77070363-001-01-5, BRD-K77070363-001-01-5, BRD-K77070363-001-01-5	Phase 1
U-99194	dopamine receptor antagonist	DRD3			BRD-K70281171-050-08-9	Preclinical
UAMC-00039	dipeptidyl peptidase inhibitor	DPP4, DPP7			BRD-K38966689-300-02-9, BRD-K38966689-300-01-5	Preclinical
UB-165	acetylcholine receptor agonist	CHRNA3, CHRNA4, CHRNB2			BRD-A14574269-051-03-0, BRD-A14574269-051-03-0, BRD-A14574269-051-02-2	Preclinical
ubenimex	leukotriene synthesis inhibitor	LTA4H, RNPEP	hematologic malignancy	acute myeloid leukemia (AML)	BRD-K59574735-001-13-9, BRD-K59574735-001-11-8, BRD-K59574735-001-11-8, BRD-K59574735-001-12-6	Launched
UBP-296	glutamate receptor antagonist	GRIK1			BRD-A45499626-001-04-9, BRD-A45499626-001-04-9, BRD-A45499626-001-03-6	Preclinical
UBP-302	glutamate receptor antagonist	GRIK1			BRD-K79753741-001-02-5, BRD-K79753741-001-03-3, BRD-K79753741-001-03-3, BRD-K79753741-001-01-7	Preclinical
UBP-310	glutamate receptor antagonist	GRIK1, GRIK5			BRD-K09597601-001-01-2, BRD-K09597601-001-02-9	Preclinical
UC-112	XIAP inhibitor	XIAP			BRD-K73610817-001-10-9, BRD-K73610817-001-09-7, BRD-K73610817-001-09-7	Preclinical
UCL-2077	slow afterhyperpolarization channel blocker				BRD-K50325075-001-03-9, BRD-K50325075-001-02-1, BRD-K50325075-001-04-9	Preclinical
udenafil	phosphodiesterase inhibitor		urology	erectile dysfunction	BRD-K00003266-001-01-9	Launched
UF-010	HDAC inhibitor	HDAC1, HDAC2, HDAC3, HDAC8			BRD-K20480395-001-01-6, BRD-K20480395-001-02-9, BRD-K20480395-001-02-9	Preclinical
ufenamate	cyclooxygenase inhibitor	PTGS1, PTGS2	dermatology	eczema, dermatitis	BRD-K84173274-001-01-6, BRD-K84173274-001-01-6	Launched
UH-232-(+)	dopamine receptor antagonist	DRD2, DRD3, DRD4, HTR1A			BRD-K66715657-050-02-9, BRD-K66715657-050-01-0	Preclinical
UK-356618	metalloproteinase inhibitor	MMP13, MMP14, MMP2, MMP3, MMP9			BRD-K57011718-001-02-3, BRD-K57011718-001-02-3, BRD-K57011718-001-02-3, BRD-K57011718-001-01-5, BRD-K57011718-001-01-5	Preclinical
UK-383367	procollagen C-endopeptidase inhibitor	BMP1			BRD-K06294530-001-03-1, BRD-K06294530-001-01-5, BRD-K06294530-001-01-5, BRD-K06294530-001-04-9, BRD-K06294530-001-04-9, BRD-K06294530-001-02-3	Phase 1
UK-5099	monocarboxylate transporter inhibitor	SLC16A1			BRD-K19558579-001-01-0, BRD-K19558579-001-01-0, BRD-K19558579-001-02-9	Preclinical
uki-1	urokinase inhibitor				BRD-K00003367-001-01-9	Preclinical
ulifloxacin			infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-A61633223-001-02-8, BRD-A61633223-001-01-0	Launched
umeclidinium	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema	BRD-K46692793-004-01-8, BRD-K46692793-004-01-8, BRD-K46692793-004-02-9, BRD-K46692793-004-02-9	Launched
unbs-5162	CC chemokine receptor antagonist				BRD-K30933884-001-01-0, BRD-K30933884-001-01-0, BRD-K30933884-001-02-9	Phase 1
UNC0224	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			BRD-K77428767-001-01-7, BRD-K77428767-001-02-5, BRD-K77428767-001-02-5, BRD-K77428767-001-02-5	Preclinical
UNC0321	histone lysine methyltransferase inhibitor	EHMT2			BRD-K74236984-001-04-8, BRD-K74236984-001-05-5, BRD-K74236984-001-05-5	Preclinical
UNC0631	histone lysine methyltransferase inhibitor	EHMT2			BRD-K13060017-001-01-3, BRD-K13060017-001-01-3, BRD-K13060017-001-01-3, BRD-K13060017-001-01-3, BRD-K13060017-001-02-1, BRD-K13060017-001-02-1, BRD-K13060017-001-02-1	Preclinical
UNC0638	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			BRD-K86856088-001-06-9, BRD-K86856088-001-07-7, BRD-K86856088-001-08-5, BRD-K86856088-001-08-5	Preclinical
UNC0642	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			BRD-K60130390-001-02-1, BRD-K60130390-001-02-1, BRD-K60130390-001-04-7, BRD-K60130390-001-03-9	Preclinical
UNC0646	histone lysine methyltransferase inhibitor	EHMT2			BRD-K87465484-001-02-7, BRD-K87465484-001-04-3, BRD-K87465484-001-03-5	Preclinical
UNC0737	histone lysine methyltransferase inhibitor	EHMT1, EHMT2			BRD-K02988401-001-01-2	Preclinical
UNC1215	L3MBTL antagonist	L3MBTL3			BRD-K83189926-001-05-9, BRD-K83189926-001-03-1, BRD-K83189926-001-04-9	Preclinical
UNC1999	histone lysine methyltransferase inhibitor	EZH2			BRD-K26989966-001-05-0, BRD-K26989966-001-04-3, BRD-K26989966-001-04-3, BRD-K26989966-001-03-5, BRD-K26989966-001-03-5, BRD-K26989966-001-03-5, BRD-K26989966-001-03-5	Preclinical
UNC2025	FLT3 inhibitor, MER tyrosine kinase inhibitor	FLT3, MERTK			BRD-K91283740-003-01-6, BRD-K91283740-003-01-6	Preclinical
UNC2250	MER tyrosine kinase inhibitor	MERTK			BRD-K01773560-001-01-6, BRD-K01773560-001-01-6, BRD-K01773560-001-02-4, BRD-K01773560-001-03-9	Preclinical
UNC2327	protein arginine N-methyltransferase inhibitor	PRMT3			BRD-K60635008-001-02-9, BRD-K60635008-001-01-5, BRD-K60635008-001-01-5	Preclinical
UNC3230	phosphatidyl-inositol activator	PIP5K1C			BRD-K46344388-001-02-9, BRD-K46344388-001-01-3	Preclinical
UNC669	L3MBTL antagonist	L3MBTL1			BRD-K21906513-001-03-2, BRD-K21906513-001-04-0, BRD-K21906513-001-05-9	Preclinical
UNC926	MBT inhibitor	L3MBTL1			BRD-K22229656-003-02-9, BRD-K22229656-003-01-5, BRD-K22229656-003-01-5	Preclinical
undecylenic-acid	other antifungal		infectious disease	tinea pedis, tinea corporis	BRD-K19189338-001-03-2, BRD-K19189338-001-05-7	Launched
upadacitinib	JAK inhibitor				BRD-K00003286-001-01-9	Launched
upamostat	serine protease inhibitor				BRD-K00003218-001-01-9	Phase 2
UPF-1069	PARP inhibitor	PARP2			BRD-K77950083-001-04-1, BRD-K77950083-001-03-3, BRD-K77950083-001-02-5, BRD-K77950083-001-02-5, BRD-K77950083-001-05-9	Preclinical
uprifosbuvir	antiviral				BRD-K00003526-001-01-9	Preclinical
uprosertib	AKT inhibitor	AKT1, AKT2, AKT3			BRD-K38332599-001-01-3, BRD-K38332599-001-01-3, BRD-K38332599-001-02-9, BRD-K38332599-001-02-9	Phase 2
uracil		DPYD, UCKL1			BRD-K80129304-001-10-9, BRD-K80129304-001-09-9, BRD-K80129304-001-08-1, BRD-K80129304-001-08-1	Launched
uracil-mustard	DNA synthesis inhibitor		hematologic malignancy	non-Hodgkin lymphoma (NHL)	BRD-K10180294-001-07-3, BRD-K10180294-001-04-0, BRD-K10180294-001-06-5	Launched
urapidil	adrenergic receptor antagonist	HTR1A	cardiology	hypertension	BRD-K73196317-003-15-5, BRD-K73196317-003-21-9, BRD-K73196317-003-21-9, BRD-K73196317-003-21-9, BRD-K73196317-003-13-0, BRD-K73196317-003-14-8	Launched
URB597	FAAH inhibitor	FAAH, FAAH2, TRPA1			BRD-K92169341-001-14-9, BRD-K92169341-001-14-9, BRD-K92169341-001-12-0, BRD-K92169341-001-11-2, BRD-K92169341-001-11-2, BRD-K92169341-001-11-2, BRD-K92169341-001-10-4	Phase 1
urea	hydroxy radical formation stimulant	ARG1, CA2, CTNNB1	dermatology	psoriasis, xerosis cutis, ichthyosis vulgaris, eczema, keratosis, dermatitis	BRD-K88052444-001-10-9, BRD-K88052444-001-08-8, BRD-K88052444-001-08-8	Launched
urethane	local anesthetic				BRD-K24297741-001-05-2, BRD-K24297741-001-07-9	Preclinical
uric-acid		PYGL			BRD-K01295354-001-02-8	Phase 3
uridine-triacetate			nephrology	orotic aciduria	BRD-K18323388-001-01-1	Launched
URMC-099	mixed lineage kinase inhibitor	CDKL2, DAPK3, FLT3, LRRK2, MAP3K10, MAP3K11, MAP3K2, MAP3K9, SRPK2			BRD-K66908976-001-01-8, BRD-K66908976-001-01-8	Preclinical
urolithin-A	antioxidant				BRD-K00003383-001-01-9	Phase 3
ursodeoxycholyltaurine	cholesterol inhibitor				BRD-K45245728-236-02-9, BRD-K45245728-236-02-9, BRD-K45245728-335-01-4	Phase 3
V-51	adrenergic receptor antagonist				BRD-K75052463-001-01-4, BRD-K75052463-001-01-4	Phase 1
vaborbactam	beta lactamase inhibitor				BRD-K00003306-001-01-9	Launched
vadadustat	hypoxia inducible factor prolyl hydroxylase inhibitor				BRD-K00003407-001-01-9	Phase 3
val-tyr	angiotensin converting enzyme inhibitor				BRD-K00004630-001-01-9	Preclinical
valaciclovir	DNA polymerase inhibitor		infectious disease	shingles, virus herpes simplex (HSV)	BRD-K46435977-003-12-9, BRD-K46435977-003-11-1, BRD-K46435977-003-13-7	Launched
valbenazine	vesicular monoamine transporter inhibitor		neurology/psychiatry	dyskinesia	BRD-K00003233-001-01-9	Launched
valdecoxib	cyclooxygenase inhibitor	CA12, PTGS2			BRD-K12994359-001-19-2, BRD-K12994359-001-18-4, BRD-K12994359-001-18-4	Withdrawn
valethamate	acetylcholine receptor antagonist	CHRM1, CHRM4, CHRM5	obstetrics/gynecology	labor induction	BRD-A56613951-004-01-1	Launched
valnemulin	bacterial 50S ribosomal subunit inhibitor		infectious disease, gastroenterology	dysentry, colitis, pneumonia	BRD-K22938173-003-02-9	Launched
valnoctamide	arachidonic acid acylation inhibitor, benzodiazepine receptor agonist		neurology/psychiatry	sleeplessness	BRD-A96644976-001-01-5	Launched
valpromide	epoxide hydolase inhibitor		neurology/psychiatry	epilepsy	BRD-K54698528-001-01-2	Launched
valrocemide					BRD-K32804101-001-01-8	Phase 2
valrubicin	DNA inhibitor, topoisomerase inhibitor	TOP2A	oncology	bladder cancer	BRD-K72951360-001-01-4, BRD-K72951360-001-01-4, BRD-K72951360-001-01-4, BRD-K72951360-001-02-9	Launched
valsartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure, congestive heart failure	BRD-K45158365-001-11-4, BRD-K45158365-001-11-4, BRD-K45158365-001-11-4, BRD-K45158365-001-12-2, BRD-K45158365-001-12-2, BRD-K45158365-001-10-6, BRD-K45158365-001-13-9, BRD-K45158365-001-13-9	Launched
valspodar	P glycoprotein inhibitor	ABCB1			BRD-K19412342-001-01-6, BRD-K19412342-001-02-4, BRD-K19412342-001-02-4	Phase 3
vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA	oncology	medullary thyroid cancer (MTC)	BRD-K77625799-001-13-9, BRD-K77625799-001-13-9, BRD-K77625799-001-07-7, BRD-K77625799-001-07-7, BRD-K77625799-001-07-7, BRD-K77625799-001-07-7, BRD-K77625799-001-07-7, BRD-K77625799-001-07-7	Launched
vanillin		ABAT, ALDH5A1			BRD-K24258499-001-08-9, BRD-K24258499-001-05-8, BRD-K24258499-001-05-8	Preclinical
vanillylacetone					BRD-K33510429-001-03-1, BRD-K33510429-001-02-3	Preclinical
vaniprevir	serine protease inhibitor				BRD-K00003445-001-01-9, BRD-K00003445-001-01-9	Phase 3
vanitiolide					BRD-K26502378-001-07-9, BRD-K26502378-001-08-9	Preclinical
vanoxerine	dopamine reuptake inhibitor	SLC6A3			BRD-K32501161-300-07-0, BRD-K32501161-300-07-0, BRD-K32501161-300-12-9, BRD-K32501161-300-06-2, BRD-K32501161-300-06-2, BRD-K32501161-300-06-2	Phase 3
vapendavir	antiviral				BRD-K00004577-001-01-9	Phase 2
vardenafil	phosphodiesterase inhibitor	PDE5A, PDE6G, PDE6H	urology	erectile dysfunction	BRD-K13926615-003-03-3, BRD-K13926615-003-03-3, BRD-K13926615-003-09-9, BRD-K13926615-394-02-8	Launched
varenicline	acetylcholine receptor agonist	CHRNA3, CHRNA4, CHRNA6, CHRNA7	neurology/psychiatry	smoking cessation	BRD-K18855837-045-02-9	Launched
varespladib	secretory phospholipase inhibitor	PLA2G2A			BRD-K09711437-001-04-3	Phase 3
vasopressin	vasopressin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	gastroenterology	abdominal distension	BRD-K73028949-001-02-8	Launched
vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	EGFR, FLT1, FLT4, KDR, PDGFRB			BRD-K70163715-300-04-0, BRD-K70163715-036-01-6, BRD-K70163715-300-05-7	Phase 3
vatinoxan	adrenergic receptor antagonist				BRD-K00003277-003-01-9	Preclinical
VBY-825	cathepsin inhibitor	CTSB, CTSL, CTSS			BRD-K36338614-001-01-3, BRD-K36338614-001-02-1, BRD-K36338614-001-02-1, BRD-K36338614-001-02-1	Preclinical
VCH-916	HCV inhibitor				BRD-K75956464-237-01-5, BRD-K75956464-237-01-5, BRD-K75956464-237-02-9	Phase 1
VE-821	ATR kinase inhibitor	ATR			BRD-K26756394-001-04-9, BRD-K26756394-001-02-2, BRD-K26756394-001-02-2, BRD-K26756394-001-02-2	Preclinical
VE-822	ATR kinase inhibitor	ATM, ATR, MTOR, PIK3CG			BRD-K04701033-001-04-7, BRD-K04701033-001-04-7, BRD-K04701033-001-04-7, BRD-K04701033-001-04-7, BRD-K04701033-001-04-7, BRD-K04701033-001-01-3, BRD-K04701033-001-03-9, BRD-K04701033-001-03-9	Phase 2
vecabrutinib	Bruton's tyrosine kinase (BTK) inhibitor				BRD-K00003503-001-01-9	Phase 1/Phase 2
vedaprofen	anti-inflammatory agent	PTGS2	neurology/psychiatry, endocrinology	pain relief, fever	BRD-K00004714-001-01-9	Launched
velaresol					BRD-K00004580-001-01-9	Preclinical
veledimex	cytochrome P450 inhibitor				BRD-K00003235-001-01-9	Phase 2
veliflapon	leukotriene synthesis inhibitor	ALOX5AP			BRD-K12852738-001-01-2	Phase 3
veliparib	PARP inhibitor	PARP1, PARP2			BRD-K87142802-001-06-9	Phase 3
velneperit	neuropeptide receptor antagonist	NPY5R			BRD-K06357403-001-02-2, BRD-K06357403-001-01-4	Phase 2
velpatasvir	antiviral		infectious disease	hepatitis C	BRD-K00003133-001-01-9	Launched
vemurafenib	RAF inhibitor	BRAF, RAF1	oncology	melanoma	BRD-K56343971-001-14-8, BRD-K56343971-001-14-8, BRD-K56343971-001-14-8, BRD-K56343971-001-14-8, BRD-K56343971-001-14-8, BRD-K56343971-001-12-2, BRD-K56343971-001-12-2, BRD-K56343971-001-12-2, BRD-K56343971-001-10-6, BRD-K56343971-001-10-6, BRD-K56343971-001-10-6	Launched
venetoclax	BCL inhibitor	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	BRD-K62391742-001-08-9, BRD-K62391742-001-08-9, BRD-K62391742-001-08-9, BRD-K62391742-001-08-9, BRD-K62391742-001-09-7, BRD-K62391742-001-09-7, BRD-K62391742-001-09-7, BRD-K62391742-001-09-7, BRD-K62391742-001-09-7, BRD-K62391742-001-03-0, BRD-K62391742-001-03-0, BRD-K62391742-001-03-0	Launched
venlafaxine	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotoninâ€“norepinephrine reuptake inhibitor (SNRI)	SLC6A2, SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD), panic disorders, social anxiety disorder	BRD-K01826548-003-14-9, BRD-K01826548-003-12-9, BRD-K01826548-003-13-9, BRD-K01826548-003-13-9	Launched
VER-155008	HSP inhibitor	HSPA1A			BRD-K32330832-001-02-8, BRD-K32330832-001-01-0, BRD-K32330832-001-01-0, BRD-K32330832-001-01-0, BRD-K32330832-001-01-0, BRD-K32330832-001-01-0, BRD-K32330832-001-01-0, BRD-K32330832-001-01-0, BRD-K32330832-001-01-0, BRD-K32330832-001-01-0, BRD-K32330832-001-01-0, BRD-K32330832-001-01-0	Preclinical
veralipride	dopamine receptor antagonist				BRD-K00003433-001-01-9	Preclinical
verapamil	calcium channel blocker	CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CYP3A4, KCNA10, KCNA7, KCNH2, KCNJ11, NALCN, SCN5A, SLC29A4, SLC6A4	cardiology	hypertension	BRD-A09533288-003-29-6, BRD-A09533288-003-31-2, BRD-A09533288-003-31-2, BRD-A09533288-003-31-2	Launched
verbascoside	NFkB pathway inhibitor, PKC inhibitor				BRD-K36201510-001-06-7, BRD-K36201510-001-06-7	Phase 2/Phase 3
vercirnon	CC chemokine receptor antagonist	CCR9			BRD-K47929404-001-01-0, BRD-K47929404-001-01-0	Phase 3
verdinexor	exportin antagonist				BRD-K00004674-001-01-9	Preclinical
verdiperstat	myeloperoxidase inhibitor				BRD-K00004612-001-01-9	Phase 3
vericiguat	guanylate cyclase stimulant				BRD-K00003234-001-01-9	Phase 3
verinurad	urate transporter inhibitor	SLC22A12			BRD-K36741660-001-01-1	Phase 2
vernakalant	potassium channel blocker	KCNA5	cardiology	atrial fibrillation (AF)	BRD-K19741547-003-01-7, BRD-K19741547-003-01-7, BRD-K19741547-003-02-9, BRD-K19741547-003-02-9	Launched
verteporfin	photosensitizing agent		ophthalmology	macular degeneration	BRD-K81849500-001-08-9, BRD-K81849500-001-08-9, BRD-K81849500-001-07-7, BRD-K81849500-001-06-9, BRD-K81849500-001-02-8, BRD-K81849500-001-05-1, BRD-K81849500-001-01-0	Launched
verubecestat	beta secretase inhibitor				BRD-K00003229-001-01-9	Phase 3
verubulin	tubulin polymerization inhibitor	TUBB			BRD-K42673188-001-01-1, BRD-K42673188-001-01-1, BRD-K42673188-001-01-1, BRD-K42673188-003-01-7	Phase 2
verucerfont	corticotropin releasing factor receptor antagonist				BRD-K00003180-001-01-9	Phase 2
vesamicol	acetylcholinesterase inhibitor	SLC18A3			BRD-K14765469-003-13-0, BRD-K14765469-003-13-0, BRD-K14765469-003-14-9, BRD-K14765469-003-12-2, BRD-K14765469-003-12-2	Preclinical
vesnarinone	phosphodiesterase inhibitor	KCNH2, PDE3A	cardiology	congestive heart failure	BRD-K13414800-001-01-3, BRD-K13414800-001-01-3, BRD-K13414800-001-01-3	Launched
VGX-1027	tumor necrosis factor receptor antagonist	TLR4			BRD-A32269193-001-02-9, BRD-A32269193-001-01-5, BRD-A32269193-001-01-5	Phase 1
vicriviroc	CC chemokine receptor antagonist	CCR5			BRD-K84748119-050-03-9, BRD-K84748119-050-01-1, BRD-K84748119-050-01-1	Phase 3
vidarabine	antiviral	ADA	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)	BRD-K72093121-001-17-1, BRD-K72093121-001-16-3	Launched
vigabatrin	GABA aminotransferase inhibitor	ABAT, SLC32A1	neurology/psychiatry	seizures, spasms	BRD-K01825700-213-01-9, BRD-K01825700-001-02-9	Launched
vilanterol	adrenergic receptor agonist	ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)		Launched
vilazodone	serotonin reuptake inhibitor	DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4	neurology/psychiatry	depression	BRD-K58010567-003-02-2, BRD-K58010567-003-04-9, BRD-K58010567-003-04-9, BRD-K58010567-003-01-4, BRD-K58010567-003-03-0	Launched
vildagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	BRD-K00003565-001-01-9	Launched
viloxazine	norepinephrine reuptake inhibitor	SLC6A2	neurology/psychiatry	depression	BRD-A59198242-003-03-9, BRD-A59198242-003-03-9, BRD-A59198242-003-02-9	Launched
vinburnine	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	neurology/psychiatry	stroke	BRD-K40227168-001-12-9, BRD-K40227168-001-13-9	Launched
vincamine	adrenergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4			BRD-K40902647-001-10-9	Withdrawn
vindesine	tubulin polymerization inhibitor	TUBB, TUBB1	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma	BRD-K59753975-001-02-6, BRD-K59753975-001-02-6, BRD-K59753975-001-02-6, BRD-K59753975-001-02-6	Launched
vinorelbine	tubulin polymerization inhibitor	TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	non-small cell lung cancer (NSCLC)	BRD-K04269837-346-01-8, BRD-K04269837-346-03-9	Launched
viomycin	protein synthesis inhibitor		infectious disease	tuberculosis	BRD-A42379279-065-03-8	Launched
vipadenant	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K56565215-001-01-9, BRD-K56565215-001-01-9, BRD-K56565215-001-01-9, BRD-K56565215-001-01-9	Phase 1
vismodegib	hedgehog pathway inhibitor, smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	BRD-K44827188-001-06-0, BRD-K44827188-001-06-0, BRD-K44827188-001-06-0, BRD-K44827188-001-04-5	Launched
visomitin	antioxidant				BRD-K00003375-004-01-9, BRD-K00003375-004-01-9	Preclinical
vitamin-B12			hematology	megaloblastic anemia	BRD-K00003629-001-01-9	Launched
vitamin-E	LDL oxidation inhibitor, PKC inhibitor	ALOX5, DGKA, NR1I2, PPP2CA, PPP2CB, PRKCA, PRKCB, SEC14L2, SEC14L3, SEC14L4			BRD-K97091514-001-11-4	Launched
vixotrigine	sodium channel blocker				BRD-K00003141-003-01-9	Phase 2
VLX1570	deubiquitinase inhibitor				BRD-K00003343-001-01-9	Phase 1/Phase 2
VLX600	antitumor agent, ubiquitin C-terminal hydrolase inhibitor	TP53, USP14			BRD-K26122255-001-01-7, BRD-K26122255-001-01-7, BRD-K26122255-001-02-9, BRD-K26122255-001-02-9, BRD-K26122255-001-02-9, BRD-K26122255-001-02-9	Phase 1
VL285	PROTAC				BRD-K00005338-001-01-9	Preclinical
voclosporin	calcineurin inhibitor				BRD-K00003472-001-01-9	Phase 3
volasertib	PLK inhibitor	PLK1			BRD-K69776681-001-06-1, BRD-K69776681-001-03-8, BRD-K69776681-001-03-8, BRD-K69776681-001-03-8, BRD-K69776681-001-03-8, BRD-K69776681-001-07-9, BRD-K69776681-001-07-9, BRD-K69776681-001-07-9	Phase 3
volinanserin	serotonin receptor antagonist	HTR2A, HTR2B, HTR2C, KCNH2			BRD-K23647661-001-03-0, BRD-K23647661-001-02-2	Phase 3
vonoprazan	potassium-competitive acid antagonist	ATP4A	gastroenterology	peptic ulcer disease (PUD)	BRD-K32768103-001-04-9, BRD-K32768103-051-02-6, BRD-K32768103-051-03-4, BRD-K32768103-051-03-4, BRD-K32768103-051-03-4	Launched
vorapaxar	thrombin inhibitor	F2R	cardiology	myocardial infarction, peripheral artery disease (PAD)	BRD-K93442924-001-03-4, BRD-K93442924-001-03-4, BRD-K93442924-001-03-4, BRD-K93442924-001-03-4	Launched
vorasidenib	isocitrate dehydrogenase inhibitor				BRD-K00003460-001-01-9	Preclinical
voreloxin	topoisomerase inhibitor	TOP2A			BRD-K23677682-003-01-2, BRD-K23677682-003-01-2, BRD-K23677682-003-04-9	Phase 3
voriconazole	cytochrome P450 inhibitor	CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1	infectious disease	esophageal candidiasis, aspergillosis, skin infections	BRD-K06557128-001-07-0, BRD-K06557128-001-07-0, BRD-K06557128-001-08-8, BRD-K06557128-001-10-9, BRD-K06557128-001-06-2	Launched
vorinostat	HDAC inhibitor	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	BRD-K81418486-001-66-9, BRD-K81418486-001-66-9, BRD-K81418486-001-66-9, BRD-K81418486-001-51-7, BRD-K81418486-001-47-5, BRD-K81418486-001-47-5, BRD-K81418486-001-47-5, BRD-K81418486-001-47-5, BRD-K81418486-001-47-5, BRD-K81418486-001-47-5, BRD-K81418486-001-47-5, BRD-K81418486-001-44-2, BRD-K81418486-001-44-2, BRD-K81418486-001-44-2, BRD-K81418486-001-44-2	Launched
vortioxetine	serotonin receptor agonist, serotonin receptor antagonist	HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR5A, HTR6, HTR7, SLC6A4	neurology/psychiatry	depression	BRD-K53963539-001-01-8, BRD-K53963539-004-02-0, BRD-K53963539-004-02-0, BRD-K53963539-004-02-0, BRD-K53963539-001-03-9	Launched
voruciclib	CDK9 inhibitor				BRD-K00004725-001-01-9	Phase 1
voxelotor	hemoglobin modulator				BRD-K43639297-001-01-9, BRD-K43639297-001-01-9	Launched
voxtalisib	mTOR inhibitor, PI3K inhibitor	MTOR, PIK3CA			BRD-K56291712-001-01-0, BRD-K56291712-001-01-0, BRD-K56291712-001-02-9	Phase 2
VP-20629	beta amyloid antagonist	PLA2G2E, SLC36A1			BRD-K21071223-001-02-8	Phase 1
VS-4718	focal adhesion kinase inhibitor				BRD-K09877029-001-01-2, BRD-K09877029-001-01-2, BRD-K09877029-001-01-2, BRD-K09877029-001-01-2, BRD-K09877029-001-01-2, BRD-K09877029-001-01-2, BRD-K09877029-001-01-2, BRD-K09877029-001-02-9	Phase 1
VT-464	cytochrome P450 inhibitor	CYP17A1			BRD-K72005722-001-01-2, BRD-K72005722-001-01-2, BRD-K72005722-001-01-2, BRD-K72005722-001-01-2, BRD-K72005722-001-02-9	Phase 2
VTP-27999	renin inhibitor	REN			BRD-K81694556-003-02-9, BRD-K81694556-003-01-9	Phase 1
VUF10166	serotonin receptor antagonist	HTR3A, HTR3B			BRD-K11046126-001-03-9, BRD-K11046126-001-02-0	Preclinical
VUF10460	histamine receptor agonist	HRH4			BRD-K90082312-001-02-9, BRD-K90082312-001-01-5, BRD-K90082312-001-01-5	Preclinical
VUF11207	CC chemokine receptor agonist	ACKR3			BRD-A93717708-051-02-9, BRD-A93717708-051-01-2	Preclinical
VU0155069	phospholipase inhibitor	PLD1			BRD-K48535733-003-02-0, BRD-K48535733-003-01-2, BRD-K48535733-003-01-2, BRD-K48535733-003-03-9	Preclinical
VU0238429	acetylcholine receptor allosteric modulator	CHRM5			BRD-K24187789-001-02-5, BRD-K24187789-001-02-5, BRD-K24187789-001-01-7, BRD-K24187789-001-01-7, BRD-K24187789-001-03-9, BRD-K24187789-001-03-9	Preclinical
VU0240551	potassium/chloride cotransporter inhibitor	SLC12A5			BRD-K27074404-001-08-4	Preclinical
VU0357121	glutamate receptor positive allosteric modulator	GRM5			BRD-K86109159-001-03-9, BRD-K86109159-001-03-9, BRD-K86109159-001-03-9, BRD-K86109159-001-02-6, BRD-K86109159-001-02-6, BRD-K86109159-001-02-6, BRD-K86109159-001-02-6	Preclinical
VU0360172	glutamate receptor positive allosteric modulator	GRM5			BRD-K83649660-003-03-0, BRD-K83649660-003-04-9	Preclinical
VU0361737	glutamate receptor positive allosteric modulator	GRM4			BRD-K45462423-001-04-5, BRD-K45462423-001-03-7, BRD-K45462423-001-05-9, BRD-K45462423-001-05-9, BRD-K45462423-001-02-9	Preclinical
VU0364439	glutamate receptor positive allosteric modulator	GRM4			BRD-K72687424-001-04-9, BRD-K72687424-001-03-4, BRD-K72687424-001-02-6	Preclinical
VU0364739	phospholipase inhibitor	PLD2			BRD-K93317811-003-02-2, BRD-K93317811-003-02-2, BRD-K93317811-003-04-9	Preclinical
VU0364770	glutamate receptor positive allosteric modulator	GRM4			BRD-K66527818-001-03-9, BRD-K66527818-001-03-9, BRD-K66527818-001-02-6	Preclinical
VU0422288	glutamate receptor positive allosteric modulator	GRM3			BRD-K68674163-001-01-7, BRD-K68674163-001-02-9, BRD-K68674163-001-02-9	Preclinical
VU10010	acetylcholine receptor allosteric modulator	CHRM4			BRD-K12483104-001-01-2, BRD-K12483104-001-01-2, BRD-K12483104-001-02-9, BRD-K12483104-001-02-9	Preclinical
VU152100	acetylcholine receptor allosteric modulator	CHRM4			BRD-K87727457-001-01-5, BRD-K87727457-001-02-9, BRD-K87727457-001-02-9	Preclinical
VU1545	glutamate receptor positive allosteric modulator	GRM5			BRD-K48371964-001-06-5, BRD-K48371964-001-06-5, BRD-K48371964-001-07-9	Preclinical
VU29	glutamate receptor potentiator	GRM5			BRD-K54783522-001-02-9, BRD-K54783522-001-01-8, BRD-K54783522-001-01-8	Preclinical
VU591	potassium channel blocker	KCNJ1			BRD-K72063794-003-01-0, BRD-K72063794-003-02-9, BRD-K72063794-003-02-9, BRD-K72063794-003-02-9	Preclinical
VX-11e	MAP kinase inhibitor	MAPK1			BRD-K93725829-001-03-8, BRD-K93725829-001-03-8, BRD-K93725829-001-03-8	Preclinical
VX-222	HCV inhibitor				BRD-K70610771-001-03-9, BRD-K70610771-001-02-9	Phase 2
VX-702	p38 MAPK inhibitor	IL1B, IL6, MAPK11, MAPK12, MAPK14, TNF			BRD-K07736136-001-04-6, BRD-K07736136-001-04-6, BRD-K07736136-001-04-6, BRD-K07736136-001-05-9, BRD-K07736136-001-03-8, BRD-K07736136-001-03-8	Phase 2
VX-745	p38 MAPK inhibitor	MAPK11, MAPK12, MAPK14			BRD-K91900765-001-08-4, BRD-K91900765-001-08-4, BRD-K91900765-001-07-6, BRD-K91900765-001-07-6, BRD-K91900765-001-05-0, BRD-K91900765-001-06-8	Phase 2
VX-765	caspase inhibitor	CASP1			BRD-K78430341-001-02-5	Phase 2
W-54011	anaphylatoxin chemotactic receptor antagonist	C5AR1			BRD-A00559310-003-02-9, BRD-A00559310-003-01-1	Preclinical
walrycin-B	transcriptional regulatory protein WalR				BRD-K01129913-001-01-5, BRD-K01129913-001-01-5, BRD-K01129913-001-01-5, BRD-K01129913-001-01-5	Preclinical
warfarin	vitamin K antagonist	VKORC1	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction	BRD-K25991148-001-02-9, BRD-K25991148-001-02-9	Launched
WAY-100635	serotonin receptor antagonist	HTR1A			BRD-K69812556-050-11-9, BRD-K69812556-050-11-9, BRD-K69812556-305-02-0	Phase 1
WAY-161503	serotonin receptor agonist	HTR2C			BRD-A62021152-003-04-2, BRD-A62021152-003-04-2, BRD-A62021152-003-04-2, BRD-A62021152-003-03-4	Preclinical
WAY-170523	metalloproteinase inhibitor	MMP13			BRD-K36198571-001-03-8, BRD-K36198571-001-03-8, BRD-K36198571-001-02-0, BRD-K36198571-001-02-0, BRD-K36198571-001-04-9	Preclinical
WAY-200070	estrogen receptor agonist	ERBB2, ERBB3, ERBB4, ESR2			BRD-K08223200-001-02-9, BRD-K08223200-001-01-1, BRD-K08223200-001-03-9	Preclinical
WAY-207024	gonadotropin releasing factor hormone receptor antagonist	GNRHR, HRH2, TACR2			BRD-K08657056-300-01-1, BRD-K08657056-300-01-1, BRD-K08657056-300-01-1, BRD-K08657056-300-02-9, BRD-K08657056-300-02-9	Preclinical
WAY-208466	serotonin receptor agonist	DRD2, HTR2A, HTR2C, HTR6, HTR7			BRD-K63483542-300-01-6, BRD-K63483542-300-01-6, BRD-K63483542-300-02-9	Preclinical
WAY-213613	glutamate inhibitor	SLC1A2			BRD-K96758128-001-02-6, BRD-K96758128-001-01-8, BRD-K96758128-001-01-8, BRD-K96758128-001-03-9	Preclinical
WAY-255348	progesterone receptor antagonist				BRD-K00004556-001-01-9	Preclinical
WAY-316606	secreted frizzled related protein inhibitor	SFRP1			BRD-K61871885-001-01-3, BRD-K61871885-001-01-3, BRD-K61871885-003-01-9	Preclinical
WAY-362450	FXR agonist	NR1H4			BRD-K54640016-001-05-9, BRD-K54640016-001-04-7	Phase 1
WAY-600	mTOR inhibitor	MTOR			BRD-K85920262-001-02-1, BRD-K85920262-001-02-1, BRD-K85920262-001-04-9	Preclinical
WAY-629	serotonin receptor agonist	HTR2C			BRD-K55430733-003-02-4, BRD-K55430733-003-03-9	Preclinical
WB-4101	adrenergic receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HTR1A			BRD-A01493904-003-13-9, BRD-A01493904-003-12-1, BRD-A01493904-003-12-1	Preclinical
WDR5-0103	histone lysine methyltransferase inhibitor	WDR5			BRD-K47726410-001-01-2, BRD-K47726410-001-01-2, BRD-K47726410-001-02-0	Preclinical
WEHI-345-analog	SRC inhibitor				BRD-K55487946-001-01-3, BRD-K55487946-001-01-3	Preclinical
WH-4-023	SRC inhibitor	LCK, SRC			BRD-K50199947-001-03-4, BRD-K50199947-001-07-9, BRD-K50199947-001-07-9	Preclinical
WHI-P154	JAK inhibitor	EGFR, JAK1, JAK2, JAK3			BRD-K07487750-001-05-8, BRD-K07487750-001-03-3, BRD-K07487750-001-04-1, BRD-K07487750-001-04-1, BRD-K07487750-001-06-9	Preclinical
WIKI4	tankyrase inhibitor, WNT pathway inhibitor	TNKS2			BRD-K19316653-001-02-0	Preclinical
WIN-18446	aldehyde dehydrogenase inhibitor	ALDH1A2			BRD-K30930903-001-01-3	Preclinical
WIN-64338	bradykinin receptor antagonist	BDKRB2			BRD-K22662557-300-02-5, BRD-K22662557-300-03-9, BRD-K22662557-300-01-7, BRD-K22662557-300-01-7, BRD-K22662557-300-01-7	Preclinical
wiskostatin	actin related protein inhibitor, neural Wiskott-Aldrich syndrome protein inhibitor	WASL			BRD-A18579359-001-05-9, BRD-A18579359-001-05-9, BRD-A18579359-001-04-9	Preclinical
wnt-c59	porcupine inhibitor	PORCN			BRD-K78455053-001-03-9, BRD-K78455053-001-03-9, BRD-K78455053-001-02-0, BRD-K78455053-001-02-0, BRD-K78455053-001-02-0, BRD-K78455053-001-01-2, BRD-K78455053-001-01-2, BRD-K78455053-001-01-2	Preclinical
WP1066	STAT inhibitor	STAT3			BRD-K05445342-001-05-3, BRD-K05445342-001-05-3, BRD-K05445342-001-05-3, BRD-K05445342-001-02-0, BRD-K05445342-001-06-9	Phase 1
WP1130	deubiquitinase inhibitor	JAK2, UCHL5, USP14, USP9X			BRD-K43644456-001-03-2, BRD-K43644456-001-03-2, BRD-K43644456-001-03-2, BRD-K43644456-001-04-0, BRD-K43644456-001-04-0, BRD-K43644456-001-04-0, BRD-K43644456-001-04-0	Preclinical
WP921					BRD-K00005248-001-01-9	Preclinical
WR99210	dihydrofolate reductase inhibitor	TYMS	infectious disease	malaria	BRD-K45973863-001-01-4	Preclinical
WWL-113	carboxylesterase inhibitor	CES3			BRD-K49389158-001-02-9, BRD-K49389158-001-01-3	Preclinical
WWL-123	monoacylglycerol lipase inhibitor	ABHD6			BRD-K83176916-001-01-4, BRD-K83176916-001-01-4, BRD-K83176916-001-01-4, BRD-K83176916-001-02-9	Preclinical
WY-16922	histamine release inhibitor				BRD-K43419711-001-01-4	Phase 1
WYE-125132	mTOR inhibitor	MTOR			BRD-K00003540-001-01-9	Preclinical
WYE-354	mTOR inhibitor	MTOR			BRD-K77008974-001-04-9, BRD-K77008974-001-03-2	Preclinical
WYE-687	mTOR inhibitor	MTOR			BRD-K49900195-300-01-8, BRD-K49900195-300-02-9	Preclinical
WZ-3146	EGFR inhibitor	EGFR			BRD-K73293050-001-03-1, BRD-K73293050-001-03-1	Preclinical
WZ-4002	EGFR inhibitor	EGFR, ERBB2			BRD-K72420232-001-13-1, BRD-K72420232-001-13-1, BRD-K72420232-001-12-3	Preclinical
WZ4003	AMPK inhibitor	NUAK1, NUAK2			BRD-K45909031-001-01-5, BRD-K45909031-001-01-5, BRD-K45909031-001-01-5, BRD-K45909031-001-01-5	Preclinical
WZ8040	EGFR inhibitor	EGFR			BRD-K81728688-001-07-7, BRD-K81728688-001-04-4, BRD-K81728688-001-04-4	Preclinical
WZ811	CC chemokine receptor antagonist	CXCR4			BRD-K25359048-001-03-9, BRD-K25359048-001-02-6, BRD-K25359048-001-02-6, BRD-K25359048-001-02-6, BRD-K25359048-001-02-6	Preclinical
xaliproden	serotonin receptor agonist	HTR1A			BRD-K88358234-003-05-5, BRD-K88358234-003-05-5, BRD-K88358234-003-04-8, BRD-K88358234-003-06-9	Phase 3
xanomeline	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7			BRD-K72815923-034-02-0, BRD-K72815923-034-01-2	Phase 3
xanthone	antimalarial agent				BRD-K27135764-001-08-7, BRD-K27135764-001-09-5	Preclinical
XAV-939	tankyrase inhibitor	TNKS, TNKS2			BRD-K12762134-001-10-4, BRD-K12762134-001-07-0, BRD-K12762134-001-07-0, BRD-K12762134-001-06-2	Preclinical
XBD173	benzodiazepine receptor ligand	TSPO			BRD-K45875383-001-02-0, BRD-K45875383-001-03-9, BRD-K45875383-001-01-2	Phase 2
XD-14	bromodomain inhibitor	BRD2, BRD3, BRD4, BRDT			BRD-K69211575-001-01-9, BRD-K69211575-001-02-9	Preclinical
XE-991	potassium channel blocker	KCNQ1, KCNQ2, KCNQ3, KCNQ4, KCNQ5			BRD-K42748308-300-03-9, BRD-K42748308-300-02-0	Preclinical
xenalipin					BRD-K99506538-001-03-8	Phase 2
xibenolol	adrenergic receptor antagonist				BRD-A21446384-001-01-1	Phase 3
xilobam					BRD-K79633074-001-01-8	Phase 1
xipamide	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema, hypertension	BRD-K27393415-001-01-0, BRD-K27393415-001-01-0	Launched
XL019	JAK inhibitor	JAK1, JAK2, JAK3			BRD-K04266228-001-04-6, BRD-K04266228-001-05-3, BRD-K04266228-001-02-0, BRD-K04266228-001-03-8, BRD-K04266228-001-03-8	Phase 1
XL041	LXR agonist				BRD-K00003439-001-01-9	Preclinical
XL147	PI3K inhibitor	PIK3CA, PIK3CD, PIK3CG			BRD-K95901403-001-04-5, BRD-K95901403-001-06-9	Phase 2
XL228	Abl kinase inhibitor, insulin growth factor receptor inhibitor, SRC inhibitor	IGF1R, SRC			BRD-K14274271-001-02-8, BRD-K14274271-001-02-8, BRD-K14274271-001-02-8, BRD-K14274271-001-01-0	Phase 1
XL388	mTOR inhibitor	MTOR			BRD-K03549949-001-02-9, BRD-K03549949-001-01-0	Preclinical
XL647	EGFR inhibitor, VEGFR inhibitor	EGFR, EPHB4, ERBB2, FLT4, KDR			BRD-K03765900-001-01-9, BRD-K03765900-001-01-9, BRD-K03765900-001-01-9, BRD-K03765900-001-01-9	Phase 3
XL888	HSP inhibitor				BRD-K00003558-001-01-9	Phase 1
XMD17-109	MAP kinase inhibitor	MAPK7			BRD-K48449981-001-02-7, BRD-K48449981-001-02-7, BRD-K48449981-001-01-9, BRD-K48449981-001-01-9, BRD-K48449981-001-01-9	Preclinical
XMD8-92	MAP kinase inhibitor	DCLK2, MAPK7, PLK4, TNK1			BRD-K50387473-001-11-0, BRD-K50387473-001-09-4, BRD-K50387473-001-10-2	Preclinical
xylazine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	neurology/psychiatry	anesthetic	BRD-K21565985-003-24-9, BRD-K21565985-001-22-5, BRD-K21565985-003-02-3	Launched
xylometazoline	adrenergic receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C	otolaryngology, allergy	nasal congestion, allergic rhinitis	BRD-K08356259-003-25-9, BRD-K08356259-003-24-7, BRD-K08356259-003-23-9	Launched
xylose					BRD-K10759144-001-03-5, BRD-K10759144-001-04-3	Launched
Y-11	focal adhesion kinase inhibitor	PTK2			BRD-K09317629-004-02-9, BRD-K09317629-004-01-7	Preclinical
Y-134	estrogen receptor antagonist	ESR1, ESR2			BRD-K94832621-001-03-1, BRD-K94832621-001-02-3, BRD-K94832621-001-02-3, BRD-K94832621-001-02-3, BRD-K94832621-001-04-9	Preclinical
Y-26763	potassium channel activator	KCNJ8			BRD-K45117373-001-02-9, BRD-K45117373-001-03-9, BRD-K45117373-001-03-9	Phase 1
Y-27152	potassium channel activator	KCNJ8			BRD-K42679050-001-02-1, BRD-K42679050-001-03-9	Phase 1
Y-27632	rho associated kinase inhibitor	PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2			BRD-K44084986-300-09-2, BRD-K44084986-300-09-2, BRD-K44084986-300-09-2, BRD-K44084986-300-08-4, BRD-K44084986-300-07-6	Preclinical
Y-29794	prolyl endopeptidase inhibitor	PREP			BRD-K48449073-034-02-7, BRD-K48449073-034-03-9	Preclinical
Y-320	interleukin inhibitor	IL17A			BRD-K96259238-001-01-4, BRD-K96259238-001-02-9	Preclinical
Y-39983	rho associated kinase inhibitor	ROCK1, ROCK2			BRD-K56751279-300-04-9, BRD-K56751279-300-01-4, BRD-K56751279-300-01-4, BRD-K56751279-300-01-4, BRD-K56751279-300-01-4, BRD-K56751279-300-01-4, BRD-K56751279-300-01-4	Phase 2
YC-1	guanylyl cyclase activator	GUCY1A2, GUCY1A3, GUCY1B3, HIF1A			BRD-K60476892-001-16-1, BRD-K60476892-001-17-9	Preclinical
YIL-781	ghrelin receptor antagonist	GHSR			BRD-K91403886-003-01-4, BRD-K91403886-003-02-9	Preclinical
YK-4-279	apoptosis inhibitor	EWSR1, FLI1			BRD-A62182663-001-04-8, BRD-A62182663-001-03-0	Preclinical
YL0919	selective serotonin reuptake inhibitor (SSRI)				BRD-K00003390-003-01-9	Preclinical
YM-022	CCK receptor antagonist	CCKBR			BRD-K09436144-001-01-7	Phase 2
YM-201636	PI3K inhibitor				BRD-K48488978-001-05-3, BRD-K48488978-001-05-3, BRD-K48488978-001-05-3	Preclinical
YM-244769	sodium/calcium exchange inhibitor				BRD-K52087522-300-02-9, BRD-K52087522-300-01-2	Preclinical
YM-298198	glutamate receptor antagonist	GRM1			BRD-K59650319-003-03-3, BRD-K59650319-003-04-9, BRD-K59650319-003-04-9	Preclinical
YM-298198-desmethyl	glutamate receptor antagonist	GRM1			BRD-K48059230-003-02-9, BRD-K48059230-003-03-9	Preclinical
YM-511	aromatase inhibitor	CYP19A1			BRD-K38398115-001-01-9	Phase 2
YM-58483	calcium channel blocker	TRPC3, TRPC5, TRPM4			BRD-K42563464-001-02-7, BRD-K42563464-001-01-9, BRD-K42563464-001-01-9, BRD-K42563464-001-01-9, BRD-K42563464-001-01-9, BRD-K42563464-001-01-9, BRD-K42563464-001-01-9, BRD-K42563464-001-01-9, BRD-K42563464-001-01-9	Preclinical
YM-750	ACAT inhibitor	SOAT1			BRD-K91716465-001-01-2, BRD-K91716465-001-01-2	Phase 1
YM-90709	IL5 inhibitor	CSF2RB, IL5RA			BRD-K06712146-001-03-8, BRD-K06712146-001-04-9, BRD-K06712146-001-02-0	Preclinical
YM-976	phosphodiesterase inhibitor	PDE4A			BRD-K12932420-001-03-1, BRD-K12932420-001-04-9, BRD-K12932420-001-02-3, BRD-K12932420-001-02-3	Phase 1
YO-01027	gamma secretase inhibitor				BRD-K04622161-001-04-9, BRD-K04622161-001-03-1, BRD-K04622161-001-02-3	Preclinical
yoda-1	piezo channel activator	PIEZO1			BRD-K88570498-001-01-9, BRD-K88570498-001-01-9, BRD-K88570498-001-02-9	Preclinical
YS-035	calcium channel blocker				BRD-K06208435-003-08-2, BRD-K06208435-003-09-9	Preclinical
YS-201	calcium receptor antagonist				BRD-K00004746-001-01-9	Preclinical
YZ9	phosphofructokinase inhibitor	MIF, PFKFB3			BRD-K53438416-001-02-9, BRD-K53438416-001-01-9, BRD-K53438416-001-01-9	Preclinical
Y16	rho associated kinase inhibitor	RHOA			BRD-K81865756-001-02-5, BRD-K81865756-001-01-7	Preclinical
zacopride	serotonin receptor antagonist	HTR3A, HTR3B, HTR4, HTR5A			BRD-K01826799-003-03-9, BRD-K01826799-003-02-9	Phase 2
zafirlukast	leukotriene receptor antagonist	CYSLTR1, CYSLTR2	pulmonary	asthma	BRD-K71289571-001-11-4, BRD-K71289571-001-11-4, BRD-K71289571-001-11-4	Launched
zalcitabine	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K85925969-001-17-4, BRD-K85925969-001-17-4, BRD-K85925969-001-16-6, BRD-K85925969-001-19-9, BRD-K85925969-001-19-9	Launched
zaldaride	calmodulin antagonist	CALM1			BRD-A26032986-050-03-9, BRD-A26032986-050-02-1, BRD-A26032986-050-02-1, BRD-A26032986-050-04-9	Phase 3
zaltidine	histamine receptor antagonist	HRH2			BRD-K12261274-001-02-4, BRD-K12261274-001-01-6	Phase 3
zaltoprofen	cyclooxygenase inhibitor		endocrinology, neurology/psychiatry	fever, pain relief	BRD-A00578795-001-04-3, BRD-A00578795-001-05-9	Launched
ZAMI-633	urease inhibitor				BRD-K11984358-001-01-3	Phase 3
zamifenacin	acetylcholine receptor antagonist	CHRM3			BRD-K80451230-051-03-4, BRD-K80451230-051-02-6, BRD-K80451230-051-04-9	Phase 3
zanubrutinib	Bruton's tyrosine kinase (BTK) inhibitor				BRD-K00003413-001-01-9	Launched
ZAPA					BRD-K44825564-065-01-4, BRD-K44825564-065-02-9	Preclinical
zaprinast	phosphodiesterase inhibitor	GPR35, PDE1A, PDE4D, PDE5A, PDE9A			BRD-K16542329-001-16-8, BRD-K16542329-001-16-8, BRD-K16542329-001-14-3, BRD-K16542329-001-13-5, BRD-K16542329-001-13-5	Phase 2
zardaverine	phosphodiesterase inhibitor	PDE4D			BRD-K37561857-001-18-9, BRD-K37561857-001-18-9, BRD-K37561857-001-18-9, BRD-K37561857-001-17-1, BRD-K37561857-001-17-1, BRD-K37561857-001-17-1, BRD-K37561857-001-15-5, BRD-K37561857-001-15-5	Phase 2
zatebradine	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			BRD-K92446736-003-03-0, BRD-K92446736-001-01-8, BRD-K92446736-003-02-2	Phase 3
ZCL-278	CDC inhibitor	CDC42			BRD-K22829793-001-04-9, BRD-K22829793-001-03-6, BRD-K22829793-001-02-8, BRD-K22829793-001-01-0	Preclinical
ZD-0947	potassium channel activator				BRD-K00004620-001-01-9	Preclinical
ZD-2079	adrenergic receptor agonist	ADRB3			BRD-K64157027-003-02-7, BRD-K64157027-003-03-9	Phase 2
ZD-7114	adrenergic receptor agonist	ADRB3			BRD-K28971625-003-02-9, BRD-K28971625-003-01-4, BRD-K28971625-003-01-4, BRD-K28971625-003-01-4	Phase 1
ZD-7155	angiotensin receptor antagonist	AGTR1			BRD-K11373525-003-03-9, BRD-K11373525-003-02-1, BRD-K11373525-003-02-1, BRD-K11373525-003-02-1, BRD-K11373525-003-02-1	Preclinical
ZD-7288	HCN channel blocker	HCN1, HCN2, HCN3, HCN4			BRD-K18678457-003-03-6, BRD-K18678457-003-03-6, BRD-K18678457-003-03-6, BRD-K18678457-003-04-9, BRD-K18678457-003-04-9, BRD-K18678457-003-02-8	Phase 2
zeatin					BRD-K90033078-001-08-7	Phase 1
zibotentan	endothelin receptor antagonist	EDNRA			BRD-K31553034-001-03-0, BRD-K31553034-001-03-0, BRD-K31553034-001-03-0	Phase 3
zidovudine	nucleoside reverse transcriptase inhibitor	TERT	infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS)	BRD-K72903603-001-24-4, BRD-K72903603-001-27-9, BRD-K72903603-001-26-9	Launched
zileuton	leukotriene synthesis inhibitor, lipoxygenase inhibitor	ALOX5	pulmonary	asthma	BRD-A56359832-001-15-2, BRD-A56359832-001-12-9, BRD-A56359832-001-13-7, BRD-A56359832-001-11-1, BRD-A56359832-001-16-9	Launched
zilpaterol	adrenergic receptor agonist	ADRB2	endocrinology	weight-gain aid	BRD-K42816473-001-01-0	Launched
zimelidine	selective serotonin reuptake inhibitor (SSRI)	MAOA, MAOB, SLC6A4			BRD-K46914825-300-07-9, BRD-K46914825-300-01-0	Withdrawn
zindotrine	phosphodiesterase inhibitor				BRD-K26598477-001-01-0	Phase 2
ziprasidone	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A4	neurology/psychiatry	schizophrenia, bipolar disorder	BRD-K29582115-066-01-2, BRD-K29582115-003-03-1	Launched
ziritaxestat	autotaxin inhibitor				BRD-K00003431-001-01-9	Phase 3
ZK-164015	estrogen receptor antagonist	ESR1, ESR2			BRD-K05151076-001-03-4, BRD-K05151076-001-02-6, BRD-K05151076-001-04-9	Preclinical
ZK-200775	kainate receptor antagonist				BRD-K67525671-001-03-3, BRD-K67525671-001-02-5, BRD-K67525671-001-02-5, BRD-K67525671-001-04-9	Phase 2
ZK-811752	CC chemokine receptor antagonist	CCR1			BRD-K91825936-001-02-0, BRD-K91825936-001-01-2, BRD-K91825936-001-01-2, BRD-K91825936-001-01-2, BRD-K91825936-001-01-2, BRD-K91825936-001-03-9, BRD-K91825936-001-03-9	Phase 2
ZK-93423	benzodiazepine receptor agonist	GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2			BRD-K33882852-003-03-6, BRD-K33882852-003-03-6, BRD-K33882852-003-04-9, BRD-K33882852-003-02-8, BRD-K33882852-003-02-8, BRD-K33882852-003-02-8, BRD-K33882852-003-02-8	Phase 3
ZK-93426	benzodiazepine receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA5			BRD-K68392338-003-03-8, BRD-K68392338-003-04-9, BRD-K68392338-003-04-9, BRD-K68392338-003-02-0	Phase 1
ZLN005					BRD-K73073971-001-02-9, BRD-K73073971-001-01-7, BRD-K73073971-001-01-7, BRD-K73073971-001-01-7, BRD-K73073971-001-01-7	Preclinical
ZLN024	AMPK activator	PRKAA1, PRKAB1, PRKAG1			BRD-K64103579-003-01-5, BRD-K64103579-003-02-9, BRD-K64103579-003-02-9	Preclinical
ZM-226600	Kir6 channel (KATP) activator				BRD-A62209527-001-05-9, BRD-A62209527-001-04-5	Preclinical
ZM-241385	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K19605405-001-03-5, BRD-K19605405-001-03-5, BRD-K19605405-001-04-9, BRD-K19605405-001-04-9, BRD-K19605405-001-02-7, BRD-K19605405-001-02-7	Preclinical
ZM-306416	Abl kinase inhibitor, SRC inhibitor, VEGFR inhibitor	EGFR, FLT1, FLT4, KDR			BRD-K41337261-003-02-8, BRD-K41337261-003-02-8, BRD-K41337261-003-04-9, BRD-K41337261-001-03-0, BRD-K41337261-001-03-0, BRD-K41337261-001-03-0	Preclinical
ZM-323881	VEGFR inhibitor	KDR			BRD-K67831364-003-04-1, BRD-K67831364-003-06-9, BRD-K67831364-003-05-8, BRD-K67831364-003-05-8, BRD-K67831364-003-03-3	Preclinical
ZM-336372	RAF inhibitor	BRAF, LCK, MAPK14, RAF1			BRD-K73789395-001-09-9, BRD-K73789395-001-13-1, BRD-K73789395-001-14-9, BRD-K73789395-001-10-7	Preclinical
ZM-39923	JAK inhibitor	JAK1, JAK3			BRD-K40624912-003-17-9, BRD-K40624912-003-15-5, BRD-K40624912-003-12-2, BRD-K40624912-003-13-0, BRD-K40624912-003-14-8	Preclinical
ZM-447439	Aurora kinase inhibitor	AURKA, AURKB			BRD-K72703948-001-10-1, BRD-K72703948-001-09-3, BRD-K72703948-001-12-7, BRD-K72703948-001-12-7	Preclinical
zolantidine	histamine receptor antagonist				BRD-K08996725-332-07-9, BRD-K08996725-332-01-7	Preclinical
zoledronic-acid	bone resorption inhibitor	FDPS, GGPS1	endocrinology	Paget's disease	BRD-K84253429-001-06-9, BRD-K84253429-001-04-4, BRD-K84253429-001-03-6	Launched
zoliflodacin	antibacterial 				BRD-K00003264-001-01-9	Phase 3
zolimidine	mucus protecting agent		gastroenterology	peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD)	BRD-K45125084-001-01-4	Launched
zolmitriptan	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F	neurology/psychiatry	migraine headache	BRD-K54314721-001-12-9, BRD-K54314721-001-11-0, BRD-K54314721-001-10-2, BRD-K54314721-001-09-4	Launched
zomepirac	prostaglandin synthesis inhibitor	PTGDR2			BRD-K81326768-236-12-5, BRD-K81326768-236-11-7, BRD-K81326768-001-04-0	Withdrawn
zometapine					BRD-K14571191-001-01-6	Phase 2
zoniporide	sodium/hydrogen exchanger inhibitor	SLC9A1			BRD-K43992824-300-01-0, BRD-K43992824-300-02-9	Phase 3
zonisamide	sodium channel blocker, T-type calcium channel blocker	CA1, CA10, CA11, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9, CACNA1G, CACNA1H, CACNA1I, MAOA, MAOB, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	seizures, epilepsy	BRD-K48300629-001-17-8, BRD-K48300629-001-14-5, BRD-K48300629-001-13-7, BRD-K48300629-001-13-7	Launched
zopolrestat		AKR1B1, AKR1B10			BRD-K47710001-001-03-7, BRD-K47710001-001-03-7	Phase 2
zosuquidar	P glycoprotein inhibitor	ABCB1, ABCB4			BRD-K70557564-305-04-4, BRD-K70557564-305-03-6	Phase 3
zotarolimus	mTOR inhibitor	FKBP1A	cardiology	coronary artery restenosis	BRD-K46843573-001-01-9, BRD-K46843573-001-01-9, BRD-K46843573-001-01-9	Launched
zotepine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA2B, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR2A, HTR2C, HTR6, HTR7, SLC6A2, SLC6A4	neurology/psychiatry	schizophrenia	BRD-K64557645-001-02-4, BRD-K64557645-001-02-4, BRD-K64557645-001-02-4, BRD-K64557645-001-03-9	Launched
zoxazolamine	myorelaxant				BRD-K66353228-001-15-9, BRD-K66353228-001-14-6, BRD-K66353228-001-13-8	Phase 2
ZSET1446	nicotinic receptor agonist				BRD-K35984734-001-02-9	Preclinical
ZSTK-474	PI3K inhibitor	PIK3CB, PIK3CD, PIK3CG			BRD-K63068307-001-10-9, BRD-K63068307-001-08-9	Phase 1/Phase 2
zuclopenthixol	dopamine receptor antagonist	ADRA1A, ADRA2A, DRD1, DRD2, DRD5, HRH1, HTR2A	neurology/psychiatry	schizophrenia, bipolar disorder	BRD-K28761384-001-10-9, BRD-K28761384-300-01-0, BRD-K28761384-300-01-0	Launched
zuranolone	GABA receptor agonist				BRD-K00003448-001-01-9	Phase 3
Z160	N-type calcium channel blocker	CACNA2D1			BRD-K16037980-001-01-1, BRD-K16037980-001-02-9, BRD-K16037980-001-02-9	Phase 2
1,12-Besm	polyamine biosynthesis inhibitor				BRD-K04603573-376-01-3	Phase 2
1,2,3,4,5,6-hexabromocyclohexane	JAK inhibitor	JAK2			BRD-K06817181-001-02-3, BRD-K06817181-001-03-9, BRD-K06817181-001-03-9	Preclinical
1,3-dipropyl-8-phenylxanthine	adenosine receptor antagonist				BRD-K41853443-001-03-9, BRD-K41853443-001-02-9	Preclinical
1,4-butanediol	benzodiazepine receptor agonist, gamma hydroxybutyric acid agonist	MAN1B1, PLA2G2A, PLA2G2E			BRD-K22346679-001-06-3	Phase 1
1,5-dicaffeoylquinic-acid					BRD-K53083666-001-01-0, BRD-K53083666-001-02-9	Phase 1
1-((Z)-3-chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium					BRD-K88956297-003-01-9	Preclinical
1-(1,2-diphenylethyl)piperidine-(+/-)	glutamate receptor antagonist				BRD-K01825681-050-02-9, BRD-K01825681-050-01-9	Preclinical
1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol					BRD-A95802703-001-01-0	Preclinical
1-acetyl-4-methylpiperazine	acetylcholine receptor agonist				BRD-K96055017-003-02-7, BRD-K96055017-003-03-9	Preclinical
1-azakenpaullone	glycogen synthase kinase inhibitor	CCNB1, CDK1, CDK5, GSK3B			BRD-K03273112-001-01-8, BRD-K03273112-001-01-8, BRD-K03273112-001-01-8, BRD-K03273112-001-01-8, BRD-K03273112-001-01-8, BRD-K03273112-001-02-6	Preclinical
1-deoxymannojirimycin	alpha mannosidase inhibitor	MAN2A1			BRD-K89665618-003-04-9, BRD-K89665618-003-02-5	Preclinical
1-EBIO	potassium channel activator	KCNN1, KCNN2, KCNN3, KCNN4			BRD-K70586315-001-03-2, BRD-K70586315-001-04-9, BRD-K70586315-001-04-9, BRD-K70586315-001-02-4	Preclinical
1-ethyl-2-pyrrolidone	transdermal absorption-enhancing compound				BRD-K08288352-001-03-6	Preclinical
1-hexadecanal	sphingosine 1-phosphate receptor substrate	DBI, RHO			BRD-K35114608-001-01-7	Preclinical
1-hexadecanol			dermatology	cosmetic	BRD-K37203094-001-02-5, BRD-K37203094-001-03-3, BRD-K37203094-001-06-6	Launched
1-naphthyl-PP1	SRC inhibitor	SRC			BRD-K29542628-001-03-9, BRD-K29542628-001-03-9, BRD-K29542628-001-03-9, BRD-K29542628-001-04-7, BRD-K29542628-001-04-7, BRD-K29542628-001-04-7	Preclinical
1-octacosanol					BRD-K03083257-001-01-6	Phase 2
1-octanol		GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1			BRD-K09338665-001-08-9, BRD-K09338665-001-07-1	Phase 2
1-phenylbiguanide	serotonin receptor agonist	HTR3A, HTR3B			BRD-K31491153-003-07-9, BRD-K31491153-003-05-9	Preclinical
1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone-oxime					BRD-A37752546-001-01-9, BRD-A37752546-001-01-9, BRD-A37752546-001-01-9, BRD-A37752546-001-02-9	Preclinical
1S,2R-phenylpropanolamine	adrenergic receptor agonist				BRD-K27853494-003-04-7	Withdrawn
10-DEBC	AKT inhibitor	PIM1			BRD-K70792160-003-04-6, BRD-K70792160-003-04-6, BRD-K70792160-003-07-9, BRD-K70792160-003-06-1	Preclinical
10-hydroxycamptothecin	topoisomerase inhibitor	TOP1			BRD-K63784565-001-08-9, BRD-K63784565-001-08-9, BRD-K63784565-001-05-4, BRD-K63784565-001-06-2, BRD-K63784565-001-06-2	Preclinical
10058-F4	c-Myc inhibitor				BRD-K49460120-001-06-6, BRD-K49460120-001-05-8, BRD-K49460120-001-05-8, BRD-K49460120-001-05-8, BRD-K49460120-001-02-5	Preclinical
12-O-tetradecanoylphorbol-13-acetate	PKC activator	KCNT2, TRPV4			BRD-K68552125-001-05-3, BRD-K68552125-001-05-3, BRD-K68552125-001-05-3, BRD-K68552125-001-05-3, BRD-K68552125-001-07-9, BRD-K68552125-001-07-9	Phase 2
1400W	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			BRD-K30237152-300-02-5, BRD-K30237152-300-02-5	Preclinical
16,16-dimethylprostaglandin-e2	prostanoid receptor agonist	HPGD			BRD-K92301463-001-05-5, BRD-K92301463-001-06-9, BRD-K92301463-001-06-9	Phase 2
17-hydroxyprogesterone-caproate	progesterone receptor agonist	AR, ESR1, ESR2, NR1H4, NR1I2, NR3C1, PGR	obstetrics/gynecology	spontaneous preterm birth	BRD-K70264088-001-17-9	Launched
2'-C-methylguanosine	HCV inhibitor				BRD-K78092779-001-01-6	Preclinical
2'-MeCCPA	adenosine receptor agonist	ADORA1			BRD-K63932022-001-02-3, BRD-K63932022-001-02-3, BRD-K63932022-001-01-5, BRD-K63932022-001-01-5, BRD-K63932022-001-03-9	Preclinical
2,3-cis/exo-camphanediol					BRD-K44602126-001-01-3	Phase 1
2,3-cis/exo-pinanediol					BRD-A75263867-001-01-1	Phase 1
2,3-DCPE	BCL-XL downregulator	BCL2L1			BRD-K61734568-003-03-9, BRD-K61734568-003-02-1, BRD-K61734568-003-02-1, BRD-K61734568-003-02-1	Preclinical
2,4-dinitrochlorobenzene	thioredoxin inhibitor	TXN			BRD-K97833335-001-08-2	Phase 2
2,4-dinitrophenol	ATP synthase inhibitor	APP			BRD-K21910317-001-12-3	Preclinical
2,5-furandimethanol	hemoglobin modulator	HBB			BRD-K29791386-001-01-8	Phase 2
2,6-dimethylpiperidine					BRD-A21276153-001-01-1, BRD-A21276153-001-02-9	Preclinical
2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one					BRD-K46989997-001-01-8	Preclinical
2-(1-adamantylamino)benzoic-acid					BRD-K75167327-001-01-6	Preclinical
2-(3-mercaptopropyl)pentanedioic-acid	glutamate carboxypeptidase inhibitor	FOLH1			BRD-A66788520-001-01-7, BRD-A66788520-001-01-7	Phase 1
2-[1-(4-piperonyl)piperazinyl]benzothiazole	serotonin receptor agonist	HTR4			BRD-K91868854-001-04-9, BRD-K91868854-001-03-6	Preclinical
2-aminobenzenesulfonamide	carbonic anhydrase inhibitor	CA12, CA14, CA2, CA6, CA9			BRD-K32681104-001-11-6	Preclinical
2-APB	1,4,5-trisphosphate inhibitor	TRPC1, TRPC3, TRPC4, TRPC5, TRPC6, TRPC7, TRPM2, TRPM3, TRPM6, TRPV1, TRPV6			BRD-K13346085-001-05-9, BRD-K13346085-001-04-7	Preclinical
2-BFI	imidazoline receptor ligand	ADRA2A, ADRA2B, ADRA2C, MAOA, MAOB			BRD-K22745370-003-02-3	Preclinical
2-chloro-N6-cyclopentyladenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K70088346-001-02-4, BRD-K70088346-001-06-9, BRD-K70088346-001-01-6, BRD-K70088346-001-01-6	Preclinical
2-chloroadenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B			BRD-K79511609-001-20-0, BRD-K79511609-001-20-0, BRD-K79511609-001-21-9	Preclinical
2-chloropyrazine					BRD-K84075000-001-06-9, BRD-K84075000-001-05-5	Preclinical
2-CMDO	dopamine receptor antagonist	DRD2, DRD4			BRD-K92588747-051-03-9, BRD-K92588747-051-02-7, BRD-K92588747-051-02-7, BRD-K92588747-051-02-7	Preclinical
2-deoxy-2-([methyl(nitroso)carbamoyl]amino)hexose			oncology, endocrinology	pancreatic cancer, hypoglycemia	BRD-A55902763-001-01-3	Preclinical
2-deoxyglucose	glycolysis inhibitor	SLC2A1, SLC2A2, SLC2A3, SLC2A4			BRD-K97808269-001-02-7, BRD-K97808269-001-02-7, BRD-K97808269-001-03-9	Phase 2
2-ethoxybenzoic-acid	analgesic agent				BRD-K04843302-001-02-5	Phase 1
2-ethyl-1,3-hexanediol					BRD-A55455283-001-02-1, BRD-A55455283-001-02-1, BRD-A55455283-001-01-3	Preclinical
2-fluoro-2-deoxy-D-galactose		LCT			BRD-A53037300-001-01-0	Phase 1
2-fluorofucose					BRD-K00004677-001-01-9	Phase 1
2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione					BRD-A52169337-001-01-9, BRD-A52169337-001-02-7	Preclinical
2-hydroxyethyl-salicylate			neurology/psychiatry	pain relief	BRD-K41866823-001-01-3	Launched
2-hydroxyflutamide	androgen receptor antagonist	AR			BRD-K82027074-001-08-3, BRD-K82027074-001-07-5	Phase 2
2-hydroxysaclofen	GABA receptor antagonist	GABBR1, GABBR2			BRD-A27924917-001-03-3, BRD-A27924917-001-03-3, BRD-A27924917-001-03-3, BRD-A27924917-001-03-3, BRD-A27924917-001-03-3, BRD-A27924917-001-04-9, BRD-A27924917-001-04-9	Preclinical
2-iminobiotin	nitric oxide synthase inhibitor	NOS1, NOS2			BRD-K07954936-001-02-9, BRD-K07954936-001-01-3	Phase 2
2-iodohippuric-acid					BRD-K56634222-001-03-0, BRD-K56634222-001-04-9	Preclinical
2-iodomelatonin	melatonin receptor agonist	MTNR1A, MTNR1B, NQO2			BRD-K25649279-001-03-9, BRD-K25649279-001-02-0	Preclinical
2-methyl-5-hydroxytryptamine	serotonin receptor agonist	HTR1B, HTR1D, HTR1E, HTR1F, HTR3A, HTR3B, HTR6			BRD-K64137799-003-03-3, BRD-K64137799-003-02-5, BRD-K64137799-003-02-5	Preclinical
2-methyl-5-nitrophenol					BRD-K22327730-001-02-9, BRD-K22327730-001-01-1	Preclinical
2-methylimidazole	cholesterol inhibitor				BRD-K68534611-001-07-8	Preclinical
2-octyldodecan-1-ol					BRD-A51407134-001-02-7, BRD-A51407134-001-01-9, BRD-A51407134-001-01-9	Preclinical
2-oleoylglycerol	glucose dependent insulinotropic receptor ligand	GPR119			BRD-K77087341-001-02-4, BRD-K77087341-001-02-4	Phase 1
2-oxoglutaric-acid		OXGR1			BRD-K89712525-001-03-9, BRD-K89712525-001-02-1	Preclinical
2-oxopropanoate	pyruvate dehydrogenase kinase inhibitor	ABAT			BRD-K86587225-236-02-5	Preclinical
2-phenylmelatonin	melatonin receptor agonist	MTNR1A, MTNR1B			BRD-K41869275-001-03-6, BRD-K41869275-001-03-6, BRD-K41869275-001-03-6, BRD-K41869275-001-04-9, BRD-K41869275-001-02-8	Preclinical
2-PMDQ	adrenergic receptor antagonist	ADRA1A			BRD-A04661934-001-03-9, BRD-A04661934-001-02-9	Preclinical
2-pyridylethylamine	histamine receptor agonist	HRH1			BRD-K17874705-300-04-0, BRD-K17874705-300-03-2, BRD-K17874705-300-03-2	Preclinical
2-TEDC	lipoxygenase inhibitor	ALOX12			BRD-K89072800-001-02-9, BRD-K89072800-001-01-8	Preclinical
2-thiouracil					BRD-K58819470-001-06-9, BRD-K58819470-001-05-9, BRD-K58819470-001-04-2	Preclinical
20-HETE	ion channel antagonist				BRD-K00005345-001-01-9	Preclinical
20-hydroxyecdysone	ecdysone receptor modulator				BRD-K28343777-001-01-6	Phase 2
3'-fluorobenzylspiperone	dopamine receptor ligand	DRD2			BRD-K45662124-050-02-3, BRD-K45662124-050-03-9, BRD-K45662124-050-03-9, BRD-K45662124-050-01-5	Preclinical
3,3'-diindolylmethane	CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor	AR, HIF1A, IFNG, PI3			BRD-K37846922-001-09-4, BRD-K37846922-001-10-2, BRD-K37846922-001-10-2	Phase 3
3,4-DCPG-(+/-)	glutamate receptor agonist	GRM8			BRD-A49947412-001-03-9, BRD-A49947412-001-02-0	Preclinical
3,4-DCPG-(R)	glutamate receptor antagonist				BRD-K06204668-001-03-9, BRD-K06204668-001-02-6	Preclinical
3,4-DCPG-(S)	glutamate receptor agonist	GRM8			BRD-K86305586-001-03-9, BRD-K86305586-001-03-9, BRD-K86305586-001-02-3	Preclinical
3,4-methylenedioxy-beta-nitrostyrene	SRC inhibitor, SYK inhibitor	SRC, SYK			BRD-K42205652-001-02-7, BRD-K42205652-001-02-7, BRD-K42205652-001-02-7, BRD-K42205652-001-05-0, BRD-K42205652-001-05-0, BRD-K42205652-001-05-0	Preclinical
3,5-DHPG-(S)	glutamate receptor agonist	GRM1			BRD-K57796080-001-04-9, BRD-K57796080-001-04-9, BRD-K57796080-001-03-7	Preclinical
3-(4-methylbenzylidene)camphor	endocrine disruptor		dermatology	sunscreen lotion	BRD-A55464252-001-01-2, BRD-A55464252-001-02-0	Launched
3-alpha-bis-(4-fluorophenyl)-methoxytropane	dopamine uptake inhibitor	CHRM1, SLC6A2, SLC6A3, SLC6A4			BRD-K00004218-003-01-9	Preclinical
3-alpha-hydroxy-5-beta-androstan-17-one		HSD17B11, IGHG2, SULT2A1			BRD-A43598550-001-09-4	Preclinical
3-amino-benzamide	PARP inhibitor	PARP1			BRD-K08703257-001-12-1, BRD-K08703257-001-13-9, BRD-K08703257-001-13-9	Phase 2
3-anilinopropan-1-ol					BRD-K49721826-001-02-7, BRD-K49721826-001-03-9	Preclinical
3-AQC	serotonin receptor agonist	HTR3A			BRD-K38370968-050-02-9, BRD-K38370968-050-02-9, BRD-K38370968-050-01-3	Preclinical
3-bromo-7-nitroindazole	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			BRD-K24689407-001-07-1, BRD-K24689407-001-07-1, BRD-K24689407-001-08-9, BRD-K24689407-001-06-3	Preclinical
3-bromocamphor					BRD-K00004535-001-01-9	Launched
3-bromopyruvate	hexokinase inhibitor	HK2			BRD-K92980438-001-05-8, BRD-K92980438-001-04-1, BRD-K92980438-001-03-3	Preclinical
3-carboxy-4-hydroxyphenylglycine-(R)	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			BRD-K76592088-001-02-1, BRD-K76592088-001-03-9	Preclinical
3-carboxy-4-hydroxyphenylglycine-(S)	glutamate receptor antagonist	GRM1, GRM5			BRD-K61585876-001-01-0, BRD-K61585876-001-02-9	Preclinical
3-CPMT	dopamine reuptake inhibitor				BRD-K00004217-003-01-9	Preclinical
3-deazaadenosine	adenosylhomocysteinase inhibitor	AHCY			BRD-A79431551-001-01-1	Phase 2
3-deazauridine	cytidine deaminase inhibitor				BRD-A26105646-001-06-1	Preclinical
3-hydroxy-3-phenylpentanamide	GABA receptor modulator				BRD-A66143912-001-01-1, BRD-A66143912-001-01-1	Phase 1
3-indolebutyric-acid		B2M, HLA-A, TRAC, TRBC1			BRD-K43187796-001-02-3	Preclinical
3-MATIDA	glutamate receptor antagonist	GRM1			BRD-A87125127-001-02-2, BRD-A87125127-001-03-9	Preclinical
3-methyladenine	PI3K inhibitor	PI3			BRD-K81647657-001-04-3, BRD-K81647657-001-04-3, BRD-K81647657-001-05-0	Preclinical
3-MPPI	adrenergic receptor ligand	ADRA1A			BRD-K62581435-001-04-9, BRD-K62581435-001-04-9, BRD-K62581435-001-03-8	Preclinical
3PO	phosphofructokinase inhibitor	PFKFB3			BRD-K58413118-001-01-8, BRD-K58413118-001-01-8	Preclinical
4,4'-DDT					BRD-K51799616-001-05-5	Preclinical
4,4-pentamethylenepiperidine	M2 channel blocker				BRD-K49545903-003-01-4, BRD-K49545903-003-02-9	Preclinical
4,5,6,7-tetrabromobenzotriazole	casein kinase inhibitor	AKT1, CHEK1, CSNK2A1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SGK1			BRD-K97118047-001-03-8, BRD-K97118047-001-06-9, BRD-K97118047-001-06-9, BRD-K97118047-001-04-6	Preclinical
4-(aminomethyl)benzoic-acid	hemostatic agent				BRD-K00003517-001-01-9	Preclinical
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	serotonin receptor antagonist	HTR2A			BRD-K47337578-034-03-3, BRD-K47337578-034-04-9, BRD-K47337578-034-04-9, BRD-K47337578-034-02-5	Preclinical
4-acetyl-1,1-dimethylpiperazinium	acetylcholine receptor agonist				BRD-K97019106-005-02-9, BRD-K97019106-005-03-9	Preclinical
4-aminohippuric-acid		SLC22A6	nephrology	renal diagnostic agent	BRD-K65544384-001-15-8, BRD-K65544384-236-01-0, BRD-K65544384-236-03-6, BRD-K65544384-001-14-1, BRD-K65544384-236-02-8	Launched
4-carboxy-3-hydroxyphenylglycine-(RS)	glutamate receptor agonist, glutamate receptor antagonist	GRM1			BRD-A80383043-001-03-3, BRD-A80383043-001-04-9	Preclinical
4-carboxy-3-hydroxyphenylglycine-(S)	glutamate receptor agonist, glutamate receptor antagonist	GRM1, GRM2			BRD-K74133873-001-01-7, BRD-K74133873-001-02-9	Preclinical
4-chlorophenylguanidine	urokinase inhibitor	PLAUR			BRD-K39160765-003-03-9, BRD-K39160765-003-02-9	Preclinical
4-CMTB	free fatty acid receptor agonist	FFAR2			BRD-A54139254-001-10-9, BRD-A54139254-001-09-2, BRD-A54139254-001-09-2	Preclinical
4-DAMP	cholinergic receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5			BRD-K29313239-005-10-9, BRD-K29313239-005-09-4	Preclinical
4-galactosyllactose					BRD-A32796301-001-01-6	Preclinical
4-HQN	PARP inhibitor	PARP1			BRD-K91758890-001-10-0, BRD-K91758890-001-11-9	Preclinical
4-hydroxy-phenazone					BRD-K49759007-001-12-9, BRD-K49759007-001-11-9, BRD-K49759007-001-11-9	Preclinical
4-IBP	sigma receptor agonist	SIGMAR1			BRD-K62537556-001-02-5	Preclinical
4-iodo-L-phenylalanine		DPP4			BRD-K66664625-001-02-9, BRD-K66664625-001-01-2	Preclinical
4-iodo-6-phenylpyrimidine	macrophage migration inhibiting factor inhibitor	MIF			BRD-K25690923-001-02-4	Preclinical
4-methylgenistein	protein tyrosine kinase inhibitor	CYP19A1, ESRRA, ESRRB, ESRRG, FASN			BRD-K73303757-001-21-6	Preclinical
4-methylhistamine	histamine receptor agonist	HRH4			BRD-K70821460-300-02-4	Preclinical
4-mu-8C	IRE1 inhibitor	ERN1			BRD-K81316007-001-02-9, BRD-K81316007-001-02-9, BRD-K81316007-001-01-8, BRD-K81316007-001-01-8, BRD-K81316007-001-01-8	Preclinical
4-P-PDOT	melatonin receptor antagonist	MTNR1A, MTNR1B			BRD-K00004224-001-01-9	Preclinical
4-phenolsulfonic-acid					BRD-K41024817-325-01-0	Preclinical
4-PPBP	sigma receptor ligand	SIGMAR1			BRD-K78061844-050-02-7, BRD-K78061844-050-03-9, BRD-K78061844-050-01-9	Preclinical
4-propylbenzoic-acid					BRD-K42108215-001-01-5	Preclinical
4-pyrimidinecarbonitrile					BRD-K04552268-001-02-4	Preclinical
4-tert-butylphenol					BRD-K06338106-001-01-4, BRD-K06338106-001-04-9	Preclinical
4BP-TQS	nicotinic receptor agonist	CHRNA7			BRD-A18598741-001-01-2, BRD-A18598741-001-02-9	Preclinical
4EGI-1	protein synthesis inhibitor	EIF4E			BRD-K00004308-001-01-9	Preclinical
4SC-202	HDAC inhibitor	HDAC1			BRD-K11773281-001-02-0, BRD-K11773281-001-01-2, BRD-K11773281-001-01-2, BRD-K11773281-075-02-4, BRD-K11773281-075-02-4, BRD-K11773281-075-02-4, BRD-K11773281-075-02-4, BRD-K11773281-075-01-6	Phase 1
5'-chloro-5'-deoxy-ENBA-(+/-)	adenosine receptor agonist	ADORA1			BRD-K00004289-001-01-9	Preclinical
5,7-dichlorokynurenic-acid	glutamate receptor antagonist	GLRA2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			BRD-K60287130-001-06-5, BRD-K60287130-001-05-7, BRD-K60287130-001-08-9	Preclinical
5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one					BRD-K58146797-001-01-2	Preclinical
5-aminolevulinic-acid	oxidizing agent	ALAD	oncology, dermatology	glioma, actinic keratosis (AK)	BRD-K57631554-003-07-0, BRD-K57631554-003-06-2	Launched
5-BDBD	purinergic receptor antagonist	P2RX4			BRD-K33690734-001-02-3, BRD-K33690734-001-02-3, BRD-K33690734-001-01-5, BRD-K33690734-001-01-5, BRD-K33690734-001-03-9, BRD-K33690734-001-03-9	Preclinical
5-carboxamidotryptamine	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR6, HTR7			BRD-K92382976-050-02-9, BRD-K92382976-050-01-1	Preclinical
5-fluoro-3-pyridyl-methanol					BRD-K73381198-001-01-1	Preclinical
5-fluoropyrimidine	kinase inhibitor				BRD-K00004679-001-01-9	Phase 3
5-fluorouracil	thymidylate synthase inhibitor	DPYD, TYMS	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma	BRD-K24844714-001-25-2, BRD-K24844714-001-25-2, BRD-K24844714-001-25-2, BRD-K24844714-001-24-5, BRD-K24844714-001-24-5	Launched
5-FP	thymidylate synthase inhibitor	TYMS			BRD-K34437622-001-08-0, BRD-K34437622-001-06-4	Phase 1
5-HMF					BRD-K86799112-001-04-6, BRD-K86799112-001-02-0, BRD-K86799112-001-03-8	Phase 2
5-hydroxyectoine					BRD-K03871161-001-01-9, BRD-K03871161-001-01-9, BRD-K03871161-001-02-9	Preclinical
5-hydroxymethyl-tolterodine	acetylcholine receptor antagonist	CHRM3			BRD-K24603946-001-05-9, BRD-K24603946-001-02-1, BRD-K24603946-001-03-9, BRD-K24603946-001-03-9	Phase 1
5-hydroxytryptophan	neurotransmitter	SLC36A1, SLC36A2	neurology/psychiatry	insomnia	BRD-A73930134-001-02-2, BRD-A73930134-001-03-0, BRD-A73930134-001-04-8	Launched
5-iodo-A-85380	acetylcholine receptor agonist				BRD-K90065682-300-03-4, BRD-K90065682-300-02-6	Phase 2
5-methylfurmethiodide	acetylcholine receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			BRD-K45437867-005-04-1, BRD-K45437867-005-03-3	Preclinical
5-methylhydantoin-(D)					BRD-K06050544-001-03-1, BRD-K06050544-001-04-9	Preclinical
5-methylhydantoin-(L)					BRD-K56033645-001-07-5	Preclinical
5-octanoylsalicylic-acid	protein kinase activator				BRD-K00004681-001-01-9	Preclinical
6,7-dehydro-17-acetoxy-progesterone	steroidal progestin				BRD-K48329353-001-03-9, BRD-K48329353-001-01-3, BRD-K48329353-001-01-3	Preclinical
6-aminochrysene	transferase inhibitor				BRD-K00656370-001-10-5	Phase 2
6-aminopenicillanic-acid					BRD-K30284967-001-01-8, BRD-K30284967-001-02-9	Preclinical
6-benzylaminopurine	purinergic receptor activator				BRD-K62929068-001-26-9, BRD-K62929068-001-16-5, BRD-K62929068-001-16-5	Preclinical
6-chloromelatonin	melatonin receptor agonist	MTNR1A, MTNR1B			BRD-K34663752-001-10-9, BRD-K34663752-001-10-9, BRD-K34663752-001-11-9, BRD-K34663752-001-09-1	Preclinical
6-diazo-5-oxo-L-norleucine	glutamate receptor antagonist, glutaminase inhibitor				BRD-K84924563-001-04-9, BRD-K84924563-001-03-8	Preclinical
6-iodo-nordihydrocapsaicin	TRPV antagonist	TRPV1			BRD-K49236613-001-03-9, BRD-K49236613-001-02-3	Preclinical
7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one					BRD-K77756533-001-01-4	Preclinical
7-chlorokynurenic-acid	glutamate receptor antagonist	GRIN1, GRIN2A, GRIN2B, GRIN2C			BRD-K84214706-001-06-5, BRD-K84214706-001-06-5, BRD-K84214706-001-05-7, BRD-K84214706-001-07-9	Preclinical
7-hydroxy-DPAT	dopamine receptor agonist	DRD2, DRD3			BRD-K01826780-004-09-9, BRD-K01826780-004-08-9, BRD-K01826780-004-08-9, BRD-K01826780-004-07-9	Preclinical
7-hydroxy-PIPAT	dopamine receptor ligand	DRD3			BRD-K01825667-050-01-9	Preclinical
7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	CDK1, CHEK1, CHEK2, GSK3B, LCK, MAPK14, MARK1, MARK3, PDPK1, PRKCA, PRKCB, PRKCD, PRKCE, PRKCG			BRD-K45293975-001-02-0, BRD-K45293975-001-01-2, BRD-K45293975-001-01-2	Phase 2
7-keto-DHEA	steroid				BRD-K07785030-001-01-6	Launched
7-methoxytacrine	acetylcholinesterase inhibitor	ACHE			BRD-K53156626-001-01-3, BRD-K53156626-001-01-3	Phase 2
7-methylxanthine	adenosine receptor antagonist				BRD-K41592905-001-01-6, BRD-K41592905-001-01-6, BRD-K41592905-001-01-6	Phase 2
7-nitroindazole	nitric oxide synthase inhibitor	NOS1, NOS2, NOS3			BRD-K04430056-001-18-5, BRD-K04430056-236-02-1, BRD-K04430056-001-17-7	Preclinical
8-bromo-cAMP	PKA activator				BRD-A09554849-236-08-9, BRD-A09554849-236-08-9, BRD-A09554849-236-07-6, BRD-A09554849-236-07-6, BRD-A09554849-236-07-6	Preclinical
8-bromo-cGMP	PKA activator	PRKG1			BRD-A00077618-236-08-9, BRD-A00077618-236-08-9, BRD-A00077618-236-07-6, BRD-A00077618-236-07-6	Preclinical
8-hydroxy-DPAT	serotonin receptor agonist	HTR5A, HTR7			BRD-K01826732-004-09-9, BRD-K01826732-004-08-9	Preclinical
8-hydroxy-PIPAT	dopamine receptor ligand	DRD2, DRD3			BRD-A60594020-034-01-1, BRD-A60594020-034-02-9	Preclinical
8-M-PDOT	melatonin receptor agonist	MTNR1A, MTNR1B			BRD-A07232941-001-03-5, BRD-A07232941-001-02-7	Preclinical
80841-78-7					BRD-K03044000-001-01-8	Preclinical
9-aminoacridine					BRD-K00535541-001-04-8, BRD-K00535541-001-05-5, BRD-K00535541-001-06-3, BRD-K00535541-001-06-3, BRD-K00535541-001-06-3	Preclinical
9-aminocamptothecin	topoisomerase inhibitor	TOP1			BRD-K09291936-001-13-3, BRD-K09291936-001-13-3	Phase 2
9-anthracenecarboxylic-acid		ANO1, CLCN1			BRD-K62607075-001-04-9, BRD-K62607075-001-03-6	Preclinical
cortisone	glucocorticoid receptor agonist	NR3C1	gastroenterology, rheumatology, dermatology	ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema	BRD-K00025572-001-01-9	Launched
oleanolic-acid	G protein-coupled receptor agonist	GPBAR1			BRD-K90647725-001-10-9, BRD-K90647725-001-07-3, BRD-K90647725-001-06-5	Preclinical
natamycin	fungal ergosterol inhibitor		ophthalmology, infectious disease	conjunctivitis, fungal keratosis, blepharitis	BRD-K90563805-213-01-9, BRD-K90563805-001-03-4, BRD-K90563805-001-04-2, BRD-K90563805-001-02-6, BRD-K90563805-001-05-9, BRD-K90563805-001-06-7	Launched
drospirenone	mineralocorticoid receptor antagonist	AR, NR3C2, PGR	endocrinology	contraceptive	BRD-K04394237-001-04-5, BRD-K04394237-001-04-5, BRD-K04394237-001-04-5, BRD-K04394237-001-04-5, BRD-K04394237-001-06-0, BRD-K04394237-001-03-7, BRD-K04394237-001-05-2	Launched
mometasone-furoate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-K60640630-001-11-0, BRD-K60640630-001-11-0, BRD-K60640630-001-10-2, BRD-K60640630-001-10-2, BRD-K60640630-001-10-2, BRD-K60640630-001-12-9, BRD-K60640630-001-12-9	Launched
darolutamide	androgen receptor antagonist	AR	oncology	prostate cancer	BRD-A44971162-001-01-9, BRD-A44971162-001-02-7	Launched
flumethasone	glucocorticoid receptor agonist	NR3C1, PLA2G1B	otolaryngology, infectious disease, dermatology	otitis, ear infections, corticosteroid-responsive dermatoses	BRD-K61496577-001-21-9, BRD-K61496577-001-20-2, BRD-K61496577-001-19-4, BRD-K61496577-001-19-4, BRD-K61496577-001-19-4, BRD-K61496577-001-19-4	Launched
ethinyl-estradiol	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2, NR1I2	endocrinology	contraceptive	BRD-K48195008-001-19-9, BRD-K48195008-001-19-9, BRD-K48195008-001-19-9, BRD-K48195008-001-19-9, BRD-K48195008-001-17-3, BRD-K48195008-001-18-1	Launched
cefamandole-nafate	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, urinary tract infections, respiratory tract infections	BRD-K17903788-236-01-9, BRD-K17903788-236-02-7, BRD-K17903788-236-03-5	Launched
NMDA	glutamate receptor agonist	GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D			BRD-K62414032-001-13-8, BRD-K62414032-001-13-8, BRD-K62414032-001-12-0, BRD-K62414032-001-15-9, BRD-K62414032-001-15-9	Preclinical
fulvestrant	estrogen receptor antagonist	ESR1, ESR2, GPER1	oncology	breast cancer	BRD-A85667082-001-10-1, BRD-A85667082-001-10-1, BRD-A85667082-001-11-9, BRD-A85667082-001-11-9, BRD-A85667082-001-11-9, BRD-A85667082-001-12-7, BRD-A85667082-001-12-7, BRD-A85667082-001-12-7, BRD-A85667082-001-12-7, BRD-A85667082-001-12-7, BRD-A85667082-001-13-5, BRD-A85667082-001-13-5, BRD-A85667082-001-13-5	Launched
norgestimate	progesterone receptor agonist	ESR1, PGR	endocrinology	contraceptive	BRD-K38041788-001-02-9, BRD-K38041788-001-01-1	Launched
docetaxel	tubulin polymerization inhibitor	BCL2, MAP2, MAP4, MAPT, NR1I2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)	BRD-K30577245-341-01-9, BRD-K30577245-341-01-9, BRD-K30577245-001-04-3, BRD-K30577245-001-05-0, BRD-K30577245-001-05-0, BRD-K30577245-001-05-0, BRD-K30577245-001-05-0	Launched
icariin	phosphodiesterase inhibitor	PDE5A			BRD-K65639003-001-11-9, BRD-K65639003-001-10-8, BRD-K65639003-001-10-8, BRD-K65639003-001-10-8, BRD-K65639003-001-09-0, BRD-K65639003-001-09-0, BRD-K65639003-001-09-0, BRD-K65639003-001-09-0	Phase 3
stavudine	DNA directed DNA polymerase inhibitor, nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K93880783-001-27-4, BRD-K93880783-001-29-9, BRD-K93880783-001-26-6, BRD-K93880783-001-26-6, BRD-K93880783-001-26-6, BRD-K93880783-001-28-2	Launched
micafungin	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia, peritonitis, esophageal candidiasis	BRD-K40407248-236-01-6, BRD-K40407248-001-04-9, BRD-K40407248-236-02-4	Launched
valganciclovir	DNA synthesis inhibitor		infectious disease	cytomegalovirus (CMV)	BRD-K01825663-001-01-9	Launched
ascorbic-acid	antioxidant	SLC23A1, SLC23A2	endocrinology	scurvy	BRD-A85242401-001-11-5, BRD-A85242401-001-10-7, BRD-A85242401-001-09-9, BRD-A85242401-001-12-3, BRD-A85242401-001-05-7, BRD-A85242401-001-07-3	Launched
homatropine	acetylcholine receptor antagonist	CHRM1	ophthalmology	uveal tract inflammation, pupil dilation	BRD-K01826529-004-11-9, BRD-K01826529-004-10-9, BRD-K01826529-004-10-9, BRD-K01826529-004-09-9, BRD-K01826529-004-09-9	Launched
argatroban	thrombin inhibitor	F2	hematology	heparin-induced thrombocytopenia (HIT)	BRD-A48261811-001-07-3, BRD-A48261811-001-08-1, BRD-A48261811-001-08-1, BRD-A48261811-001-09-9	Launched
bacampicillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections	BRD-A41698174-003-13-8, BRD-A41698174-003-11-2, BRD-A41698174-003-12-0	Launched
sulpiride	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	BRD-A55272860-001-16-1, BRD-A55272860-001-16-1, BRD-A55272860-001-15-3, BRD-A55272860-001-18-9, BRD-A55272860-001-14-6	Launched
beclomethasone-dipropionate	glucocorticoid receptor agonist	GPR97, NR3C1	allergy	allergic rhinitis	BRD-K97810537-001-13-6, BRD-K97810537-001-15-9, BRD-K97810537-001-15-9, BRD-K97810537-001-12-8, BRD-K97810537-001-14-4, BRD-K97810537-001-14-4	Launched
orteronel	androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor	CYP17A1			BRD-K00674894-001-02-2, BRD-K00674894-001-01-4, BRD-K00674894-001-01-4	Phase 3
aloxistatin	protease inhibitor	CTSG			BRD-K91188791-001-15-9, BRD-K91188791-001-15-9, BRD-K91188791-001-18-3, BRD-K91188791-001-18-3, BRD-K91188791-001-17-5, BRD-K91188791-001-17-5, BRD-K91188791-001-14-2	Phase 3
flucloxacillin	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology, dermatology, gastroenterology	gram-positive bacterial infections, tonsillitis, sinusitis, pneumonia, eczema, endocarditis, meningitis, enteritis, bacterial septicemia	BRD-K27871792-236-01-0, BRD-K27871792-001-01-8	Launched
L-ascorbyl-6-palmitate					BRD-A45419686-001-04-9, BRD-A45419686-001-02-3, BRD-A45419686-001-03-1, BRD-A45419686-001-05-9, BRD-A45419686-001-05-9	Preclinical
epacadostat	indoleamine 2,3-dioxygenase inhibitor	IDO1			BRD-K79450420-001-03-4, BRD-K79450420-001-01-8, BRD-K79450420-001-01-8, BRD-K79450420-001-02-6	Phase 3
acarbose	glucosidase inhibitor	AMY2A, MGAM	endocrinology	diabetes mellitus	BRD-K44276885-001-06-6, BRD-K44276885-001-06-6, BRD-K44276885-001-08-2, BRD-K44276885-001-08-2, BRD-K44276885-001-08-2, BRD-K44276885-001-05-8, BRD-K44276885-001-07-4	Launched
loxoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	PTGS2	neurology/psychiatry	pain relief	BRD-K01825691-001-04-9, BRD-K01825691-001-01-9, BRD-K01825691-001-01-9, BRD-K01825691-001-02-9	Launched
estriol	estrogen receptor agonist	ESR1, ESR2	endocrinology, obstetrics/gynecology, infectious disease	menopause, vaginal atrophy, urinary tract infections	BRD-K17016787-001-17-9, BRD-K17016787-001-16-7, BRD-K17016787-001-13-4, BRD-K17016787-001-15-9	Launched
estradiol	estrogen receptor agonist	ESR1, ESR2, GPER1, KCNMA1, NR1I2	endocrinology	contraceptive	BRD-K18910433-001-43-2, BRD-K18910433-001-43-2, BRD-K18910433-001-43-2, BRD-K18910433-001-43-2, BRD-K18910433-001-36-6, BRD-K18910433-001-36-6, BRD-K18910433-001-42-4, BRD-K18910433-001-42-4, BRD-K18910433-001-42-4, BRD-K18910433-001-42-4	Launched
perindopril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension, myocardial infarction, coronary artery disease (CAD)	BRD-K92731339-227-04-9, BRD-K92731339-227-05-6, BRD-K92731339-227-07-9, BRD-K92731339-227-08-9, BRD-K92731339-227-08-9	Launched
oxaliplatin	DNA inhibitor		oncology	colorectal cancer	BRD-K78960041-001-07-3, BRD-K78960041-001-07-3, BRD-K78960041-001-05-7, BRD-K78960041-001-05-7, BRD-K78960041-001-03-2, BRD-K78960041-001-08-9, BRD-K78960041-001-08-9, BRD-K78960041-001-02-4	Launched
medrysone	glucocorticoid receptor agonist	NR3C1	ophthalmology	conjunctivitis, episcleritis	BRD-K56515112-001-23-9, BRD-K56515112-001-21-6, BRD-K56515112-001-22-4	Launched
enoxolone	gap junction modulator	HSD11B1	gastroenterology, otolaryngology	peptic ulcer disease (PUD), common cold	BRD-K96137854-001-18-9, BRD-K96137854-001-18-9, BRD-K96137854-001-18-9, BRD-K96137854-001-20-9, BRD-K96137854-001-17-1	Launched
paromomycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	amebiasis	BRD-K36524108-065-06-5, BRD-K36524108-065-04-0, BRD-K36524108-065-07-3, BRD-K36524108-065-05-7, BRD-K36524108-065-03-2	Launched
BVT-948	tyrosine phosphatase inhibitor	PTPN1, PTPN11, PTPN2			BRD-K68567222-001-01-2, BRD-K68567222-001-01-2	Preclinical
clindamycin	protein synthesis inhibitor		infectious disease	respiratory tract infections, pneumonia, skin infections, gynecologic infections, intra-abdominal infections, bacterial septicemia, bone and joint infections	BRD-K23586533-003-04-9, BRD-K23586533-003-01-6, BRD-K23586533-001-03-6, BRD-K23586533-001-03-6, BRD-K23586533-001-03-6, BRD-K23586533-003-02-4	Launched
linagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	BRD-K96550715-003-01-4, BRD-K96550715-003-01-4, BRD-K96550715-001-03-4, BRD-K96550715-001-06-9, BRD-K96550715-001-04-2, BRD-K96550715-001-04-2, BRD-K96550715-001-02-6	Launched
naloxone	opioid receptor antagonist	CREB1, ESR1, OPRD1, OPRK1, OPRM1, TLR4	pulmonary	respiratory depression	BRD-K67511046-003-16-9, BRD-K67511046-003-16-9, BRD-K67511046-003-14-4, BRD-K67511046-003-15-1, BRD-K67511046-001-02-3, BRD-K67511046-001-02-3	Launched
cefamandole	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, urinary tract infections, respiratory tract infections	BRD-K27130738-236-14-1, BRD-K27130738-236-15-8	Launched
carmoterol	adrenergic receptor agonist	ADRB2			BRD-K25095405-001-01-5	Phase 2
streptozotocin	DNA alkylating agent		oncology	pancreatic cancer	BRD-K34411947-001-14-1, BRD-K34411947-001-15-8, BRD-K34411947-001-13-3, BRD-K34411947-001-12-5, BRD-K34411947-001-11-7, BRD-K34411947-001-17-4	Launched
clobetasol-propionate	glucocorticoid receptor agonist	NR3C1, PLA2G1B	dermatology	corticosteroid-responsive dermatoses	BRD-K10799896-001-24-7, BRD-K10799896-001-26-2, BRD-K10799896-001-25-4, BRD-K10799896-001-25-4, BRD-K10799896-001-25-4	Launched
sparfloxacin	bacterial DNA gyrase inhibitor	TOP2A			BRD-K07612980-001-08-9, BRD-K07612980-001-07-9, BRD-K07612980-001-07-9, BRD-K07612980-001-04-6, BRD-K07612980-001-05-3, BRD-K07612980-001-05-3	Withdrawn
desonide	glucocorticoid receptor agonist	NR3C1, PLA2G1B	gastroenterology	Crohn's disease	BRD-K21528677-001-05-9, BRD-K21528677-001-05-9, BRD-K21528677-001-04-4, BRD-K21528677-001-04-4, BRD-K21528677-001-02-8, BRD-K21528677-001-03-6, BRD-K21528677-001-03-6	Launched
dexamethasone	glucocorticoid receptor agonist	ANXA1, NOS2, NR0B1, NR3C1, NR3C2	endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis	BRD-K38775274-001-24-7, BRD-K38775274-001-29-9, BRD-K38775274-001-22-1, BRD-K38775274-001-22-1, BRD-K38775274-001-22-1, BRD-K38775274-001-23-9, BRD-K38775274-001-23-9	Launched
paclitaxel	tubulin polymerization inhibitor	BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)	BRD-K62008436-001-25-4, BRD-K62008436-001-22-1, BRD-K62008436-001-22-1, BRD-K62008436-001-18-9, BRD-K62008436-001-18-9, BRD-K62008436-001-23-9, BRD-K62008436-001-23-9, BRD-K62008436-001-24-7, BRD-K62008436-001-24-7	Launched
inosine	neurotrophic agent	PARP1, PNP			BRD-K79612754-001-22-9, BRD-K79612754-001-21-7, BRD-K79612754-001-20-9, BRD-K79612754-001-19-1	Launched
methyllycaconitine	acetylcholine receptor antagonist	CHRNA7			BRD-K43192255-048-02-8, BRD-K43192255-048-02-8, BRD-K43192255-048-01-0, BRD-K43192255-048-03-6	Preclinical
potassium-canrenoate	mineralocorticoid receptor antagonist	NR3C2	cardiology	edema	BRD-K46556543-001-01-4, BRD-K46556543-001-01-4, BRD-K46556543-001-01-4, BRD-K46556543-237-09-7, BRD-K46556543-237-11-9, BRD-K46556543-237-10-5, BRD-K46556543-237-10-5	Launched
etoposide	topoisomerase inhibitor	TOP2A, TOP2B	oncology	non-small cell lung cancer (NSCLC)	BRD-K37798499-001-24-9, BRD-K37798499-001-25-6, BRD-K37798499-001-18-1, BRD-K37798499-001-27-2, BRD-K37798499-001-27-2, BRD-K37798499-001-22-3, BRD-K37798499-001-21-5	Launched
fenticonazole	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	BRD-A33697453-008-03-9, BRD-A33697453-008-04-9, BRD-A33697453-008-04-9	Launched
olesoxime	apoptosis stimulant				BRD-K18210059-001-01-8, BRD-K18210059-001-02-6	Phase 2/Phase 3
17-PA	glucocorticoid receptor agonist				BRD-K07395323-001-01-0, BRD-K07395323-001-02-9	Preclinical
hydrocortisone-butyrate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses, eczema	BRD-K99199077-001-17-9, BRD-K99199077-001-16-1	Launched
lacitol	laxative		gastroenterology	constipation	BRD-K40787673-001-02-1, BRD-K40787673-001-01-3, BRD-K40787673-001-07-9	Launched
pregnenolone	glutamate receptor modulator	SULT2B1	rheumatology	rheumatoid arthritis	BRD-K43880410-001-16-9, BRD-K43880410-001-15-1, BRD-K43880410-001-14-4, BRD-K43880410-001-14-4	Launched
cefuroxime-axetil	bacterial cell wall synthesis inhibitor		otolaryngology	pharyngitis, tonsillitis, otitis, sinusitis	BRD-A22303829-001-01-6, BRD-A22303829-001-02-4, BRD-A22303829-001-03-9	Launched
biotin	vitamin B	ACACA, ACACB, HLCS, MCCC1, MCCC2, PC, PCCA, PCCB, SLC5A6			BRD-K89210380-001-14-5, BRD-K89210380-001-15-9, BRD-K89210380-001-13-7	Launched
physostigmine	acetylcholinesterase inhibitor, cholinesterase inhibitor	ACHE, BCHE	cardiology, neurology/psychiatry, ophthalmology, gastroenterology	hypotension, Alzheimer's disease, glaucoma, gastroparesis	BRD-K25650355-065-02-0, BRD-K25650355-065-02-0, BRD-K25650355-059-19-7, BRD-K25650355-059-19-7, BRD-K25650355-059-19-7, BRD-K25650355-059-19-7, BRD-K25650355-059-18-9, BRD-K25650355-059-18-9, BRD-K25650355-059-20-5, BRD-K25650355-059-20-5	Launched
azithromycin	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	pelvic inflammatory disease, pneumonia	BRD-K74501079-001-17-3, BRD-K74501079-001-17-3, BRD-K74501079-001-15-7, BRD-K74501079-335-01-9, BRD-K74501079-001-19-9, BRD-K74501079-001-18-1, BRD-K74501079-001-18-1	Launched
cephalexin	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	respiratory tract infections, otitis, skin infections, bone and joint infections, genitourinary tract infections	BRD-K90733503-001-08-7, BRD-K90733503-001-07-9, BRD-K90733503-001-06-1, BRD-K90733503-001-10-3, BRD-K90733503-001-09-5, BRD-K90733503-001-05-3	Launched
triamcinolone	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-K77554836-001-15-9, BRD-K77554836-001-15-9, BRD-K77554836-001-15-9, BRD-K77554836-001-15-9, BRD-K77554836-001-15-9, BRD-K77554836-001-11-6, BRD-K77554836-001-11-6, BRD-K77554836-001-11-6, BRD-K77554836-001-14-0, BRD-K77554836-001-14-0, BRD-K77554836-001-13-2	Launched
estrone	estrogen receptor agonist, estrogenic hormone	ESR1, ESR2	endocrinology	menopause	BRD-K81839095-001-31-9, BRD-K81839095-001-30-1, BRD-K81839095-001-25-1, BRD-K81839095-001-25-1, BRD-K81839095-001-29-3, BRD-K81839095-001-29-3	Launched
cyclothiazide	glutamate receptor modulator	CA2, GRIA1, GRIA2, GRIA3, GRIA4, SLC12A3	cardiology	hypertension	BRD-A38675539-001-13-5, BRD-A38675539-001-13-5, BRD-A38675539-001-11-9, BRD-A38675539-001-14-3, BRD-A38675539-001-12-7, BRD-A38675539-001-10-1	Launched
ceforanide	penicillin binding protein inhibitor		infectious disease	gram-negative bacterial infections	BRD-K37848908-001-06-4, BRD-K37848908-001-05-6, BRD-K37848908-001-05-6	Launched
fludrocortisone-acetate		NR3C2	endocrinology	Addison's disease, adrenogenital syndrome	BRD-K06408664-001-03-5, BRD-K06408664-001-03-5, BRD-K06408664-001-04-9, BRD-K06408664-001-04-9, BRD-K06408664-001-02-7	Launched
cefditoren-pivoxil	bacterial cell wall synthesis inhibitor		infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis	BRD-K72167406-001-04-7, BRD-K72167406-001-02-1, BRD-K72167406-001-03-9, BRD-K72167406-001-06-9	Launched
norethindrone	progesterone receptor agonist	PGR	obstetrics/gynecology	endometriosis	BRD-K92073408-001-15-7, BRD-K92073408-001-15-7, BRD-K92073408-001-15-7, BRD-K92073408-001-15-7, BRD-K92073408-001-16-5, BRD-K92073408-001-16-5, BRD-K92073408-001-14-0	Launched
estradiol-valerate	estrogen receptor agonist	ESR1	oncology, endocrinology, obstetrics/gynecology	prostate cancer, hypoestrogenism, menopause, vaginal atrophy	BRD-K66766661-001-21-9, BRD-K66766661-001-19-2, BRD-K66766661-001-19-2, BRD-K66766661-001-19-2, BRD-K66766661-001-20-0, BRD-K66766661-001-20-0, BRD-K66766661-001-20-0	Launched
cefpiramide	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	BRD-K92872987-001-02-9, BRD-K92872987-001-01-1, BRD-K92872987-236-03-9	Launched
rocuronium	acetylcholine receptor antagonist	CHRM2, CHRNA2, HTR3A	neurology/psychiatry	anesthetic	BRD-K43305603-004-03-6, BRD-K43305603-004-03-6, BRD-K43305603-004-02-8	Launched
dichlorisone-acetate					BRD-K54187111-001-10-9, BRD-K54187111-001-09-2, BRD-K54187111-001-07-6, BRD-K54187111-001-08-4	Phase 2
4-phenyl-1,2,3,4-tetrahydroisoquinoline	dopamine release inhibitor				BRD-A40504327-003-02-9, BRD-A40504327-003-03-9	Preclinical
loxistatin-acid	cysteine peptidase inhibitor	CTSB			BRD-K21937671-001-10-0, BRD-K21937671-001-09-2, BRD-K21937671-001-11-8	Preclinical
coenzyme-I		AASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1, AKR1C2, AKR1C3, AKR1C4, ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, ALDH3A2, ALDH3B1, ALDH3B2, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDH9A1, AMT, BDH1, BLVRA, BLVRB, CDO1, CYB5R3, CYP17A1, CYP4A11, DHCR7, DHFR, DLAT, DLD, EHHADH, GAPDH, GAPDHS, GLUD1, GLUD2, GPD1, GSR, H6PD, HADH, HADHA, HIBADH, HMGCR, HMOX1, HMOX2, HPGD, HSD11B1, HSD11B2, HSD17B1, HSD17B10, HSD17B2, HSD17B3, HSD17B4, HSD17B7, HSD17B8, HSD3B1, HSD3B2, IDH3A, IDH3B, IDH3G, IMPDH1, IMPDH2, LDHA, LDHAL6A, LDHAL6B, LDHB, LDHC, MDH1, MDH2, ME1, ME2, ME3, MSMO1, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MTHFD1, MTHFD2, NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA13, NDUFA2, NDUFA3, NDUFA4, NDUFA4L2, NDUFA5, NDUFA6, NDUFA7, NDUFA8, NDUFA9, NDUFAB1, NDUFB1, NDUFB10, NDUFB2, NDUFB3, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFB8, NDUFB9, NDUFC1, NDUFC2, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS5, NDUFS6, NDUFS7, NDUFS8, NDUFV1, NDUFV2, NDUFV3, NNT, NQO2, NSDHL, OGDH, PDHA1, PDHA2, PDHB, PHGDH, PYCR1, PYCR2, QDPR, RDH5, SORD, TSTA3, TYR, UGDH			BRD-K01825730-304-02-9, BRD-K01825730-304-01-9	Phase 2
artemether	antimalarial agent	ATP1A1	infectious disease	malaria	BRD-K39621635-001-09-7, BRD-K39621635-001-07-1, BRD-K39621635-001-05-5, BRD-K39621635-001-08-9, BRD-K39621635-001-06-3	Launched
OG-L002	histone lysine demethylase inhibitor	KDM1A			BRD-K26349472-001-02-1, BRD-K26349472-001-01-3, BRD-K26349472-001-01-3, BRD-K26349472-001-01-3, BRD-K26349472-001-01-3, BRD-K26349472-001-03-9	Preclinical
colchicine	microtubule inhibitor	GLRA1, GLRA2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8	rheumatology, endocrinology	gout, fever	BRD-K00259736-001-16-4, BRD-K00259736-001-18-0, BRD-K00259736-001-18-0	Launched
escitalopram	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	depression, generalized anxiety disorder (GAD)	BRD-K70301876-034-13-7, BRD-K70301876-034-13-7, BRD-K70301876-034-15-9, BRD-K70301876-034-14-5, BRD-K01825597-034-02-9	Launched
doxapram	potassium channel blocker		pulmonary, neurology/psychiatry	respiratory depression, central nervous system depression, acute hypercapnia (AHC)	BRD-K01825594-311-04-9, BRD-K01825594-311-02-9, BRD-K01825594-311-03-9	Launched
ivermectin	benzodiazepine receptor agonist	CHRNA7, P2RX7	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies	BRD-K85554912-001-08-9, BRD-K85554912-001-08-9, BRD-K85554912-001-08-9, BRD-K85554912-001-05-5, BRD-K85554912-001-09-9, BRD-K85554912-001-06-3, BRD-K85554912-001-06-3, BRD-K85554912-001-07-1	Launched
rivaroxaban	coagulation factor inhibitor	F10	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE)	BRD-K37130656-001-03-8, BRD-K37130656-001-04-6, BRD-K37130656-001-04-6	Launched
vinflunine	microtubule inhibitor		oncology	bladder cancer	BRD-K64120610-046-01-9, BRD-K64120610-046-01-9, BRD-K64120610-001-01-4, BRD-K64120610-001-01-4	Launched
golgicide-A	ARF inhibitor	GBF1			BRD-A57886255-001-01-1, BRD-A57886255-001-01-1, BRD-A57886255-001-02-9, BRD-A57886255-001-02-9, BRD-A57886255-001-03-9	Preclinical
kanamycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	BRD-K08327065-065-05-0, BRD-K08327065-065-04-3, BRD-K08327065-065-06-8	Launched
OTX015	bromodomain inhibitor	BRD2, BRD3, BRD4			BRD-K43471985-001-05-5, BRD-K43471985-001-05-5, BRD-K43471985-001-03-0, BRD-K43471985-001-03-0, BRD-K43471985-001-03-0	Phase 1/Phase 2
meropenem	bacterial cell wall synthesis inhibitor		infectious disease	skin infections, intra-abdominal infections, meningitis	BRD-K01612348-001-11-4, BRD-K01612348-001-14-8, BRD-K01612348-001-12-2, BRD-K01612348-001-13-0	Launched
cortisone-acetate	glucocorticoid receptor agonist	NR3C1	pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease	asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis	BRD-K86161929-001-13-3, BRD-K86161929-001-13-3, BRD-K86161929-001-11-7, BRD-K86161929-001-12-5, BRD-K86161929-001-15-9	Launched
cinchonidine	P glycoprotein inhibitor				BRD-K39079086-001-06-8, BRD-K39079086-001-06-8, BRD-K39079086-001-08-9, BRD-K39079086-001-07-6	Phase 1
etomidate	GABA receptor modulator	ADRA2B, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ	neurology/psychiatry	general anaesthetic	BRD-K55055802-001-09-4, BRD-K55055802-001-10-2, BRD-K55055802-001-08-6	Launched
cytisine	acetylcholine receptor agonist	CHRNA2, CHRNA3, CHRNA4, CHRNA6, CHRNA7, CHRNB2, CHRNB4	neurology/psychiatry	nicotinism	BRD-K74186897-001-13-2, BRD-K74186897-001-13-2, BRD-K74186897-001-11-6, BRD-K74186897-001-10-8, BRD-K74186897-001-12-4	Launched
esomeprazole	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, peptic ulcer disease (PUD)	BRD-K61443506-236-02-0, BRD-K61443506-237-01-0, BRD-K61443506-239-01-6, BRD-K61443506-239-03-9	Launched
oxytetracycline	bacterial 30S ribosomal subunit inhibitor		infectious disease, urology	chlamydia, urinary tract infections, skin infections, ear infections, gonorrhea, urethritis, Lyme disease	BRD-K01826559-001-11-9, BRD-K01826559-001-10-9, BRD-K01826559-001-08-9, BRD-K01826559-001-09-9	Launched
cholecalciferol		VDR	endocrinology	vitamin D deficiency	BRD-K62779383-001-08-9, BRD-K62779383-001-07-1, BRD-K62779383-001-05-5, BRD-K62779383-001-05-5	Launched
AZD8186	PI3K inhibitor	PIK3CB, PIK3CD			BRD-K47289408-001-01-5, BRD-K47289408-001-01-5, BRD-K47289408-001-01-5, BRD-K47289408-001-02-3	Phase 1
nicergoline	adrenergic receptor antagonist	ADRA1A	rheumatology, neurology/psychiatry, cardiology, hematology	Raynaud's disease, migraine headache, atherosclerosis, thrombosis	BRD-K76810206-001-07-3, BRD-K76810206-001-10-9, BRD-K76810206-001-10-9, BRD-K76810206-001-08-1	Launched
lumefantrine	antimalarial agent	ATP1A1	infectious disease	malaria	BRD-A05926236-001-04-6, BRD-A05926236-001-05-3, BRD-A05926236-001-03-8	Launched
peficitinib	JAK inhibitor	JAK1, JAK2, JAK3	rheumatology	rheumatoid arthritis	BRD-A14577621-001-01-5	Launched
cyanocobalamin	methylmalonyl CoA mutase stimulant, vitamin B	MUT	hematology, infectious disease, gastroenterology	anemia, fish tapeworm infestation, celiac disease	BRD-A18627414-001-05-6, BRD-A18627414-001-06-4, BRD-A18627414-001-04-9, BRD-A18627414-001-04-9, BRD-A18627414-001-04-9	Launched
vincristine	tubulin polymerization inhibitor	TUBA4A, TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	BRD-K12251893-065-06-2, BRD-K12251893-065-01-3, BRD-K12251893-065-05-4, BRD-K12251893-065-02-1, BRD-K12251893-065-02-1, BRD-K12251893-065-04-7, BRD-K12251893-065-03-9	Launched
budesonide	glucocorticoid receptor agonist	NR3C1	gastroenterology	Crohn's disease	BRD-A34299591-001-25-7, BRD-A34299591-001-27-3, BRD-A34299591-001-28-1, BRD-A34299591-001-26-5, BRD-A34299591-001-30-7, BRD-A34299591-001-30-7, BRD-A34299591-001-22-4, BRD-A34299591-001-29-9, BRD-A34299591-001-31-5	Launched
ursolic-acid	ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor	HSD11B1, PLA2G1B, PTPN1, PYGM			BRD-K68185022-001-12-2, BRD-K68185022-001-14-8, BRD-K68185022-001-14-8, BRD-K68185022-001-14-8, BRD-K68185022-001-14-8	Phase 2/Phase 3
edoxudine	DNA directed DNA polymerase inhibitor		infectious disease	virus herpes simplex (HSV)	BRD-K86892782-001-18-9, BRD-K86892782-001-17-0	Launched
prednisone	glucocorticoid receptor agonist	HSD11B1, NR3C1	endocrinology, rheumatology, infectious disease, dermatology, ophthalmology, hematology, gastroenterology, neurology/psychiatry	congenital adrenal hyperplasia, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, bursitis, osteoarthritis, epicondylitis, dermatomyositis, psoriasis, mycosis, conjunctivitis, anemia, ulcerative colitis, enteritis, multiple sclerosis, meningitis	BRD-K85883481-001-26-9, BRD-K85883481-001-26-9, BRD-K85883481-001-22-4, BRD-K85883481-001-25-7, BRD-K85883481-001-24-0	Launched
aloin	angiogenesis inhibitor				BRD-K02074536-001-04-9, BRD-K02074536-001-01-9, BRD-K02074536-001-02-7, BRD-K02074536-001-03-5	Preclinical
bivalirudin	thrombin inhibitor	F2	cardiology	angina pectoris	BRD-K73504359-019-03-9, BRD-K73504359-001-01-3, BRD-K73504359-001-01-3, BRD-K73504359-019-01-5, BRD-K73504359-019-02-9, BRD-K73504359-019-02-9	Launched
trifluridine	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	TYMS	infectious disease	virus herpes simplex (HSV)	BRD-K03243820-001-24-6, BRD-K03243820-001-25-3, BRD-K03243820-001-25-3, BRD-K03243820-001-25-3, BRD-K03243820-001-25-3, BRD-K03243820-001-23-8, BRD-K03243820-001-22-0, BRD-K03243820-001-22-0, BRD-K03243820-001-22-0	Launched
rauwolscine	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C, HTR1B, HTR1D, HTR1E, HTR2B			BRD-K77474816-003-14-1, BRD-K77474816-003-15-9, BRD-K77474816-003-15-9, BRD-K77474816-003-13-3	Preclinical
cefonicid	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	BRD-K34058848-304-03-1, BRD-K34058848-304-02-3, BRD-K34058848-304-01-5	Launched
biapenem	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia, pneumonia, urinary tract infections	BRD-A80321291-001-05-7, BRD-A80321291-001-04-0, BRD-A80321291-001-06-5, BRD-A80321291-001-01-6, BRD-A80321291-001-02-4, BRD-A80321291-001-03-2, BRD-A80321291-001-03-2	Launched
naltrexone	opioid receptor antagonist	OPRD1, OPRK1, OPRM1, SIGMAR1	neurology/psychiatry	abstinence from alcohol	BRD-K88172511-003-21-1, BRD-K88172511-003-22-9, BRD-K88172511-003-19-5, BRD-K88172511-003-20-3	Launched
betamethasone-dipropionate	anti-inflammatory agent	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-K58148589-001-03-6, BRD-K58148589-001-04-9, BRD-K58148589-001-02-8, BRD-K58148589-001-02-8	Launched
progesterone	progesterone receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, CYP17A1, ESR1, NR3C2, OPRK1, PGR, TRPC5	obstetrics/gynecology, endocrinology	infertility, amenorrhea	BRD-K64994968-001-32-5, BRD-K64994968-001-33-3	Launched
nanchangmycin	other antibiotic				BRD-A73871920-236-03-6, BRD-A73871920-236-03-6, BRD-A73871920-236-03-6, BRD-A73871920-236-03-6	Preclinical
doxifluridine	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	BRD-K58262659-001-12-9, BRD-K58262659-001-10-5, BRD-K58262659-001-10-5, BRD-K58262659-001-09-7, BRD-K58262659-001-09-7	Launched
ouabain	ATPase inhibitor	ATP1A1	cardiology	hypertension, cardiac arrythmia	BRD-K33277808-331-01-3, BRD-K33277808-331-01-3, BRD-K33277808-331-01-3, BRD-K33277808-001-03-9, BRD-K33277808-001-03-9, BRD-K33277808-001-03-9, BRD-K33277808-001-01-2, BRD-K33277808-001-01-2, BRD-K33277808-001-01-2, BRD-K33277808-001-01-2, BRD-K33277808-001-02-0, BRD-K33277808-001-02-0	Launched
carbidopa	aromatic L-amino acid decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	BRD-K78712176-001-13-3, BRD-K78712176-001-14-1, BRD-K78712176-001-11-7, BRD-K78712176-001-15-8, BRD-K78712176-001-12-5	Launched
cephalomannine	DNA polymerase inhibitor				BRD-K68904758-001-04-3, BRD-K68904758-001-02-7, BRD-K68904758-001-03-5	Preclinical
cefoperazone	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	BRD-K02292852-001-06-9, BRD-K02292852-001-04-7, BRD-K02292852-001-02-1	Launched
exemestane	aromatase inhibitor	CYP19A1	oncology	breast cancer	BRD-K33425534-001-10-9, BRD-K33425534-001-12-5, BRD-K33425534-001-11-7, BRD-K33425534-001-11-7	Launched
ceftazidime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, skin infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections, meningitis	BRD-K52117081-345-03-1, BRD-K52117081-001-03-0, BRD-K52117081-396-01-8, BRD-K52117081-001-02-2, BRD-K52117081-345-04-9	Launched
troxerutin	antioxidant				BRD-K73529671-001-05-9, BRD-K73529671-001-04-5, BRD-K73529671-001-02-9, BRD-K73529671-001-03-7	Launched
citicoline	glutathione transferase stimulant, membrane permeability enhancer	ACHE, SLC1A2	neurology/psychiatry, ophthalmology	stroke, Alzheimer's disease, senile dementia, Parkinson's Disease, attention-deficit/hyperactivity disorder (ADHD), glaucoma	BRD-K01827268-396-12-9, BRD-K01827268-396-12-9, BRD-K01827268-236-03-9	Launched
hydrocortisone	glucocorticoid receptor agonist	ANXA1, NOS2, NR3C1, NR3C2	dermatology, neurology/psychiatry	eczema, psoriasis, seborrheic dermatitis, itching	BRD-K93568044-001-30-4, BRD-K93568044-001-32-0, BRD-K93568044-001-32-0, BRD-K93568044-001-31-2, BRD-K93568044-001-31-2, BRD-K93568044-001-33-9	Launched
crizotinib-(S)	MTH1 inhibitor	NUDT1			BRD-K40308497-001-03-9, BRD-K40308497-001-03-9, BRD-K40308497-001-02-0, BRD-K40308497-001-02-0, BRD-K40308497-001-02-0, BRD-K40308497-001-01-2, BRD-K40308497-001-01-2, BRD-K40308497-001-01-2, BRD-K40308497-001-01-2, BRD-K40308497-001-01-2	Preclinical
deoxycorticosterone-acetate	progestogen hormone	NR3C2			BRD-K24556098-001-19-1, BRD-K24556098-001-19-1, BRD-K24556098-001-17-5, BRD-K24556098-001-17-5, BRD-K24556098-001-17-5, BRD-K24556098-001-18-3, BRD-K24556098-001-20-9, BRD-K24556098-001-16-7	Preclinical
amphotericin-b	membrane permeability enhancer		infectious disease	fungal infection	BRD-K27352494-001-04-4, BRD-K27352494-001-03-6, BRD-K27352494-001-03-6, BRD-K27352494-001-05-1, BRD-K27352494-001-06-9	Launched
cefuroxime	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	BRD-K02733959-236-06-9, BRD-K02733959-236-07-7, BRD-K02733959-236-05-1	Launched
rutin	antioxidant, capillary stabilizing agent, nitric oxide scavenger	AKR1C3	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis	BRD-K20482099-001-11-0, BRD-K20482099-001-12-9, BRD-K20482099-001-09-4, BRD-K20482099-001-10-2	Launched
gambogic-acid	caspase activator	BCL2			BRD-K08542803-001-01-5, BRD-K08542803-001-01-5, BRD-K08542803-001-02-3, BRD-K08542803-001-02-3, BRD-K08542803-001-03-1	Phase 2
AT13148	protein kinase inhibitor	AKT1, AKT2, AKT3, ROCK1, ROCK2, SGK3			BRD-K32127727-001-02-6, BRD-K32127727-001-03-4, BRD-K32127727-001-04-2, BRD-K32127727-001-04-2, BRD-K32127727-001-01-8	Phase 1
enocitabine	DNA synthesis inhibitor	CMPK1, RRM1, TYMS	hematologic malignancy	acute myeloid leukemia (AML)	BRD-K32007074-001-02-9, BRD-K32007074-001-01-1	Launched
fluocinolone-acetonide	glucocorticoid receptor agonist	NR3C1, SERPINA6	dermatology	seborrheic dermatitis	BRD-K94353609-001-22-9, BRD-K94353609-001-22-9, BRD-K94353609-001-21-6, BRD-K94353609-001-20-8, BRD-K94353609-001-20-8	Launched
hyoscyamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4	gastroenterology, urology, neurology/psychiatry, allergy	peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis	BRD-K40530731-001-12-9, BRD-K40530731-001-11-6, BRD-K40530731-001-10-8	Launched
AGN-192403	imidazoline receptor ligand	NISCH			BRD-A18074780-003-02-0, BRD-A18074780-003-02-0, BRD-A18074780-003-02-0	Preclinical
tropisetron	serotonin receptor antagonist	GLRA1, GLRA2, GLRB, HTR3A, HTR4	gastroenterology	nausea, vomiting	BRD-K50866992-003-10-3, BRD-K50866992-003-09-5, BRD-K50866992-003-09-5, BRD-K50866992-003-11-9	Launched
dehydroepiandrosterone	protein synthesis stimulant	ESR1, ESR2, G6PD, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, HSD17B1, NR1I2, NR1I3, PPARA, SIGMAR1, SULT2A1, SULT2B1	endocrinology	menopause	BRD-K41256143-001-13-5, BRD-K41256143-001-12-7	Launched
mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	AR, NR1I2, NR3C1, PGR	endocrinology	hyperglycemia, diabetes mellitus	BRD-K37270826-001-29-2, BRD-K37270826-001-29-2, BRD-K37270826-001-31-8, BRD-K37270826-001-31-8, BRD-K37270826-001-27-6, BRD-K37270826-001-27-6, BRD-K37270826-001-27-6, BRD-K37270826-001-27-6, BRD-K37270826-001-32-9, BRD-K37270826-001-32-9, BRD-K37270826-001-30-0, BRD-K37270826-001-26-8	Launched
bromocriptine	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7	endocrinology, neurology/psychiatry	hyperprolactinemia, Parkinson's Disease, acromegaly	BRD-K14496212-066-03-0, BRD-K14496212-066-04-8, BRD-K14496212-066-05-9, BRD-K14496212-066-02-2	Launched
GNTI	opioid receptor antagonist	OPRK1, OPRM1			BRD-K64748124-300-06-9, BRD-K64748124-300-01-7	Preclinical
oxytocin	oxytocin receptor agonist	AVPR1A, AVPR1B, AVPR2, OXTR	obstetrics/gynecology	labor induction	BRD-K25243230-001-01-2, BRD-K25243230-001-02-0	Launched
betamethasone-valerate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-K34032314-001-04-1, BRD-K34032314-001-02-5, BRD-K34032314-001-03-3, BRD-K34032314-001-05-8	Launched
mangafodipir	contrast agent		radiology	contrast agent	BRD-K57365211-314-01-4, BRD-K57365211-314-03-9, BRD-K57365211-314-02-2	Launched
D-limonene					BRD-K20879694-001-01-7, BRD-K20879694-001-02-5	Phase 1
ginkgolide-B	platelet activating factor receptor antagonist	GLRA1, GLRA2, GLRA3, GLRB, HTR3A, HTR3B			BRD-K93816012-001-09-9, BRD-K93816012-001-10-9, BRD-K93816012-001-07-3, BRD-K93816012-001-07-3, BRD-K93816012-001-08-1, BRD-K93816012-001-08-1	Phase 3
dihydroartemisinin	antimalarial agent		infectious disease	malaria	BRD-K62213621-001-03-9, BRD-K62213621-001-02-4, BRD-K62213621-001-02-4, BRD-K62213621-001-01-6	Launched
vecuronium	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry	muscle relaxant	BRD-K20168442-004-08-9, BRD-K20168442-004-07-1, BRD-K20168442-004-06-3	Launched
brinzolamide	carbonic anhydrase inhibitor	CA1, CA12, CA14, CA2, CA4, CA5A, CA7	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	BRD-K74913225-001-14-0, BRD-K74913225-001-16-9, BRD-K74913225-001-12-4, BRD-K74913225-001-13-2	Launched
finasteride	5 alpha reductase inhibitor	AKR1D1, SRD5A1, SRD5A2	endocrinology	androgenetic alopecia	BRD-K01095011-001-15-9, BRD-K01095011-001-15-9, BRD-K01095011-001-16-9, BRD-K01095011-001-16-9, BRD-K01095011-001-14-2	Launched
mevastatin	HMGCR inhibitor	HMGCR			BRD-K94441233-001-15-5, BRD-K94441233-001-15-5, BRD-K94441233-001-15-5, BRD-K94441233-001-17-1, BRD-K94441233-001-17-1, BRD-K94441233-001-17-1, BRD-K94441233-001-19-9, BRD-K94441233-001-16-3, BRD-K94441233-001-13-0, BRD-K94441233-001-12-2, BRD-K94441233-001-12-2, BRD-K94441233-001-12-2, BRD-K94441233-001-12-2, BRD-K94441233-001-12-2	Preclinical
brefeldin-A	protein synthesis inhibitor	ARF1, CYTH2			BRD-K77841042-001-15-8, BRD-K77841042-001-15-8, BRD-K77841042-001-19-9, BRD-K77841042-001-11-7, BRD-K77841042-001-11-7, BRD-K77841042-001-14-1	Preclinical
cefprozil	bacterial cell wall synthesis inhibitor		otolaryngology, infectious disease, pulmonary	pharyngitis, tonsillitis, otitis, sinusitis, respiratory tract infections, skin infections, bronchitis	BRD-K24871708-001-01-4, BRD-K24871708-002-03-8, BRD-K24871708-002-04-6, BRD-K24871708-002-04-6, BRD-K24871708-002-02-0	Launched
idoxuridine	DNA directed DNA polymerase inhibitor, DNA synthesis inhibitor		infectious disease	virus herpes simplex (HSV)	BRD-K76634210-001-15-9, BRD-K76634210-001-12-1, BRD-K76634210-001-12-1, BRD-K76634210-001-14-7, BRD-K76634210-001-14-7	Launched
cefsulodin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	BRD-K03907181-236-06-8, BRD-K03907181-236-05-0, BRD-K03907181-236-04-3, BRD-K03907181-236-07-6	Launched
dydrogesterone	progesterone receptor agonist	PGR	obstetrics/gynecology	infertility	BRD-K68620903-001-11-4, BRD-K68620903-001-12-9, BRD-K68620903-001-10-6, BRD-K68620903-001-09-8	Launched
aminopterin	dihydrofolate reductase inhibitor	DHFR, SLC46A1			BRD-K87544030-001-02-8, BRD-K87544030-001-01-0	Phase 3
ergocalciferol	vitamin analog	VDR	endocrinology, orthopedics	hypoparathyroidism, rickets, hypophosphatemia	BRD-K56155962-001-15-4, BRD-K56155962-001-15-4, BRD-K56155962-001-12-1, BRD-K56155962-001-12-1, BRD-K56155962-001-16-2, BRD-K56155962-001-16-2, BRD-K56155962-001-11-3, BRD-K56155962-001-11-3, BRD-K56155962-001-11-3	Launched
cefpodoxime	bacterial cell wall synthesis inhibitor		otolaryngology, infectious disease, pulmonary	pharyngitis, pneumonia, bronchitis, gonorrhea, skin infections, urinary tract infections, sinusitis, tonsillitis	BRD-A34205213-001-03-9, BRD-A34205213-001-03-9, BRD-A34205213-001-04-7	Launched
yohimbine	adrenergic receptor antagonist	ADRA2A, ADRA2B, ADRA2C, DRD2, DRD3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR5A, HTR7, KCNJ1, KCNJ10, KCNJ11, KCNJ12, KCNJ14, KCNJ15, KCNJ8	cardiology	cardiac arrythmia, bradycardia	BRD-K35586044-003-15-4, BRD-K35586044-003-14-7, BRD-K35586044-003-16-2, BRD-K35586044-003-16-2	Launched
formestane	aromatase inhibitor	CYP19A1	oncology	breast cancer	BRD-A26503646-001-16-6, BRD-A26503646-001-16-6, BRD-A26503646-001-20-9, BRD-A26503646-001-18-2	Launched
thiostrepton	FOXM1 inhibitor, protein synthesis inhibitor	FOXM1	obstetrics/gynecology	mastitis	BRD-K58049875-001-03-9, BRD-K58049875-001-03-9, BRD-K58049875-001-01-3, BRD-K58049875-001-01-3, BRD-K58049875-001-01-3, BRD-K58049875-001-02-1, BRD-K58049875-001-04-7	Launched
ticarcillin	lactamase inhibitor		infectious disease	gram-negative bacterial infections	BRD-K29229654-304-04-6, BRD-K29229654-304-04-6, BRD-K29229654-304-02-0, BRD-K29229654-304-03-8, BRD-K29229654-304-05-3	Launched
capecitabine	DNA synthesis inhibitor, thymidylate synthase inhibitor	TYMS	oncology	breast cancer, colorectal cancer	BRD-K61192372-001-06-3, BRD-K61192372-001-08-9, BRD-K61192372-001-08-9, BRD-K61192372-001-08-9, BRD-K61192372-001-05-5, BRD-K61192372-001-07-1, BRD-K61192372-001-07-1	Launched
nalbuphine	opioid receptor agonist, opioid receptor antagonist	OPRD1, OPRK1, OPRM1	neurology/psychiatry	pain relief	BRD-K66404838-001-02-4, BRD-K66404838-310-01-1, BRD-K66404838-310-01-1, BRD-K66404838-003-11-1	Launched
dexamethasone-acetate	glucocorticoid receptor agonist		endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis	BRD-K47635719-001-21-1, BRD-K47635719-001-22-9, BRD-K47635719-001-22-9, BRD-K47635719-001-20-3, BRD-K47635719-001-20-3	Launched
atropine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	ophthalmology	cycloplegia, mydriasis, amblyopia	BRD-K01825666-330-02-9, BRD-K01825666-001-03-9, BRD-K01825666-330-01-9	Launched
bucladesine	adenosine receptor agonist, cAMP stimulant	PRKACA	dermatology	skin ulcer	BRD-A94624445-236-18-8, BRD-A94624445-236-19-9, BRD-A94624445-236-19-9, BRD-A94624445-236-17-0, BRD-K01825692-001-01-9, BRD-K01825692-001-01-9	Launched
cabotegravir	HIV integrase inhibitor				BRD-K76819217-001-02-2, BRD-K76819217-001-01-4	Phase 3
cyproterone-acetate	androgen receptor antagonist	ADORA1, AR	oncology	prostate cancer	BRD-K41141507-001-17-0, BRD-K41141507-001-15-4, BRD-K41141507-001-18-9, BRD-K41141507-001-16-2	Launched
azlocillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections, gram-negative bacterial infections	BRD-K60663764-236-04-7, BRD-K60663764-236-04-7, BRD-K60663764-236-05-4, BRD-K60663764-236-03-9, BRD-K60663764-236-07-9	Launched
RTA-408	nitric oxide production inhibitor	NFE2L2			BRD-K56211775-001-02-0, BRD-K56211775-001-01-2, BRD-K56211775-001-03-8	Phase 2
tacrolimus	calcineurin inhibitor	FKBP1A	transplant	organ rejection	BRD-K69608737-001-08-6, BRD-K69608737-001-10-2, BRD-K69608737-001-10-2, BRD-K69608737-001-09-4, BRD-K69608737-001-09-4, BRD-K69608737-001-09-4	Launched
prulifloxacin	bacterial DNA gyrase inhibitor		infectious disease, pulmonary, gastroenterology	urinary tract infections, bronchitis, diarrhea	BRD-A92341659-001-03-2, BRD-A92341659-001-04-0	Launched
5-hydroxydecanoic-acid					BRD-K01666923-236-01-9	Preclinical
cefmetazole	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, skin infections	BRD-K48470486-236-11-6, BRD-K48470486-236-10-8, BRD-K48470486-236-12-4	Launched
spironolactone	mineralocorticoid receptor antagonist	AR, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1H, CACNA1I, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3, CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, CYP11B2, NR3C1, NR3C2, PGR, SHBG	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia	BRD-K90027355-001-16-6, BRD-K90027355-001-21-9, BRD-K90027355-001-21-9, BRD-K90027355-001-19-0, BRD-K90027355-001-20-8, BRD-K90027355-001-13-3, BRD-K90027355-001-13-3	Launched
5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione		TLR7			BRD-K87535339-001-01-6	Preclinical
usniacin-(+)	MAP kinase activator	PTPN1			BRD-A99182808-001-05-8, BRD-A12417644-001-07-6, BRD-A12417644-001-06-8	Preclinical
trilostane	3beta-hydroxy-delta5-steroid dehydrogenase inhibitor		endocrinology	Cushing's syndrome	BRD-A04497688-001-05-9, BRD-A04497688-001-03-4, BRD-A04497688-001-04-2	Launched
abiraterone	androgen biosynthesis inhibitor	CYP11B1, CYP17A1	oncology	prostate cancer	BRD-K50071428-001-04-9, BRD-K50071428-001-03-3, BRD-K50071428-001-03-3	Launched
ethisterone	progestogen hormone	TYR	endocrinology	amenorrhea	BRD-K03981224-001-19-3, BRD-K03981224-001-22-9, BRD-K03981224-001-21-9	Launched
prednisolone	glucocorticoid receptor agonist	NR3C1, NR3C2, SERPINA6	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	BRD-A27887842-001-04-0, BRD-A27887842-001-04-0, BRD-A27887842-001-04-0, BRD-A27887842-001-05-7, BRD-A27887842-001-05-7	Launched
paliperidone	dopamine receptor antagonist, serotonin receptor antagonist	DRD2, HTR2A	neurology/psychiatry	schizophrenia	BRD-A99888680-001-06-9, BRD-A99888680-001-04-6, BRD-A99888680-001-05-3, BRD-A99888680-001-03-8	Launched
vinblastine	microtubule inhibitor, tubulin polymerization inhibitor	JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma	BRD-K06519765-065-01-6, BRD-K06519765-065-01-6, BRD-K06519765-065-02-4, BRD-K06519765-001-03-7, BRD-K06519765-065-04-0, BRD-K06519765-065-04-0, BRD-K06519765-001-02-9, BRD-K06519765-001-01-1, BRD-K06519765-001-01-1, BRD-K06519765-001-01-1, BRD-K06519765-065-03-2	Launched
cisplatin	DNA alkylating agent, DNA synthesis inhibitor	XIAP	oncology	testicular carcinoma, ovarian cancer, bladder cancer	BRD-K69172251-001-10-5, BRD-K69172251-001-11-3, BRD-K69172251-001-09-7, BRD-K69172251-001-08-9, BRD-K69172251-001-08-9	Launched
SB-590885	RAF inhibitor	BRAF			BRD-K78809024-001-03-2, BRD-K78809024-001-05-7, BRD-K78809024-001-05-7, BRD-K78809024-001-02-4	Preclinical
ramipril	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	BRD-K89348303-001-14-7, BRD-K89348303-001-16-2, BRD-K89348303-001-18-9, BRD-K89348303-001-18-9, BRD-K89348303-001-17-0	Launched
colistimethate	bacterial permeability inducer		infectious disease	gram-negative bacterial infections	BRD-K01666924-319-01-9	Launched
uridine-5'-triphosphate	purinergic receptor activator	P2RY11, P2RY2, P2RY4, P2RY6, UCK2			BRD-K01825013-385-04-9	Launched
geniposidic-acid	cyclooxygenase inhibitor				BRD-K73771095-001-03-3, BRD-K73771095-001-03-3, BRD-K73771095-001-04-9, BRD-K73771095-001-02-5	Preclinical
cyclosporin-A	calcineurin inhibitor	ABCB11, CAMLG, FPR1, PPIA, PPIF, PPP3CA, PPP3R2, SLC10A1, SLCO1B1, SLCO1B3	rheumatology, dermatology	rheumatoid arthritis, psoriasis	BRD-K13533483-001-19-9, BRD-K13533483-001-19-9, BRD-K13533483-001-20-9, BRD-K13533483-001-20-9, BRD-K13533483-001-20-9, BRD-K13533483-001-20-9, BRD-K13533483-001-18-9, BRD-K13533483-001-16-2, BRD-K13533483-001-16-2, BRD-K13533483-001-16-2, BRD-K13533483-001-16-2, BRD-K13533483-001-16-2, BRD-K13533483-001-16-2, BRD-K13533483-001-17-0	Launched
TAK-715	p38 MAPK inhibitor	MAPK14			BRD-K52751261-001-08-7, BRD-K52751261-001-08-7, BRD-K52751261-001-06-1, BRD-K52751261-001-06-1, BRD-K52751261-001-10-9	Phase 2
acadesine	AMPK activator				BRD-K53448858-001-08-8, BRD-K53448858-001-09-6, BRD-K53448858-001-07-0	Phase 3
sesamin	NFkB pathway inhibitor				BRD-K11631773-001-11-6, BRD-K11631773-001-10-8, BRD-K11631773-001-12-4	Preclinical
sulfisoxazole-acetyl	folic acid antagonist		infectious disease, otolaryngology	meningitis, urinary tract infections, otitis, trachoma	BRD-K84810336-001-01-9	Launched
erythromycin	NFkB pathway inhibitor	MLNR	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	BRD-K63550407-001-16-9, BRD-K63550407-001-12-7, BRD-K63550407-028-04-7, BRD-K63550407-001-13-5, BRD-K63550407-001-14-3	Launched
mizoribine	immunosuppressant, inosine monophosphate dehydrogenase inhibitor	IMPDH1	transplant, rheumatology	organ rejection, nephrotic syndrome	BRD-K88061624-001-20-6, BRD-K88061624-001-21-4, BRD-K88061624-001-22-2, BRD-K88061624-001-23-9	Launched
methscopolamine	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3	gastroenterology	peptic ulcer disease (PUD)	BRD-K48619321-004-19-9, BRD-K48619321-004-19-9, BRD-K48619321-004-16-8, BRD-K48619321-004-17-6, BRD-K48619321-004-18-4	Launched
sofosbuvir	HCV inhibitor		infectious disease	hepatitis C, hepatitis C	BRD-K00026984-001-02-9, BRD-K00026984-001-02-9, BRD-K00026984-001-02-9	Launched
ethynodiol-diacetate		ESR1, PGR	endocrinology	contraceptive	BRD-K46331928-001-09-9, BRD-K46331928-001-05-8, BRD-K46331928-001-05-8, BRD-K46331928-001-06-6, BRD-K46331928-001-08-2	Launched
carbadox	other antibiotic		infectious disease, gastroenterology	dysentry, enteritis	BRD-K56735750-001-06-8, BRD-K56735750-001-10-9, BRD-K56735750-001-10-9, BRD-K56735750-001-09-2, BRD-K56735750-001-07-6, BRD-K56735750-001-07-6	Launched
olopatadine	histamine receptor antagonist	HRH1, S100A1, S100A12, S100A13, S100A2, S100B	ophthalmology	conjunctivitis	BRD-K67637637-003-11-8, BRD-K67637637-003-12-6, BRD-K67637637-003-12-6	Launched
doxercalciferol	vitamin D receptor agonist	VDR	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism	BRD-K82928892-001-02-5, BRD-K82928892-001-02-5, BRD-K82928892-001-04-1, BRD-K82928892-001-03-3	Launched
curcumol	JAK inhibitor	JAK1, JAK2, JAK3			BRD-K41933240-001-04-9, BRD-K41933240-001-04-9, BRD-K41933240-001-02-4, BRD-K41933240-001-02-4, BRD-K41933240-001-03-2	Phase 1
GW-5074	leucine rich repeat kinase inhibitor, RAF inhibitor	NTRK1, RAF1			BRD-K39520573-001-05-9, BRD-K39520573-001-03-8, BRD-K39520573-001-03-8, BRD-K39520573-001-04-6, BRD-K39520573-001-04-6, BRD-K39520573-001-02-0	Phase 1/Phase 2
amoxicillin	penicillin binding protein inhibitor	CYP2C19, SLC15A1, SLC15A2, SLC22A6	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections	BRD-K55044200-001-16-1, BRD-K55044200-236-03-1, BRD-K55044200-236-02-3, BRD-K55044200-236-04-9, BRD-K55044200-001-15-3, BRD-K55044200-001-14-6	Launched
DMSO	control vehicle				BRD-M56212252-001-01-0	Preclinical
deforolimus	mTOR inhibitor	MTOR			BRD-K62304154-001-03-4, BRD-K62304154-001-04-2, BRD-K62304154-001-04-2	Phase 3
ergosterol	vitamin D precursor				BRD-K03039262-001-03-7, BRD-K03039262-001-03-7, BRD-K03039262-001-04-5, BRD-K03039262-001-04-5, BRD-K03039262-001-05-2	Preclinical
levonorgestrel	estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist	PGR	endocrinology	contraceptive	BRD-K35189033-001-28-7, BRD-K35189033-001-28-7, BRD-K35189033-001-30-3, BRD-K35189033-001-30-3, BRD-K35189033-001-30-3, BRD-K35189033-001-26-1, BRD-K35189033-001-26-1, BRD-K35189033-001-29-5, BRD-K35189033-001-29-5, BRD-K35189033-001-31-1	Launched
sophocarpine					BRD-K66845263-001-03-0, BRD-K66845263-001-04-8, BRD-K66845263-001-02-2	Phase 3
ambroxol	sodium channel blocker	CYP3A4	pulmonary	bronchitis	BRD-K56558538-003-14-3, BRD-K56558538-003-13-5, BRD-K56558538-003-12-7, BRD-K56558538-003-15-9, BRD-K56558538-003-15-9, BRD-K56558538-003-11-9	Launched
amygdalin	caspase activator	CASP3			BRD-K03504028-001-09-9, BRD-K03504028-001-07-6, BRD-K03504028-001-07-6, BRD-K03504028-001-07-6, BRD-K03504028-001-07-6, BRD-K03504028-001-08-4	Phase 2
carboplatin	DNA alkylating agent, DNA inhibitor		oncology	ovarian cancer	BRD-K90947825-001-03-5, BRD-K90947825-001-05-0, BRD-K90947825-001-02-7, BRD-K90947825-001-02-7, BRD-K90947825-001-02-7, BRD-K90947825-001-07-9, BRD-K90947825-001-04-3	Launched
griseofulvin	tubulin polymerization inhibitor	KRT12	infectious disease	ringworm, tinea pedis	BRD-K08273968-001-16-6, BRD-K08273968-001-16-6, BRD-K08273968-001-19-0	Launched
oxyclozanide			infectious disease	fascioliasis	BRD-K07283971-001-01-3, BRD-K07283971-001-01-3, BRD-K07283971-001-01-3, BRD-K07283971-001-01-3, BRD-K07283971-001-01-3	Launched
everolimus	mTOR inhibitor	MTOR	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma	BRD-K13514097-001-09-9, BRD-K13514097-001-09-9, BRD-K13514097-001-04-6, BRD-K13514097-001-04-6, BRD-K13514097-001-04-6, BRD-K13514097-001-04-6, BRD-K13514097-001-04-6, BRD-K13514097-001-04-6, BRD-K13514097-001-05-3, BRD-K13514097-001-05-3	Launched
oxonic-acid	uricase inhibitor				BRD-K31468676-237-02-6, BRD-K31468676-237-01-8	Preclinical
erythromycin-ethylsuccinate	cytochrome P450 inhibitor, protein synthesis inhibitor	ABCB1, ALB, CYP3A4, CYP51A1, KCNH2, MLNR, SLC47A1	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma	BRD-K51677086-001-15-9, BRD-K51677086-001-12-0, BRD-K51677086-001-13-8, BRD-K51677086-001-14-6	Launched
GDC-0879	RAF inhibitor	BRAF			BRD-K67578145-001-10-5, BRD-K67578145-001-09-7, BRD-K67578145-001-09-7, BRD-K67578145-001-12-1	Preclinical
minoxidil	KATP activator, Kir6 channel (KATP) activator, vasodilator	ABCC9, KCNJ1, KCNJ10, KCNJ11, KCNJ8, PTGS1	endocrinology	androgenetic alopecia	BRD-K06902185-001-21-9, BRD-K06902185-003-01-7, BRD-K06902185-001-16-9, BRD-K06902185-001-22-7, BRD-K06902185-001-17-7	Launched
betulinic-acid	apoptosis stimulant, NFkB pathway inhibitor	GPBAR1			BRD-K45401373-001-21-7, BRD-K45401373-001-20-9, BRD-K45401373-001-22-5	Phase 1/Phase 2
7-aminocephalosporanic-acid	beta lactamase inhibitor				BRD-K65377893-001-08-2, BRD-K65377893-001-07-4	Preclinical
eucalyptol	acetylcholinesterase inhibitor	ACHE	dental	gingivitis	BRD-K29996876-001-10-1, BRD-K29996876-001-09-3	Launched
dirithromycin	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	BRD-K52756523-001-27-0, BRD-K52756523-001-27-0, BRD-K52756523-001-27-0, BRD-K52756523-001-24-7, BRD-K52756523-001-28-8, BRD-K52756523-001-25-4, BRD-K52756523-001-25-4, BRD-K52756523-001-31-9, BRD-K52756523-001-26-2, BRD-K52756523-001-29-6	Launched
diosgenin	steroid				BRD-K28690501-001-03-9, BRD-K28690501-001-02-1	Preclinical
cinoctramide					BRD-K08699567-001-01-9, BRD-K08699567-001-02-9	Preclinical
abiraterone-acetate	androgen biosynthesis inhibitor	CYP17A1	oncology	prostate cancer	BRD-K24048528-001-03-9, BRD-K24048528-001-01-7, BRD-K24048528-001-01-7, BRD-K24048528-001-02-5, BRD-K24048528-001-02-5	Launched
sitosterol					BRD-K79402892-001-08-9, BRD-K79402892-001-06-7, BRD-K79402892-001-07-5	Preclinical
clarithromycin	bacterial 50S ribosomal subunit inhibitor	CYP3A4	otolaryngology, pulmonary, infectious disease	pharyngitis, tonsillitis, sinusitis, bronchitis, pneumonia, skin infections, otitis	BRD-K49668410-001-16-2, BRD-K49668410-001-18-8, BRD-K49668410-001-18-8, BRD-K49668410-001-18-8, BRD-K49668410-001-20-9	Launched
JQ1-(+)	bromodomain inhibitor	BRD4, BRDT			BRD-K54606188-001-16-4, BRD-K54606188-001-13-1, BRD-K54606188-001-13-1, BRD-K54606188-001-13-1, BRD-K54606188-001-13-1, BRD-K54606188-001-13-1, BRD-K54606188-001-13-1	Preclinical
retapamulin	protein synthesis inhibitor		infectious disease	impetigo	BRD-K33082088-001-03-3	Launched
artesunate	DNA synthesis inhibitor		infectious disease	malaria	BRD-K54634444-001-05-9, BRD-K54634444-001-05-9, BRD-K54634444-001-05-9, BRD-K54634444-001-04-2, BRD-K54634444-001-04-2	Launched
levocetirizine	histamine receptor antagonist	HRH1	allergy	allergic rhinitis, urticaria	BRD-K27184429-300-01-3, BRD-K27184429-300-01-3, BRD-K27184429-300-01-3, BRD-K27184429-300-02-1	Launched
bergenin	interleukin inhibitor	IL1B, TNF			BRD-K04176066-001-09-1, BRD-K04176066-001-10-9, BRD-K04176066-001-08-3	Preclinical
ruxolitinib	JAK inhibitor	JAK1, JAK2, JAK3, TYK2	hematologic malignancy, hematology	myelofibrosis, polycythemia vera	BRD-K53972329-001-07-0, BRD-K53972329-001-07-0, BRD-K53972329-001-07-0, BRD-K53972329-001-07-0, BRD-K53972329-001-01-3, BRD-K53972329-001-01-3, BRD-K53972329-001-01-3	Launched
CCMI	acetylcholine receptor allosteric modulator	CHRNA7			BRD-K16338837-001-01-8, BRD-K16338837-001-02-6, BRD-K16338837-001-02-6, BRD-K16338837-001-03-9, BRD-K16338837-001-03-9	Preclinical
VER-49009	HSP inhibitor	HSP90AA1			BRD-K38548312-001-01-0, BRD-K38548312-001-01-0, BRD-K38548312-001-01-0, BRD-K38548312-001-01-0, BRD-K38548312-001-02-9	Preclinical
LDN-57444	ubiquitin C-terminal hydrolase inhibitor				BRD-K94485812-001-01-1, BRD-K94485812-001-03-7, BRD-K94485812-001-02-9, BRD-K94485812-001-02-9	Preclinical
doripenem	bacterial cell wall synthesis inhibitor	DPEP1	infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis	BRD-K45319714-002-02-7, BRD-K45319714-002-04-3, BRD-K45319714-002-03-5, BRD-K45319714-002-05-0, BRD-K45319714-002-01-9	Launched
bardoxolone-methyl	nuclear factor erythroid derived, like (NRF2) activator	PPARG, STAT3			BRD-K69694239-001-02-2, BRD-K69694239-001-02-2, BRD-K69694239-001-02-2, BRD-K69694239-001-03-0	Phase 3
diosmin	aryl hydrocarbon receptor agonist, capillary stabilizing agent	AHR	cardiology, hematology, dermatology	chronic venous insufficiency (CVI), edema, deep vein thrombosis (DVT), statis dermatitis, heavy leg syndrome	BRD-K94436377-001-10-2, BRD-K94436377-001-13-9, BRD-K94436377-001-13-9, BRD-K94436377-001-11-0, BRD-K94436377-001-12-8	Launched
chloramphenicol	bacterial 50S ribosomal subunit inhibitor	CD55	infectious disease, endocrinology	meningitis, fever, cholera	BRD-K08111712-001-16-7, BRD-K08111712-001-16-7, BRD-K08111712-001-16-7, BRD-K08111712-001-14-2	Launched
sucralose					BRD-K58968598-001-04-9, BRD-K58968598-001-02-8, BRD-K58968598-001-03-6, BRD-K58968598-001-03-6, BRD-K58968598-001-03-6	Launched
alvespimycin	HSP inhibitor	HSP90AA1			BRD-K83988098-003-03-4, BRD-K83988098-003-03-4, BRD-K83988098-001-02-0, BRD-K83988098-001-02-0, BRD-K83988098-001-02-0, BRD-K83988098-001-02-0, BRD-K83988098-003-07-9, BRD-K83988098-003-07-9	Phase 2
cloxacillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	BRD-K01244426-236-12-1, BRD-K01244426-236-12-1, BRD-K01244426-323-14-9, BRD-K01244426-323-07-7, BRD-K01244426-323-08-5	Launched
cephapirin	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	BRD-K49880111-236-09-2, BRD-K49880111-236-10-0, BRD-K49880111-236-11-8	Launched
pancuronium	acetylcholine receptor antagonist	CHRM2, CHRM3, CHRNA1, CHRNA2	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant	BRD-K50817623-303-08-9, BRD-K50817623-303-05-7, BRD-K50817623-303-07-9, BRD-K50817623-303-06-5	Launched
batimastat	matrix metalloprotease inhibitor	ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8			BRD-K82818427-001-04-8, BRD-K82818427-001-04-8, BRD-K82818427-001-04-8, BRD-K82818427-001-04-8, BRD-K82818427-001-04-8, BRD-K82818427-001-04-8, BRD-K82818427-001-04-8, BRD-K82818427-001-05-9, BRD-K82818427-001-02-2, BRD-K82818427-001-02-2, BRD-K82818427-001-02-2, BRD-K82818427-001-02-2	Phase 3
mupirocin	isoleucyl-tRNA synthetase inhibitor		infectious disease	impetigo	BRD-K15262564-001-14-3, BRD-K15262564-001-16-8, BRD-K15262564-001-15-0	Launched
vinpocetine	phosphodiesterase inhibitor, sodium channel blocker	PDE1A, PDE1C	neurology/psychiatry	stroke, senile dementia	BRD-K53318339-001-24-9, BRD-K53318339-001-27-9, BRD-K53318339-001-27-9, BRD-K53318339-001-23-1, BRD-K53318339-001-26-4	Launched
CD-1530	retinoid receptor agonist	RARG			BRD-K09619322-001-03-8, BRD-K09619322-001-03-8, BRD-K09619322-001-03-8, BRD-K09619322-001-03-8, BRD-K09619322-001-03-8, BRD-K09619322-001-04-9	Preclinical
artemisinin	DNA synthesis inhibitor	CYP2B6	infectious disease	malaria	BRD-K13112821-001-18-2, BRD-K13112821-001-16-6, BRD-K13112821-001-14-1, BRD-K13112821-001-19-9, BRD-K13112821-001-17-4, BRD-K13112821-001-17-4	Launched
calcitriol	vitamin D receptor agonist	VDR	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis	BRD-K27316855-001-15-8, BRD-K27316855-001-15-8, BRD-K27316855-001-15-8, BRD-K27316855-001-15-8, BRD-K27316855-001-13-3, BRD-K27316855-001-13-3, BRD-K27316855-001-19-0, BRD-K27316855-001-19-0, BRD-K27316855-001-19-0, BRD-K27316855-001-19-0	Launched
dutasteride	5 alpha reductase inhibitor	SRD5A1, SRD5A2, SRD5A3	urology	benign prostatic hyperplasia (BPH)	BRD-K30373883-001-03-9, BRD-K30373883-001-02-8, BRD-K30373883-001-02-8	Launched
GSK690693	AKT inhibitor	AKT1, AKT2, AKT3, PAK4, PAK6, PAK7, PRKCQ, PRKG1, PRKX			BRD-K25325018-001-05-6, BRD-K25325018-001-05-6, BRD-K25325018-001-05-6, BRD-K25325018-001-05-6, BRD-K25325018-001-02-3, BRD-K25325018-001-06-4	Phase 1
megestrol-acetate	progesterone receptor agonist	NR3C1, PGR	neurology/psychiatry, endocrinology	anorexia, cachexia	BRD-K19507340-001-28-9, BRD-K19507340-001-26-2, BRD-K19507340-001-22-1, BRD-K19507340-001-27-9, BRD-K19507340-001-25-4, BRD-K19507340-001-25-4	Launched
NMS-E973	HSP inhibitor				BRD-K58770988-001-01-8, BRD-K58770988-001-01-8, BRD-K58770988-001-01-8, BRD-K58770988-001-01-8, BRD-K58770988-001-02-6	Preclinical
pravastatin	HMGCR inhibitor	HMGCR, SLCO1B1	endocrinology, cardiology	hypercholesterolemia, myocardial infarction, hyperlipidemia	BRD-K60511616-236-07-1, BRD-K60511616-236-06-3, BRD-K60511616-236-09-9, BRD-K60511616-236-09-9, BRD-K60511616-236-08-9, BRD-K60511616-236-08-9	Launched
ezetimibe	cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist	ANPEP, NPC1L1, SOAT1	endocrinology, metabolism	hyperlipidemia, hypercholesterolemia, sitosterolemia	BRD-K42260897-001-08-4, BRD-K42260897-001-07-6, BRD-K42260897-001-07-6, BRD-K42260897-001-07-6, BRD-K42260897-001-07-6, BRD-K42260897-001-10-9, BRD-K42260897-001-10-9, BRD-K42260897-001-09-2	Launched
cinnarazine	calcium channel blocker		neurology/psychiatry, gastroenterology, ophthalmology	Meniere's disease, nausea, vomiting, Cogan's syndrome	BRD-K07220430-001-20-9, BRD-K07220430-001-19-2, BRD-K07220430-001-18-4, BRD-K07220430-001-18-4	Launched
uridine	dopamine receptor agonist	LSM6, TYMP			BRD-K13050303-001-18-1, BRD-K13050303-001-18-1, BRD-K13050303-001-17-3	Phase 2
cytidine		UCK2			BRD-K71847383-001-12-5, BRD-K71847383-001-12-5, BRD-K71847383-001-13-3, BRD-K71847383-001-13-3	Launched
neohesperidin-dihydrochalcone					BRD-K61032563-001-05-9, BRD-K61032563-001-02-9, BRD-K61032563-001-02-9	Preclinical
tanespimycin	HSP inhibitor	HSP90AA1			BRD-K81473043-001-22-9, BRD-K81473043-001-14-6, BRD-K81473043-001-14-6, BRD-K81473043-001-14-6, BRD-K81473043-001-23-9, BRD-K81473043-001-23-9, BRD-K81473043-001-19-5, BRD-K81473043-001-19-5, BRD-K81473043-001-19-5	Phase 3
beta-carotene					BRD-K74225533-001-08-8, BRD-K74225533-001-10-4, BRD-K74225533-001-12-0, BRD-K74225533-001-09-6	Launched
cabergoline	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7	endocrinology	hyperprolactinemia	BRD-K86882815-001-05-7, BRD-K86882815-001-05-7, BRD-K86882815-001-03-2, BRD-K86882815-001-03-2, BRD-K86882815-001-03-2, BRD-K86882815-001-06-9	Launched
nedaplatin	DNA inhibitor		oncology	non-small cell lung cancer (NSCLC), small cell lung cancer, esophageal cancer	BRD-K73469236-001-01-8, BRD-K73469236-001-01-8, BRD-K73469236-001-02-9	Launched
calcifediol	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	BRD-K77175907-001-08-0, BRD-K77175907-001-08-0, BRD-K77175907-002-01-3, BRD-K77175907-002-01-3, BRD-K77175907-001-06-4, BRD-K77175907-001-10-6	Launched
geniposide	GLP receptor agonist	GLP1R			BRD-K57275767-001-04-9, BRD-K57275767-001-02-4, BRD-K57275767-001-03-2, BRD-K57275767-001-03-2	Preclinical
cyclovirobuxin-D	calcium channel modulator				BRD-K27799744-001-02-8, BRD-K27799744-001-03-6, BRD-K27799744-001-04-4	Preclinical
sclareolide	other antifungal				BRD-K72925150-001-10-3, BRD-K72925150-001-11-1, BRD-K72925150-001-14-5	Launched
NNC-63-0532	opioid receptor agonist	OPRL1			BRD-K72904818-001-02-9, BRD-K72904818-001-03-9, BRD-K72904818-001-03-9, BRD-K72904818-001-01-1, BRD-K72904818-001-01-1, BRD-K72904818-001-01-1	Preclinical
rose-bengal	contrast agent, immunostimulant		radiology	diagnostic agent	BRD-K33623053-304-01-7, BRD-K33623053-304-02-5, BRD-K33623053-304-02-5	Launched
tofacitinib	JAK inhibitor	JAK1, JAK2, JAK3	rheumatology	rheumatoid arthritis	BRD-K31283835-048-03-6, BRD-K31283835-001-08-4, BRD-K31283835-001-08-4, BRD-K31283835-001-08-4, BRD-K31283835-001-08-4, BRD-K31283835-048-04-4, BRD-K31283835-048-04-4, BRD-K31283835-048-04-4	Launched
aztreonam	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections	BRD-K62607865-001-11-9, BRD-K62607865-236-02-4, BRD-K62607865-001-09-7, BRD-K62607865-001-09-7, BRD-K62607865-236-01-6	Launched
etodolac	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis, rheumatoid arthritis	BRD-A74667430-001-25-1, BRD-A74667430-001-23-6, BRD-A74667430-001-26-9	Launched
dolasetron	serotonin receptor antagonist	HTR3A	gastroenterology	nausea, vomiting	BRD-K28029915-066-03-3, BRD-K28029915-066-04-9, BRD-K28029915-001-02-2	Launched
cefoselis	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-K72339976-065-03-9, BRD-K72339976-065-01-3, BRD-K72339976-065-04-7, BRD-K72339976-065-02-1	Launched
ceftriaxone	bacterial cell wall synthesis inhibitor		infectious disease, otolaryngology	gonorrhea, pneumonia, otitis, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis, surgical prophylaxis	BRD-K96734425-324-01-5, BRD-K96734425-304-01-7	Launched
spectinomycin	bacterial 30S ribosomal subunit inhibitor		pulmonary	airsacculitis, chronic respiratory disease	BRD-K11905747-300-11-3, BRD-K11905747-300-10-5, BRD-K11905747-300-09-7, BRD-K11905747-300-08-9, BRD-K11905747-300-12-1	Launched
pergolide	dopamine receptor agonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C			BRD-K60770992-066-27-9, BRD-K60770992-066-26-8, BRD-K60770992-066-25-0, BRD-K60770992-066-25-0, BRD-K60770992-066-25-0	Withdrawn
pyrvinium-pamoate	androgen receptor antagonist	AR	infectious disease	pinworm	BRD-K39479472-096-06-9, BRD-K39479472-096-04-7	Launched
fluticasone-propionate	glucocorticoid receptor agonist	NR3C1, NR3C2, PGR, PLA2G4A	dermatology	corticosteroid-responsive dermatoses	BRD-K62310379-001-12-1, BRD-K62310379-001-14-9, BRD-K62310379-001-13-9, BRD-K62310379-001-13-9, BRD-K62310379-001-13-9, BRD-K62310379-001-10-5	Launched
L-165041	PPAR receptor agonist	PPARD			BRD-K98372770-001-09-0, BRD-K98372770-001-10-9, BRD-K98372770-001-08-2, BRD-K98372770-001-08-2	Preclinical
2-methoxyestradiol	hypoxia inducible factor inhibitor	COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB			BRD-K44408410-001-21-8, BRD-K44408410-001-22-6, BRD-K44408410-001-22-6, BRD-K44408410-001-22-6, BRD-K44408410-001-22-6, BRD-K44408410-001-17-6, BRD-K44408410-001-17-6, BRD-K44408410-001-17-6	Phase 2
hesperidin	flavanone glycoside	AURKB, CACNA1B			BRD-K38903228-001-11-9, BRD-K38903228-001-13-5, BRD-K38903228-001-13-5, BRD-K38903228-001-13-5, BRD-K38903228-001-12-7, BRD-K38903228-001-14-9	Launched
loteprednol	glucocorticoid receptor agonist, phospholipase inhibitor	NR3C1	ophthalmology	conjunctivitis	BRD-K39983086-001-06-1, BRD-K39983086-001-06-1, BRD-K39983086-001-07-9, BRD-K39983086-001-08-9, BRD-K39983086-001-08-9	Launched
chenodeoxycholic-acid	11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist	HSD11B1, NR1H4	cardiology, gastroenterology	cerebral cholesterosis, gallstones	BRD-K18135438-001-14-2, BRD-K18135438-001-14-2, BRD-K18135438-001-16-7, BRD-K18135438-001-16-7, BRD-K18135438-001-16-7	Launched
chlorazanil					BRD-K21452876-003-01-8	Preclinical
costunolide	telomerase inhibitor				BRD-K26833429-001-04-4, BRD-K26833429-001-03-6, BRD-K26833429-001-07-9, BRD-K26833429-001-02-8, BRD-K26833429-001-02-8, BRD-K26833429-001-02-8, BRD-K26833429-001-02-8	Preclinical
huperzine-A	acetylcholinesterase inhibitor	ACHE			BRD-K62240499-001-05-9, BRD-K62240499-001-05-9, BRD-K62240499-001-05-9, BRD-K62240499-001-04-2, BRD-K62240499-001-04-2, BRD-K62240499-001-06-7	Phase 2
chlorogenic-acid	antioxidant	SLC37A4	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis	BRD-K47114202-001-16-9, BRD-K47114202-001-14-6, BRD-K47114202-001-14-6, BRD-K47114202-001-15-3	Launched
dapagliflozin	sodium/glucose cotransporter inhibitor	SLC5A1, SLC5A2	endocrinology	diabetes mellitus	BRD-K58160573-001-04-7, BRD-K58160573-001-05-4, BRD-K58160573-001-05-4	Launched
nizatidine	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)	BRD-K73589491-001-13-9, BRD-K73589491-001-13-9, BRD-K73589491-001-11-2, BRD-K73589491-001-11-2, BRD-K73589491-001-11-2, BRD-K73589491-001-12-0	Launched
BMS-754807	IGF-1 inhibitor	AKT1, IGF1R			BRD-K13049116-001-04-0, BRD-K13049116-001-04-0, BRD-K13049116-001-04-0, BRD-K13049116-001-04-0, BRD-K13049116-001-03-2, BRD-K13049116-001-03-2, BRD-K13049116-001-03-2, BRD-K13049116-001-05-7, BRD-K13049116-001-05-7, BRD-K13049116-001-05-7, BRD-K13049116-001-05-7	Phase 2
silibinin	cytochrome P450 inhibitor	ALOX5	gastroenterology	hepatic cirrhosis	BRD-K80353138-001-12-1, BRD-K80353138-001-17-9, BRD-K80353138-001-13-9, BRD-K80353138-001-16-2	Launched
bekanamycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	BRD-K73425385-001-05-9, BRD-K73425385-001-01-9, BRD-K73425385-065-04-8, BRD-K73425385-065-04-8	Launched
fosfomycin	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections	BRD-K81101512-238-06-9, BRD-K81101512-234-01-9, BRD-K81101512-304-02-8	Launched
hyodeoxycholic-acid	atherosclerosis formation inhibitor				BRD-K44009692-001-02-3, BRD-K44009692-001-03-1, BRD-K44009692-001-03-1	Phase 1
satraplatin	DNA alkylating agent				BRD-K42497885-001-01-1, BRD-K42497885-001-02-9	Phase 3
3,3'-dichlorobenzaldazine	glutamate receptor modulator	GRM5			BRD-K82903013-001-02-9, BRD-K82903013-001-01-4	Preclinical
BIX-02188	MEK inhibitor	MAP2K5			BRD-K20290250-001-02-1, BRD-K20290250-001-02-1, BRD-K20290250-001-03-9, BRD-K20290250-001-03-9, BRD-K20290250-001-01-3, BRD-K20290250-001-01-3	Preclinical
bortezomib	NFkB pathway inhibitor, proteasome inhibitor	PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)	BRD-K88510285-001-18-6, BRD-K88510285-001-18-6, BRD-K88510285-001-18-6, BRD-K88510285-001-18-6, BRD-K88510285-001-18-6, BRD-K88510285-001-18-6, BRD-K88510285-001-18-6, BRD-K88510285-001-17-8, BRD-K88510285-001-17-8, BRD-K88510285-001-17-8, BRD-K88510285-001-17-8, BRD-K88510285-001-25-1, BRD-K88510285-001-22-8, BRD-K88510285-001-11-1, BRD-K88510285-001-11-1, BRD-K88510285-001-11-1, BRD-K88510285-001-11-1	Launched
fludarabine	ribonucleotide reductase inhibitor	ADA, DCK, POLA1, RRM1, RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	BRD-K66788707-001-15-0, BRD-K66788707-001-14-3, BRD-K66788707-001-14-3, BRD-K66788707-001-14-3, BRD-K66788707-001-17-6, BRD-K66788707-001-17-6	Launched
clindamycin-phosphate	protein synthesis inhibitor		obstetrics/gynecology	bacterial vaginosis	BRD-K27771035-001-02-5, BRD-K27771035-001-04-1	Launched
mezlocillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections, gram-positive bacterial infections	BRD-K45114938-236-02-6, BRD-K45114938-236-03-4, BRD-K45114938-236-01-8	Launched
cycloserine-(D)	bacterial cell wall synthesis inhibitor	GRIN1	infectious disease	tuberculosis, tuberculosis	BRD-K87226815-001-21-3, BRD-K87226815-001-17-1, BRD-K87226815-001-20-5, BRD-K87226815-001-18-9, BRD-K87226815-001-19-7	Launched
cryptotanshinone	acetylcholinesterase inhibitor, STAT inhibitor	STAT3			BRD-K33336844-001-11-1, BRD-K33336844-001-10-3, BRD-K33336844-001-09-5, BRD-K33336844-001-12-9	Preclinical
azacitidine	DNA methyltransferase inhibitor	DNMT1, DNMT3A	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)	BRD-K03406345-001-21-1, BRD-K03406345-001-21-1, BRD-K03406345-001-21-1, BRD-K03406345-001-21-1, BRD-K03406345-001-21-1, BRD-K03406345-001-21-1, BRD-K03406345-001-24-5, BRD-K03406345-001-27-8, BRD-K03406345-001-27-8, BRD-K03406345-001-27-8, BRD-K03406345-001-27-8	Launched
PHA-665752	c-Met inhibitor	MET			BRD-K95435023-001-07-7, BRD-K95435023-001-08-5, BRD-K95435023-001-10-1, BRD-K95435023-001-10-1, BRD-K95435023-001-11-9, BRD-K95435023-001-09-3	Preclinical
ulipristal	progesterone receptor antagonist	PGR	endocrinology	contraceptive	BRD-K64381438-001-02-0, BRD-K64381438-001-03-8, BRD-K64381438-001-03-8, BRD-K64381438-001-03-8, BRD-K64381438-001-04-9	Launched
rifapentine	RNA polymerase inhibitor	CYP2C8, CYP2C9, CYP3A4	infectious disease	tuberculosis	BRD-K28346421-001-08-4, BRD-K28346421-001-07-6, BRD-K28346421-001-07-6, BRD-K28346421-001-06-8, BRD-K28346421-001-06-8	Launched
3-deazaneplanocin-A	histone lysine methyltransferase inhibitor	EZH2			BRD-K77791657-001-01-1, BRD-K77791657-003-02-9, BRD-K77791657-003-01-7, BRD-K77791657-003-01-7	Preclinical
4E1RCat	protein synthesis inhibitor	EIF4E, EIF4G1			BRD-K67173685-001-07-7, BRD-K67173685-001-08-5, BRD-K67173685-001-09-9, BRD-K67173685-001-06-9, BRD-K67173685-001-06-9	Preclinical
astragaloside-a	anti-inflammatory agent				BRD-K08188887-001-03-9, BRD-K08188887-001-02-4	Preclinical
guanaben-acetate	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	cardiology	hypertension	BRD-K62736196-015-10-2, BRD-K62736196-015-09-4, BRD-K62736196-015-13-6, BRD-K62736196-015-13-6, BRD-K62736196-015-11-0	Launched
epirubicin	topoisomerase inhibitor	CHD1, TOP2A	oncology	breast cancer	BRD-K04548931-003-13-2, BRD-K04548931-003-16-5, BRD-K04548931-003-16-5, BRD-K04548931-003-16-5, BRD-K04548931-003-16-5, BRD-K04548931-003-08-2, BRD-K04548931-003-08-2, BRD-K04548931-003-08-2, BRD-K04548931-003-08-2	Launched
isosorbide	nitric oxide stimulant		cardiology	angina pectoris, coronary artery disease (CAD)	BRD-K47178855-001-03-4, BRD-K47178855-001-02-6, BRD-K47178855-001-04-2, BRD-K47178855-001-04-2, BRD-K47178855-001-01-8, BRD-K47178855-001-01-8	Launched
roxithromycin	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	respiratory tract infections, urinary tract infections, skin infections	BRD-K38684403-001-07-9, BRD-K38684403-001-04-7, BRD-K38684403-001-05-4	Launched
naloxone-benzoylhydrazone	opioid receptor antagonist	OPRK1, OPRM1			BRD-K70898774-001-05-0, BRD-K70898774-001-04-3, BRD-K70898774-001-03-5, BRD-K70898774-001-03-5	Preclinical
zebularine	DNA methyltransferase inhibitor	CDA, DNMT1			BRD-K87714311-001-02-7, BRD-K87714311-001-05-9, BRD-K87714311-001-05-9, BRD-K87714311-001-04-3, BRD-K87714311-001-03-5	Preclinical
lubiprostone	chloride channel activator	CLCN2	gastroenterology	constipation, irritable bowel syndrome	BRD-K33814251-001-03-9, BRD-K33814251-001-01-4, BRD-K33814251-001-02-2	Launched
rasagiline	monoamine oxidase inhibitor	BCL2, MAOB	neurology/psychiatry	Parkinson's Disease	BRD-K58114536-066-03-5, BRD-K58114536-066-04-3, BRD-K58114536-001-01-6, BRD-K58114536-001-01-6, BRD-K58114536-066-02-7, BRD-K58114536-066-02-7	Launched
chlorprothixene	dopamine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, HRH1, HTR2A, HTR2B, HTR2C	neurology/psychiatry	schizophrenia, bipolar disorder	BRD-K36207157-001-10-9, BRD-K36207157-001-09-6, BRD-K36207157-001-07-0, BRD-K36207157-001-07-0, BRD-K36207157-001-07-0, BRD-K36207157-001-07-0, BRD-K36207157-001-08-8	Launched
SU11274	hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor	MET			BRD-K02965346-001-07-5, BRD-K02965346-001-07-5, BRD-K02965346-001-07-5, BRD-K02965346-001-06-7	Preclinical
sulisobenzone			dermatology	sunscreen lotion	BRD-K38602774-001-03-2, BRD-K38602774-001-03-2, BRD-K38602774-002-01-4	Launched
voglibose	glucosidase inhibitor	MGAM	endocrinology	diabetes mellitus, hyperglycemia	BRD-K66850609-001-06-6, BRD-K66850609-001-05-8, BRD-K66850609-001-07-4	Launched
tetrandrine	calcium channel blocker	SLC6A3			BRD-K08078237-001-19-8, BRD-K08078237-001-19-8, BRD-K08078237-001-20-6, BRD-K08078237-001-20-6	Preclinical
dicloxacillin	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	BRD-K05673000-323-14-9, BRD-K05673000-236-12-1, BRD-K05673000-323-13-5, BRD-K05673000-323-12-7	Launched
vancomycin	bacterial cell wall synthesis inhibitor		infectious disease	endocarditis	BRD-K91065602-003-08-9, BRD-K91065602-003-08-9, BRD-K91065602-003-07-9, BRD-K91065602-001-01-8, BRD-K91065602-003-05-5, BRD-K91065602-003-04-8	Launched
levodropropizine	antitussive		pulmonary	cough suppressant	BRD-K83551379-001-03-9, BRD-K83551379-001-02-6, BRD-K83551379-001-01-8	Launched
pralidoxime	acetylcholinesterase inhibitor	ACHE, BCHE	critical care	organophosphate poisoning	BRD-K84281997-003-09-2, BRD-K84281997-066-03-2, BRD-K84281997-003-08-4, BRD-K84281997-003-08-4	Launched
10-deacetylbaccatin	antitumor agent				BRD-K96631475-001-03-2, BRD-K96631475-001-02-4, BRD-K96631475-001-02-4, BRD-K96631475-001-04-0	Preclinical
cilastatin	dehydropeptidase inhibitor	DPEP1			BRD-K85518562-236-08-9, BRD-K85518562-236-09-7	Launched
wortmannin	PI3K inhibitor	PI4KA, PI4KB, PIK3CA, PIK3CD, PIK3CG, PIK3R1, PLK1, PRKDC			BRD-K87343924-001-16-9, BRD-K87343924-001-12-3, BRD-K87343924-001-15-6	Preclinical
adenosine	adenosine receptor agonist	ADORA1, ADORA2A, ADORA2B, ADORA3, PI4K2A, PI4K2B, TRPM4	cardiology	Wolff-Parkinson-White Syndrome (WPW)	BRD-K01577834-001-15-1, BRD-K01577834-001-15-1, BRD-K01577834-001-16-9, BRD-K01577834-001-16-9	Launched
idarubicin	topoisomerase inhibitor	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	BRD-K69650333-003-14-0, BRD-K69650333-003-14-0, BRD-K69650333-003-13-2, BRD-K69650333-003-13-2, BRD-K69650333-003-13-2	Launched
EPZ-5676	histone lysine methyltransferase inhibitor	DOT1L			BRD-K26531771-001-01-4, BRD-K26531771-001-01-4, BRD-K26531771-001-01-4, BRD-K26531771-001-01-4, BRD-K26531771-001-01-4, BRD-K26531771-001-03-9, BRD-K26531771-001-02-2, BRD-K26531771-001-02-2, BRD-K26531771-001-02-2, BRD-K26531771-001-02-2	Phase 1
limonin	HIV protease inhibitor				BRD-K05906022-001-05-1, BRD-K05906022-001-05-1, BRD-K05906022-001-07-9	Preclinical
halcinonide	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-K81709173-001-11-9, BRD-K81709173-001-09-5, BRD-K81709173-001-09-5, BRD-K81709173-001-09-5, BRD-K81709173-001-09-5, BRD-K81709173-001-10-3	Launched
dienogest	progesterone receptor agonist	PGR	endocrinology, obstetrics/gynecology	contraceptive, endometriosis	BRD-K50853363-001-03-9, BRD-K50853363-001-03-9, BRD-K50853363-001-02-3	Launched
torcetrapib	cholesteryl ester transfer protein inhibitor	CETP			BRD-K55675242-001-02-2, BRD-K55675242-001-03-0, BRD-K55675242-001-03-0, BRD-K55675242-001-04-9	Phase 3
MK-2048	HIV integrase inhibitor				BRD-K03128512-001-03-6, BRD-K03128512-001-02-8, BRD-K03128512-001-04-4	Preclinical
rifampin	RNA polymerase inhibitor	NR1I2, SLCO1A2, SLCO1B1, SLCO1B3	infectious disease	tuberculosis, meningitis	BRD-K01507359-001-23-7, BRD-K01507359-001-23-7, BRD-K01507359-001-24-9, BRD-K01507359-001-22-9, BRD-K01507359-001-22-9	Launched
piperacillin	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections, skin infections, pelvic inflammatory disease, pneumonia	BRD-K86873305-236-17-0, BRD-K86873305-236-16-2, BRD-K86873305-236-15-4, BRD-K86873305-236-18-8, BRD-K86873305-236-19-6, BRD-K86873305-236-14-7, BRD-K86873305-236-14-7	Launched
acetylcysteine	mucolytic agent	ACY1, CHUK, GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3A, GSS, IKBKB, RELA, SLC7A11	gastroenterology	acetaminophen overdose, hepatic injury	BRD-K59058747-001-20-9, BRD-K59058747-001-19-1, BRD-K59058747-001-18-3	Launched
cyclocytidine	DNA synthesis inhibitor, RNA synthesis inhibitor				BRD-K67536197-003-11-4, BRD-K67536197-003-12-9, BRD-K67536197-003-10-6, BRD-K67536197-003-10-6	Preclinical
gemcitabine	ribonucleotide reductase inhibitor	CMPK1, RRM1, RRM2, TYMS	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer	BRD-K15108141-001-08-2, BRD-K15108141-001-08-2, BRD-K15108141-001-08-2, BRD-K15108141-001-08-2, BRD-K15108141-003-04-7, BRD-K15108141-001-06-6, BRD-K15108141-001-06-6, BRD-K15108141-001-06-6, BRD-K15108141-001-06-6, BRD-K15108141-001-06-6, BRD-K15108141-003-05-4, BRD-K15108141-003-05-4	Launched
orbifloxacin	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	BRD-K63001556-001-11-9, BRD-K63001556-001-11-9, BRD-K63001556-001-08-8, BRD-K63001556-001-10-4, BRD-K63001556-001-10-4, BRD-K63001556-001-09-6	Launched
C646	histone acetyltransferase inhibitor	EP300			BRD-K73383190-001-03-1, BRD-K73383190-001-03-1, BRD-K73383190-001-03-1, BRD-K73383190-001-04-9, BRD-K73383190-001-04-9, BRD-K73383190-001-02-3, BRD-K73383190-001-02-3, BRD-K73383190-001-02-3, BRD-K73383190-001-02-3	Preclinical
fluocinonide	glucocorticoid receptor agonist	NR3C1, SERPINA6, SMO	dermatology	seborrheic dermatitis, eczema	BRD-K57886322-001-18-9, BRD-K57886322-001-16-6, BRD-K57886322-001-16-6, BRD-K57886322-001-16-6, BRD-K57886322-001-16-6, BRD-K57886322-001-16-6, BRD-K57886322-001-17-4	Launched
LY2608204	glucokinase activator	GCK			BRD-K12068470-001-03-3, BRD-K12068470-001-05-9, BRD-K12068470-001-02-5, BRD-K12068470-001-02-5, BRD-K12068470-001-02-5, BRD-K12068470-001-02-5, BRD-K12068470-001-04-1	Phase 2
curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CHRM3, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH			BRD-K07572174-001-43-6, BRD-K07572174-001-39-4, BRD-K07572174-001-39-4, BRD-K07572174-001-39-4, BRD-K07572174-001-39-4, BRD-K07572174-001-38-6	Launched
boronophenylalanine					BRD-K50122911-001-01-2, BRD-K50122911-001-02-0	Phase 2
NH125	eukaryotic translation elongation factor 2 inhibitor				BRD-K31086665-005-04-6, BRD-K31086665-005-04-6, BRD-K31086665-005-04-6, BRD-K31086665-005-04-6, BRD-K31086665-005-01-2	Preclinical
sertraline	selective serotonin reuptake inhibitor (SSRI)	SLC6A3, SLC6A4	neurology/psychiatry, obstetrics/gynecology	depression, obsessive compulsive disorder (OCD), panic disorders, posttraumatic stress disorder, premenstrual syndrome, social anxiety disorder	BRD-K82036761-003-17-9, BRD-K82036761-003-19-5, BRD-K82036761-003-16-1, BRD-K82036761-003-21-9, BRD-K82036761-003-20-3, BRD-K82036761-003-20-3, BRD-K82036761-003-20-3	Launched
genipin	choleretic agent				BRD-K28824103-001-03-6, BRD-K28824103-001-03-6, BRD-K28824103-001-04-4, BRD-K28824103-001-02-8	Preclinical
oxacillin	bacterial cell wall synthesis inhibitor		infectious disease	staphylococcal infections	BRD-K96786677-323-04-9, BRD-K96786677-323-02-0, BRD-K96786677-323-03-8, BRD-K96786677-236-02-4, BRD-K96786677-236-02-4, BRD-K96786677-236-02-4	Launched
cytarabine	ribonucleotide reductase inhibitor	POLA1, POLB, POLD1, POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)	BRD-K33106058-001-20-0, BRD-K33106058-001-20-0	Launched
irinotecan	topoisomerase inhibitor	TOP1, TOP1MT	oncology	colorectal cancer	BRD-K08547377-003-06-5, BRD-K08547377-003-07-3, BRD-K08547377-003-07-3, BRD-K08547377-003-05-7, BRD-K08547377-001-04-4, BRD-K08547377-001-04-4, BRD-K08547377-003-04-0, BRD-K08547377-001-06-9, BRD-K08547377-394-03-5	Launched
cefodizime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, skin infections, gonorrhea	BRD-K22641081-304-01-8, BRD-K22641081-304-01-8, BRD-K22641081-001-01-0	Launched
linsidomine	nitric oxide donor		urology	erectile dysfunction	BRD-K72922393-003-16-0, BRD-K72922393-003-16-0, BRD-K72922393-003-17-8	Launched
floxuridine	DNA synthesis inhibitor	TYMS	oncology	colorectal cancer	BRD-K47832606-001-30-1, BRD-K47832606-001-30-1, BRD-K47832606-001-30-1	Launched
amodiaquine	histamine receptor agonist	HNMT	infectious disease	malaria	BRD-K91290917-300-01-8, BRD-K91290917-300-01-8, BRD-K91290917-336-05-3, BRD-K91290917-336-05-3, BRD-K91290917-336-05-3, BRD-K91290917-336-05-3	Launched
alprostadil	prostanoid receptor agonist	CATSPER1, CATSPER2, CATSPER3, CATSPER4, PTGDR, PTGER1, PTGER2, PTGER4, PTGIR	cardiology	congenital heart defects	BRD-K52459643-001-15-1, BRD-K52459643-001-18-9, BRD-K52459643-001-18-9, BRD-K52459643-001-17-7	Launched
sulbentine	other antifungal				BRD-K72384124-001-10-9, BRD-K72384124-001-08-0	Preclinical
lovastatin	HMGCR inhibitor	HDAC2, HMGCR, ITGAL, NR1I2	cardiology, endocrinology	coronary heart disease, myocardial infarction, hypercholesterolemia	BRD-K09416995-001-43-1, BRD-K09416995-001-43-1, BRD-K09416995-001-43-1, BRD-K09416995-001-39-9, BRD-K09416995-001-39-9, BRD-K09416995-001-39-9, BRD-K09416995-001-44-9, BRD-K09416995-001-40-7, BRD-K09416995-001-38-1	Launched
tirapazamine	DNA inhibitor				BRD-K92968657-001-02-4, BRD-K92968657-001-02-4, BRD-K92968657-001-02-4, BRD-K92968657-001-02-4, BRD-K92968657-001-01-6	Phase 3
ceftiofur	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia, respiratory tract infections	BRD-K82960980-003-01-9, BRD-K82960980-236-05-9, BRD-K82960980-003-03-5, BRD-K82960980-003-02-7	Launched
zanamivir	neuraminidase inhibitor	NEU2	infectious disease	influenza A virus infection	BRD-K23067689-001-04-9, BRD-K23067689-001-03-9, BRD-K23067689-001-02-1	Launched
gynostemma-extract	calcium channel modulator				BRD-K58775955-001-04-9, BRD-K58775955-001-02-4, BRD-K58775955-001-03-2	Phase 2
eseroline-(-)	acetylcholinesterase inhibitor	OPRD1, OPRM1			BRD-K13629382-051-06-6	Preclinical
fimasartan	angiotensin receptor antagonist	AGTR1	cardiology	hypertension, congestive heart failure	BRD-K21586122-001-02-7, BRD-K21586122-001-02-7, BRD-K21586122-001-01-9	Launched
paeoniflorin	anticonvulsant				BRD-K83631119-001-04-9, BRD-K83631119-001-02-1, BRD-K83631119-001-03-9	Preclinical
forskolin	adenylyl cyclase activator	ADCY2, ADCY5, GNAS			BRD-K09602097-001-20-1, BRD-K09602097-001-20-1, BRD-K09602097-001-13-6, BRD-K09602097-001-23-5, BRD-K09602097-001-23-5, BRD-K09602097-001-23-5	Launched
DMeOB	glutamate receptor modulator	GRM5			BRD-K36775483-001-02-9, BRD-K36775483-001-01-4	Preclinical
cepharanthine	NFkB pathway inhibitor				BRD-K96194081-001-10-2, BRD-K96194081-001-12-8, BRD-K96194081-001-13-6, BRD-K96194081-001-13-6, BRD-K96194081-001-11-0, BRD-K96194081-001-11-0, BRD-K96194081-001-11-0	Phase 2
tranexamic-acid	antifibrinolytic, plasminogen activator inhibitor	PLG	hematology	hemophilia	BRD-K15014948-001-11-1, BRD-K15014948-001-10-3, BRD-K15014948-213-01-3, BRD-K15014948-001-09-5, BRD-K15014948-001-12-9	Launched
sirolimus	mTOR inhibitor	FKBP1A, MTOR	transplant, pulmonary	organ rejection, lymphangioleiomyomatosis	BRD-K84937637-001-13-1, BRD-K84937637-001-13-1, BRD-K84937637-001-13-1, BRD-K84937637-001-13-1, BRD-K84937637-001-09-9, BRD-K84937637-001-11-5, BRD-K84937637-001-11-5, BRD-K84937637-001-11-5	Launched
naringin	cytochrome P450 inhibitor	SLCO1A2			BRD-K02953697-001-10-9, BRD-K02953697-001-09-2	Preclinical
gestodene	contraceptive agent		endocrinology	contraceptive	BRD-K97197005-001-04-9, BRD-K97197005-001-03-2	Launched
triptolide	RNA polymerase inhibitor	RELA			BRD-K39484304-001-14-0, BRD-K39484304-001-14-0, BRD-K39484304-001-16-5, BRD-K39484304-001-16-5, BRD-K39484304-001-16-5, BRD-K39484304-001-11-6, BRD-K39484304-001-11-6	Phase 3
eplerenone	cytochrome P450 inhibitor	NR3C2	cardiology	congestive heart failure, hypertension	BRD-K19761926-001-03-6, BRD-K19761926-001-02-8, BRD-K19761926-001-07-9, BRD-K19761926-001-07-9, BRD-K19761926-001-07-9, BRD-K19761926-001-04-4, BRD-K19761926-001-04-4, BRD-K19761926-001-04-4	Launched
miglitol	glucosidase inhibitor	GAA, GANAB, GANC, MGAM	endocrinology	diabetes mellitus	BRD-K44779798-001-10-7, BRD-K44779798-001-12-9, BRD-K44779798-001-12-9, BRD-K44779798-001-11-5	Launched
nystatin	fungal ergosterol inhibitor		infectious disease	esophageal candidiasis, skin infections, yeast infection	BRD-K21656326-001-01-4, BRD-K21656326-001-02-2, BRD-K21656326-001-04-9	Launched
geldanamycin	HSP inhibitor	HSP90AA1			BRD-K43570081-001-02-4, BRD-K43570081-001-02-4, BRD-K43570081-001-04-0, BRD-K43570081-001-05-9	Preclinical
alogliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	BRD-K83003151-057-03-9, BRD-K83003151-057-02-4, BRD-K83003151-057-01-6, BRD-K83003151-057-01-6, BRD-K83003151-057-01-6	Launched
telaprevir	HCV inhibitor	CTSA, PGR	infectious disease	hepatitis C	BRD-K72912098-001-04-9, BRD-K72912098-001-04-9, BRD-K72912098-001-03-1, BRD-K72912098-001-02-3, BRD-K72912098-001-02-3, BRD-K72912098-001-02-3, BRD-K72912098-001-02-3	Launched
cyclovalone	breast cancer resistance protein inhibitor	ABCG2	gastroenterology	bile stimulation	BRD-K59866480-001-07-3, BRD-K59866480-001-07-3, BRD-K59866480-001-07-3, BRD-K59866480-001-09-9, BRD-K59866480-001-08-1	Launched
stigmasterol					BRD-K41422683-001-02-2, BRD-K41422683-001-05-5	Preclinical
delanzomib	proteasome inhibitor	CMA1, CTSG, CYP3A4, ELANE			BRD-K59325863-001-04-4, BRD-K59325863-001-04-4, BRD-K59325863-001-01-0, BRD-K59325863-001-01-0, BRD-K59325863-001-03-6, BRD-K59325863-001-03-6, BRD-K59325863-001-02-8, BRD-K59325863-001-02-8, BRD-K59325863-001-02-8	Phase 1/Phase 2
sulbactam	beta lactamase inhibitor		infectious disease	skin infections, intra-abdominal infections, gynecologic infections	BRD-K44133266-001-13-9, BRD-K44133266-001-13-9, BRD-K44133266-001-10-0, BRD-K44133266-001-10-0, BRD-K44133266-236-03-7, BRD-K44133266-001-12-6, BRD-K44133266-236-02-9	Launched
puerarin	serotonin receptor antagonist				BRD-K89048337-001-07-9, BRD-K89048337-001-08-9, BRD-K89048337-001-06-9	Phase 2
triciribine	AKT inhibitor	AKT1, AKT2, AKT3			BRD-K80431395-001-04-0, BRD-K80431395-001-12-9, BRD-K80431395-001-08-1, BRD-K80431395-001-08-1, BRD-K80431395-001-09-9, BRD-K80431395-001-09-9, BRD-K80431395-001-09-9, BRD-K80431395-001-09-9, BRD-K80431395-001-07-3	Phase 1/Phase 2
zinc-undecylenate	other antifungal		infectious disease	tinea pedis	BRD-K13330768-001-01-1, BRD-K13330768-001-02-9	Launched
epothilone-A	microtubule stabilizing agent				BRD-K71823332-001-03-7, BRD-K71823332-001-03-7	Preclinical
prednisolone-acetate	glucocorticoid receptor agonist	NR3C1	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis	BRD-K45664306-001-19-6, BRD-A01643550-001-04-9, BRD-K45664306-001-20-4, BRD-K45664306-001-21-9	Launched
ursodiol	nuclear factor erythroid derived, like (NRF2) activator	AKR1C2, NR1H4	gastroenterology	gallstones	BRD-K15697815-001-15-4, BRD-K15697815-001-16-2	Launched
asiatic-acid	apoptosis stimulant	PYGM			BRD-K35079116-001-02-5, BRD-K35079116-001-02-5, BRD-K35079116-001-02-5, BRD-K35079116-001-02-5, BRD-K35079116-001-03-3, BRD-K35079116-001-03-3, BRD-K35079116-001-04-1, BRD-K35079116-001-04-1	Preclinical
levofloxacin	bacterial DNA gyrase inhibitor	TOP2A	infectious disease, otolaryngology, pulmonary, urology	pneumonia, sinusitis, bronchitis, skin infections, prostatitis, urinary tract infections, pyelonephritis, anthrax, plague	BRD-K09471561-001-18-2, BRD-K09471561-001-20-8	Launched
tylosin	protein synthesis inhibitor		infectious disease, gastroenterology	gram-positive bacterial infections, colitis	BRD-K37753391-046-02-4, BRD-K37753391-001-05-9, BRD-K37753391-046-03-2	Launched
noscapine	bradykinin receptor antagonist, tubulin polymerization inhibitor	SIGMAR1	pulmonary	cough suppressant	BRD-K89237706-003-02-6, BRD-K89237706-001-12-9, BRD-K89237706-001-12-9, BRD-K89237706-003-11-9, BRD-K89237706-003-03-4	Launched
endoxifen	estrogen receptor antagonist	ESR1			BRD-K62752296-003-01-3, BRD-K62752296-003-02-1	Phase 2
pranlukast	leukotriene receptor antagonist	CYSLTR1, CYSLTR2, IL5, MUC2, NFKB1, RNASE3, TNF	pulmonary	bronchospasm, asthma	BRD-K97045029-001-02-7, BRD-K97045029-001-02-7, BRD-K97045029-001-02-7, BRD-K97045029-001-02-7, BRD-K97045029-001-02-7, BRD-K97045029-001-02-7, BRD-K97045029-001-07-9, BRD-K97045029-001-07-9, BRD-K97045029-001-04-3, BRD-K97045029-001-04-3, BRD-K97045029-001-04-3, BRD-K97045029-001-04-3	Launched
streptomycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	tuberculosis	BRD-K07166362-330-01-0, BRD-K07166362-330-02-8, BRD-K07166362-065-03-9	Launched
daunorubicin	RNA synthesis inhibitor, topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)	BRD-K43389675-001-02-1, BRD-K43389675-001-02-1, BRD-K43389675-001-02-1, BRD-K43389675-003-19-1, BRD-K43389675-003-19-1, BRD-K43389675-003-19-1, BRD-K43389675-003-19-1, BRD-K43389675-003-19-1, BRD-K43389675-003-19-1, BRD-K43389675-003-20-9, BRD-K43389675-003-16-7, BRD-K43389675-003-16-7, BRD-K43389675-003-16-7, BRD-K43389675-003-16-7	Launched
mestranol	estrogen receptor agonist	ESR1	endocrinology	contraceptive	BRD-K31920458-001-24-9, BRD-K31920458-001-22-8, BRD-K31920458-001-22-8, BRD-K31920458-001-23-6	Launched
pentagastrin	CCK receptor agonist	CCKBR	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic	BRD-K78789465-001-02-4, BRD-K78789465-001-01-6	Launched
alfacalcidol	vitamin D receptor agonist	CYP27B1, VDR	endocrinology	vitamin D deficiency	BRD-K49522529-001-02-9, BRD-K49522529-001-02-9, BRD-K49522529-001-01-1, BRD-K49522529-001-01-1, BRD-K49522529-001-03-7, BRD-K49522529-001-03-7	Launched
acetophenazine	dopamine receptor antagonist	DRD1, DRD2	neurology/psychiatry	psychosis	BRD-K42938903-332-01-1, BRD-K42938903-332-02-9	Launched
cyclopiazonic-acid	ATPase inhibitor	ATP2A1			BRD-A10420615-001-05-1, BRD-A10420615-001-05-1, BRD-A10420615-001-04-4	Preclinical
A-804598	purinergic receptor antagonist	P2RX7			BRD-K94313941-001-03-9, BRD-K76894955-001-02-1, BRD-K76894955-001-02-1	Preclinical
MC1568	HDAC inhibitor	HDAC2			BRD-K24031866-001-03-9, BRD-K24031866-001-02-1, BRD-K24031866-001-02-1, BRD-K24031866-001-01-3	Preclinical
ribavirin	antiviral	ADK, ENPP1, IMPDH1, IMPDH2, NT5C2	infectious disease	hepatitis C	BRD-K60369935-001-19-9, BRD-K60369935-001-19-9, BRD-K60369935-001-17-5, BRD-K60369935-001-15-9, BRD-K60369935-001-18-3	Launched
polydatin	ICAM1 expression inhibitor	ICAM1			BRD-K43236057-001-07-1, BRD-K43236057-001-09-7	Phase 2
teniposide	topoisomerase inhibitor	TOP2A, TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	BRD-K10362825-001-03-4, BRD-K10362825-001-03-4, BRD-K10362825-001-04-2, BRD-K10362825-001-04-2	Launched
ampicillin	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, meningitis, bacterial septicemia, endocarditis, urinary tract infections, gastrointestinal infections	BRD-K68432770-236-24-9, BRD-K68432770-236-20-7, BRD-K68432770-236-23-1, BRD-K68432770-236-23-1, BRD-K68432770-236-22-3, BRD-K68432770-236-21-5, BRD-K68432770-236-19-9, BRD-K68432770-341-07-2, BRD-K68432770-341-05-6	Launched
simvastatin	HMGCR inhibitor	HMGCR, ITGB2	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia	BRD-K22134346-001-28-0, BRD-K22134346-001-28-0, BRD-K22134346-001-22-3, BRD-K22134346-001-22-3, BRD-K22134346-001-22-3, BRD-K22134346-001-22-3, BRD-K22134346-001-24-9, BRD-K22134346-001-21-5, BRD-K22134346-001-30-6	Launched
isotretinoin	retinoid receptor agonist	RARA, RARB, RARG	dermatology	acne vulgaris (AV)	BRD-K76723084-001-23-2, BRD-K76723084-001-25-7, BRD-K76723084-001-25-7, BRD-K76723084-001-24-0, BRD-K76723084-001-22-4	Launched
darifenacin	acetylcholine receptor antagonist	CHRM1, CHRM2, CHRM3, CHRM4, CHRM5	urology	urinary incontinence	BRD-K95773607-004-05-9, BRD-K95773607-004-04-6, BRD-K95773607-004-03-8	Launched
tobramycin	bacterial 30S ribosomal subunit inhibitor		infectious disease	bacterial septicemia, respiratory tract infections, meningitis, skin infections, urinary tract infections	BRD-K05619559-001-10-1, BRD-K05619559-001-12-7, BRD-K05619559-001-12-7	Launched
spaglumic-acid	glutamate receptor antagonist	GRM3	allergy	allergic conjunctivitis, allergic rhinitis	BRD-K68405354-001-07-2, BRD-K68405354-001-08-0, BRD-K68405354-001-08-0, BRD-K68405354-001-06-4	Launched
nafcillin	bacterial cell wall synthesis inhibitor	CYP1A2, CYP3A4, SLC22A6	infectious disease	gram-positive bacterial infections	BRD-K18574842-323-18-9, BRD-K18574842-236-17-7, BRD-K18574842-323-11-6, BRD-K18574842-323-10-8	Launched
captopril	angiotensin converting enzyme inhibitor	ACE, LTA4H, MMP2, MMP9	cardiology, endocrinology, nephrology	hypertension, congestive heart failure, myocardial infarction, diabetes mellitus, diabetic nephropathy	BRD-K54529596-001-25-5, BRD-K54529596-001-26-3, BRD-K54529596-001-26-3, BRD-K54529596-001-26-3, BRD-K54529596-001-28-9	Launched
benzamil	sodium channel blocker	ASIC1, PKD2L1, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC8A1			BRD-K87158025-003-08-7, BRD-K87158025-001-01-6, BRD-K87158025-003-09-9	Phase 2
pimecrolimus	calcineurin inhibitor		dermatology	eczema	BRD-K92107055-001-02-9, BRD-K92107055-001-01-9	Launched
amsacrine	topoisomerase inhibitor	KCNH2, TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL)	BRD-K68346641-001-02-2, BRD-K68346641-001-02-2, BRD-K68346641-001-02-2, BRD-K68346641-001-01-4	Launched
PRT062607	SYK inhibitor	FGR, MAP3K9, SYK			BRD-K53734668-003-04-6, BRD-K53734668-003-04-6, BRD-K53734668-003-04-6, BRD-K53734668-003-04-6, BRD-K53734668-003-04-6, BRD-K53734668-003-02-0, BRD-K53734668-003-02-0, BRD-K53734668-003-02-0, BRD-K53734668-003-02-0, BRD-K53734668-003-01-2, BRD-K53734668-003-01-2, BRD-K53734668-003-01-2	Phase 2
quinine	hemozoin biocrystallization inhibitor	GP9, KCNB2, KCNN4, SLC29A4	infectious disease	malaria	BRD-K07940445-310-02-9, BRD-K07940445-001-02-4, BRD-K07940445-003-07-9	Launched
methylprednisolone	glucocorticoid receptor agonist	NR3C1	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis	BRD-K35240538-001-24-7, BRD-K35240538-001-25-4, BRD-K35240538-001-25-4, BRD-K35240538-001-25-4, BRD-K35240538-001-26-2, BRD-K35240538-001-26-2	Launched
baicalin	beta glucuronidase inhibitor	PREP	neurology/psychiatry	anxiety	BRD-K49962337-001-03-9, BRD-K49962337-001-03-9, BRD-K49962337-001-02-9, BRD-K49962337-001-02-9, BRD-K49962337-001-01-1	Launched
cefotaxime	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections, bone and joint infections, pelvic inflammatory disease, intra-abdominal infections, skin infections, meningitis, urinary tract infections, bacterial septicemia, gynecologic infections	BRD-K78364995-236-18-3, BRD-K78364995-236-19-1, BRD-K78364995-236-17-5, BRD-K78364995-236-16-7	Launched
flubendazole	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites	BRD-K86003836-001-10-5, BRD-K86003836-001-10-5, BRD-K86003836-001-10-5, BRD-K86003836-001-13-9, BRD-K86003836-001-09-7	Launched
betamethasone-acetate	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	BRD-K00025439-001-01-9	Launched
formoterol	adrenergic receptor agonist	ADRB2	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm	BRD-K54006094-051-06-6, BRD-K54006094-051-06-6, BRD-K54006094-051-01-7, BRD-K54006094-051-10-9, BRD-K54006094-051-03-3, BRD-K54006094-051-03-3, BRD-K54006094-051-02-5	Launched
metaproterenol	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm, asthma, bronchitis, emphysema	BRD-K01826731-065-09-9, BRD-K01826731-065-10-9, BRD-K01826731-065-10-9, BRD-K01826731-065-10-9	Launched
brimonidine	adrenergic receptor agonist	ADRA2A, ADRA2B, ADRA2C	ophthalmology	intraocular pressure, glaucoma, ocular hypertension	BRD-K68264559-001-14-2, BRD-K68264559-045-02-4, BRD-K68264559-001-13-4, BRD-K68264559-001-13-4, BRD-K68264559-045-03-2, BRD-K68264559-045-04-0	Launched
choline	acetylcholine precursor	ACHE, BCHE, CHRNA2, PCYT1A, PCYT1B, PHOSPHO1, PLD1, PLD2			BRD-K77300776-001-01-7, BRD-K77300776-001-02-5, BRD-K77300776-003-03-9	Phase 3
RU-24969	serotonin receptor agonist	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR5A, HTR6			BRD-K00234327-001-04-8, BRD-K00234327-001-03-0, BRD-K00234327-036-05-1	Phase 1
neomycin	bacterial 30S ribosomal subunit inhibitor	CXCR4	infectious disease, gastroenterology	first-aid antibiotic, hepatic encephalopathy (HE), intra-abdominal infections	BRD-K71013094-326-02-6, BRD-K71013094-001-02-5, BRD-K71013094-065-05-3, BRD-K71013094-326-01-8, BRD-K71013094-326-03-4, BRD-K71013094-065-04-6	Launched
bismuth-subsalicylate	antacid		gastroenterology	diarrhea	BRD-K80528473-001-03-0, BRD-K80528473-001-08-9, BRD-K80528473-001-04-8, BRD-K80528473-001-07-1, BRD-K80528473-001-05-5	Launched
benethamine					BRD-K13473780-001-02-1	Preclinical
silver-sulfadiazine	PABA antagonist		critical care	sepsis	BRD-K68379918-001-01-1, BRD-K68379918-001-01-1, BRD-K68379918-001-02-9	Launched
L-glutamic-acid	glutamate receptor agonist	AADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, DNPEP, EARS2, ENPEP, EPRS, FOLH1, FPGS, FTCD, GAD1, GAD2, GATB, GCLC, GCLM, GGCX, GLS, GLS2, GLUD1, GLUD2, GLUL, GMPS, GOT1, GOT2, GPT, GPT2, GRIA1, GRIA2, GRIA3, GRIA4, GRID1, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM1, GRM2, GRM3, GRM4, GRM6, GRM7, GRM8, LGSN, NADSYN1, NAGS, OPLAH, PFAS, PGCP, PSAT1, SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7, SLC25A18, SLC25A22, SLC7A11, TAT			BRD-K62309135-001-05-2, BRD-K62309135-001-05-2	Launched
endo-IWR-1	PARP inhibitor	TNKS, TNKS2			BRD-K61314889-001-06-9, BRD-K61314889-001-05-1, BRD-K61314889-001-05-1, BRD-K61314889-001-05-1, BRD-K61314889-001-04-4, BRD-K61314889-001-04-4, BRD-K61314889-001-04-4, BRD-K61314889-001-04-4	Preclinical
pemetrexed	dihydrofolate reductase inhibitor, thymidylate synthase inhibitor	ATIC, DHFR, GART, TYMS	oncology	non-small cell lung cancer (NSCLC), mesothelioma	BRD-K32842773-434-01-8, BRD-K32842773-434-01-8, BRD-K32842773-434-01-8, BRD-K32842773-434-01-8, BRD-K32842773-304-05-4, BRD-K32842773-380-01-3, BRD-K32842773-380-01-3, BRD-K32842773-304-03-9, BRD-K32842773-304-04-7, BRD-K32842773-304-04-7, BRD-K32842773-304-06-2	Launched
guanethidine	adrenergic inhibitor	SLC6A2	cardiology	hypertension	BRD-K62676709-001-01-9, BRD-K62676709-065-05-5, BRD-K62676709-065-05-5, BRD-K62676709-065-06-9, BRD-K62676709-065-06-9	Launched
aliskiren-hemifumarate	renin inhibitor	REN	cardiology	hypertension	BRD-K30020243-051-04-1, BRD-K30020243-051-04-1, BRD-K30020243-051-05-9, BRD-K30020243-051-05-9, BRD-K30020243-051-02-5, BRD-K30020243-051-03-3	Launched
valproic-acid	benzodiazepine receptor agonist, HDAC inhibitor	ABAT, ACADSB, ALDH5A1, HDAC1, HDAC2, HDAC9, OGDH, SCN10A, SCN11A, SCN1A, SCN1B, SCN2A, SCN2B, SCN3A, SCN3B, SCN4A, SCN4B, SCN5A, SCN7A, SCN8A, SCN9A	neurology/psychiatry	epilepsy, seizures, seizures	BRD-K41260949-236-15-0, BRD-K41260949-236-15-0, BRD-K41260949-236-15-0, BRD-K41260949-236-18-4, BRD-K41260949-236-17-6, BRD-K41260949-001-18-2, BRD-K41260949-236-21-8, BRD-K41260949-236-20-0, BRD-K41260949-236-16-8, BRD-K41260949-236-19-2	Launched
bisoprolol	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	BRD-A89175223-051-14-8, BRD-A89175223-051-15-5, BRD-A89175223-051-13-0, BRD-A89175223-051-16-3, BRD-A89175223-051-16-3	Launched
darunavir	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	BRD-K84986517-001-01-8, BRD-K84986517-001-01-8, BRD-K84986517-001-01-8, BRD-K84986517-001-02-9, BRD-K84986517-001-02-9	Launched
tabimorelin	growth hormone secretagogue receptor agonist	GHSR			BRD-K53600683-051-01-5, BRD-K53600683-051-01-5, BRD-K53600683-051-02-9	Phase 2
adenine	protein synthesis stimulant	ACACB, ACP1, APRT, MTAP, PECR, SRPK2			BRD-K26060080-065-05-6, BRD-K26060080-001-11-9, BRD-K26060080-001-11-9, BRD-K26060080-003-07-3, BRD-K26060080-001-10-1	Preclinical
gadodiamide	radiopaque medium		radiology	MRI contrast agent	BRD-K38140108-001-02-9, BRD-K38140108-002-01-2	Launched
doxycycline	bacterial 30S ribosomal subunit inhibitor, metalloproteinase inhibitor	MMP8	dental	periodontitis	BRD-K01825679-003-04-9, BRD-K01825679-311-02-9, BRD-K01825679-311-02-9, BRD-K01825679-311-02-9, BRD-K01825679-311-01-9	Launched
oxelaidin	antitussive		pulmonary	cough suppressant	BRD-K17977438-048-03-2, BRD-K17977438-048-02-4, BRD-K17977438-048-06-9, BRD-K17977438-048-04-0	Launched
salicylic-acid	cyclooxygenase inhibitor, prostanoid receptor antagonist	AKR1C1, ASIC3, PTGS1, PTGS2	dermatology, endocrinology, neurology/psychiatry	acne vulgaris (AV), fever, pain relief	BRD-K93632104-001-20-9, BRD-K93632104-001-20-9, BRD-K93632104-001-19-8, BRD-K93632104-001-18-0, BRD-K93632104-001-17-2	Launched
sacubitril	neprilysin inhibitor	MME	cardiology	congestive heart failure	BRD-K91456750-001-01-9, BRD-K91456750-001-01-9, BRD-K91456750-001-01-9, BRD-K91456750-238-01-7	Launched
U-0126	MEK inhibitor	AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1			BRD-K18787491-001-10-2, BRD-K18787491-001-10-2, BRD-K18787491-001-08-6, BRD-K18787491-001-08-6, BRD-K18787491-001-14-9, BRD-K18787491-001-11-0	Preclinical
xamoterol	adrenergic receptor agonist	ADRB1			BRD-A59337442-051-07-9, BRD-A59337442-051-06-1, BRD-A59337442-051-06-1, BRD-A59337442-051-05-3	Phase 3
mesna	antioxidant		urology	hemorrhagic cystitis	BRD-K49954789-001-02-9, BRD-K49954789-001-03-7, BRD-K49954789-001-01-1	Launched
calcium-gluceptate					BRD-K35952844-238-02-0, BRD-K35952844-238-02-0, BRD-K35952844-236-01-6, BRD-K35952844-236-01-6, BRD-K35952844-238-01-2	Launched
rosuvastatin	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hyperlipidemia, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis	BRD-K82941592-238-03-7, BRD-K82941592-238-03-7, BRD-K82941592-238-07-9, BRD-K82941592-238-07-9, BRD-K82941592-238-06-9, BRD-K82941592-238-04-5, BRD-K82941592-238-04-5	Launched
acamprosate	glutamate receptor antagonist	GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM5	neurology/psychiatry	abstinence from alcohol	BRD-K26262077-238-01-5, BRD-K26262077-001-01-7, BRD-K26262077-238-03-9	Launched
gadopentetic-acid	contrast agent	PGD	radiology	contrast agent	BRD-K25106841-001-01-2	Launched
metoprolol	adrenergic receptor antagonist	ADRB1, ADRB2	cardiology	hypertension, angina pectoris, myocardial infarction	BRD-K01826568-046-15-9, BRD-K01826568-046-15-9, BRD-K01826568-046-14-9	Launched
mebhydrolin	antihistamine		allergy	allergic rhinitis, urticaria	BRD-K29713308-001-07-9, BRD-K29713308-001-01-7, BRD-K29713308-077-04-1	Launched
guanidine	HSP inhibitor	ALDH2, DLG4, GAMT, RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	BRD-K76037122-003-03-9, BRD-K76037122-001-01-7, BRD-K76037122-001-02-5	Launched
isometheptene-mucate			neurology/psychiatry	headache	BRD-A64743628-001-01-5	Launched
oxotremorine-sesquifumarate	cholinergic receptor agonist	CHRM1, CHRM2, CHRM3, CHRM4			BRD-K21936341-051-04-0, BRD-K21936341-051-08-9, BRD-K21936341-051-03-2	Preclinical
aminophylline	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3, HDAC2, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A	pulmonary	asthma, bronchitis, emphysema	BRD-K97799481-205-02-7, BRD-K97799481-205-02-7, BRD-K97799481-205-01-9, BRD-K97799481-230-01-7, BRD-K97799481-001-16-0, BRD-K97799481-001-16-0	Launched
sodium-gluconate					BRD-K93201765-236-02-9, BRD-K93201765-001-01-0	Launched
chromium-picolinate	insulin sensitizer		endocrinology	diabetes mellitus	BRD-K01029106-001-02-9, BRD-K01029106-001-01-4	Launched
abacavir	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	BRD-K17443395-065-03-0, BRD-K17443395-065-02-2, BRD-K17443395-065-02-2, BRD-K17443395-065-02-2, BRD-K17443395-065-02-2, BRD-K17443395-065-01-4	Launched
ibutilide	potassium channel blocker	CACNA1C, KCNH2	cardiology	atrial fibrillation (AF)	BRD-A74391928-051-03-9, BRD-A74391928-051-01-3, BRD-A74391928-051-04-9, BRD-A74391928-051-04-9, BRD-A74391928-051-04-9, BRD-A74391928-051-02-1, BRD-A74391928-051-02-1	Launched
AMG-837	free fatty acid receptor agonist	FFAR1			BRD-K43802723-238-02-9, BRD-K43802723-340-01-9, BRD-K43802723-340-01-9, BRD-K43802723-340-01-9, BRD-K43802723-340-01-9	Phase 1
U-50488-(-)	opioid receptor agonist	OPRK1			BRD-K53532120-003-10-3, BRD-K53532120-003-12-9, BRD-K53532120-003-11-1, BRD-K53532120-003-11-1, BRD-K53532120-003-11-1, BRD-K53532120-003-09-5	Preclinical
isamoltane	adrenergic receptor antagonist	HTR1A, HTR1B			BRD-K01825673-051-02-9, BRD-K01825673-051-01-9	Phase 1
cyclamic-acid					BRD-K50785021-001-04-7, BRD-K50785021-001-05-9, BRD-K50785021-001-03-9, BRD-K50785021-001-02-1	Preclinical
rilmenidine	adrenergic receptor agonist, imidazoline receptor agonist	ADRA2A	cardiology	hypertension	BRD-K01638814-051-16-8, BRD-K01638814-011-01-4, BRD-K01638814-011-01-4	Launched
sulfanilate-zinc					BRD-K04254814-001-01-8	Preclinical
pitavastatin	HMGCR inhibitor	HMGCR	endocrinology	hyperlipidemia	BRD-K75958547-238-03-9, BRD-K75958547-238-04-9, BRD-K75958547-238-04-9, BRD-K75958547-238-02-8, BRD-K75958547-238-02-8, BRD-K75958547-238-01-0, BRD-K75958547-238-01-0, BRD-K75958547-238-01-0, BRD-K75958547-238-01-0	Launched
TAK-875	insulin secretagogue	FFAR1			BRD-K58501140-001-02-9, BRD-K58501140-002-01-0, BRD-K58501140-002-01-0, BRD-K58501140-002-01-0, BRD-K58501140-002-01-0, BRD-K58501140-002-01-0	Phase 3
3-methyl-GABA	GABA aminotransferase activator	ABAT			BRD-K01825682-074-02-9, BRD-K01825682-077-01-9	Preclinical
aminosalicylate	cyclooxygenase inhibitor	ALOX5, CHUK, PLA2G2E, PTGS1, PTGS2	gastroenterology	inflammatory bowel disease, ulcerative colitis	BRD-K80267133-001-17-7, BRD-K80267133-325-22-9, BRD-K80267133-001-18-5, BRD-K80267133-001-19-3	Launched
strontium-ranelate	bone formation stimulant, bone resorption inhibitor	CASR	orthopedics, rheumatology	osteoporosis, osteoarthritis	BRD-K83146339-001-04-0, BRD-K83146339-001-02-4, BRD-K83146339-001-03-2, BRD-K83146339-001-05-7	Launched
diminazene-aceturate	angiotensin converting enzyme activator	AOC1, PRDX5, PRSS1			BRD-K92848252-001-01-9, BRD-K92848252-001-02-7, BRD-K92848252-001-03-5, BRD-K92848252-001-03-5	Phase 3
quetiapine	dopamine receptor antagonist, serotonin receptor antagonist	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A2	neurology/psychiatry	schizophrenia, bipolar disorder	BRD-K68867920-001-11-0, BRD-K68867920-051-12-3, BRD-K68867920-051-11-5, BRD-K68867920-051-11-5	Launched
mitiglinide	insulin secretagogue	ABCC8, KCNJ10, PPARG	endocrinology	diabetes mellitus	BRD-K52959329-238-01-9, BRD-K52959329-238-02-9	Launched
sisomicin	protein synthesis inhibitor		ophthalmology	conjunctivitis, punctate keratitis	BRD-K71772032-001-01-3, BRD-K71772032-315-02-5, BRD-K71772032-315-01-7, BRD-K71772032-315-03-9	Launched
fluvastatin	HMGCR inhibitor	HMGCR	endocrinology, cardiology	hypercholesterolemia, congenital heart defects	BRD-K66296774-001-07-9, BRD-K66296774-236-12-1, BRD-K66296774-236-12-1, BRD-K66296774-236-11-3, BRD-K66296774-236-11-3, BRD-K66296774-236-11-3, BRD-K66296774-236-11-3, BRD-K66296774-236-11-3, BRD-K66296774-236-11-3, BRD-K66296774-236-10-5	Launched
eliglustat	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	BRD-K86410485-001-01-5, BRD-K86410485-001-01-5, BRD-K86410485-046-01-0, BRD-K86410485-046-01-0, BRD-K86410485-046-01-0	Launched
cysteamine	tissue transglutaminase inhibitor	NPY2R, SST	metabolism	cystinosis	BRD-K92611362-003-03-9, BRD-K92611362-001-02-6	Launched
terbutaline	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm, bronchitis, emphysema	BRD-A50157456-065-21-4, BRD-A50157456-065-21-4, BRD-A50157456-065-20-6	Launched
betaine	nitric oxide donor		metabolism	homocystinuria	BRD-K12014493-001-02-2	Launched
lobeline	acetylcholine receptor antagonist	CHRNA10, CHRNA9, SLC18A2	neurology/psychiatry	smoking cessation	BRD-K66206289-003-22-1, BRD-K66206289-065-01-4, BRD-K66206289-003-20-5, BRD-K66206289-003-23-9, BRD-K66206289-003-21-3	Launched
lithium-citrate			neurology/psychiatry	bipolar disorder, depression	BRD-M41245765-001-04-2, BRD-M41245765-001-05-9, BRD-M41245765-001-03-4, BRD-M41245765-341-06-9	Launched
zofenopril-calcium	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	BRD-K46654563-238-02-9, BRD-K46654563-238-02-9, BRD-K46654563-238-01-0, BRD-K46654563-238-01-0, BRD-K46654563-238-01-0	Launched
MRS-3777	adenosine receptor antagonist	ADORA1, ADORA2A, ADORA2B, ADORA3			BRD-K10575656-034-03-9, BRD-K10575656-034-03-9, BRD-K10575656-034-04-9, BRD-K10575656-034-01-0, BRD-K10575656-034-01-0, BRD-K10575656-034-01-0, BRD-K10575656-034-02-9	Preclinical
cyanopindolol	adrenergic receptor antagonist	ADRB1, HTR1A, HTR1D			BRD-K01825675-051-01-9, BRD-K01825675-051-02-9, BRD-K01825675-051-02-9	Phase 2
citric-acid	coagulation factor inhibitor	AKR1B1, ANG, APRT, BHMT, C8G, CA4, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A1, IL4I1, ITPA, LSM6, MDH2, MIF, PDE5A, PKD2L1, PLEKHA1, RNASE1, RNASE3, SRC, TNFSF13B, UCK2			BRD-K76792669-001-08-1	Preclinical
gadoteridol	radiopaque medium		radiology	MRI contrast agent	BRD-A72401848-001-02-2, BRD-A72401848-001-01-4	Launched
atorvastatin	HMGCR inhibitor	AHR, DPP4, HMGCR	neurology/psychiatry, cardiology	stroke, heart attack	BRD-K69726342-238-05-9, BRD-K69726342-238-05-9, BRD-K69726342-238-05-9, BRD-K69726342-238-03-2, BRD-K69726342-238-03-2, BRD-K69726342-238-03-2, BRD-K69726342-001-03-4, BRD-K69726342-001-03-4, BRD-K69726342-238-02-4, BRD-K69726342-238-02-4, BRD-K69726342-238-02-4	Launched
piroctone-olamine			infectious disease	fungal infection	BRD-A96510685-213-03-7	Launched
hexonic-acid					BRD-A63267145-001-01-0, BRD-A63267145-001-02-9	Preclinical
sitagliptin	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	BRD-K19416115-366-02-7, BRD-K19416115-001-05-3, BRD-K19416115-001-05-3	Launched
pyrithione-zinc	ATP synthase inhibitor	KCNQ1, KCNQ2, KCNQ4, KCNQ5	dermatology	dandruff, cosmetic	BRD-K16136380-001-01-7, BRD-K16136380-001-01-7, BRD-K16136380-001-01-7, BRD-K16136380-001-03-3, BRD-K16136380-001-02-5, BRD-K16136380-001-04-9	Launched
antimonyl					BRD-A74328360-409-01-0, BRD-A74328360-409-02-8	Phase 1
tempol	free radical scavenger				BRD-K95053546-001-03-5, BRD-K95053546-001-02-7, BRD-K95053546-001-01-9	Phase 2
amikacin	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	BRD-K88043978-002-08-9, BRD-K88043978-002-09-7, BRD-K88043978-315-02-8, BRD-K88043978-315-11-9, BRD-K88043978-315-03-6, BRD-K88043978-002-10-5	Launched
tocofersolan	antioxidant		cardiology	cerebral cholesterosis	BRD-K57305459-001-02-9, BRD-K57305459-001-01-4	Launched
sitafloxacin	bacterial DNA gyrase inhibitor		infectious disease	buruli ulcer	BRD-K10836013-002-02-9, BRD-K10836013-001-01-3, BRD-K10836013-001-01-3, BRD-K10836013-001-01-3	Launched
histamine	histamine receptor agonist	HRH1, HRH2, HRH3, HRH4	allergy	allergic rhinitis	BRD-K01674964-300-10-5, BRD-K01674964-300-07-1, BRD-K01674964-001-19-0, BRD-K01674964-300-08-9, BRD-K01674964-316-01-0, BRD-K01674964-300-06-3	Launched
sertaconazole	sterol demethylase inhibitor		infectious disease	tinea pedis	BRD-K01825659-008-03-9, BRD-K01825659-001-01-9, BRD-K01825659-001-01-9, BRD-K01825659-001-01-9, BRD-K01825659-001-01-9	Launched
auranofin	NFkB pathway inhibitor	IKBKB, PRDX5, TRPA1	rheumatology	rheumatoid arthritis	BRD-K45995181-001-06-9, BRD-K45995181-001-04-6, BRD-K45995181-001-04-6, BRD-K45995181-001-05-3	Launched
oseltamivir-phosphate	neuraminidase inhibitor	CES1, NEU1, NEU2	infectious disease	influenza A virus infection	BRD-K76011241-001-01-8, BRD-K76011241-011-04-9, BRD-K76011241-011-04-9, BRD-K76011241-011-02-5, BRD-K76011241-001-02-6	Launched
NKP-1339	HSP inhibitor				BRD-K74796838-236-01-7, BRD-K74796838-236-02-9	Phase 1
oxprenolol	adrenergic receptor antagonist	ADRB1	cardiology	angina pectoris, hypertension, cardiac arrythmia	BRD-A43671941-003-11-9, BRD-A43671941-003-11-9	Launched
EUK-134	catalase stimulant	APP, SOD2			BRD-K19741031-001-02-2, BRD-K19741031-001-02-2, BRD-K19741031-001-01-4, BRD-K19741031-001-03-0	Preclinical
dimetridazole	bacterial DNA inhibitor		infectious disease	protozoan infection	BRD-K72728560-001-01-4	Launched
chlorophyllin-copper	cytochrome P450 inhibitor				BRD-A92960111-314-01-2, BRD-A92960111-314-02-0	Phase 1
YM-155	survivin inhibitor	BIRC5			BRD-K76703230-004-09-9, BRD-K76703230-004-09-9, BRD-K76703230-004-04-1, BRD-K76703230-004-04-1, BRD-K76703230-004-03-3	Phase 2
